0000874015-16-000112.txt : 20160226 0000874015-16-000112.hdr.sgml : 20160226 20160225190802 ACCESSION NUMBER: 0000874015-16-000112 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 114 CONFORMED PERIOD OF REPORT: 20151231 FILED AS OF DATE: 20160226 DATE AS OF CHANGE: 20160225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 161457476 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 10-K 1 form10k.htm ISIS PHARMACEUTICALS INC 10-K 12-31-2015  

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
     
 
FORM 10-K
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2015
 
Commission file number 0-19125
     

Ionis Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
 
Delaware
 
33-0336973
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer Identification No.)
 
2855 Gazelle Court, Carlsbad, CA 92010
(Address of principal executive offices, including zip code)
 
760-931-9200
(Registrant’s telephone number, including area code)

 
Securities registered pursuant to Section 12(b) of the Act: None
 
Securities registered pursuant to Section 12(g) of the Act: Common Stock, $.001 Par Value

     

Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No 
 
Indicate by check mark whether the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  No 
 
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No 
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. 
 
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer
 
Accelerated filer
 
 
 
Non-accelerated filer
(Do not check if a smaller reporting company)
 
Smaller reporting company
 
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No 
 
The approximate aggregate market value of the voting common stock held by non-affiliates of the Registrant, based upon the last sale price of the common stock reported on The NASDAQ Global Select Market was $5,760,508,916 as of June 30, 2015.*
 
The number of shares of voting common stock outstanding as of February 19, 2016 was 120,658,638.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s definitive Proxy Statement to be filed on or about April 15, 2016 with the Securities and Exchange Commission in connection with the Registrant’s annual meeting of stockholders to be held on June 3, 2016 are incorporated by reference into Part III of this Report. The Exhibit Index (Item No. 15) located on pages 68 to 73 incorporates several documents by reference as indicated therein.

   
* Excludes 19,785,891 shares of common stock held by directors and officers and by stockholders whose beneficial ownership is known by the Registrant to exceed 10 percent of the common stock outstanding at June 30, 2015. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the Registrant, or that such person is controlled by or under common control with the Registrant.



FORWARD-LOOKING STATEMENTS

This report on Form 10-K and the information incorporated herein by reference includes forward-looking statements regarding our business, the business of Akcea Therapeutics, Inc., a subsidiary of Ionis Pharmaceuticals, and the therapeutic and commercial potential of our technologies and products in development, including nusinersen, IONIS-TTRRx and volanesorsen. Any statement describing our goals, expectations, financial or other projections, intentions or beliefs, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Our forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this report on Form 10-K, including those identified in Item 1A entitled “Risk Factors”. Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, you are cautioned not to rely on these forward-looking statements.

In this report, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals, Inc. and its subsidiaries.

TRADEMARKS

Ionis PharmaceuticalsTM is a trademark of Ionis Pharmaceuticals, Inc.

Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.

Regulus Therapeutics® is a registered trademark of Regulus Therapeutics Inc. 

KYNAMRO® is a registered trademark of Genzyme Corporation

Glybera® is a registered trademark of uniQure NV


CORPORATE INFORMATION

We incorporated in California in 1989 and in January 1991 we changed our state of incorporation to Delaware. In December 2015, we changed our name to Ionis Pharmaceuticals, Inc. from Isis Pharmaceuticals, Inc. Our principal offices are in Carlsbad, California. We make available, free of charge, on our website, www.ionispharma.com, our reports on Forms 10-K, 10-Q, 8-K and amendments thereto, as soon as reasonably practical after we file such materials with the Securities and Exchange Commission. Any information that we include on or link to our website is not a part of this report or any registration statement that incorporates this report by reference. You may also read and copy our filings at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-732-0330. The SEC also maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is www.sec.gov.

In December 2014, we formed our wholly owned subsidiary, Akcea Therapeutics, Inc., as a Delaware corporation, with its principal office in Cambridge, Massachusetts, to develop and commercialize drugs for people with serious cardiometabolic disorders.
1

IONIS PHARMACEUTICALS, INC.
FORM 10-K
For the Fiscal Year Ended December 31, 2015
Table of Contents
PART I
   
   
Page
Item 1.
Business
3
Item 1A.
Risk Factors
35
Item 1B.
Unresolved Staff Comments
41
Item 2.
Properties
41
Item 3.
Legal Proceedings
41
Item 4.
Mine Safety Disclosures
41
 
PART II
 
   
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
41
Item 6.
Selected Financial Data
43
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
43
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
61
Item 8.
Financial Statements and Supplementary Data
61
Item 9.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
61
Item 9A.
Controls and Procedures
61
Item 9B.
Other Information
64
     
PART III
 
   
Item 10.
Directors, Executive Officers and Corporate Governance
64
Item 11.
Executive Compensation
64
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
64
Item 13.
Certain Relationships and Related Transactions, and Director Independence
65
Item 14.
Principal Accounting Fees and Services
65
     
PART IV
 
   
Item 15.
Exhibits, Financial Statement Schedules
66
     
Signatures
   

2



PART I
 
Item 1. Business
 
Overview

We are leaders in discovering and developing RNA-targeted therapeutics. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we have developed a large, diverse and advanced pipeline of potentially first-in-class and/or best-in-class drugs that we believe can provide high value for patients with significant unmet medical needs. In this way, we believe that we are fundamentally changing medicine with the goal to improve the quality of and save lives.

We have discovered and are developing three potentially transformational drugs, nusinersen, IONIS-TTRRx and volanesorsen, which we believe are close to commercialization. We designed each of these three drugs to treat patients with orphan diseases who have limited or no therapeutic options. In total, we are developing these three drugs for six different patient populations. In 2015, we completed target enrollment in the first pivotal Phase 3 study for each of these three drugs, and we anticipate reporting data from these studies in the first half of 2017. We designed nusinersen to treat patients with spinal muscular atrophy, or SMA, a severe motor-neuron disease that is the leading genetic cause of infant mortality. We designed IONIS-TTRRx to treat patients with transthyretin amyloidosis, or TTR amyloidosis, a fatal disease in which patients experience progressive buildup of amyloid plaque deposits in tissues throughout the body, including peripheral nerves, heart, intestinal tract, kidney and bladder. We designed volanesorsen to treat patients with diseases associated with extremely high levels of triglycerides, including patients with two severe and rare genetic conditions called familial chylomicronemia syndrome, or FCS, and patients with familial partial lipodystrophy, or FPL. We anticipate that the data from our pivotal Phase 3 studies of these drugs, if positive, will support global regulatory filings for each drug. We believe that the significant unmet medical need and the severity of these diseases could warrant a rapid path to market. Already our partners for these programs, Biogen for nusinersen and GSK for IONIS-TTRRx, are preparing to commercialize these drugs. Our wholly owned subsidiary, Akcea Therapeutics Inc., or Akcea, is preparing to commercialize volanesorsen. All three companies are engaging in pre-commercialization activities to understand the patient journey, build disease awareness with physicians and patients and develop their launch plans.

Nusinersen has the potential to be a transformational drug for infants and children with SMA. We are evaluating nusinersen in a broad development program designed to support marketing authorization for infants and children with this devastating disease. In our open-label studies, we have observed increases in the median event-free age in infants and increases in muscle function scores in infants and children with SMA. Although the studies are open-label with small numbers of patients, the totality of the data across these studies and multiple measures of activity suggest nusinersen could provide significant therapeutic benefit. Together with Biogen, we are conducting a broad development plan that supports a potentially rapid path to market for nusinersen.

IONIS-TTRRx is potentially a first-in-class and best-in-class drug for the treatment of all forms of TTR amyloidosis. It is one drug, given as one subcutaneous injection, once a week. We and GSK are evaluating IONIS-TTRRx in a broad development program designed to support marketing authorization of IONIS-TTRRx for all forms of TTR amyloidosis: familial amyloid polyneuropathy, or FAP, and the cardiomyopathy form of TTR amyloidosis, which includes both familial amyloid cardiomyopathy, or FAC, and wild-type TTR, or wt-TTR. Together, these forms of TTR amyloidosis represent a large potential market for IONIS-TTRRx. In our open-label extension study we have observed substantial TTR reductions in patients with FAP. In a Phase 2 open-label, investigator-initiated study, Dr. Merrill Benson, professor of pathology and lab medicine and molecular genetics at Indiana University School of Medicine, observed sustained reductions in TTR and evidence of disease stabilization in patients with the cardiomyopathy form of TTR amyloidosis.

Volanesorsen has the potential to significantly improve the lives of patients who, because of their severely elevated triglycerides, are at constant risk of pancreatitis, which can require hospitalization and can be life-threatening. In our Phase 2 clinical program, patients with elevated triglycerides treated with volanesorsen showed significantly improved lipid profiles with substantial reductions of triglycerides and other risk factors of cardiovascular disease. To maximize the value of volanesorsen and other earlier-stage drugs for serious cardiometabolic disorders, we formed Akcea Therapeutics to focus on developing and commercializing these drugs. Akcea’s pipeline includes volanesorsen, IONIS-APOCIII-LRx, IONIS-APO(a)-LRx and IONIS-ANGPTL3-LRx. Moving these drugs into a company that we own and control allows us to retain substantial value from them and ensures Ionis’ core focus remains on innovation. Akcea is building development and commercialization expertise in lipid and cardiometabolic diseases, including highly trained, specialized medical, marketing and sales teams, to successfully commercialize volanesorsen and the other lipid drugs in its pipeline.

In addition to our Phase 3 programs, we have a pipeline of drugs with the potential to be first-in-class and/or best-in-class drugs to treat patients with inadequately treated diseases. Our pipeline has over a dozen drugs in Phase 2 development, many of which we believe have the potential to be significant commercial opportunities. In particular, IONIS-FXIRx and IONIS-APO(a)-LRx are representative of the value we have created. IONIS-FXIRx is the first antithrombotic in development that has shown it can decrease the risk of blood vessel obstruction caused by a blood clot without increasing bleeding risk. Given the unique profile of IONIS-FXIRx, we believe that IONIS-FXIRx has the potential to be an important therapy for the many patients who need an antithrombotic but cannot take currently available therapies due to the high risk of bleeding. Because of the significant commercial opportunities for this drug, we licensed it to Bayer HealthCare, a leader in developing and commercializing antithrombotics. Bayer plans to conduct a robust development program to maximize the commercial value of IONIS-FXIRx. We are eligible to participate in this value through significant milestone payments and substantial royalties in the low-to-high 20 percent range on gross margins. IONIS-APO(a)-LRx is the first and only drug in clinical development designed to selectively and robustly lower Lp(a), a key driver of cardiovascular disease. We believe that addressing Lp(a) is the next important horizon in lipid-focused cardiovascular disease treatment. In our clinical studies, we observed significant and sustained reductions in Lp(a) after only a single dose of IONIS-APO(a)-LRx. With our support, Akcea has designed a broad development program to evaluate IONIS-APO(a)-LRx in patients who are at significant cardiovascular risk due to their high Lp(a) levels. In addition to these two examples, our Phase 2 pipeline includes drugs to treat patients with diseases spanning numerous therapeutic areas, including severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases. We plan to expand the therapeutic reach of our technology by adding three to five new drugs to our pipeline every year.
3


We believe that our technology is the most versatile and most efficient drug discovery technology today. We can develop drugs to act upon disease targets in many different tissues, including the liver, muscle, kidney, brain, lung, eye, tumors and others. Many of these disease targets are inaccessible with other types of drugs. Our drugs also work through numerous different cellular mechanisms, allowing us to develop drugs that can decrease or increase the production of a target protein involved in disease and remove disease-causing RNAs. In our clinical studies, we have demonstrated that we can administer our drugs by numerous different routes of administration, including oral, local, intrathecal and subcutaneous administration. The recent advances we have made in our technology have already translated into significant value in many of our newer drugs, which patients tolerate better and which are more potent than our earlier Generation 2 drugs. We continue to advance our RNA technology to create even better medicines and to expand the reach of our technology. We actively patent the advances we have made across all areas of our technology and the drugs we are developing. In this way, we have amassed a substantial intellectual property position that provides us with extensive protection for our drugs and our technology.

We have established alliances with a cadre of leading global pharmaceutical companies that are working alongside us in developing our drugs, advancing our technology and preparing to commercialize our products. Our partners bring resources and expertise that augment and build upon our internal capabilities. The depth of our knowledge and expertise with antisense technology provides us the flexibility to partner our drugs at what we believe is the optimal time to maximize the near- and long-term value of our drugs. We have distinct partnering strategies that we employ based on the specific program, therapeutic area and the expertise and resources our potential partners may bring to the collaboration. We have strategic partnerships with Biogen and AstraZeneca through which we can broadly expand our drug discovery efforts to new disease targets in specific therapeutic areas that are outside of our expertise or in which our partners can provide tools and resources to complement our drug discovery efforts. We also form early stage research and development partnerships that allow us to expand the application of our technology to new therapeutic areas. For example, we established a collaboration with Janssen, which brings together our RNA-targeted technology platform and Janssen’s expertise in autoimmune disorders and therapeutic formulation to discover and develop antisense drugs to treat autoimmune disorders in the gastrointestinal, or GI, tract. Additionally, we form development and commercialization partnerships that enable us to leverage our partner’s global expertise and resources needed to support large commercial opportunities. For example, we licensed IONIS-FXIRx to Bayer to develop and commercialize IONIS-FXIRx for the prevention of thrombosis. As a leader in the antithrombotic market, Bayer has the expertise, resources and commitment to broadly develop IONIS-FXIRx. Lastly, we also work with a consortium of companies that can exploit our drugs and technologies outside our primary areas of focus. We refer to these companies as satellite companies.

Through our partnerships, we have created a broad and sustaining base of potential license fees, upfront payments, milestone payments, royalties, and earn out payments while controlling our drug development expenses. We have the potential to earn significant revenue from all of our partnerships. Since 2007, we have received more than $1.7 billion in cash from upfront and licensing fees, equity purchase payments, milestone payments and research and development funding from our partnerships. We have the potential to earn nearly $12 billion in future milestone payments and licensing fees from our current partnerships. We also have the potential to share in the future commercial success of our inventions and drugs resulting from our partnerships through earn out or royalty arrangements.

Corporate Highlights in 2015 and early 2016

We formed a wholly owned subsidiary, Akcea Therapeutics, to develop and commercialize our lipid drugs, volanesorsen, IONIS-APOCIII-LRx, IONIS-APO(a)-LRx and IONIS-ANGPTL3-LRx.
We licensed IONIS-FXIRx to Bayer to develop and commercialize IONIS-FXIRx for the prevention of thrombosis.
We and AstraZeneca formed a strategic collaboration to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, primarily focused on targets in the kidney, and renal diseases.
We formed an alliance with Janssen to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal tract.
We received more than $320 million in payments from our partners in 2015.
We changed our name to Ionis Pharmaceuticals, Inc. in December 2015 and our stock now trades under the ticker symbol “IONS”.

Drug Development Highlights in 2015 and early 2016

We continued to make significant advances in our pipeline and completed target enrollment for three pivotal phase 3 studies, including:
CHERISH, a Phase 3 study evaluating nusinersen in children with SMA.
NEURO-TTR, a Phase 3 study evaluating IONIS-TTRRx in patients with FAP.
APROACH, a Phase 3 study evaluating volanesorsen in patients with FCS.
We and our partners reported positive data from 13 clinical studies. These data exemplify the broad applicability and potential for antisense drugs to provide therapeutic benefit for many different diseases. These data include:
Phase 2 data from two ongoing open-label studies in which infants and children with SMA treated with nusinersen experienced increases in muscle function scores. Additionally, there were no events of death or permanent ventilation reported in 2015 in nusinersen-treated infants in the ongoing Phase 2 clinical study.
Data from the ongoing open-label extension study of NEURO-TTR in which patients with FAP treated with IONIS-TTRRx for at least three months experienced reductions in TTR protein of up to 92 percent with a mean maximum (nadir) reduction of 76 percent compared to baseline.
Phase 2 data from an ongoing open-label, investigator-initiated study in patients with FAC and patients with wt-TTR treated with IONIS-TTRRx  for 12 months preliminarily evidencing disease stabilization and sustained TTR reductions.
Phase 2 data in which patients with high lipoprotein(a), or Lp(a), treated with IONIS-APO(a)Rx experienced reductions in Lp(a) of up to 94 percent.
4


Phase 1/2 data in which patients with high Lp(a) treated with IONIS-APO(a)-LRx experienced a greater than 30-fold increase in potency over IONIS-APO(a)Rx, the non-LICA Lp(a) drug. Patients also experienced dose-dependent reductions in Lp(a) of up to 97 percent and 99 percent after a single dose and multiple doses of IONIS-APO(a)-LRx, respectively.
Clinical and preclinical data in patients with cancer, including advanced/metastatic hepatocellular carcinoma and diffuse large B cell lymphoma, treated with IONIS-STAT3-2.5Rx evidencing antitumor activity.
Phase 2 data in which patients with type 2 diabetes treated with IONIS-PTP1BRx experienced statistically significant mean reductions in body weight and HbA1c (0.7 percentage point).
Phase 1 results in which healthy volunteers dosed with IONIS-ANGPTL3Rx experienced significant reductions of up to 93 percent in angiopoietin-like 3 protein, up to 63 percent in triglycerides and up to 46 percent in total cholesterol.
Phase 1 results in which healthy volunteers dosed with IONIS-PKKRx experienced significant, dose-dependent reductions of prekallikrein of up to 95 percent.
Phase 3 data from the FOCUS FH study evaluating Kynamro in patients with severe heterozygous familial hypercholesterolemia. This study met its primary endpoint with a statistically significant reduction of LDL-Cholesterol, or LDL-C.
We published clinical data from our novel lipid drugs, volanesorsen and IONIS-APO(a)Rx, in the New England Journal of Medicine and The Lancet, respectively.
The U.S. Food and Drug Administration, or FDA, granted volanesorsen orphan drug designation for the treatment of patients with FCS.
The European Medicines Agency, or EMA, granted IONIS-HTTRx orphan drug designation for the treatment of patients with Huntington’s Disease.
We, together with our partners, continued to advance our pipeline of drugs, initiating 11 clinical studies, including one Phase 3 study and six Phase 2 studies.

Drug Discovery and Development
 
Introduction to Drug Discovery
 
Proteins are essential working molecules in a cell. Almost all human diseases result from inappropriate protein production, improper protein activity or loss of a protein. Scientists use traditional drug discovery methods to design drugs to interact with the proteins in the body that are supporting or causing a disease. Antisense drugs are different from traditional small molecule drugs because antisense drugs can modify the production of proteins by targeting RNAs. In this way, antisense drugs can reduce the production of a disease-causing protein or increase the production of a protein that, when absent, causes disease. Antisense drugs also can treat disease by targeting and reducing RNAs that may be causing disease. RNAs are naturally occurring molecules in the body that primarily provide the information the cell needs to produce proteins. When our antisense drugs bind to the specific RNAs of a particular gene, they will ultimately alter the production of the protein encoded in the target gene or, in the case of disease-causing RNAs, degrade the RNA.

Our Development Projects
 
We are the leader in the discovery and development of an exciting class of RNA-targeted drugs called antisense drugs. With our proprietary drug discovery platform, we can rapidly identify drugs from a wealth of potential targets to treat a broad range of diseases. We focus our efforts in therapeutic areas where our drugs will work best, efficiently screening many targets in parallel and carefully selecting the best drugs. By combining this efficiency with our rational approach to selecting disease targets, we have built a large and diverse portfolio of drugs we designed to treat a variety of health conditions, with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological diseases, and cancer. We are developing antisense drugs for systemic, intrathecal and local delivery. We expect to continue to add new drugs to our pipeline, building a broad proprietary portfolio of drugs to treat many diseases and creating opportunities to generate substantial revenue. We also continue to improve our scientific understanding of our drugs, including how our drugs impact the biological processes of the diseases we target.

With our expertise in discovering and characterizing novel antisense drugs, our scientists can optimize the properties of our antisense drugs for use with particular targets. Our scientists have made significant advances in chemistries. Our Generation 2.0+ antisense drugs have increased potency and an improved side effect profile over our earlier generation drugs. Our scientists have further improved upon our second-generation chemistry with our Generation 2.5 chemistry, an advancement that further increases the potency of our drugs and broadens the tissues in which our drugs can work. We currently have four Generation 2.5 drugs in development, and we expect that some of our future drugs will also incorporate our Generation 2.5 chemistry. In addition to improving the chemical foundation of our drugs, we have also created LIgand-Conjugated Antisense, or LICA, technology, which we designed to enhance the delivery of our drugs to particular tissues. We believe that our LICA technology could further enhance the potency of our drugs. For example, our LICA technology directed toward liver targets produced a ten-fold increase in potency in preclinical studies in both our second-generation and our Generation 2.5 drugs. Our first clinical data from a LICA drug demonstrated an increase in potency that was more than 30-fold greater than what we observed with our non-LICA drug to the same target. We currently have eight second-generation LICA drugs in our pipeline, all of which we designed to inhibit targets in the liver. We expect we can also enhance some of our future drugs, including our Generation 2.5 drugs, with our LICA technology.
 
We have utilized our chemistry advancements to expand the therapeutic and commercial opportunities of our pipeline. These advancements, along with the manufacturing and analytical processes that are the same for all of our drugs, shorten our timeline from initial concept to the first human dose when compared to small molecule drugs.
5



The above table lists our pipeline, including the disease indications, our development partner if the drug is partnered, and the development status of each drug. Typically, the names of our drugs incorporate the target of the drug, such as IONIS-TTRRx. In this case, TTR is the target of the drug. Unless indicated otherwise, the majority of the drugs in our pipeline are Generation 2.0+ antisense drugs. We differentiate our Generation 2.5 drugs by adding a 2.5 notation at the end of the drug name, such as IONIS-DMPK-2.5Rx. We differentiate our LICA drugs by adding an L at the end of the drug name, such as IONIS-APO(a)-LRx. We also plan to add Generation 2.5 drugs that incorporate our LICA technology. We will identify these drugs by the addition of both the 2.5 and L into the drug name. As the drugs in our pipeline advance in clinical development, we will adopt nonproprietary names given to each drug from the United States Adopted Names Council. For example, nusinersen is a nonproprietary name that we obtained for ISIS-SMNRx. Once we or our partners establish a brand name, we will adopt the brand name.

With a pipeline as large and advanced as ours, we have a number of clinical events each year as we initiate new clinical studies, complete and report data from clinical studies and add new drugs to our pipeline. In 2016, we plan to initiate multiple clinical studies, report data on multiple drugs and add three to five new drugs into development.

Our Phase 3 Drugs
We have three drugs for which we are conducting pivotal Phase 3 studies: nusinersen, IONIS-TTRRx and volanesorsen. Each of these drugs has the potential to transform the treatment of patients with an orphan disease, and we believe all three of these drugs are close to commercialization. In 2015,we completed target enrollment in a Phase 3 study for each of these drugs. We expect to have Phase 3 data for all three drugs in the first half of 2017 and potentially file for marketing authorization in the 2017/2018 timeframe if the data are positive.

Nusinersen – Nusinersen is an antisense drug we and Biogen are developing to treat patients with spinal muscular atrophy, or SMA. SMA is a severe motor-neuron disease that is the leading genetic cause of infant mortality. SMA occurs from a deletion or mutation of a gene responsible for producing a protein critical for normal cellular function. We designed nusinersen to compensate for this underlying genetic defect by increasing the production of the protein from a closely related gene. In January 2012, we and Biogen entered into an alliance that provides Biogen with an option to develop and commercialize nusinersen. We discovered nusinersen in collaboration with Dr. Adrian R. Krainer at Cold Spring Harbor Laboratory.
6


 SMA affects approximately 30,000 to 35,000 patients in the United States, Europe and Japan. One in 50 people, approximately six million people in the United States, carry the gene mutation that causes SMA. Carriers experience no symptoms and do not develop the disease. When both parents are carriers, however, there is a one in four chance their child will have SMA. SMA is caused by a loss of, or defect in, the survival motor neuron 1, or SMN1, gene leading to a decrease in the survival motor neuron, or SMN protein. SMN is critical to the health and survival of nerve cells in the spinal cord that are responsible for neuro-muscular growth and function. The severity of SMA correlates with the amount of SMN protein produced in motor neurons. Infants with Type I SMA, the most severe life-threatening form, produce very little SMN protein and have a significantly shortened life expectancy of less than two years according to natural history studies that researchers have conducted in patients with SMA. In a 2009 paper by Rudnik-Schöneborn, the median age for event-free survival in infants with Type I SMA was 6.2 months. In a contemporaneous study published in 2014 by the Pediatric Neuromuscular Clinical Research group, or PNCR, the median age for event-free survival in infants with two copies of SMN2 was 10.5 months. Children with Type II SMA generally have more copies of the SMN2 gene and have greater amounts of SMN protein than Type 1 infants but still have a shortened lifespan. Type II SMA patients are never able to walk. Children with Type III SMA have a normal lifespan but incur additional life-long physical disabilities as they grow.

We are evaluating nusinersen in a broad Phase 3 program. We have completed target enrollment in the Phase 3 study, CHERISH, in children with SMA and expect to complete enrollment in the Phase 3 study, ENDEAR, in infants with SMA in the second quarter of 2016. CHERISH is a randomized, international, double-blind, sham-procedure controlled fifteen month study in approximately 120 children with SMA who are non-ambulatory. We designed this study to support an application for marketing authorization of nusinersen in children with SMA. CHERISH is evaluating the efficacy and safety of a 12 mg dose of nusinersen with a primary endpoint of a change in the Hammersmith Functional Motor Scale-Expanded, or HFMSE, a validated method to measure changes in muscle function in children with SMA. We also included additional efficacy endpoints in the study. ENDEAR is a randomized, international, double-blind, sham-procedure controlled, thirteen month study in approximately 110 infants diagnosed with SMA. We designed this study to support an application for marketing authorization of nusinersen in infants with SMA. ENDEAR is evaluating the efficacy and safety of a 12 mg dose of nusinersen with a primary endpoint of survival or time to permanent ventilation. We also included additional efficacy endpoints in the study. We plan to report data from both ENDEAR and CHERISH in 2017.

The FDA has granted Orphan Drug Designation and Fast Track Status to nusinersen for the treatment of patients with SMA. The EMA has granted Orphan Drug Designation to nusinersen for the treatment of patients with SMA.

IONIS-TTRRxIONIS-TTRRx is an antisense drug we and GSK are developing to treat patients with all forms of TTR amyloidosis. TTR amyloidosis is a severe, progressive and fatal disease. In all forms of TTR amyloidosis TTR protein forms amyloid deposits in various tissues and organs, including peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to organ failure and eventually death. Together with GSK, we are developing IONIS-TTRRx as one drug with one product presentation, in one broad development plan for the treatment of patients with all forms of TTR amyloidosis. We designed IONIS-TTRRx to be administered as one subcutaneous injection, once a week for all TTR amyloidosis patients.

TTR amyloidosis is a single disease that clinicians characterize into three forms that can have multiple overlapping clinical manifestations: FAP, FAC and wt-TTR. FAP affects approximately 10,000 patients worldwide. FAP patients primarily have TTR build up in the peripheral nervous system, but can also have significant TTR build up in multiple organs. FAP is a painful, fatal disease that ultimately leads to multi-organ failure and death within five to 15 years after symptom onset and diagnosis. FAC affects approximately 40,000 patients worldwide and wt-TTR amyloidosis affects approximately 200,000 patients worldwide. While both FAC and wt-TTR differ in the genetic cause of TTR amyloidosis, both diseases progress in similar ways. Patients with FAC and wt-TTR amyloidosis have TTR build up in the heart muscle and succumb to heart failure within three to five years after symptom onset and diagnosis. TTR amyloidosis is fatal and there are limited therapeutic options to treat patients with this disease.

We are evaluating IONIS-TTRRx in a broad Phase 3 development program. We have completed target enrollment in the NEURO-TTR study which is a randomized, double-blind, placebo-controlled, international, Phase 3 study of IONIS-TTRRx in FAP patients. We plan to report data from this study in 2017. We designed this study to support an application for marketing authorization of IONIS-TTRRx in patients with FAP. Our study is measuring the effects of IONIS-TTRRx on neurological dysfunction and on quality-of-life. In 2016, our partner, GSK, plans to initiate a Phase 3 outcome study, CARDIO-TTR, in all forms of TTR amyloid cardiomyopathy, including both FAC and wt-TTR amyloidosis. In 2016, GSK is also planning to initiate a small Phase 3 study in Japan in patients with FAP to support Japanese regulatory filings.

The FDA has granted Orphan Drug Designation and Fast Track Status to IONIS-TTRRx for the treatment of patients with FAP. The EMA has granted Orphan Drug Designation to IONIS-TTRRx for the treatment of patients with all types of TTR amyloidosis.

Volanesorsen – Volanesorsen is an antisense drug we and Akcea are developing to treat patients with FCS and patients with FPL. We designed volanesorsen to reduce ApoC-III, a protein the liver produces that regulates triglyceride metabolism in the blood. Physicians associate higher levels of ApoC-III with a higher risk of cardiovascular disease. Akcea is responsible for developing and commercializing volanesorsen.

Both FCS and FPL are ultra-orphan diseases, each affecting an estimated 3,000 to 5,000 patients worldwide. FCS is often associated with triglyceride levels higher than 2,000 mg/dL. Because of their extremely high triglyceride levels, FCS patients are at significant risk of many serious health conditions, including frequent episodes of pancreatitis, which can require hospitalization and can be life-threatening. FPL is associated with the inability of a patient to store fat, resulting in high triglyceride levels that are often above 1,000 mg/dL and increased risk for pancreatitis. In addition, most patients with FPL have diabetes and other metabolic abnormalities. Current treatment options do not reduce triglyceride levels enough to reduce the risk of serious illness in patients with FCS or FPL. We believe that the robust triglyceride reduction and the improvements in glucose control we observed in our Phase 2 program support our evaluation of volanesorsen in both of these patient populations.
7


We are evaluating volanesorsen in a broad Phase 3 development program. We have completed target enrollment in the APPROACH study, which is a randomized, double-blind, placebo-controlled, international Phase 3 study in patients with FCS. We are also evaluating volanesorsen in a Phase 3 study, BROADEN, in patients with FPL. BROADEN is a randomized, double-blind, placebo-controlled, international study in patients with FPL. The primary endpoint of both APPROACH and BROADEN is percent change in fasting triglycerides from baseline after three months of dosing with volanesorsen.

The FDA and EMA have granted Orphan Drug Designation to volanesorsen for the treatment of patients with FCS.

Akcea Therapeutics: Our Wholly Owned Subsidiary to Develop and Commercialize Drugs for Cardiometabolic Disorders

Akcea Therapeutics, our wholly owned subsidiary, is a company focused on developing and commercializing potentially transformative medicines for people with serious cardiometabolic diseases caused by lipid disorders. This report includes financial information for this separate business segment in Note 7, Segment Information and Concentration of Business Risk, in the Notes to the Consolidated Financial Statements. Since its formation in late 2014, Akcea has advanced its portfolio of development-stage drugs covering multiple targets and diseases. We believe each drug in the Akcea portfolio has the potential to treat several diseases with substantial overlap in the treating physician community, particularly among lipid disease thought leaders. Akcea is building expertise in lipids and cardiometabolic diseases which it can leverage across its entire portfolio.

Akcea plans to develop and successfully commercialize globally a portfolio of our cardiometabolic drugs. These drugs include volanesorsen, IONIS-APOCIII-LRx, IONIS-APO(a)-LRx and IONIS-ANGPTL3-LRx. In 2015, Akcea enhanced its development and commercial capabilities by hiring several seasoned professionals whose collective experience includes multiple rare disease launches over two decades and deep clinical and commercial experience focused primarily on lipid disorders, cardiovascular disease and endocrinology.

Also in 2015, Akcea advanced the commercial development activities for volanesorsen in patients with FCS. These activities include:

Increasing the understanding of the patients and treating physicians who take care of these patients;
Increasing awareness of FCS;
Enhancing the speed and quality of diagnosis; and
Understanding the burden of disease.

Akcea plans to leverage these same commercialization activities across its portfolio to commercialize its drugs for rare populations. Akcea may establish relationships with large pharmaceutical companies to co-commercialize select Akcea drugs for large patient populations that require a substantial sales force.

In 2016, Akcea plans to prepare the regulatory filings for volanesorsen so it can file for marketing authorization as quickly as possible after reporting Phase 3 FCS data in 2017, assuming the data are positive. Akcea also plans to continue to build the development, regulatory, and commercial infrastructure required to commercialize volanesorsen, including a specialized clinical field force and physician and patient support teams. Akcea intends to build these functions in the United States and Europe first.

We granted Akcea exclusive rights to develop and commercialize volanesorsen, IONIS-APOCIII-LRx, IONIS-APO(a)-LRx, and IONIS-ANGPTL3-LRx as part of its formation. Akcea is responsible for globally developing and commercializing these drugs. Ionis will provide business support services to Akcea and Akcea will compensate Ionis for providing such services. Below is Akcea’s product pipeline that includes the disease type, disease indication and the stage of development for each drug.

Akcea’s Cardiometabolic Disease Pipeline

8



Volanesorsen – Volanesorsen is an antisense drug we and Akcea are developing to treat patients with FCS and FPL. For more information on the development plan for volanesorsen see the drug description under Our Phase 3 Drugs.

IONIS-APO(a)-LRx IONIS-APO(a)-LRx is a LICA drug we designed to reduce apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a), or Lp(a). Lp(a) is an independent risk factor for cardiovascular disease. Physicians associate high levels of Lp(a) with an increased risk of atherosclerosis, coronary heart disease, heart attack and stroke. IONIS-APO(a)-LRx is the first and only clinical program to selectively reduce Lp(a) in patients by inhibiting apo(a).

Unlike other cardiovascular risk factors, Lp(a) levels are genetically determined and remain constant throughout the life of the individual. This means that patients who have high Lp(a) levels have been exposed to high levels of Lp(a) for their entire life. The European Atherosclerosis Society recommends that Lp(a) be less than or equal to 50 mg/dL. Diet and lifestyle changes have little impact on Lp(a) levels and current therapies do not adequately reduce Lp(a) to acceptable levels in patients with elevated Lp(a). Even patients who can control their LDL-C remain at high-risk of cardiovascular events if they have high levels of Lp(a). As a result, there is a significant need for a highly specific drug that can lower Lp(a).

Physicians characterize calcific aortic valve stenosis, or CAVS, as the progressive restriction of a patient’s supply of oxygenated blood to the rest of the patient’s body due to calcium deposits on the aortic valve. Aortic valve replacement, or AVR, is the only option once CAVS progresses to a severe stage and/or the patient is symptomatic with fainting, shortness of breath, or congestive heart failure. Patients with elevated Lp(a) levels experience a faster progression of CAVS leading to the need for AVR. Therefore, an effective medical therapy to reduce the progression of CAVS and delay the need for AVR could potentially improve symptoms, enhance heart function and reduce mortality in patients with CAVS.

We completed a Phase 1/2 study for IONIS-APO(a)-LRx in subjects with high Lp(a). We and Akcea plan to develop IONIS-APO(a)-LRx in a broad program that addresses near, mid and long-term commercial opportunities that include patients with recurrent cardiovascular events and high Lp(a); patients with CAVS and high Lp(a); and patients with cardiovascular disease and high Lp(a).

IONIS-ANGPTL3-LRx IONIS-ANGPTL3-LRx is a LICA drug we designed to reduce angiopoietin-like 3 protein, or ANGPTL3, an independent risk factor for cardiovascular disease. ANGPTL3 is a glycoprotein that is principally expressed in the liver and regulates lipid, glucose and energy metabolism. People with elevated levels of ANGPTL3 have high LDL-C and triglyceride levels, which physicians associate with an increased risk of premature heart attacks, increased arterial wall thickness and multiple metabolic abnormalities, such as insulin resistance. In contrast, people with lower levels of ANGPTL3 have lower LDL-C and triglyceride levels. We designed IONIS-ANGPTL3-LRx to treat multiple dyslipidemias from rare lipid disorders to broader cardiometabolic disease, including mixed dyslipidemia. Akcea is responsible for developing and commercializing IONIS-ANGPTL3-LRx.

Patients with mixed dyslipidemia often have elevated LDL-C, and triglyceride levels. These patients frequently also have low levels of HDL. A growing body of clinical data demonstrates an association between elevated cholesterol and triglycerides and increased cardiovascular risk. Further, the increasing obesity rates throughout the world have fueled the development of metabolic syndrome, a disorder characterized by dyslipidemia, loss in insulin sensitivity and increased fat accumulation in the liver.

Genome-wide association studies have confirmed the association of mutations in ANGPTL3 with improvements in lipid levels. Patients with dyslipidemia often have multiple cardiovascular and metabolic risk factors that remain challenging to treat. Despite existing therapies, there remains an unmet need for a therapy that could significantly decrease multiple cardiovascular risk factors, such as LDL-C and triglycerides. Our preclinical data suggests that reducing ANGPTL3 could improve lipid parameters, including LDL-C, triglycerides, and total cholesterol, as well as metabolic parameters, such as insulin sensitivity.

Akcea is evaluating IONIS-ANGPTL3-LRx in a randomized, placebo-controlled, dose-escalation Phase 1/2 study in healthy volunteers with elevated triglycerides and in patients with familial hypercholesterolemia.

Cardiovascular Franchise

Cardiovascular disease is an area of focus for us. Our cardiovascular franchise includes the drugs Akcea is developing that we describe above and other drugs. The drugs in our cardiovascular franchise target all the key components of cardiovascular disease, including various atherogenic lipids, inflammation and thrombosis. Volanesorsen is our most advanced drug in this franchise.

IONIS’ Cardiovascular Disease Pipeline
 
IONIS-TTRRxIONIS-TTRRx is an antisense drug we designed to reduce the production of TTR to treat patients with all forms of TTR amyloidosis, including the cardiomyopathy forms in which TTR protein accumulates in heart muscle leading to heart failure. For more information on the development plan for IONIS-TTRRx see the drug description under Our Phase 3 Drugs.
9


IONIS-FXIRxIONIS-FXIRx is an antisense drug we designed to reduce the production of Factor XI. Factor XI is important in the growth of blood clots. High levels of Factor XI increase the risk of thrombosis, which is the formation of a blood clot inside blood vessels. Thrombosis can cause heart attacks and strokes. People who are deficient in Factor XI have a lower incidence of these events with minimal increase in bleeding risk. Although currently available anticoagulants reduce the risk of thrombosis, physicians associate these anticoagulants with increased bleeding, which can be fatal. Given the mechanism of Factor XI inhibition, IONIS-FXIRx has the potential for physicians to use it broadly as an antithrombotic in many different therapeutic settings for which there is a need for additional safe and well tolerated antithrombotic drugs.

In May 2015, we exclusively licensed IONIS-FXIRx to Bayer. Bayer plans to evaluate the therapeutic profile of IONIS-FXIRx in patients for whom currently available antithrombotics may not be used, such as in patients with a high risk of bleeding due to multiple co-morbidities. After successful completion of ongoing activities at Ionis, Bayer will assume all global development, regulatory and commercialization responsibilities for IONIS-FXIRx.

We completed a Phase 2 open-label, comparator-controlled global study evaluating IONIS-FXIRx in patients undergoing total knee replacement surgery. The study compared the safety and activity of IONIS-FXIRx to enoxaparin. In this study patients treated with 300 mg of IONIS-FXIRx experienced a seven-fold lower rate of venous thromboembolic events, such as blood clots in a deep vein or in a lung, compared to those patients treated with enoxaparin. The data from this study was published in the New England Journal of Medicine in December 2014.

We are currently evaluating IONIS-FXIRx in a Phase 2 study in patients with end-stage renal disease on hemodialysis. We designed this study to further characterize the profile of IONIS-FXIRx and to provide essential data for Bayer’s future clinical development program for IONIS-FXIRx.

IONIS-APO(a)-LRxIONIS-APO(a)-LRx is a LICA drug we designed to reduce apolipoprotein(a) in the liver to offer a direct approach for reducing Lp(a). We and Akcea are developing IONIS-APO(a)-LRx for patients with high Lp(a). For more information on the development plan for IONIS-APO(a)-LRx, see the drug description under Akcea Therapeutics.

IONIS-ANGPTL3-LRx IONIS-ANGPTL3-LRx is a LICA drug we designed to reduce ANGPTL3, an independent risk factor for cardiovascular disease. We and Akcea are developing IONIS-ANGPTL3-LRx for patients with mixed dyslipidemias. For more information on the development plan for IONIS-ANGPTL3-LRx, see the drug description under Akcea Therapeutics.

Severe and Rare Disease Franchise

Our severe and rare disease franchise is the largest franchise in our pipeline. We are discovering and developing antisense drugs to treat patients with severe and rare and neurological diseases who need new treatment options.  We believe our antisense technology could offer effective therapies for these patients. According to the National Institutes of Health, or NIH, there are approximately 5,000 to 8,000 rare diseases and more than 600 neurological diseases, many life-threatening or fatal. Unfortunately, patients with many of these severe and rare diseases have few effective therapies available. Since most of these diseases are genetic or have a genetic component, parents often pass the disease to their children, creating a legacy of the disease and resulting in profound effects on the family. We are evaluating nusinersen, the most advanced neurological drug in our pipeline, in two Phase 3 studies to treat infants and children with SMA.

Due to the severe nature of these diseases and the lack of available treatments, there is an opportunity for more flexible and efficient development paths to the market. This means that, in some cases, the studies necessary for us to demonstrate proof-of-concept with a particular drug may also be the studies that complete our marketing registration package, thereby providing us with a relatively rapid path to market for potential new treatments for these devastating and often fatal diseases.

IONIS’ Severe and Rare Disease Pipeline

10


Kynamro – Kynamro (mipomersen sodium) injection is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet, to reduce low density lipoprotein-cholesterol, or LDL-C, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol in patients with HoFH. Kynamro is approved for use in patients with HoFH in the United States and several other countries.

Nusinersen – Nusinersen is an antisense drug we designed to treat patients with SMA. SMA is a severe motor-neuron disease that is the leading genetic cause of infant mortality. Together with Biogen, we are developing nusinersen to treat all forms of SMA. For more information on the development plan for nusinersen, see the drug description under Our Phase 3 Drugs.

IONIS-TTRRx – IONIS-TTRRx is an antisense drug we designed to treat all forms of TTR amyloidosis. TTR amyloidosis is a severe, progressive and fatal disease. For more information on the development plan for IONIS-TTRRx see the drug description under Our Phase 3 Drugs.

Volanesorsen – Volanesorsen is an antisense drug we and Akcea are developing to treat patients with FCS and FPL. For more information on the development plan for volanesorsen see the drug description under Our Phase 3 Drugs.

IONIS-DMPK-2.5Rx IONIS-DMPK-2.5Rx is an antisense drug we designed to reduce the toxic dystrophia myotonica-protein kinase, or DMPK, RNA to treat patients with myotonic dystrophy type 1, or DM1. Together with Biogen, we are developing IONIS-DMPK-2.5Rx to treat patients with DM1.

DM1 is a genetic neuromuscular disease caused by a defect in the DMPK gene which causes the accumulation of toxic DMPK RNA. Physicians characterize DM1 by progressive muscle atrophy, weakness, disabling muscle spasms and prolonged muscle contractions. DM1 also affects many other organs within the body and patients can also experience insulin insensitivity, cataracts and infertility. Currently, there are no disease-modifying therapies for patients with DM1 and currently available treatments are intended only to manage symptoms.

We are evaluating IONIS-DMPK-2.5Rx in a randomized, placebo-controlled, dose-escalation Phase 1/2 clinical study in patients with DM1.

The FDA has granted Orphan Drug Designation for IONIS-DMPK-2.5Rx for the treatment of patients with DM1.

IONIS-HTTRxIONIS-HTTRx is an antisense drug we designed to reduce the production of the huntingtin, or HTT, protein, which is the genetic cause of Huntington's disease, or HD. We are collaborating with Roche to develop IONIS-HTTRx to treat patients with HD.

HD is a rare, genetic, progressive neurological disease resulting in deterioration in mental abilities and physical control. HD is a triplet repeat disorder and is one of a large family of genetic diseases in which the body mistakenly repeats certain gene sequences. The resulting HTT protein gradually damages neurons in the brain. Symptoms of HD usually appear between the ages of 30 to 50 years and continually worsen over a 10 to 25 year period. Ultimately, the weakened individual succumbs to pneumonia, heart failure or other complications. Presently, there is no effective disease-modifying treatment, and current approaches only focus on managing the severity of some disease symptoms.

We are evaluating IONIS-HTTRx in a randomized, placebo-controlled, dose escalation, Phase 1/2 clinical study in patients with early stage HD.

The FDA and EMA have granted Orphan Drug Designation for IONIS-HTTRx to treat patients with HD.

IONIS-SOD1RxIONIS-SOD1Rx is an antisense drug we designed to reduce the production of superoxide dismutase 1, or SOD1, which is the best understood genetic cause of familial amyotrophic lateral sclerosis, or ALS. We are collaborating with Biogen to develop IONIS-SOD1Rx to treat patients with an inherited form of ALS, SOD1-ALS.

ALS is a rare, fatal neurodegenerative disorder. Patients with ALS suffer progressive degeneration of the motor neurons, which results in a declining quality of life and ultimately death. The second most common familial form of ALS is SOD1-ALS, in which patients have a mutation in the SOD1 gene that causes a progressive loss of motor neurons. As a result, patients with SOD1-ALS experience muscle weakness, loss of movement, difficulty in breathing and swallowing and eventually succumb to their disease. Currently, treatment options for patients with ALS are extremely limited with no drugs that significantly slow disease progression.

We are evaluating IONIS-SOD1Rx in a randomized, placebo-controlled, dose escalation, Phase 1/2 clinical study in patients with ALS, including patients with SOD1-ALS.

IONIS-APO(a)-LRxIONIS-APO(a)-LRx is a LICA drug we designed to reduce apolipoprotein(a) in the liver to offer a direct approach for reducing Lp(a). We and Akcea are developing IONIS-APO(a)-LRx for patients with recurrent cardiovascular disease and high Lp(a). For more information on the development plan for IONIS-APO(a)-LRx, see the drug description under Akcea Therapeutics.

IONIS-ANGPTL3-LRx IONIS-ANGPTL3-LRx is a LICA drug designed to reduce ANGPTL3, an independent risk factor for cardiovascular disease. We and Akcea are developing IONIS-ANGPTL3-LRx for patients with mixed dyslipidemias. For more information on the development plan for IONIS-ANGPTL3-LRx, see the drug description under Akcea Therapeutics.
11


IONIS-PKKRxIONIS-PKKRx is an antisense drug we designed to reduce the production of prekallikrein, or PKK, to treat patients with hereditary angioedema, or HAE. HAE is a rare genetic disease that is characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea and can be fatal if swelling occurs in the larynx. PKK plays an important role in acute attacks of HAE. By inhibiting the production of PKK, IONIS-PKKRx could be an effective prophylactic approach to preventing HAE attacks. In patients with frequent or severe attacks, doctors may use prophylactic treatment approaches to prevent and reduce the severity of HAE attacks. However, current prophylactic treatment approaches are very limited and have significant tolerability issues leaving patients with few therapeutic options.

We have completed a Phase 1 study evaluating IONIS-PKKRx in healthy volunteers.

Cancer Franchise
 
Cancer is an area of significant unmet medical need. Cancer is an extremely complex disease that involves a large number of targets. With our technology, we can evaluate a very broad and diverse range of targets and identify their involvement in different types of cancers. Using the information we gain early in research on each of these targets, we can quickly identify promising targets for anti-cancer drugs. We preferentially select anti-cancer targets that provide a multi-faceted approach to treating cancer.

Our cancer franchise consists of anti-cancer antisense drugs that act upon biological targets associated with cancer progression and/or treatment resistance. We have a strategic alliance with AstraZeneca, which includes an anti-cancer collaboration that expands our anti-cancer efforts and supports an aggressive and broad clinical development plan for IONIS-STAT3-2.5Rx. AstraZeneca brings significant experience that enables the identification of novel genetic and epigenetic targets for cancer. Combining AstraZeneca’s expertise with our drug discovery technology, we plan to expand our cancer franchise with a number of promising new anti-cancer targets.
 
Our Generation 2.5 chemistry enhances the potency and effectiveness of our antisense drugs, and potentially allows us to extend the applicability of our technology to cancers that are difficult to treat. For instance, data from a Phase 1/2 clinical study of IONIS-STAT3-2.5Rx showed evidence of antitumor activity in patients with cancer, including advanced/metastatic hepatocellular carcinoma.

IONIS’ Oncology Pipeline

IONIS-AR-2.5Rx IONIS-AR-2.5Rx is an antisense drug we designed to treat patients with prostate cancer by reducing the production of all known forms of androgen receptor, or AR, including variants of the AR gene. Prostate cancer is the second leading cause of cancer deaths in American men. Prostate cancer growth, proliferation and progression are all androgen-dependent, and AR function is involved in disease progression at all stages of prostate cancer. For patients diagnosed with metastatic prostate cancer, current treatments largely involve opposing the action of androgens by blocking the AR or removing circulating androgens. Although androgen deprivation therapy approaches are initially effective in delaying disease progression, patients with metastatic prostate cancer will progress in their disease. Resistance to current therapies is frequent and can occur through a variety of mechanisms, including the activation of AR signaling in tumor cells through the amplification, over expression and mutation of the AR gene. Because IONIS-AR-2.5Rx can inhibit the production of all known forms of AR, we believe that this drug has the potential to be useful in treating patients with all stages of prostate cancer, including those who are resistant to current therapies.

AstraZeneca completed an open-label, dose-escalation, Phase 1/2 clinical study of IONIS-AR-2.5Rx in patients with advanced tumors for which the androgen receptor pathway is potentially a contributing factor. We plan to continue developing IONIS-AR-2.5Rx, independent of AstraZeneca.

IONIS-STAT3-2.5RxIONIS-STAT3-2.5Rx, also referred to as AZD9150, is an antisense drug we designed to reduce the production of signal transducer and activator of transcription 3, or STAT3, to treat patients with cancer. IONIS-STAT3-2.5Rx is a part of our collaboration with AstraZeneca to discover and develop anti-cancer drugs. We believe the significant potency we observed in our preclinical studies with IONIS-STAT3-2.5Rx broadens the therapeutic opportunities for IONIS-STAT3-2.5Rx into many different types of cancer where STAT3 is implicated.

STAT3 is a protein involved in the translation of key factors critical for tumor cell growth and survival. STAT3 is over-active in a variety of cancers, including brain, lung, breast, bone, liver and multiple myeloma. Physicians believe that overactivity in STAT3 prevents cancer cell death and promotes tumor cell growth.

We and AstraZeneca have evaluated IONIS-STAT3-2.5Rx in patients with advanced metastatic hepatocellular carcinoma and advanced lymphoma. AstraZeneca is evaluating IONIS-STAT3-2.5Rx in combination with MEDI4736, AstraZeneca's investigational anti-PD-L1 drug, in patients with head and neck cancer. AstraZeneca also plans to start an additional clinical study evaluating IONIS-STAT3-2.5Rx in combination with MEDI4736 in patients with diffuse large B cell lymphoma.
12


Metabolic Franchise
 
Metabolic disorders are chronic diseases that affect millions of people. There is a significant need for new therapies for these patients. According to the Centers for Disease Control and Prevention, diabetes affects more than 29 million people in the United States, or nine percent of the population, with type 2 diabetes constituting 90 to 95 percent of those cases.
 
We designed the majority of our drugs in our metabolic disease franchise to be effective alone or when added to existing therapies to treat metabolic diseases, such as diabetes. One hurdle for traditional drug development is that most traditional drugs cannot selectively target a disease-causing protein without also affecting closely related proteins, which often results in unwanted side effects. We design our antisense drugs to target the gene responsible for producing the disease-causing protein while avoiding unwanted effects on closely related proteins, thereby reducing the risk of side effects.
 
We have reported positive Phase 2 data from IONIS-GCGRRx and IONIS-PTP1BRx, the most advanced drugs in our metabolic franchise. We designed these two drugs and our third drug, IONIS-GCCRRx, to act upon targets in the liver or fat tissue through a distinct mechanism to improve insulin sensitivity, reduce glucose production, or affect other metabolic aspects of this complex disease. In addition to our work in diabetes, we are also evaluating other metabolic syndromes, including obesity and nonalcoholic steatohepatitis, or NASH. Obesity has reached global epidemic proportions in both adults and children. According to the World Health Organization, in 2014, there were more than 600 million adults over the age of 18 who were obese and in 2013, there were 42 million children under the age of five who were overweight or obese. Obesity is a major risk factor for a number of chronic diseases, including type 2 diabetes, dyslipidemia, hypertension and cardiovascular diseases. Despite the growing epidemic, there are very few weight loss drugs that have been approved to treat patients with obesity. Although many anti-obesity drugs have entered development, most of them have not been approved due to their adverse effects in the CNS and/or heart. There is an unmet medical need for drugs that can cause weight loss by acting on peripheral tissues without causing cardiac or CNS related side effects. In 2015, we initiated a Phase 2 clinical study evaluating IONIS-FGFR4Rx in patients who are obese. Currently, it is estimated that two to three percent of the general population have NASH. However, with the growing obesity epidemic, the number of patients with NASH should also continue to rise. About 20 percent of NASH patients are reported to develop cirrhosis, and 30 to 40 percent of patients with NASH cirrhosis experience liver-related death. IONIS-DGAT2Rx is an antisense drug we designed to treat patients with NASH.

IONIS’ Metabolic Disease Pipeline

IONIS-GCGRRxIONIS-GCGRRx is an antisense drug we designed to reduce the production of glucagon receptors, or GCGR, to treat patients with type 2 diabetes. GCGR is a receptor for the hormone glucagon. Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose, particularly in type 2 diabetes. We are developing IONIS-GCGRRx to provide better glucose control for patients with type 2 diabetes. Given the unique mechanism of action, we believe that physicians could use IONIS-GCGRRx in diabetic patients with severe hyperglycemia who are not controlled with current treatments and who could benefit from a drug that significantly decreases glucose levels and preserves pancreatic function.

Although glucose is an important source of energy for people’s bodies and is vital to people’s health, uncontrolled increases in glucose can lead to serious health problems, such as diabetes. In patients with advanced diabetes, uncontrolled glucagon action can lead to a significant increase in blood glucose level. In addition, reducing GCGR produces more active glucagon-like peptide, or GLP-1, a hormone that preserves pancreatic function and enhances insulin secretion.

We completed a double-blind, randomized, placebo-controlled, Phase 2 study of IONIS-GCGRRx in patients with type 2 diabetes who were poorly controlled on stable metformin therapy. We have initiated a second Phase 2 study of IONIS-GCGRRx in patients with type 2 diabetes to identify the optimal dose and schedule to achieve glucose control with manageable glucagon receptor-related liver enzyme elevations.

IONIS-GCCRRx- IONIS-GCCRRx is an antisense drug we designed to reduce the production of glucocorticoid receptor, or GCCR, to treat patients with type 2 diabetes. Glucocorticoid hormones affect a variety of processes throughout the body, including the production of liver glucose and fat storage. Excessive GCCR activity in the liver and fat is associated with obesity, insulin resistance and glucose intolerance.

Physicians recognize that inhibiting GCCR is an attractive strategy for improving glycemic and lipid control in patients with type 2 diabetes. However, the side effects associated with systemic GCCR inhibition have challenged traditional drug developers. Targeted reduction of GCCR in the liver and fat tissues with antisense drugs is an attractive therapeutic approach because it can lower glucose and lipids without causing potential side effects associated with systemic GCCR inhibition.

We completed a Phase 2 study of IONIS-GCCRRx in patients with type 2 diabetes.

IONIS-PTP1BRxIONIS-PTP1BRx is an antisense drug we designed to reduce the production of protein tyrosine phosphatase-1B, or PTP-1B, to treat patients with type 2 diabetes. PTP-1B is a phosphatase that negatively regulates insulin receptor signaling and is responsible for turning off the activated insulin receptor. Reducing PTP-1B enhances insulin activity. We designed IONIS-PTP1BRx to increase the body's sensitivity to the natural hormone, insulin, resulting in better glucose control for patients with type 2 diabetes. Because of its unique mechanism, IONIS-PTP1BRx may help treat patients with type 2 diabetes without causing weight gain or hypoglycemia, also known as low blood sugar.
13



Scientists have long recognized PTP-1B as an attractive target for treating diabetes. However, efforts to develop drugs that target PTP-1B have been challenging due to the structural similarities among closely related protein phosphatases. Targeted reduction of PTP-1B with an antisense drug represents an ideal therapeutic approach because we design our drugs to specifically reduce the PTP-1B mRNA, without affecting mRNAs of other protein phosphatases. This approach eliminates the off-target side effects observed with traditional small-molecule drugs.

We believe that physicians may use IONIS-PTP1BRx in combination with most of the other commonly used diabetes drugs, including insulin, GLP-1 agonists, and more traditional drugs like metformin, to treat patients with diabetes. The clinical development plan for IONIS-PTP1BRx focuses on two types of diabetic patients. The first type are those who are inadequately controlled on insulin, helping them utilize insulin more efficiently and the second type are those who are beginning to fail oral therapies, extending the time they have before becoming dependent on insulin.

We have completed a randomized, double-blind, placebo-controlled, Phase 2 study of IONIS-PTP1BRx study in obese patients with type 2 diabetes taking metformin or metformin plus sulfonylurea.

IONIS-FGFR4Rx IONIS-FGFR4Rx is an antisense drug we designed to reduce the production of fibroblast growth factor receptor 4, or FGFR4, to treat obese patients. FGFR4 is expressed in the liver and fat tissues, and plays an important role regulating fat burning and body weight. Reducing FGFR4 decreases the body's ability to store fat while it simultaneously increases fat burning and energy expenditure. Many anti-obesity drugs act in the brain to suppress appetite, commonly resulting in central nervous system, or CNS, side effects. However, IONIS-FGFR4Rx does not distribute to the brain or CNS and therefore should not produce any CNS side effects. IONIS-FGFR4Rx is the first drug in our metabolic franchise to treat obesity and utilizes technology we in-licensed from Verva Pharmaceuticals Ltd.

We completed a Phase 1 study of IONIS-FGFR4Rx in healthy volunteers. We initiated a double blind, placebo-controlled, Phase 2 study of IONIS-FGFR4Rx in obese patients in July 2015.

IONIS-DGAT2Rx IONIS-DGAT2Rx is an antisense drug we designed to reduce the production of DGAT2, or diacylglycerol acyltransferase 2, to treat patients with NASH. NASH is a common liver disease characterized by excessive triglycerides in the liver with concurrent inflammation and cellular damage. As NASH progresses, scarring, or fibrosis, begins to accumulate in the liver. Ultimately, cirrhosis of the liver develops and the liver can no longer function normally. Currently, liver transplantation is the only treatment for advanced cirrhosis and liver failure. Because of the high prevalence of NASH, it has recently become the third most common indication for liver transplantation in the United States.

DGAT2 is an enzyme that catalyzes the final step in triglyceride synthesis in the liver. Reducing the production of DGAT2 should therefore decrease triglyceride synthesis in the liver. In animal models of obesity and fatty liver disease, antisense inhibition of DGAT2 significantly improved liver damage, lowered blood lipid levels and reversed diet-induced insulin resistance.

We are evaluating IONIS-DGAT2Rx in a randomized, placebo-controlled, dose-escalation, Phase 1 study in healthy, overweight volunteers. We designed this study to give us valuable insights on the effects of IONIS-DGAT2Rx in a patient population that is closely matched to patients with NASH.

Other Drugs in Development

Together with our partners, we continue to advance drugs in clinical development that are outside of our core therapeutic areas, such as the antiviral drugs we and GSK are developing. 

IONIS’ Pipeline of Drugs in Development for Viral Infection or Ocular Disease



IONIS-GSK4-LRxIONIS-GSK4-LRx is a LICA drug we designed to reduce an undisclosed ocular target. Together with GSK, we are developing IONIS-GSK4-LRx to treat patients with an undisclosed ocular disease.

IONIS-HBVRx and IONIS-HBV-LRxIONIS-HBVRx and IONIS-HBV-LRx are antisense drugs we designed to reduce the production of viral proteins associated with hepatitis B virus, or HBV. These include proteins associated with infection and replication, including the hepatitis B surface antigen, which is present in both acute and chronic infections and is associated with a poor prognosis in patients with chronic HBV infection. IONIS-HBV-LRx is the first anti-infective drug in development that incorporates our LICA technology, which we designed to increase drug potency by enhancing drug delivery to target tissue. Together with GSK, we are evaluating IONIS-HBVRx and IONIS-HBV-LRx to treat HBV infection.

HBV infection is a serious health problem that can lead to significant and potentially fatal health conditions. Chronic HBV infection is one of the most common persistent viral infections in the world. Currently available therapies, including oral antiviral agents or injectable interferons, do not clear HBV and do not effectively clear HBV antigens from these patients. As a result, patients cannot fully control their HBV infection and therefore, achieve sustained disease remission. Many of these patients are at elevated risk for severe liver complications such as cirrhosis and primary liver cancer.
14


We have completed a randomized, placebo-controlled, dose-escalation, Phase 1 study of IONIS-HBVRx in healthy volunteers. In January 2016, GSK initiated a Phase 1 study evaluating IONIS-HBV-LRx in healthy volunteers. The Phase 1 study of IONIS-HBV-LRx is a randomized, placebo-controlled, dose-escalation study in healthy volunteers. We have designed this study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of IONIS-HBV-LRx.

Preclinical Drugs in Development

The efficiency and broad applicability of our technology provides us with nearly unlimited targets against which to develop drugs. Our goal is to add three to five new drugs into the pipeline every year. In 2015, we far exceeded this goal and added nine new drugs into development. Already in 2016, we have added two new drugs into development. On average, it takes 12 to 18 months to complete the preclinical studies necessary to support clinical development.

IONIS’ Preclinical Pipeline


Satellite Company Drugs in Development

We have successfully developed novel drugs we designed to treat many different diseases. In therapeutic areas that are outside of our core areas of development, we have licensed our drugs to highly focused satellite companies that have the specific expertise and resources to continue developing the drugs. For our satellite company drugs, we refer to the drug by the partner’s own compound number, such as ATL1103 or RG-101. We have listed these drugs below in the Satellite Company pipeline.

IONIS’ Satellite Company Pipeline

* Named Patient Supply (see below).
15


Alicaforsen – Alicaforsen is an antisense drug we designed to reduce the production of intercellular adhesion molecule 1, or ICAM-1. Ulcerative colitis, or UC, is an inflammatory bowel disease of the colon, a part of the large intestine, and pouchitis is an inflammation of the surgically constructed internal pouch created in UC patients who have had their diseased colons removed. In 2007, we licensed alicaforsen to Atlantic Pharmaceuticals for pouchitis, UC and other inflammatory diseases. Atlantic Pharmaceuticals is developing alicaforsen for the treatment of UC and currently supplies alicaforsen in response to physicians' requests under international Named Patient Supply regulations for patients with inflammatory bowel disease.

ATL1103 – ATL1103 is an antisense drug we designed to reduce the production of the growth hormone receptor, or GHr, to treat patients with acromegaly. Acromegaly is a serious chronic life threatening disease triggered by excess secretion of GHr by benign pituitary tumors. In 2001, we licensed ATL1103 to Antisense Therapeutics Limited, or ATL. In May 2015, ATL entered into an exclusive license agreement that provides Strongbridge Biopharma with development and commercialization rights to ATL1103 for endocrinology applications outside Australia and New Zealand.

RG-012 – RG-012 is an anti-miR, or an antisense oligonucleotide inhibitor of microRNA, targeting microRNA-21, or miR-21, to treat patients with Alport syndrome. Alport syndrome is a life-threatening genetic kidney disease with no approved therapy. While there is little known information on the progression of this disease, scientists believe that miR-21 plays a critical role because they have observed increased miR-21 levels in animal models of Alport syndrome and in patients with chronic kidney disease. Regulus is developing RG-012 in a strategic alliance with Genzyme, a Sanofi company, to treat Alport syndrome. In June 2015, Regulus initiated a randomized, double-blind, placebo-controlled, single ascending dose Phase 1 study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of RG-012.

Custirsen – Custirsen is an antisense drug we designed to improve survival in patients with advanced cancer. We and OncoGenex jointly discovered and conducted the initial development of custirsen. In July 2008, we and OncoGenex amended the co-development agreement pursuant to which OncoGenex became solely responsible for the costs, development and commercialization of custirsen as an adjunct therapy to enhance the effectiveness of chemotherapy. OncoGenex is evaluating custirsen in two Phase 3 studies, AFFINITY and ENSPIRIT. The AFFINITY study is evaluating custirsen in combination with cabazitaxel/prednisone as a second-line chemotherapy in men with CRPC. The ENSPIRIT study is evaluating custirsen as a second-line treatment in patients with NSCLC.

Apatorsen – Apatorsen is an antisense drug we designed to reduce the production of heat shock protein 27, or Hsp27, to treat patients with cancer. In January 2005, we entered into an agreement with OncoGenex to develop apatorsen. Under the terms of the agreement, OncoGenex is responsible for all development costs and activities. OncoGenex and collaborators are evaluating apatorsen in multiple Phase 2 studies in patients with cancer.

Plazomicin – Plazomicin is an aminoglycoside drug that Achaogen, Inc. is developing for the treatment of multi-drug resistant gram-negative bacterial infections. Aminoglycosides are a group of antibiotics that inhibit bacterial protein synthesis that physicians can use to treat serious bacterial infections. In 2006, we licensed our proprietary aminoglycoside program to Achaogen. Achaogen discovered plazomicin based on technology licensed from us. Achaogen is currently evaluating plazomicin in a Phase 3 study in patients with serious multi-drug resistant infection due to carbapenem-resistant Enterobacteriaceae, or CRE. In September 2014, Achaogen initiated a Phase 3 study, CARE, to evaluate the efficacy of plazomicin in patients with infections caused by CRE. Achaogen announced that it has a special protocol assessment, or SPA, with the FDA for this Phase 3 study. Achaogen plans to initiate a second Phase 3 study of plazomicin for the treatment of patients with complicated urinary tract infections.

ATL1102 – ATL1102 is an antisense drug we designed to reduce the production of CD49d, a subunit of Very Late Antigen-4, or VLA-4, for the treatment of patients with multiple sclerosis, or MS. Results from preclinical studies demonstrate that inhibition of VLA-4 could positively affect a number of inflammatory diseases, including MS. In 2001, we licensed ATL1102 to ATL. ATL is currently undertaking a chronic toxicology study in primates to support a potential Phase 2b trial of ATL1102 in patients with MS.

RG-101 – RG-101 is an anti-miR targeting microRNA-122, or miR-122, to treat patients with hepatitis C virus, or HCV. RG-101 is wholly owned by Regulus, but Regulus has entered into a clinical trial collaboration with GSK. Regulus is evaluating RG-101 as part of an HCV combination regimen with GSK’s investigational HCV compound. Regulus completed a Phase 1/2 study in patients with HCV and is evaluating RG-101 in a Phase 2 study in combination with direct acting antivirals in patients with HCV. Regulus is also evaluating RG-101 in a Phase 1 study in patients with severe renal insufficiency or end-stage renal disease.

RG-125 – RG-125, also referred to as AZD4076, is an anti-miR targeting microRNA-103/107, or miR-103/107, for the treatment of NASH in patients with type 2 diabetes/pre-diabetes. Regulus reported that inhibition of miR-103/107 with anti-miRs led to a sustained reduction in fasting glucose and fasting insulin levels in mouse models. RG-125 is part of the strategic alliance between Regulus and AstraZeneca to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases and oncology.

Regulus and AstraZeneca are evaluating RG-125 in a Phase 1 study for the treatment of NASH in patients with type 2 diabetes or pre-diabetes.

Antisense Technology

Our antisense technology is an innovative platform for discovering first-in-class or best-in-class drugs for treating disease. We believe this technology represents an important advance in the way we treat disease because, unlike most other drug technologies that target existing proteins in the body, antisense technology is an RNA-targeted drug technology. The unique properties of antisense drugs provide several advantages over traditional drug discovery technologies. These advantages include:

Direct application to diseases at the genetic level by targeting RNA: antisense technology represents a direct route from gene to drug. The explosion in genomic information has led to the discovery of many new disease-causing proteins and RNAs, and has created new opportunities accessible to antisense technology.
16


Precise specificity: we design antisense drugs to target a single RNA, which minimizes or eliminates the possibility our drugs will bind to unintended targets which can cause unwanted side effects.
Good drug properties: antisense drugs distribute well throughout the body without the need for special formulations or vehicles. They also have a relatively long half-life of approximately two to four weeks, which means patients and/or healthcare providers can dose our drugs once a week. Antisense drugs using our more advanced technology also have the potential for patients and/or their healthcare providers to dose our drugs once a month, once a quarter or even less frequently.
Ability to combine with other drugs: because antisense drugs do not interact with the enzymes that metabolize or break down other drugs, physicians can use our drugs in combination with other drugs.
Broad applications to multiple disease targets, multiple tissues and multiple mechanisms: there are virtually no “undruggable” targets with antisense technology.
Efficient discovery and early development: because of the efficiency of our antisense technology, our drug discovery and early development costs and success rates compare favorably to small molecule or antibody drug discovery and development.

We identify antisense drugs to treat diseases for which there is a large unmet medical need, including severe and rare diseases for which there are limited or no current treatments or in diseases for which we believe our drugs have a competitive advantage over existing therapies.

Technology Overview

We use our core technology platform to discover and develop drugs that affect targets in the body at the genetic level. Genes contain the information necessary to produce proteins. A gene is made up of nucleotides containing the nucleoside bases: adenine, thymine, guanine, and cytosine, commonly known as A, T, G and C, which are linked together to form a two-stranded structure that resembles a twisted ladder, known as deoxyribonucleic acid, or DNA. The nucleotides on one side of the ladder bind weakly to complementary nucleotides on the other strand according to specific rules; for example, A pairs with T and G pairs with C, creating the ladder’s rungs (figure 1). Scientists call this highly specific nucleotide pairing hybridization. The sequence or order of these nucleotides establishes the cell’s recipes for making proteins. Each protein’s instructions reside in a corresponding segment of DNA known as a gene.
Figure 1: Illustration of DNA.


Figure 2: Transcription of information contained in a gene, or DNA, to mRNA.
17


The instructions for making a protein are transcribed from a gene, or DNA, into a different genetic molecule called messenger RNA. This process starts with the partial uncoiling of the two complementary strands of the DNA. One strand acts as a template and information stored in the DNA template strand is copied into a complementary RNA (figure 2). Messenger RNA, or mRNA, are mature, fully processed RNA that code for proteins. Ribosomes, the cell’s factories for manufacturing proteins, translate mRNA into proteins. The ribosome reads the encoded information, the mRNA’s nucleotide sequence, and in doing so, strings together amino acids to form a specific protein (figure 3).


Figure 3: Translation of the protein-coding information contained in mRNA to protein.

We primarily use our antisense technology to interrupt the cell’s protein production process by preventing the mRNA instructions from reaching the ribosome, thus inhibiting the production of the protein. The mRNA sequence of nucleotides that carries the information for protein production is called the ‘sense’ strand. Scientists call the complementary nucleotide chain that binds specifically to the sense strand is called the “antisense” strand. We use the information contained in mRNA to design chemical structures, that we call antisense oligonucleotides or antisense drugs, which resemble DNA and RNA and are the complement of RNA. Our antisense drugs can selectively bind to an mRNA that codes for a specific protein and will not bind to closely related RNAs, providing a level of specificity that is better than traditional drugs. As a result, we can design antisense drugs that selectively inhibit the disease-causing member of the protein group without interfering with those members of the protein group necessary for normal bodily functions. This unique specificity means that antisense drugs may be less toxic than traditional drugs because we can design them to minimize the impact on unintended targets. We can also design antisense drugs to increase the production of beneficial proteins.

We have developed the majority of the drugs in our pipeline using our advanced screens to produce drugs with what we believe are the best possible safety and tolerability profiles. We refer to our drugs that have passed these advanced screens as Generation 2.0+ drugs. We continue to advance our antisense technology to create even more potent drugs that we can use in more tissues and against more targets. These advances allow us to expand the mechanisms through which we can use our drugs. These advancements provide us with greater opportunities to use our antisense drugs to treat a greater number of diseases and reach more patient populations. Today several of our early stage drugs and those entering our pipeline use our most advanced antisense technology, including our next generation chemistry, Generation 2.5, and our LICA technology.

Generation 2.5 chemistry is an advancement that we believe increases the potency of our drugs by up to 10-fold over our Generation 2+ drugs. This increase in potency enables our drugs to engage targets in a broader array of tissues. We have published data demonstrating that our Generation 2.5 drugs generally have enhanced potency over our Generation 2.0+ drugs and are broadly distributed throughout the body to multiple tissues including liver, kidney, lung, muscle, adipose, adrenal gland, peripheral nerves and tumor tissues. Our Generation 2.5 drugs constitute some of our recently added new drugs.

In addition to improving the chemical foundation of our drugs, we design our LICA technology to enhance the delivery of our drugs to particular tissues. This technology adds specific chemical structures or molecules, such as conjugates, onto antisense drugs to increase the efficiency of drug uptake in a particular tissue. We have demonstrated that our LICA technology can further enhance the potency of our drugs. For example, our LICA technology directed toward liver targets has produced a greater than thirty fold increase in potency in a Phase 1 study of IONIS-APO(a)-LRx. We can combine our LICA technology with both our Generation 2.0+ and our Generation 2.5 drugs to increase the potency of these drugs. We designed these first LICA drugs to inhibit targets in the liver. We are also developing LICA conjugation technology that we can use to target other tissues. We expect that we can enhance some of our future drugs, including our Generation 2.5 drugs with our LICA technology.
18


Antisense Targets and Mechanisms

There are more than a dozen different antisense mechanisms that we can exploit with our antisense technology. The majority of the drugs in our pipeline bind to mRNAs and inhibit the production of disease-causing proteins. Our antisense technology is broadly applicable to many different antisense mechanisms, including RNA splicing, exon skipping, RNA interference, or RNAi, and enhancing protein translation to increase protein production. We have also recently published research showing that we can use our antisense technology with CRISPR/Cas9, a gene editing system. Our work in this area provides an important step toward development of a potential therapeutic application for CRISPR technology.

The antisense drugs we design to inhibit the production of disease-causing proteins or reduce harmful RNAs bind to the target RNA via highly specific nucleotide pairing, or hybridizing, and recruiting a cellular enzyme called ribonuclease H1, or RNase H1, to degrade the target RNA. The drug itself remains intact during this process, so it can remain active against additional target RNA molecules and repeatedly trigger their degradation (figure 4). Examples of our clinical development stage antisense drugs that use the RNase H1 mechanism to reduce disease protein production include, IONIS-TTRRx, volanesorsen, IONIS-FXIRx, IONIS-APO(a)-LRx and others.
Figure 4: Antisense drug using the RNase H mechanism of action.

Nusinersen is an example of an antisense drug that modulates RNA splicing to increase protein production of the SMN protein (figure 5), which is critical to the health and survival of nerve cells in the spinal cord that are responsible for neuro-muscular function. The SMN protein is deficient in patients with SMA. There are a number of other diseases, including cystic fibrosis and Duchenne muscular dystrophy, which are the result of splicing disorders. These are diseases we could potentially treat using antisense modulation of splicing.
 
Figure 5: Antisense drug altering splicing of the SMN2 mRNA.
19


Because there are many different types of RNA that exist within the body, our antisense technology is not limited to RNA sequences that translate into proteins. We can also develop drugs that target non-coding RNAs, such as toxic RNAs. For example, DM1 is a form of muscular dystrophy that is caused by an abnormally long, toxic RNA that accumulates in cells and prevents the production of proteins essential for normal cellular function. We designed IONIS-DMPK-2.5Rx to target and reduce the toxic DMPK RNA that causes this disease. In a mouse model of the disease, we observed effective reductions of the toxic RNA that led to a sustained reversal of disease symptoms for up to one year.

Another RNA target for our antisense technology is microRNAs. To date, scientists have identified more than 700 microRNAs in the human genome, and have shown that the absence or presence of specific microRNAs in various cells is associated with specific human diseases, including cancer, viral infection, metabolic disorders and inflammatory disease. To fully exploit the therapeutic opportunities of targeting microRNAs, we co-founded Regulus Therapeutics as a company focused on the discovery, development and commercialization of microRNA-based therapeutics. Regulus has reported human proof-of-concept data for RG-101 in HCV patients. These data demonstrated that treatment with a single subcutaneous dose of RG-101 as a single agent resulted in significant and sustained reductions in HCV RNA in a varied group of patients.

We are also making progress in designing antisense drugs to target long, non-coding RNAs, or lncRNAs. These lncRNAs do not make proteins but may regulate other genes. In 2014, we published a paper in Nature in which we were the first to show that targeted reduction of an lncRNA with an antisense compound can ameliorate certain cognitive deficits in a mouse model of Angelman syndrome, or AS. Moreover, these studies demonstrate the potential therapeutic benefits of an antisense drugs for the treatment of AS.

Because the efficiency of our core technology platform can support multiple target-based antisense research programs without significantly increasing costs, we can develop antisense drugs to target a broad range of diseases, efficiently producing a large and broad proprietary portfolio of drugs. We are currently pursuing antisense drug discovery programs focused on various severe and rare, cardiovascular, neurologic and metabolic diseases, and cancer.

Collaborative Arrangements and Licensing Agreements

Overview

We are leaders in RNA-targeted therapeutics and we have established alliances with a cadre of leading global pharmaceutical companies that are working alongside us in developing our drugs, advancing our technology and preparing to commercialize our drugs. Our partners bring resources and expertise that augment and build upon our internal capabilities. The depth of our knowledge and expertise with antisense technology provides us the flexibility to partner our drugs at what we believe is the optimal time to maximize the near- and long-term value of our drugs. We have distinct partnering strategies that we employ based on the specific program, therapeutic area and the expertise and resources our potential partners may bring to the collaboration.

We form strategic partnerships through which we can broadly expand our drug discovery efforts to new disease targets in specific therapeutic areas in which our partners can provide tools and resources to complement our drug discovery efforts. For instance, we established a broad strategic alliance with Biogen that pairs Biogen’s extensive resources and expertise in neurological diseases with our antisense technology. Together we are creating a franchise of novel potential drugs for neurological diseases that we believe will expand both our pipeline and Biogen’s pipeline with promising new drugs.

We form early stage research and development partnerships that allow us to expand the application of our technology to new therapeutic areas. For example, we established a collaboration with Janssen, which brings together our RNA-targeted technology platform and Janssen’s expertise in autoimmune disorders and therapeutic formulation to discover and develop antisense drugs to treat autoimmune disorders in the gastrointestinal, or GI, tract.

We form late stage development and commercialization partnerships that enable us to leverage our partner’s global expertise and resources needed to support large commercial opportunities. For example, we licensed IONIS-FXIRx to Bayer to develop and commercialize IONIS-FXIRx for the prevention of thrombosis. As a leader in the antithrombotic market, Bayer has the expertise, resources and commitment to broadly develop IONIS-FXIRx.

We also work with a consortium of companies that can exploit our drugs and technologies outside our primary areas of focus. We refer to these companies as satellite companies. Through our satellite company collaborations, we expand the reach and potential of RNA-targeting therapeutics into disease areas that are outside of our core focus.

Through our partnerships we have created a broad and sustaining base of potential license fees, upfront payments, milestone payments, royalties and earn out payments while controlling our drug development expenses. In all of our partnerships, we benefit from the expertise our partners bring to our drugs. By coupling our efficient drug discovery technology with the resources and expertise of our partners we believe we can maximize the value of our drugs and our technology.

Strategic Partnerships

AstraZeneca

Cardiometabolic and Renal Diseases Collaboration

In July 2015, we and AstraZeneca formed a strategic collaboration to discover and develop antisense therapies for treating cardiovascular and metabolic diseases primarily focused on targets in the kidney, and renal diseases. As part of the agreement, we granted AstraZeneca an exclusive license to a preclinical program and the option to license a drug for each target advanced under this research collaboration. Upon acceptance of a drug development candidate, AstraZeneca will be responsible for all further global development, regulatory and commercialization activities for such drug. Under the terms of the agreement, we received a $65 million upfront payment. We are eligible to receive license fees and substantive milestone payments of up to more than $4 billion. In addition, we are eligible to receive tiered royalties up to the low teens on sales from any product that AstraZeneca successfully commercializes under this collaboration agreement.
20


Oncology Collaboration

In December 2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense drugs for cancer. As part of the agreement, we granted AstraZeneca an exclusive license to develop and commercialize IONIS-STAT3-2.5Rx for the treatment of cancer and an option to license up to three anti-cancer drugs under a separate research program. AstraZeneca is responsible for all global development, regulatory and commercialization activities for IONIS-STAT3-2.5Rx. We and AstraZeneca have evaluated IONIS-STAT3-2.5Rx in patients with advanced metastatic hepatocellular carcinoma and advanced lymphoma. AstraZeneca is evaluating IONIS-STAT3-2.5Rx in combination with MEDI4736, AstraZeneca's investigational anti-PD-L1 drug, in patients with head and neck cancer. For the research program, we are responsible for identifying a development candidate for each of the three anti-cancer research programs. AstraZeneca has the option to license drugs resulting from each of the three anti-cancer research programs, and if AstraZeneca exercises its option for a drug, it will be responsible for all further global development, regulatory and commercialization activities for such drug.

Under the terms of the agreement, we received $31 million in upfront payments. We are eligible to receive milestone payments and license fees from AstraZeneca as programs advance in development. In addition, we are eligible to receive tiered royalties up to the low to mid-teens on sales from any drugs resulting from these programs. If AstraZeneca successfully develops IONIS-STAT3-2.5Rx and the three drugs under the research program, we could receive license fees and milestone payments of $750 million. From inception through February 2016, we have generated more than $70 million in payments under this oncology collaboration.

For additional details about our collaboration agreements with AstraZeneca, including other financial information and termination provisions, see Note 6, Collaborative Arrangements and Licensing Agreements, in the Notes to the Consolidated Financial Statements.

Biogen

We have established four strategic collaborations with Biogen focused on using antisense technology to advance the treatment of neurological and neuromuscular disorders. These collaborations combine our expertise in creating antisense drugs with Biogen's expertise in developing therapies for neurological disorders. We and Biogen are currently developing six drugs to treat neurological diseases under these collaborations, including nusinersen, IONIS-DMPK-2.5Rx, IONIS-SOD1Rx, formerly ISIS-BIIB3Rx, and three drugs to treat undisclosed neurodegenerative diseases, IONIS-BIIB4Rx, IONIS-BIIB5Rx, and IONIS-BIIB6Rx. In addition to these six drugs, we and Biogen are evaluating numerous additional targets for the development of drugs to treat neurological diseases.

Nusinersen

In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize nusinersen for the treatment of SMA. We are currently conducting a Phase 3 study evaluating nusinersen in infants with SMA, which we expect to be fully enrolled in the second quarter of 2016. We are also conducting a Phase 3 study evaluating nusinersen in children with SMA, for which we have completed target enrollment. In addition, we are evaluating nusinersen in two Phase 2 open-label studies, one in children with SMA and one in infants with SMA. Patients from all of these studies continue to have access to nusinersen through open-label extension dosing. We are responsible for completing the studies we are currently conducting. Biogen has the option to license nusinersen. If Biogen exercises its option, it will pay us a license fee and will assume all other global development, regulatory and commercialization responsibilities. Biogen may exercise this option upon completion of and data review of the first successful Phase 2/3 trial or completion of both Phase 2/3 trials. An amendment in December 2014 provided for additional opt-in scenarios, based on the filing or the acceptance of a new drug application or marketing authorization application with the FDA or EMA. Under the terms of the agreement, we received an upfront payment of $29 million and we are eligible to receive up to $346 million in a license fee and payments. We are also eligible to receive tiered royalties up to the mid-teens on any sales of nusinersen. From inception through February 2016, we have generated nearly $150 million in payments for advancing nusinersen, including a $2 million milestone payment we earned in February 2016 for further advancing the Phase 3 study of nusinersen in infants.

IONIS-DMPK-2.5Rx

In June 2012, we and Biogen entered into a second and separate collaboration agreement to develop and commercialize a novel antisense drug, IONIS-DMPK-2.5Rx, targeting DMPK for the treatment of DM1. We are responsible for global development of the drug through the completion of the first Phase 2 clinical trial. We are currently evaluating IONIS-DMPK-2.5Rx in a Phase 1/2 clinical study in patients with DM1. Biogen has the option to license the drug through the completion of the first Phase 2 trial. If Biogen exercises its option, it will assume all other global development, regulatory and commercialization responsibilities. Under the terms of the agreement, we received an upfront payment of $12 million. Over the term of the collaboration, we are eligible to receive up to $263 million in a license fee and substantive milestone payments. In addition, we are eligible to receive tiered royalties up to the mid-teens on any sales of IONIS-DMPK-2.5Rx. From inception through February 2016, we have generated more than $35 million in payments for advancing IONIS-DMPK-2.5Rx.

Neurology

In December 2012, we and Biogen entered into a third and separate collaboration agreement to develop and commercialize novel antisense drugs to up to three targets to treat neurological or neuromuscular diseases. We are responsible for the development of each of the drugs through the completion of the initial Phase 2 clinical study for such drug. Biogen has the option to license a drug from each of the three programs through the completion of the first Phase 2 study for each program. We are currently advancing IONIS-BIIB4Rx under this collaboration. If Biogen exercises its option for a drug, it will assume all further global development, regulatory and commercialization responsibilities for that drug. Under the terms of the agreement, we received an upfront payment of $30 million. Over the term of the collaboration, we are eligible to receive up to $259 million in a license fee and substantive milestone payments per program. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any drugs resulting from each of the three programs. From inception through February 2016, we have generated nearly $45 million in payments under this collaboration, including the $3 million milestone payment we earned in February 2016 for the continued development of IONIS-BIIB4Rx.
21


Strategic Neurology

In September 2013, we and Biogen entered into a fourth and separate collaboration agreement, which is a long-term strategic relationship focused on applying antisense technology to advance the treatment of neurological diseases. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for neurological diseases and has the option to license drugs resulting from this collaboration. The exclusivity for neurological diseases will last through September 2019, and may be extended for any drug development programs being pursued under the collaboration. We will usually be responsible for drug discovery and early development of antisense drugs and Biogen will have the option to license antisense drugs after Phase 2 proof of concept. We are currently advancing three drugs, IONIS-SOD1Rx, IONIS-BIIB5Rx, and IONIS-BIIB6Rx, under this collaboration. If Biogen exercises its option for a drug, it will assume all further global development, regulatory and commercialization responsibilities for that drug. Biogen will be responsible for all of the drug discovery and development activities for drugs using other modalities.

Under the terms of the agreement, we received an upfront payment of $100 million and are eligible to receive milestone payments, license fees and royalty payments for all drugs developed through this collaboration, with the specific amounts dependent upon the modality of the molecule advanced by Biogen. For each antisense molecule that is chosen for drug discovery and development under this collaboration, we are eligible to receive up to approximately $260 million in a license fee and substantive milestone payments. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any antisense drugs developed under this collaboration. If other modalities are chosen, such as small molecules or monoclonal antibodies, we are eligible to receive up to $90 million in substantive milestone payments. In addition, we are eligible to receive tiered single-digit royalties on sales from any drugs using non-antisense modalities developed under this collaboration. From inception through February 2016, we have generated more than $140 million in payments under this collaboration.

For additional details about our collaboration agreements with Biogen, including other financial information and termination provisions, see Note 6, Collaborative Arrangements and Licensing Agreements, in the Notes to the Consolidated Financial Statements.

Research, Development and Commercialization Partners

Bayer

In May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXIRx for the prevention of thrombosis. We are responsible for completing our ongoing Phase 2 study of IONIS-FXIRx in patients with end-stage renal disease on hemodialysis. Bayer is responsible for all other development and commercialization activities for IONIS-FXIRx. Under the terms of the agreement, we are eligible to receive $155 million in near-term payments, including a $100 million upfront payment we received in the second quarter of 2015 and a $55 million milestone payment that we are eligible to receive upon advancement of the program following the Phase 2 study in patients with end-stage renal disease on hemodialysis. Over the term of the agreement, we are eligible to receive up to $375 million in license fees, substantive milestone payments and other payments. In addition, we are eligible to receive tiered royalties in the low-to-high 20 percent range on gross margins of IONIS-FXIRx.

For additional details about our collaboration agreement with Bayer, including other financial information and termination provisions, see Note 6, Collaborative Arrangements and Licensing Agreements, in the Notes to the Consolidated Financial Statements.

Genzyme Corporation, a Sanofi company

In January 2008, we entered into an alliance with Genzyme focused on the licensing and co-development of Kynamro. The license and co-development agreement provided Genzyme with exclusive worldwide rights for all therapeutic purposes to our patents and know-how related to Kynamro. The transaction included a $175 million licensing fee and a $150 million equity investment by Genzyme in our stock. From inception through January 2016, we have generated $375 million in a license fee, milestone payments and an equity investment for advancing Kynamro in development. In January 2016, we terminated our license agreement with Genzyme.

GSK

In March 2010, we entered into an alliance with GSK using our antisense drug discovery platform to discover and develop new drugs against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness. Our alliance currently comprises five drugs in development, including our Phase 3 drug, IONIS-TTRRx. GSK has the exclusive option to license drugs resulting from this alliance at Phase 2 proof-of-concept for a license fee. If GSK exercises its exclusive option for any drugs resulting from this alliance, it will be responsible for all further global development, regulatory and commercialization activities for such drug. Under the terms of the agreement, we received $38 million in upfront and expansion payments.

In October 2012, we and GSK amended the original agreement to reflect an accelerated clinical development plan for IONIS-TTRRx. We are currently evaluating IONIS-TTRRx in a broad Phase 3 development program. We have completed target enrollment for our Phase 3 study in patients with FAP. In September 2015, we and GSK amended the development plan for IONIS-TTRRx to support the Phase 3 cardiomyopathy study, which GSK plans to conduct. In addition to IONIS-TTRRx, we have four drugs in development with GSK. We are developing two antisense drugs we designed to reduce the production of viral proteins associated with HBV infection; IONIS-HBVRx and IONIS-HBV-LRx, a follow-on drug using our LICA technology. We are also developing IONIS-GSK4-LRx and IONIS-RHO-2.5Rx, which are antisense drugs we designed to treat ocular diseases.

Under our agreement, if GSK successfully develops all five drugs for one or more indications and achieves pre-agreed sales targets, we could receive payments of more than $1.0 billion. From inception through February 2016, we have generated more than $150 million in payments under this alliance with GSK, including a $1.5 million payment we generated in January 2016 when GSK further advanced IONIS-HBV-LRx. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any product that GSK successfully commercializes under this alliance.
22


For additional details about our collaboration agreement with GSK, including other financial information and termination provisions, see Note 6, Collaborative Arrangements and Licensing Agreements, in the Notes to the Consolidated Financial Statements.

Janssen Biotech, Inc., a pharmaceutical company of Johnson & Johnson

In December 2014, we entered into a collaboration agreement with Janssen Biotech, Inc. to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders of the GI tract. Janssen has the option to license drugs from us through the designation of a development candidate for up to three programs. Prior to option exercise we are responsible for the discovery activities to identify a development candidate. If Janssen exercises an option for one of the programs, it will be responsible for the global development, regulatory and commercial activities under that program. Under the terms of the agreement, we received $35 million in upfront payments. We are eligible to receive nearly $800 million in milestone payments and license fees for these programs. In addition, we are eligible to receive tiered royalties up to the near teenson sales from any drugs resulting from this collaboration.

For additional details about our collaboration agreement with Janssen, including other financial information and termination provisions, see Note 6, Collaborative Arrangements and Licensing Agreements, in the Notes to the Consolidated Financial Statements.

Roche

In April 2013, we formed an alliance with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, to develop treatments for HD based on our antisense technology. Roche has the option to license the drugs from us through the completion of the first Phase 1 trial. Under the agreement, we are responsible for the discovery and development of an antisense drug targeting HTT protein. We are currently evaluating a drug targeting HTT, IONIS-HTTRx, in a Phase 1/2 clinical study in patients with early stage HD. If Roche exercises its option, it will be responsible for global development, regulatory and commercialization activities for any drug arising out of the collaboration. We are also working collaboratively with Roche on the discovery of an antisense drug utilizing Roche's "brain shuttle" program. Under the terms of the agreement, we received an upfront payment of $30 million in April 2013. We are eligible to receive up to $362 million in a license fee and milestone payments. In addition, we are eligible to receive up to $136.5 million in milestone payments for each additional drug successfully developed and up to $50 million in commercial milestones if a drug using Roche's proprietary brain shuttle technology is successfully commercialized. We are also eligible to receive tiered royalties up to the mid-teens on product sales from any drugs resulting from this alliance. From inception through February 2016, we have generated nearly $55 million in payments under this alliance with Roche.

For additional details about our collaboration agreement with Roche, including other financial information and termination provisions, see Note 6, Collaborative Arrangements and Licensing Agreements, in the Notes to the Consolidated Financial Statements.

Satellite Company Collaborations

Achaogen, Inc.

In 2006, we exclusively licensed to Achaogen, Inc. specific know-how, patents and patent applications relating to aminoglycosides. In exchange, Achaogen agreed to certain payment obligations related to aminoglycosides Achaogen developed. Achaogen is developing plazomicin, an aminoglycoside Achaogen discovered based on the technology we licensed to Achaogen. In connection with the license, Achaogen issued to us $1.5 million of Achaogen Series A Preferred Stock. If Achaogen successfully develops and commercializes two drugs under our agreement, we will receive payments totaling up to $49.3 million for the achievement of key clinical, regulatory and sales events. Through February 2016, we have earned $7 million in milestone payments from Achaogen, including a $4 million milestone payment we earned in September 2014 when Achaogen initiated a Phase 3 study of plazomicin in patients with serious multi-drug resistant, gram-negative bacterial infections. We are also eligible to receive royalties on sales of drugs resulting from the program. Achaogen is solely responsible for the continued development of plazomicin.

Alnylam Pharmaceuticals, Inc.

In March 2004, we entered into an alliance with Alnylam to develop and commercialize RNAi therapeutics. Under the terms of the agreement, we exclusively licensed to Alnylam our patent estate relating to antisense motifs and mechanisms and oligonucleotide chemistry for double-stranded RNAi therapeutics in exchange for a $5 million technology access fee, participation in fees from Alnylam’s partnering programs, as well as future milestone and royalty payments from Alnylam. For each drug Alnylam develops under this alliance, we may receive up to $3.4 million in milestone payments. We also have the potential to earn a portion of payments that Alnylam receives from licenses of our technology it grants to its partners plus royalties. We retained rights to a limited number of double-stranded RNAi therapeutic targets and all rights to single-stranded RNAi, or ssRNAi, therapeutics.

In turn, Alnylam nonexclusively licensed to us its patent estate relating to antisense motifs and mechanisms and oligonucleotide chemistry to research, develop and commercialize single-stranded antisense therapeutics, ssRNAi therapeutics, and to research double-stranded RNAi compounds. We also received a license to develop and commercialize double-stranded RNAi drugs targeting a limited number of therapeutic targets on a nonexclusive basis. If we develop or commercialize an RNAi-based drug using Alnylam’s technology, we will pay Alnylam up to $3.4 million in milestone payments for specified development and regulatory events, plus royalties. To date, we do not have an RNAi-based drug in development.

In 2015, we and Alnylam entered into an alliance in which we formed an intellectual property cross-license under which we and Alnylam each obtained exclusive license rights to four therapeutic programs. Alnylam granted us an exclusive, royalty-bearing license to its chemistry, RNA targeting mechanism and target-specific intellectual property for oligonucleotides against four targets. In exchange, we granted Alnylam an exclusive, royalty-bearing license to our chemistry, RNA targeting mechanism and target-specific intellectual property for oligonucleotides against four targets. Alnylam also granted us a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for single-stranded antisense therapeutics. In turn, we granted Alnylam a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for double-stranded RNAi therapeutics. Through February 2016, we have generated nearly $70 million from Alnylam.
23

      
 
  Antisense Therapeutics Limited
 
In 2001, we licensed ATL1102 and ATL1103 to ATL, an Australian company publicly traded on the Australian Stock Exchange. ATL is currently undertaking a chronic toxicology study in primates to support a potential Phase 2b trial of ATL1102 in patients with MS. In addition, ATL is currently developing ATL1103 for growth and sight disorders. We are eligible to receive royalties on sales of ATL1102 and ATL1103. We may also receive a portion of the fees ATL receives if it licenses ATL1102 or ATL1103.

Atlantic Pharmaceuticals Limited

In March 2007, we licensed alicaforsen to Atlantic Pharmaceuticals, a UK-based specialty pharmaceutical company founded in 2006. Atlantic Pharmaceuticals is developing alicaforsen for the treatment of UC and other inflammatory diseases. Atlantic Pharmaceuticals is initially developing alicaforsen for pouchitis, a UC indication, followed by UC and other inflammatory diseases. In exchange for the exclusive, worldwide license to alicaforsen, we received a $2 million upfront payment from Atlantic Pharmaceuticals in the form of equity. In 2010, Atlantic Pharmaceuticals began supplying alicaforsen under international named patient supply regulations for patients with IBD for which we receive royalties. Additionally, in 2013 we received an advance payment in the form of equity for the initial royalties that we will earn from Atlantic Pharmaceuticals. Under the agreement, we could receive milestone payments totaling up to $1.4 million for the achievement of regulatory milestones for multiple indications. 

OncoGenex Technologies Inc., a subsidiary of OncoGenex Pharmaceuticals Inc.

Custirsen

In November 2001, we established a drug development collaboration with OncoGenex, a biotechnology company committed to the development of cancer therapeutics for patients with drug resistant and metastatic cancers, to co-develop and commercialize custirsen, an anti-cancer antisense drug that targets clusterin. OncoGenex is currently evaluating custirsen in two Phase 3 studies. In July 2008, we and OncoGenex amended the co-development agreement pursuant to which OncoGenex became solely responsible for the costs, development and commercialization of custirsen. In exchange, OncoGenex agreed to pay us royalties on sales of custirsen and to share consideration it receives from licensing custirsen to a third party, except for consideration OncoGenex receives for the fair market value of equity and reimbursement of research and development expenses. Under the amended agreement, we assigned to OncoGenex our rights in the patents claiming the composition and therapeutic methods of using custirsen and granted OncoGenex a worldwide, nonexclusive license to our know-how and patents covering our core antisense technology and manufacturing technology solely for use with custirsen. In addition, we agreed that so long as OncoGenex or its commercialization partner is using commercially reasonable efforts to develop and commercialize custirsen, we will not research, develop or commercialize an antisense compound designed to modulate clusterin. The amended agreement will continue until OncoGenex or its commercialization partner is no longer developing or commercializing custirsen or until we terminate the agreement for OncoGenex’s uncured failure to make a payment required under the agreement.

OGX-225

In August 2003, we and OncoGenex entered into a second and separate agreement for the development of an antisense anti-cancer drug, OGX-225. OncoGenex is responsible for all development costs and activities. OncoGenex issued to us $0.8 million of OncoGenex securities as payment for an upfront fee. In addition, OncoGenex will pay us milestone payments totaling up to $3.5 million for the achievement of key development and regulatory milestones. In addition, we are eligible to receive royalties on future product sales of OGX-225.

Apatorsen

In January 2005, we entered into a third and separate agreement with OncoGenex to allow for the development of an additional antisense anti-cancer drug, apatorsen. OncoGenex and collaborators are evaluating apatorsen in multiple Phase 2 studies in patients with cancer. OncoGenex is responsible for all development costs and activities. OncoGenex will pay us milestone payments totaling up to $5.8 million for the achievement of key development and regulatory milestones. In addition, we are eligible to receive royalties on future product sales of the drug.

Regulus Therapeutics Inc.

In September 2007, we and Alnylam established Regulus as a company focused on the discovery, development and commercialization of microRNA-targeting therapeutics. We and Alnylam retain rights to develop and commercialize, on pre-negotiated terms, microRNA therapeutic products that Regulus decides not to develop either by itself or with a partner. Regulus is addressing therapeutic opportunities that arise from alterations in microRNA expression. Since microRNAs may act as master regulators of the genome, affecting the expression of multiple genes in a disease pathway, microRNA therapeutics define a new platform for drug discovery and development. MicroRNAs may also prove to be an attractive new tool for characterizing diseases. Regulus focuses its drug discovery and development efforts in numerous therapeutic areas, including cancer, fibrosis, and viral infections. Regulus currently has three drugs in clinical development. Regulus is evaluating RG-101 in a Phase 2 study in patients with HCV and in a Phase 1 study in patients with severe renal insufficiency or end-stage renal disease. Regulus is also evaluating RG-012 in a Phase 1 study to treat patients with Alport syndrome. Regulus and AstraZeneca are also evaluating RG-125 in a Phase 1 study for the treatment of NASH in patients with type 2 diabetes or pre-diabetes. We are eligible to receive royalties on any future product sales of these drugs.

For additional details about our satellite company arrangements, see Note 6, Collaborative Arrangements and Licensing Agreements, in the Notes to the Consolidated Financial Statements.
24


External Project Funding

We are pursuing discovery and development projects that provide us with new therapeutic applications for antisense drugs. These programs represent opportunities for us and our technology. In some cases, we have funded these studies through support from our partners or disease advocacy groups and foundations. For example, we received external funding support for our ALS and Huntington’s disease programs.

CHDI Foundation, Inc.

Starting in November 2007, CHDI provided financial and scientific support to our Huntington’s disease drug discovery program through our development collaboration. In April 2013, we formed an alliance with Roche to develop treatments for Huntington’s disease. Under the terms of our agreement with CHDI, we will reimburse CHDI for a portion of its support of our Huntington’s disease program out of the payments we receive from Roche. We made payments of $5 million and $3 million to CHDI in 2015 and 2013, respectively, associated with the progression of our Huntington’s disease program. If we achieve pre-specified milestones under our collaboration with Roche, we will make additional payments to CHDI up to $4 million, upon which our obligation to CHDI will be complete.

The Ludwig Institute; Center for Neurological Studies

In October 2005, we entered into a collaboration agreement with the Ludwig Institute, the Center for Neurological Studies and researchers from these institutions to discover and develop antisense drugs for ALS and other neurodegenerative diseases. Under this agreement, we agreed to pay the Ludwig Institute and Center for Neurological Studies modest milestone payments and royalties on any antisense drugs resulting from the collaboration.

Intellectual Property Sale and Licensing Agreements

We have a broad patent portfolio covering our products and technologies. We believe our patent estate represents the largest and most valuable nucleic acid therapeutics-oriented patent estate in the pharmaceutical industry. While the principal purpose of our intellectual property portfolio is to protect our products and those of our partners described above, our intellectual property is a strategic asset that we are exploiting to generate near-term revenues and that we expect will also provide us with revenue in the future. We have an active intellectual property sales and licensing program in which we sell or license aspects of our intellectual property to companies. Through this program, we also license our non-antisense patents. To date, we have generated nearly $420 million from our intellectual property sale and licensing program that helps support our internal drug discovery and development programs.

Sales of Intellectual Property

Abbott Molecular Inc.

In January 2009, we sold our former subsidiary, Ibis Biosciences, to Abbott Molecular Inc., or AMI, pursuant to a stock purchase agreement for a total acquisition price of $215 million plus the earn out payments described below. Under the stock purchase agreement, we are eligible to receive earn out payments from AMI equal to a percentage of Ibis’ revenue related to sales of Ibis systems, which AMI launched in 2014 as IRIDICA, including instruments, assay kits and successor products. Once cumulative net sales reach $140 million, and through December 31, 2025, we are eligible to earn out payments in any year that net sales exceed $50 million for the applicable year. The earn out payments will equal five percent of Ibis’ cumulative net sales over $140 million and up to $2.1 billion, and three percent of Ibis’ cumulative net sales over $2.1 billion. AMI may reduce these earn out payments from five percent to as low as 2.5 percent and from three percent to as low as 1.5 percent, respectively, upon the occurrence of certain events.

In-Licensing Arrangements

University of Massachusetts

We have a license agreement with the University of Massachusetts under which we acquired an exclusive license to the University of Massachusetts’ patent rights related to nusinersen. If we successfully develop and commercialize a drug incorporating the technology we licensed from the University of Massachusetts, we will pay a milestone payment to the University of Massachusetts of $0.3 million for the achievement of a key regulatory milestone. In addition, we will pay the University of Massachusetts a portion of any sublicense revenue we receive in consideration for sublicensing its technology, and a royalty on sales of nusinersen in the United States if our product incorporates the technology we licensed from the University of Massachusetts.

Verva Pharmaceuticals Ltd.

We have a license agreement with Verva under which we acquired an exclusive license to Verva’s antisense patent rights related to IONIS-FGFR4Rx. If we successfully develop and commercialize a drug incorporating the technology Verva licensed to us, we will pay milestone payments to Verva totaling up to $6.1 million for the achievement of key patent, clinical, and regulatory milestones. If we convert our license from an exclusive license to a nonexclusive license we could significantly reduce the milestone payments due to Verva. In addition, we will also pay royalties to Verva on sales of IONIS-FGFR4Rx if our product incorporates the technology we licensed from Verva.

Cold Spring Harbor Laboratory

We have a collaboration and license agreement with the Cold Spring Harbor Laboratory under which we acquired an exclusive license to the Cold Spring Harbor Laboratory’s patent rights related to nusinersen. If we successfully develop and commercialize a drug incorporating the technology we licensed from the Cold Spring Harbor Laboratory, we will pay a portion of any sublicense revenue and post licensing milestone payments we receive in consideration for sublicensing the Cold Spring Harbor Laboratory’s technology up to $11.3 million and a royalty on sales of nusinersen if our product incorporates the technology we licensed from the Cold Spring Harbor Laboratory.
25



Manufacturing
 
In the past, except for small quantities, it was generally expensive and difficult to produce chemically modified oligonucleotides like the antisense drugs we use in our research and development programs. As a result, we have dedicated significant resources to develop ways to improve manufacturing efficiency and capacity. Since we can use variants of the same nucleotide building blocks and the same type of equipment to produce our oligonucleotide drugs, we found that the same techniques we used to efficiently manufacture one oligonucleotide drug could help improve the manufacturing processes for many other oligonucleotide drugs. By developing several proprietary chemical processes to scale up our manufacturing capabilities, we have greatly reduced the cost of producing oligonucleotide drugs. For example, we have significantly reduced the cost of raw materials through improved yield efficiency, while at the same time increasing our capacity to make the drugs. Through both our internal research and development programs and collaborations with outside vendors we may achieve even greater efficiency and further cost reductions.
 
Our drug substance manufacturing facility is located in a 28,700 square foot building in Carlsbad, California. We lease this building under a lease that has an initial term ending on December 31, 2031 with an option to extend the lease for up to four additional five-year periods. In addition, we have a 25,800 square foot building that houses support functions for our manufacturing activities. We lease this facility under a lease that has an initial term ending in June 2021 with an option to extend the lease for up to two additional five-year periods. Our manufacturing facility is subject to periodic inspections by the FDA to ensure that it is operating in compliance with current Good Manufacturing Practices, or cGMP, requirements.

As part of our collaborations we may agree to manufacture clinical trial materials and/or commercial supply for our partners. For example, in the past we have manufactured clinical supply materials for AstraZeneca, Bayer, Biogen, and GSK.
 
We believe we have sufficient manufacturing capacity to meet our current internal research and development needs, including the Phase 3 clinical trials we have for IONIS-TTRRx, nusinersen, and volanesorsen, as well as our current and future obligations under existing agreements with our partners for commercial, research and development needs. We believe that we have, or will be able to develop or acquire, sufficient supply capacity to meet our anticipated needs, including the initial launch supplies for nusinersen, and volanesorsen. GSK intends to provide the initial launch supplies for IONIS-TTRRx. We also believe that with reasonably anticipated benefits from increases in scale and improvements in chemistry, we can manufacture antisense drugs at commercially competitive prices.

Patents and Proprietary Rights
 
Our success depends, in part, on our ability to obtain patent protection for our products in the United States and other countries. As of February 10, 2016, we owned or exclusively licensed more than 1,300 issued patents worldwide. We focus our resources on patents and new patent applications that drive value for our company.
 
We own or control patents that provide exclusivity for products in our pipeline and patents that provide exclusivity for our core technology in the field of antisense more generally. Our core technology patents include claims to chemically modified nucleosides and oligonucleotides as well as antisense drug designs utilizing these chemically modified nucleosides. These core claims are each independent of specific therapeutic target, nucleic acid sequence, or clinical indication. We also own a large number of patents claiming specific antisense compounds having nucleic acid sequences complementary to therapeutic target nucleic acids, independent of the particular chemical modifications incorporated into the antisense compound. Most importantly, we seek and obtain issued patent claims to specifically protect each of our drugs. For example, we file and seek to obtain claims covering each drug’s nucleic acid sequence and precise drug design. In sum, we maintain our competitive advantage in the field of antisense technology by protecting our core platform technology, which applies to most of our drugs, and by creating multiple layers of patent protection for each of our specific drugs in development.

Type of Patent Claim
   
Description
     
1. Chemically Modified Nucleosides and Oligonucleotides
1. Antisense Drug Design Motifs
2. Therapeutic Methods
3. Antisense Sequence
4. Drug Composition
 
1. Target and sequence independent
2. Sequence independent
3. Chemistry independent
4. Specific claim to drug candidates
     
     

Chemically Modified Nucleosides and Oligonucleotides
 
The most broadly applicable of our patents are those that claim modified nucleosides and oligonucleotides comprising the modified nucleosides that we incorporate into our antisense drugs to increase their therapeutic efficacy. Nucleosides and chemically modified nucleosides are the basic building blocks of our antisense drugs, therefore claims that cover any oligonucleotide incorporating one of our proprietary modified nucleosides can apply to a wide array of antisense mechanisms of action as well as several therapeutic targets. Of particular note are our patents covering our proprietary 2’-O-(2-methoxy) ethyl modified nucleosides, incorporated into many of our development compounds, as well as our Generation 2.5 compounds, the constrained-ethyl nucleosides, or cEt nucleosides. 
26


The following are some of our patents in this category:
 
Jurisdiction
 
Patent No.
 
Title
 
Expiration
 
Description of Claims
 
 
 
 
 
 
 
 
 
United States
 
7,101,993
 
OLIGONUCLEOTIDES CONTAINING 2’O-MODIFIED PURINES
 
2023
 
Covers certain MOE nucleosides and oligonucleotides containing these nucleotides.
United States
 
7,399,845
 
6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS
 
2027
 
Covers our cEt nucleosides and oligonucleotides containing these nucleoside analogs.
United States
 
7,741,457
 
6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS
 
2027
 
Covers our cEt nucleosides and oligonucleotides containing these nucleoside analogs.
United States
 
8,022,193
 
6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS
 
2027
 
Covers our cEt nucleosides and oligonucleotides containing these nucleoside analogs.
United States
 
7,569,686
 
COMPOUNDS AND METHODS FOR SYNTHESIS OF BICYCLIC NUCLEIC ACID ANALOGS
 
2027
 
Covers methods of synthesizing our cEt nucleosides.
Europe
 
EP1984381
 
6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS
 
2027
 
Covers our cEt nucleosides and oligonucleotides containing these nucleoside analogs.

Antisense Drug Design Motifs
 
MOE Gapmers
 
Other Ionis patents claim oligonucleotides comprising specific antisense drug design motifs, or patterns of nucleoside modifications at specified positions in the oligonucleotide. Patent claims covering our antisense drug design motifs are independent of nucleic acid sequence, so they cover oligonucleotides having the recited motif, regardless of cellular target or clinical indication. The claimed motifs generally confer properties that optimize oligonucleotides for a particular antisense mechanism of action, such as ribonuclease H, or RNase H, RNAi, or splicing. We have designed oligonucleotides incorporating motifs, which we refer to as chimeric compounds or gapmers to exploit the RNase H mechanism to achieve target RNA reduction. Almost all of our drugs, including volanesorsen and IONIS-TTRRx, contain this gapmer antisense drug design motif. In fact, we own a U.S. patent that covers each of our second generation gapmer antisense drugs until March of 2023. We also have issued patents covering other gapmer drug designs, and methods of lowering a target RNA in an animal with these gapmer compositions. The following patent is one example of our patents in this category.

Jurisdiction
 
Patent/
Application
No.
 
Title
 
Expiration
 
Description of Claims
United States
 
7,015,315
 
GAPPED OLIGONUCLEOTIDES
 
2023
 
Covers 2’-O-alkyl-O-alkyl gapmer oligonucleotides.
 
Bicyclic Nucleoside Gapmer Oligonucleotides
 
In addition, we have pursued patent claims to antisense drug design motifs incorporating bicyclic nucleoside analogs, which include locked nucleic acids, or LNAs. In Europe, we have granted claims drawn to short gapmer oligonucleotides with bicyclic nucleosides, which include locked nucleic acids, in the wings for the treatment of cardiovascular or metabolic disorders. We have also successfully obtained issued patent claims covering gapmer antisense drug design motifs that incorporate our cEt modified nucleosides. Santaris opposed granted patent EP2092065 and EP2410053 and in April 2015, the claims of EP2092065 were successfully upheld in amended form. We intend to vigorously defend EP2410053 in future proceedings. The following patents are some examples of our issued patents in this category:

Jurisdiction
 
Patent/
Application
No.
 
Title
 
Expiration
 
Description of Claims
Europe
 
EP2021472
 
COMPOUNDS AND METHODS FOR MODULATING GENE EXPRESSION
 
2027
 
Short gapmer oligonucleotides, 10 to 14 nucleotides in length, with bicyclic nucleosides, which includes cEt locked nucleic acids, in the wings for the treatment of cardiovascular or metabolic disorders
United States
 
7,750,131
 
6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS
 
2027
 
Covers cEt containing gapmer compounds
Europe
 
EP2092065
 
ANTISENSE COMPOUNDS
 
2027
 
Gapmer compounds having wings comprised of 2’-MOE and bicyclic nucleosides
Europe
 
EP2410053
 
ANTISENSE COMPOUNDS
 
2027
 
Gapmer compounds having wings comprised of 2’-MOE and bicyclic nucleosides

27


Ligand-Conjugated Antisense (LICA) Technology

We have also pursued patent claims to new chemistries created to enhance targeting of antisense drugs to specific tissues and cells in order to improve a drug’s potency. Our N-acetyl-galactosamine (GalNAc) LICA drugs are designed to provide an increase in potency for targets in the liver. We have successfully obtained issued patent claims covering our primary GalNAc LICA (THA) conjugated to any modified oligonucleotide, including gapmers, double-stranded siRNA compounds, and fully modified oligonucleotides. The following patents are some examples of our issued patents in this category:

Jurisdiction
 
Patent/
Application
No.
 
Title
 
Expiration
 
Description of Claims
United States
 
9,127,276
 
CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
 
2034
 
Covers our primary THA LICA conjugate having any type of linker and conjugated to any group of nucleosides, including gapmers, double-stranded siRNA compounds, and fully modified oligonucleotides
United States
 
9,181,549
 
CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
 
2034
 
Covers our primary THA conjugate having our preferred linker and cleavable moiety conjugated to any oligomeric compound or any nucleoside having a 2’-MOE modification or a cEt modification

Therapeutic Methods of Treatment and Antisense Drug Sequences
 
In addition to our broad core patents, we also own hundreds of patents, worldwide, with claims to antisense sequences and compounds directed to particular therapeutically important targets or methods of achieving clinical endpoints using these antisense compounds. Target patents may also include claims reciting the specific nucleic acid sequences utilized by our products, independent of chemical modifications and motifs. In addition, our product specific patents typically include claims combining specific nucleic acid sequences with nucleoside modifications and motifs. In this way, we seek patent claims narrowly tailored to protect our products specifically, in addition to the broader core antisense patents described above.

 Survival Motor Neuron and nusinersen
 
Nusinersen is protected by a suite of patents in the United States and in Europe from generic competition in the United States until at least 2030 and in Europe until 2026. These issued patents include: (i) the Bennett patent related to methods of altering mRNA processing (i.e., splicing) with a fully modified 2’MOE oligonucleotide, (ii) a patent licensed from the University of Massachusetts drawn to antisense compounds having the sequence of nusinersen, independent of chemical modification and uses of such compounds for treating SMA, and (iii) a joint patent with Cold Spring Harbor Laboratory claiming fully modified 2’MOE compositions targeting SMN2, including the precise composition of matter of nusinersen. Those patents should protect nusinersen from generic and antisense innovator competition in the United States until at least 2030 without patent term extension. The table below lists the key U.S. and European issued patents protecting nusinersen:

Jurisdiction
 
Patent No.
 
Title
 
Expiration
 
Description of Claims
United States
 
6,210,892
 
ALTERATION OF CELLULAR BEHAVIOR BY MODULATION OF MRNA PROCESSING
 
2018
 
Broad claims of altering mRNA processing with a fully modified 2’MOE oligonucleotide.
United States
 
8,361,977
 
COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
 
2030
 
Sequence and chemistry (full 2’-MOE) of nusinersen
 
Europe
 
1910395
 
COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
 
2026
 
Sequence and chemistry (full 2’-MOE) of nusinersen
 
United States
 
7,838,657
 
SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES
 
2027
 
Oligonucleotides having sequence of nusinersen (chemistry independent)
United States
 
8,110,560
 
SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES
 
2025
 
Methods of using antisense oligonucleotides having sequence of nusinersen to alter splicing of SMN2 and/or to treat SMA
United States
 
8,980,853
 
COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT
 
2030
 
Methods of administering nusinersen
 
Transthyretin and IONIS-TTRRx
 
We obtained issued claims covering IONIS-TTRRx in the United States. The issued U.S. claims should protect IONIS-TTRRx from generic competition in the United States until at least 2031. We are also pursuing additional patent applications designed to protect IONIS-TTRRx in the United States and other foreign jurisdictions, including Europe and Japan. The table below lists the current issued U.S. patents protecting IONIS-TTRRx:
 
Jurisdiction
 
Patent No.
 
Title
 
Expiration
 
Description of Claims
United States
 
8,101,743
 
MODULATION OF TRANSTHYRETIN EXPRESSION
 
2025
 
Antisense sequence and chemistry of IONIS-TTRRx
United States
 
8,697,860
 
DIAGNOSIS AND TREATMENT OF DISEASE
 
2031
 
Composition of IONIS-TTRRx
United States
 
9,061,044
 
MODULATION OF TRANSTHYRETIN EXPRESSION
 
2031
 
Sodium salt composition of IONIS-TTRRx
 
In some cases, the patent term can be extended to recapture a portion of the term lost during FDA regulatory review.
28


Apolipoprotein C-III and volanesorsen
 
We have obtained patent claims in the United States drawn to the use of antisense compounds complementary to a broad active region of human Apo C-III including the site targeted by volanesorsen. Similar claims complementary to any site on human Apo C-III have granted in Australia. We obtained issued patent claims to the specific antisense sequence and chemical composition of volanesorsen in the United States, Australia, and Europe. The issued U.S. claims should protect volanesorsen from generic competition in the United States until at least 2023. In addition, we will seek additional patent term extension to recapture a portion of the term lost during FDA regulatory review, extending the term of this patent beyond 2023. We are also pursuing additional patent applications designed to protect the volanesorsen composition in Canada and additional methods of use in jurisdictions worldwide. The table below lists the key U.S, European and Australian issued patents:
 
Jurisdiction
 
Patent No.
 
Title
 
Expiration
 
Description of Claims
United States
 
7,598,227
 
MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
 
2023
 
Methods of treating hyperlipidemia, lowering cholesterol levels and lowering triglyceride levels with an antisense compound comprising an antisense oligonucleotide 15-30 linked nucleosides specifically hybridizable within a nucleotide region of apoCIII targeted by volanesorsen
United States
 
7,750,141
 
MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
 
2023
 
Antisense sequence and chemistry of volanesorsen
 
Europe
 
EP1622597
 
MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
 
2023
 
Antisense sequence and chemistry of volanesorsen
Australia
 
2004231550
 
MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
 
2023
 
Compounds 12-50 nucleobases in length specifically hybridizable with SEQ ID 4 (apoCIII), the antisense sequence and chemistry of volanesorsen and methods of their use in treating hyperlipidemia, lowering cholesterol levels and lowering triglyceride levels
United States
 
9,157,082
 
MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
 
2032
 
Methods of using APOCIII antisense oligonucleotides for reducing pancreatitis and chylomicronemia and increasing HDL
 
ApoB 100 and KYNAMRO
 
In 2008, we obtained patent claims in the United States drawn to the use of both single-stranded and double-stranded antisense drugs complementary to any site of the mRNA of human apoB, regardless of chemistry or antisense mechanism of action. The patent provides broad protection of the apoB franchise, including KYNAMRO and potential future follow-on compounds. Similar claims granted in Australia and Japan in 2009 and 2010, respectively. Additional claims have granted in Europe covering the use 5-10-5 MOE gapmers targeting ApoB. We obtained issued claims to the specific antisense sequence and chemical composition of KYNAMRO in the United States, Australia, South Africa, India, Japan and the European Union. The issued U.S. claims should protect KYNAMRO from generic competition in the United States until at least 2025. We are also pursuing additional patent applications designed to protect KYNAMRO in these and other jurisdictions including Canada. The table below lists the key issued patent claims designed to protect KYNAMRO in the applicable jurisdiction:
 
Jurisdiction
 
Patent No.
 
Title
 
Expiration
 
Description of Claims
United States
 
7,407,943
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2021
 
Methods of inhibiting expression of apoB, decreasing serum cholesterol, decreasing lipoprotein levels, decreasing serum triglycerides in a human with an antisense compound 12 to 30 nucleotide in length and 100% complementary to human apoB wherein the compound is not a ribozyme.
Australia
 
2002-326481
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2022
 
An isolated oligonucleotide compound 12 to 30 nucleobases in length 100% complementary to at least a 12-nucleobase portion of a nucleic acid molecule having nucleotides 151-12820 of SEQ ID 3 (apoB) which is not a ribozyme and use of such compound in therapy
Japan
 
4471650
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2022
 
Use of an antisense oligonucleotide 12 to 30 nucleobases in length and 100% complementary to human apoB having one or more modifications and inhibiting expression of apoB by at least 90% in primary hepatocytes when present at a concentration of 300 nM for preparation of a medicament for decreasing serum cholesterol, and decreasing lipoprotein levels in a human
Europe
 
EP2174945
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2022
 
Use of an antisense oligonucleotide 20 nucleobases in length and 100% complementary to human apoB having a 5-10-5 MOE motif for treating conditions associated with ApoB
United States
 
7,511,131
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2025
 
Antisense sequence and composition of matter of Kynamro
29


Europe
 
EP1569695
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2023
 
Antisense sequence and composition of matter of Kynamro
Europe
 
EP2336318
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2023
 
Antisense sequence and composition of matter of Kynamro
India
 
219847
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2023
 
Antisense sequence and composition of matter of Kynamro
Australia
 
2003294281
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2023
 
Antisense sequence and composition of matter of Kynamro
South Africa
 
2005/03690
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2023
 
Antisense sequence and composition of matter of Kynamro
Japan
 
4986109
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2023
 
Antisense sequence and composition of matter of Kynamro
Europe
 
EP2409713
 
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
 
2025
 
Kynamro for use in treating a human with hypercholesterolemia, wherein the oligonucleotide is administered at 200mg once per week by subcutaneous injection

Custirsen
 
Issued patent claims have been obtained from an application jointly filed by Ionis and OncoGenex to protect the specific chemical composition of custirsen in the United States. The issued U.S. claims should protect custirsen from generic competition in the United States until at least 2021. The table below lists the U.S. issued patent:
 
Jurisdiction
 
Patent No.
 
Title
 
Expiration
 
Description of Claims
United States
 
6,900,187
 
TRPM-2 ANTISENSE THERAPY USING AN OLIOGNUCLEOTIDE HAVING 2’-O-(2-METHOXY)ETHYL MODIFICATIONS
 
2021
 
Antisense sequence and composition of custirsen

RNAi Motifs and Mechanisms - The Crooke Patents
 
The Crooke Patents, which are the result of the early work by Dr. Crooke and co-workers exploring oligonucleotides that activate double-stranded ribonucleases, or dsRNases, cover chemically modified, RNA-containing oligonucleotides and methods for exploiting the RNAi pathway with these oligonucleotides until June 2016. We licensed the Crooke Patents to Alnylam for the development of double-stranded therapeutics and to Regulus for the development of microRNA-targeting therapeutics. Although these patents do not cover any of the drugs in our development pipeline, these patents are important in the field of ssRNAi compounds, in which we have made great strides to progress this approach toward a viable therapeutic platform. The following patents have issued out of the Crooke Patent family:
 
Jurisdiction
 
Patent No.
 
Title
 
Expiration
 
Description of Claims
United States
 
5,898,031
 
OLIGORIBONUCLEOTIDES FOR CLEAVING RNA
 
2016
 
Oligonucleotides comprising regions of RNA nucleosides and regions of nucleosides having stabilizing chemical modifications. Such oligonucleotides are suitable for use in single- and double-stranded applications.
United States
 
6,107,094
 
OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
 
2016
 
Compounds and methods that use oligonucleotides having both RNA nucleosides and chemically modified nucleosides, including methods that rely on a dsRNase to reduce target RNA and compounds having nucleosides with improved affinity and/or stability.
United States
 
7,432,249
 
OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
 
2016
 
Pharmaceutical compositions comprising a diluent or carrier and a single-stranded antisense oligonucleotide having a plurality of RNA nucleosides and at least one sugar modification.
United States
 
7,432,250
 
OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
 
2016
 
Methods for treating a patient by administering an antisense compound having a plurality of RNA nucleosides and at least one sugar modification.
United States
 
7,629,321
 
OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
 
2016
 
Methods for cleaving a target RNA in a cell by contacting the cell with a single-stranded antisense compound having a plurality of RNA nucleosides and at least one sugar modification.
United States
 
7,695,902
 
OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
 
2016
 
Methods of activating a dsRNase by contacting the dsRNase with a double-stranded antisense oligonucleotide where at least one strand has a plurality of RNA nucleosides and at least one sugar modification. The methods may be performed inside a cell.

30


Manufacturing Patents
 
We also own patents claiming methods of manufacturing and purifying oligonucleotides. These patents claim methods for improving oligonucleotide drug manufacturing, including processes for large-scale oligonucleotide synthesis and purification. These methods allow us to manufacture oligonucleotides at lower cost by, for example, eliminating expensive manufacturing steps.
 
We also rely on trade secrets, proprietary know-how and continuing technological innovation to develop and maintain a competitive position in antisense therapeutics.

Government Regulation
 
Regulation by government authorities in the United States and other countries is a significant component in the development, manufacture and commercialization of pharmaceutical products and services. In addition to regulations enforced by the FDA and relevant foreign regulatory authorities, we are also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.
 
Extensive regulation by United States and foreign governmental authorities governs our manufacture, development and potential sale of our drugs. In particular, pharmaceutical products are subject to nonclinical and clinical testing, as well as other approval requirements, by the FDA in the United States under the Federal Food, Drug and Cosmetic Act and other laws and by comparable agencies in those foreign countries in which we conduct business. Various federal, state and foreign statutes also govern or influence the manufacture, safety, labeling, storage, record keeping, marketing and quality of our drugs. State, local, and other authorities also regulate pharmaceutical manufacturing facilities and procedures.
 
 Our manufacturing facility is subject to periodic inspection by the FDA and other foreign equivalents to ensure that it is operating in compliance with current good manufacturing practices, or cGMP, requirements. Marketing authorization for each new drug will require a rigorous manufacturing pre-approval inspection by regulatory authorities.
 
For any approved drug, domestic and foreign sales of the drug will depend, in part, on the availability and amount of reimbursement by third party payors, including governments and private health plans. Governments may regulate coverage, reimbursement and pricing of drugs to control cost or affect use of our drugs. Private health plans may also seek to manage cost and use by implementing coverage and reimbursement limitations. Within the European Union, or EU, a variety of payors pay for drugs, with governments being the primary source of payment. Governments may determine or influence reimbursement of drugs. Governments may also set prices or otherwise regulate pricing. Negotiating prices with governmental authorities can delay commercialization of a drug. These pricing and reimbursement procedures could impact our commercial partners’, including our wholly owned subsidiary, Akcea’s, ability to successfully commercialize our approved drugs.

Our operations may be directly, or indirectly through our customers, distributors, or other business partners, subject to various federal and state fraud and abuse laws, including, without limitation, anti-kickback statutes and false claims statutes. These laws may impact, among other things, our commercialization partners’ proposed sales, marketing and education programs.
 
The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits certain individuals and entities, including us, from promising, paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, directly or indirectly, to obtain or retain business or an improper advantage. If we violate the FCPA, it could result in large civil and criminal penalties and could result in an adverse effect on our reputation, operations, and financial condition. We could also face collateral consequences such as debarment and the loss of export privileges.

Competition 

Our Business in General
 
Some of our drugs may compete with existing therapies for market share. In addition, there are a number of companies pursuing the development of oligonucleotide-based technologies and the development of pharmaceuticals utilizing these technologies. These companies include specialized pharmaceutical firms and large pharmaceutical companies acting either independently or together with biopharmaceutical companies. Our drugs are differentiated from traditional small molecule drugs by their chemistry, how they move in the body, how they act in the body, delivery technology, and formulations.

Our products under development address numerous markets. The diseases our drugs target for which we have or may receive marketing authorization will determine our competition. For some of our products, an important factor in competition may be the timing of market introduction of competitive products. Accordingly, the relative speed with which we can develop products, complete the clinical trials and marketing authorization processes and supply commercial quantities of the products to the market are important competitive factors. We expect to compete among products approved for sale based on a variety of factors, including, among other things, product efficacy, safety, mechanism of action, dosing convenience, marketing and sales strategy and tactics, availability, price, and reimbursement.
 
The current key competition for our three Phase 3 drugs, nusinersen, IONIS-TTRRx and volanesorsen, and our approved drug Kynamro is set forth below.
31


Nusinersen

We believe that the following drugs could compete with nusinersen:

Drug
Company
Drug Description
Phase
Admin/Dosing
Efficacy(1)
Safety(1)
AVXS-101
AveXis
Gene therapy that corrects the SMN1 gene using the
AAV9 Vector
1
Infusion
All 15 patients enrolled in the study were event free as of Dec 31, 2015. All patients experienced either improvement or stabilization in motor skills relative to their baseline measurement
 
Well tolerated to date
RG7800
 
PTC Therapeutics/ Roche/ SMA Foundation
 
 
 
A small molecule drug that modulates splicing of the
SMN2 gene
2
 
 
 
Oral
Up to three-fold increases in the ratio of full length SMN2 mRNA to SMN2Δ7 mRNA and up to two-fold increases in SMN protein were observed in plasma versus baseline in SMA patients
RG7800 on clinical hold due to non-clinical safety finding
 
RG7916
 
PTC Therapeutics/ Roche/ SMA Foundation
 
A small molecule drug that modulates splicing of the
SMN2 gene
1
Oral
None reported
None reported
LMI070
Novartis
A small molecule drug that modulates splicing of the
SMN2 gene
 
1/2
Oral
None reported
None reported

(1)
Taken from public documents including respective company press releases, company presentations, and scientific presentations.

We believe that nusinersen’s closest competitor is AVXS-101. AVXS-101 is currently in a Phase 1 study for infants with Type 1 SMA. While the data released thus far on the AVXS-101 study is encouraging, it is still early in development. In addition, other gene therapies have had difficulty providing lasting therapeutic benefit. Also AveXis has stated it needs to scale its manufacturing capabilities to be able to manufacture larger quantities of AVXS-101. Further, no company has yet to successfully commercialize a gene therapy, which may create significant barriers for AVXS-101.

IONIS-TTRRx

We believe that the following drugs could compete with IONIS-TTRRx:

Drug
Company
Drug Description
Phase
Admin/Dosing
Efficacy*
Safety*
Patisiran
Alnylam
An RNAi drug formulated with lipid nanoparticles to inhibit TTR mRNA
3
Infusion every 3 weeks with pre-treatment with steroids
~90% mean maximum reduction in TTR
Mild flushing (25.9%) and infusion-related reactions (18.5%) in Phase 2 OLE
Revusiran
Alnylam
An RNAi drug conjugated with GalNAC to inhibit TTR mRNA in liver cells
3
Weekly large volume subcutaneous injection
~87% mean maximum reduction in TTR
Injection site reactions (ISRs) reported in 44% of patients in the Phase 2 OLE, 3 patients discontinued OLE due to ISRs or diffuse rash
 
Tafamidis
Pfizer
A small molecule drug to stabilize TTR Protein
3, Approved in the EU
Daily oral capsule
In 45% of patients taking Tafamidis, nerve function either improved or stabilized, compared with 30% of patients taking placebo
 
Urinary tract infection, vaginal infection, upper abdominal pain and diarrhea
Diflunisal
N/A Generic
A non-steroid anti-inflammatory agent
Approved
Daily oral capsule/doses
Improved nerve function as shown by lower Neuropathy Impairment Score plus 7 nerve tests, or NIS+7. The NIS+7 score increased by 25.0 points in the placebo group versus 8.7 points in the diflunisal group
In two studies repurposing diflunisal for use in TTR amyloidosis, drug-related adverse events that led to discontinuation were: gastrointestinal bleeding, low platelets, deterioration of renal function, congestive heart failure, glaucoma and nausea.
 
Tolcapone
SOM Biotech
Small molecule repurposed generic drug
1/2
Daily oral dose
Shows binding and stabilization of TTR in humans
No drug related adverse events reported
ALN-TTRsc02
Alnylam
An RNAi drug conjugated with GalNAC to inhibit TTR mRNA in liver cells
Preclinical
Monthly or quarterly
No data in humans
No data in humans

32


(1)
Taken from public documents including respective company press releases, company presentations, and scientific presentations. Diflunisal efficacy and safety came from the published papers of two investigator sponsored studies, Berk JL, Suhr OB, Obici L, et al. Repurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial. JAMA. 2013;310(24):2658-2667 and Sekijima YS, Toja K, Morita H, et al. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015;22(2):79-83.

We believe that of the drugs that are in development or on the market, IONIS-TTRRx’s closest competitors are patisiran and revusiran. Alnylam is developing patisiran for the polyneuropathy form of TTR amyloidosis. Patisiran is an intravenously administered RNAi molecule that is formulated with lipid nanoparticles to enable delivery of the drug to the liver. It is administered via an infusion by a healthcare provider every three weeks. Patients receiving patisiran are pretreated with steroids to prevent infusion related reactions. Alnylam is also developing revusiran for the cardiomyopathy form of TTR amyloidosis. Revusiran is a subcutaneously administered RNAi molecule that is Alnylam's first generation GalNAc drug and is dosed at 500 mg per week as two subcutaneous injections. In early clinical studies, IONIS-TTRRx, patisiran and revusiran produced similar TTR reductions in treated subjects. Because we have completed target enrollment in our fifteen month study, ahead of Alnylam's eighteen month study, we believe that IONIS-TTRRx will be the first RNA-targeted drug on the market. We also believe that the overall product profile of IONIS-TTRRx. as a single, once weekly, subcutaneous injection with no pretreatment is superior to the drugs detailed above. 

Volanesorsen

We believe that the following drugs could compete with volanesorsen:

Drug
Company
Drug Description
Phase
Admin/Dosing
Efficacy(1)
Safety(1)
Glybera
uniQure NV
Adeno-associated Virus Gene therapy
Approved in EU, Suspended development in the US
A single treatment involving multiple injections
Showed a reduction in blood fat levels after meals in some patients. There was also a reduction in the number of pancreatitis attacks in some patients.
 
Common side effects include: leg pain following injection, headache, tiredness, high body temperature, bruising and potential damage to muscle tissue
Metreleptin
Aegerion
 
A synthetic form of the hormone leptin
2
Reconstituted subcutaneous injection
44.4% mean reduction in triglycerides at 4 months in patients with abnormal triglyceride levels
 
Anti-metreleptin antibodies, hypoglycemia, hypersensitivity, risk of T-cell lymphoma

(1)
Taken from public documents including respective company press releases, company presentations, and scientific presentations.

Glybera is approved only in the EU for a subset of FCS patients whose disease has been confirmed by genetic testing and who have detectable levels of a specific protein in their blood. UniQure NV has announced it is not pursuing marketing authorization in the United States. Metreleptin is being tested in FPL patients who also have NASH. Volanesorsen is currently in Phase 3 development to treat patients with FCS and patients with FPL. To date, volanesorsen has shown the highest percent of triglyceride reductions compared to existing treatments, such as fibrates, regardless of starting triglyceride levels prior to dosing with volanesorsen. Based on our broad Phase 2 data for the treatment of different patients including patients with FCS, we believe that volanesorsen will work equally well as a single agent or in combination with other triglyceride-lowering drugs on the market. 

Kynamro

Kynamro is currently approved in the United States and certain other countries to reduce LDL-C, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol in patients with HoFH. We believe that the following drugs compete with Kynamro:

Drug
Company
Drug Description
Phase
Admin/Dosing
Efficacy(1)
Safety(1)
Lomitapide
Aegerion
A small molecule drug that inhibits microsomal triglyceride transfer protein
 
Approved
Titrate up, 5-60 mg oral daily
40% reduction in LDL-C from baseline (change from mean 336 mg/dL LDL-C to 190 mg/dL LDL-C) at week 26 in Phase 3 study
 
Hepatic steatosis, risk of steatohepatitis, transaminase abnormalities, risk for drug-induced liver injury, risk for deficiencies in fat-soluble vitamins and essential fatty acids
Evolocumab
Amgen
A monoclonal antibody drug that inhibits PCSK9 protein
 
Approved
Monthly sub-q
TESLA (phase 2/3 in HOFH): 31% mean reduction in LDL-C from baseline
 
nasopharyngitis, upper respiratory tract infections, influenza, arthralgia, and back pain

(1)
Taken from public documents including respective company press releases, company presentations, and scientific presentations

The primary competitor for Kynamro is lomitapide, an oral small molecule that blocks the absorption of fat in the digestive system. In the lomitapide label, concurrent use of lomitapide and common medications for HoFH patients who have cardiovascular disease, including simvastatin and warfarin, need to be closely monitored due to drug-drug interactions with potentially harmful outcomes. Kynamro has no restrictions with these medications or diet restrictions, which may be advantageous for HoFH patients who are on a broad range of therapies due to the severity of their disease. Evolocumab will not work in the HoFH patients that do not have LDL-receptor function and should have variable effect in patients that have variable levels of LDL-receptor activity. Kynamro works in HoFH patients regardless of LDL-receptor function. Kynamro sales could be affected if Kynamro’s product profile is not advantageous when compared to these other drugs, as some patients may prefer these other drugs over Kynamro.
33



Employees
 
As of February 19, 2016, we employed 428 people, including 14 Akcea employees. A significant number of our management and professional employees have had prior experience with pharmaceutical, biotechnology or medical product companies. Collective bargaining agreements do not cover any of our employees, and management considers relations with our employees to be good.

Executive Officers of Ionis
 
The following sets forth certain information regarding our executive officers as of February 19, 2016:
 
Name
 
Age
 
Position
Stanley T. Crooke, M.D., Ph.D.
 
70
 
Chairman, Chief Executive Officer and President
B. Lynne Parshall, J.D.
 
61
 
Director, Chief Operating Officer
C. Frank Bennett, Ph.D.
 
59
 
Senior Vice President, Antisense Research
Sarah Boyce
 
44
 
Chief Business Officer
Richard S. Geary, Ph.D.
 
58
 
Senior Vice President, Development
Elizabeth L. Hougen
 
54
 
Senior Vice President, Finance and Chief Financial Officer
Brett P. Monia, Ph.D.
 
54
 
Senior Vice President, Drug Discovery and Corporate Development
Patrick R. O’Neil, Esq.
 
42
 
Senior Vice President, Legal, General Counsel and Corporate Secretary
 

STANLEY T. CROOKE, M.D., Ph.D.
 
Chairman, Chief Executive Officer and President
 
Dr. Crooke is a founder of Ionis and has been Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Ionis, from 1980 until January 1989, Dr. Crooke was employed by SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories.
 
B. LYNNE PARSHALL, J.D.
 
Director, Chief Operating Officer
 
Ms. Parshall has served as a Director of Ionis since September 2000. She has been our Chief Operating Officer since December 2007 and previously served as our Chief Financial Officer from June 1994 to December 2012. She also served as our Corporate Secretary through 2014 and has served in various executive roles since November 1991. Prior to joining Ionis, Ms. Parshall practiced law at Cooley LLP, outside counsel to Ionis, where she was a partner from 1986 to 1991. Ms. Parshall is a member of the American, California and San Diego bar associations.
 
C. FRANK BENNETT, Ph.D.
 
Senior Vice President, Antisense Research
 
Dr. Bennett was promoted to Senior Vice President, Antisense Research in January 2006. From June 1995 to January 2006, Dr. Bennett served as our Vice President, Research. From March 1993 to June 1995, he was Director, Molecular Pharmacology, and from May 1992 to March 1993, he was an Associate Director in our Molecular and Cellular Biology department. Prior to joining Ionis in 1989, Dr. Bennett was employed by SmithKline and French Laboratories in various research positions. He is an external member of the Scientific Advisory Board of Experimental Therapeutics Center in Singapore.
 
SARAH BOYCE
 
Chief Business Officer
 
Ms. Boyce joined Ionis in January 2015 as our Chief Business Officer. Prior to joining Ionis, Ms. Boyce was Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc. from 2012 to 2014. She was Vice President, Global Head Nephrology Therapeutics Area of Alexion Pharmaceuticals from 2010 to 2011. She held various positions at Novartis Group AG, including Vice President, Global Program Head, Pediatric and Specialty from 2000 to 2010. Prior to that, Ms. Boyce held positions at Bayer Pharmaceuticals and Roche.

RICHARD S. GEARY, Ph.D.
 
Senior Vice President, Development
 
Dr. Geary was promoted to Senior Vice President, Development in August 2008. From August 2003 to August 2008, Dr. Geary served as our Vice President, Preclinical Development. From November 1995 to August 2003, he held various positions within the Preclinical Development department. Prior to joining Ionis in 1995, Dr. Geary was Senior Research Scientist and Group Leader for the bioanalytical and preclinical pharmacokinetics group in the Applied Chemistry Department at Southwest Research Institute.
34


ELIZABETH L. HOUGEN
 
Senior Vice President, Finance and Chief Financial Officer
 
Ms. Hougen was promoted to Senior Vice President, Finance and Chief Financial Officer in January 2013. From January 2007 to December 2012, Ms. Hougen served as our Vice President, Finance and Chief Accounting Officer and from May 2000 to January 2007, she served as our Vice President, Finance. Prior to joining Ionis in 2000, Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.
 
BRETT P. MONIA, Ph.D.
 
Senior Vice President, Drug Discovery and Corporate Development
 
Dr. Monia was promoted to Senior Vice President, Drug Discovery and Corporate Development in January 2012. From February 2009 to January 2012, Dr. Monia served as our Vice President, Drug Discovery and Corporate Development and from October 2000 to February 2009, he served as our Vice President, Preclinical Drug Discovery. From October 1989 to October 2000 he held various positions within our Molecular Pharmacology department.
 
PATRICK R. O’NEIL, Esq.
 
Senior Vice President, Legal, General Counsel and Corporate Secretary
 
Mr. O’Neil was promoted to Senior Vice President, Legal and General Counsel in January 2013. Starting in January 2015, Mr. O'Neil also serves as our Corporate Secretary. From September 2010 to January 2013, Mr. O’Neil served as our Vice President, Legal and General Counsel and from January 2009 to September 2010, he served as our Vice President, Legal and Senior Transactions Counsel. From October 2001 to January 2009 he held various positions within our Legal department. Prior to joining Ionis, Mr. O’Neil was an associate at Cooley LLP.


Item 1A. RISK FACTORS

Investing in our securities involves a high degree of risk. You should consider carefully the following information about the risks described below, together with the other information contained in this report and in our other public filings in evaluating our business. If any of the following risks actually occur, our business could be materially harmed, and our financial condition and results of operations could be materially and adversely affected. As a result, the trading price of our securities could decline, and you might lose all or part of your investment.

Risks Associated with our Ionis Core and Akcea Therapeutics Businesses

If the market does not accept our drugs, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro we are not likely to generate revenues or become consistently profitable.

Even if our drugs are authorized for marketing, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro our success will depend upon the medical community, patients and third party payors accepting our drugs as medically useful, cost-effective and safe. Even when the FDA or foreign regulatory authorities authorize our or our partners' drugs for commercialization, doctors may not prescribe our drugs to treat patients. We and our partners may not successfully commercialize additional drugs.

Additionally, in many of the markets where we may sell our drugs in the future, if we cannot agree with the government regarding the price we can charge for our drugs, then we may not be able to sell our drugs in that market.

The degree of market acceptance for our drugs, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro, depends upon a number of factors, including the:

receipt and scope of marketing authorizations;
establishment and demonstration in the medical and patient community of the efficacy and safety of our drugs and their potential advantages over competing products;
cost and effectiveness of our drugs compared to other available therapies;
patient convenience of the dosing regimen for our drugs; and
reimbursement policies of government and third-party payors.

Based on the profile of our drugs, physicians, patients, patient advocates, payors or the medical community in general may not accept and/or use any drugs that we may develop. In addition, cost control initiatives by governments or third party payors could decrease the price received for our drugs or increase patient coinsurance to a level that makes our drugs, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro, unaffordable.

If we or our partners fail to compete effectively, our drugs, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro, will not contribute significant revenues.

Our competitors engage in drug discovery throughout the world, are numerous, and include, among others, major pharmaceutical companies and specialized biopharmaceutical firms. Other companies engage in developing antisense technology. Our competitors may succeed in developing drugs that are:

priced lower than our drugs;
safer than our drugs;
more effective than our drugs; or
more convenient to use than our drugs.
35


These competitive developments could make our drugs, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro, obsolete or non-competitive.

Certain of our partners are pursuing other technologies or developing other drugs either on their own or in collaboration with others, including our competitors, to treat the same diseases our own collaborative programs target. Competition may negatively impact a partner's focus on and commitment to our drugs and, as a result, could delay or otherwise negatively affect the commercialization of our drugs, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro.

Many of our competitors have substantially greater financial, technical and human resources than we do. In addition, many of these competitors have significantly greater experience than we do in conducting preclinical testing and human clinical studies of new pharmaceutical products and in obtaining FDA and other regulatory authorizations of such products. Accordingly, our competitors may succeed in obtaining regulatory authorization for products earlier than we do. Marketing and sales capability is another factor relevant to the competitive position of our drugs, and we will rely on our partners and Akcea to provide this capability.

There are several pharmaceutical and biotechnology companies engaged in the development or commercialization of products against targets that are also targets of products in our development pipeline. For example, drugs like AVXS-101, RG7800, RG7916, and LM1070 could compete with nusinersen, drugs like patisiran, revusiran, tafamadis, diflunisal, tolcapone and ALN-TTRsc02 could compete with IONIS-TTRRx, drugs like Glybera and metreleptin could compete with volanesorsen and drugs like lomitapide and evolocumab could compete with Kynamro.

Following approval our drugs, including nusinersen, IONIS-TTRRx and volanesorsen, could be subject to regulatory limitations. Kynamro is subject to regulatory limitations.

Following approval of a drug, we and our partners must comply with comprehensive government regulations regarding the manufacture, marketing and distribution of drug products. We or our partners may not obtain the labeling claims necessary or desirable to successfully commercialize our drug products, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro.

The FDA and foreign regulatory authorities have the authority to impose significant restrictions on an approved drug product through the product label and on advertising, promotional and distribution activities. For example Kynamro is subject to a Boxed Warning and is only available through a Risk Evaluation and Mitigation Strategy.

In addition, when approved, the FDA or a foreign regulatory authority may condition approval on the performance of post-approval clinical studies or patient monitoring, which could be time consuming and expensive. If the results of such post-marketing studies are not satisfactory, the FDA or a foreign regulatory authority may withdraw marketing authorization or may condition continued marketing on commitments from us or our partners that may be expensive and/or time consuming to fulfill.

If we or others identify side effects after any of our drug products are on the market, or if manufacturing problems occur subsequent to regulatory approval, we or our partners may lose regulatory approval, or we or our partners may need to conduct additional clinical studies and/or change the labeling of our drug products including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro.

If we or our partners fail to obtain regulatory approval for our drugs, including nusinersen, IONIS-TTRRx, volanesorsen, and additional approvals for Kynamro we or our partners cannot sell them in the applicable markets.

We cannot guarantee that any of our drugs, including nusinersen, IONIS-TTRRx and volanesorsen, will be safe and effective, or will be approved for commercialization. In addition, we cannot guarantee that Kynamro will be approved in additional markets outside the United States or for additional indications. We and our partners must conduct time-consuming, extensive and costly clinical studies to show the safety and efficacy of each of our drugs, including nusinersen, IONIS-TTRRx and volanesorsen, before they can be approved for sale. We must conduct these studies in compliance with FDA regulations and with comparable regulations in other countries.

We and our partners may not obtain necessary regulatory approvals on a timely basis, if at all, for any of our drugs. It is possible that regulatory agencies will not approve any of our drugs including, nusinersen, IONIS-TTRRx and volanesorsen for marketing or additional marketing authorizations for Kynamro. If the FDA or another regulatory agency believes that we or our partners have not sufficiently demonstrated the safety or efficacy of any of our drugs, including nusinersen, IONIS-TTRRx and volanesorsen, the agency will not approve the specific drug or will require additional studies, which can be time consuming and expensive and which will delay or harm commercialization of the drug.

Failure to receive marketing authorization for our drugs nusinersen, IONIS-TTRRx and volanesorsen, or additional authorizations for Kynamro, or delays in these authorizations could prevent or delay commercial introduction of the drug, and, as a result, could negatively impact our ability to generate revenue from product sales.

If the results of clinical testing indicate that any of our drugs are not suitable for commercial use we may need to abandon one or more of our drug development programs.

Drug discovery and development has inherent risks and the historical failure rate for drugs is high. Antisense drugs are a relatively new approach to therapeutics. If we cannot demonstrate that our drugs are safe and effective for human use, we may need to abandon one or more of our drug development programs.

In the past, we have invested in clinical studies of drugs that have not met the primary clinical end points in their Phase 3 studies. Similar results could occur in clinical studies for our drugs, including nusinersen, IONIS-TTRRx and volanesorsen. If any of our drugs in clinical studies, including nusinersen, IONIS-TTRRx and volanesorsen, do not show sufficient efficacy in patients with the targeted indication, it could negatively impact our development and commercialization goals for the drug and our stock price could decline.
36


Even if our drugs are successful in preclinical and human clinical studies, the drugs may not be successful in late-stage clinical studies.

Successful results in preclinical or initial human clinical studies, including the Phase 2 results for some of our drugs in development, may not predict the results of subsequent clinical studies, including the Phase 3 studies for nusinersen, IONIS-TTRRx and volanesorsen, and subsequent studies for Kynamro. There are a number of factors that could cause a clinical study to fail or be delayed, including:

the clinical study may produce negative or inconclusive results;
regulators may require that we hold, suspend or terminate clinical research for noncompliance with regulatory requirements;
we, our partners, the FDA or foreign regulatory authorities could suspend or terminate a clinical study due to adverse side effects of a drug on subjects in the trial;
we may decide, or regulators may require us, to conduct additional preclinical testing or clinical studies;
enrollment in our clinical studies may be slower than we anticipate;
the cost of our clinical studies may be greater than we anticipate; and
the supply or quality of our drugs or other materials necessary to conduct our clinical studies may be insufficient, inadequate or delayed.

Any failure or delay in the clinical studies, including the Phase 3 studies for nusinersen, IONIS-TTRRx and volanesorsen, and subsequent studies for Kynamro, could reduce the commercial potential or viability of our drugs.

If we cannot manufacture our drugs or contract with a third party to manufacture our drugs at costs that allow us to charge competitive prices to buyers, we cannot market our products profitably.

To successfully commercialize any of our drugs, we or our partner would need to establish large-scale commercial manufacturing capabilities either on our own or through a third party manufacturer. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical trial and commercial manufacturing capacity. We have limited experience manufacturing pharmaceutical products of the chemical class represented by our drugs, called oligonucleotides, on a commercial scale for the systemic administration of a drug. There are a small number of suppliers for certain capital equipment and raw materials that we use to manufacture our drugs, and some of these suppliers will need to increase their scale of production to meet our projected needs for commercial manufacturing. Further, we must continue to improve our manufacturing processes to allow us to reduce our drug costs. We may not be able to manufacture our drugs at a cost or in quantities necessary to make commercially successful products.

Also, manufacturers, including us, must adhere to the FDA's current Good Manufacturing Practices regulations and similar regulations in foreign countries, which the applicable regulatory authorities enforce through facilities inspection programs. We and our contract manufacturers may not comply or maintain compliance with Good Manufacturing Practices, or similar foreign regulations. Non-compliance could significantly delay or prevent receipt of marketing authorization for our drugs, including authorizations for nusinersen, IONIS-TTRRx and volanesorsen, or result in enforcement action after authorization that could limit the commercial success of our drugs, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro.

We depend on third parties to conduct our clinical studies for our drugs and any failure of those parties to fulfill their obligations could adversely affect our development and commercialization plans.

We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct our clinical studies for our drugs and expect to continue to do so in the future. For example, we use clinical research organizations, such as Icon Clinical Research Limited, INC Research Toronto, Inc. and Medpace for the clinical studies for our drugs, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro. We rely heavily on these parties for successful execution of our clinical studies, but do not control many aspects of their activities. For example, the investigators are not our employees. However, we are responsible for ensuring that these third parties conduct each of our clinical studies in accordance with the general investigational plan and approved protocols for the study. Third parties may not complete activities on schedule, or may not conduct our clinical studies in accordance with regulatory requirements or our stated protocols. The failure of these third parties to carry out their obligations or a termination of our relationship with these third parties could delay or prevent the development, marketing authorization and commercialization of our drugs, including authorizations for nusinersen, IONIS-TTRRx and volanesorsen or additional authorizations for Kynamro.

Risks Associated with our Businesses as a Whole

We have incurred losses, and our business will suffer if we fail to consistently achieve profitability in the future.

Because drug discovery and development requires substantial lead-time and money prior to commercialization, our expenses have generally exceeded our revenue since we were founded in January 1989. As of December 31, 2015, we had an accumulated deficit of approximately $1.1 billion and stockholders’ equity of approximately $200.8 million. Most of the losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Most of our revenue has come from collaborative arrangements, with additional revenue from research grants and the sale or licensing of our patents, as well as interest income. We may incur additional operating losses over the next several years, and these losses may increase if we cannot increase or sustain revenue. We may not successfully develop any additional products or achieve or sustain future profitability.
37


Since corporate partnering is a significant part of our strategy to fund the development and commercialization of our development programs, if any of our collaborative partners fail to fund our collaborative programs, or if we cannot obtain additional partners, we may have to delay or stop progress on our drug development programs.

To date, corporate partnering has played a significant role in our strategy to fund our development programs and to add key development resources. We plan to continue to rely on additional collaborative arrangements to develop and commercialize our unpartnered drugs. However, we may not be able to negotiate favorable collaborative arrangements for these drug programs. If we cannot continue to secure additional collaborative partners, our revenues could decrease and the development of our drugs could suffer.
For example, we do not intend to commercialize Kynamro ourselves. If we cannot find a suitable partner for Kynamro, we will not receive any revenue for Kynamro.

Our corporate partners are developing and/or funding many of the drugs in our development pipeline. If any of these pharmaceutical companies stops developing and/or funding these drugs, our business could suffer and we may not have, or be willing to dedicate, the resources available to develop these drugs on our own.

Our collaborators can terminate their relationships with us under certain circumstances, many of which are outside of our control. In the past, based on the disappointing results of Phase 3 clinical studies, we had a partner discontinue its investment in one of our drugs.

Even with funding from corporate partners, if our partners do not effectively perform their obligations under our agreements with them, it would delay or stop the progress of our drug development programs.

In addition to receiving funding, we enter into collaborative arrangements with third parties to:

conduct clinical studies;
seek and obtain marketing authorization; and
manufacture, market and sell our drugs.

Once we have secured a collaborative arrangement to further develop and commercialize one of our drug development programs, such as our collaborations with AstraZeneca, Bayer, Biogen, GSK, and Roche these collaborations may not continue or result in commercialized drugs, or may not progress as quickly as we first anticipated.

For example, a collaborator such as AstraZeneca, Bayer, Biogen, GSK, or Roche, could determine that it is in its financial interest to:

pursue alternative technologies or develop alternative products that may be competitive with the drug that is part of the collaboration with us;
pursue higher-priority programs or change the focus of its own development programs; or
choose to devote fewer resources to our drugs than it does for its own drugs.

If any of these occur, it could affect our partner's commitment to the collaboration with us and could delay or otherwise negatively affect the commercialization of our drugs, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro.

If we do not progress in our programs as anticipated, the price of our securities could decrease.

For planning purposes, we estimate and may disclose the timing of a variety of clinical, regulatory and other milestones, such as when we anticipate a certain drug will enter the clinic, when we anticipate completing a clinical study, or when we anticipate filing an application for marketing authorization. We base our estimates on present facts and a variety of assumptions. Many underlying assumptions are outside of our control. If we do not achieve milestones in accordance with our or our investors' expectations, including milestones related to the Phase 3 programs for nusinersen, IONIS-TTRRx, volanesorsen and Kynamro, the price of our securities could decrease.

If we cannot protect our patents or our other proprietary rights, others may compete more effectively against us.

Our success depends to a significant degree upon whether we can continue to develop and secure intellectual property rights to proprietary products and services. However, we may not receive issued patents on any of our pending patent applications in the United States or in other countries. In addition, the scope of any of our issued patents may not be sufficiently broad to provide us with a competitive advantage. Furthermore, other partners may successfully challenge, invalidate or circumvent our issued patents or patents licensed to us so that our patent rights do not create an effective competitive barrier or revenue source.

Intellectual property litigation could be expensive and prevent us from pursuing our programs.

From time to time we have to defend our intellectual property rights. If we are involved in an intellectual property dispute, we sometimes need to litigate to defend our rights or assert them against others. Disputes can involve arbitration, litigation or proceedings declared by the United States Patent and Trademark Office or the International Trade Commission or foreign patent authorities. Intellectual property litigation can be extremely expensive, and this expense, as well as the consequences should we not prevail, could seriously harm our business. For example, in November 2013 we filed a patent infringement lawsuit against Gilead Sciences Inc. in the United States District Court of the Northern District of California. Intellectual property lawsuits may be costly and may not be resolved in our favor.
38


If a third party claims that our drugs or technology infringe its patents or other intellectual property rights, we may have to discontinue an important product or product line, alter our products and processes, pay license fees or cease certain activities. We may not be able to obtain a license to needed intellectual property on favorable terms, if at all. There are many patents issued or applied for in the biotechnology industry, and we may not be aware of patents or patent applications held by others that relate to our business. This is especially true since patent applications in the United States are filed confidentially for the first 18 months. Moreover, the validity and breadth of biotechnology patents involve complex legal and factual questions for which important legal issues remain.

If we fail to obtain timely funding, we may need to curtail or abandon some of our programs.

Many of our drugs are undergoing clinical studies or are in the early stages of research and development. All of our drug programs will require significant additional research, development, preclinical and/or clinical testing, marketing authorization and/or commitment of significant additional resources prior to their successful commercialization. As of December 31, 2015, we had cash, cash equivalents and short-term investments equal to $779.2 million. If we do not meet our goals to successfully commercialize our drugs, including nusinersen, IONIS-TTRRx, volanesorsen and Kynamro, or to license our drugs and proprietary technologies, we will need additional funding in the future. Our future capital requirements will depend on many factors, such as the following:

changes in existing collaborative relationships and our ability to establish and maintain additional collaborative arrangements;
continued scientific progress in our research, drug discovery and development programs;
the size of our programs and progress with preclinical and clinical studies;
the time and costs involved in obtaining marketing authorizations;
competing technological and market developments, including the introduction by others of new therapies that address our markets; and
the profile and launch timing of our drugs, including nusinersen, IONIS-TTRRx and volanesorsen.

If we need additional funds, we may need to raise them through public or private financing. Additional financing may not be available at all or on acceptable terms. If we raise additional funds by issuing equity securities, the shares of existing stockholders will be diluted and the price, as well as the price of our other securities, may decline. If adequate funds are not available or not available on acceptable terms, we may have to cut back on one or more of our research, drug discovery or development programs. For example, in January 2005 we terminated the development of two lower priority drugs, ISIS 14803 and ISIS 104838. Alternatively, we may obtain funds through arrangements with collaborative partners or others, which could require us to give up rights to certain of our technologies or drugs.

The loss of key personnel, or the inability to attract and retain highly skilled personnel, could make it more difficult to run our business and reduce our likelihood of success.

We are dependent on the principal members of our management and scientific staff. We do not have employment agreements with any of our executive officers that would prevent them from leaving us. The loss of our management and key scientific employees might slow the achievement of important research and development goals. It is also critical to our success that we recruit and retain qualified scientific personnel to perform research and development work. We may not be able to attract and retain skilled and experienced scientific personnel on acceptable terms because of intense competition for experienced scientists among many pharmaceutical and health care companies, universities and non-profit research institutions. In addition, failure to succeed in clinical studies may make it more challenging to recruit and retain qualified scientific personnel.

If the price of our securities continues to be highly volatile, this could make it harder for you to liquidate your investment and could increase your risk of suffering a loss.

The market price of our common stock, like that of the securities of many other biopharmaceutical companies, has been and is likely to continue to be highly volatile. These fluctuations in our common stock price may significantly affect the trading price of our securities. During the 12 months preceding December 31, 2015, the market price of our common stock ranged from $37.38 to $77.80 per share. Many factors can affect the market price of our securities, including, for example, fluctuations in our operating results, announcements of collaborations, clinical study results, technological innovations or new products being developed by us or our competitors, governmental regulation, marketing authorization, changes in payors' reimbursement policies, developments in patent or other proprietary rights, public concern regarding the safety of our drugs and general market conditions.

We are exposed to potential product liability claims, and insurance against these claims may not be available to us at a reasonable rate in the future or at all.

Our business exposes us to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of therapeutic products, including potential product liability claims related to Kynamro, nusinersen, IONIS-TTRRx and volanesorsen. We have clinical study insurance coverage and commercial product liability insurance coverage. However, this insurance coverage may not be adequate to cover claims against us, or be available to us at an acceptable cost, if at all. Regardless of their merit or eventual outcome, products liability claims may result in decreased demand for our drug products, injury to our reputation, withdrawal of clinical study volunteers and loss of revenues. Thus, whether or not we are insured, a product liability claim or product recall may result in losses that could be material.

Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.

Our research, development and manufacturing activities involve the use of potentially harmful biological materials as well as materials, chemicals and various radioactive compounds that could be hazardous to human health and safety or the environment. We store these materials and various wastes resulting from their use at our facilities in Carlsbad, California pending ultimate use and disposal. We cannot completely eliminate the risk of contamination, which could cause:

interruption of our research, development and manufacturing efforts;
injury to our employees and others;
environmental damage resulting in costly clean up; and
liabilities under federal, state and local laws and regulations governing health and human safety, as well as the use, storage, handling and disposal of these materials and resultant waste products.
39


In such an event, we may be held liable for any resulting damages, and any liability could exceed our resources. Although we carry insurance in amounts and types that we consider commercially reasonable, we do not have insurance coverage for losses relating to an interruption of our research, development or manufacturing efforts caused by contamination, and the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be adversely affected.

If a natural or man-made disaster strikes our research, development or manufacturing facilities or otherwise affects our business, it could delay our progress developing and commercializing our drugs.

We manufacture our research and clinical supplies in a manufacturing facility located in Carlsbad, California. The facilities and the equipment we use to research, develop and manufacture our drugs would be costly to replace and could require substantial lead time to repair or replace. Our facilities may be harmed by natural or man-made disasters, including, without limitation, earthquakes, floods, fires and acts of terrorism; and if our facilities are affected by a disaster, our development and commercialization efforts would be delayed. Although we possess insurance for damage to our property and the disruption of our business from casualties, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. In addition, our development and commercialization activities could be harmed or delayed by a shutdown of the U.S. government, including the FDA.

Provisions in our certificate of incorporation, other agreements and Delaware law may prevent stockholders from receiving a premium for their shares.

Our certificate of incorporation provides for classified terms for the members of our board of directors. Our certificate also includes a provision that requires at least 66 2/3 percent of our voting stockholders to approve a merger or certain other business transactions with, or proposed by, any holder of 15 percent or more of our voting stock, except in cases where certain directors approve the transaction or certain minimum price criteria and other procedural requirements are met.

Our certificate of incorporation also requires that any action required or permitted to be taken by our stockholders must be taken at a duly called annual or special meeting of stockholders and may not be taken by written consent. In addition, only our board of directors, chairman of the board or chief executive officer can call special meetings of our stockholders. We have in the past, and may in the future, implement a stockholders' rights plan, also called a poison pill, which could make it uneconomical for a third party to acquire our company on a hostile basis. In addition, our board of directors has the authority to fix the rights and preferences of, and issue shares of preferred stock, which may have the effect of delaying or preventing a change in control of our company without action by our stockholders.

The provisions of our convertible senior notes could make it more difficult or more expensive for a third party to acquire us. Upon the occurrence of certain transactions constituting a fundamental change, holders of the notes will have the right, at their option, to require us to repurchase all of their notes or a portion of their notes, which may discourage certain types of transactions in which our stockholders might otherwise receive a premium for their shares over the then current market prices.

These provisions, as well as Delaware law, including Section 203 of the Delaware General Corporation Law, and other of our agreements, may discourage certain types of transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices, and may limit the ability of our stockholders to approve transactions that they think may be in their best interests.

Future sales of our common stock in the public market could adversely affect the trading price of our securities.

Future sales of substantial amounts of our common stock in the public market, or the perception that such sales could occur, could adversely affect trading prices of our securities. For example, we may issue approximately 11.2 million shares of our common stock upon conversion of our convertible senior notes. The addition of any of these shares into the public market may have an adverse effect on the price of our securities.

Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance.

Each year we are required to evaluate our internal controls systems in order to allow management to report on and our Independent Registered Public Accounting Firm to attest to, our internal controls as required by Section 404 of the Sarbanes-Oxley Act. As a result, we continue to incur additional expenses and divert our management's time to comply with these regulations. In addition, if we cannot continue to comply with the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory authorities, such as the SEC, the Public Company Accounting Oversight Board, or PCAOB, or The Nasdaq Global Market. Any such action could adversely affect our financial results and the market price of our common stock.

The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. On July 21, 2010, the Dodd-Frank Wall Street Reform and Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt, or where the SEC has adopted, additional rules and regulations in these areas such as "say on pay" and proxy access. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business.
40


Negative conditions in the global credit markets and financial services and other industries may adversely affect our business.

The global credit markets, the financial services industry, the U.S. capital markets, and the U.S. economy as a whole have in the past experienced periods of substantial turmoil and uncertainty characterized by unprecedented intervention by the U.S. federal government and the failure, bankruptcy, or sale of various financial and other institutions. It is possible that a crisis in the global credit markets, the U.S. capital markets, the financial services industry or the U.S. economy may adversely affect our business, vendors and prospects, as well as our liquidity and financial condition. More specifically, our insurance carriers and insurance policies covering all aspects of our business may become financially unstable or may not be sufficient to cover any or all of our losses and may not continue to be available to us on acceptable terms, or at all.

Item 1B. Unresolved Staff Comments

Not applicable.

Item 2. Properties

As of February 19, 2016, we occupied the following properties, which are all leased:

Property Description
Location
 
Square Footage
   
Initial Lease Term
End Date
 
Lease Extension Options
Ionis laboratory and office space facility
Carlsbad, CA
   
176,000
     
2031
 
Four, five-year options to extend
Ionis manufacturing facility
Carlsbad, CA
   
28,700
     
2031
 
Four, five-year options to extend
Ionis adjacent manufacturing facility
Carlsbad, CA
   
25,800
     
2021
 
Two, five-year options to extend
Akcea office space facility
Cambridge, MA
   
6,100
     
2018
 
None
       
236,600
            

Under our lease agreements for our 176,000 and 28,700 square foot facilities, we have the option to purchase the facilities, independent of each other at the end of each year from 2016 through 2020, and at the end of 2026 and 2031. 

We believe our existing facilities are adequate for our requirements in the foreseeable future and that we have sufficient manufacturing capacity to meet our current and future obligations under existing agreements with our partners for commercial, research and development needs, including for the Phase 3 clinical trials for nusinersen, IONIS-TTRRx and volanesorsen.


Item 3. Legal Proceedings

Gilead Litigation
 
In August 2013, Gilead Sciences Inc. filed a suit in the United States District Court of the Northern District of California related to United States Patent Nos. 7,105,499 and 8,481,712 that are jointly owned by Merck Sharp & Dohme Corp. and Ionis Pharmaceuticals, Inc. In the suit Gilead is asking the court to determine that Gilead's activities do not infringe any valid claim of the named patents and that the patents are not valid. We and Merck Sharp & Dohme Corp. filed our answer denying Gilead's noninfringement and invalidity contentions, contending that Gilead's commercial sale and offer for sale of sofosbuvir prior to the expiration of the '499 and '712 patents infringes those patents, and requesting monetary damages to compensate for such infringement. Under our agreement with Merck, Merck is responsible for the costs of this suit. Gilead filed a motion for summary judgment alleging invalidity of the asserted patents. In February 2016, the court denied the motion. In the same order, the court granted our motion for summary judgement for a finding of infringement, but noted that Gilead may still pursue its invalidity defenses at trial. The trial for this case is scheduled to begin March 7, 2016.

Item 4. Mine Safety Disclosures

Not applicable.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our common stock is traded publicly through The Nasdaq Global Select Market under the symbol “IONS.” Prior to our name change in December 2015, we traded under the symbol “ISIS.” The following table presents quarterly information on the price range of our common stock. This information indicates the high and low sale prices reported by The Nasdaq Global Select Market. These prices do not include retail markups, markdowns or commissions.

 
 
HIGH
   
LOW
 
2015
 
   
 
First Quarter
 
$
77.80
   
$
57.60
 
Second Quarter
 
$
71.50
   
$
55.62
 
Third Quarter
 
$
58.73
   
$
37.38
 
Fourth Quarter
 
$
65.34
   
$
38.30
 
2014
               
First Quarter
 
$
62.66
   
$
38.04
 
Second Quarter
 
$
45.04
   
$
22.25
 
Third Quarter
 
$
43.42
   
$
27.37
 
Fourth Quarter
 
$
67.12
   
$
35.26
 

41


As of February 19, 2016, there were approximately 606 stockholders of record of our common stock. We have never paid dividends and do not anticipate paying any dividends in the foreseeable future.

Set forth below is a table and chart comparing the total return on an indexed basis of $100 invested on December 31, 2010 in our common stock, the NASDAQ Composite Index (total return) and the NASDAQ Biotechnology Index. The total return assumes reinvestment of dividends.

Performance Graph (1)
*$100 invested on December 31, 2010 in stock or index, including reinvestment of dividends. Fiscal year ending December 31.

COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN
Among Ionis Pharmaceuticals, Inc., the NASDAQ Composite Index,
and the NASDAQ Biotechnology Index
 
 
 
Dec-10
   
Dec-11
   
Dec-12
   
Dec-13
   
Dec-14
   
Dec-15
 
Ionis Pharmaceuticals, Inc.
 
$
100.00
   
$
71.25
   
$
103.16
   
$
393.68
   
$
610.08
   
$
611.96
 
NASDAQ Composite Index
 
$
100.00
   
$
100.53
   
$
116.92
   
$
166.19
   
$
188.78
   
$
199.95
 
NASDAQ Biotechnology Index
 
$
100.00
   
$
113.92
   
$
153.97
   
$
263.29
   
$
348.49
   
$
369.06
 

                                                                                                                                                                                              
(1)  This section is not “soliciting material,” is not deemed “filed” with the SEC, is not subject to the liabilities of Section 18 of the Exchange Act and is not to be incorporated by reference in any of our filings under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

42


Item 6. Selected Financial Data

Set forth below are our selected consolidated financial data (in thousands, except per share amounts):

 
Years Ended December 31,
 
 
2015
 
2014
 
2013
 
2012
 
2011
 
Consolidated Statement of Operations Data:
 
 
 
 
 
Revenue
 
$
283,703
   
$
214,161
   
$
147,285
   
$
102,049
   
$
99,086
 
Research, development and patent expenses
 
$
322,292
   
$
241,751
   
$
184,033
   
$
158,458
   
$
157,397
 
Net loss attributable to Ionis Pharmaceuticals, Inc. common stockholders
 
$
(88,278
)
 
$
(38,984
)
 
$
(60,644
)
 
$
(65,478
)
 
$
(84,801
)
Basic and diluted net loss per share attributable to Ionis Pharmaceuticals, Inc. common stockholders
 
$
(0.74
)
 
$
(0.33
)
 
$
(0.55
)
 
$
(0.65
)
 
$
(0.85
)
Shares used in computing basic and diluted net loss per share
   
119,719
     
117,691
     
110,502
     
100,576
     
99,656
 

 
 
As of December 31,
 
 
 
2015
   
2014
   
2013
   
2012
   
2011
 
Consolidated Balance Sheet:
 
   
   
   
   
 
Cash, cash equivalents and short-term investments
 
$
779,183
   
$
728,832
   
$
656,761
   
$
374,446
   
$
343,664
 
Working capital
 
$
688,127
   
$
721,265
   
$
637,698
   
$
349,116
   
$
284,027
 
Investment in Regulus Therapeutics Inc.(1)
 
$
24,792
   
$
81,881
   
$
52,096
   
$
33,622
   
$
4,424
 
Total assets
 
$
956,105
   
$
955,809
   
$
847,156
   
$
545,686
   
$
484,894
 
Long-term debt and other obligations, less current portion
 
$
606,439
   
$
582,697
   
$
370,954
   
$
288,598
   
$
232,924
 
Accumulated deficit
 
$
(1,094,872
)
 
$
(1,006,594
)
 
$
(967,610
)
 
$
(906,966
)
 
$
(841,488
)
Stockholders’ equity
 
$
200,790
   
$
257,780
   
$
378,390
   
$
182,766
   
$
171,434
 
                                         
 
(1) In October 2012, Regulus completed an IPO and we changed to accounting for our investment in Regulus at fair value from the equity method because our ownership in Regulus dropped below 20 percent and we no longer had significant influence over Regulus’ operating and financial policies. Our investment in Regulus is further described in Note 2, Investments, in the Notes to the Consolidated Financial Statements.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are leaders in discovering and developing RNA-targeted therapeutics. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we have developed a large, diverse and advanced pipeline of potentially first-in-class and/or best-in-class drugs that we believe can provide high value for patients with significant unmet medical needs. In this way, we believe that we are fundamentally changing medicine with the goal to improve the quality of and save lives.

We have discovered and are developing three potentially transformational drugs, nusinersen, IONIS-TTRRx and volanesorsen, which we believe are close to commercialization. We designed each of these three drugs to treat patients with orphan diseases who have limited or no therapeutic options. In total, we are developing these three drugs for six different patient populations. In 2015, we completed target enrollment in the first pivotal Phase 3 study for each of these three drugs, and we anticipate reporting data from these studies in the first half of 2017. We designed nusinersen to treat patients with spinal muscular atrophy, or SMA, a severe motor-neuron disease that is the leading genetic cause of infant mortality. We designed IONIS-TTRRx to treat patients with transthyretin amyloidosis, or TTR amyloidosis, a fatal disease in which patients experience progressive buildup of amyloid plaque deposits in tissues throughout the body, including peripheral nerves, heart, intestinal tract, kidney and bladder. We designed volanesorsen to treat patients with diseases associated with extremely high levels of triglycerides, including patients with two severe and rare genetic conditions called FCS and FPL. We anticipate that the data from our pivotal Phase 3 studies, if positive, will support global regulatory filings for each drug. We believe that the significant unmet medical need and the severity of these diseases could warrant a rapid path to market. Already our partners for these programs, Biogen for nusinersen and GSK for IONIS-TTRRx, are preparing to commercialize these drugs. Our wholly owned subsidiary, Akcea Therapeutics, is preparing to commercialize volanesorsen. All three companies are engaging in pre-commercialization activities to understand the patient journey, build disease awareness with physicians and patients and develop their launch plans.

In addition to our Phase 3 programs, we have a pipeline of drugs with the potential to be first-in-class and/or best-in-class drugs to treat patients with inadequately treated diseases. Our pipeline has over a dozen drugs in Phase 2 development, many of which we believe have the potential to be significant commercial opportunities. In particular, IONIS-FXIRx and IONIS-APO(a)-LRx are representative of the value we have created. IONIS-FXIRx is the first antithrombotic in development that has shown it can decrease the risk of blood vessel obstruction caused by a blood clot without increasing bleeding risk. Because of the significant commercial opportunities for this drug, we licensed it to Bayer HealthCare, a leader in developing and commercializing antithrombotics. IONIS-APO(a)-LRx is the first and only drug in clinical development designed to selectively and robustly lower Lp(a), a key driver of cardiovascular disease. We believe that addressing Lp(a) is the next important horizon in lipid-focused cardiovascular disease treatment. With our support, Akcea has designed a broad development program to evaluate IONIS-APO(a)-LRx in patients who are at significant cardiovascular risk due to their high Lp(a) levels. In addition to these two examples, our Phase 2 pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases. We plan to expand the therapeutic reach of our technology by adding three to five new drugs to our pipeline every year.
43


We believe that our technology is the most versatile and most efficient drug discovery technology today. We can develop drugs to act upon disease targets in many different tissues, including the liver, muscle, kidney, brain, lung, eye, tumors and others. , Many of which are inaccessible with other types of drugs. Our drugs also work through numerous different cellular mechanisms, allowing us to develop drugs that can decrease or increase the production of a target protein involved in disease and remove disease-causing RNAs. In our clinical studies, we have demonstrated that we can administer our drugs by numerous different routes of administration, including oral, local, intrathecal and subcutaneous administration. The recent advances we have made in our technology have already translated into significant value in many of our newer drugs, which patients tolerate better and which are more potent than our earlier Generation 2 drugs. We continue to advance our RNA technology to create even better medicines and to expand the reach of our technology. We actively patent the advances we have made across all areas of our technology and the drugs we are developing. In this way, we have amassed a substantial intellectual property position that provides us with extensive protection for our drugs and our technology.

We have established alliances with a cadre of leading global pharmaceutical companies who are working alongside us in advancing our technology, developing our drugs and preparing to commercialize our drugs. We believe that using our partners’ resources, expertise and global commercialization capabilities maximizes the value of our drugs. We have strategic partners, Biogen and AstraZeneca, who partner with us on the development of drugs within specific therapeutic areas. We also have partnerships with GSK, Janssen, Bayer and Roche, who work with us to develop specific drugs in our pipeline. In addition to gaining access to high quality partners, disease and technology-specific expertise and global commercialization reach, our partners provide us with significant revenue through upfront fees, license fees and milestone payments. We have the potential to earn significant revenue from all of our partnerships. Since 2007, we have received more than $1.7 billion in cash from upfront and licensing fees, equity purchase payments, milestone payments and research and development funding from our partnerships. We have the potential to earn nearly $12 billion in future milestone payments and licensing fees from our current partnerships. We also have the potential to share in the future commercial success of our inventions and drugs resulting from our partnerships through earn out or royalty arrangements.

Financial Highlights

The following is a summary of our financial results (in thousands):

   
2015
   
2014
   
2013
 
Total revenue
 
$
283,703
   
$
214,161
   
$
147,285
 
Total operating expenses
 
$
359,465
   
$
261,891
   
$
198,951
 
Loss from operations
 
$
(75,762
)
 
$
(47,730
)
 
$
(51,666
)
Net loss
 
$
(88,278
)
 
$
(38,984
)
 
$
(60,644
)
Cash, cash equivalents and short-term investments
 
$
779,183
   
$
728,832
   
$
656,761
 


Our financial highlights above illustrate that over the past several years we have successfully increased our revenue and our cash balance, ending each year in a better financial position than we began. During this time, we advanced three important new drugs into Phase 3 development, initiated five Phase 3 studies on these drugs, advanced 12 Phase 2 drugs and multiple Phase 1 drugs and translated our technological innovations into the next wave of drugs to enter clinical development. During 2015, we received more than $320 million from our partners and increased our cash balance, reflecting the successes of our partnerships. As our drugs successfully advance, we generate cash and revenue from our partners. In addition to cash and revenue, our partners provide expertise and additional resources, which we believe will maximize the commercial value of our partnered drugs. 

Business Segments

In 2015, we began reporting our financial results in two reportable segments, Ionis Core, previously referred to as Drug Discovery and Development, and Akcea Therapeutics, our wholly owned subsidiary. Segment loss from operations includes revenue less operating expenses attributable to each segment.

In our Ionis Core segment we are exploiting a novel drug discovery platform we created to generate a broad pipeline of first-in-class or best-in-class drugs for us and our partners. Our Ionis Core segment generates revenue from a multifaceted partnering strategy.

We formed Akcea to develop and commercialize drugs for cardiometabolic disorders. Moving our lipid drugs into a company that we own and control ensures that our core focus at Ionis remains on innovation while allowing us to maintain control over and retain more value from our lipid drugs.

Critical Accounting Policies

We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States. As such, we make certain estimates, judgments and assumptions that we believe are reasonable, based upon the information available to us. These judgments involve making estimates about the effect of matters that are inherently uncertain and may significantly impact our quarterly or annual results of operations and financial condition. Each quarter, our senior management reviews the development, selection and disclosure of such estimates with the audit committee of our board of directors. In the following paragraphs, we describe the specific risks associated with these critical accounting policies and we caution that future events rarely develop exactly as one may expect, and that best estimates may require adjustment.
44


The following are our significant accounting policies, which we believe are the most critical to aid in fully understanding and evaluating our reported financial results:

Assessing the propriety of revenue recognition and associated deferred revenue;
Determining the proper valuation of investments in marketable securities and other equity investments;
Determining the appropriate cost estimates for unbilled preclinical studies and clinical development activities; and
Estimating our net deferred income tax asset valuation allowance.

Descriptions of these critical accounting policies follow.

Revenue Recognition

We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In the instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.

Arrangements with multiple deliverables

Our collaboration agreements typically contain multiple elements, or deliverables, including technology licenses or options to obtain technology licenses, research and development services, and in certain cases manufacturing services, and we allocate the consideration to each unit of accounting based on the relative selling price of each deliverable.

Identifying deliverables and units of accounting

We evaluate the deliverables in our collaboration agreements to determine whether they meet the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. When the delivered items in an arrangement have "stand-alone value" to our customer, we account for the deliverables as separate units of accounting. Delivered items have stand-alone value if they are sold separately by any vendor or the customer could resell the delivered items on a stand-alone basis. For example, in May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXIRx for the prevention of thrombosis. As part of the agreement, Bayer paid us a $100 million upfront payment in the second quarter of 2015. We are also eligible to receive milestone payments and tiered royalties on  gross margins of IONIS-FXIRx. We are responsible for completing the ongoing development services for IONIS-FXIRx and for providing an initial supply of active pharmaceutical ingredient, or API. Bayer is responsible for all other development and commercialization activities for IONIS-FXIRx. Since this agreement has multiple elements, we evaluated the deliverables in this arrangement when we entered into the agreement and determined that certain deliverables have stand-alone value. Below is a list of the three units of accounting under our agreement:

The exclusive license we granted to Bayer to develop and commercialize IONIS-FXIRx for the treatment of thrombosis;
The development services we agreed to perform for IONIS-FXIRx; and 
The initial supply of API.

We determined that each of these three units of accounting have stand-alone value. The exclusive license we granted to Bayer has stand-alone value because it is an exclusive license that gives Bayer the right to develop IONIS-FXIRx or to sublicense its rights. The development services and the initial supply of API each have stand-alone value because Bayer or another third party could provide these items without our assistance.

Measurement and allocation of arrangement consideration

Our collaborations may provide for various types of payments to us including upfront payments, funding of research and development, milestone payments, licensing fees and royalties on product sales. We initially allocate the amount of consideration that is fixed and determinable at the time the agreement is entered into and exclude contingent consideration. We allocate the consideration to each unit of accounting based on the relative selling price of each deliverable. We use the following hierarchy of values to estimate the selling price of each deliverable: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price, or BESP. BESP reflects our best estimate of what the selling price would be if we regularly sold the deliverable on a stand-alone basis. We recognize the revenue allocated to each unit of accounting as we deliver the related goods or services. If we determine that we should treat certain deliverables as a single unit of accounting, then we recognize the revenue ratably over our estimated period of performance.

We determined that the allocable arrangement consideration for the Bayer collaboration was $100 million and we allocated it based on the relative BESP of each unit of accounting. We engaged a third party, independent valuation expert to assist us with determining BESP. We estimated the selling price of the license granted for IONIS-FXIRx by using the relief from royalty method. Under this method, we estimated the amount of income, net of taxes, for IONIS-FXIRx. We then discounted the projected income to present value. The significant inputs we used to determine the projected income of the license included:

Estimated future product sales;
Estimated royalties on future product sales;
Contractual milestone payments;
Expenses we expect to incur;
Income taxes; and
An appropriate discount rate.
45


We estimated the selling price of the ongoing development services by using our internal estimates of the cost to perform the specific services and estimates of expected cash outflows to third parties for services and supplies over the expected period that we will perform the development services. The significant inputs we used to determine the selling price of the ongoing development services included:

The number of internal hours we will spend performing these services;
The estimated cost of work we will perform;
The estimated cost of work that we will contract with third parties to perform; and
The estimated cost of drug product we will use.

We determine the selling price of our API consistently for all of our partnerships. On an annual basis, we calculate our fully absorbed cost to manufacture API. We then determine the unit price we will charge our partners by dividing our fully absorbed costs by the quantity of API we expect to produce during the year.

For purposes of determining BESP of the services we will perform and the API in our Bayer transaction, accounting guidance required us to include a markup for a reasonable profit margin.

Based on the units of accounting under the agreement, we allocated the $100 million upfront payment from Bayer as follows:

$91.2 million to the IONIS-FXIRx exclusive license;
$4.3 million for ongoing development services; and
$4.5 million for the delivery of API.

Assuming a constant selling price for the other elements in the arrangement, if there was an assumed ten percent increase or decrease in the estimated selling price of the IONIS-FXIRx license, we determined that the revenue we would have allocated to the IONIS-FXIRx license would change by approximately one percent, or $0.9 million, from the amount we recorded.

Timing of revenue recognition

We recognize revenue as we deliver each item under the arrangement and the related revenue is realizable and earned. For example, we recognized revenue for the exclusive license we granted Bayer for IONIS-FXIRx in the second quarter of 2015 because that was when we delivered the license. We also recognize revenue over time. Our collaborative agreements typically include a research and/or development project plan outlining the activities the agreement requires each party to perform during the collaboration. We must estimate our period of performance when the agreements we enter into do not clearly define such information. We estimate the period of time over which we will complete the activities for which we are responsible and use that period of time as our period of performance for purposes of revenue recognition. We then recognize revenue ratably over such period. We have made estimates of our continuing obligations under numerous agreements and in certain instances the timing of satisfying these obligations change as the development plans for our drugs progress. Accordingly, our estimates may change in the future. If our estimates and judgments change over the course of our collaboration agreements, it may affect the timing and amount of revenue that we recognize in future periods.

The following are the periods over which we are recognizing revenue for each of our units of accounting under our Bayer agreement:

We recognized the portion of the consideration attributed to the IONIS-FXIRx license immediately because we delivered the license and earned the revenue; 
We are recognizing the amount attributed to the ongoing development services for IONIS-FXIRx over the period of time we are performing the services; and
We will recognize the amount attributed to the API supply when we deliver it to Bayer.

Multiple agreements

From time to time, we may enter into separate agreements at or near the same time with the same customer. We evaluate such agreements to determine whether they should be accounted for individually as distinct arrangements or whether the separate agreements are, in substance, a single multiple element arrangement. We evaluate whether the negotiations are conducted jointly as part of a single negotiation, whether the deliverables are interrelated or interdependent, whether fees in one arrangement are tied to performance in another arrangement, and whether elements in one arrangement are essential to another arrangement. Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that they are, in effect, part of a single arrangement. For example, since early 2012, we have entered into four collaboration agreements with Biogen:

In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize nusinersen for SMA. As part of the collaboration, we received a $29 million upfront payment and we are responsible for global development of nusinersen through completion of Phase 2/3 clinical trials.

In June 2012, we entered into a second and separate collaboration agreement with Biogen to develop and commercialize a novel antisense drug targeting DMPK. As part of the collaboration, we received a $12 million upfront payment and we are responsible for global development of the drug through the completion of a Phase 2 clinical trial.

In December 2012, we entered into a third and separate collaboration agreement with Biogen to discover and develop antisense drugs against three targets to treat neurological or neuromuscular disorders. As part of the collaboration, we received a $30 million upfront payment and we are responsible for the discovery of a lead antisense drug for each of three targets.
46


In September 2013, we entered into a fourth and separate collaboration agreement with Biogen to leverage antisense technology to advance the treatment of neurological diseases. We granted Biogen exclusive rights to the use of our antisense technology to develop therapies for neurological diseases as part of this broad collaboration. We received a $100 million upfront payment and we are responsible for discovery and early development through the completion of a Phase 2 clinical trial for each antisense drug identified during the six-year term of this collaboration, while Biogen is responsible for the creation and development of small molecule treatments and biologics.

All four of these collaboration agreements give Biogen the option to license one or more drugs resulting from the specific collaboration. If Biogen exercises an option, it will pay us a license fee and will assume future development, regulatory and commercialization responsibilities for the licensed drug. We are also eligible to receive milestone payments associated with the research and/or development of the drugs prior to licensing, milestone payments if Biogen achieves pre-specified regulatory milestones, and royalties on any product sales from any drugs resulting from these collaborations.

We evaluated all four of the Biogen agreements to determine whether we should account for them as separate agreements. We determined that we should account for the agreements separately because we conducted the negotiations independently of one another, each agreement focuses on different drugs, there are no interrelated or interdependent deliverables, there are no provisions in any of these agreements that are essential to the other agreement, and the payment terms and fees under each agreement are independent of each other. We also evaluated the deliverables in each of these agreements to determine whether they met the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. For all four of these agreements, we determined that the options did not have stand-alone value because Biogen cannot pursue the development or commercialization of the drugs resulting from these collaborations until it exercises the respective option or options. As such, for each agreement we considered the deliverables to be a single unit of accounting and we are recognizing the upfront payment for each of the agreements over the respective estimated period of our performance.

Milestone payments

Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and/ or commercialization events. These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraph.

Prior to the first stage in the life-cycle of our drugs, we perform a significant amount of work using our proprietary antisense technology to design chemical compounds that interact with specific genes that are good targets for drug discovery. From these research efforts, we hope to identify a development candidate. The designation of a development candidate is the first stage in the life-cycle of our drugs. A development candidate is a chemical compound that has demonstrated the necessary safety and efficacy in preclinical animal studies to warrant further study in humans.

During the first step of the development stage, we or our partners study our drugs in Investigational New Drug, or IND,-enabling studies, which are animal studies intended to support an IND application and/or the foreign equivalent. An approved IND allows us or our partners to study our development candidate in humans. If the regulatory agency approves the IND, we or our partners initiate Phase 1 clinical trials in which we typically enroll a small number of healthy volunteers to ensure the development candidate is safe for use in patients. If we or our partners determine that a development candidate is safe based on the Phase 1 data, we or our partners initiate Phase 2 studies that are generally larger scale studies in patients with the primary intent of determining the efficacy of the development candidate.

The final step in the development stage is Phase 3 studies to gather the necessary safety and efficacy data to request marketing authorization from the FDA and/or foreign equivalents. The Phase 3 studies typically involve large numbers of patients and can take up to several years to complete. If the data gathered during the trials demonstrates acceptable safety and efficacy results, we or our partner will submit an application to the FDA and/or its foreign equivalents for marketing authorization. This stage of the drug’s life-cycle is the regulatory stage.

If a drug achieves marketing authorization, it moves into the commercialization stage, during which our partner will market and sell the drug to patients. Although our partner will ultimately be responsible for marketing and selling the partnered drug, our efforts to discover and develop a drug that is safe, effective and reliable contributes significantly to our partner’s ability to successfully sell the drug. The FDA and its foreign equivalents have the authority to impose significant restrictions on an approved drug through the product label and on advertising, promotional and distribution activities. Therefore, our efforts designing and executing the necessary animal and human studies are critical to obtaining claims in the product label from the regulatory agencies that would allow us or our partner to successfully commercialize our drug. Further, the patent protection afforded our drugs as a result of our initial patent applications and related prosecution activities in the United States and foreign jurisdictions are critical to our partner’s ability to sell our drugs without competition from generic drugs. The potential sales volume of an approved drug is dependent on several factors including the size of the patient population, market penetration of the drug, and the price charged for the drug.

Generally, the milestone events contained in our partnership agreements coincide with the progression of our drugs from development, to marketing authorization and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug progresses through the stages of its life-cycle, the value of the drug generally increases.

Development milestones in our partnerships may include the following types of events:

Designation of a development candidate. Following the designation of a development candidate, IND-enabling animal studies for a new development candidate generally take 12 to 18 months to complete;
Initiation of a Phase 1 clinical trial. Generally, Phase 1 clinical trials take one to two years to complete;
Initiation or completion of a Phase 2 clinical trial. Generally, Phase 2 clinical trials take one to three years to complete;
Initiation or completion of a Phase 3 clinical trial. Generally, Phase 3 clinical trials take two to four years to complete.
47


Regulatory milestones in our partnerships may include the following types of events:

Filing of regulatory applications for marketing authorization such as a New Drug Application, or NDA, in the United States or a Marketing Authorization Application, or MAA, in Europe. Generally, it takes six to twelve months to prepare and submit regulatory filings.
Marketing authorization in a major market, such as the United States, Europe or Japan. Generally it takes one to two years after an application is submitted to obtain authorization from the applicable regulatory agency.

Commercialization milestones in our partnerships may include the following types of events:

First commercial sale in a particular market, such as in the United States or Europe.
Product sales in excess of a pre-specified threshold, such as annual sales exceeding $1 billion. The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.

We assess whether a substantive milestone exists at the inception of our agreements. When a substantive milestone is achieved, we recognize revenue related to the milestone payment immediately. For our existing licensing and collaboration agreements in which we are involved in the discovery and/or development of the related drug or provide the partner with access to new technologies we discover, we have determined that the majority of future development, regulatory and commercialization milestones are substantive. For example, we consider most of the milestones associated with our strategic alliance with Biogen substantive because we are using our antisense drug discovery platform to discover and develop new drugs against targets for neurological diseases. We also consider milestones associated with our alliance with Alnylam substantive because we provide Alnylam ongoing access to our technology to develop and commercialize RNAi therapeutics. In evaluating if a milestone is substantive we consider whether:

Substantive uncertainty exists as to the achievement of the milestone event at the inception of the arrangement;
The achievement of the milestone involves substantive effort and can only be achieved based in whole or in part on our performance or the occurrence of a specific outcome resulting from our performance;
The amount of the milestone payment appears reasonable either in relation to the effort expended or to the enhancement of the value of the delivered items;
There is no future performance required to earn the milestone; and
The consideration is reasonable relative to all deliverables and payment terms in the arrangement.

If any of these conditions are not met, we do not consider the milestone to be substantive and we defer recognition of the milestone payment and recognize it as revenue over our estimated period of performance, if any. Further information about our collaborative arrangements can be found in Note 6, Collaborative Arrangements and Licensing Agreements, in the Notes to the Consolidated Financial Statements.

Licensing and royalty revenue

We often enter into agreements to license our proprietary patent rights on an exclusive or non-exclusive basis in exchange for license fees and/or royalties. We generally recognize as revenue immediately those licensing fees and royalties for which we have no significant future performance obligations and are reasonably assured of collecting the resulting receivable. For example, during 2014, we recognized $9.5 million in revenue from Alnylam related to its license of our technology to one of its partners because we had no performance obligations and collectability was reasonably assured.

Valuation of Investments

We consider all liquid investments with maturities of three months or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than three months from date of purchase. We classify our short-term investments as “available-for-sale” and carry them at fair market value based upon prices for identical or similar items on the last day of the fiscal period. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.

We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investments in equity securities in publicly held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. Our Level 3 investments include investments in the equity securities of publicly held biotechnology companies for which we calculated a lack of marketability discount because there were restrictions on when we could trade the securities. Historically, we have determined the lack of marketability discount by using a Black-Scholes model to value a hypothetical put option to approximate the cost of hedging the stock until the restriction ended. The majority of our securities have been classified as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices.

In November 2014, we participated as a selling shareholder in Regulus' equity offering and as a result we were subject to trading restrictions on our remaining shares through January 2015. Therefore, at December 31, 2014, our equity securities of Regulus included a lack of marketability discount, and as a result, were classified as a Level 3 investment. These securities were transferred to Level 1 in the first quarter of 2015, when the trading restrictions ended. At December 31, 2015 and 2013, we did not have any investments classified as Level 3.
48


We have equity investments in privately and publicly held biotechnology companies that we have received as part of a technology license or collaboration agreement. We account for our equity investments in publicly held companies at fair value and record unrealized gains and losses related to temporary increases and decreases in the stock price of these publicly held companies as a separate component of comprehensive income (loss). We account for equity investments in privately held companies under the cost method of accounting because we own less than 20 percent and do not have significant influence over their operations. We hold one cost method investment in Atlantic Pharmaceuticals Limited. Realization of our equity position in this company is uncertain. When realization of our investment is uncertain, we record a full valuation allowance. In determining if and when a decrease in market value below our cost in our equity positions is temporary or other-than-temporary, we examine historical trends in the stock price, the financial condition of the company, near term prospects of the company and our current need for cash. If we determine that a decline in value in either a public or private investment is other-than-temporary, we recognize an impairment loss in the period in which the other-than-temporary decline occurs.

During 2015, 2014 and 2013, we realized a net gain on investments we sold of $20.3 million, $21.2 million, and $2.4 million, respectively. Our net gain for 2015 and 2014 was primarily from the $20.2 million and $19.9 million gain we realized when we sold a portion of our stock in Regulus, respectively. We have reflected this gain in a separate line called “Gain on investment in Regulus Therapeutics Inc.” on our Consolidated Statements of Operations. See further discussion about our investment in Regulus in Note 2, Investments, in the Notes to the Consolidated Financial Statements. Our net gain on investments for 2013 related to the sale of stock in several of our satellite companies. 

Estimated Liability for Clinical Development Costs

We record accrued liabilities related to expenses for which service providers have not yet billed us. These liabilities are for products or services that we have received, specifically related to ongoing preclinical studies and clinical trials. These costs primarily relate to third-party clinical management costs, laboratory and analysis costs, toxicology studies and investigator grants. We have numerous drugs in concurrent preclinical studies and clinical trials at several clinical sites throughout the world. In order to ensure that we have adequately provided for ongoing preclinical and clinical development costs during the period in which we incur such costs, we maintain an accrual to cover these costs. We update our estimate for this accrual on at least a quarterly basis. The assessment of these costs is a subjective process that requires judgment. Upon settlement, these costs may differ materially from the amounts accrued in our consolidated financial statements. Our historical accrual estimates have not been materially different from our actual amounts.

Valuation Allowance for Net Deferred Tax Assets

We record a valuation allowance to offset any net deferred tax assets if, based upon the available evidence, it is more likely than not that we will not recognize some or all of the deferred tax assets. Except for 2009, we have had net losses since inception, and as a result, we have established a 100 percent valuation allowance for our net deferred tax asset. If we determine that we are able to realize a portion or all of these deferred tax assets in the future, we will record an adjustment to the valuation allowance.

Results of Operations

Years Ended December 31, 2015 and December 31, 2014

Revenue

Total revenue for 2015 was $283.7 million, compared to $214.2 million for 2014. We earned $115.7 million of revenue from milestone payments from our partners, $91.2 million from the license fee we recognized from our Bayer collaboration and $76.8 million primarily from the amortization of upfront fees and manufacturing services we performed for our partners during 2015.

Our revenue fluctuates based on the nature and timing of payments under agreements with our partners and consists primarily of revenue from the amortization of upfront fees, milestone payments and license fees.

Research and Development Revenue Under Collaborative Agreements

Research and development revenue under collaborative agreements for 2015 was $281.4 million, compared to $202.5 million for 2014. Our revenue for 2015 consisted of the following:

$91.2 million from Bayer in connection with our exclusive license agreement for IONIS-FXIRx;
$72.6 million from Biogen for advancing the Phase 3 program for nusinersen, advancing IONIS-DMPK-2.5Rx and IONIS-BIIB4Rx, and validating three new targets for neurological disorders;
$22 million from Roche for initiating a Phase 1/2 study of IONIS-HTTRx;
$20 million from GSK for advancing the Phase 3 study of IONIS-TTRRx and initiating a Phase 1 study of IONIS-GSK4-LRx; and
$75.6 million primarily from the amortization of upfront fees and manufacturing services we performed for our partners.
 
Already in the first quarter of 2016, we have generated $7.3 million in milestone payments from Biogen for advancing the Phase 3 program for nusinersen, advancing IONIS-BIIB4Rx and from GSK when GSK initiated the Phase 1 study for IONIS-HBV-LRx.
 
Licensing and Royalty Revenue

Our revenue from licensing activities and royalties for 2015 was $2.3 million, compared to $11.6 million for 2014. The decrease in 2015 compared to 2014 was primarily a result of the $9.5 million in sublicensing revenue we earned in 2014 from Alnylam related to its license of our technology to one of its partners.
49


Operating Expenses

Operating expenses for 2015 were $359.5 million, and increased compared to $261.9 million for 2014 as a result of the following:

We are conducting more later-stage clinical trials in 2015 than we did in 2014, including the continuation of our Phase 3 programs for nusinersen, IONIS-TTRRx and volanesorsen. As drugs move forward to more advanced stages of development, including into larger, longer clinical studies, the cost of development increases. As our Phase 3 programs continue to progress in 2016, we expect the costs associated with these programs to continue to increase modestly.
Akcea operating expenses increased in 2015 as it began building its commercial infrastructure and advanced the pre-commercialization activities necessary to successfully launch volanesorsen within the next few years. Akcea’s operating expenses for 2016 will increase as it expands these activities.
Since we grant the majority of our stock-options in January, we had an increase in stock compensation expense because our stock price was higher in January 2015 compared to January 2014.

In 2015, we began disclosing segment information for Akcea, our wholly owned subsidiary. We have revised 2014 for comparative purposes to show operating expenses for Akcea-related projects.

Our operating expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2015
   
2014
 
Ionis Core
 
$
256,512
   
$
208,811
 
Akcea Therapeutics
   
47,887
     
21,697
 
Elimination of intercompany activity
   
(4,248
)
   
 
Subtotal
   
300,151
     
230,508
 
Non-cash compensation expense related to equity awards
   
59,314
     
31,383
 
Total operating expenses
 
$
359,465
   
$
261,891
 

In order to analyze and compare our results of operations to other similar companies, we believe it is important to exclude non-cash compensation expense related to equity awards from our operating expenses. We believe non-cash compensation expense is not indicative of our operating results or cash flows from our operations. Further, we internally evaluate the performance of our operations excluding it.

Research, Development and Patent Expenses

Our research, development and patent expenses consist of expenses for antisense drug discovery, antisense drug development, manufacturing and operations and R&D support expenses.

The following table sets forth information on research, development and patent expenses (in thousands):

 
Year Ended
December 31,
 
 
2015
 
2014
 
Research, development and patent expenses
 
$
278,654
   
$
215,908
 
Non-cash compensation expense related to equity awards
   
43,638
     
25,843
 
Total research, development and patent expenses
 
$
322,292
   
$
241,751
 

Our research, development and patent expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2015
   
2014
 
Ionis Core
 
$
240,006
   
$
195,007
 
Akcea Therapeutics
   
42,896
     
20,901
 
Elimination of intercompany activity
   
(4,248
)
   
 
Subtotal
   
278,654
     
215,908
 
Non-cash compensation expense related to equity awards
   
43,638
     
25,843
 
Total research, development and patent expenses
 
$
322,292
   
$
241,751
 

For 2015, our total research, development and patent expenses were $278.7 million, compared to $215.9 for 2014, and were higher primarily due to the progression of our drugs currently in Phase 3 trials. All amounts exclude non-cash compensation expense related to equity awards.
50


Antisense Drug Discovery

We use our proprietary antisense technology to generate information about the function of genes and to determine the value of genes as drug discovery targets. We use this information to direct our own antisense drug discovery research, and that of our partners. Antisense drug discovery is also the function that is responsible for advancing our antisense core technology.

As we continue to advance our antisense technology, we are investing in our drug discovery programs to expand our and our partners' drug pipelines. We anticipate that our existing relationships and collaborations, as well as prospective new partners, will continue to help fund our research programs and contribute to the advancement of the science by funding core antisense technology research.

Our antisense drug discovery expenses were as follows (in thousands) and are part of our Ionis Core business segment:

 
Year Ended
December 31,
 
 
2015
 
2014
 
Antisense drug discovery expenses
 
$
49,331
   
$
43,620
 
Non-cash compensation expense related to equity awards
   
11,914
     
7,290
 
Total antisense drug discovery expenses
 
$
61,245
   
$
50,910
 

Antisense drug discovery expenses for 2015 were $49.3 million, and were slightly higher as expected, compared to $43.6 million for 2014. Expenses were higher because we conducted more research activities to support our partnerships in 2015 compared to 2014. All amounts exclude non-cash compensation expense related to equity awards.

Antisense Drug Development

The following table sets forth research and development expenses for our major antisense drug development projects (in thousands):

   
Year Ended
December 31,
 
   
2015
   
2014
 
Nusinersen
 
$
35,164
   
$
19,064
 
Volanesorsen
   
21,348
     
9,337
 
IONIS-TTRRx
   
19,560
     
10,927
 
Other antisense development projects
   
60,028
     
50,272
 
Development overhead expenses
   
36,117
     
31,318
 
Total antisense drug development, excluding non-cash compensation expense related to equity awards
   
172,217
     
120,918
 
Non-cash compensation expense related to equity awards
   
16,208
     
9,640
 
Total antisense drug development expenses
 
$
188,425
   
$
130,558
 

Antisense drug development expenses were $172.2 million for 2015, compared to $120.9 million for 2014. Expenses for 2015 were higher compared to 2014 primarily due to the progression of our drugs currently in Phase 3 trials. As drugs move forward to more advanced stages of development, including into larger, longer clinical studies, the costs of development increase. All amounts exclude non-cash compensation expense related to equity awards.

Our antisense drug development expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2015
   
2014
 
Ionis Core
 
$
137,092
   
$
102,862
 
Akcea Therapeutics
   
35,125
     
18,056
 
Non-cash compensation expense related to equity awards
   
16,208
     
9,640
 
Total antisense drug development expenses
 
$
188,425
   
$
130,558
 

We may conduct multiple clinical trials on a drug candidate, including multiple clinical trials for the various indications we may be studying. Furthermore, as we obtain results from trials we may elect to discontinue clinical trials for certain drug candidates in certain indications in order to focus our resources on more promising drug candidates or indications. Our Phase 1 and Phase 2 programs are clinical research programs that fuel our Phase 3 pipeline. When our products are in Phase 1 or Phase 2 clinical trials, they are in a dynamic state in which we may adjust the development strategy for each product. Although we may characterize a product as "in Phase 1" or "in Phase 2," it does not mean that we are conducting a single, well-defined study with dedicated resources. Instead, we allocate our internal resources on a shared basis across numerous products based on each product's particular needs at that time. This means we are constantly shifting resources among products. Therefore, what we spend on each product during a particular period is usually a function of what is required to keep the products progressing in clinical development, not what products we think are most important. For example, the number of people required to start a new study is large, the number of people required to keep a study going is modest and the number of people required to finish a study is large. However, such fluctuations are not indicative of a shift in our emphasis from one product to another and cannot be used to accurately predict future costs for each product. And, because we always have numerous drugs in preclinical and early stage clinical research, the fluctuations in expenses from drug to drug, in large part, offset one another. If we partner a drug, it may affect the size of a trial, its timing, its total cost and the timing of the related costs.
51


Manufacturing and Operations

Expenditures in our manufacturing and operations function consist primarily of personnel costs, specialized chemicals for oligonucleotide manufacturing, laboratory supplies and outside services. Our manufacturing and operations function is responsible for providing drug supplies to antisense drug development, our Akcea subsidiary and our collaboration partners. Our manufacturing procedures include testing to satisfy good laboratory and good manufacturing practice requirements.

Our manufacturing and operations expenses were as follows (in thousands):

 
Year Ended
December 31,
 
 
2015
 
2014
 
Manufacturing and operations expenses
 
$
28,588
   
$
24,763
 
Non-cash compensation expense related to equity awards
   
4,563
     
2,934
 
Total manufacturing and operations expenses
 
$
33,151
   
$
27,697
 

Manufacturing and operations expenses were $28.6 million for 2015, and increased compared to $24.8 million for 2014. The increase in manufacturing and operations expenses was primarily related to the manufacturing activities needed to support the increase in our drug development activities. All amounts exclude non-cash compensation expense related to equity awards.

Our manufacturing and operations expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2015
   
2014
 
Ionis Core
 
$
25,633
   
$
22,425
 
Akcea Therapeutics
   
7,203
     
2,338
 
Elimination of intercompany activity
   
(4,248
)
   
 
Subtotal
   
28,588
     
24,763
 
Non-cash compensation expense related to equity awards
   
4,563
     
2,934
 
Total manufacturing and operations expenses
 
$
33,151
   
$
27,697
 

R&D Support

In our research, development and patent expenses, we include support costs such as rent, repair and maintenance for buildings and equipment, utilities, depreciation of laboratory equipment and facilities, amortization of our intellectual property, information technology costs, procurement costs and waste disposal costs. We call these costs R&D support expenses.

The following table sets forth information on R&D support expenses (in thousands):

   
Year Ended
December 31,
 
   
2015
   
2014
 
Personnel costs
 
$
10,210
   
$
9,875
 
Occupancy
   
7,854
     
7,357
 
Patent expenses
   
2,785
     
2,933
 
Depreciation and amortization
   
2,911
     
2,243
 
Insurance
   
1,320
     
1,197
 
Other
   
3,438
     
3,002
 
Total R&D support expenses, excluding non-cash compensation expense related to equity awards
   
28,518
     
26,607
 
Non-cash compensation expense related to equity awards
   
10,953
     
5,979
 
Total R&D support expenses
 
$
39,471
   
$
32,586
 

R&D support expenses for 2015 were $28.5 million, and increased slightly compared to $26.6 million for 2014. All amounts exclude non-cash compensation expense related to equity awards.

Our R&D support expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2015
   
2014
 
Ionis Core
 
$
27,950
   
$
26,100
 
Akcea Therapeutics
   
568
     
507
 
Non-cash compensation expense related to equity awards
   
10,953
     
5,979
 
Total R&D support expenses
 
$
39,471
   
$
32,586
 

52


General and Administrative Expenses

General and administrative expenses include corporate costs required to support our company, our employees and our stockholders. These costs include personnel and outside costs in the areas of legal, human resources, investor relations, and finance. Additionally, we include in general and administrative expenses such costs as rent, repair and maintenance of buildings and equipment, depreciation and utilities costs that we need to support the corporate functions listed above.

The following table sets forth information on general and administrative expenses (in thousands):

 
Year Ended
December 31,
 
 
2015
 
2014
 
General and administrative expenses
 
$
21,497
   
$
14,600
 
Non-cash compensation expense related to equity awards
   
15,676
     
5,540
 
Total general and administrative expenses
 
$
37,173
   
$
20,140
 

General and administrative expenses were $21.5 million for 2015, and increased compared to $14.6 million for 2014 primarily due to the addition of Akcea and an increase in personnel costs. Expenses for Akcea will increase as it continues to build the commercial infrastructure and advance the pre-commercialization activities necessary for the commercial launch of volanesorsen. All amounts exclude non-cash compensation expense related to equity awards.

Our general and administrative expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2015
   
2014
 
Ionis Core
 
$
16,506
   
$
13,804
 
Akcea Therapeutics
   
4,991
     
796
 
Non-cash compensation expense related to equity awards
   
15,676
     
5,540
 
Total general and administrative expenses
 
$
37,173
   
$
20,140
 

Akcea Therapeutics, Inc.

The following table sets forth information on operating expenses (in thousands) for our Akcea Therapeutics business segment:

   
Year Ended
December 31,
 
   
2015
   
2014
 
Development and patent expenses
 
$
42,896
   
$
20,901
 
General and administrative expenses
   
4,991
     
796
 
Total operating expenses, excluding non-cash compensation expense related to equity awards
   
47,887
     
21,697
 
Non-cash compensation expense related to equity awards
   
6,496
     
 
Total Akcea Therapeutics operating expenses
 
$
54,383
   
$
21,697
 

Expenses for Akcea were $47.9 million for 2015, and increased compared to $21.7 million for 2014. The increase in expenses was primarily due to Akcea’s Phase 3 program for volanesorsen, which continued to advance, and the progression of its other drugs, including IONIS-APO(a)-LRx and IONIS-ANGPTL3Rx. Also, starting in 2015, Akcea incurred additional general and administrative costs necessary to operate, including costs to begin to build the commercial infrastructure and advance the pre-commercialization activities necessary to successfully launch volanesorsen within the next few years. We expect that these costs will continue to increase in 2016. For 2015 and 2014, we allocated a portion of Ionis' R&D support expenses, which are included in Development and patent expenses in the table above, to Akcea for work we performed on behalf of Akcea. For 2015 and 2014, we also allocated a portion of Ionis' general and administrative expenses, which are included in General and administrative expenses in the table above, to Akcea for work we performed on behalf of Akcea. All amounts exclude non-cash compensation expense related to equity awards.

Investment Income

Investment income for 2015 was $4.3 million, compared to $2.7 million for 2014. The increase in investment income was primarily due to a higher average cash balance and an improvement in the market conditions during 2015 compared to 2014.

Interest Expense

Interest expense includes non-cash amortization of the debt discount and debt issuance costs plus interest expense payable in cash for our 1 percent and 2¾ percent notes, non-cash interest expense related to the long-term financing liability for our primary facility and other miscellaneous debt.
53


The following table sets forth information on interest expense (in thousands):

   
Year Ended
December 31,
 
   
2015
   
2014
 
2¾ percent notes:
       
Non-cash amortization of the debt discount and debt issuance costs
 
$
2,530
   
$
7,210
 
Interest expense payable in cash
   
1,684
     
5,074
 
1 percent notes:
               
Non-cash amortization of the debt discount and debt issuance costs
   
20,678
     
2,364
 
Interest expense payable in cash
   
4,999
     
597
 
Non-cash interest expense for long-term financing liability
   
6,665
     
6,622
 
Other
   
176
     
342
 
Total interest expense
 
$
36,732
   
$
22,209
 

Interest expense for 2015 was $36.7 million, compared to $22.2 million for 2014. The increase in interest expense was primarily due to the increase in non-cash amortization of the debt discount and debt issuance costs for our 1 percent notes we issued in November 2014. In 2015 we had more debt outstanding but our interest expense payable in cash only modestly increased because our 1 percent notes have a lower interest rate than our 2¾ percent notes.

In November 2014, we completed a $500 million convertible debt offering. The notes mature in 2021 and bear interest at 1 percent. We used a substantial portion of the net proceeds from the issuance of the 1 percent notes to repurchase $140 million in principal of our 2¾ percent convertible notes. The new principal balance of the 2¾ percent notes is $61.2 million. We record non-cash amortization of the debt discount on our convertible notes because we account for our convertible notes by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. As a result, we assigned a value to the debt component of our convertible notes equal to the estimated fair value of similar debt instruments without the conversion feature. This means we recorded our convertible notes at a discount that we are amortizing over the life of the notes as non-cash interest expense.

Gain on Investment in Regulus Therapeutics Inc.

In 2015, we recorded a gain on our investment in Regulus of $20.2 million, compared to a gain of $19.9 million for 2014 related to our sale of a portion of our Regulus common stock in each year.

Early Retirement of Debt

In 2014, we recorded a $8.3 million non-cash loss on early retirement of debt, reflecting the early retirement of a large portion of our 2¾ percent convertible notes in November 2014. We did not recognize any loss on early retirement of debt in 2015.

Income Tax Expense (Benefit)

In 2015, we recorded a net tax expense of $0.4 million due to excess tax benefits related to share-based compensation. In 2014, we recorded a net tax benefit of $15.4 million, of which $12.8 million related to our application of the intraperiod tax allocation rules that required us to record a tax benefit in continuing operations to offset the tax provision we recorded directly to other comprehensive income primarily related to the unrealized gains on our equity investment in Regulus. In addition, $4.3 million of the tax benefit we recorded in 2014 related to a tax refund we received in 2015 from the State of California Franchise Tax Board related to the California franchise taxes we paid for the tax year ended December 31, 2009.

Net Loss and Net Loss per Share

Net loss for 2015 was $88.3 million, compared to $39.0 million for 2014. Basic and diluted net loss per share for 2015 was $0.74, compared to $0.33 for 2014. We had a higher net loss in 2015 primarily due to the increase in expenses related to our three Phase 3 programs.

Net Operating Loss Carryforward

At December 31, 2015, we had federal and California tax net operating loss carryforwards of approximately $734.7 million and $886.5 million, respectively. Our federal tax loss carryforwards begin to expire in 2023. A portion of our California tax loss carryforwards expire in 2015. At December 31, 2015, we also had federal and California research and development tax credit carryforwards of approximately $146.8 million and $44.7 million, respectively. Our Federal research and development tax credit carryforwards began expiring in 2004 and will continue to expire unless we use them prior to expiration. Our California research and development tax credit carryforwards are available indefinitely.

Years Ended December 31, 2014 and December 31, 2013

Revenue

Total revenue for the year ended December 31, 2014 was $214.2 million compared to $147.3 million for 2013. Our revenue fluctuates based on the nature and timing of payments under agreements with our partners and consists primarily of revenue from the amortization of upfront fees, milestone payments and license fees.
54


Research and Development Revenue Under Collaborative Agreements

Research and development revenue under collaborative agreements for the year ended December 31, 2014 was $202.5 million compared to $144.2 million for 2013. We earned $135.0 million in milestone payments during 2014 compared to $82.8 million in 2013. The revenue from milestone payments in 2014 was primarily comprised of:

$80.0 million from Biogen, for advancing nusinersen, initiating a Phase 1 study of IONIS-DMPK-2.5Rx, validating two targets to treat neurological disorders, and advancing a third drug into development;
$28.5 million from GSK related to advancing IONIS-TTRRx, IONIS-HBVRx, IONIS-GSK4-LRx, and IONIS-RHO-2.5Rx;
$22.1 million from AstraZeneca related to the initiation of a Phase 1 clinical study of IONIS-AR-2.5Rx and advancing IONIS-STAT3-2.5Rx; and
$4.0 million from Achaogen when Achaogen initiated a Phase 3 study of plazomicin.

Licensing and Royalty Revenue

Our revenue from licensing activities and royalties for the year ended December 31, 2014 was $11.6 million and increased compared to $3.1 million for 2013. The increase in 2014 was primarily a result of the $9.5 million in revenue we earned from Alnylam related to its license of our technology to one of its partners.

Operating Expenses

Operating expenses for the year ended December 31, 2014 were $261.9 million compared to $199.0 million for 2013. The expected increase in operating expenses was primarily due to higher costs associated with our Phase 3 programs for nusinersen, IONIS-TTRRx and volanesorsen and an increase in stock compensation expense due to the increase in our stock price in January 2014 compared to January 2013.

In 2015, we began disclosing segment information for Akcea, our wholly owned subsidiary. We have revised 2014 and 2013 for comparative purposes to show operating expenses for Akcea-related projects.

Our operating expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2014
   
2013
 
Ionis Core
 
$
208,811
   
$
174,631
 
Akcea Therapeutics
   
21,697
     
12,902
 
Subtotal
   
230,508
     
187,533
 
Non-cash compensation expense related to equity awards
   
31,383
     
11,418
 
Total operating expenses
 
$
261,891
   
$
198,951
 

Research, Development and Patent Expenses

Our research, development and patent expenses consist of expenses for antisense drug discovery, antisense drug development, manufacturing and operations and R&D support expenses.

The following table sets forth information on research, development and patent expenses (in thousands):

 
Year Ended
December 31,
 
 
2014
 
2013
 
Research, development and patent expenses
 
$
215,908
   
$
174,360
 
Non-cash compensation expense related to equity awards
   
25,843
     
9,673
 
Total research, development and patent expenses
 
$
241,751
   
$
184,033
 
 
Our research, development and patent expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2014
   
2013
 
Ionis Core
 
$
195,007
   
$
162,228
 
Akcea Therapeutics
   
20,901
     
12,132
 
Subtotal
   
215,908
     
174,360
 
Non-cash compensation expense related to equity awards
   
25,843
     
9,673
 
Total research, development and patent expenses
 
$
241,751
   
$
184,033
 

For the year ended December 31, 2014, total research, development and patent expenses were $215.9 million compared to $174.4 million for 2013, and were higher primarily due to more costs incurred in 2014 compared to 2013 associated with the clinical studies of the three drugs we currently have in Phase 3 studies, which we continued to advance. In addition, we progressed numerous drugs in our pipeline into later stage clinical trials. We initiated Phase 2 studies for several of the drugs in our pipeline beginning in the second half of 2013, which were ongoing in 2014, and we have advanced several drugs into clinical development. All amounts exclude non-cash compensation expense related to equity awards.
55


Antisense Drug Discovery

Our antisense drug discovery expenses were as follows (in thousands) and are part of our Ionis Core business segment:

 
Year Ended
December 31,
 
 
2014
 
2013
 
Antisense drug discovery expenses
 
$
43,620
   
$
42,402
 
Non-cash compensation expense related to equity awards
   
7,290
     
2,878
 
Total antisense drug discovery expenses
 
$
50,910
   
$
45,280
 

Antisense drug discovery expenses were $43.6 million for the year ended December 31, 2014, and were essentially flat compared to $42.4 million for 2013. All amounts exclude non-cash compensation expense related to equity awards.

Antisense Drug Development

The following table sets forth expenses for our major antisense drug development projects (in thousands):

   
Year Ended
December 31,
 
   
2014
   
2013
 
Nusinersen
 
$
19,064
   
$
6,938
 
IONIS-TTRRx
   
10,927
     
4,174
 
Volanesorsen
   
9,337
     
5,730
 
Other antisense development products
   
50,272
     
36,782
 
Development overhead expenses
   
31,318
     
24,171
 
Total antisense drug development, excluding non-cash compensation expense related to equity awards
   
120,918
     
77,795
 
Non-cash compensation expense related to equity awards
   
9,640
     
3,202
 
Total antisense drug development expenses
 
$
130,558
   
$
80,997
 

Antisense drug development expenditures were $120.9 million for the year ended December 31, 2014 compared to $77.8 million for 2013. Expenses in 2014 were higher compared to 2013 primarily due to the progression of numerous drugs in our pipeline into later stage clinical trials, including our three drugs currently in Phase 3 trials. Beginning in the second half of 2013, we initiated Phase 2 studies for several of the drugs in our pipeline, which were ongoing in 2014, and we advanced several drugs into clinical development.
 
Our antisense drug development expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2014
   
2013
 
Ionis Core
 
$
102,862
   
$
67,006
 
Akcea Therapeutics
   
18,056
     
10,789
 
Non-cash compensation expense related to equity awards
   
9,640
     
3,202
 
Total antisense drug development expenses
 
$
130,558
   
$
80,997
 

Manufacturing and Operations

Expenditures in our manufacturing and operations function consist primarily of personnel costs, specialized chemicals for oligonucleotide manufacturing, laboratory supplies and outside services. This function is responsible for providing drug supplies to antisense drug discovery and antisense drug development, including the analytical testing to satisfy good laboratory and good manufacturing practices requirements.

Our manufacturing and operations expenses were as follows (in thousands):

 
Year Ended
December 31,
 
 
2014
 
2013
 
Manufacturing and operations expenses
 
$
24,763
   
$
20,509
 
Non-cash compensation expense related to equity awards
   
2,934
     
1,295
 
Total manufacturing and operations expenses
 
$
27,697
   
$
21,804
 

56


Our manufacturing and operations expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2014
   
2013
 
Ionis Core
 
$
22,425
   
$
19,614
 
Akcea Therapeutics
   
2,338
     
895
 
Subtotal
   
24,763
     
20,509
 
Non-cash compensation expense related to equity awards
   
2,934
     
1,295
 
Total manufacturing and operations expenses
 
$
27,697
   
$
21,804
 
 
Manufacturing and operations expenses for the year ended December 31, 2014 were $24.8 million, and increased compared to $20.5 million for 2013, primarily because we manufactured more drug product to support the increase in our drug development activities. In 2014, our manufacturing expenses included drug product to support the Phase 3 trial for volanesorsen and additional costs associated with manufacturing drug product using our LICA technology. All amounts exclude non-cash compensation expense related to equity awards.

R&D Support

The following table sets forth information on R&D support expenses (in thousands):

   
Year Ended
December 31,
 
   
2014
   
2013
 
Personnel costs
 
$
9,875
   
$
9,571
 
Occupancy
   
7,357
     
6,897
 
Patent expenses
   
2,933
     
10,321
 
Depreciation and amortization
   
2,243
     
2,464
 
Insurance
   
1,197
     
1,108
 
Other
   
3,002
     
3,293
 
Total R&D support expenses, excluding non-cash compensation expense related to equity awards
   
26,607
     
33,654
 
Non-cash compensation expense related to equity awards
   
5,979
     
2,298
 
Total R&D support expenses
 
$
32,586
   
$
35,952
 

R&D support expenses for the year ended December 31, 2014 were $26.6 million compared to $33.7 million for 2013 and decreased primarily due to lower patent expenses in 2014. Patent expenses were higher in 2013 primarily due to non-cash charges for patents and patent applications that we wrote off in 2013 due to a careful restructuring of our patent portfolio to focus our resources on patents and new patent applications that drive value for our company. All amounts exclude non-cash compensation expense related to equity awards.

Our R&D support expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2014
   
2013
 
Ionis Core
 
$
26,100
   
$
33,206
 
Akcea Therapeutics
   
507
     
448
 
Non-cash compensation expense related to equity awards
   
5,979
     
2,298
 
Total R&D support expenses
 
$
32,586
   
$
35,952
 

General and Administrative Expenses

The following table sets forth information on general and administrative expenses (in thousands):

 
Year Ended
December 31,
 
 
2014
 
2013
 
General and administrative expenses
 
$
14,600
   
$
13,173
 
Non-cash compensation expense related to equity awards
   
5,540
     
1,745
 
Total general and administrative expenses
 
$
20,140
   
$
14,918
 

General and administrative expenses for the year ended December 31, 2014 were $14.6 million and increased compared to $13.2 million for 2013. The increase was due to consulting expenses we incurred. All amounts exclude non-cash compensation expense related to equity awards.
57


Our general and administrative expenses by segment were as follows (in thousands):

   
Year Ended
December 31,
 
   
2014
   
2013
 
Ionis Core
 
$
13,804
   
$
12,403
 
Akcea Therapeutics
   
796
     
770
 
Non-cash compensation expense related to equity awards
   
5,540
     
1,745
 
Total general and administrative expenses
 
$
20,140
   
$
14,918
 

Akcea Therapeutics, Inc.

The following table sets forth information on operating expenses (in thousands) for our Akcea Therapeutics business segment:

 
Year Ended
December 31,
 
 
2014
 
2013
 
Development and patent expenses
 
$
20,901
   
$
12,132
 
General and administrative expenses
   
796
     
770
 
Total Akcea Therapeutics operating expenses
 
$
21,697
   
$
12,902
 

Akcea’s operating expenses were $21.7 million for the year ended December 31, 2014 and increased compared to $12.9 million for 2013. The increase in expenses was primarily due to Akcea’s Phase 3 program for volanesorsen, which continued to advance, and other projects, including IONIS-APO(a)-LRx and IONIS-ANGPTL3Rx. For 2014 and 2013, we allocated a portion of Ionis' R&D support expenses, which are included in Development and patent expenses in the table above, to Akcea for work we performed on behalf of Akcea. For 2014 and 2013, we also allocated a portion of Ionis' general and administrative expenses, which are included in General and administrative expenses in the table above, to Akcea for work we performed on behalf of Akcea.

Investment Income

Investment income for the year ended December 31, 2014 totaled $2.7 million compared to $2.1 million for 2013. The increase in investment income was primarily due to a higher average cash balance and increased yields.

Interest Expense

Interest expense includes non-cash amortization of the debt discount and debt issuance costs plus interest expense payable in cash for our 1 percent and 2¾ percent convertible notes, non-cash interest expense related to the long-term financing liability for our primary facility and other miscellaneous debt.

The following table sets forth information on interest expense (in thousands):

   
Year Ended,
December 31
 
   
2014
   
2013
 
2¾ percent notes:
       
Non-cash amortization of the debt discount and debt issuance costs
 
$
7,210
   
$
6,759
 
Interest expense payable in cash
   
5,074
     
5,534
 
1 percent notes:
               
Non-cash amortization of the debt discount and debt issuance costs
   
2,364
     
 
Interest expense payable in cash
   
597
     
 
Non-cash interest expense for long-term financing liability
   
6,622
     
6,568
 
Other
   
342
     
494
 
Total interest expense
 
$
22,209
   
$
19,355
 

Interest expense for the year ended December 31, 2014 was $22.2 million compared to $19.4 million in 2013. The increase in interest expense was primarily due to a higher average carrying value of the liability portion of our debt and a slight increase in interest expense payable in cash because we had more debt outstanding in 2014 compared to 2013. 

Gain on Investments, Net

Net gain on investments for the year ended December 31, 2014 was $1.3 million compared to $2.4 million for 2013. The net gain on investments in 2014 was primarily due to the $1.3 million gain we realized when we sold the common stock of Achaogen we owned. During 2013, the gain consisted of sales of stock we held in several satellite companies.
58


Gain on Investment in Regulus Therapeutics Inc.

In 2014, we realized a gain on our investment in Regulus of $19.9 million when we sold a portion of our stock. We did not sell any of our stock in Regulus in 2013.

Early Retirement of Debt

In 2014, we recorded a $8.3 million non-cash loss on early retirement of debt, reflecting the early retirement of a large portion of our 2¾ percent convertible notes in November 2014. We did not recognize any loss on early retirement of debt in 2013.

Income Tax Benefit

In 2014, we recorded a net tax benefit of $15.4 million, of which $12.8 million related to our application of the intraperiod tax allocation rules that required us to record a tax benefit in continuing operations to offset the tax provision we recorded directly to other comprehensive income primarily related to the unrealized gains on our equity investment in Regulus. In addition, $4.3 million of the tax benefit we recorded in 2014 related to a tax refund we received in 2015 from the State of California Franchise Tax Board related to the California franchise taxes we paid for the tax year ended December 31, 2009. The increase in 2014 compared to 2013 was due to larger unrealized gains year over year and the tax refund we recorded in 2014.

Net Loss and Net Loss Per Share

Net loss for the year ended December 31, 2014 was $39.0 million compared $60.6 million for 2013. Basic and diluted net loss per share for the year ended December 31, 2014 was $0.33 compared to $0.55  for 2013. Our net loss for the year ended December 31, 2014 decreased significantly compared to 2013 due to the significant increase in revenue that we earned from our partners in 2014, offset mostly by the planned increase in operating expenses associated with our advancing pipeline of drugs. The decrease in our net loss was further impacted by the $19.9 million gain we realized in 2014 from the sale of a portion of our stock in Regulus, the $15.4 million net tax benefit we recorded in 2014 offset, in part, by the $8.3 million non-cash loss we recorded in 2014 on the early retirement of a large portion of our 2¾ percent convertible notes.

Liquidity and Capital Resources

We have financed our operations with revenue primarily from research and development collaborative agreements. Additionally, we have earned revenue from the sale or licensing of our intellectual property. We have also financed our operations through the sale of our equity securities and the issuance of long-term debt. From our inception through December 31, 2015, we have earned approximately $1.8 billion in revenue from contract research and development and the sale and licensing of our intellectual property. From the time we were founded through December 31, 2015, we have raised net proceeds of approximately $1.1 billion from the sale of our equity securities and we have borrowed approximately $1.3 billion under long-term debt arrangements to finance a portion of our operations.

At December 31, 2015, we had cash, cash equivalents and short-term investments of $779.2 million and stockholders’ equity of $200.8 million. In comparison, we had cash, cash equivalents and short-term investments of $728.8 million and stockholders’ equity of $257.8 million at December 31, 2014. We received a substantial amount of cash in 2015, including more than $320 million in payments from our partners.

At December 31, 2015, we had consolidated working capital of $688.1 million compared to $721.3 million at December 31, 2014. Working capital decreased in 2015 primarily due to the decrease in our investment in Regulus and an increase in payables.  The decrease in our investment in Regulus was a result of us selling a portion of our stock in Regulus, in which we received $25.5 million in proceeds in 2015 and Regulus’ stock price declining at December 31, 2015 compared to December 31, 2014, as other biotech companies have also experienced declines over this same time period.
 
As of December 31, 2015, our debt and other obligations totaled $644.8 million compared to $643.5 million at December 31, 2014.

The following table summarizes our contractual obligations as of December 31, 2015. The table provides a breakdown of when obligations become due. We provide a more detailed description of the major components of our debt in the paragraphs following the table:

 
 
Payments Due by Period (in millions)
 
Contractual Obligations
(selected balances described below)
 
Total
   
Less than
1 year
   
1-3 years
   
3-5 years
   
After
5 years
 
1 percent convertible senior notes (principal and interest payable)
 
$
530.0
   
$
5.0
   
$
10.0
   
$
10.0
   
$
505.0
 
percent convertible senior notes (principal and interest payable)
 
$
68.0
   
$
1.7
   
$
3.4
   
$
62.9
   
$
 
Financing arrangements (principal and interest payable)
 
$
9.0
   
$
9.0
   
$
   
$
   
$
 
Facility rent payments
 
$
125.6
   
$
6.5
   
$
13.5
   
$
14.3
   
$
91.3
 
Other obligations (principal and interest payable)
 
$
1.3
   
$
0.1
   
$
0.1
   
$
0.1
   
$
1.0
 
Operating leases
 
$
24.6
   
$
2.0
   
$
3.5
   
$
3.0
   
$
16.1
 
Total
 
$
758.5
   
$
24.3
   
$
30.5
   
$
90.3
   
$
613.4
 

Our contractual obligations consist primarily of our convertible debt. In addition, we also have facility leases, equipment financing arrangements and other obligations.
59


Convertible Debt Summary

In November 2014, we completed a $500 million offering of convertible senior notes, which mature in 2021 and bear interest at 1 percent. We used a substantial portion of the net proceeds from the issuance of the 1 percent notes convertible senior notes to repurchase $140 million in principal of our 2¾ percent convertible senior notes. As a result, the new principal balance of the 2¾ percent notes is $61.2 million.

At December 31, 2015 our outstanding convertible debt was as follows (amounts in millions except price per share data):

 
1 Percent Convertible
Senior Notes
 
2¾ Percent Convertible
Senior Notes
 
Outstanding principal balance
 
$
500.0
   
$
61.2
 
Issue date
November 2014
 
August 2012
 
Maturity date
November 2021
 
October 2019
 
Interest rate
1 percent
 
2¾ percent
 
Conversion price per share
 
$
66.81
   
$
16.63
 
Total shares of common stock subject to conversion
   
7.5
     
3.7
 

Interest is payable semi-annually for both the 1 percent and 2¾ percent notes. The notes are convertible under certain conditions, at the option of the note holders. We settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both.

1 Percent Convertible Senior Notes

We may not redeem the 1 percent notes prior to maturity, and no sinking fund is provided for them. Holders of the 1 percent notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indenture governing the 1 percent notes, at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest.

2¾ Percent Convertible Senior Notes

We may redeem the 2¾ percent notes at our option, in whole or in part, on or after October 5, 2016 if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the trading day immediately preceding the date we provide the redemption notice exceeds 130 percent of the applicable conversion price for the 2¾ percent notes on each such day. The redemption price for the 2¾ percent notes will equal 100 percent of the principal amount being redeemed, plus accrued and unpaid interest, plus $90 per each $1,000 principal amount being redeemed. Holders of the 2¾ percent notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indenture governing the 2¾ percent notes, at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest.

Financing Arrangements

In June 2015, we entered into a five-year revolving line of credit agreement with Morgan Stanley Private Bank, National Association, or Morgan Stanley. We amended the credit agreement in February 2016 to increase the amount available for us to borrow. Under the amended credit agreement, Morgan Stanley will provide a maximum of $30 million of revolving credit for general working capital purposes. Any loans under the credit agreement have interest payable monthly in arrears at a rate based on our option of:

(i)
a floating rate equal to the one-month London Interbank Offered Rate, or LIBOR, in effect plus 1.25 percent per annum;
(ii)
a fixed rate equal to LIBOR plus 1.25 percent for a period of one, two, three, four, six, or twelve months as elected by us; or
(iii)
a fixed rate equal to the LIBOR swap rate during the period of the loan.

Additionally, we will pay 0.25 percent per annum, payable quarterly in arrears, for any amount unused under the credit facility beginning after June 2016. As of December 31, 2015 we had $8.5 million in outstanding borrowings under the credit facility, which were used to fund our capital equipment needs and is consistent with our historical practice to finance these costs. As of December 31, 2015, our outstanding borrowings under this credit facility were at a weighted average interest rate of 1.67 percent.

The credit agreement includes customary affirmative and negative covenants and restrictions. We are in compliance with all covenants of the credit agreement.

In October 2008, we entered into an equipment financing loan agreement. As of December 31, 2015, our outstanding borrowings under this loan agreement were at a weighted average interest rate of 4.39 percent. The carrying balance under this loan agreement at December 31, 2015 and 2014 was $0.5 million and $3.2 million, respectively. Our remaining outstanding balance is due in June 2016 and interest is payable monthly. 
60


Research and Development Facility Lease Obligation

In March 2010, we entered into a lease agreement with an affiliate of BioMed Realty, L.P. Under the lease, BioMed constructed our facility in Carlsbad, California. The lease has an initial term of 20 years with an option to extend the lease for up to four five-year periods. Our rent under this lease is based on a percentage of the total construction costs spent by BioMed to acquire the land and build the facility. Accounting rules required us to record the cost of the facility as a fixed asset with a corresponding liability. We are depreciating the building over its economic life and we apply our rent payments, which began on January 1, 2012, against the liability over the term of the lease.

In addition to contractual obligations, we had outstanding purchase orders as of December 31, 2015 for the purchase of services, capital equipment and materials as part of our normal course of business.

We plan to continue to enter into collaborations with partners to provide for additional revenue to us and we may incur additional cash expenditures related to our obligations under any of the new agreements we may enter into. We currently intend to use our cash, cash equivalents and short-term investments to finance our activities. However, we may also pursue other financing alternatives, like issuing additional shares of our common stock, issuing debt instruments, refinancing our existing debt, or securing lines of credit. Whether we use our existing capital resources or choose to obtain financing will depend on various factors, including the future success of our business, the prevailing interest rate environment and the condition of financial markets generally.

As part of Akcea’s formation, we made an initial cash investment in the company to fund Akcea’s operations. As Akcea continues to progress we may seek additional capital to fund Akcea’s future operating needs. As such, we may pursue various financing alternatives, like issuing shares of Ionis’ or Akcea’s stock in private or public financings, issuing Ionis or Akcea debt instruments, or securing lines of credit.  We may also consider entering into collaborations specific to Akcea’s pipeline with partners to provide for additional operating cash.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to changes in interest rates primarily from our long-term debt arrangements and, secondarily, investments in certain short-term investments. We primarily invest our excess cash in highly liquid short-term investments of the U.S. Treasury, reputable financial institutions, corporations, U.S. government agencies and securities issued by states of the United States and political subdivisions of the states with strong credit ratings. We typically hold our investments for the duration of the term of the respective instrument. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk sensitive instruments, positions or transactions to manage exposure to interest rate changes. Accordingly, we believe that, while the securities we hold are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments.

Item 8. Financial Statements and Supplementary Data

We filed our consolidated financial statements and supplementary data required by this item as exhibits hereto, and listed them under Item 15(a)(1) and (2), and incorporate them herein by reference.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

There have been no reported disagreements on any matter of accounting principles or procedures or financial statement disclosure in 2015 with our Independent Registered Public Accounting Firm.

Item 9A. Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or Exchange Act) that are designed to ensure that information we are required to disclose in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We designed and evaluate our disclosure controls and procedures recognizing that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance and not absolute assurance of achieving the desired control objectives.

As of the end of the period covered by this report on Form 10-K, we carried out an evaluation of our disclosure controls and procedures under the supervision of, and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2015.
61


Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f). Our internal control over financial reporting is a process designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with United States generally accepted accounting principles.

As of December 31, 2015, we assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting under the 2013 “Internal Control—Integrated Framework,” issued by the Committee of Sponsoring Organizations, or COSO, of the Treadway Commission, under the supervision of, and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on that assessment, our management concluded that we maintained effective internal control over financial reporting as of December 31, 2015.

Ernst & Young LLP, an independent registered public accounting firm, audited the effectiveness of our internal control over financial reporting as of December 31, 2015, as stated in their attestation report, which is included elsewhere herein.

Changes in Internal Control over Financial Reporting

The above assessment did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

62


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Stockholders of Ionis Pharmaceuticals, Inc. (formerly Isis Pharmaceuticals, Inc.)

We have audited Ionis Pharmaceuticals, Inc.’s (formerly Isis Pharmaceuticals, Inc.) internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). Ionis Pharmaceuticals, Inc.’s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, Ionis Pharmaceuticals, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2015, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Ionis Pharmaceuticals, Inc. as of December 31, 2015 and 2014, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2015 of Ionis Pharmaceuticals, Inc. and our report dated February 25, 2016 expressed an unqualified opinion thereon.
 
 
/s/ ERNST & YOUNG LLP
 
 
San Diego, California
 
February 25, 2016
 

63

Item 9B. Other Information

In June 2015 we and Morgan Stanley Private Bank, National Association entered into a Line of Credit Agreement.

In February 2016, we and Morgan Stanley amended the loan documents to increase the amount available under the agreement to $30 million and revise a financial covenant relating to our debt to net worth ratio.

Item 10. Directors, Executive Officers and Corporate Governance

We incorporate by reference the information required by this Item with respect to directors and the Audit Committee from the information under the caption “ELECTION OF DIRECTORS,” including in particular the information under “Nominating, Governance and Review Committee” and “Audit Committee,” contained in our definitive Proxy Statement (the “Proxy Statement”), which we will file on or about April 15, 2016 with the Securities and Exchange Commission in connection with the solicitation of proxies for our 2016 Annual Meeting of Stockholders to be held on June 3, 2016.

We incorporate by reference the required information concerning our Code of Ethics from the information under the caption “Code of Ethics and Business Conduct” contained in the Proxy Statement. Our Code of Ethics and Business Conduct is posted on our website at www.ionispharma.com(1). We intend to disclose future amendments to, or waivers from, our Code of Ethics and Business Conduct on our website.

Item 1, Part I of this Report contains information concerning our executive officers. We incorporate by reference the information required by this Item concerning compliance with Section 16(a) of the Securities Exchange Act of 1934, as amended, from the information under the caption “Section 16(a) Beneficial Ownership Reporting Compliance” contained in the Proxy Statement.
 ________________
(1)
Any information that is included on or linked to our website is not part of this Form 10-K.

Item 11. Executive Compensation

We incorporate by reference the information required by this item to the information under the caption “EXECUTIVE COMPENSATION,” “Compensation Committee Interlocks and Insider Participation” and “COMPENSATION COMMITTEE REPORT” contained in the Proxy Statement.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

We incorporate by reference the information required by this item to the information under the captions “SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT” contained in the Proxy Statement.

Securities Authorized for Issuance under Equity Compensation Plans

The following table sets forth information regarding outstanding options and shares reserved for future issuance under our equity compensation plans as of December 31, 2015.
 
Plan Category
 
Number of Shares
to be Issued
Upon Exercise of
Outstanding Options
   
Weighted Average
Exercise Price of
Outstanding Options
   
Number of Shares
Remaining
Available for
Future Issuance
 
 
Equity compensation plans approved by stockholders(a)
   
7,996,753
   
$
33.31
     
6,863,085
 
(c)
Equity compensation plans not approved by stockholders(b)
   
44,025
   
$
14.66
     
-
 
 
                                     
Total
   
8,040,778
   
$
33.21
     
6,863,085
 
 
 ________________
(a) Consists of four Ionis plans: 1989 Stock Option Plan, Amended and Restated 2002 Non-Employee Directors’ Stock Option Plan, 2011 Equity Incentive Plan and Employee Stock Purchase Plan, or ESPP.
 
(b) Consists of the 2000 Broad-Based Equity Incentive Plan, more fully described below. The 2000 Broad-Based Equity Incentive Plan expired on January 5, 2010.
 
(c) Of these shares, 481,764 remained available for purchase under the ESPP as of December 31, 2015. The ESPP incorporates an evergreen formula pursuant to which on January 1 of each year, we automatically increase the aggregate number of shares reserved for issuance under the plan by 150,000 shares.
 
64


Description of 2000 Broad-Based Equity Incentive Plan

We adopted the 2000 Broad-Based Equity Incentive Plan, or the 2000 Plan, to provide our employees, officers, directors and consultants an opportunity to benefit from increases in the value of our common stock through the granting of non-statutory stock options, stock bonuses and rights to purchase restricted stock. At the time we adopted the 2000 Plan, we were not required to seek the approval of our stockholders. The Board delegated administration of the 2000 Plan to the Compensation Committee of the Board. The Board has the power to construe and interpret the 2000 Plan.

As of December 31, 2015, the 2000 Plan had 5,990,000 shares authorized for issuance, options to purchase an aggregate of 44,025 shares were granted and outstanding under the 2000 Plan, option holders had exercised options to purchase an aggregate of 5,492,172 shares under the 2000 Plan, and no shares remained available for grant thereunder. The 2000 Plan expired on January 5, 2010, so we may no longer grant new options under the 2000 Plan.

Options granted under the 2000 Plan generally have a term of seven or ten years, have an exercise price equal to the fair market value at the time of grant, can only be exercised with a cash payment and vest at the rate of 25 percent per year after the first year and then at the rate of 2.08 percent per month thereafter during the option holder’s employment or service as a consultant, employee or director. If any change is made in the common stock subject to the 2000 Plan, or subject to any stock award, without the receipt of consideration by us (through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving the receipt of consideration by us), we will adjust the outstanding stock awards appropriately in the class(es) and number of securities and price per share of common stock subject to such outstanding stock awards. Our board of directors will make such adjustments, and its determination will be final, binding and conclusive. We will not treat the conversion of any of our convertible securities as a transaction without receipt of consideration.

In the event of our dissolution or liquidation, all outstanding stock awards will terminate immediately prior to such event.

In the event of:

a sale, lease or other disposition of all or substantially all of our assets;

a merger or consolidation in which we are not the surviving corporation; or

reverse merger in which we are the surviving corporation but the shares of common stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise;

then any surviving corporation or acquiring corporation will assume any stock awards outstanding under the 2000 Plan or will substitute similar stock awards (including an award to acquire the same consideration paid to the stockholders in the transaction for those outstanding under the 2000 Plan). In the event any surviving corporation or acquiring corporation refuses to assume such stock awards or to substitute similar stock awards for those outstanding under the 2000 Plan, then with respect to stock awards held by participants whose continuous service has not terminated, we will accelerate the vesting of such stock awards in full and the stock awards will terminate if not exercised (if applicable) at or prior to such event.

Item 13. Certain Relationships and Related Transactions, and Director Independence

We incorporate by reference the information required by this item to the information under the captions “Independence of the Board of Directors” and “Certain Relationships and Related Transactions” contained in the Proxy Statement.

Item 14. Principal Accounting Fees and Services

We incorporate by reference the information required by this item to the information under the caption “Ratification of Selection of Independent Auditors” contained in the Proxy Statement.

65

PART IV
 
Item 15. Exhibits, Financial Statement Schedules
 
(a)(1) Index to Financial Statements
 
We submitted the consolidated financial statements required by this item in a separate section beginning on page F-1 of this Report.
 
(a)(2) Index to Financial Statement Schedules
 
We omitted these schedules because they are not required, or are not applicable, or the required information is shown in the consolidated financial statements or notes thereto.
 
(a)(3) Index to Exhibits
 
See Index to Exhibits beginning on page 68.
 
(b) Exhibits
 
We listed the exhibits required by this Item under Item 15(a)(3).
 
(c) Financial Statement Schedules
 
None.

66

SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized on the 25th day of February, 2016.
 
 
IONIS PHARMACEUTICALS, INC.
 
 
 
 
By:
/s/ STANLEY T. CROOKE
 
 
Stanley T. Crooke, M.D., Ph.D.
 
 
Chairman of the Board, President and Chief Executive Officer (Principal executive officer)
 
POWER OF ATTORNEY
 
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Stanley T. Crooke and Elizabeth L. Hougen, or any of them, his or her attorney-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Report, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
 
Signatures
 
Title
 
Date
 
 
 
 
 
/s/ STANLEY T. CROOKE
 
Chairman of the Board, President, and Chief Executive Officer
 
February 25, 2016
Stanley T. Crooke, M.D., Ph.D.
 
(Principal executive officer)
 
 
 
 
 
 
 
/s/ B. LYNNE PARSHALL
 
Director, Chief Operating Officer and Secretary
 
February 25, 2016
B. Lynne Parshall, J.D.
 
 
 
 
 
 
 
 
 
/s/ ELIZABETH L. HOUGEN
 
Senior Vice President, Finance and Chief Financial Officer
 
February 25, 2016
Elizabeth L. Hougen
 
(Principal financial and accounting officer)
 
 
 
 
 
 
 
/s/ SPENCER R. BERTHELSEN
 
Director
 
February 25, 2016
Spencer R. Berthelsen, M.D.
 
 
 
 
 
 
 
 
 
/s/ BREAUX CASTLEMAN
 
Director
 
February 25, 2016
Breaux Castleman
 
 
 
 
 
 
 
 
 
/s/ JOSEPH KLEIN
 
Director
 
February 25, 2016
Joseph Klein, III
 
 
 
 
 
 
 
 
 
/s/ JOSEPH LOSCALZO
 
Director
 
February 25, 2016
Joseph Loscalzo, M.D., Ph.D.
 
 
 
 
 
 
 
 
 
/s/ FREDERICK T. MUTO
 
Director
 
February 25, 2016
Frederick T. Muto, Esq.
 
 
 
 
 
 
 
 
 
/s/ JOSEPH H. WENDER
 
Director
 
February 25, 2016
Joseph H. Wender
 
 
 
 

67


INDEX TO EXHIBITS
 
Exhibit
Number
 
Description of Document
3.1
 
Amended and Restated Certificate of Incorporation filed June 19, 1991. (1)
 
 
 
3.2
 
Certificate of Amendment to Restated Certificate of Incorporation filed June 17, 2014. (35)
     
3.3
 
Certificate of Amendment to Restated Certificate of Incorporation filed December 18, 2015. (41)
 
 
 
3.4
 
Amended and Restated Bylaws. (41)
 
 
 
4.1
 
Certificate of Designation of the Series C Junior Participating Preferred Stock. (9)
 
 
 
4.2
 
Specimen Common Stock Certificate. (1)
 
 
 
4.3
 
Indenture, dated as of August 13, 2012, between the Registrant and Wells Fargo Bank, National Association, as trustee, including Form of 2¾ percent Convertible Senior Note due 2019. (24)
     
4.4
 
Indenture, dated as of November 17, 2014, between the Registrant and Wells Fargo Bank, National Association, as trustee, including Form of 1.00 percent Convertible Senior Note due 2021. (34)
 
 
 
10.1
 
Form of Indemnity Agreement entered into between the Registrant and its Directors and Officers with related schedule. (30)
 
 
 
10.2*
 
Registrant’s 1989 Stock Option Plan, as amended. (21)
 
 
 
10.3*
 
Registrant’s Amended and Restated 2000 Employee Stock Purchase Plan. (11)
 
 
 
10.4
 
Form of Employee Assignment of Patent Rights. (1)
 
 
 
10.5*
 
Registrant’s 2000 Broad-Based Equity Incentive Stock Option Plan and related form of option agreement. (5)
 
 
 
10.6
 
Patent Rights Purchase Agreement between the Registrant and Gilead Sciences, Inc., dated December 18, 1998. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (4)
 
 
 
10.7
 
Collaboration and License Agreement between the Registrant and Hybridon, Inc., dated May 24, 2001. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (10)
 
 
 
10.8
 
License and Co-Development Agreement between the Registrant and Genzyme Corporation dated June 24, 2008. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (6)
 
 
 
10.9
 
Amendment #1 to the Research, Development and License Agreement dated May 11, 2011 by and between the Registrant and Glaxo Group Limited. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (7)
 
 
 
10.10
 
Amended and Restated Collaboration and License Agreement between the Registrant and Antisense Therapeutics Ltd dated February 8, 2008. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (3)
 
 
 
10.11
 
Amended and Restated License Agreement between the Registrant and Atlantic Pharmaceuticals Limited dated November 30, 2009. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (19)
 
10.12
 
Amended and Restated License Agreement dated July 2, 2008 between the Registrant and OncoGenex Technologies Inc. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (13)
 
 
 
10.13
 
Lease Agreement between the Registrant and BMR-Gazelle Court LLC dated March 30, 2010. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (20)
 
 
 
10.14
 
Second Amendment to Lease Agreement dated May 15, 2011 between the Registrant and BMR-Gazelle Court LLC, with First Amendment to Lease Agreement included. (7)
 
 
 
10.15
 
Registrant’s Amended and Restated 10b5-1 Trading Plan dated September 12, 2013. (27)
 
 
 
10.16*
 
Registrant’s Amended and Restated 2002 Non-Employee Directors’ Stock Option Plan, as amended. (35)
 
 
 
10.17*
 
Registrant’s Form of 2002 Non-Employee Directors’ Stock Option Agreement. (16)
68


 
 
 
10.18*
 
Form of Restricted Stock Unit Agreement for Restricted Stock Units granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors’ Stock Option Plan. (26)
 
 
 
10.19*
 
Amended and Restated Severance Agreement dated December 3, 2008 between the Registrant and Stanley T. Crooke. (12)
 
 
 
10.20*
 
Amended and Restated Severance Agreement dated December 3, 2008 between the Registrant and B. Lynne Parshall. (12)
     
10.21*
 
Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan (15)
 
 
 
10.22
 
Loan Agreement dated October 15, 2008 between the Registrant and RBS Asset Finance, Inc. (18)
 
 
 
10.23*
 
Form of Option Agreement under the 2011 Equity Incentive Plan. (37)
 
 
 
10.24*
 
Form of Restricted Stock Unit Agreement for Restricted Stock Units granted under the 2011 Equity Incentive Plan. (23)
 
 
 
10.25
 
Second Amendment to Lease Agreement between the Registrant and BMR-2282 Faraday Avenue LLC dated March 30, 2010. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (20)
 
 
 
10.26*
 
Form of Option Agreement under the 1989 Stock Option Plan. (37)
 
 
 
10.27*
 
Form of Option Agreement for Options Granted after March 8, 2005 under the 2000 Broad-Based Equity Incentive Plan. (8)
 
 
 
10.28*
 
Form of Option Agreement for Options Granted after March 8, 2005 under the 2002 Non-Employee Director’s Stock Option Plan. (8)
 
 
 
10.29
 
Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated March 30, 2010. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (20)
 
 
 
10.30
 
First Amendment to Loan Agreement between the Registrant and RBS Asset Finance, Inc. dated September 30, 2009. (19)
 
 
 
10.31
 
Lease Agreement dated September 6, 2005 between the Registrant and BMR-2282 Faraday Avenue LLC. (14)
     
10.32
 
Stock Purchase Agreement dated December 17, 2008, among the Registrant, Ibis Biosciences, Inc. and Abbott Molecular Inc. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (18)
 
 
 
10.33
 
Research Agreement dated August 10, 2011 between the Registrant and CHDI Foundation, Inc. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (2)
 
 
 
10.34
 
Amendment No. 1 to Amended and Restated License Agreement between the Registrant and OncoGenex Technologies Inc. dated December 18, 2009. (19)
 
 
 
10.35
 
Second Amendment to Loan Agreement dated November 15, 2010 between the Registrant and RBS Asset Finance, Inc. (17)
 
 
 
10.36
 
Development, Option and License Agreement between the Registrant and Biogen Idec International Holding Ltd. dated January 3, 2012. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (25)
 
 
 
10.37
 
Third Amendment to Loan Agreement dated June 24, 2012 between the Registrant and RBS Asset Finance, Inc. (26)
 
 
 
10.38
 
DMPK Research, Development, Option and License Agreement between the Registrant and Biogen Idec MA Inc. dated June 27, 2012. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (26)
 
 
 
10.39
 
Amendment #2 to Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated October 30, 2012. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (30)
 
 
 
10.40
 
Collaboration, License and Development Agreement between the Registrant and AstraZeneca AB dated December 7, 2012. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (30)
69


 
 
 
10.41
 
Neurology Drug Discovery and Development Collaboration, Option and License Agreement between the Registrant and Biogen Idec MA Inc. dated December 10, 2012. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (30)
 
 
 
10.42
 
HTT Research, Development, Option and License Agreement among the Registrant, F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc. dated April 8, 2013. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (28)
 
 
 
10.43
 
Letter Agreement between the Registrant and CHDI Foundation, Inc. dated April 8, 2013. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (28)
 
 
 
10.44
 
Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement between the Registrant and Biogen Idec MA Inc. dated September 5, 2013. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (27)
     
10.45
 
Amendment #1 to Collaboration, License and Development Agreement between the Registrant and AstraZeneca AB dated August 13, 2013. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (27)
     
10.46
 
Letter Agreement Amendment between the Registrant and Biogen Idec International Holding Ltd dated January 27, 2014. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (31)
     
10.47
 
Amendment No. 3 to the Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated July 10, 2013. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (32)
     
10.48
 
Amendment #4 to the Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated April 10, 2014. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (32)
     
10.49
 
Amendment #5 to the Research, Development and License Agreement among the Registrant, Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited dated June 27, 2014. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (32)
     
10.50
 
Exclusive License Agreement between the Registrant and the University of Massachusetts dated January 14, 2010. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (33)
     
10.51
 
Amended and Restated Collaboration and License Agreement between the Registrant and Cold Spring Harbor Laboratory dated October 26, 2011. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (33)
     
10.52
 
Amendment to Amended and Restated Collaboration and License Agreement between the Registrant and Cold Spring Harbor Laboratory dated March 14, 2014. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (33)
     
10.53
 
Amendment #1 to the Development, Option and License Agreement between the Registrant and Biogen Idec International Holding Ltd. dated December 15, 2014. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (36)
     
10.54
 
Research Collaboration, Option and License Agreement between the Registrant and Janssen Biotech Inc. dated December 22, 2014. Portions of this exhibit have been omitted and separately filed with the SEC. (36)
     
10.55
 
Amendment No.2 to the Collaboration, License and Development Agreement between the Registrant and AstraZeneca AB dated October 15, 2014. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment. (36)
     
10.56
 
Strategic Collaboration Agreement between the Registrant and AstraZeneca AB dated July 31, 2015. Portions of this exhibit have been omitted and separately filed with the SEC. (37)
     
10.57
 
Amendment #6 to Research, Development and License Agreement between the Registrant, Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited dated September 2, 2015. Portions of this exhibit have been omitted and separately filed with the SEC. (37)
     
10.58
 
Amendment Number One to the Second Amended and Restated Strategic Collaboration and License Agreement between the Registrant and Alnylam Pharmaceuticals, Inc. dated July 13, 2015. Portions of this exhibit have been omitted and separately filed with the SEC. (37)
     
10.59
 
License Agreement between the Registrant and Bayer Pharma AG dated May 1, 2015. Portions of this exhibit have been omitted and separately filed with the SEC. (38)
70


     
10.60
 
Line of Credit Agreement between the Registrant and Morgan Stanley Private Bank, National Association dated June 16, 2015. (38)
     
10.61
 
Second Amended and Restated Strategic Collaboration and License Agreement between the Registrant and Alnylam Pharmaceuticals, Inc. dated January 8, 2015. Portions of this exhibit have been omitted and separately filed with the SEC. (39)
     
10.62
 
Amendment #1 to HTT Research, Development, Option and License Agreement between the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. dated January 9, 2015. Portions of this exhibit have been omitted and separately filed with the SEC. (39)
     
10.63
 
Amendment No.1 to Loan Documents between the Registrant and Morgan Stanley Private Bank, National Association dated December 30, 2015. (40)
 
10.64
 
Amendment No.2 to Line of Credit Agreement between the Registrant and Morgan Stanley Private Bank, National Association dated February 24, 2016.
 
 
 
14.1
 
Registrant’s Code of Ethics and Business Conduct. (29)
 
 
 
21.1
 
List of Subsidiaries for the Registrant.
 
 
 
23.1
 
Consent of Independent Registered Public Accounting Firm.
 
 
 
24.1
 
Power of Attorney (22)
 
 
 
31.1
 
Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
31.2
 
Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
32.1
 
Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
101
 
The following financial statements from the Ionis Pharmaceuticals, Inc. Annual Report on Form 10-K for the year ended December 31, 2015, formatted in Extensive Business Reporting Language (XBRL): (i) consolidated balance sheets, (ii) consolidated statements of operations, (iii) consolidated statements of stockholders’ equity, (iv) consolidated statements of cash flows, and (v) notes to consolidated financial statements (detail tagged).
 
(1)
 
Filed as an exhibit to the Registrant’s Registration Statement on Form S-1 (No. 33-39640) or amendments thereto and incorporated herein by reference.
 
 
 
(2)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 and incorporated herein by reference.
 
 
 
(3)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 and incorporated herein by reference.
 
 
 
(4)
 
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 1998 and incorporated herein by reference.
 
 
 
(5)
 
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 1999 and incorporated herein by reference.
 
 
 
(6)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 and incorporated herein by reference.
 
(7)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 and incorporated herein by reference.
 
 
 
(8)
 
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2004 and incorporated herein by reference.
 
 
 
(9)
 
Filed as an exhibit to Registrant’s Report on Form 8-K dated filed December 13, 2000 and incorporated herein by reference.
 
 
 
(10)
 
Filed as an exhibit to the Registrant’s report on Form 10-Q as amended for the quarter ended June 30, 2001 and incorporated herein by reference.
 
 
 
(11)
 
Filed as an exhibit to Registrant’s Notice of Annual Meeting and Proxy Statement for the 2009 Annual Meeting of Stockholders, filed with the SEC on April 20, 2009, and incorporated herein by reference.
71


 
 
 
(12)
 
Filed as an exhibit to the Registrant’s Current Report on Form 8-K filed December 5, 2008 and incorporated herein by reference.
 
 
 
(13)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 and incorporated herein by reference.
 
 
 
(14)
 
Filed as an exhibit to Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 and incorporated herein by reference.
 
 
 
(15)
 
Filed as an exhibit to the Registrant’s Notice of 2011 Annual Meeting of Stockholders and Proxy Statement filed with the SEC on April 28, 2011, and incorporated herein by reference.
 
 
 
(16)
 
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2001 and incorporated herein by reference.
 
 
 
(17)
 
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010 and incorporated herein by reference.
 
 
 
(18)
 
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2008 and incorporated herein by reference.
 
 
 
(19)
 
Filed as an exhibit to the Registrant’s Annual Report as Form 10-K for the year ended December 31, 2009 and incorporated herein by reference.
 
 
 
(20)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 and incorporated herein by reference.
 
 
 
(21)
 
Filed as an exhibit to Registrant’s Notice of Annual Meeting and Proxy Statement for the 2012 Annual Meeting of Stockholders, filed with the SEC on April 16, 2012, and incorporated herein by reference.
 
 
 
(22)
 
Filed as part of the Annual Report on Form 10-K for the year ended December 31, 2013, and incorporated herein by reference.
 
 
 
(23)
 
Filed as an exhibit to the Registrant’s Registration Statement on Form S-8 filed with the SEC on August 8, 2011, and incorporated herein by reference.
 
 
 
(24)
 
Filed as an exhibit to the Registrant’s Report on Form 8-K filed August 13, 2012 and incorporated herein by reference.
(25)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and incorporated herein by reference.
 
 
 
(26)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and incorporated herein by reference.
 
 
 
(27)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 and incorporated herein by reference.
 
 
 
(28)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 and incorporated herein by reference.
 
 
 
(29)
 
Filed as an exhibit to the Registrant’s Report on Form 8-K filed on December 9, 2013 and incorporated herein by reference.
 
 
 
(30)
 
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference.
     
(31)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 and incorporated herein by reference.
     
(32)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 and incorporated herein by reference.
     
(33)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 and incorporated herein by reference.
     
(34)
 
Filed as an exhibit to the Registrant’s Current Report on Form 8-K filed November 21, 2014 and incorporated herein by reference.
     
(35)
 
Filed as an exhibit to the Registrant’s Notice of Annual Meeting and Proxy Statement, for the 2014 Annual Meeting of Stockholders, filed with the SEC on April 25, 2014, and incorporated herein by reference.
72


(36)
 
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2014 and incorporated herein by reference.
(37)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 and incorporated herein by reference.
(38)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 and incorporated herein by reference.
(39)
 
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 and incorporated herein by reference.
(40)
 
Filed as an exhibit to the Registrant’s Current Report on Form 8-K filed January 5, 2016 and incorporated herein by reference.
(41)
 
Filed as an exhibit to the Registrant’s Current Report on Form 8-K filed December 18, 2015 and incorporated herein by reference.
*
 
Indicates management compensatory plans and arrangements as required to be filed as exhibits to this Report pursuant to Item 14(c).


73

IONIS PHARMACEUTICALS, INC.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 
 
Page
Report of Independent Registered Public Accounting Firm
F-2
Consolidated Balance Sheets at December 31, 2015 and 2014
F-3
Consolidated Statements of Operations for the years ended December 31, 2015, 2014 and 2013
F-4
Consolidated Statements of Comprehensive Loss for the years ended December 31, 2015, 2014 and 2013
F-5
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2015, 2014 and 2013
F-6
Consolidated Statements of Cash Flows for the years ended December 31, 2015, 2014 and 2013
F-7
Notes to Consolidated Financial Statements
F-9

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
The Board of Directors and Stockholders of Ionis Pharmaceuticals, Inc. (formerly Isis Pharmaceuticals, Inc.)
 
We have audited the accompanying consolidated balance sheets of Ionis Pharmaceuticals, Inc. (formerly Isis Pharmaceuticals, Inc.) as of December 31, 2015 and 2014, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2015. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
 
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
 
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Ionis Pharmaceuticals, Inc. at December 31, 2015 and 2014, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2015, in conformity with U.S. generally accepted accounting principles.
 
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Ionis Pharmaceuticals, Inc.’s internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 25, 2016 expressed an unqualified opinion thereon.
 
 
/s/ ERNST & YOUNG LLP
 
San Diego, California
February 25, 2016

F-2

IONIS PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)

   
December 31,
 
   
2015
   
2014
 
ASSETS
       
Current assets:
       
Cash and cash equivalents
 
$
128,797
   
$
142,998
 
Short-term investments
   
650,386
     
585,834
 
Contracts receivable
   
11,356
     
3,903
 
Inventories
   
6,899
     
6,290
 
Investment in Regulus Therapeutics Inc.
   
24,792
     
81,881
 
Other current assets
   
14,773
     
15,691
 
Total current assets
   
837,003
     
836,597
 
Property, plant and equipment, net
   
90,233
     
88,958
 
Patents, net
   
19,316
     
17,186
 
Deposits and other assets
   
9,553
     
13,068
 
Total assets
 
$
956,105
   
$
955,809
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
Accounts payable
 
$
28,355
   
$
17,984
 
Accrued compensation
   
16,065
     
12,302
 
Accrued liabilities
   
28,105
     
30,451
 
Current portion of long-term obligations
   
9,029
     
2,882
 
Current portion of deferred contract revenue
   
67,322
     
51,713
 
Total current liabilities
   
148,876
     
115,332
 
Long-term deferred contract revenue
   
134,306
     
127,797
 
1 percent convertible senior notes
   
347,214
     
327,486
 
2¾ percent convertible senior notes
   
50,361
     
48,014
 
Long-term obligations, less current portion
   
2,341
     
7,669
 
Long-term financing liability for leased facility
   
72,217
     
71,731
 
Total liabilities
   
755,315
     
698,029
 
Stockholders’ equity:
               
Common stock, $0.001 par value; 300,000,000 shares authorized, 120,351,480 and 118,442,726 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively
   
120
     
118
 
Additional paid-in capital
   
1,309,107
     
1,224,509
 
Accumulated other comprehensive income (loss)
   
(13,565
)
   
39,747
 
Accumulated deficit
   
(1,094,872
)
   
(1,006,594
)
Total stockholders’ equity
   
200,790
     
257,780
 
Total liabilities and stockholders’ equity
 
$
956,105
   
$
955,809
 


See accompanying notes.

F-3

IONIS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except for per share amounts)

   
Years Ended December 31,
 
   
2015
   
2014
   
2013
 
Revenue:
           
Research and development revenue under collaborative agreements
 
$
281,360
   
$
202,514
   
$
144,194
 
Licensing and royalty revenue
   
2,343
     
11,647
     
3,091
 
Total revenue
   
283,703
     
214,161
     
147,285
 
                         
Expenses:
                       
Research, development and patent expenses
   
322,292
     
241,751
     
184,033
 
General and administrative
   
37,173
     
20,140
     
14,918
 
Total operating expenses
   
359,465
     
261,891
     
198,951
 
                         
Loss from operations
   
(75,762
)
   
(47,730
)
   
(51,666
)
                         
Other income (expense):
                       
Investment income
   
4,302
     
2,682
     
2,085
 
Interest expense
   
(36,732
)
   
(22,209
)
   
(19,355
)
Gain on investments, net
   
75
     
1,256
     
2,378
 
Gain on investment in Regulus Therapeutics Inc.
   
20,211
     
19,902
     
 
Loss on early retirement of debt
   
     
(8,292
)
   
 
                         
Loss before income tax (expense) benefit
   
(87,906
)
   
(54,391
)
   
(66,558
)
                         
Income tax (expense) benefit
   
(372
)
   
15,407
     
5,914
 
                         
Net loss
 
$
(88,278
)
 
$
(38,984
)
 
$
(60,644
)
                         
Basic and diluted net loss per share
 
$
(0.74
)
 
$
(0.33
)
 
$
(0.55
)
Shares used in computing basic and diluted net loss per share
   
119,719
     
117,691
     
110,502
 


See accompanying notes.

F-4

IONIS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands)

 
Years Ended December 31,
 
 
2015
 
2014
 
2013
 
       
Net loss
 
$
(88,278
)
 
$
(38,984
)
 
$
(60,644
)
Unrealized (losses) gains on investments, net of tax
   
(33,101
)
   
40,079
     
10,253
 
 Reclassification adjustment for realized gains included in net loss
   
(20,211
)
   
(21,412
)
   
(1,653
)
                         
Comprehensive loss
 
$
(141,590
)
 
$
(20,317
)
 
$
(52,044
)


See accompanying notes.

F-5

IONIS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Years Ended December 31, 2015, 2014 and 2013
(In thousands)

   
Common stock
   
Additional Paid
In Capital
   
 
Accumulated Other
Comprehensive
Income (Loss)
   
Accumulated Deficit
   
Total Stockholders’
Equity
 
Description
 
Shares
   
Amount
                 
Balance at December 31, 2012
   
101,481
   
$
102
   
$
1,077,150
   
$
12,480
   
$
(906,966
)
 
$
182,766
 
Net loss
   
     
     
     
     
(60,644
)
   
(60,644
)
Change in unrealized gains (losses), net of tax
   
     
     
     
8,600
     
     
8,600
 
Issuance of common stock in connection with employee stock plans
   
5,372
     
5
     
62,953
     
     
     
62,958
 
Issuance of public common stock
   
9,618
     
9
     
173,283
     
     
     
173,292
 
Share-based compensation expense
   
     
     
11,418
     
     
     
11,418
 
Balance at December 31, 2013
   
116,471
   
$
116
   
$
1,324,804
   
$
21,080
   
$
(967,610
)
 
$
378,390
 
Net loss
   
     
     
     
     
(38,984
)
   
(38,984
)
Change in unrealized gains (losses), net of tax
   
     
     
     
18,667
     
     
18,667
 
Issuance of common stock in connection with employee stock plans
   
1,972
     
2
     
23,071
     
     
     
23,073
 
2¾ percent convertible senior notes redemption, equity portion
   
     
     
(326,444
)
   
     
     
(326,444
)
1 percent convertible senior notes, equity portion, net of issuance costs
   
     
     
170,232
     
     
     
170,232
 
Share-based compensation expense
   
     
     
31,383
     
     
     
31,383
 
Excess tax benefits from share-based compensation awards
   
     
     
1,463
     
     
     
1,463
 
Balance at December 31, 2014
   
118,443
   
$
118
   
$
1,224,509
   
$
39,747
   
$
(1,006,594
)
 
$
257,780
 
Net loss
   
     
     
     
     
(88,278
)
   
(88,278
)
Change in unrealized gains (losses), net of tax
   
     
     
     
(53,312
)
   
     
(53,312
)
Issuance of common stock in connection with employee stock plans
   
1,908
     
2
     
24,888
     
     
     
24,890
 
Share-based compensation expense
   
     
     
59,314
     
     
     
59,314
 
Excess tax benefits from share-based compensation awards
   
     
     
396
     
     
     
396
 
Balance at December 31, 2015
   
120,351
   
$
120
   
$
1,309,107
   
$
(13,565
)
 
$
(1,094,872
)
 
$
200,790
 


See accompanying notes.

F-6

IONIS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

   
Years Ended December 31,
 
   
2015
   
2014
   
2013
 
Operating activities:
           
Net loss
 
$
(88,278
)
 
$
(38,984
)
 
$
(60,644
)
Adjustments to reconcile net loss to net cash provided by operating activities:
                       
Depreciation
   
6,984
     
6,380
     
6,591
 
Amortization of patents
   
1,381
     
1,142
     
1,184
 
Amortization of licenses
   
1,873
     
1,882
     
2,007
 
Amortization of premium on investments, net
   
7,812
     
7,470
     
5,572
 
Amortization of debt issuance costs
   
1,133
     
595
     
415
 
Amortization of 2¾ convertible senior notes discount
   
2,347
     
6,723
     
6,344
 
Amortization of 1 percent convertible senior notes discount
   
19,728
     
2,256
     
 
Amortization of long-term financing liability for leased facility
   
6,665
     
6,622
     
6,567
 
Share-based compensation expense
   
59,314
     
31,383
     
11,418
 
Gain on investment in Regulus Therapeutics Inc.
   
(20,211
)
   
(19,902
)
   
 
Loss on early retirement of debt
   
     
8,292
     
 
Gain on investments, net
   
(75
)
   
(1,256
)
   
(2,378
)
Non-cash losses related to patents, licensing and property, plant and equipment
   
1,881
     
1,305
     
6,306
 
Tax benefit from other unrealized gains on securities
   
     
(12,835
)
   
(5,914
)
Changes in operating assets and liabilities:
                       
Contracts receivable
   
(7,453
)
   
7,199
     
(10,580
)
Inventories
   
(609
)
   
1,743
     
(1,912
)
Other current and long-term assets
   
(4,319
)
   
(1,750
)
   
(1,091
)
Accounts payable
   
9,211
     
4,824
     
66
 
Income taxes
   
     
(4,034
)
   
 
Accrued compensation
   
3,763
     
134
     
4,290
 
Deferred rent
   
205
     
153
     
217
 
Accrued liabilities
   
(2,345
)
   
8,358
     
6,691
 
Deferred contract revenue
   
22,118
     
(11,415
)
   
88,344
 
Net cash provided by operating activities
   
21,125
     
6,285
     
63,493
 
Investing activities:
                       
Purchases of short-term investments
   
(493,467
)
   
(391,883
)
   
(425,554
)
Proceeds from the sale of short-term investments
   
419,584
     
294,727
     
172,762
 
Purchases of property, plant and equipment
   
(7,692
)
   
(7,518
)
   
(1,552
)
Acquisition of licenses and other assets, net
   
(4,056
)
   
(3,586
)
   
(3,810
)
Proceeds from the sale of Regulus Therapeutics, Inc.
   
25,527
     
22,949
     
 
Proceeds from the sale of strategic investments
   
52
     
2,463
     
2,428
 
Net cash used in investing activities
   
(60,052
)
   
(82,848
)
   
(255,726
)
Financing activities:
                       
Proceeds from equity awards
   
24,888
     
23,071
     
62,958
 
Proceeds from issuance of 1 percent convertible senior notes, net of issuance costs
   
     
487,035
     
 
Repurchase of $140 million principal amount of the 2¾ percent convertible senior notes
   
     
(441,394
)
   
 
Proceeds from borrowing on line of credit facility
   
8,500
     
     
 
Proceeds from public common stock offering
   
     
     
173,292
 
Proceeds from equipment financing arrangement
   
     
     
2,513
 
Excess tax benefits from share-based compensation awards
   
396
     
1,463
     
 
Principal payments on debt and capital lease obligations
   
(9,058
)
   
(10,587
)
   
(11,039
)
Net cash provided by financing activities
   
24,726
     
59,588
     
227,724
 
Net (decrease) increase in cash and cash equivalents
   
(14,201
)
   
(16,975
)
   
35,491
 
Cash and cash equivalents at beginning of year
   
142,998
     
159,973
     
124,482
 
Cash and cash equivalents at end of year
 
$
128,797
   
$
142,998
   
$
159,973
 
F-7

IONIS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

Supplemental disclosures of cash flow information:
           
Interest paid
 
$
6,800
   
$
6,353
   
$
6,000
 
Supplemental disclosures of non-cash investing and financing activities:
                       
Amounts accrued for capital and patent expenditures
 
$
1,162
   
$
2,151
   
$
704
 


See accompanying notes.

F-8

IONIS PHARMACEUTICALS, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Significant Accounting Policies

Basis of presentation
 
The consolidated financial statements include the accounts of Ionis Pharmaceuticals, Inc. ("we", "us" or "our") and our wholly owned subsidiary, Akcea Therapeutics, Inc., which we formed in December 2014. In December 2015, we changed our name from Isis Pharmaceuticals, Inc. to Ionis Pharmaceuticals, Inc.

Organization and business activity
 
We incorporated in California on January 10, 1989. In conjunction with our initial public offering, we reorganized as a Delaware corporation in April 1991. We were organized principally to develop human therapeutic drugs using antisense technology.

Basic and diluted net loss per share

We compute basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period. As we incurred a net loss for 2015, 2014 and 2013, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. Common stock from the following would have had an anti-dilutive effect on net loss per share:

percent convertible senior notes (for 2014 and 2015);
2¾ percent convertible senior notes;
Dilutive stock options;
Unvested restricted stock units; and
Employee Stock Purchase Plan, or ESPP.

Revenue recognition

We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In the instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.

Arrangements with multiple deliverables

Our collaboration agreements typically contain multiple elements, or deliverables, including technology licenses or options to obtain technology licenses, research and development services, and in certain cases manufacturing services, and we allocate the consideration to each unit of accounting based on the relative selling price of each deliverable.

Identifying deliverables and units of accounting

We evaluate the deliverables in our collaboration agreements to determine whether they meet the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. When the delivered items in an arrangement have "stand-alone value" to our customer, we account for the deliverables as separate units of accounting. Delivered items have stand-alone value if they are sold separately by any vendor or the customer could resell the delivered items on a stand-alone basis. For example, in May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXIRx for the prevention of thrombosis. As part of the agreement, Bayer paid us a $100 million upfront payment in the second quarter of 2015. We are also eligible to receive milestone payments and tiered royalties on gross margins of IONIS-FXIRx. We are responsible for completing the ongoing development services for IONIS-FXIRx and for providing an initial supply of active pharmaceutical ingredient, or API. Bayer is responsible for all other development and commercialization activities for IONIS-FXIRx. Since this agreement has multiple elements, we evaluated the deliverables in this arrangement when we entered into the agreement and determined that certain deliverables have stand-alone value. Below is a list of the three units of accounting under our agreement:

The exclusive license we granted to Bayer to develop and commercialize IONIS-FXIRx for the treatment of thrombosis;
The development services we agreed to perform for IONIS-FXIRx; and 
The initial supply of API.

We determined that each of these three units of accounting have stand-alone value. The exclusive license we granted to Bayer has stand-alone value because it is an exclusive license that gives Bayer the right to develop IONIS-FXIRx or to sublicense its rights. The development services and the initial supply of API each have stand-alone value because Bayer or another third party could provide these items without our assistance.

Measurement and allocation of arrangement consideration

Our collaborations may provide for various types of payments to us including upfront payments, funding of research and development, milestone payments, licensing fees and royalties on product sales. We initially allocate the amount of consideration that is fixed and determinable at the time the agreement is entered into and exclude contingent consideration. We allocate the consideration to each unit of accounting based on the relative selling price of each deliverable. We use the following hierarchy of values to estimate the selling price of each deliverable: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price, or BESP. BESP reflects our best estimate of what the selling price would be if we regularly sold the deliverable on a stand-alone basis. We recognize the revenue allocated to each unit of accounting as we deliver the related goods or services. If we determine that we should treat certain deliverables as a single unit of accounting, then we recognize the revenue ratably over our estimated period of performance.
F-9


We determined that the allocable arrangement consideration for the Bayer collaboration was $100 million and we allocated it based on the relative BESP of each unit of accounting. We engaged a third party, independent valuation expert to assist us with determining BESP. We estimated the selling price of the license granted for IONIS-FXIRx by using the relief from royalty method. Under this method, we estimated the amount of income, net of taxes, for IONIS-FXIRx. We then discounted the projected income to present value. The significant inputs we used to determine the projected income of the license included:

Estimated future product sales;
Estimated royalties on future product sales;
Contractual milestone payments;
Expenses we expect to incur;
Income taxes; and
An appropriate discount rate.

We estimated the selling price of the ongoing development services by using our internal estimates of the cost to perform the specific services and estimates of expected cash outflows to third parties for services and supplies over the expected period that we will perform the development services. The significant inputs we used to determine the selling price of the ongoing development services included:

The number of internal hours we will spend performing these services;
The estimated cost of work we will perform;
The estimated cost of work that we will contract with third parties to perform; and
The estimated cost of drug product we will use.

We determine the selling price of our API consistently for all of our partnerships. On an annual basis, we calculate our fully absorbed cost to manufacture API. We then determine the unit price we will charge our partners by dividing our fully absorbed costs by the quantity of API we expect to produce during the year.

For purposes of determining BESP of the services we will perform and the API in our Bayer transaction, accounting guidance required us to include a markup for a reasonable profit margin.

Based on the units of accounting under the agreement, we allocated the $100 million upfront payment from Bayer as follows:

$91.2 million to the IONIS-FXIRx exclusive license;
$4.3 million for ongoing development services; and
$4.5 million for the delivery of API.

Assuming a constant selling price for the other elements in the arrangement, if there was an assumed ten percent increase or decrease in the estimated selling price of the IONIS-FXIRx license, we determined that the revenue we would have allocated to the IONIS-FXIRx license would change by approximately one percent, or $0.9 million, from the amount we recorded.

Timing of revenue recognition

We recognize revenue as we deliver each item under the arrangement and the related revenue is realizable and earned. For example, we recognized revenue for the exclusive license we granted Bayer for IONIS-FXIRx in the second quarter of 2015 because that was when we delivered the license. We also recognize revenue over time. Our collaborative agreements typically include a research and/or development project plan outlining the activities the agreement requires each party to perform during the collaboration. We must estimate our period of performance when the agreements we enter into do not clearly define such information. We estimate the period of time over which we will complete the activities for which we are responsible and use that period of time as our period of performance for purposes of revenue recognition. We then recognize revenue ratably over such period. We have made estimates of our continuing obligations under numerous agreements and in certain instances the timing of satisfying these obligations change as the development plans for our drugs progress. Accordingly, our estimates may change in the future. If our estimates and judgments change over the course of our collaboration agreements, it may affect the timing and amount of revenue that we recognize in future periods.

The following are the periods over which we are recognizing revenue for each of our units of accounting under our Bayer agreement:

We recognized the portion of the consideration attributed to the IONIS-FXIRx license immediately because we delivered the license and earned the revenue; 
We are recognizing the amount attributed to the ongoing development services for IONIS-FXIRx over the period of time we are performing the services; and
We will recognize the amount attributed to the API supply when we deliver it to Bayer.

Multiple agreements

From time to time, we may enter into separate agreements at or near the same time with the same customer. We evaluate such agreements to determine whether they should be accounted for individually as distinct arrangements or whether the separate agreements are, in substance, a single multiple element arrangement. We evaluate whether the negotiations are conducted jointly as part of a single negotiation, whether the deliverables are interrelated or interdependent, whether fees in one arrangement are tied to performance in another arrangement, and whether elements in one arrangement are essential to another arrangement. Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that they are, in effect, part of a single arrangement. For example, since early 2012, we have entered into four collaboration agreements with Biogen:
F-10


In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize nusinersen for spinal muscular atrophy, or SMA. As part of the collaboration, we received a $29 million upfront payment and we are responsible for global development of nusinersen through completion of Phase 2/3 clinical trials.

In June 2012, we entered into a second and separate collaboration agreement with Biogen to develop and commercialize a novel antisense drug targeting DMPK, or dystrophia myotonica-protein kinase. As part of the collaboration, we received a $12 million upfront payment and we are responsible for global development of the drug through the completion of a Phase 2 clinical trial.

In December 2012, we entered into a third and separate collaboration agreement with Biogen to discover and develop antisense drugs against three targets to treat neurological or neuromuscular disorders. As part of the collaboration, we received a $30 million upfront payment and we are responsible for the discovery of a lead antisense drug for each of three targets.

In September 2013, we entered into a fourth and separate collaboration agreement with Biogen to leverage antisense technology to advance the treatment of neurological diseases. We granted Biogen exclusive rights to the use of our antisense technology to develop therapies for neurological diseases as part of this broad collaboration. We received a $100 million upfront payment and we are responsible for discovery and early development through the completion of a Phase 2 clinical trial for each antisense drug identified during the six-year term of this collaboration, while Biogen is responsible for the creation and development of small molecule treatments and biologics.

All four of these collaboration agreements give Biogen the option to license one or more drugs resulting from the specific collaboration. If Biogen exercises an option, it will pay us a license fee and will assume future development, regulatory and commercialization responsibilities for the licensed drug. We are also eligible to receive milestone payments associated with the research and/or development of the drugs prior to licensing, milestone payments if Biogen achieves pre-specified regulatory milestones, and royalties on any product sales from any drugs resulting from these collaborations.

We evaluated all four of the Biogen agreements to determine whether we should account for them as separate agreements. We determined that we should account for the agreements separately because we conducted the negotiations independently of one another, each agreement focuses on different drugs, there are no interrelated or interdependent deliverables, there are no provisions in any of these agreements that are essential to the other agreement, and the payment terms and fees under each agreement are independent of each other. We also evaluated the deliverables in each of these agreements to determine whether they met the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. For all four of these agreements, we determined that the options did not have stand-alone value because Biogen cannot pursue the development or commercialization of the drugs resulting from these collaborations until it exercises the respective option or options. As such, for each agreement we considered the deliverables to be a single unit of accounting and we are recognizing the upfront payment for each of the agreements over the respective estimated period of our performance.

Milestone payments

Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and/ or commercialization events. These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraph.

Prior to the first stage in the life-cycle of our drugs, we perform a significant amount of work using our proprietary antisense technology to design chemical compounds that interact with specific genes that are good targets for drug discovery. From these research efforts, we hope to identify a development candidate. The designation of a development candidate is the first stage in the life-cycle of our drugs. A development candidate is a chemical compound that has demonstrated the necessary safety and efficacy in preclinical animal studies to warrant further study in humans.

During the first step of the development stage, we or our partners study our drugs in Investigational New Drug, or IND, -enabling studies, which are animal studies intended to support an IND application and/or the foreign equivalent. An approved IND allows us or our partners to study our development candidate in humans. If the regulatory agency approves the IND, we or our partners initiate Phase 1 clinical trials in which we typically enroll a small number of healthy volunteers to ensure the development candidate is safe for use in patients. If we or our partners determine that a development candidate is safe based on the Phase 1 data, we or our partners initiate Phase 2 studies that are generally larger scale studies in patients with the primary intent of determining the efficacy of the development candidate.

The final step in the development stage is Phase 3 studies to gather the necessary safety and efficacy data to request marketing authorization from the FDA and/or foreign equivalents. The Phase 3 studies typically involve large numbers of patients and can take up to several years to complete. If the data gathered during the trials demonstrates acceptable safety and efficacy results, we or our partner will submit an application to the FDA and/or its foreign equivalents for marketing authorization. This stage of the drug’s life-cycle is the regulatory stage.

If a drug achieves marketing authorization, it moves into the commercialization stage, during which our partner will market and sell the drug to patients. Although our partner will ultimately be responsible for marketing and selling the partnered drug, our efforts to discover and develop a drug that is safe, effective and reliable contributes significantly to our partner’s ability to successfully sell the drug. The FDA and its foreign equivalents have the authority to impose significant restrictions on an approved drug through the product label and on advertising, promotional and distribution activities. Therefore, our efforts designing and executing the necessary animal and human studies are critical to obtaining claims in the product label from the regulatory agencies that would allow us or our partner to successfully commercialize our drug. Further, the patent protection afforded our drugs as a result of our initial patent applications and related prosecution activities in the United States and foreign jurisdictions are critical to our partner’s ability to sell our drugs without competition from generic drugs. The potential sales volume of an approved drug is dependent on several factors including the size of the patient population, market penetration of the drug, and the price charged for the drug.
F-11


Generally, the milestone events contained in our partnership agreements coincide with the progression of our drugs from development, to marketing authorization and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug progresses through the stages of its life-cycle, the value of the drug generally increases.

Development milestones in our partnerships may include the following types of events:

Designation of a development candidate. Following the designation of a development candidate, IND-enabling animal studies for a new development candidate generally take 12 to 18 months to complete;
Initiation of a Phase 1 clinical trial. Generally, Phase 1 clinical trials take one to two years to complete;
Initiation or completion of a Phase 2 clinical trial. Generally, Phase 2 clinical trials take one to three years to complete;
Initiation or completion of a Phase 3 clinical trial. Generally, Phase 3 clinical trials take two to four years to complete.

Regulatory milestones in our partnerships may include the following types of events:

Filing of regulatory applications for marketing authorization such as a New Drug Application, or NDA, in the United States or a Marketing Authorization Application, or MAA, in Europe. Generally, it takes six to twelve months to prepare and submit regulatory filings.
Marketing authorization in a major market, such as the United States, Europe or Japan. Generally it takes one to two years after an application is submitted to obtain authorization from the applicable regulatory agency.

Commercialization milestones in our partnerships may include the following types of events:

First commercial sale in a particular market, such as in the United States or Europe.
Product sales in excess of a pre-specified threshold, such as annual sales exceeding $1 billion. The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.

We assess whether a substantive milestone exists at the inception of our agreements. When a substantive milestone is achieved, we recognize revenue related to the milestone payment immediately. For our existing licensing and collaboration agreements in which we are involved in the discovery and/or development of the related drug or provide the partner with access to new technologies we discover, we have determined that the majority of future development, regulatory and commercialization milestones are substantive. For example, we consider most of the milestones associated with our strategic alliance with Biogen substantive because we are using our antisense drug discovery platform to discover and develop new drugs against targets for neurological diseases. We also consider milestones associated with our alliance with Alnylam Pharmaceuticals, Inc. substantive because we provide Alnylam ongoing access to our technology to develop and commercialize RNA interference, or RNAi, therapeutics. In evaluating if a milestone is substantive we consider whether:

Substantive uncertainty exists as to the achievement of the milestone event at the inception of the arrangement;
The achievement of the milestone involves substantive effort and can only be achieved based in whole or in part on our performance or the occurrence of a specific outcome resulting from our performance;
The amount of the milestone payment appears reasonable either in relation to the effort expended or to the enhancement of the value of the delivered items;
There is no future performance required to earn the milestone; and
The consideration is reasonable relative to all deliverables and payment terms in the arrangement.

If any of these conditions are not met, we do not consider the milestone to be substantive and we defer recognition of the milestone payment and recognize it as revenue over our estimated period of performance, if any. Further information about our collaborative arrangements can be found in Note 6, Collaborative Arrangements and Licensing Agreements.

Licensing and royalty revenue

We often enter into agreements to license our proprietary patent rights on an exclusive or non-exclusive basis in exchange for license fees and/or royalties. We generally recognize as revenue immediately those licensing fees and royalties for which we have no significant future performance obligations and are reasonably assured of collecting the resulting receivable. For example, during 2014, we recognized $9.5 million in revenue from Alnylam related to its license of our technology to one of its partners because we had no performance obligations and collectability was reasonably assured.

Research, development and patent expenses

Our research and development expenses include wages, benefits, facilities, supplies, external services, clinical trial and manufacturing costs and other expenses that are directly related to our research and development operations. We expense research and development costs as we incur them. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. For the years ended December 31, 2015, 2014 and 2013, research and development expenses were $319.5 million, $238.9 million and $173.7 million, respectively. A portion of the costs included in research and development expenses are costs associated with our collaboration agreements. For the years ended December 31, 2015, 2014 and 2013, research and development costs of approximately $161.7 million, $85.6 million and $51.0 million, respectively, were related to our collaborative agreements.
F-12


We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We amortize patent costs over the useful life of the patent, beginning with the date the United States Patent and Trademark Office, or foreign equivalent, issues the patent. The weighted average remaining amortizable life of our issued patents was 10.2 years at December 31, 2015.

The cost of our patents capitalized on our consolidated balance sheet at December 31, 2015 and 2014 was $27.5 million and $25.0 million, respectively. Accumulated amortization related to patents was $8.2 million and $7.8 million at December 31, 2015 and 2014, respectively.

Based on existing patents, estimated amortization expense related to patents in each of the next five years is as follows:

Years Ending December 31,
 
Amortization
(in millions)
 
2016
 
$
1.4
 
2017
 
$
1.3
 
2018
 
$
1.2
 
2019
 
$
1.1
 
2020
 
$
1.0
 

We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. When we identify patents and patent applications that we are not actively pursuing, we write off any associated costs. In 2015, 2014 and 2013, patent expenses were $2.8 million, $2.9 million and $10.3 million, respectively, and included non-cash charges related to the write-down of our patent costs to their estimated net realizable values of $1.1 million, $1.3 million and $6.4 million, respectively.

Concentration of credit risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, short-term investments and receivables. We place our cash equivalents and short-term investments with reputable financial institutions. We primarily invest our excess cash in commercial paper and debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody’s, Standard & Poor’s, or S&P, or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.

Cash, cash equivalents and short-term investments

We consider all liquid investments with maturities of three months or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than three months from date of purchase. We classify our short-term investments as “available-for-sale” and carry them at fair market value based upon prices for identical or similar items on the last day of the fiscal period. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.

We have equity investments in privately and publicly held biotechnology companies that we have received as part of a technology license or collaboration agreement. At December 31, 2015, we held ownership interests of less than 20 percent in each of the respective companies.

We account for our equity investments in publicly held companies at fair value and record unrealized gains and losses related to temporary increases and decreases in the stock of these publicly held companies as a separate component of comprehensive income (loss). We account for equity investments in privately held companies under the cost method of accounting because we own less than 20 percent and do not have significant influence over their operations. We hold one cost method investment in Atlantic Pharmaceuticals Limited. Realization of our equity position in this company is uncertain. When realization of our investment is uncertain, we record a full valuation allowance. In determining if and when a decrease in market value below our cost in our equity positions is temporary or other-than-temporary, we examine historical trends in the stock price, the financial condition of the company, near term prospects of the company and our current need for cash. If we determine that a decline in value in either a public or private investment is other-than-temporary, we recognize an impairment loss in the period in which the other-than-temporary decline occurs.

Inventory valuation

We capitalize the costs of raw materials that we purchase for use in producing our drugs because until we use these raw materials they have alternative future uses. We include in inventory raw material costs for drugs that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single drug. For example, if one of our drugs failed, we could use the raw materials for that drug to manufacture our other drugs. We expense these costs when we deliver the drugs to our partners, or as we provide these drugs for our own clinical trials. We reflect our inventory on the balance sheet at the lower of cost or market value under the first-in, first-out method, or FIFO. We review inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value. We consider several factors in estimating the net realizable value, including shelf life of raw materials, alternative uses for our drugs and clinical trial materials, and historical write-offs. We did not record any inventory write-offs for the years ended December 31, 2015, 2014 or 2013. Total inventory was $6.9 million and $6.3 million as of December 31, 2015 and 2014, respectively.
F-13



Property, plant and equipment

We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):

    Estimated Useful Lives    
December 31,
 
   
(in years)
   
2015
   
2014
 
Computer software, laboratory, manufacturing and other equipment
 
3 to 10
   
$
56,822
   
$
49,772
 
Building and building systems
 
25 to 40
     
48,163
     
48,521
 
Land improvements
   
20
     
2,853
     
2,853
 
Leasehold improvements
 
5 to 20
     
39,061
     
37,935
 
Furniture and fixtures
 
5 to 10
     
5,842
     
5,732
 
             
152,741
     
144,813
 
Less accumulated depreciation
           
(72,706
)
   
(66,053
)
             
80,035
     
78,760
 
Land
           
10,198
     
10,198
 
 Total
         
$
90,233
   
$
88,958
 

We depreciate our leasehold improvements using the shorter of the estimated useful life or remaining lease term.

Fair value of financial instruments
 
We have estimated the fair value of our financial instruments. The amounts reported for cash, accounts receivable, accounts payable and accrued expenses approximate the fair value because of their short maturities. We report our investment securities at their estimated fair value based on quoted market prices for identical or similar instruments.

Long-lived assets
 
We evaluate long-lived assets, which include property, plant and equipment, patent costs, and exclusive licenses acquired from third parties, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets. We recorded charges of $1.9 million, $1.3 million and $6.4 million for the years ended December 31, 2015, 2014 and 2013, respectively, related primarily to the write-down of intangible assets.

Use of estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Stock-based compensation expense

We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our ESPP based on the estimated fair value of the award on the date of grant. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our Consolidated Statements of Operations. We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.

We use the Black-Scholes model as our method of valuing option awards and stock purchase rights under our ESPP. On the grant date, we use our stock price and assumptions regarding a number of highly complex and subjective variables to determine the estimated fair value of stock-based payment awards. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Option-pricing models were developed for use in estimating the value of traded options that have no vesting or hedging restrictions and are fully transferable. Because our employee stock options have certain characteristics that are significantly different from traded options, and because changes in the subjective assumptions can materially affect the estimated value, in management’s opinion, the existing valuation models may not provide an accurate measure of the fair value of our employee stock options. Although we determine the estimated fair value of employee stock options using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.

We recognize compensation expense for option awards using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), an entity recognizes compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.

The fair value of RSUs is based on the market price of our common stock on the date of grant. The RSUs we have granted vest annually over a four-year period.

See Note 4, Stockholders’ Equity, for additional information regarding our share-based compensation plans.
F-14



Accumulated other comprehensive income (loss)

Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on investments, net of taxes, and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive income to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive income for the years ended December 31, 2015, 2014 and 2013 (in thousands):
 
   
Year Ended December 31,
 
   
2015
   
2014
   
2013
 
Beginning balance accumulated other comprehensive income
 
$
39,747
   
$
21,080
   
$
12,480
 
Unrealized (losses) gains on securities, net of tax (1)
   
(33,101
)
   
40,079
     
10,253
 
Amounts reclassified from accumulated other comprehensive (loss) income (2)
   
(20,211
)
   
(21,412
)
   
(1,653
)
Net other comprehensive (loss) income for the period
   
(53,312
)
   
18,667
     
8,600
 
Ending balance accumulated other comprehensive (loss) income
 
$
(13,565
)
 
$
39,747
   
$
21,080
 


(1) Other comprehensive income includes income tax expense of $12.8 million and $5.9 million for the years ended December 31, 2014 and 2013, respectively. There was no tax expense for other comprehensive income for the year ended December 31, 2015.

(2) Amounts for 2015 are included in the separate line called “Gain on investment in Regulus Therapeutics Inc.” on our Consolidated Statement of Operations. For 2014, $19.9 million is included in a separate line called “Gain on investment in Regulus Therapeutics Inc.”, with the remaining amount included in a separate line called “Gain on investments, net” on our Consolidated Statement of Operations. Amounts for 2013 are included in a separate line called “Gain on investments, net” on our Consolidated Statement of Operations.

Convertible debt

We account for convertible debt instruments, including our 1 percent and 2¾ percent notes, that may be settled in cash upon conversion (including partial cash settlement) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. We determine the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, we estimate fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense.

We assign a value to the debt component of our convertible notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording our debt at a discount. We are amortizing the debt discount over the life of the convertible notes as additional non-cash interest expense utilizing the effective interest method. For additional information, see Note 3, Long-Term Obligations and Commitments.

Segment information

In 2015, we began operating as two segments, our Ionis Core segment, previously referred to as Drug Discovery and Development, and Akcea Therapeutics, which consists of the operations of our wholly owned subsidiary, Akcea Therapeutics, Inc. We formed Akcea to develop and commercialize drugs for cardiometabolic disorders. We provide segment financial information and results for our Ionis Core segment and our Akcea Therapeutics segment based on the segregation of revenues and expenses that our chief decision maker reviews to assess operating performance and to make operating decisions. We use judgments and estimates in determining the allocation of shared expenses to the two segments.

Fair value measurements

We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investment in equity securities in publicly held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. Our Level 3 investments include our investments in the equity securities of publicly held biotechnology companies for which we calculated a lack of marketability discount because there were restrictions on when we could trade the securities. Historically, we have determined the lack of marketability discount by using a Black-Scholes model to value a hypothetical put option to approximate the cost of hedging the stock until the restriction ends. The majority of our securities have been classified as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices. During 2015 and 2014, there were no transfers between our Level 1 and Level 2 investments. We recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.
F-15



We measure the following major security types at fair value on a recurring basis. The following summary breaks down the fair-value hierarchy that we valued each security with at December 31, 2015 and 2014 (in thousands):

   
At
December 31, 2015
   
Quoted Prices in
Active Markets
(Level 1)
   
Significant Other
Observable
Inputs
(Level 2)
   
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents (1)
 
$
88,902
   
$
88,902
   
$
   
$
 
Corporate debt securities (2)
   
438,426
     
     
438,426
     
 
Debt securities issued by U.S. government agencies (2)
   
89,253
     
     
89,253
     
 
Debt securities issued by the U.S. Treasury (2)
   
2,601
     
2,601
     
     
 
Debt securities issued by states of the United States and political subdivisions of the states (3)
   
127,656
     
     
127,656
     
 
Investment in Regulus Therapeutics Inc.
   
24,792
     
24,792
     
     
 
Total
 
$
771,630
   
$
116,295
   
$
655,335
   
$
 

   
At
December 31, 2014
   
Quoted Prices in
Active Markets
(Level 1)
   
Significant Other
Observable
Inputs
(Level 2)
   
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents (1)
 
$
104,680
   
$
104,680
   
$
   
$
 
Corporate debt securities (4)
   
372,002
     
     
372,002
     
 
Debt securities issued by U.S. government agencies (2)
   
109,855
     
     
109,855
     
 
Debt securities issued by the U.S. Treasury (5)
   
19,017
     
19,017
     
     
 
Debt securities issued by states of the United States and political subdivisions of the states (6)
   
105,033
     
     
105,033
     
 
Investment in Regulus Therapeutics Inc.
   
81,881
     
     
     
81,881
 
Total
 
$
792,468
   
$
123,697
   
$
586,890
   
$
81,881
 


(1) Included in cash and cash equivalents on our consolidated balance sheet.

(2) Included in short-term investments on our consolidated balance sheet.

(3) $7.5 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(4) $0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(5) $10 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(6) $9.3 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

In the first quarter of 2014, Achaogen completed an initial public offering. As a result, we stopped using the cost method of accounting for our equity investment in Achaogen and instead we began accounting for it at fair value. Until September 2014, the fair value of our investment in Achaogen included a lack of marketability discount because there were restrictions on when we could trade the securities. As such, we classified our Achaogen stock as a Level 3 investment. In September 2014, we reclassified our investment in Achaogen to a Level 1 investment because the contractual trading restrictions on the shares we owned ended and we subsequently sold all of our shares in 2014.

In November 2014, Regulus completed a public offering. As part of the offering, we sold shares of Regulus' common stock and became subject to trading restrictions on our remaining shares through January 2015. Therefore, at December 31, 2014, we recorded a lack of marketability discount on our investment in Regulus and classified it as a Level 3 investment. At the end of January 2015, we reclassified our investment in Regulus to a Level 1 investment because the contractual trading restrictions on the shares we owned ended.

The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2015 and 2014 (in thousands):

   
Year Ended
December 31,
 
   
2015
   
2014
 
Beginning balance of Level 3 investments
 
$
81,881
   
$
 
Transfers into Level 3 investments
   
     
108,009
 
Total gains (losses) included in accumulated other comprehensive income (loss)
   
22,377
     
(24,897
)
Transfers out of Level 3 investments
   
(104,258
)
   
(1,231
)
Ending balance of Level 3 investments
 
$
   
$
81,881
 

F-16



Impact of recently issued accounting standards
 
In May 2014, the FASB issued accounting guidance on the recognition of revenue from customers. Under this guidance, an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects what the entity expects in exchange for the goods or services. This guidance also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance as originally issued is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016.
In July 2015, the FASB issued updated accounting guidance to allow for an optional one year deferral from the original effective date. As a result, we will adopt this guidance beginning on January 1, 2018. The guidance allows us to select one of two methods of adoption, either the full retrospective approach, meaning the guidance would be applied to all periods presented, or modified retrospective, meaning the cumulative effect of applying the guidance would be recognized as an adjustment to our opening retained earnings balance. We are currently determining the adoption method and timing as well as the effects the adoption will have on our consolidated financial statements and disclosures.

In August 2014, the FASB issued accounting guidance on how and when to disclose going-concern uncertainties in the financial statements. This guidance will require us to perform interim and annual assessments to determine our ability to continue as a going concern within one year from the date that we issue our financial statements. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016. We will adopt this guidance in our fiscal year beginning January 1, 2017. We do not expect this guidance to have any effect on our consolidated financial statements.

In February 2015, the FASB issued accounting guidance which amends existing consolidation guidance for entities that are required to evaluate whether they should consolidate certain legal entities. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015. We will adopt this guidance in our fiscal year beginning January 1, 2016. We do not expect this guidance to have any effect on our consolidated financial statements.

In April 2015, the FASB issued accounting guidance to simplify the presentation of debt issuance costs. The amended guidance requires us to present debt issuance costs as a direct deduction from the carrying amount of the related debt liability rather than as an asset. The guidance does not require us to change how we recognize and measure our debt issuance costs. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015, with early adoption permitted. We will adopt this guidance in our fiscal year beginning January 1, 2016. We do not expect this guidance to have a material impact on our consolidated financial statements.

In April 2015, the FASB issued accounting guidance to clarify the accounting for fees paid in cloud computing arrangements. The amendment provides guidance to customers about whether a cloud computing arrangement includes a software license element consistent with the acquisition of other software licenses or if the arrangement excludes a software license and should be accounted for as a service contract. The guidance does not change the accounting for service contracts. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015. We will adopt this guidance in our fiscal year beginning January 1, 2016 on a prospective basis. We do not expect this guidance to have a material impact on our consolidated financial statements.

In July 2015, the FASB issued accounting guidance to simplify the remeasurement of inventory. The amended guidance applies to entities that value inventory under methods other than last-in first-out (LIFO) or the retail inventory method and applies to us because we value our inventory under the FIFO method. The amended guidance requires us to measure our inventory at the lower of cost and net realizable value. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015 on a prospective basis. We will adopt this guidance in our fiscal year beginning January 1, 2016. We do not expect this guidance to have any effect on our consolidated financial statements.

In November 2015, the FASB issued accounting guidance to simplify the classification of deferred income tax assets and liabilities to always be classified as current, compared to the previous treatment, which required us to allocate our deferred tax assets between current and noncurrent. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016 on a prospective or retrospective basis, with early adoption permitted. We adopted this guidance on a prospective basis and reflected it in our consolidated balance sheet at December 31, 2015.

In January 2016, the FASB issued amended accounting guidance related to the recognition, measurement, presentation, and disclosure of certain financial instruments. The amended guidance requires us to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and for us to recognize the changes in fair value in our net income (loss), instead of recognizing changes in value through accumulated other comprehensive income, as we currently do under the existing guidance. The amended guidance also changes several disclosure requirements for financial instruments, including the methods and significant assumptions we use to estimate fair value. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2017. We will adopt this guidance on January 1, 2018 and we will make any adjustments to beginning balances through a cumulative-effect adjustment to accumulated deficit on that date. We are currently determining the effects the adoption will have on our consolidated financial statements and disclosures.

2. Investments

As of December 31, 2015, we have primarily invested our excess cash in debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody’s, S&P or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.
F-17



The following table summarizes the contract maturity of the available-for-sale securities we held as of December 31, 2015:

One year or less
 
49 %
After one year but within two years
 
27 %
After two years but within three and a half years
 
24 %
Total
 
100 %

As illustrated above, at December 31, 2015, 76 percent of our available-for-sale securities had a maturity of less than two years.

All of our available-for-sale securities are available to us for use in our current operations. As a result, we categorize all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.

At December 31, 2015, we had an ownership interest of less than 20 percentin one private company and two public companies with which we conduct business. The privately held company is Atlantic Pharmaceuticals Limited and the publicly traded companies are Antisense Therapeutics Limited and Regulus. We account for equity investments in the privately held company under the cost method of accounting and we account for equity investments in the publicly traded companies at fair value. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments.

During 2015, 2014 and 2013, we realized a net gain on investments we sold of $20.3 million, $21.2 million, and $2.4 million, respectively. Our net gain for 2015 and 2014 was primarily from the $20.2 million and $19.9 million gain we realized when we sold a portion of our stock in Regulus, respectively. We have reflected this gain in a separate line called “Gain on investment in Regulus Therapeutics Inc.”, on our Consolidated Statements of Operations. Our net gain on investments for 2013 related to the sale of stock in several of our satellite companies. As of December 31, 2015, we owned approximately five percent of Regulus’ equity, with a carrying balance of $24.8 million on our consolidated balance sheet.

The following is a summary of our investments (in thousands):

     
Gross Unrealized
     
December 31, 2015
 
Cost
   
Gains
   
Losses
   
Estimated
Fair Value
 
Available-for-sale securities (1):
               
Corporate debt securities
 
$
181,670
   
$
5
   
$
(250
)
 
$
181,425
 
Debt securities issued by U.S. government agencies
   
50,559
     
1
     
(19
)
   
50,541
 
Debt securities issued by the U.S. Treasury
   
2,604
     
     
(3
)
   
2,601
 
Debt securities issued by states of the United States and political subdivisions of the states (2)
   
79,414
     
18
     
(88
)
   
79,344
 
Total securities with a maturity of one year or less
   
314,247
     
24
     
(360
)
   
313,911
 
Corporate debt securities
   
258,703
     
3
     
(1,705
)
   
257,001
 
Debt securities issued by U.S. government agencies
   
38,956
     
     
(244
)
   
38,712
 
Debt securities issued by states of the United States and political subdivisions of the states
   
48,552
     
3
     
(243
)
   
48,312
 
Total securities with a maturity of more than one year
   
346,211
     
6
     
(2,192
)
   
344,025
 
Total available-for-sale securities
 
$
660,458
   
$
30
   
$
(2,552
)
 
$
657,936
 
Equity securities:
                               
Regulus Therapeutics Inc.
 
$
7,162
   
$
17,630
   
$
   
$
24,792
 
Total equity securities
 
$
7,162
   
$
17,630
   
$
   
$
24,792
 
Total available-for-sale and equity securities
 
$
667,620
   
$
17,660
   
$
(2,552
)
 
$
682,728
 

     
Gross Unrealized
     
December 31, 2014
 
Cost
   
Gains
   
Losses
   
Estimated
Fair Value
 
Available-for-sale securities (1):
               
Corporate debt securities (2)
 
$
219,856
   
$
89
   
$
(89
)
 
$
219,856
 
Debt securities issued by U.S. government agencies
   
47,496
     
7
     
(27
)
   
47,476
 
Debt securities issued by the U.S. Treasury (2)
   
19,008
     
9
     
     
19,017
 
Debt securities issued by states of the United States and political subdivisions of the states (2)
   
45,196
     
19
     
(53
)
   
45,162
 
Total securities with a maturity of one year or less
   
331,556
     
124
     
(169
)
   
331,511
 
Corporate debt securities
   
152,730
     
16
     
(600
)
   
152,146
 
Debt securities issued by U.S. government agencies
   
62,530
     
     
(151
)
   
62,379
 
Debt securities issued by states of the United States and political subdivisions of the states
   
60,073
     
32
     
(234
)
   
59,871
 
Total securities with a maturity of more than one year
   
275,333
     
48
     
(985
)
   
274,396
 
Total available-for-sale securities
 
$
606,889
   
$
172
   
$
(1,154
)
 
$
605,907
 
Equity securities:
                               
Regulus Therapeutics Inc.
 
$
12,477
   
$
69,404
   
$
   
$
81,881
 
Total equity securities
 
$
12,477
   
$
69,404
   
$
   
$
81,881
 
Total available-for-sale and equity securities
 
$
619,366
   
$
69,576
   
$
(1,154
)
 
$
687,788
 

(1) Our available-for-sale securities are held at amortized cost.

F-18

(2) Includes investments classified as cash equivalents on our consolidated balance sheet.
 
Investments we consider to be temporarily impaired at December 31, 2015 are as follows (in thousands):

       
Less than 12 months of
Temporary Impairment
   
More than 12 months of
Temporary Impairment
   
Total Temporary
Impairment
 
   
Number of
Investments
   
Estimated
Fair Value
   
Unrealized
Losses
   
Estimated
Fair Value
   
Unrealized
Losses
   
Estimated
Fair Value
   
Unrealized
Losses
 
Corporate debt securities
   
397
   
$
406,098
   
$
(1,908
)
 
$
16,066
   
$
(47
)
 
$
422,164
   
$
(1,955
)
Debt securities issued by U.S. government agencies
   
19
     
71,842
     
(262
)
   
1,001
     
(1
)
   
72,843
     
(263
)
Debt securities issued by the U.S. Treasury
   
2
     
2,601
     
(3
)
   
     
     
2,601
     
(3
)
Debt securities issued by states of the United States and political subdivisions of the states
   
230
     
59,882
     
(173
)
   
29,634
     
(158
)
   
89,516
     
(331
)
Total temporarily impaired securities
   
648
   
$
540,423
   
$
(2,346
)
 
$
46,701
   
$
(206
)
 
$
587,124
   
$
(2,552
)

We believe that the decline in value of these securities is temporary and primarily related to the change in market interest rates since purchase. We believe it is more likely than not that we will be able to hold these securities to maturity. Therefore, we anticipate full recovery of their amortized cost basis at maturity.

3. Long-Term Obligations and Commitments

The carrying value of our long-term obligations was as follows (in thousands):

   
December 31,
 
   
2015
   
2014
 
1 percent convertible senior notes
 
$
347,214
   
$
327,486
 
2¾ percent convertible senior notes
   
50,361
     
48,014
 
Long-term financing liability for leased facility
   
72,217
     
71,731
 
Equipment financing arrangement
   
515
     
3,226
 
Leases and other obligations
   
2,341
     
7,325
 
Total
 
$
472,648
   
$
457,782
 
Less: current portion
   
(515
)
   
(2,882
)
Total Long-Term Obligations
 
$
472,133
   
$
454,900
 

Convertible Notes

In November 2014, we completed a $500 million offering of convertible senior notes, which mature in 2021 and bear interest at 1 percent. We raised $487 million of proceeds, net of issuance costs. We used a substantial portion of the net proceeds from the issuance of the 1 percent convertible senior notes to repurchase $140 million in principal of our 2¾ percent convertible senior notes at a price of $441.9 million, including accrued interest. As a result, the new principal balance of the 2¾ percent notes is $61.2 million. We recognized an $8.3 million non-cash loss as a result of the early retirement of a portion of the 2¾ percent notes.

At December 31, 2015 we had the following convertible debt outstanding (amounts in millions except price per share data):

   
1 Percent
Convertible Senior Notes
   
2¾ Percent
Convertible Senior Notes
 
Outstanding balance
 
$
500
   
$
61
 
Issue date
 
November 2014
   
August 2012
 
Maturity date
 
November 2021
   
October 2019
 
Interest rate
 
1 percent
   
2¾ percent
 
Conversion price per share
 
$
66.81
   
$
16.63
 
Total shares of common stock subject to conversion
   
7.5
     
3.7
 

Interest is payable semi-annually in arrears on May 15 and November 15 of each year for the 1 percent notes and on April 1 and October 1 for the 2 ¾ percent notes.

The 1 percent notes are convertible at the option of the note holders prior to July 1, 2021 only under certain conditions. On or after July 1, 2021, the notes are initially convertible into approximately 7.5 million shares of common stock at a conversion price of approximately $66.81 per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the 1 percent notes prior to maturity, and no sinking fund is provided for them. If we undergo a fundamental change, holders may require us to purchase for cash all or any portion of their 1 percent notes at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.
F-19


The 2¾ percent notes are convertible at the option of the note holders prior to July 1, 2019 only under certain conditions. On or after July 1, 2019, the notes are convertible into approximately 3.7 million shares of common stock at a conversion price of approximately $16.63 per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We can redeem the 2¾ percent notes at our option, in whole or in part, on or after October 5, 2016 if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the trading day immediately preceding the date we provide the redemption notice exceeds 130 percent of the applicable conversion price for the 2¾ percent notes on each such day. The redemption price for the 2¾ percent notes will equal 100 percent of the principal amount being redeemed, plus accrued and unpaid interest, plus $90 per each $1,000 principal amount being redeemed. Holders of the 2¾ percent notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indenture governing these notes, at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest.

For the 2¾ percent notes, the price of our common stock exceeded the conversion threshold price during the quarter ended December 31, 2015. As a result, the 2¾ percent notes are convertible at the option of the holders during the quarter ending March 31, 2016. As of December 31, 2015, the if-converted value of the 2¾ percent notes, which assumes that the notes will be converted into shares of our common stock, exceeded the principal amount by $166.9 million. We did not include the potential effect of the conversion of our convertible notes into our common stock in the computation of diluted net loss per share because the effect would have been anti-dilutive.

We account for our convertible notes using an accounting standard that requires us to assign a value to our convertible debt equal to the estimated fair value of similar debt instruments without the conversion feature and to record the remaining portion in equity. As a result, we recorded our convertible notes at a discount, which we are amortizing as additional non-cash interest expense over the expected life of the respective debt. We determined our nonconvertible debt borrowing rate using a combination of the present value of the debt’s cash flows and a Black-Scholes valuation model. The following table summarizes the nonconvertible borrowing rate, effective interest rate and amortization period of our debt discount for our convertible notes:

 
1 Percent
Convertible Senior Notes
2¾ Percent
Convertible Senior Notes
Nonconvertible debt borrowing rate
7.4 percent
8.0 percent
Effective interest rate
7.8 percent
 8.8 percent
Amortization period of debt discount
7 years
7 years

Interest expense for the year ended December 31, 2015, 2014 and 2013 included $23.2 million, $9.6 million and $6.8 million, respectively, of non-cash interest expense related to the amortization of the debt discount and debt issuance costs for our convertible notes.

The following table summarizes information about the equity and liability components of our outstanding convertible notes, (in thousands). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement:

   
December 31,
 
   
2015
   
2014
 
2¾ Percent Convertible Senior Notes
       
Fair value of outstanding notes
 
$
215,320
   
$
223,900
 
Principal amount of convertible notes outstanding
 
$
61,247
   
$
61,247
 
Unamortized portion of debt discount
 
$
10,886
   
$
13,233
 
Long-term debt
 
$
50,361
   
$
48,014
 
Carrying value of equity component
 
$
18,714
   
$
18,714
 
                 
1 Percent Convertible Senior Notes
               
Fair value of outstanding notes
 
$
555,000
   
$
568,000
 
Principal amount of convertible notes outstanding
 
$
500,000
   
$
500,000
 
Unamortized portion of debt discount
 
$
152,786
   
$
172,514
 
Long-term debt
 
$
347,214
   
$
327,486
 
Carrying value of equity component
 
$
174,770
   
$
174,770
 

Financing Arrangements

In June 2015, we entered into a five-year revolving line of credit agreement with Morgan Stanley Private Bank, National Association, or Morgan Stanley. We amended the credit agreement in February 2016 to increase the amount available for us to borrow. Under the amended credit agreement, we can borrow up to a maximum of $30 million of revolving credit for general working capital purposes. Under the credit agreement interest is payable monthly in arrears on the outstanding principal at a rate based on our option of:

(i)
a floating rate equal to the one-month London Interbank Offered Rate, or LIBOR, in effect plus 1.25 percent per annum;
(ii)
a fixed rate equal to LIBOR plus 1.25 percent for a period of one, two, three, four, six, or twelve months as elected by us; or
(iii)
a fixed rate equal to the LIBOR swap rate during the period of the loan.
F-20


Additionally, we will pay 0.25 percent per annum, payable quarterly in arrears, for any amount unused under the credit facility beginning after June 1, 2016. As of December 31, 2015 we had $8.5 million in outstanding borrowings under the credit facility, which were used to fund our capital equipment needs and is consistent with our historical practice to finance these costs. As of December 31, 2015, our outstanding borrowings under this credit facility were at a weighted average interest rate of 1.67 percent.

The credit agreement includes customary affirmative and negative covenants and restrictions. We are in compliance with all covenants of the credit agreement.

In October 2008, we entered into an equipment financing loan agreement. As of December 31, 2015, our outstanding borrowings under this loan agreement were at a weighted average interest rate of 4.39 percent. The carrying balance under this loan agreement at December 31, 2015 and 2014 was $0.5 million and $3.2 million, respectively. Our remaining outstanding balance is due in June 2016 and interest is payable monthly. 

Maturity Schedules

Annual debt and other obligation maturities, including fixed and determinable interest, at December 31, 2015 are as follows (in thousands):

2016
 
$
15,767
 
2017
   
6,744
 
2018
   
6,744
 
2019
   
6,744
 
2020
   
66,304
 
Thereafter
   
505,960
 
Subtotal
 
$
608,263
 
Less: current portion
   
(9,029
)
Less: fixed and determinable interest
   
(37,655
)
Less: unamortized portion of debt discount
   
(163,672
)
Plus: Deferred rent
   
2,006
 
Total
 
$
399,913
 

Operating Leases

We lease office, laboratory and manufacturing space under non-cancelable operating leases with terms through December 2031. We are located in three buildings in Carlsbad, California, which consists of laboratory, manufacturing and office space. Our facilities include a primary research and development facility, a manufacturing facility and a building adjacent to our manufacturing facility. We account for the lease of our primary research and development facility as a financing obligation as discussed below. Our manufacturing facility is used for our drug development business and was built to meet current Good Manufacturing Practices and the facility adjacent to our manufacturing facility has laboratory and office space that we use to support our manufacturing activities. The lease for our manufacturing facility expires in 2031 and has four five-year options to extend. Under the lease agreement, we have the option to purchase the facility at the end of each year from 2016 through 2020, and at the end of 2026 and 2031. The lease for the facility adjacent to our manufacturing facility has an initial term ending in June 2021 with an option to extend the lease for up to two five-year periods. Additionally, Akcea leases office space in a building in Cambridge, Massachusetts. The lease for Akcea has a three-year term and expires in July 2018. We also lease office equipment under non-cancelable operating leases with terms through June 2017.

Annual future minimum payments under operating leases as of December 31, 2015 are as follows (in thousands):

   
Operating
Leases
 
2016
 
$
1,879
 
2017
   
1,878
 
2018
   
1,597
 
2019
   
1,474
 
2020
   
1,527
 
Thereafter
   
16,125
 
Total minimum payments
 
$
24,480
 

Rent expense for the year ended December 31, 2015 was $2.0 million and was $1.8 million each of the years ended December 31, 2014 and 2013. We recognize rent expense on a straight line basis over the lease term for the lease on our manufacturing facility, the lease on our building adjacent to our manufacturing facility and Akcea’s office space, which resulted in a deferred rent balance of $2.0 million and $1.8 million at December 31, 2015 and 2014, respectively.
F-21


Research and Development Facility Lease Obligation

In March 2010, we entered into a lease agreement with an affiliate of BioMed Realty, L.P., or BioMed. Under the lease, BioMed constructed our primary research and development facility in Carlsbad, California. The lease expires in 2031 and has four five-year options to extend. Under the lease agreement, we have the option to purchase the facility and land at the end of each year from 2016 through 2020, and at the end of 2026 and 2031. To gain early access to the facility, we agreed to modify our lease with BioMed to accept additional responsibility. As a result, we recorded the costs for the facility as a fixed asset and we also recorded a corresponding liability in our non-current liabilities as a long-term financing obligation. In July 2011, we took possession of the facility and began depreciating the cost of the facility over its economic useful life. At December 31, 2015 and 2014, the facility and associated parcel of land had a net book value of $62.2 million and $64.4 million, respectively, which included $9.9 million and $7.7 million, respectively, of accumulated depreciation. We are applying our rent payments, which began on January 1, 2012, against the liability over the term of the lease.

In conjunction with the lease agreement with BioMed, we purchased a parcel of land for $10.1 million and subsequently sold it to BioMed. Since we have the option to purchase the facility, including the land, we have continuing involvement in the land, which requires us to account for the purchase and sale of the land as a financing transaction. As such, our property, plant and equipment at December 31, 2015 and 2014 included the value of the land. Additionally, we have recorded a corresponding amount in our non-current liabilities as a long-term financing obligation. Since land is not a depreciable asset, the value of the land and financing obligation we recorded will not change until we exercise our purchase option or the lease terminates.

Annual future rent payments as of December 31, 2015 for our primary research and development facility are as follows (in thousands):

   
Future Rent
Payments
 
2016
 
$
6,550
 
2017
   
6,550
 
2018
   
6,943
 
2019
   
6,943
 
2020
   
7,359
 
Thereafter
   
91,205
 
Total minimum payments
 
$
125,550
 

4. Stockholders’ Equity

Preferred Stock

We are authorized to issue up to 15,000,000 shares of “blank check” Preferred Stock. As of December 31, 2015, there were no shares of Preferred Stock outstanding. We have designated Series C Junior Participating Preferred Stock but have no issued or outstanding shares as of December 31, 2015.

Common Stock

At December 31, 2015 and 2014, we had 300,000,000 shares of common stock authorized, of which 120,351,480 and 118,442,726 were issued and outstanding, respectively. As of December 31, 2015, total common shares reserved for future issuance were 18,512,177.

During the years ending December 31, 2015, 2014 and 2013, we issued 1,908,000, 1,972,000 and 5,372,000 shares of common stock, respectively, for stock option exercises, vesting of restricted stock units, and ESPP purchases. We received net proceeds from these transactions of $24.9 million, $23.1 million and $63.0 million in 2015, 2014 and 2013, respectively.

Stock Plans

1989 Stock Option Plan

In June 1989, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that, as amended, provides for the issuance of non-qualified and incentive stock options for the purchase of up to 20,000,000 shares of common stock to our employees, directors, and consultants. The plan expires in January 2024. The 1989 Plan does not allow us to grant stock bonuses or restricted stock awards and prohibits us from repricing any options outstanding under the plan unless our stockholders approve the repricing. Options vest over a four-year period, with 25 percent exercisable at the end of one year from the date of the grant and the balance vesting ratably, on a monthly basis, thereafter and have a term of seven years. At December 31, 2015, a total of 3,619,716 options were outstanding, of which options to purchase 2,927,597 shares were exercisable, and 13,462 shares were available for future grant under the 1989 Plan.

2000 Broad Based Equity Incentive Plan

In January 2000, we adopted the 2000 Broad-Based Equity Incentive Plan (the 2000 Plan), which, as amended, provided for the issuance of non-qualified stock options for the purchase of up to 5,990,000 shares of common stock to our employees, directors, and consultants. Typically options expire seven or ten years from the date of grant. Options granted under this plan generally vest over a four-year period, with 25 percent exercisable at the end of one year from the date of the grant and the balance vesting ratably, on a monthly basis thereafter. At December 31, 2015, a total of 44,025 options were outstanding and exercisable, and no shares were available for future grant under the 2000 Plan. The 2000 Plan expired on January 5, 2010, so we may no longer grant new options under the 2000 Plan.
F-22


Change of Control Under 1989 Plan and 2000 Plan

With respect to both the 1989 Plan and 2000 Plan, in the event of:

a sale, lease or other disposition of all or substantially all of our assets;

a merger or consolidation in which we are not the surviving corporation; or

reverse merger in which we are the surviving corporation but the shares of common stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise,

then any surviving corporation or acquiring corporation will assume any stock awards outstanding under the 2000 Plan and the 1989 Plan or will substitute similar stock awards (including an award to acquire the same consideration paid to the shareholders in the transaction for those outstanding under the 2000 Plan and the 1989 Plan). In the event any surviving corporation or acquiring corporation refuses to assume such stock awards or to substitute similar stock awards for those outstanding under the 2000 Plan and the 1989 Plan, then with respect to stock awards held by participants whose continuous service has not terminated, such stock awards automatically vest in full and the stock awards will terminate if not exercised (if applicable) at or prior to such event.

2011 Equity Incentive Plan

In March 2011, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance cash awards to our employees, directors, and consultants. In June 2015, after receiving approval from our stockholders, we amended our 2011 Equity Incentive Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2011 Equity Incentive Plan from 5,500,000 to 11,000,000. The plan expires in June 2021. The 2011 Plan does not allow us to reduce the exercise price of any outstanding stock options or stock appreciation rights or cancel any outstanding stock options or stock appreciation rights that have an exercise price or strike price greater than the current fair market value of the common stock in exchange for cash or other stock awards unless our stockholders approve such action. Currently we anticipate awarding only options and restricted stock unit awards to our employees, directors and consultants. Under the 2011 Plan, stock options cannot vest in a period of less than two years and restricted stock unit awards cannot vest in a period of less than three years. We have granted restricted stock unit awards to our employees under the 2011 Plan which vest annually over a four-year period. At December 31, 2015, a total of 3,832,225 options were outstanding, of which 659,254 were exercisable, 712,034 restricted stock unit awards were outstanding, and 5,989,752 shares were available for future grant under the 2011 Plan.

Under the 2011 Plan, we may issue a stock award with additional acceleration of vesting and exercisability upon or after a change in control. In the absence of such provisions, no such acceleration will occur. The stock options and restricted stock unit awards we issue to our chief executive officer and chief operating officer will accelerate upon a change of control, as defined in the 2011 Plan.

Corporate Transactions and Change in Control under 2011 Plan

In the event of certain significant corporate transactions, our Board of Directors has the discretion to take one or more of the following actions with respect to outstanding stock awards under the 2011 Plan:

arrange for assumption, continuation, or substitution of a stock award by a surviving or acquiring entity (or its parent company);
arrange for the assignment of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award to the surviving or acquiring corporation (or its parent company);
accelerate the vesting and exercisability of a stock award followed by the termination of the stock award;
arrange for the lapse of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award;
cancel or arrange for the cancellation of a stock award, to the extent not vested or not exercised prior to the effective date of the corporate transaction, in exchange for cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and
arrange for the surrender of a stock award in exchange for a payment equal to the excess of (a) the value of the property the holder of the stock award would have received upon the exercise of the stock award, over (b) any exercise price payable by such holder in connection with such exercise.
 
2002 Non-Employee Directors’ Stock Option Plan

In September 2001, our Board of Directors adopted, and the stockholders subsequently approved, an amendment and restatement of the 1992 Non-Employee Directors’ Stock Option Plan, which provides for the issuance of non-qualified stock options and restricted stock units to our non-employee directors. The name of the resulting plan is the 2002 Non-Employee Directors’ Stock Option Plan (the 2002 Plan). In June 2015, after receiving approval from our stockholders, we amended our 2002 Non-Employee Directors Stock Option Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2002 Non-Employee Directors Stock Option Plan from 1,200,000 to 2,000,000. Options under this plan expire ten years from the date of grant. Options granted become exercisable in four equal annual installments beginning one year after the date of grant. At December 31, 2015, a total of 544,812 options were outstanding, of which 309,319 were exercisable, 38,621 restricted stock unit awards were outstanding, and 859,871 shares were available for future grant under the 2002 Plan.
F-23


Employee Stock Purchase Plan

In June 2009, our Board of Directors adopted, and the stockholders subsequently approved, the amendment and restatement of the ESPP and we reserved an additional 150,000 shares of common stock for issuance thereunder. In each of the subsequent years, we reserved an additional 150,000 shares of common stock for the ESPP resulting in a total of 3,224,596 million shares authorized under the plan as of December 31, 2015. The ESPP permits full-time employees to purchase common stock through payroll deductions (which cannot exceed 10 percent of each employee’s compensation) at the lower of 85 percent of fair market value at the beginning of the purchase period or the end of each six-month purchase period. Under the amended and restated ESPP, employees must hold the stock they purchase for a minimum of six months from the date of purchase. During 2015, employees purchased and we issued to employees 38,372 shares under the ESPP at a weighted average price of $37.43 per share. At December 31, 2015, there were 481,764 shares available for purchase under the ESPP.

Stock Option Activity

The following table summarizes the stock option activity for the year ended December 31, 2015 (in thousands, except per share and contractual life data):

   
Number of
Shares
   
Weighted
Average Exercise
Price
Per Share
 
Average
Remaining
Contractual Term
(Years)
 
Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2014
   
7,379
   
$
19.52
     
Granted
   
2,550
   
$
61.02
     
Exercised
   
(1,674
)
 
$
14.07
     
Cancelled/forfeited/expired
   
(214
)
 
$
42.43
     
Outstanding at December 31, 2015
   
8,041
   
$
33.21
     
4.57
   
$
232,581
 
Exercisable at December 31, 2015
   
3,940
   
$
16.43
     
3.32
   
$
179,273
 

The weighted-average estimated fair values of options granted were $27.44, $17.54 and $7.10 for the years ended December 31, 2015, 2014 and 2013, respectively. The total intrinsic value of options exercised during the years ended December 31, 2015, 2014 and 2013 were $84.7 million, $62.8 million and $69.6 million, respectively, which we determined as of the date of exercise. The amount of cash received from the exercise of stock options was $23.6 million, $22.4 million and $62.0 million for the years ended December 31, 2015, 2014 and 2013, respectively. For the year ended December 31, 2015, the weighted-average fair value of options exercised was $64.69. As of December 31, 2015, total unrecognized compensation cost related to non-vested stock-based compensation plans was $45.7 million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of 1.3 years.

Restricted Stock Unit Activity

The following table summarizes the RSU activity for the year ended December 31, 2015 (in thousands, except per share data):

   
Number of
Shares
   
Weighted
Average
Grant Date
Fair Value
Per Share
 
Non-vested at December 31, 2014
   
638
   
$
30.52
 
Granted
   
348
   
$
65.69
 
Vested
   
(196
)
 
$
27.40
 
Cancelled/forfeited
   
(39
)
 
$
42.87
 
Non-vested at December 31, 2015
   
751
   
$
47.47
 

For the years ended December 31, 2015, 2014 and 2013, the weighted-average grant date fair value of RSUs granted was $65.69, $44.94 and $17.42 per RSU, respectively. As of December 31, 2015, total unrecognized compensation cost related to RSUs was $16.0 million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of 1.2 years.

Stock-based Compensation Expense and Valuation Information

The following table summarizes stock-based compensation expense for the years ended December 31, 2015, 2014 and 2013 (in thousands), which was allocated as follows and includes $6.5 million of stock-based compensation expense for Akcea employees in 2015:

 
Year Ended
December 31,
 
 
2015
 
2014
 
2013
 
Research, development and patents
 
$
43,638
   
$
25,843
   
$
9,673
 
General and administrative
   
15,676
     
5,540
     
1,745
 
Total
 
$
59,314
   
$
31,383
   
$
11,418
 

F-24


Determining Fair Value

Valuation. We measure stock-based compensation expense for equity-classified awards, principally related to stock options, RSUs, and stock purchase rights under the ESPP at the grant date, based on the estimated fair value of the award and we recognize the expense over the employee’s requisite service period. We value RSUs based on the market price of our common stock on the date of grant.

We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP. The expected term of stock options granted represents the period of time that we expect them to be outstanding. We estimate the expected term of options granted based on actual and projected exercise patterns. We recognize compensation expense for stock options granted, RSUs, and stock purchase rights under the ESPP using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), an entity recognizes compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.

For the years ended December 31, 2015, 2014 and 2013, we used the following weighted-average assumptions in our Black-Scholes calculations:

Employee Stock Options:

 
December 31,
 
2015
 
2014
 
2013
Risk-free interest rate
1.5 %
 
1.7 %
 
1.1 %
Dividend yield
0.0 %
 
0.0 %
 
0.0 %
Volatility
53.8 %
 
50.1 %
 
51.1 %
Expected life
4.5 years
 
4.7 years
 
5.1 years

Board of Director Stock Options:

 
December 31,
 
2015
 
2014
 
2013
Risk-free interest rate
2.1 %
 
2.2 %
 
2.2 %
Dividend yield
0.0 %
 
0.0 %
 
0.0 %
Volatility
52.2 %
 
54.2 %
 
52.7 %
Expected life
6.9 years
 
6.9 years
 
7.2 years

ESPP:

 
December 31,
 
2015
 
2014
 
2013
Risk-free interest rate
0.1 %
 
0.1 %
 
0.1 %
Dividend yield
0.0 %
 
0.0 %
 
0.0 %
Volatility
51.7 %
 
60.1 %
 
62.9 %
Expected life
6 months
 
6 months
 
6 months

Risk-Free Interest Rate. We base the risk-free interest rate assumption on observed interest rates appropriate for the term of our stock option plans or ESPP.

Dividend Yield. We base the dividend yield assumption on our history and expectation of dividend payouts. We have not paid dividends in the past and do not expect to in the future.

Volatility. We use an average of the historical stock price volatility of our stock for the Black-Scholes model. We computed the historical stock volatility based on the expected term of the awards.

Expected Life. The expected term of stock options we have granted represents the period of time that we expect them to be outstanding. We estimated the expected term of options we have granted based on actual and projected exercise patterns.

Forfeitures. We reduce stock-based compensation expense for estimated forfeitures. We estimate forfeitures at the time of grant and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We estimate forfeitures based on historical experience. Our historical forfeiture estimates have not been materially different from our actual forfeitures.
F-25



5. Income Taxes

The provisions for income taxes on income from continuing operations were as follows (in thousands):

   
Year Ended December 31,
 
   
2015
   
2014
   
2013
 
Current:
           
Federal
 
$
379
   
$
263
   
$
 
State
   
(7
)
   
(4,295
)
   
2
 
Total current
   
372
     
(4,032
)
   
2
 
                         
Deferred:
                       
Federal
   
     
(8,948
)
   
(5,082
)
State
   
     
(2,427
)
   
(834
)
Total deferred
   
     
(11,375
)
   
(5,916
)
Income tax expense (benefit)
 
$
372
   
$
(15,407
)
 
$
(5,914
)

In periods in which we have a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as other comprehensive income, intraperiod tax allocation rules require us to allocate the tax provision to the other categories of earnings. We then record a related tax benefit in continuing operations. During 2015, we recorded unrealized losses on our investments in available-for-sale securities in other comprehensive income, therefore we did not have to allocate our tax provision to our other categories of earnings. However, during 2014 and 2013, we recorded unrealized gains on our investments in available-for-sale securities and had to allocate our tax provision between continuing operations and other comprehensive income. As a result, for the years ended December 31, 2014 and 2013, we recorded a $12.8 million and $5.9 million tax benefit, respectively, in continuing operations and a $12.8 million and $5.9 million tax expense, respectively, in other comprehensive income.

In December 2014, we reached an agreement with the State of California Franchise Tax Board with regard to California franchise tax we paid for the tax year ended December 31, 2009. As part of the agreement, we received a franchise tax refund of $4.3 million in 2015 and our research credit carry-forward to December 31, 2010 increased by $4.3 million. We recognized an income tax benefit for the refund in the fourth quarter of 2014. The increase in our research credit carry-forward increased our deferred tax assets but did not impact our consolidated balance sheet as we recorded a full valuation allowance on our deferred tax assets.

The reconciliation between our effective tax rate on income from continuing operations and the statutory U.S. tax rate is as follows (in thousands):

   
Year Ended December 31,
 
   
2015
   
2014
   
2013
 
Pre-tax loss
 
$
(87,906
)
     
$
(54,391
)
     
$
(66,558
)
   
                                     
Statutory rate
   
(30,767
)
   
35.0
%
   
(19,035
)
   
35.0
%
   
(23,295
)
   
35.0
%
State income tax net of federal benefit
   
1
     
0.0
%
   
(3,125
)
   
5.7
%
   
(3,823
)
   
5.7
%
Net change in valuation allowance
   
69,499
     
(79.1
)%
   
29,547
     
(54.3
)%
   
28,850
     
(43.3
)%
Loss on debt extinguishment
   
     
0.0
%
   
2,406
     
(4.4
)%
   
     
0.0
%
Tax credits
   
(41,284
)
   
47.0
%
   
(23,628
)
   
43.4
%
   
(15,839
)
   
23.8
%
California franchise tax refund
   
     
0.0
%
   
(2,795
)
   
5.1
%
   
     
0.0
%
Deferred tax true-up
   
1,496
     
(1.7
)%
   
977
     
(1.8
)%
   
8,023
     
(12.1
)%
Other
   
1,427
     
(1.6
)%
   
246
     
(0.5
)%
   
170
     
(0.2
)%
Effective rate
 
$
372
     
(0.4
)%
 
$
(15,407
)
   
28.2
%
 
$
(5,914
)
   
8.9
%

Significant components of our deferred tax assets and liabilities as of December 31, 2015 and 2014 are as follows (in thousands):

   
Year Ended
December 31,
 
   
2015
   
2014
 
Deferred Tax Assets:
       
Net operating loss carryovers
 
$
218,493
   
$
231,654
 
R&D credits
   
153,601
     
93,594
 
Deferred revenue
   
45,110
     
58,836
 
Stock-based compensation
   
31,093
     
21,553
 
Other
   
19,655
     
15,549
 
Total deferred tax assets
 
$
467,952
   
$
421,186
 
                 
Deferred Tax Liabilities:
               
Convertible debt
 
$
(55,928
)
 
$
(73,733
)
Unrealized gain in other comprehensive income
   
(5,288
)
   
(27,878
)
Intangible and capital assets
   
(2,643
)
   
(3,641
)
Net deferred tax asset
 
$
404,093
   
$
315,934
 
Valuation allowance
   
(404,093
)
   
(315,934
)
                 
Net deferreds
 
$
   
$
 

F-26



We have net deferred tax assets relating primarily to net operating loss carryforwards, or NOL’s, and research and development tax credit carryforwards. Subject to certain limitations, we may use these deferred tax assets to offset taxable income in future periods. Since we have a history of losses and the likelihood of future profitability is not assured, we have provided a full valuation allowance for the deferred tax assets in our balance sheet as of December 31, 2015. If we determine that we are able to realize a portion or all of these deferred tax assets in the future, we will record an adjustment to increase their recorded value and a corresponding adjustment to increase income or additional paid in capital, as appropriate, in that same period.

We recognize excess tax benefits associated with share-based compensation to stockholders' equity only when realized. We follow the with-and-without approach excluding any indirect effects of the excess tax deductions to determine when we should realize excess tax benefits relating to share-based compensation. Under this approach, we do not realize our excess tax benefits related to share-based compensation until after we utilize all other our tax benefits available to us. During the year ended December 31, 2015, we realized $0.4 million of such excess tax benefits, and accordingly, we recorded a corresponding credit to additional paid-in capital.  As of December 31, 2015, we had $76.9 million of unrealized excess tax benefits associated with share-based compensation. We will account for the tax benefits as a credit to additional paid-in capital, if and when we realize them, rather than a reduction of the provision for income taxes.

At December 31, 2015, we had federal and California tax net operating loss carryforwards of approximately $734.7 million and $886.5 million, respectively. Our federal tax loss carryforwards will begin to expire in 2023, unless we use them before then. Our California loss carryforwards continue to expire in 2015. At December 31, 2015, we also had federal and California research and development tax credit carryforwards of approximately $146.8 million and $44.7 million, respectively. Our Federal research and development tax credit carryforwards begin to expire in 2018. Our California research and development tax credit carryforwards are available indefinitely. In 2009, we had a substantial amount of taxable income and we used a portion of our Federal NOL carryforwards to reduce our federal income taxes.

We analyze filing positions in all of the federal and state jurisdictions where we file income tax returns, and all open tax years in these jurisdictions to determine if we have any uncertain tax positions on any of our income tax returns. We recognize the impact of an uncertain tax position on an income tax return at the largest amount that the relevant taxing authority is more-likely-than not to sustain upon audit. We do not recognize uncertain income tax positions if they have less than 50 percent likelihood of the applicable tax authority sustaining our position.

The following table summarizes our gross unrecognized tax benefits (in thousands):

   
Year Ended December 31,
 
   
2015
   
2014
   
2013
 
Beginning balance of unrecognized tax benefits
 
$
27,365
   
$
23,964
   
$
10,872
 
Decrease for prior period tax positions
   
     
(1,653
)
   
 
Increase for prior period tax positions
   
215
     
     
9,821
 
Increase for current period tax positions
   
23,677
     
5,054
     
3,271
 
Ending balance of unrecognized tax benefits
 
$
51,257
   
$
27,365
   
$
23,964
 

At December 31, 2015 we had $33.3 million of tax benefits included in our unrecognized tax benefits that, if we recognized them, would reduce our annual effective tax rate subject to the valuation allowance.

We do not foresee any material changes to our gross unrecognized tax benefits within the next twelve months. We recognize interest and/or penalties related to income tax matters in income tax expense. We did not recognize any accrued interest and penalties related to gross unrecognized tax benefits during the year ended December 31, 2015.

Due to the carryforward of unutilized net operating losses and research and development credits, we are subject to taxation in the United States and various state jurisdictions. Our tax years for 1998 and forward are subject to examination by the U.S. tax authorities and our tax years for 2002 and forward are subject to examination by the California tax authorities.

6. Collaborative Arrangements and Licensing Agreements

Strategic Partnerships

AstraZeneca

Cardiometabolic and Renal Diseases Collaboration

In July 2015, we and AstraZeneca formed a strategic collaboration to discover and develop antisense therapies for treating cardiovascular and metabolic diseases primarily focused on targets in the kidney, and renal diseases. As part of the agreement, we granted AstraZeneca an exclusive license to a preclinical program and the option to license a drug for each target advanced under this research collaboration. Upon acceptance of a drug development candidate, AstraZeneca will be responsible for all further global development, regulatory and commercialization activities for such drug. Under the terms of the agreement, we received a $65 million upfront payment. Since this agreement has multiple elements, we evaluated the deliverables in this arrangement and determined that none of the deliverables have stand-alone value because of the early stage of research for this collaboration. Therefore, we concluded there is one unit of accounting and we are amortizing the $65 million upfront payment through August 2021. We are eligible to receive license fees and substantive milestone payments of up to more than $4 billion, including up to $1.1 billion for the achievement of development milestones and up to $2.9 billion for regulatory milestones. We will earn the next milestone payment of $25 million under this collaboration upon identification of the first drug candidate to move into development. In addition, we are eligible to receive tiered royalties up to the low teens on sales from any product that AstraZeneca successfully commercializes under this collaboration agreement.
F-27


Oncology Collaboration

In December 2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense drugs for cancer. As part of the agreement, we granted AstraZeneca an exclusive license to develop and commercialize IONIS-STAT3-2.5Rx for the treatment of cancer and an option to license up to three anti-cancer drugs under a separate research program. AstraZeneca is responsible for all global development, regulatory and commercialization activities for IONIS-STAT3-2.5Rx. We and AstraZeneca have evaluated IONIS-STAT3-2.5Rx in patients with advanced metastatic hepatocellular carcinoma and advanced lymphoma. AstraZeneca is evaluating IONIS-STAT3-2.5Rx in combination with MEDI4736, AstraZeneca's investigational anti-PD-L1 drug, in patients with head and neck cancer. For the research program, we are responsible for identifying a development candidate for each of the three anti-cancer research programs. AstraZeneca has the option to license drugs resulting from each of the three anti-cancer research programs, and if AstraZeneca exercises its option for a drug, it will be responsible for all further global development, regulatory and commercialization activities for such drug.

Under the terms of the agreement, we received $31 million in upfront payments. We recorded revenue of $11.5 million upon receipt of these payments and we have amortized $11.9 million into revenue as we have performed development activities under this collaboration. We are recognizing the remaining $7.6 million related to the option to license three drugs under the research program through December 2016. In January 2016, we and AstraZeneca amended the agreement for the research program. Under the amended terms of the agreement, we can earn an additional $5 million in milestone payments for advancing a drug under our research program.

We are eligible to receive milestone payments and license fees from AstraZeneca as programs advance in development. In addition, we are eligible to receive tiered royalties up to the low to mid-teens on sales from any drugs resulting from these programs. If AstraZeneca successfully develops IONIS-STAT3-2.5Rx and the three drugs under the research program, we could receive license fees and substantive milestone payments of nearly $750 million, including up to $226 million for the achievement of development milestones and up to $485 million for the achievement of regulatory milestones. From inception through December 2015, we have received $63.5 million in milestone payments and upfront fees under this oncology collaboration. We will earn the next milestone payment of $15 million if we further advance a cancer drug under our research program with AstraZeneca.

Each of our agreements with AstraZeneca will continue until the expiration of all payment obligations under the applicable agreement. In addition, the agreement, or any program under the applicable agreement, may terminate early under the following situations:

AstraZeneca may terminate the agreement or any program at any time by providing written notice to us;
AstraZeneca may terminate the agreement or any program by providing written notice if we undergo a change of control with a third party; and
Either we or AstraZeneca may terminate the agreement or any program by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement, or the entire agreement if the other party becomes insolvent.

During 2015, 2014 and 2013 we earned revenue of $6.4 million, $27.7 million and $29.1 million, respectively, from our relationship with AstraZeneca, which represented two percent, 13 percent and 20 percent, respectively, of our total revenue for those periods. Our balance sheets at December 31, 2015 and 2014 included deferred revenue of $63.3 million and $4.4 million, respectively, related to our relationship with AstraZeneca.

Biogen

We have established four strategic collaborations with Biogen focused on using antisense technology to advance the treatment of neurological and neuromuscular disorders. These collaborations combine our expertise in creating antisense drugs with Biogen's expertise in developing therapies for neurological disorders. We and Biogen are currently developing six drugs to treat neurological diseases under these collaborations, including nusinersen, IONIS-DMPK-2.5Rx, IONIS-SOD1Rx, formerly ISIS-BIIB3Rx, and three drugs to treat undisclosed neurodegenerative diseases, IONIS-BIIB4Rx, IONIS-BIIB5Rx, and IONIS-BIIB6Rx. In addition to these six drugs, we and Biogen are evaluating numerous additional targets for the development of drugs to treat neurological diseases.

Nusinersen

In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize nusinersen for the treatment of SMA. We are currently conducting a Phase 3 study evaluating nusinersen in infants with SMA, which we expect to be fully enrolled in the second quarter of 2016. We are also conducting a Phase 3 study evaluating nusinersen in children with SMA, for which we have completed target enrollment. In addition, we are evaluating nusinersen in two Phase 2 open-label studies, one in children with SMA and one in infants with SMA. Patients from all of these studies continue to have access to nusinersen through open-label extension dosing. We are responsible for completing the studies we are currently conducting. Biogen has the option to license nusinersen. If Biogen exercises its option, it will pay us a license fee and will assume all other global development, regulatory and commercialization responsibilities. Biogen may exercise this option upon completion of and data review of the first successful Phase 2/3 trial or completion of both Phase 2/3 trials. An amendment in December 2014 provided for additional opt-in scenarios, based on the filing or the acceptance of a new drug application or marketing authorization application with the FDA or EMA. In June 2015, we and Biogen amended the development plan for nusinersen to include conducting the open-label extension study for the Phase 3 studies in infants and children. As a result of the change to the development plan, we earned an $11 million milestone payment when we initiated the Phase 3 open-label extension study and we are eligible to earn additional milestone and other payments.

Under the terms of the agreement, we received an upfront payment of $29 million, which we are amortizing through February 2017. We are also eligible to receive a license fee, milestone payments and tiered royalties up to the mid-teens on any sales of nusinersen. Over the term of the collaboration, we are eligible to receive up to $346 million in a license fee and payments, including up to $121 million in substantive milestone and other payments associated with the clinical development of nusinersen prior to licensing and up to $150 million in substantive milestone payments if Biogen achieves pre-specified regulatory milestones. From inception through December 2015, we have received more than $130 million in milestone payments and upfront fees for advancing nusinersen. In 2015, we earned $40 million for advancing the studies we are conducting in infants and children with SMA. In addition we earned a $2 million milestone payment in February 2016 for further advancing the Phase 3 study of nusinersen in infants. We will earn the next milestone payment of $2 million if we further advance the Phase 3 study of nusinersen in infants.
F-28


IONIS-DMPK-2.5Rx

In June 2012, we and Biogen entered into a second and separate collaboration agreement to develop and commercialize a novel antisense drug, IONIS-DMPK-2.5Rx, targeting DMPK for the treatment of myotonic dystrophy type 1, or DM1. We are responsible for global development of the drug through the completion of the first Phase 2 clinical trial. We are currently evaluating IONIS-DMPK-2.5Rx in a Phase 1/2 clinical study in patients with DM1. Biogen has the option to license the drug through the completion of the first Phase 2 trial. If Biogen exercises its option, it will assume all other global development, regulatory and commercialization responsibilities. Under the terms of the agreement, we received an upfront payment of $12 million, which we are amortizing through October 2018. In June 2015, we and Biogen amended the development plan for IONIS-DMPK-2.5Rx under which we are eligible to earn additional milestone payments of up to $4.2 million for further advancing the Phase 1/2 study of IONIS-DMPK-2.5Rx. Over the term of the collaboration, we are eligible to receive up to $263 million in a license fee and substantive milestone payments, including up to $63 million in development milestone payments and up to $130 million in milestone payments if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on any sales of IONIS-DMPK-2.5Rx. From inception through December 2015, we have received nearly $39 million in milestone payments and upfront fees for advancing IONIS-DMPK-2.5Rx, including a $2.8 million milestone payment we earned in November 2015. We will earn the next milestone payment of $1.4 million if we further advance the Phase 1/2 study for IONIS-DMPK-2.5Rx and we will earn a $35 million milestone payment if we initiate a Phase 2 study for IONIS-DMPK-2.5Rx.

Neurology

In December 2012, we and Biogen entered into a third and separate collaboration agreement to develop and commercialize novel antisense drugs to up to three targets to treat neurological or neuromuscular diseases. We are responsible for the development of each of the drugs through the completion of the initial Phase 2 clinical study for such drug. Biogen has the option to license a drug from each of the three programs through the completion of the first Phase 2 study for each program. We are currently advancing IONIS-BIIB4Rx under this collaboration. If Biogen exercises its option for a drug, it will assume all further global development, regulatory and commercialization responsibilities for that drug. Under the terms of the agreement, we received an upfront payment of $30 million, which we are amortizing through December 2020. Over the term of the collaboration, we are eligible to receive up to $259 million in a license fee and substantive milestone payments per program. We are eligible to receive up to $59 million in development milestone payments to support research and development of each program, including amounts related to the cost of clinical trials. We are also eligible to receive up to $130 million in milestone payments per program if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any drugs resulting from each of the three programs. In February 2015, we earned a $10 million milestone payment when we initiated an IND-enabling toxicology study of IONIS-BIIB4Rx, a drug for an undisclosed target designed to treat a neurodegenerative disease. From inception through December 2015, we have received $40 million in milestone payments and upfront fees under this collaboration, not including the $3 million milestone payment we earned in February 2016. We will earn the next milestone payment of up to $10 million for the continued development of IONIS-BIIB4Rx.

Strategic Neurology

In September 2013, we and Biogen entered into a fourth and separate collaboration agreement, which is a long-term strategic relationship focused on applying antisense technology to advance the treatment of neurological diseases. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for neurological diseases and has the option to license drugs resulting from this collaboration. The exclusivity for neurological diseases will last through September 2019, and may be extended for any drug development programs being pursued under the collaboration. We will usually be responsible for drug discovery and early development of antisense drugs and Biogen will have the option to license antisense drugs after Phase 2 proof of concept. We are currently advancing three drugs, IONIS-SOD1Rx, IONIS-BIIB5Rx, and IONIS-BIIB6Rx under this collaboration. If Biogen exercises its option for a drug, it will assume all further global development, regulatory and commercialization responsibilities for that drug. Biogen will be responsible for all of the drug discovery and development activities for drugs using other modalities.

Under the terms of the agreement, we received an upfront payment of $100 million and are eligible to receive milestone payments, license fees and royalty payments for all drugs developed through this collaboration, with the specific amounts dependent upon the modality of the molecule advanced by Biogen. If we have a change of control during the first six years of the collaboration, we may be required to refund Biogen a portion of the $100 million upfront payment, with the amount of the potential refund decreasing ratably as we progress through the initial six-year term of the collaboration. We are amortizing the $100 million upfront payment through September 2019. Because the amortization period for the upfront payment will never be less than the initial six-year term of the collaboration, the amount of revenue we recognize from the upfront payment will never exceed the amount that Biogen could potentially require us to refund.

For each antisense molecule that is chosen for drug discovery and development under this collaboration, we are eligible to receive up to approximately $260 million in a license fee and substantive milestone payments. We are eligible to receive up to approximately $60 million for the achievement of research and development milestones, including amounts related to the cost of clinical trials, and up to $130 million for the achievement of regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any antisense drugs developed under this collaboration. If other modalities are chosen, such as small molecules or monoclonal antibodies, we are eligible to receive up to $90 million in substantive milestone payments, including up to $35 million for the achievement of research and development milestones and up to $55 million for the achievement of regulatory milestones. In addition, we are eligible to receive tiered single-digit royalties on sales from any drugs using non-antisense modalities developed under this collaboration. From inception through December 2015, we have received $135 million in milestone payments and upfront fees under this collaboration. In December 2015, we earned a $5 million milestone payment for validating a fifth target under this collaboration. We will earn the next milestone payment of up to $10 million if we choose another target to advance under this collaboration.
F-29


Each of our agreements with Biogen will continue until the earlier of the date all of Biogen's options to obtain the exclusive licenses under the applicable agreement expire unexercised or, if Biogen exercises its option, until the expiration of all payment obligations under the applicable agreement. In addition, each agreement, or any program under an agreement, may terminate early under the following situations:

Biogen may terminate the agreement or any program at any time by providing written notice to us;
Under specific circumstances, if we are acquired by a third party with a product that directly competes with a compound being developed under the agreement, Biogen may terminate the affected program by providing written notice to us;
If, within a specified period of time, any required clearance of a transaction contemplated by an agreement under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, is not received, then either we or Biogen may terminate the affected program by providing written notice to the other party; and
Either we or Biogen may terminate any program by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement with respect to the affected program, or the entire agreement if the other party becomes insolvent.

During 2015, 2014 and 2013, we earned revenue of $106.2 million, $123.2 million and $37.0 million, respectively, from our relationship with Biogen, which represented 37 percent, 58 percent and 25 percent, respectively, of our total revenue for those periods. Our balance sheets at December 31, 2015 and 2014 included deferred revenue of $91.6 million and $118.1 million, respectively, related to our relationship with Biogen.

Research, Development and Commercialization Partners

Bayer

In May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXIRx for the prevention of thrombosis. We are responsible for completing our ongoing Phase 2 study of IONIS-FXIRx in patients with end-stage renal disease on hemodialysis. Bayer is responsible for all other development and commercialization activities for IONIS-FXIRx.

Under the terms of the agreement, we are eligible to receive $155 million in near-term payments, including a $100 million upfront payment we received in the second quarter of 2015 and a $55 million milestone payment that we are eligible to receive upon advancement of the program following the Phase 2 study in patients with end-stage renal disease on hemodialysis. We recorded revenue of $91.2 million related to the license for IONIS-FXIRx in June 2015 and we are recognizing the remaining $8.8 million related to the ongoing development activities for IONIS-FXIRx through July 2016.

Over the term of the agreement, we are eligible to receive up to $375 million in license fees, substantive milestone payments and other payments, including up to $120 million for the achievement of development milestones and up to $110 million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties in the low-to-high 20 percent range on gross margins of IONIS-FXIRx. We will earn the next milestone payment of $55 million upon the advancement of the program following the ongoing Phase 2 study of IONIS-FXIRx in patients with end-stage renal disease on hemodialysis.

Our agreement with Bayer will continue until the expiration of all payment obligations under the agreement. In addition, the agreement, or any program under the agreement, may terminate early under the following situations:

Bayer may terminate the agreement or any program at any time by providing written notice to us;
Either we or Bayer may terminate the agreement or any program by providing written notice to the other party upon the other party’s uncured failure to perform a material obligation under the agreement, or the entire agreement if the other party becomes insolvent.

During 2015 we earned revenue of $93.4 million, from our relationship with Bayer, which represented 33 percent of our total revenue for the period. Our consolidated balance sheet at December 31, 2015 included deferred revenue of $6.7 million related to our relationship with Bayer.

Genzyme Corporation, a Sanofi company

In January 2008, we entered into an alliance with Genzyme focused on the licensing and co-development of Kynamro. The license and co-development agreement provided Genzyme with exclusive worldwide rights for all therapeutic purposes to our patents and know-how related to Kynamro. The transaction included a $175 million licensing fee and a $150 million equity investment by Genzyme in our stock. From inception through December 2015, we have received $375 million in a license fee, milestone payments and an equity investment for advancing Kynamro in development. In January 2016, we terminated our license agreement with Genzyme.

During 2015 and 2014, we did not earn any revenue from our relationship with Genzyme. During 2013, we earned revenue of $32.5 million from our relationship with Genzyme, which represented 22 percent of our total revenue for that year.

GSK

In March 2010, we entered into an alliance with GSK using our antisense drug discovery platform to discover and develop new drugs against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness. Our alliance currently comprises five drugs in development, including our Phase 3 drug IONIS-TTRRx. GSK has the exclusive option to license drugs resulting from this alliance at Phase 2 proof-of-concept for a license fee. If GSK exercises its exclusive option for any drugs resulting from this alliance, it will be responsible for all further global development, regulatory and commercialization activities for such drug. Under the terms of the agreement, we received $38 million in upfront and expansion payments, which we are amortizing through March 2017.
F-30


In October 2012, we and GSK amended the original agreement to reflect an accelerated clinical development plan for IONIS-TTRRx. We are currently evaluating IONIS-TTRRx in a broad Phase 3 development program. We have completed target enrollment in the Phase 3 study in patients with FAP. From inception through December 2015, we have earned $60 million from GSK related to the development of IONIS-TTRRx, primarily in milestone payments. We are also eligible to earn an additional $10 million pre-licensing milestone payment associated with our ongoing study of IONIS-TTRRx. In addition, under the amended agreement, we and GSK increased the regulatory and commercial milestone payments we can earn should IONIS-TTRRx receive marketing authorization and meet pre-agreed sales targets. In September 2015, we and GSK amended the development plan for IONIS-TTRRx to support the Phase 3 cardiomyopathy study, which GSK plans to conduct.

In addition to IONIS-TTRRx, we have four drugs in development with GSK. We are developing two antisense drugs we designed to reduce the production of viral proteins associated with hepatitis B virus, or HBV, infection; IONIS-HBVRx and IONIS-HBV-LRx, a follow-on drug using our LICA technology. We are also developing IONIS-GSK4-LRx and IONIS-RHO-2.5Rx, which are antisense drugs we designed to treat ocular diseases.

Under our agreement, if GSK successfully develops all five drugs for one or more indications and achieves pre-agreed sales targets, we could receive license fees and substantive milestone payments of more than $1.0 billion, including up to $183.5 million for the achievement of development milestones, up to $363.5 million for the achievement of regulatory milestones and up to $348 million for the achievement of commercialization milestones. Through December 2015, we have received $135 million in milestone payments and upfront fees under this alliance with GSK, not including a $1.5 million payment we earned in January 2016 when GSK further advanced IONIS-HBV-LRx. We will earn the next milestone payment of up to $5 million if we further advance a program under this collaboration. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any product that GSK successfully commercializes under this alliance.

Our alliance with GSK will continue until the earlier of the date that all of GSK's options to obtain the exclusive licenses under the agreement expire unexercised or, if GSK exercises its option, until the expiration of all payment obligations under the agreement. In addition, the agreement, or any program under the agreement, may terminate early under the following situations:

GSK may terminate any program, other than the IONIS-TTRRx program, at any time by providing written notice to us;
GSK may terminate the IONIS-TTRRx program by providing written notice to us after reviewing specific data from the Phase 3 study for the program; and
Either we or GSK may terminate any program by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement with respect to the affected program, or the entire agreement if the other party becomes insolvent.

During 2015, 2014 and 2013, we earned revenue of $33.3 million, $37.3 million and $35.3 million, respectively, from our relationship with GSK, which represented 12 percent, 17 percent and 24 percent, respectively, of our total revenue for those years. Our balance sheets at December 31, 2015 and 2014 included deferred revenue of $4.9 million and $10.0 million, respectively, related to our relationship with GSK.

Janssen Biotech, Inc., a pharmaceutical company of Johnson & Johnson

In December 2014, we entered into a collaboration agreement with Janssen Biotech, Inc. to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders of the gastrointestinal tract. Janssen has the option to license drugs from us through the designation of a development candidate for up to three programs. Prior to option exercise we are responsible for the discovery activities to identify a development candidate. If Janssen exercises an option for one of the programs, it will be responsible for the global development, regulatory and commercial activities under that program. Under the terms of the agreement, we received $35 million in upfront payments, which we are amortizing through December 2018. We are eligible to receive nearly $800 million in license fees and substantive milestone payments for these programs, including up to $175 million for the achievement of development milestones, up to $420 million for the achievement of regulatory milestones and up to $180 million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties up to the near teens on sales from any drugs resulting from this collaboration. We will earn the next milestone payment of $5 million if Janssen chooses another target to advance under this collaboration.

Our agreement with Janssen will continue until the earlier of the date that all of Janssen’s options to obtain the exclusive licenses under the agreement expire unexercised or, if Janssen exercises its option, until the expiration of all payment obligations under the agreement. In addition, the agreement, or any program under the agreement, may terminate early under the following situations:

Janssen may terminate the agreement or any program at any time by providing written notice to us; and
Either we or Janssen may terminate any program by providing written notice to the other party upon the other party’s uncured failure to perform a material obligation under the agreement, or the entire agreement if the other party becomes insolvent.

During 2015 we earned revenue of $8.9 million from our relationship with Janssen. During 2014 and 2013 we did not earn any revenue from our relationship with Janssen. Our balance sheet at December 31, 2015 included deferred revenue of $26.3 million related to our relationship with Janssen.
F-31


Roche

In April 2013, we formed an alliance with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, to develop treatments for Huntington's disease, or HD, based on our antisense technology. Roche has the option to license the drugs from us through the completion of the first Phase 1 trial. Under the agreement, we are responsible for the discovery and development of an antisense drug targeting huntingtin, or HTT, protein. We are currently evaluating a drug targeting HTT, IONIS-HTTRx, in a Phase 1/2 clinical study in patients with early stage HD. If Roche exercises its option, it will be responsible for global development, regulatory and commercialization activities for any drug arising out of the collaboration. We are also working collaboratively with Roche on the discovery of an antisense drug utilizing Roche's "brain shuttle" program. Under the terms of the agreement, we received an upfront payment of $30 million in April 2013, which we are amortizing through January 2017. We are eligible to receive up to $362 million in a license fee and substantive milestone payments including up to $67 million for the achievement of development milestones, up to $170 million for the achievement of regulatory milestones and up to $80 million for the achievement of commercialization milestones. In addition, we are eligible to receive up to $136.5 million in milestone payments for each additional drug successfully developed and up to $50 million in commercial milestone payments if a drug using Roche's proprietary brain shuttle technology is successfully commercialized. We are also eligible to receive tiered royalties up to the mid-teens on any product sales of drugs resulting from this alliance. Through December 2015, we have received $52 million in milestone payments and upfront fees under this alliance with Roche. We will earn the next milestone payment of $10 million if Roche initiates a Phase 2 trial for IONIS-HTTRx.

Our alliance with Roche will continue until the earlier of the date Roche's option to obtain the exclusive license under the agreement expires unexercised or, if Roche exercises its option, until the expiration of all payment obligations under the agreement. In addition, the agreement may terminate early under the following situations:

Roche may terminate the agreement at any time by providing written notice to us;
Either we or Roche may terminate the agreement by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement or if the other party becomes insolvent; and
Either we or Roche may terminate the brain shuttle program if at least one development candidate is not designated under such program by a mutually agreed deadline.

During 2015, 2014 and 2013, we earned revenue of $31.2 million, $8.7 million and $5.1 million, respectively from our relationship with Roche, which represented 11 percent, four percent and three percent, respectively, of our total revenue for those years. Our balance sheet at December 31, 2015 and 2014 included deferred revenue of $8.8 million and $17.0 million, respectively related to our relationship with Roche.

Satellite Company Collaborations

Achaogen, Inc.

In 2006, we exclusively licensed to Achaogen, Inc. specific know-how, patents and patent applications relating to aminoglycosides. In exchange, Achaogen agreed to certain payment obligations related to aminoglycosides Achaogen developed. Achaogen is developing plazomicin, an aminoglycoside Achaogen discovered based on the technology we licensed to Achaogen. In connection with the license, Achaogen issued to us $1.5 million of Achaogen Series A Preferred Stock. If Achaogen successfully develops and commercializes two drugs under our agreement, we will receive payments totaling up to $49.3 million for the achievement of key clinical, regulatory and sales events. Through December 2015, we have earned $7 million in milestone payments from Achaogen, including a $4 million milestone payment we earned in September 2014 when Achaogen initiated a Phase 3 study of plazomicin in patients with serious multi-drug resistant, gram-negative bacterial infections. We will earn the next milestone payment of $7.5 million if Achaogen obtains regulatory approval for plazomicin in a major market. We are also eligible to receive royalties on sales of drugs resulting from the program. Achaogen is solely responsible for the continued development of plazomicin.

During 2015 and 2013, we did not earn any revenue from our relationship with Achaogen. During 2014 we earned revenue of $4 million from our relationship with Achaogen and we sold all of the Achaogen stock we owned resulting in net proceeds of $1.3 million.

Alnylam Pharmaceuticals, Inc.

In March 2004, we entered into an alliance with Alnylam to develop and commercialize RNAi therapeutics. Under the terms of the agreement, we exclusively licensed to Alnylam our patent estate relating to antisense motifs and mechanisms and oligonucleotide chemistry for double-stranded RNAi therapeutics in exchange for a $5 million technology access fee, participation in fees from Alnylam’s partnering programs, as well as future milestone and royalty payments from Alnylam. For each drug Alnylam develops under this alliance, we may receive up to $3.4 million in milestone payments, including up to $1.1 million for the achievement of development milestones and $2.3 million for regulatory milestones. We will earn the next milestone payment of $0.4 million if Alnylam initiates a Phase 1 study for a drug in Alnylam’s pipeline. We also have the potential to earn royalties on drug sales and a portion of payments that Alnylam receives from licenses of our technology it grants to its partners plus royalties. We retained rights to a limited number of double-stranded RNAi therapeutic targets and all rights to single-stranded RNAi, or ssRNAi, therapeutics.

In turn, Alnylam nonexclusively licensed to us its patent estate relating to antisense motifs and mechanisms and oligonucleotide chemistry to research, develop and commercialize single-stranded antisense therapeutics, ssRNAi therapeutics, and to research double-stranded RNAi compounds. We also received a license to develop and commercialize double-stranded RNAi drugs targeting a limited number of therapeutic targets on a nonexclusive basis. If we develop or commercialize an RNAi-based drug using Alnylam’s technology, we will pay Alnylam up to $3.4 million in milestone payments for specified development and regulatory events, plus royalties. To date, we do not have an RNAi-based drug in development.
F-32


In 2015, we and Alnylam entered into an alliance in which we formed an intellectual property cross-license under which we and Alnylam each obtained exclusive license rights to four therapeutic programs. Alnylam granted us an exclusive, royalty-bearing license to its chemistry, RNA targeting mechanism and target-specific intellectual property for oligonucleotides against four targets. In exchange, we granted Alnylam an exclusive, royalty-bearing license to our chemistry, RNA targeting mechanism and target-specific intellectual property for oligonucleotides against four targets. Alnylam also granted us a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for single-stranded antisense therapeutics. In turn, we granted Alnylam a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for double-stranded RNAi therapeutics. Through December 2015, we have received nearly $70 million from Alnylam.

During 2015, 2014 and 2013, we earned revenue from our relationship with Alnylam totaling $1.3 million, $9.9 million and $1.5 million, respectively.

Antisense Therapeutics Limited

In 2001 we licensed ATL1102 and ATL1103 to ATL, an Australian company publicly traded on the Australian Stock Exchange. ATL is currently undertaking a chronic toxicology study in primates to support a potential Phase 2b trial of ATL1102 in patients with multiple sclerosis, or MS. In addition, ATL is currently developing ATL1103 for growth and sight disorders. We are eligible to receive royalties on sales of ATL1102 and ATL1103. We may also receive a portion of the fees ATL receives if it licenses ATL1102 or ATL1103. At December 31, 2015 and 2014, we owned less than ten percent of ATL’s equity. During 2015, 2014 and 2013, we did not earn any revenue from our relationship with ATL. 

Atlantic Pharmaceuticals Limited

In March 2007, we licensed alicaforsen to Atlantic Pharmaceuticals, a UK-based specialty pharmaceutical company founded in 2006. Atlantic Pharmaceuticals is developing alicaforsen for the treatment of ulcerative colitis, or UC, and other inflammatory diseases. Atlantic Pharmaceuticals is initially developing alicaforsen for pouchitis, a UC indication, followed by UC and other inflammatory diseases. In exchange for the exclusive, worldwide license to alicaforsen, we received a $2 million upfront payment from Atlantic Pharmaceuticals in the form of equity. Under the agreement, we could receive milestone payments totaling up to $1.4 million for the achievement of regulatory milestones for multiple indications. We will earn the next milestone payment of $0.6 million if Atlantic Pharmaceuticals submits an NDA for alicaforsen with the FDA. In 2010, Atlantic Pharmaceuticals began supplying alicaforsen under international named patient supply regulations for patients with inflammatory bowel disease, or IBD, for which we receive royalties.

In 2010 and 2013, we agreed to sell Atlantic Pharmaceuticals alicaforsen drug substance in return for shares of Atlantic Pharmaceuticals’ common stock. Additionally, in 2013 we received an advance payment in the form of equity for the initial royalties that we will earn from Atlantic Pharmaceuticals. We recorded a full valuation allowance for all of the equity we received from Atlantic Pharmaceuticals, including the upfront payment, because realization of value from the equity is uncertain. At December 31, 2015 and 2014, we owned approximately 11 percent and 12 percent, respectively, of Atlantic Pharmaceuticals’ equity. We earned $0.7 million related to royalties and sales of drug substance in 2013. Because the payments were made in equity, we did not record any revenue. During 2015 and 2014, our revenue was negligible from our relationship with Atlantic Pharmaceuticals.

OncoGenex Technologies Inc., a subsidiary of OncoGenex Pharmaceuticals Inc.

Custirsen

In November 2001, we established a drug development collaboration with OncoGenex, a biotechnology company committed to the development of cancer therapeutics for patients with drug resistant and metastatic cancers, to co-develop and commercialize custirsen, an anti-cancer antisense drug that targets clusterin. OncoGenex is currently evaluating custirsen in two Phase 3 studies. In July 2008, we and OncoGenex amended the co-development agreement pursuant to which OncoGenex became solely responsible for the costs, development and commercialization of custirsen. In exchange, OncoGenex agreed to pay us royalties on sales of custirsen and to share consideration it receives from licensing custirsen to a third party, except for consideration OncoGenex receives for the fair market value of equity and reimbursement of research and development expenses. Under the amended agreement, we assigned to OncoGenex our rights in the patents claiming the composition and therapeutic methods of using custirsen and granted OncoGenex a worldwide, nonexclusive license to our know-how and patents covering our core antisense technology and manufacturing technology solely for use with custirsen. In addition, we agreed that so long as OncoGenex or its commercialization partner is using commercially reasonable efforts to develop and commercialize custirsen, we will not research, develop or commercialize an antisense compound designed to modulate clusterin. The amended agreement will continue until OncoGenex or its commercialization partner is no longer developing or commercializing custirsen or until we terminate the agreement for OncoGenex’s uncured failure to make a payment required under the agreement.

OGX-225

In August 2003, we and OncoGenex entered into a second and separate agreement for the development of an antisense anti-cancer drug, OGX-225. OncoGenex is responsible for all development costs and activities. OncoGenex issued to us $0.8 million of OncoGenex securities as payment for an upfront fee. In addition, OncoGenex will pay us milestone payments totaling up to $3.5 million for the achievement of key development and regulatory milestones, including up to $1.5 million for the achievement of development milestones and up to $2 million for the achievement of regulatory milestones. In addition, we are eligible to receive royalties on future product sales of OGX-225. As of December 31, 2015, OncoGenex had not achieved any milestone events related to OGX-225. We will earn the next milestone payment of $0.5 million if OncoGenex initiates a Phase 2 study for OGX-225.
F-33


Apatorsen

In January 2005, we entered into a third and separate agreement with OncoGenex to allow for the development of an additional antisense anti-cancer drug, apatorsen. OncoGenex and collaborators are evaluating apatorsen in multiple Phase 2 studies in patients with cancer. OncoGenex is responsible for all development costs and activities. OncoGenex will pay us milestone payments totaling up to $5.8 million for the achievement of key development and regulatory milestones, including up to $1.3 million for the achievement of development milestones and up to $4.5 million for the achievement of regulatory milestones. In addition, we are eligible to receive royalties on future product sales of the drug. We will earn the next milestone payment of $1.3 million if OncoGenex initiates a Phase 3 study for apatorsen.

During 2015, 2014 and 2013, we did not earn any revenue from our relationship with OncoGenex.

Regulus Therapeutics Inc.

In September 2007, we and Alnylam established Regulus as a company focused on the discovery, development and commercialization of microRNA-targeting therapeutics. We and Alnylam retain rights to develop and commercialize, on pre-negotiated terms, microRNA therapeutic products that Regulus decides not to develop either by itself or with a partner. Regulus is addressing therapeutic opportunities that arise from alterations in microRNA expression. Since microRNAs may act as master regulators of the genome, affecting the expression of multiple genes in a disease pathway, microRNA therapeutics define a new platform for drug discovery and development. MicroRNAs may also prove to be an attractive new tool for characterizing diseases. Regulus focuses its drug discovery and development efforts in numerous therapeutic areas, including cancer, fibrosis, and viral infections. Regulus currently has three drugs in clinical development. Regulus is evaluating RG-101 in a Phase 2 study in patients with HCV and in a Phase 1 study in patients with severe renal insufficiency or end-stage renal disease. Regulus is also evaluating RG-012 in a Phase 1 study to treat patients with Alport syndrome. Regulus and AstraZeneca are also evaluating RG-125 in a Phase 1 study for the treatment of NASH in patients with type 2 diabetes or pre-diabetes. We are eligible to receive royalties on any future product sales of these drugs.

During 2015, 2014 and 2013, we did not earn any revenue from our relationship with Regulus. During 2015 and 2014, we sold a portion of our Regulus stock, resulting in a gain of $20.2 million and $19.9 million, respectively, and proceeds of $25.5 million and $22.9 million, respectively. As of December 31, 2015, we owned approximately 2.8 million shares, approximately five percent of Regulus’ equity, with a net carrying value of $24.8 million.

External Project Funding

CHDI Foundation, Inc.

Starting in November 2007, CHDI provided financial and scientific support to our Huntington’s disease drug discovery program through our development collaboration. In April 2013, we formed an alliance with Roche to develop treatments for Huntington’s disease. Under the terms of our agreement with CHDI, we will reimburse CHDI for a portion of its support of our Huntington’s disease program out of the payments we receive from Roche. We made payments of $5 million and $3 million to CHDI in 2015 and 2013, respectively, associated with the progression of our Huntington’s disease program. If we achieve pre-specified milestones under our collaboration with Roche, we will make additional payments to CHDI up to $4 million, upon which our obligation to CHDI will be complete.

During 2015, our revenue earned from our relationship with CHDI was negligible and during 2014, we did not earn any revenue. During 2013, we earned revenue of $0.4 million from our relationship with CHDI.

The Ludwig Institute; Center for Neurological Studies

In October 2005, we entered into a collaboration agreement with the Ludwig Institute, the Center for Neurological Studies and researchers from these institutions to discover and develop antisense drugs for amyotrophic lateral sclerosis, or ALS, and other neurodegenerative diseases. Under this agreement, we agreed to pay the Ludwig Institute and Center for Neurological Studies modest milestone payments and royalties on any antisense drugs resulting from the collaboration.

Intellectual Property Sale and Licensing Agreements

Sales of Intellectual Property

Abbott Molecular Inc.

In January 2009, we sold our former subsidiary, Ibis Biosciences, to Abbott Molecular Inc., or AMI, pursuant to a stock purchase agreement for a total acquisition price of $215 million plus the earn out payments described below.

Under the stock purchase agreement, we are eligible to receive earn out payments from AMI equal to a percentage of Ibis’ revenue related to sales of Ibis systems, which AMI launched in 2014 as IRIDICA, including instruments, assay kits and successor products. Once cumulative net sales reach $140 million, and through December 31, 2025, we are eligible to earn out payments in any year that net sales exceed $50 million for the applicable year. The earn out payments will equal five percent of Ibis’ cumulative net sales over $140 million and up to $2.1 billion, and three percent of Ibis’ cumulative net sales over $2.1 billion. AMI may reduce these earn out payments from five percent to as low as 2.5 percent and from three percent to as low as 1.5 percent, respectively, upon the occurrence of certain events. During 2015, 2014 and 2013, we did not earn any revenue from our relationship with AMI.
F-34


In-Licensing Arrangements

University of Massachusetts

We have a license agreement with the University of Massachusetts under which we acquired an exclusive license to the University of Massachusetts’ patent rights related to nusinersen. If we successfully develop and commercialize a drug incorporating the technology we licensed from the University of Massachusetts, we will pay a milestone payment to the University of Massachusetts of $0.3 million for the achievement of a key regulatory milestone. In addition, we will pay the University of Massachusetts a portion of any sublicense revenue we receive in consideration for sublicensing its technology, and a royalty on sales of nusinersen in the United States if our product incorporates the technology we licensed from the University of Massachusetts.

Verva Pharmaceuticals Ltd.

We have a license agreement with Verva under which we acquired an exclusive license to Verva’s antisense patent rights related to IONIS-FGFR4Rx. If we successfully develop and commercialize a drug incorporating the technology Verva licensed to us, we will pay milestone payments to Verva totaling up to $6.1 million for the achievement of key patent, clinical, and regulatory milestones. If we convert our license from an exclusive license to a nonexclusive license we could significantly reduce the milestone payments due to Verva. In addition, we will also pay royalties to Verva on sales of IONIS-FGFR4Rx if our product incorporates the technology we licensed from Verva.

Cold Spring Harbor Laboratory

We have a collaboration and license agreement with the Cold Spring Harbor Laboratory under which we acquired an exclusive license to the Cold Spring Harbor Laboratory’s patent rights related to nusinersen. If we successfully develop and commercialize a drug incorporating the technology we licensed from the Cold Spring Harbor Laboratory, we will pay a portion of any sublicense revenue and post licensing milestone payments we receive in consideration for sublicensing the Cold Spring Harbor Laboratory’s technology up to $11.3 million and a royalty on sales of nusinersen if our product incorporates the technology we licensed from the Cold Spring Harbor Laboratory.

7. Segment Information and Concentration of Business Risk

In 2015, we began reporting our financial results in two reportable segments, Ionis Core, previously referred to as Drug Discovery and Development, and Akcea Therapeutics, our wholly owned subsidiary. Segment loss from operations includes revenue less operating expenses attributable to each segment.

In our Ionis Core segment, we are exploiting a novel drug discovery platform we created to generate a broad pipeline of first-in-class or best-in-class drugs for us and our partners. Our Ionis Core segment generates revenue from a multifaceted partnering strategy.

We formed Akcea to develop and commercialize drugs for cardiometabolic disorders. Moving our lipid drugs into a company that we own and control ensures that our core focus at Ionis remains on innovation while allowing us to maintain control over and retain more value from our lipid drugs. To date, Akcea has not earned any revenue.

The following is our segment information for 2015 (in thousands):

2015
 
Ionis Core
   
Akcea Therapeutics
   
Elimination of Intercompany Activity
   
Total
 
Revenue:
               
Research and development
 
$
285,608
   
$
   
$
(4,248
)
 
$
281,360
 
Licensing and royalty
   
2,343
     
     
     
2,343
 
Total segment revenue
 
$
287,951
   
$
   
$
(4,248
)
 
$
283,703
 
Loss from operations
 
$
(21,378
)
 
$
(54,384
)
 
$
   
$
(75,762
)
Total assets
 
$
1,004,150
   
$
55,354
   
$
(103,399
)
 
$
956,105
 

The following is our segment information for 2014 and 2013 (in thousands) revised for comparative purposes to show operating expense for Akcea-related projects in 2014 and 2013:

2014
 
Ionis Core
   
Akcea Therapeutics
   
Total
 
Revenue:
           
Research and development
 
$
202,514
   
$
   
$
202,514
 
Licensing and royalty
   
11,647
     
     
11,647
 
Total segment revenue
 
$
214,161
   
$
   
$
214,161
 
Loss from operations
 
$
(26,033
)
 
$
(21,697
)
 
$
(47,730
)

2013
 
Ionis Core
   
Akcea Therapeutics
   
Total
 
Revenue:
           
Research and development
 
$
147,380
   
$
   
$
144,194
 
Licensing and royalty
   
3,091
     
     
3,091
 
Total segment revenue
 
$
150,471
   
$
   
$
147,285
 
Loss from operations
 
$
(38,764
)
 
$
(12,902
)
 
$
(51,666
)

F-35



We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10 percent or more of our total revenue, was as follows:

 
2015
 
2014
 
2013
Partner A
 
37 %
   
58 %
   
25 %
Partner B
 
33 %
   
0 %
   
0 %
Partner C
 
12 %
   
17 %
   
24 %
Partner D
 
11 %
   
4 %
   
3 %
Partner E
 
2 %
   
13 %
   
20 %
Partner F
 
0 %
   
0 %
   
22 %

Contracts receivables at December 31, 2015 and December 31, 2014 were comprised of approximately 99 percent for each year from two and three significant partners, respectively.

8. Employment Benefits

We have an employee 401(k) salary deferral plan, covering all employees. Employees may make contributions by withholding a percentage of their salary up to the IRS annual limit ($18,000 and $24,000 in 2015 for employees under 50 years old and employees 50 years old or over, respectively). We made approximately $1.5 million, $1.0 million and $0.6 million in matching contributions for the years ended December 31, 2015, 2014 and 2013, respectively.

9. Legal Proceedings

From time to time, we are involved in legal proceedings arising in the ordinary course of our business. Periodically, we evaluate the status of each legal matter and assess our potential financial exposure. If the potential loss from any legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Significant judgment is required to determine the probability of a loss and whether the amount of the loss is reasonably estimable. The outcome of any proceeding is not determinable in advance. As a result, the assessment of a potential liability and the amount of accruals recorded are based only on the information available to us at the time. As additional information becomes available, we reassess the potential liability related to the legal proceeding, and may revise our estimates. We do not believe, relative to our current legal proceedings, that a loss is both probable and estimable. As such, as of December 31, 2015, we did not have a liability related to any of our current legal proceedings, including the following matters.

Gilead Litigation

In August 2013, Gilead Sciences Inc. filed a suit in the United States District Court of the Northern District of California related to United States Patent Nos. 7,105,499 and 8,481,712 that are jointly owned by Merck Sharp & Dohme Corp. and Ionis Pharmaceuticals, Inc. In the suit Gilead is asking the court to determine that Gilead's activities do not infringe any valid claim of the named patents and that the patents are not valid. We and Merck Sharp & Dohme Corp. filed our answer denying Gilead's noninfringement and invalidity contentions, contending that Gilead's commercial sale and offer for sale of sofosbuvir prior to the expiration of the '499 and '712 patents infringes those patents, and requesting monetary damages to compensate for such infringement. Under our agreement with Merck, Merck is responsible for the costs of this suit. Gilead filed a motion for summary judgment alleging invalidity of the asserted patents. In February 2016, the court denied the motion. In the same order, the court granted our motion for summary judgement for a finding of infringement, but noted that Gilead may still pursue its invalidity defenses at trial. The trial for this case is scheduled to begin March 7, 2016.

10. Quarterly Financial Data (Unaudited)

The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for the years ended December 31, 2015 and 2014 are as follows (in thousands, except per share data).

2015 Quarters
 
First
Quarter
   
Second
Quarter
   
Third
Quarter
   
Fourth
Quarter
 
Revenue
 
$
62,583
   
$
120,428
   
$
49,121
   
$
51,571
 
Operating expenses
 
$
71,913
   
$
75,782
   
$
97,259
   
$
114,511
 
Income (loss) from operations
 
$
(9,330
)
 
$
44,646
   
$
(48,138
)
 
$
(62,940
)
Net income (loss)
 
$
(16,717
)
 
$
35,648
   
$
(35,776
)
 
$
(71,433
)
Basic net income (loss) per share (1)
 
$
(0.14
)
 
$
0.30
   
$
(0.30
)
 
$
(0.59
)
Diluted net income (loss) per share (1) (2)
 
$
(0.14
)
 
$
0.29
   
$
(0.30
)
 
$
(0.59
)

2014 Quarters
 
First
Quarter
   
Second
Quarter
   
Third
Quarter
   
Fourth
Quarter
 
Revenue
 
$
28,161
   
$
57,076
   
$
44,063
   
$
84,861
 
Operating expenses
 
$
57,828
   
$
63,726
   
$
65,556
   
$
74,781
 
Income (loss) from operations
 
$
(29,667
)
 
$
(6,650
)
 
$
(21,493
)
 
$
10,080
 
Net income (loss)
 
$
(31,280
)
 
$
(12,081
)
 
$
(26,676
)
 
$
31,053
 
Basic net income (loss) per share (1)
 
$
(0.27
)
 
$
(0.10
)
 
$
(0.23
)
 
$
0.26
 
Diluted net income (loss) per share (1) (3)
 
$
(0.27
)
 
$
(0.10
)
 
$
(0.23
)
 
$
0.25
 

(1)
We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.
F-36


(2)
For the three months ended June 30, 2015, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended June 30, 2015 consisted of the following (in thousands):

Three Months Ended June 30, 2015
 
Income
(Numerator)
   
Shares
(Denominator)
   
Per-Share Amount
 
 
           
Income available to common shareholders
 
$
35,648
     
119,742
   
$
0.30
 
Effect of diluted securities:
                       
Shares issuable upon exercise of stock options
           
3,974
         
Shares issuable upon restricted stock award issuance
           
376
         
Shares issuable related to our ESPP
           
4
         
Shares issuable related to our 2¾ percent notes
   
1,047
     
3,683
         
Income available to common shareholders, plus assumed conversions
 
$
36,695
     
127,779
   
$
0.29
 

For the three months ended June 30, 2015, the calculation excludes the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.

(3)
For the three months ended December 31, 2014, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended December 31, 2014 consisted of the following (in thousands):

Three Months Ended December 31, 2014
 
Income
(Numerator)
   
Shares
(Denominator)
   
Per-Share Amount
 
 
           
Income available to common shareholders
 
$
31,053
     
118,223
   
$
0.26
 
Effect of diluted securities:
                       
Shares issuable upon exercise of stock options
           
4,189
         
Shares issuable upon restricted stock award issuance
           
418
         
Shares issuable related to our ESPP
           
9
         
Income available to common shareholders, plus assumed conversions
 
$
31,053
     
122,839
   
$
0.25
 

For the three months ended December 31, 2014, the calculation excludes the 1 percent and 2¾ percent convertible senior notes because the effect on diluted earnings per share was anti-dilutive.

F-37
EX-10.64 2 ex10_64.htm EXHIBIT 10.64

Exhibit 10.64
 
AMENDMENT NO. 2 TO LINE OF CREDIT AGREEMENT

This Amendment No. 2 to Line of Credit Agreement (the “Amendment”), dated as of February 24, 2016, is made by and between IONIS PHARMACEUTICALS, INC., f/k/a ISIS PHARMACEUTICALS, INC. (the “Borrower”), and MORGAN STANLEY PRIVATE BANK, NATIONAL ASSOCIATION, a national banking association (the “Lender”).

RECITALS

A.  The Lender and the Borrower entered into that certain Line of Credit Agreement dated as of June 16, 2015 (as amended, restated, supplemented or otherwise modified on or prior to the date hereof, the “Agreement”).

B.  The Lender and the Borrower desire to amend the Loan Documents as set forth in this Amendment.

AGREEMENT

1.            Definitions.  Capitalized terms used but not defined in this Amendment shall have the meaning given to them in the Agreement.

2.            Amendments to Agreement.

(a) The Line of Credit Commitment section in the Basic Terms of the Agreement is hereby amended and restated as follows:

“A maximum amount of $30,000,000.00, subject to adjustment as set forth under the definition of “Commitment” on Schedule I hereto.”

(b) Section 5.03(a) of the Agreement is hereby amended and restated as follows:

“(a)           Leverage Ratio.  Not permit the ratio of Funded Debt to Tangible Net Worth to exceed 5.00 to 1.00 at any time, measured on a quarterly basis.”

(c) Section 5.03(c) of the Agreement is hereby amended and restated as follows:

“(c)           Unencumbered Liquid Assets.  Maintain at all times in an account at Lender or its Affiliates a minimum of $30,000,000.00 of Unencumbered Liquid Assets.”

(d) The defined term “Commitment” in Schedule I of the Agreement is hereby amended and restated as follows:

““Commitment” means the obligation of the Lender to make Advances to the Borrower in an amount up to the lesser of (i) $30,000,000.00 or (ii) an amount equal to the sum of the amounts obtained by multiplying the aggregate Market Value of each type of Collateral in the Securities Account set forth in Column A of Exhibit A hereto times the corresponding percentage specified in Column B of Exhibit A hereto with respect to each such type of Collateral in the Securities Account, all on the terms and conditions set forth in this Agreement.”

(e) The defined term “Total Unsubordinated Liabilities” is deleted in its entirety from Schedule I of the Agreement.

(f) The following defined term is added to Schedule I of the Agreement in the appropriate alphabetical order:

““Funded Debt” means all Debt, excluding (a) accounts payable, (b) accrued compensation incurred in the ordinary course of business, (c) accrued trade (or similar) liabilities incurred in the ordinary course of business, (d) other accruals incurred in the ordinary course of business, and (e) deferred revenues.”

1


3.            Representations and Warranties.  When the Borrower signs this Amendment, the Borrower represents and warrants to the Lender that:  (a) no event has occurred and is continuing that constitutes a Default under the Agreement except those events, if any, that have been disclosed in writing to the Lender or waived in writing by the Lender, (b) the representations and warranties in the Agreement are correct in all material respects as of the date of this Amendment as if made on the date of this Amendment, (c) this Amendment does not conflict with any law, agreement, or obligation by which the Borrower is bound, and (d) if the Borrower is a business entity or a trust, this Amendment is within the Borrower's powers, has been duly authorized, and does not conflict with any of the Borrower's organizational papers.

4.            Effect of Amendment.  Except as provided in this Amendment, all of the terms and conditions of the Agreement shall remain in full force and effect.

5.            Electronic Signature; Counterparts.  This Amendment may be executed and delivered by electronic signature and in counterparts, each of which when so executed shall be deemed an original, but all such counterparts together shall constitute one and the same instrument.

[Remainder of Page Intentionally Left Blank]



The parties executed this Amendment as of the date stated at the beginning of this Amendment, intending to create an instrument executed under seal.

LENDER:
BORROWER:
       
MORGAN STANLEY PRIVATE BANK, NATIONAL ASSOCIATION
IONIS PHARMACEUTICALS, INC.
       
By:
 /s/ Mark Reardon  
By:
 /s/ Elizabeth L. Hougen  
Name: Mark Reardon
 
Name: Elizabeth L. Hougen
 
Title: Authorized Signatory
 
Title: SVP, Finance and CFO
 
 
Amendment No. 2 to Line of Credit Agreement
 


EX-21.1 3 exhibit21_1.htm EXHIBIT 21.1
Exhibit 21.1
 
LIST OF SUBSIDIARIES FOR THE REGISTRANT
 
Akcea Therapeutics, Inc., a Delaware Corporation
 
Isis USA Limited, a United Kingdom Limited Private Company
 
PerIsis I Development Corporation, a Delaware Corporation
 
Symphony GenIsis, Inc., a Delaware Corporation
 

 
EX-23.1 4 exhibit23_1.htm EXHIBIT 23.1
Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 33-55790, 33-72124, 33-75068, 33-96138  , 333-71911, 333-90811, 333-38844, 333-71116, 333-71176, 333-89066, 333-89626, 333-128156, 333-130639, 333-134380, 333-141447, 333-151076 and 333-188407) and in the related Prospectuses, as applicable, and in the Registration Statements on Form S-8 (Nos. 33-42356, 33-42970, 33-51236, 33-54840, 33-58450, 33-75150, 33-90780  , 333-05825, 333-55683, 333-40336, 333-59296, 333-91572, 333-106859, 333-116962, 333-125911, 333-133853, 333-142777, 333-151996, 333-160269, 333-168674, 333-176136, 333-184788, 333-190408 and 333-207900  ) of Ionis Pharmaceuticals, Inc. of our reports dated February 25, 2016, with respect to the consolidated financial statements of Ionis Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Ionis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2015.
 
 
/s/ ERNST & YOUNG LLP
 
 
San Diego, California
 
February 25, 2016
 
 

EX-31.1 5 exhibit31_1.htm EXHIBIT 31.1  
EXHIBIT 31.1

CERTIFICATION

I, Stanley T. Crooke, certify that:

1.
I have reviewed this Annual Report on Form 10-K of Ionis Pharmaceuticals, Inc.;

2.
Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3.
Based on my knowledge, the consolidated financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, consolidated results of operations and consolidated cash flows of the registrant as of, and for, the periods presented in this annual report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
  
Dated: February 25, 2016
 
 
 
/s/ STANLEY T. CROOKE
 
Stanley T. Crooke, M.D., Ph.D.
 
Chief Executive Officer
 

EX-31.2 6 exhibit31_2.htm EXHIBIT 31.2  
EXHIBIT 31.2

CERTIFICATION

I, Elizabeth L. Hougen, certify that:

1.
I have reviewed this Annual Report on Form 10-K of Ionis Pharmaceuticals, Inc.;

2.
Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3.
Based on my knowledge, the consolidated financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, consolidated results of operations and consolidated cash flows of the registrant as of, and for, the periods presented in this annual report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
  
Dated: February 25, 2016
 
 
 
/s/ ELIZABETH L. HOUGEN
 
Elizabeth L. Hougen
 
Chief Financial Officer
 

EX-32 7 exhibit32_1.htm EXHIBIT 32.1  
Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350),  Stanley T. Crooke, the Chief Executive Officer of Ionis Pharmaceuticals, Inc., (the "Company"), and Elizabeth L. Hougen, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

 
1.
The Company's Annual Report on Form 10-K for the year ended December 31, 2015, to which this Certification is attached as Exhibit 32.1 (the "Annual Report"), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

 
2.
The information contained in the Annual Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Annual Report and the results of operations of the Company for the period covered by the Annual Report.

Dated: February 25, 2016
 
 
 
 
 
/s/ STANLEY T. CROOKE
 
/s/ ELIZABETH L. HOUGEN
Stanley T. Crooke, M.D., Ph.D.
 
Elizabeth L. Hougen
Chief Executive Officer
 
Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to Ionis Pharmaceuticals, Inc. and will be retained by Ionis Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Ionis Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

EX-101.INS 8 ions-20151231.xml XBRL INSTANCE DOCUMENT 0000874015 2015-01-01 2015-12-31 0000874015 2015-06-30 0000874015 2016-02-19 0000874015 2015-12-31 0000874015 2014-12-31 0000874015 ions:ConvertibleSeniorNotes275PercentMember 2014-12-31 0000874015 ions:ConvertibleSeniorNotes1PercentMember 2014-12-31 0000874015 ions:ConvertibleSeniorNotes275PercentMember 2015-12-31 0000874015 ions:ConvertibleSeniorNotes1PercentMember 2015-12-31 0000874015 us-gaap:ConvertibleSubordinatedDebtMember ions:ConvertibleSeniorNotes275PercentMember 2014-12-31 0000874015 ions:ConvertibleSeniorNotes1PercentMember us-gaap:ConvertibleSubordinatedDebtMember 2014-12-31 0000874015 ions:ConvertibleSeniorNotes275PercentMember us-gaap:ConvertibleSubordinatedDebtMember 2015-12-31 0000874015 ions:ConvertibleSeniorNotes1PercentMember us-gaap:ConvertibleSubordinatedDebtMember 2015-12-31 0000874015 2014-01-01 2014-12-31 0000874015 2013-01-01 2013-12-31 0000874015 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-12-31 0000874015 us-gaap:RetainedEarningsMember 2012-12-31 0000874015 2012-12-31 0000874015 us-gaap:CommonStockMember 2012-12-31 0000874015 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000874015 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-12-31 0000874015 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0000874015 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0000874015 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0000874015 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0000874015 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000874015 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0000874015 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0000874015 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0000874015 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000874015 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0000874015 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-01-01 2013-12-31 0000874015 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000874015 us-gaap:CommonStockMember 2015-12-31 0000874015 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000874015 us-gaap:RetainedEarningsMember 2014-12-31 0000874015 us-gaap:RetainedEarningsMember 2015-12-31 0000874015 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000874015 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000874015 us-gaap:CommonStockMember 2014-12-31 0000874015 us-gaap:CommonStockMember 2013-12-31 0000874015 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000874015 us-gaap:RetainedEarningsMember 2013-12-31 0000874015 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000874015 2013-12-31 0000874015 ions:ConvertibleSeniorNotes275PercentMember 2014-01-01 2014-12-31 0000874015 ions:ConvertibleSeniorNotes1PercentMember 2014-01-01 2014-12-31 0000874015 ions:ConvertibleSeniorNotes1PercentMember 2013-01-01 2013-12-31 0000874015 ions:ConvertibleSeniorNotes1PercentMember 2015-01-01 2015-12-31 0000874015 ions:ConvertibleSeniorNotes275PercentMember 2015-01-01 2015-12-31 0000874015 ions:ConvertibleSeniorNotes275PercentMember 2013-01-01 2013-12-31 0000874015 ions:ConvertibleSeniorNotes275PercentMember us-gaap:ConvertibleSubordinatedDebtMember 2013-12-31 0000874015 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0000874015 ions:BoardOfDirectorStockOptionMember 2015-01-01 2015-12-31 0000874015 ions:AgreementEnteredIntoInMay2015Member ions:BayerHealthCareMember 2015-04-01 2015-06-30 0000874015 ions:BayerHealthCareMember ions:AgreementEnteredIntoInMay2015Member 2015-01-01 2015-12-31 0000874015 ions:BayerHealthCareMember ions:AgreementEnteredIntoInMay2015Member ions:IONISFXIMember 2015-04-01 2015-06-30 0000874015 ions:StrategicNeurologyMember ions:BiogenMember ions:CollaborativeArrangementSeptember2013Member 2013-09-01 2013-09-30 0000874015 ions:BiogenMember ions:CollaborativeArrangementJune2012Member ions:IONISDMPK25Member 2012-06-01 2012-06-30 0000874015 ions:NeurologyMember ions:CollaborativeArrangementDecember2012Member ions:BiogenMember 2012-12-01 2012-12-31 0000874015 ions:CollaborativeArrangementJanuary2012Member ions:NusinersenMember ions:BiogenMember 2012-01-01 2012-01-31 0000874015 ions:AgreementEnteredIntoInMay2015Member ions:IONISFXIActivePharmaceuticalIngredientMember ions:BayerHealthCareMember 2015-04-01 2015-06-30 0000874015 ions:BiogenMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:StrategicNeurologyMember ions:CollaborativeArrangementSeptember2013Member ions:BiogenMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:DevelopmentMilestonesPhaseOneMember ions:CollaborativeArrangementsAndLicensingAgreementsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:DevelopmentMilestonesNewDevelopmentCandidateMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000874015 us-gaap:MinimumMember ions:DevelopmentMilestonesPhaseThreeMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:DevelopmentMilestonesNewDevelopmentCandidateMember us-gaap:MinimumMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember us-gaap:MinimumMember ions:DevelopmentMilestonesPhaseTwoMember 2015-01-01 2015-12-31 0000874015 us-gaap:MinimumMember ions:DevelopmentMilestonesPhaseOneMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:DevelopmentMilestonesPhaseTwoMember ions:CollaborativeArrangementsAndLicensingAgreementsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000874015 ions:DevelopmentMilestonesPhaseThreeMember us-gaap:MaximumMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember us-gaap:MinimumMember ions:RegulatoryMilestonesMember 2015-01-01 2015-12-31 0000874015 us-gaap:MaximumMember ions:RegulatoryMilestonesMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:CommercializationMilestonesMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:AlnylamMember 2014-01-01 2014-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember 2013-01-01 2013-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember 2014-01-01 2014-12-31 0000874015 us-gaap:PatentsMember 2015-01-01 2015-12-31 0000874015 us-gaap:PatentsMember 2014-12-31 0000874015 us-gaap:PatentsMember 2015-12-31 0000874015 us-gaap:PatentsMember 2013-01-01 2013-12-31 0000874015 us-gaap:PatentsMember 2014-01-01 2014-12-31 0000874015 ions:PropertyPlantAndEquipmentExcludingLandMember 2015-12-31 0000874015 us-gaap:LandMember 2015-12-31 0000874015 us-gaap:LandImprovementsMember 2014-12-31 0000874015 us-gaap:FurnitureAndFixturesMember 2014-12-31 0000874015 ions:EquipmentAndComputerSoftwareMember 2015-12-31 0000874015 us-gaap:LandMember 2014-12-31 0000874015 us-gaap:BuildingAndBuildingImprovementsMember 2015-12-31 0000874015 ions:EquipmentAndComputerSoftwareMember 2014-12-31 0000874015 us-gaap:LeaseholdImprovementsMember 2014-12-31 0000874015 us-gaap:LandImprovementsMember 2015-12-31 0000874015 us-gaap:BuildingAndBuildingImprovementsMember 2014-12-31 0000874015 us-gaap:LeaseholdImprovementsMember 2015-12-31 0000874015 us-gaap:FurnitureAndFixturesMember 2015-12-31 0000874015 ions:PropertyPlantAndEquipmentExcludingLandMember 2014-12-31 0000874015 us-gaap:MaximumMember ions:EquipmentAndComputerSoftwareMember 2015-01-01 2015-12-31 0000874015 us-gaap:LandImprovementsMember 2015-01-01 2015-12-31 0000874015 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000874015 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000874015 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000874015 us-gaap:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2015-01-01 2015-12-31 0000874015 us-gaap:MinimumMember ions:EquipmentAndComputerSoftwareMember 2015-01-01 2015-12-31 0000874015 us-gaap:MinimumMember us-gaap:LeaseholdImprovementsMember 2015-01-01 2015-12-31 0000874015 us-gaap:MaximumMember us-gaap:LeaseholdImprovementsMember 2015-01-01 2015-12-31 0000874015 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-12-31 0000874015 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2013-01-01 2013-12-31 0000874015 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-01-01 2014-12-31 0000874015 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-12-31 0000874015 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2015-12-31 0000874015 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000874015 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2015-12-31 0000874015 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-12-31 0000874015 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2015-12-31 0000874015 us-gaap:CorporateDebtSecuritiesMember us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2014-12-31 0000874015 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2015-12-31 0000874015 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000874015 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2015-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember us-gaap:USTreasurySecuritiesMember 2014-12-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000874015 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2014-12-31 0000874015 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2014-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2015-12-31 0000874015 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0000874015 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-12-31 0000874015 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2014-12-31 0000874015 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000874015 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000874015 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000874015 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000874015 us-gaap:EquitySecuritiesMember 2013-12-31 0000874015 us-gaap:EquitySecuritiesMember 2014-12-31 0000874015 us-gaap:EquitySecuritiesMember 2015-01-01 2015-12-31 0000874015 us-gaap:EquitySecuritiesMember 2014-01-01 2014-12-31 0000874015 us-gaap:EquitySecuritiesMember 2015-12-31 0000874015 ions:RegulusTherapeuticsMember 2015-12-31 0000874015 ions:SecuritiesWithMaturityOfMoreThanOneYearMember 2015-12-31 0000874015 ions:SecuritiesWithMaturityOfMoreThanOneYearMember 2014-12-31 0000874015 ions:SecuritiesWithMaturityOfOneYearOrLessMember 2015-12-31 0000874015 ions:SecuritiesWithMaturityOfOneYearOrLessMember us-gaap:USTreasurySecuritiesMember 2015-12-31 0000874015 ions:SecuritiesWithMaturityOfOneYearOrLessMember 2014-12-31 0000874015 ions:SecuritiesWithMaturityOfMoreThanOneYearMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2014-12-31 0000874015 us-gaap:USStatesAndPoliticalSubdivisionsMember ions:SecuritiesWithMaturityOfOneYearOrLessMember 2015-12-31 0000874015 ions:SecuritiesWithMaturityOfOneYearOrLessMember us-gaap:USTreasurySecuritiesMember 2014-12-31 0000874015 us-gaap:USStatesAndPoliticalSubdivisionsMember ions:SecuritiesWithMaturityOfMoreThanOneYearMember 2014-12-31 0000874015 ions:SecuritiesWithMaturityOfMoreThanOneYearMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2015-12-31 0000874015 us-gaap:CorporateDebtSecuritiesMember ions:SecuritiesWithMaturityOfOneYearOrLessMember 2015-12-31 0000874015 us-gaap:CorporateDebtSecuritiesMember ions:SecuritiesWithMaturityOfMoreThanOneYearMember 2014-12-31 0000874015 us-gaap:USGovernmentAgenciesDebtSecuritiesMember ions:SecuritiesWithMaturityOfMoreThanOneYearMember 2015-12-31 0000874015 us-gaap:USGovernmentAgenciesDebtSecuritiesMember ions:SecuritiesWithMaturityOfOneYearOrLessMember 2015-12-31 0000874015 ions:SecuritiesWithMaturityOfMoreThanOneYearMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000874015 us-gaap:USGovernmentAgenciesDebtSecuritiesMember ions:SecuritiesWithMaturityOfOneYearOrLessMember 2014-12-31 0000874015 ions:SecuritiesWithMaturityOfOneYearOrLessMember us-gaap:CorporateDebtSecuritiesMember 2014-12-31 0000874015 us-gaap:USStatesAndPoliticalSubdivisionsMember ions:SecuritiesWithMaturityOfOneYearOrLessMember 2014-12-31 0000874015 ions:RegulusTherapeuticsMember us-gaap:EquitySecuritiesMember 2014-12-31 0000874015 us-gaap:EquitySecuritiesMember 2015-12-31 0000874015 us-gaap:EquitySecuritiesMember ions:RegulusTherapeuticsMember 2015-12-31 0000874015 us-gaap:EquitySecuritiesMember 2014-12-31 0000874015 us-gaap:USTreasurySecuritiesMember 2015-12-31 0000874015 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-12-31 0000874015 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000874015 us-gaap:USStatesAndPoliticalSubdivisionsMember 2015-12-31 0000874015 ions:LeasesAndOtherObligationsMember 2015-12-31 0000874015 ions:LongTermFinancingLiabilityForLeasedFacilityMember 2014-12-31 0000874015 us-gaap:LoansPayableMember 2015-12-31 0000874015 us-gaap:LoansPayableMember 2014-12-31 0000874015 ions:LeasesAndOtherObligationsMember 2014-12-31 0000874015 ions:LongTermFinancingLiabilityForLeasedFacilityMember 2015-12-31 0000874015 ions:ConvertibleSeniorNotes1PercentMember us-gaap:ConvertibleSubordinatedDebtMember 2014-11-30 0000874015 ions:ConvertibleSeniorNotes1PercentMember us-gaap:ConvertibleSubordinatedDebtMember 2014-11-01 2014-11-30 0000874015 ions:ConvertibleSeniorNotes275PercentMember us-gaap:ConvertibleSubordinatedDebtMember 2014-11-30 0000874015 ions:ConvertibleSeniorNotes275PercentMember us-gaap:ConvertibleSubordinatedDebtMember 2014-11-01 2014-11-30 0000874015 us-gaap:ConvertibleSubordinatedDebtMember ions:ConvertibleSeniorNotes275PercentMember 2015-01-01 2015-12-31 0000874015 us-gaap:ConvertibleSubordinatedDebtMember ions:ConvertibleSeniorNotes1PercentMember 2015-01-01 2015-12-31 0000874015 ions:ConvertibleSeniorNotes275PercentMember us-gaap:ConvertibleSubordinatedDebtMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2015-01-01 2015-12-31 0000874015 ions:MorganStanleyPrivateBankNationalAssociationMember us-gaap:RevolvingCreditFacilityMember 2015-01-01 2015-12-31 0000874015 us-gaap:SubsequentEventMember us-gaap:RevolvingCreditFacilityMember ions:MorganStanleyPrivateBankNationalAssociationMember 2016-02-25 0000874015 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember ions:MorganStanleyPrivateBankNationalAssociationMember 2015-01-01 2015-12-31 0000874015 ions:MorganStanleyPrivateBankNationalAssociationMember us-gaap:RevolvingCreditFacilityMember 2015-12-31 0000874015 ions:LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember 2015-12-31 0000874015 ions:AkceaTherapeuticsMember ions:OfficeAndLaboratorySpaceMember 2015-01-01 2015-12-31 0000874015 ions:OfficeAndLaboratorySpaceMember us-gaap:BuildingMember 2015-01-01 2015-12-31 0000874015 us-gaap:ManufacturingFacilityMember ions:OfficeAndLaboratorySpaceMember 2015-01-01 2015-12-31 0000874015 ions:OfficeAndLaboratorySpaceMember us-gaap:BuildingMember ions:AkceaTherapeuticsMember 2015-01-01 2015-12-31 0000874015 ions:OfficeAndLaboratorySpaceMember 2014-01-01 2014-12-31 0000874015 ions:OfficeAndLaboratorySpaceMember 2015-01-01 2015-12-31 0000874015 ions:OfficeAndLaboratorySpaceMember 2013-01-01 2013-12-31 0000874015 ions:OfficeAndLaboratorySpaceMember 2014-12-31 0000874015 ions:OfficeAndLaboratorySpaceMember 2015-12-31 0000874015 ions:PrimaryResearchAndDevelopmentFacilityMember 2015-01-01 2015-12-31 0000874015 ions:PrimaryResearchAndDevelopmentFacilityMember 2015-12-31 0000874015 ions:PrimaryResearchAndDevelopmentFacilityMember 2014-12-31 0000874015 2010-03-01 2010-03-31 0000874015 us-gaap:PreferredStockMember 2015-12-31 0000874015 us-gaap:SeriesCPreferredStockMember 2014-12-31 0000874015 us-gaap:PreferredStockMember 2014-12-31 0000874015 us-gaap:CommonStockMember 2014-12-31 0000874015 us-gaap:CommonStockMember 2015-12-31 0000874015 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0000874015 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0000874015 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0000874015 ions:StockOptionPlan1989Member 2015-12-31 0000874015 ions:BroadBasedEquityIncentivePlan2000Member 2015-12-31 0000874015 ions:EmployeeStockPurchasePlanMember 2015-12-31 0000874015 ions:NonemployeeDirectorsStockOptionPlan2002Member 2015-05-31 0000874015 ions:EquityIncentivePlan2011Member 2015-06-30 0000874015 ions:NonemployeeDirectorsStockOptionPlan2002Member 2015-06-30 0000874015 ions:EquityIncentivePlan2011Member 2015-05-31 0000874015 ions:BroadBasedEquityIncentivePlan2000Member 2015-01-01 2015-12-31 0000874015 ions:EquityIncentivePlan2011Member us-gaap:RestrictedStockUnitsRSUMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000874015 ions:EquityIncentivePlan2011Member us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-12-31 0000874015 us-gaap:StockOptionMember us-gaap:MinimumMember ions:EquityIncentivePlan2011Member 2015-01-01 2015-12-31 0000874015 ions:StockOptionPlan1989Member 2015-01-01 2015-12-31 0000874015 ions:BroadBasedEquityIncentivePlan2000Member us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-01-01 2015-12-31 0000874015 ions:StockOptionPlan1989Member us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-01-01 2015-12-31 0000874015 us-gaap:MinimumMember ions:BroadBasedEquityIncentivePlan2000Member 2015-01-01 2015-12-31 0000874015 ions:BroadBasedEquityIncentivePlan2000Member us-gaap:MaximumMember 2015-01-01 2015-12-31 0000874015 ions:NonemployeeDirectorsStockOptionPlan2002Member 2015-01-01 2015-12-31 0000874015 ions:EquityIncentivePlan2011Member 2015-12-31 0000874015 ions:NonemployeeDirectorsStockOptionPlan2002Member 2015-12-31 0000874015 us-gaap:ShareBasedCompensationAwardTrancheOneMember ions:NonemployeeDirectorsStockOptionPlan2002Member 2015-01-01 2015-12-31 0000874015 ions:EmployeeStockPurchasePlanMember 2009-06-01 2009-06-30 0000874015 ions:EmployeeStockPurchasePlanMember 2015-01-01 2015-12-31 0000874015 us-gaap:StockOptionMember 2014-12-31 0000874015 us-gaap:StockOptionMember 2015-01-01 2015-12-31 0000874015 us-gaap:StockOptionMember 2015-12-31 0000874015 us-gaap:StockOptionMember 2013-01-01 2013-12-31 0000874015 us-gaap:StockOptionMember 2014-01-01 2014-12-31 0000874015 us-gaap:RestrictedStockUnitsRSUMember 2014-12-31 0000874015 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0000874015 us-gaap:RestrictedStockUnitsRSUMember 2014-01-01 2014-12-31 0000874015 us-gaap:RestrictedStockUnitsRSUMember 2013-01-01 2013-12-31 0000874015 ions:ResearchDevelopmentAndPatentsMember 2015-01-01 2015-12-31 0000874015 ions:AkceaTherapeuticsMember 2015-01-01 2015-12-31 0000874015 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-12-31 0000874015 ions:ResearchDevelopmentAndPatentsMember 2014-01-01 2014-12-31 0000874015 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-12-31 0000874015 ions:ResearchDevelopmentAndPatentsMember 2013-01-01 2013-12-31 0000874015 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-12-31 0000874015 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0000874015 ions:BoardOfDirectorStockOptionMember 2014-01-01 2014-12-31 0000874015 us-gaap:EmployeeStockMember 2013-01-01 2013-12-31 0000874015 us-gaap:EmployeeStockMember 2015-01-01 2015-12-31 0000874015 us-gaap:EmployeeStockMember 2014-01-01 2014-12-31 0000874015 ions:BoardOfDirectorStockOptionMember 2013-01-01 2013-12-31 0000874015 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0000874015 us-gaap:StateAndLocalJurisdictionMember us-gaap:TaxYear2009Member us-gaap:CaliforniaFranchiseTaxBoardMember 2015-01-01 2015-12-31 0000874015 us-gaap:ResearchMember us-gaap:TaxYear2009Member us-gaap:CaliforniaFranchiseTaxBoardMember 2014-12-01 2014-12-31 0000874015 us-gaap:DomesticCountryMember 2015-12-31 0000874015 us-gaap:StateAndLocalJurisdictionMember 2015-12-31 0000874015 us-gaap:ResearchMember us-gaap:InternalRevenueServiceIRSMember 2015-12-31 0000874015 us-gaap:CaliforniaFranchiseTaxBoardMember us-gaap:ResearchMember 2015-12-31 0000874015 ions:AstraZenecaMember ions:CardiometabolicAndRenalDiseasesMember ions:CollaborativeArrangementJuly2015Member 2015-07-01 2015-07-31 0000874015 ions:CardiometabolicAndRenalDiseasesMember ions:CollaborativeArrangementJuly2015Member ions:LicenseAndSubstantiveMilestonesMember ions:AstraZenecaMember 2015-12-31 0000874015 ions:CollaborativeArrangementDecember2012Member ions:AstraZenecaMember ions:OncologyMember 2015-12-31 0000874015 ions:CollaborativeArrangementJuly2015Member ions:RegulatoryMilestonesMember ions:CardiometabolicAndRenalDiseasesMember ions:AstraZenecaMember 2015-12-31 0000874015 ions:CardiometabolicAndRenalDiseasesMember ions:AstraZenecaMember ions:DevelopmentMilestonesMember ions:CollaborativeArrangementJuly2015Member 2015-12-31 0000874015 ions:AstraZenecaMember ions:CollaborativeArrangementDecember2012Member ions:OncologyMember ions:RegulatoryMilestonesMember 2015-12-31 0000874015 ions:AstraZenecaMember ions:DevelopmentMilestonesMember ions:CollaborativeArrangementDecember2012Member ions:OncologyMember 2015-12-31 0000874015 ions:CardiometabolicAndRenalDiseasesMember ions:AstraZenecaMember ions:CollaborativeArrangementJuly2015Member 2015-12-31 0000874015 ions:AstraZenecaMember ions:CollaborativeArrangementDecember2012Member ions:OncologyMember 2012-01-01 2012-12-31 0000874015 ions:AstraZenecaMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:AstraZenecaMember 2014-01-01 2014-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:AstraZenecaMember 2013-01-01 2013-12-31 0000874015 ions:AstraZenecaMember ions:OncologyMember ions:CollaborativeArrangementDecember2012Member 2012-12-01 2013-06-30 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:AstraZenecaMember 2015-12-31 0000874015 ions:AstraZenecaMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2014-12-31 0000874015 ions:OncologyMember us-gaap:SubsequentEventMember ions:CollaborativeArrangementAmendedJanuary2016Member ions:AstraZenecaMember 2016-01-31 0000874015 ions:CardiometabolicAndRenalDiseasesMember ions:CollaborativeArrangementJuly2015Member ions:AstraZenecaMember 2015-01-01 2015-12-31 0000874015 ions:AstraZenecaMember us-gaap:CustomerConcentrationRiskMember ions:CollaborativeArrangementsAndLicensingAgreementsMember us-gaap:SalesRevenueGoodsNetMember 2014-01-01 2014-12-31 0000874015 ions:AstraZenecaMember ions:CollaborativeArrangementsAndLicensingAgreementsMember us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember 2013-01-01 2013-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:AstraZenecaMember us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember 2015-01-01 2015-12-31 0000874015 ions:DrugsToTreatUndisclosedNeurodegenerativeDiseasesMember ions:BiogenMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:DrugsToTreatNeurologicalDisordersUnderCollaborationsMember ions:BiogenMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:BiogenMember ions:Phase2StudiesInInfantsAndChildrenWithSMAMember ions:CollaborativeArrangementJanuary2012Member 2015-01-01 2015-12-31 0000874015 ions:BiogenMember ions:CollaborativeArrangementJanuary2012Member ions:Phase2StudiesInInfantsWithSMAMember 2015-01-01 2015-12-31 0000874015 ions:BiogenMember ions:CollaborativeArrangementJanuary2012Member ions:Phase2StudiesInChildrenWithSMAMember 2015-01-01 2015-12-31 0000874015 ions:NusinersenMember ions:RegulatoryMilestonesMember ions:BiogenMember 2015-12-31 0000874015 ions:BiogenMember ions:NusinersenMember ions:LicenseAndSubstantiveMilestonesMember 2015-12-31 0000874015 ions:BiogenMember ions:DevelopmentMilestonesMember ions:NusinersenMember 2015-12-31 0000874015 ions:NusinersenMember ions:BiogenMember us-gaap:MinimumMember ions:CollaborativeArrangementJanuary2012Member 2015-12-31 0000874015 us-gaap:SubsequentEventMember ions:OpenLabelExtensionStudyForPhase3StudiesInInfantsAndChildrenWithSMAMember ions:NusinersenMember ions:BiogenMember 2016-02-01 2016-02-29 0000874015 ions:NusinersenMember ions:CollaborativeArrangementJanuary2012Member ions:BiogenMember 2015-06-01 2015-06-30 0000874015 ions:BiogenMember ions:StudiesInInfantsAndChildrenWithSMAMember ions:NusinersenMember 2015-01-01 2015-12-31 0000874015 ions:NusinersenMember ions:CollaborativeArrangementJanuary2012Member ions:BiogenMember 2015-12-31 0000874015 ions:BiogenMember ions:IONISDMPK25Member ions:LicenseAndSubstantiveMilestonesMember ions:CollaborativeArrangementJune2012Member 2015-12-31 0000874015 ions:BiogenMember ions:CollaborativeArrangementJune2012Member ions:RegulatoryMilestonesMember ions:IONISDMPK25Member 2015-12-31 0000874015 ions:IONISDMPK25Member ions:CollaborativeArrangementJune2012Member ions:DevelopmentMilestonesMember ions:BiogenMember 2015-12-31 0000874015 ions:AgreementAmendedInJune2015Member ions:IONISDMPK25Member ions:BiogenMember 2015-12-31 0000874015 ions:AgreementAmendedInJune2015Member ions:BiogenMember 2015-11-01 2015-11-30 0000874015 ions:BiogenMember ions:CollaborativeArrangementJune2012Member ions:IONISDMPK25Member 2015-12-31 0000874015 ions:LicenseAndSubstantiveMilestonesMember ions:NeurologyMember ions:CollaborativeArrangementDecember2012Member ions:BiogenMember 2015-12-31 0000874015 ions:NeurologyMember ions:CollaborativeArrangementDecember2012Member ions:BiogenMember ions:RegulatoryMilestonesMember 2015-12-31 0000874015 ions:DevelopmentMilestonesMember ions:NeurologyMember ions:CollaborativeArrangementDecember2012Member ions:BiogenMember 2015-12-31 0000874015 ions:BiogenMember ions:NeurologyMember ions:CollaborativeArrangementDecember2012Member 2015-02-01 2015-02-28 0000874015 us-gaap:SubsequentEventMember ions:NeurologyMember ions:CollaborativeArrangementDecember2012Member ions:BiogenMember 2016-02-01 2016-02-29 0000874015 ions:NeurologyMember ions:BiogenMember ions:CollaborativeArrangementDecember2012Member 2015-12-31 0000874015 ions:BiogenMember ions:AntisenseMoleculeMember ions:CollaborativeArrangementSeptember2013Member ions:RegulatoryMilestonesMember 2015-12-31 0000874015 ions:LicenseAndSubstantiveMilestonesMember ions:AntisenseMoleculeMember ions:BiogenMember ions:CollaborativeArrangementSeptember2013Member 2015-12-31 0000874015 ions:CollaborativeArrangementSeptember2013Member ions:BiogenMember ions:AntisenseMoleculeMember ions:ResearchAndDevelopmentMilestonesMember 2015-12-31 0000874015 ions:CollaborativeArrangementSeptember2013Member ions:BiogenMember ions:OtherModalitiesMember ions:PreSpecifiedEventsMember 2015-12-31 0000874015 ions:CollaborativeArrangementSeptember2013Member ions:BiogenMember ions:OtherModalitiesMember ions:RegulatoryMilestonesMember 2015-12-31 0000874015 ions:BiogenMember ions:ResearchAndDevelopmentMilestonesMember ions:CollaborativeArrangementSeptember2013Member ions:OtherModalitiesMember 2015-12-31 0000874015 ions:CollaborativeArrangementSeptember2013Member ions:StrategicNeurologyMember ions:BiogenMember 2015-12-31 0000874015 ions:BiogenMember ions:StrategicNeurologyMember ions:CollaborativeArrangementSeptember2013Member 2015-12-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:BiogenMember 2013-01-01 2013-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:BiogenMember 2014-01-01 2014-12-31 0000874015 ions:BiogenMember us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:BiogenMember us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember 2013-01-01 2013-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:BiogenMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2014-01-01 2014-12-31 0000874015 ions:BiogenMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:BiogenMember 2014-12-31 0000874015 ions:AgreementEnteredIntoInMay2015Member ions:BayerHealthCareMember 2015-05-01 2015-05-31 0000874015 ions:BayerHealthCareMember ions:AgreementEnteredIntoInMay2015Member 2015-12-31 0000874015 ions:BayerHealthCareMember ions:IONISFXIMember ions:AgreementEnteredIntoInMay2015Member 2015-06-01 2015-06-30 0000874015 ions:DevelopmentMilestonesMember ions:AgreementEnteredIntoInMay2015Member 2015-05-31 0000874015 ions:AgreementEnteredIntoInMay2015Member ions:LicenseFeesMilestonePaymentsAndOtherPaymentsMember 2015-05-31 0000874015 ions:AgreementEnteredIntoInMay2015Member ions:CommercializationMilestonesMember 2015-05-31 0000874015 us-gaap:MinimumMember ions:AgreementEnteredIntoInMay2015Member ions:BayerHealthCareMember 2015-05-01 2015-05-31 0000874015 ions:AgreementEnteredIntoInMay2015Member ions:BayerHealthCareMember 2015-06-01 2015-06-30 0000874015 ions:BayerHealthCareMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:BayerHealthCareMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:BayerHealthCareMember 2015-12-31 0000874015 ions:GenzymeCorporationMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2008-01-01 2008-01-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:GenzymeCorporationMember 2015-12-31 0000874015 ions:GenzymeCorporationMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2013-01-01 2013-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:GenzymeCorporationMember 2015-01-01 2015-12-31 0000874015 ions:GenzymeCorporationMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2014-01-01 2014-12-31 0000874015 ions:GenzymeCorporationMember ions:CollaborativeArrangementsAndLicensingAgreementsMember us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember 2013-01-01 2013-12-31 0000874015 ions:IONISHBVIONISHBVLIONISGSK4LAndIONISRHO25Member ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:GlaxoSmithKlineMember 2015-01-01 2015-12-31 0000874015 ions:GlaxoSmithKlineMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:GlaxoSmithKlineMember ions:IONISHBVAndIONISHBVLMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:GlaxoSmithKlineMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2010-03-01 2010-03-31 0000874015 ions:GlaxoSmithKlineMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:IONISTTRMember ions:GlaxoSmithKlineMember 2015-12-31 0000874015 ions:GlaxoSmithKlineMember ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:DevelopmentMilestonesMember 2015-12-31 0000874015 ions:GlaxoSmithKlineMember ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:PreLicensingMilestonesMember 2015-12-31 0000874015 ions:GlaxoSmithKlineMember ions:RegulatoryMilestonesMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-12-31 0000874015 ions:CommercializationMilestonesMember ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:GlaxoSmithKlineMember 2015-12-31 0000874015 ions:PreSpecifiedEventsMember ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:GlaxoSmithKlineMember 2015-12-31 0000874015 us-gaap:SubsequentEventMember ions:GlaxoSmithKlineMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2016-01-01 2016-01-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:GlaxoSmithKlineMember 2014-01-01 2014-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:GlaxoSmithKlineMember 2013-01-01 2013-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:GlaxoSmithKlineMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2013-01-01 2013-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:GlaxoSmithKlineMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2014-01-01 2014-12-31 0000874015 ions:GlaxoSmithKlineMember us-gaap:SalesRevenueGoodsNetMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:GlaxoSmithKlineMember 2014-12-31 0000874015 ions:CollaborativeArrangementDecember2014Member ions:JanssenBiotechIncMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementDecember2014Member ions:JanssenBiotechIncMember 2015-12-31 0000874015 ions:CollaborativeArrangementDecember2014Member ions:JanssenBiotechIncMember ions:DevelopmentMilestonesMember 2015-12-31 0000874015 ions:CollaborativeArrangementDecember2014Member ions:RegulatoryMilestonesMember ions:JanssenBiotechIncMember 2015-12-31 0000874015 ions:CollaborativeArrangementDecember2014Member ions:CommercializationMilestonesMember ions:JanssenBiotechIncMember 2015-12-31 0000874015 ions:CollaborativeArrangementDecember2014Member ions:JanssenBiotechIncMember 2014-01-01 2014-12-31 0000874015 ions:JanssenBiotechIncMember ions:CollaborativeArrangementDecember2014Member 2013-01-01 2013-12-31 0000874015 ions:RocheMember ions:AgreementEnteredIntoInApril2013Member 2013-04-01 2013-04-30 0000874015 ions:DevelopmentMilestonesMember ions:AgreementEnteredIntoInApril2013Member ions:HttMember ions:RocheMember 2015-12-31 0000874015 ions:AgreementEnteredIntoInApril2013Member ions:RegulatoryMilestonesMember ions:RocheMember ions:HttMember 2015-12-31 0000874015 ions:RocheMember ions:AgreementEnteredIntoInApril2013Member 2013-04-30 0000874015 ions:AgreementEnteredIntoInApril2013Member ions:RocheMember ions:CommercializationMilestonesMember ions:BrainShuttleProgramMember 2015-12-31 0000874015 ions:RocheMember ions:HttMember ions:CommercializationMilestonesMember ions:AgreementEnteredIntoInApril2013Member 2015-12-31 0000874015 ions:DevelopmentRegulatoryAndCommercialMilestonesMember ions:AgreementEnteredIntoInApril2013Member ions:RocheMember 2015-12-31 0000874015 ions:RocheMember ions:AgreementEnteredIntoInApril2013Member 2015-12-31 0000874015 ions:AgreementEnteredIntoInApril2013Member ions:RocheMember ions:CommercializationMilestonesMember ions:BrainShuttleProgramMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:RocheMember 2014-01-01 2014-12-31 0000874015 ions:RocheMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2013-01-01 2013-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:RocheMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:RocheMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2014-01-01 2014-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember us-gaap:CustomerConcentrationRiskMember ions:RocheMember us-gaap:SalesRevenueGoodsNetMember 2015-01-01 2015-12-31 0000874015 ions:RocheMember us-gaap:SalesRevenueGoodsNetMember ions:CollaborativeArrangementsAndLicensingAgreementsMember us-gaap:CustomerConcentrationRiskMember 2013-01-01 2013-12-31 0000874015 ions:RocheMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2014-12-31 0000874015 ions:RocheMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember us-gaap:SeriesAPreferredStockMember ions:AchaogenIncMember 2006-01-01 2006-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AchaogenIncMember 2015-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AchaogenIncMember 2014-09-01 2014-09-30 0000874015 ions:AchaogenIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2015-01-01 2015-12-31 0000874015 ions:AchaogenIncMember ions:PreSpecifiedEventsMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2015-12-31 0000874015 ions:AchaogenIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2014-01-01 2014-12-31 0000874015 ions:AchaogenIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2013-01-01 2013-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AlnylamPharmaceuticalsIncMember 2004-03-01 2004-03-31 0000874015 ions:RegulatoryMilestonesMember ions:AlnylamPharmaceuticalsIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2015-09-30 0000874015 ions:AlnylamPharmaceuticalsIncMember ions:DevelopmentMilestonesMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2015-09-30 0000874015 ions:AlnylamPharmaceuticalsIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:PreSpecifiedEventsMember 2015-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AlnylamPharmaceuticalsIncMember 2015-12-31 0000874015 ions:AlnylamPharmaceuticalsIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2015-01-01 2015-12-31 0000874015 ions:AlnylamPharmaceuticalsIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2014-01-01 2014-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AlnylamPharmaceuticalsIncMember 2013-01-01 2013-12-31 0000874015 ions:AntisenseTherapeuticsLimitedMember us-gaap:MaximumMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2014-12-31 0000874015 ions:AntisenseTherapeuticsLimitedMember us-gaap:MaximumMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2015-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AntisenseTherapeuticsLimitedMember 2014-01-01 2014-12-31 0000874015 ions:AntisenseTherapeuticsLimitedMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2013-01-01 2013-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AntisenseTherapeuticsLimitedMember 2015-01-01 2015-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AtlanticPharmaceuticalsLimitedMember 2007-03-01 2007-03-31 0000874015 ions:RegulatoryMilestonesMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AtlanticPharmaceuticalsLimitedMember 2015-12-31 0000874015 ions:AtlanticPharmaceuticalsLimitedMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2015-12-31 0000874015 ions:AtlanticPharmaceuticalsLimitedMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2014-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AtlanticPharmaceuticalsLimitedMember 2013-01-01 2013-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AtlanticPharmaceuticalsLimitedMember 2015-01-01 2015-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:AtlanticPharmaceuticalsLimitedMember 2014-01-01 2014-12-31 0000874015 ions:OncoGenexTechnologiesIncMember ions:CustirsenMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2015-01-01 2015-12-31 0000874015 ions:OGX225Member ions:OncoGenexTechnologiesIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2003-08-01 2003-08-31 0000874015 ions:RegulatoryMilestonesMember ions:OGX225Member ions:OncoGenexTechnologiesIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2015-12-31 0000874015 ions:OncoGenexTechnologiesIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:DevelopmentMilestonesMember ions:OGX225Member 2015-12-31 0000874015 ions:ApatorsenMember ions:DevelopmentMilestonesMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:OncoGenexTechnologiesIncMember 2015-12-31 0000874015 ions:OGX225Member ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:OncoGenexTechnologiesIncMember ions:DevelopmentAndRegulatoryMilestonesMember 2015-12-31 0000874015 ions:OncoGenexTechnologiesIncMember ions:ApatorsenMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2015-12-31 0000874015 ions:RegulatoryMilestonesMember ions:OncoGenexTechnologiesIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:ApatorsenMember 2015-12-31 0000874015 ions:Phase3StudyMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:ApatorsenMember ions:OncoGenexTechnologiesIncMember 2015-12-31 0000874015 ions:OncoGenexTechnologiesIncMember ions:OGX225Member ions:Phase2StudyMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2015-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:OncoGenexTechnologiesIncMember 2015-01-01 2015-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:OncoGenexTechnologiesIncMember 2013-01-01 2013-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:OncoGenexTechnologiesIncMember 2014-01-01 2014-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:RegulusTherapeuticsIncMember 2015-01-01 2015-12-31 0000874015 ions:RegulusTherapeuticsIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember 2014-01-01 2014-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:RegulusTherapeuticsIncMember 2013-01-01 2013-12-31 0000874015 ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember ions:RegulusTherapeuticsIncMember 2015-12-31 0000874015 ions:RegulusTherapeuticsIncMember ions:SatelliteCompanyCollaborativeArrangementAndLicensingAgreementMember us-gaap:MaximumMember 2015-12-31 0000874015 ions:ChdiFoundationIncMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2014-01-01 2014-12-31 0000874015 ions:ChdiFoundationIncMember ions:CollaborativeArrangementsAndLicensingAgreementsMember 2015-01-01 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:ChdiFoundationIncMember 2015-12-31 0000874015 ions:CollaborativeArrangementsAndLicensingAgreementsMember ions:ChdiFoundationIncMember 2013-01-01 2013-12-31 0000874015 ions:AbbottMolecularIncMember 2009-01-01 2009-01-31 0000874015 ions:AbbottMolecularIncMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000874015 us-gaap:MaximumMember ions:AbbottMolecularIncMember 2015-01-01 2015-12-31 0000874015 ions:AbbottMolecularIncMember 2013-01-01 2013-12-31 0000874015 ions:AbbottMolecularIncMember 2015-01-01 2015-12-31 0000874015 ions:AbbottMolecularIncMember 2014-01-01 2014-12-31 0000874015 ions:InLicensingArrangementMember ions:UniversityOfMassachusettsMember 2015-12-31 0000874015 ions:VervaPharmaceuticalsLtdMember ions:InLicensingArrangementMember 2015-12-31 0000874015 ions:ColdSpringHarborLaboratoryMember ions:InLicensingArrangementMember 2015-12-31 0000874015 us-gaap:OperatingSegmentsMember ions:IonisCoreMember 2014-01-01 2014-12-31 0000874015 us-gaap:IntersegmentEliminationMember 2015-01-01 2015-12-31 0000874015 us-gaap:OperatingSegmentsMember ions:IonisCoreMember 2013-01-01 2013-12-31 0000874015 us-gaap:OperatingSegmentsMember ions:AkceaTherapeuticsMember 2013-01-01 2013-12-31 0000874015 us-gaap:OperatingSegmentsMember ions:AkceaTherapeuticsMember 2014-01-01 2014-12-31 0000874015 us-gaap:OperatingSegmentsMember ions:IonisCoreMember 2015-01-01 2015-12-31 0000874015 us-gaap:OperatingSegmentsMember ions:AkceaTherapeuticsMember 2015-01-01 2015-12-31 0000874015 us-gaap:OperatingSegmentsMember ions:IonisCoreMember 2015-12-31 0000874015 ions:AkceaTherapeuticsMember us-gaap:OperatingSegmentsMember 2015-12-31 0000874015 us-gaap:IntersegmentEliminationMember 2015-12-31 0000874015 ions:PartnerCConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2014-01-01 2014-12-31 0000874015 ions:PartnerBConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2013-01-01 2013-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:PartnerDConcentrationRiskMember 2015-01-01 2015-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:PartnerAConcentrationRiskMember 2014-01-01 2014-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:PartnerFConcentrationRiskMember 2014-01-01 2014-12-31 0000874015 ions:PartnerBConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2015-01-01 2015-12-31 0000874015 ions:PartnerCConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2015-01-01 2015-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:PartnerBConcentrationRiskMember 2014-01-01 2014-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:PartnerDConcentrationRiskMember 2013-01-01 2013-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:PartnerEConcentrationRiskMember 2014-01-01 2014-12-31 0000874015 ions:PartnerAConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2015-01-01 2015-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:PartnerFConcentrationRiskMember 2013-01-01 2013-12-31 0000874015 ions:PartnerCConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2013-01-01 2013-12-31 0000874015 us-gaap:AccountsReceivableMember ions:SignificantPartnersConcentrationRiskMember 2015-01-01 2015-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:PartnerDConcentrationRiskMember 2014-01-01 2014-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:PartnerFConcentrationRiskMember 2015-01-01 2015-12-31 0000874015 us-gaap:SalesRevenueGoodsNetMember ions:PartnerAConcentrationRiskMember 2013-01-01 2013-12-31 0000874015 ions:PartnerEConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2013-01-01 2013-12-31 0000874015 ions:PartnerEConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2015-01-01 2015-12-31 0000874015 us-gaap:AccountsReceivableMember ions:SignificantPartnersConcentrationRiskMember 2014-01-01 2014-12-31 0000874015 2014-01-01 2014-03-31 0000874015 2014-10-01 2014-12-31 0000874015 2015-07-01 2015-09-30 0000874015 2015-04-01 2015-06-30 0000874015 2014-07-01 2014-09-30 0000874015 2015-01-01 2015-03-31 0000874015 2014-04-01 2014-06-30 0000874015 2015-10-01 2015-12-31 0000874015 us-gaap:RestrictedStockMember 2014-10-01 2014-12-31 0000874015 us-gaap:EmployeeStockOptionMember 2014-10-01 2014-12-31 0000874015 us-gaap:RestrictedStockMember 2015-04-01 2015-06-30 0000874015 us-gaap:EmployeeStockOptionMember 2015-04-01 2015-06-30 iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares ions:AccountingUnit ions:Agreement ions:Target ions:Category ions:Stage ions:Segment ions:Company ions:Investment utr:D ions:Building ions:Option ions:Installment ions:Drug ions:Study ions:Candidate ions:Program ions:Partner false --12-31 2015-12-31 Yes No Yes Large Accelerated Filer 5760508916 IONIS PHARMACEUTICALS INC 0000874015 120658638 2015 FY 10-K <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">2. Investments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">As of December 31, 2015, we have primarily invested our excess cash in debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody&#8217;s, S&amp;P or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</div><div><br /></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes the contract maturity of the available-for-sale securities we held as of December 31, 2015:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 50%; border-collapse: collapse;"><tr><td style="width: 87.43%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">One year or less</div></td><td style="width: 2.82%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 9.75%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">49 %</div></td></tr><tr><td style="width: 87.43%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">After one year but within two years</div></td><td style="width: 2.82%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 9.75%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">27 %</div></td></tr><tr><td style="width: 87.43%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">After two years but within three and a half years</div></td><td style="width: 2.82%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #cceeff;">&#160;</td><td style="width: 9.75%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">24 %</div></td></tr><tr><td style="width: 87.43%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total</div></td><td style="width: 2.82%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff;">&#160;</td><td style="width: 9.75%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">100 %</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">As illustrated above, at December 31, 2015, 76 percent of our available-for-sale securities had a maturity of less than two years.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">All of our available-for-sale securities are available to us for use in our current operations. As a result, we categorize all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">At December 31, 2015, we had an ownership interest of less than 20 percent</font>in one private company and two public companies with which we conduct business. The privately held company is Atlantic Pharmaceuticals Limited and the publicly traded companies are Antisense Therapeutics Limited and Regulus. We account for equity investments in the privately held company under the cost method of accounting and we account for equity investments in the publicly traded companies at fair value. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. </div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">During</font> 2015, 2014 and 2013, we realized a net gain on investments we sold of $20.3 million, $21.2 million, and $2.4 million, respectively. Our net gain for 2015 and 2014 was primarily from the $20.2 million and $19.9 million gain we realized when we sold a portion of our stock in Regulus, respectively. We have reflected this gain in a separate line called &#8220;Gain on investment in Regulus Therapeutics Inc.&#8221;,&#160;on our Consolidated Statements of Operations. Our net gain on investments for 2013 related to the sale of stock in several of our satellite companies. As of December 31, 2015, we owned approximately five percent of Regulus&#8217; equity, with a carrying balance of $24.8 million on our consolidated balance sheet.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following is a summary of our investments (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Gross Unrealized</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">December 31, 2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Cost</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Estimated</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Available-for-sale securities (1):</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">181,670</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(250</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">181,425</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">50,559</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">50,541</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,604</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">79,414</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">18</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(88</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">79,344</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total securities with a maturity of one year or less</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">314,247</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(360</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">313,911</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">258,703</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,705</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">257,001</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">38,956</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(244</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">38,712</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,552</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(243</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,312</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total securities with a maturity of more than one year</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">346,211</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,192</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">344,025</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total available-for-sale securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">660,458</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,552</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">657,936</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Equity securities:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Regulus Therapeutics Inc.</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7,162</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">17,630</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,792</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total equity securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7,162</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">17,630</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,792</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total available-for-sale and equity securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">667,620</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">17,660</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,552</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">682,728</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Gross Unrealized</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">December 31, 2014</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Cost</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Estimated</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Available-for-sale securities (1):</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">219,856</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">89</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(89</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">219,856</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">47,496</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(27</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">47,476</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,008</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">45,196</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(53</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">45,162</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total securities with a maturity of one year or less</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">331,556</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">124</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(169</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">331,511</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">152,730</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">16</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(600</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">152,146</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">62,530</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(151</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">62,379</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">60,073</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">32</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(234</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">59,871</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total securities with a maturity of more than one year</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">275,333</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(985</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">274,396</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total available-for-sale securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">606,889</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">172</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,154</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">605,907</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Equity securities:</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Regulus Therapeutics Inc.</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">12,477</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">69,404</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total equity securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">12,477</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">69,404</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total available-for-sale and equity securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">619,366</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">69,576</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,154</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">687,788</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">(1)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">Our available-for-sale securities are held at amortized cost.</td></tr></table></div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">(2)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">Includes investments classified as cash equivalents on our consolidated balance sheet.</td></tr></table></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Investments we consider to be temporarily impaired at December 31, 2015 are as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Less than 12 months of</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Temporary Impairment</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">More than 12 months of</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Temporary Impairment</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Total Temporary</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Impairment</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr style="height: 31px;"><td valign="bottom" style="width: 30%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Number of</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Investments</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Estimated</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Estimated</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Estimated</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">397</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">406,098</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,908</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">16,066</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(47</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">422,164</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,955</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">71,842</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(262</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,001</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">72,843</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(263</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Debt securities issued by states of the United States and political subdivisions of the states</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">230</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">59,882</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(173</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">29,634</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(158</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">89,516</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(331</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total temporarily impaired securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">648</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">540,423</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,346</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">46,701</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(206</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">587,124</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,552</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">We believe that the decline in value of these securities is temporary and primarily related to the change in market interest rates since purchase. We believe it is more likely than not that we will be able to hold these securities to maturity. Therefore, we anticipate full recovery of their amortized cost basis at maturity.</div><div><br /></div></div> 2 648 19 397 230 28355000 17984000 -7812000 -5572000 -7470000 28105000 30451000 66053000 72706000 9900000 7700000 39747000 -13565000 1224509000 1309107000 0 0 170232000 0 170232000 0 0 59314000 0 0 0 0 31383000 0 0 11418000 11418000 0 59314000 31383000 1463000 0 0 0 0 396000 0 1463000 0 396000 43638000 6500000 11418000 15676000 25843000 59314000 5540000 9673000 31383000 1745000 9600000 6800000 23200000 6723000 2256000 0 19728000 2347000 6344000 6622000 6567000 6665000 595000 1133000 415000 6306000 1881000 1305000 123697000 116295000 792468000 586890000 771630000 81881000 0 655335000 956105000 955809000 1004150000 55354000 -103399000 836597000 837003000 59882000 2601000 540423000 406098000 71842000 17630000 69404000 17630000 69404000 89000 24000 19000 32000 124000 7000 0 5000 3000 9000 6000 18000 3000 1000 0 172000 0 16000 48000 30000 0 0 0 0 105033000 0 0 0 0 372002000 2601000 0 0 0 89253000 7500000 800000 0 0 0 0 0 127656000 105033000 19017000 127656000 10000000 438426000 9300000 438426000 372002000 0 2601000 0 89253000 0 0 109855000 19017000 109855000 687788000 682728000 3000 88000 234000 1705000 985000 1154000 151000 53000 2552000 27000 2192000 0 244000 360000 19000 169000 89000 600000 250000 243000 29634000 1001000 16066000 46701000 0 262000 1908000 3000 173000 2346000 17660000 69576000 2552000 1154000 12477000 7162000 7162000 12477000 2601000 89516000 72843000 422164000 587124000 2552000 1955000 331000 263000 3000 346211000 275333000 660458000 314247000 2604000 331556000 606889000 62530000 79414000 19008000 60073000 48552000 181670000 152730000 38956000 50559000 258703000 47496000 219856000 45196000 667620000 619366000 0 1000 206000 47000 158000 24792000 81881000 24792000 81881000 313911000 181425000 62379000 274396000 38712000 605907000 47476000 19017000 331511000 50541000 45162000 657936000 152146000 59871000 79344000 2601000 219856000 48312000 257001000 344025000 585834000 650386000 0 0 88902000 104680000 0 104680000 88902000 0 128797000 142998000 124482000 159973000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">6. Collaborative Arrangements and Licensing Agreements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Strategic Partnerships</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">AstraZeneca</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Cardiometabolic and Renal Diseases Collaboration</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In July 2015, we and AstraZeneca formed a strategic collaboration to discover and develop antisense therapies for treating cardiovascular and metabolic diseases primarily focused on targets in the kidney, and renal diseases. As part of the agreement, we granted AstraZeneca an exclusive license to a preclinical program and the option to license a drug for each target advanced under this research collaboration. Upon acceptance of a drug development candidate, AstraZeneca will be responsible for all further global development, regulatory and commercialization activities for such drug.&#160;Under the terms of the agreement, we received a $65 million upfront payment. Since this agreement has multiple elements, we evaluated the deliverables in this arrangement and determined that none of the deliverables have stand-alone value because of the early stage of research for this collaboration. Therefore, we concluded there is one unit of accounting and we are amortizing the $65 million upfront payment through August 2021.&#160;We are eligible to receive license fees and substantive milestone payments of up to more than $4 billion, including up to $1.1 billion for the achievement of development milestones and up to $2.9 billion for regulatory milestones. We will earn the next milestone payment of $25 million under this collaboration upon identification of the first drug candidate to move into development.&#160;In addition, we are eligible to receive tiered royalties up to the low teens on sales from any product that AstraZeneca successfully commercializes under this collaboration agreement.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Oncology Collaboration</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In December&#160;2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense drugs for cancer.&#160;As part of the agreement, we granted AstraZeneca an exclusive license to develop and commercialize IONIS-STAT3-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> for the treatment of cancer and an option to license up to three anti-cancer drugs under a separate research program. AstraZeneca is responsible for all global development, regulatory and commercialization activities for IONIS-STAT3-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. We and AstraZeneca have evaluated IONIS-STAT3-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> in patients with advanced metastatic hepatocellular carcinoma and advanced lymphoma. AstraZeneca is evaluating IONIS-STAT3-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> in combination with MEDI4736, AstraZeneca's investigational anti-PD-L1 drug, in patients with head and neck cancer. For the research program, we are responsible for identifying a development candidate for each of the three anti-cancer research programs. AstraZeneca has the option to license drugs resulting from each of the three anti-cancer research programs, and if AstraZeneca exercises its option for a drug, it will be responsible for all further global development, regulatory and commercialization activities for such drug.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Under the terms of the agreement, we received $31 million in upfront payments. We recorded revenue of $11.5 million upon receipt of these payments and we have amortized $11.9 million into revenue as we have performed development activities under this collaboration. We are recognizing the remaining $7.6 million related to the option to license three drugs under the&#160;research program through December 2016. In January 2016, we and AstraZeneca amended the agreement for the research program.<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</sub>Under the amended terms of the agreement, we can earn an additional $5 million in milestone payments for advancing a drug under our research program.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We are eligible to receive milestone payments and license fees from AstraZeneca as programs advance in development.&#160;In addition, we are eligible to receive tiered royalties up to the low to mid-teens on sales from any drugs resulting from these programs. If AstraZeneca successfully develops IONIS-STAT3-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> and the three drugs under the research program, we could receive license fees and substantive milestone payments of nearly $750 million, including up to $226 million for the achievement of development milestones and up to $485 million for the achievement of regulatory milestones.&#160;From inception through December 2015, we have received $63.5 million in milestone payments and upfront fees under this oncology collaboration. We will earn the next milestone payment of $15 million if we further advance a cancer drug under our research program with AstraZeneca.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Each of our agreements with AstraZeneca will continue until the expiration of all payment obligations under the applicable agreement. In addition, the agreement, or any program under the applicable agreement, may terminate early under the following situations:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">AstraZeneca may terminate the agreement or any program at any time by providing written notice to us;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">AstraZeneca may terminate the agreement or any program by providing written notice if we undergo a change of control with a third party; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Either we or AstraZeneca may terminate the agreement or any program by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement, or the entire agreement if the other party becomes insolvent.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015, 2014 and 2013 we earned revenue of $6.4 million, $27.7 million and $29.1 million, respectively, from our relationship with AstraZeneca, which represented two percent, 13 percent and 20 percent, respectively, of our total revenue for those periods. Our balance sheets at December 31, 2015 and 2014 included deferred revenue of $63.3 million and $4.4 million, respectively, related to our relationship with AstraZeneca.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Biogen</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have established four strategic collaborations with Biogen focused on using antisense technology to advance the treatment of neurological and neuromuscular disorders. These collaborations combine our expertise in creating antisense drugs with Biogen's expertise in developing therapies for neurological disorders. We and Biogen are currently developing six drugs to treat neurological diseases under these collaborations, including nusinersen, IONIS-DMPK-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>, IONIS-SOD1<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>, formerly ISIS-BIIB3<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>, and three drugs to treat undisclosed neurodegenerative diseases, IONIS-BIIB4<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>, IONIS-BIIB5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>,<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</sub>and IONIS-BIIB6<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. In addition to these six drugs, we and Biogen are evaluating numerous additional targets for the development of drugs to treat neurological diseases.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: left; text-indent: 36pt;">Nusinersen</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize nusinersen for the treatment of SMA. We are currently conducting a Phase 3 study evaluating nusinersen in infants with SMA, which we expect to be fully enrolled in the second quarter of 2016. We are also conducting a Phase 3 study evaluating nusinersen in children with SMA, for which we have completed target enrollment. In addition, we are evaluating nusinersen in two Phase 2 open-label studies, one in children with SMA and one in infants with SMA.&#160;Patients from all of these studies continue to have access to nusinersen through open-label extension dosing. We are responsible for completing the studies we are currently conducting. Biogen has the option to license nusinersen. If Biogen exercises its option, it will pay us a license fee and will assume all other global development, regulatory and commercialization responsibilities. Biogen may exercise this option upon completion of and data review of the first successful Phase 2/3 trial or completion of both Phase 2/3 trials. An amendment in December 2014 provided for additional opt-in scenarios, based on the filing or the acceptance of a new drug application or marketing authorization application with the FDA or EMA. In June 2015, we and Biogen amended the development plan for nusinersen to include conducting the open-label extension study for the Phase 3 studies in infants and children. As a result of the change to the development plan, we earned an $11 million milestone payment when we initiated the Phase 3 open-label extension study and we are eligible to earn additional milestone and other payments.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Under the terms of the agreement, we received an upfront payment of $29 million, which we are amortizing through February 2017. We are also eligible to receive a license fee, milestone payments and tiered royalties up to the mid-teens on any sales of nusinersen. Over the term of the collaboration, we are eligible to receive up to $346 million in a license fee and payments, including up to $121 million in substantive milestone and other payments associated with the clinical development of nusinersen prior to licensing and up to $150 million in substantive milestone payments if Biogen achieves pre-specified regulatory milestones.&#160;From inception through December 2015, we have received more than $130 million in milestone payments and upfront fees for advancing nusinersen. In 2015, we earned $40 million for advancing the studies we are conducting in infants and children with SMA. In addition we earned a $2 million milestone payment in February 2016 for further advancing the Phase 3 study of nusinersen in infants. We will earn the next milestone payment of $2 million if we further advance the Phase 3 study of nusinersen in infants.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">IONIS-DMPK-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In June&#160;2012, we and Biogen entered into a second and separate collaboration agreement to develop and commercialize a novel antisense drug, IONIS-DMPK-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx,</sub> targeting DMPK for the treatment of myotonic dystrophy type 1, or DM1. We are responsible for global development of the drug through the completion of the first Phase 2 clinical trial.&#160;We are currently evaluating IONIS-DMPK-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> in a Phase 1/2 clinical study in patients with DM1. Biogen has the option to license the drug through the completion of the first Phase 2 trial. If Biogen exercises its option, it will assume all other global development, regulatory and commercialization responsibilities. Under the terms of the agreement, we received an upfront payment of $12 million, which we are amortizing through October 2018. In June 2015, we and Biogen amended the development plan for IONIS-DMPK-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> under which we are eligible to earn additional milestone payments of up to $4.2 million for further advancing the Phase 1/2 study of IONIS-DMPK-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. Over the term of the collaboration, we are eligible to receive up to $263 million in a license fee and substantive milestone payments, including up to $63 million in development milestone payments and up to $130 million in milestone payments if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on any sales of IONIS-DMPK-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. From inception through December 2015, we have received nearly $39 million in milestone payments and upfront fees for advancing IONIS-DMPK-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>, including a $2.8 million milestone payment we earned in November 2015. We will earn the next milestone payment of $1.4 million if we further advance the Phase 1/2 study for IONIS-DMPK-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> and we will earn a $35 million milestone payment if we initiate a Phase 2 study for IONIS-DMPK-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Neurology</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In December&#160;2012, we and Biogen entered into a third and separate collaboration agreement to develop and commercialize novel antisense drugs to up to three targets to treat neurological or neuromuscular diseases. We are responsible for the development of each of the drugs through the completion of the initial Phase 2 clinical study for such drug. Biogen has the option to license a drug from each of the three programs through the completion of the first Phase 2 study for each program. We are currently advancing IONIS-BIIB4<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> under this collaboration. If Biogen exercises its option for a drug, it will assume all further global development, regulatory and commercialization responsibilities for that drug.&#160;Under the terms of the agreement, we received an upfront payment of $30 million, which we are amortizing through December 2020. Over the term of the collaboration, we are eligible to receive up to $259 million in a license fee and substantive milestone payments per program. We are eligible to receive up to $59 million in development milestone payments to support research and development of each program, including amounts related to the cost of clinical trials. We are also eligible to receive up to $130 million in milestone payments per program if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any drugs resulting from each of the three programs. In February 2015, we earned a $10 million milestone payment when we initiated an IND-enabling toxicology study of IONIS-BIIB4<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx,</sub> a drug for an undisclosed target designed to treat a neurodegenerative disease. From inception through December 2015, we have received $40 million in milestone payments and upfront fees under this collaboration, not including the $3 million milestone payment we earned in February 2016. We will earn the next milestone payment of up to $10 million for the continued development of IONIS-BIIB4<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: left; text-indent: 36pt;">Strategic Neurology</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In September&#160;2013, we and Biogen entered into a fourth and separate collaboration agreement, which is a long-term strategic relationship focused on applying antisense technology to advance the treatment of neurological diseases. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for neurological diseases and has the option to license drugs resulting from this collaboration. The exclusivity for neurological diseases will last through September 2019, and may be extended for any drug development programs being pursued under the collaboration. We will usually be responsible for drug discovery and early development of antisense drugs and Biogen will have the option to license antisense drugs after Phase 2 proof of concept. We are currently advancing three drugs, IONIS-SOD1<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>, IONIS-BIIB5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>, and IONIS-BIIB6<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> under this collaboration. If Biogen exercises its option for a drug, it will assume all further global development, regulatory and commercialization responsibilities for that drug. Biogen will be responsible for all of the drug discovery and development activities for drugs using other modalities.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Under the terms of the agreement, we received an upfront payment of $100 million and are eligible to receive milestone payments, license fees and royalty payments for all drugs developed through this collaboration, with the specific amounts dependent upon the modality of the molecule advanced by Biogen. If we have a change of control during the first six years of the collaboration, we may be required to refund Biogen a portion of the $100 million upfront payment, with the amount of the potential refund decreasing ratably as we progress through the initial six-year term of the collaboration. We are amortizing the $100 million upfront payment through September 2019. Because the amortization period for the upfront payment will never be less than the initial six-year term of the collaboration, the amount of revenue we recognize from the upfront payment will never exceed the amount that Biogen could potentially require us to refund.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">For each antisense molecule that is chosen for drug discovery and development under this collaboration, we are eligible to receive up to approximately $260 million in a license fee and substantive milestone payments. We are eligible to receive up to approximately $60 million for the achievement of research and development milestones, including amounts related to the cost of clinical trials, and up to $130 million for the achievement of regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any antisense drugs developed under this collaboration. If other modalities are chosen, such as small molecules or monoclonal antibodies, we are eligible to receive up to $90 million in substantive milestone payments, including up to $35 million for the achievement of research and development milestones and up to $55 million for the achievement of regulatory milestones. In addition, we are eligible to receive tiered single-digit royalties on sales from any drugs using non-antisense modalities developed under this collaboration. From inception through December 2015, we have received $135 million in milestone payments and upfront fees under this collaboration. In December 2015, we earned a $5 million milestone payment for validating a fifth target under this collaboration. We will earn the next milestone payment of up to $10 million if we choose another target to advance under this collaboration.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Each of our agreements with Biogen will continue until the earlier of the date all of Biogen's options to obtain the exclusive licenses under the applicable agreement expire unexercised or, if Biogen exercises its option, until the expiration of all payment obligations under the applicable agreement. In addition, each agreement, or any program under an agreement, may terminate early under the following situations:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Biogen may terminate the agreement or any program at any time by providing written notice to us;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Under specific circumstances, if we are acquired by a third party with a product that directly competes with a compound being developed under the agreement, Biogen may terminate the affected program by providing written notice to us;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">If, within a specified period of time, any required clearance of a transaction contemplated by an agreement under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, is not received, then either we or Biogen may terminate the affected program by providing written notice to the other party; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Either we or Biogen may terminate any program by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement with respect to the affected program, or the entire agreement if the other party becomes insolvent.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015, 2014 and 2013, we earned revenue of $106.2 million, $123.2 million and $37.0 million, respectively, from our relationship with Biogen, which represented 37 percent, 58 percent and 25 percent, respectively, of our total revenue for those periods. Our balance sheets at December 31, 2015 and 2014 included deferred revenue of $91.6 million and $118.1 million, respectively, related to our relationship with Biogen.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Research, Development and Commercialization Partners</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Bayer</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> for the prevention of thrombosis. We are responsible for completing our ongoing Phase 2 study of IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx </sub>in patients with end-stage renal disease on hemodialysis. Bayer is responsible for all other development and commercialization activities for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Under the terms of the agreement, we are eligible to receive $155 million in near-term payments, including a $100 million upfront payment we received in the second quarter of 2015 and a $55 million milestone payment that we are eligible to receive upon advancement of the program following the Phase 2 study in patients with end-stage renal disease on hemodialysis. We recorded revenue of $91.2 million related to the license for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> in June 2015 and we are recognizing the remaining $8.8 million related to the ongoing development activities for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx </sub>through July 2016.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Over the term of the agreement, we are eligible to receive up to $375 million in license fees, substantive milestone payments and other payments, including up to $120 million for the achievement of development milestones and up to $110 million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties in the low-to-high 20 percent range on gross margins of IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. We will earn the next milestone payment of $55 million upon the advancement of the program following the ongoing Phase 2 study of IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx </sub>in patients with end-stage renal disease on hemodialysis.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our agreement with Bayer will continue until the expiration of all payment obligations under the agreement. In addition, the agreement, or any program under the agreement, may terminate early under the following situations:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Bayer may terminate the agreement or any program at any time by providing written notice to us;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Either we or Bayer may terminate the agreement or any program by providing written notice to the other party upon the other party&#8217;s uncured failure to perform a material obligation under the agreement, or the entire agreement if the other party becomes insolvent.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015 we earned revenue of $93.4 million, from our relationship with Bayer, which represented 33 percent of our total revenue for the period. Our consolidated balance sheet at December 31, 2015 included deferred revenue of $6.7 million related to our relationship with Bayer.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Genzyme Corporation, a Sanofi company</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In January&#160;2008, we entered into an alliance with Genzyme focused on the licensing and co-development of Kynamro. The license and co-development agreement provided Genzyme with exclusive worldwide rights for all therapeutic purposes to our patents and know-how related to Kynamro. The transaction included a $175 million licensing fee and a $150 million equity investment by Genzyme in our stock. From inception through December 2015, we have received $375 million in a license fee, milestone payments and an equity investment for advancing Kynamro in development. In January 2016, we terminated our license agreement with Genzyme.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015 and 2014, we did not earn any revenue from our relationship with Genzyme. During 2013, we earned revenue of $32.5 million from our relationship with Genzyme, which represented 22 percent of our total revenue for that year.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">GSK</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In March 2010, we entered into an alliance with GSK using our antisense drug discovery platform to discover and develop new drugs against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness. Our alliance currently comprises five drugs in development, including our Phase 3 drug IONIS-TTR<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. GSK has the exclusive option to license drugs resulting from this alliance at Phase 2 proof-of-concept for a license fee. If GSK exercises its exclusive option for any drugs resulting from this alliance, it will be responsible for all further global development, regulatory and commercialization activities for such drug. Under the terms of the agreement, we received $38 million in upfront and expansion payments, which we are amortizing through March 2017.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In October 2012, we and GSK amended the original agreement to reflect an accelerated clinical development plan for IONIS-TTR<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx.</sub> We are currently evaluating IONIS-TTR<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> in a broad Phase 3 development program. We have completed target enrollment in the Phase 3 study in patients with FAP. From inception through December 2015, we have earned $60 million from GSK related to the development of IONIS-TTR<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>, primarily in milestone payments. We are also eligible to earn an additional $10 million pre-licensing milestone payment associated with our ongoing study of IONIS-TTR<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. In addition, under the amended agreement, we and GSK increased the regulatory and commercial milestone payments we can earn should IONIS-TTR<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> receive marketing authorization and meet pre-agreed sales targets. In September 2015, we and GSK amended the development plan for IONIS-TTR<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> to support the Phase 3 cardiomyopathy study, which GSK plans to conduct.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In addition to IONIS-TTR<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>, we have four drugs in development with GSK. We are developing two antisense drugs we designed to reduce the production of viral proteins associated with hepatitis B virus, or HBV, infection; IONIS-HBV<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> and IONIS-HBV-L<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>, a follow-on drug using our LICA technology. We are also developing IONIS-GSK4-L<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> and IONIS-RHO-2.5<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx,</sub> which are antisense drugs we designed to treat ocular diseases.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Under our agreement, if GSK successfully develops all five drugs for one or more indications and achieves pre-agreed sales targets, we could receive license fees and substantive milestone payments of more than $1.0 billion, including up to $183.5 million for the achievement of development milestones, up to $363.5 million for the achievement of regulatory milestones and up to $348 million for the achievement of commercialization milestones. Through December 2015, we have received $135 million in milestone payments and upfront fees under this alliance with GSK, not including a $1.5 million payment we earned in January 2016 when GSK further advanced IONIS-HBV-L<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. We will earn the next milestone payment of up to $5 million if we further advance a program under this collaboration. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any product that GSK successfully commercializes under this alliance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our alliance with GSK will continue until the earlier of the date that all of GSK's options to obtain the exclusive licenses under the agreement expire unexercised or, if GSK exercises its option, until the expiration of all payment obligations under the agreement. In addition, the agreement, or any program under the agreement, may terminate early under the following situations:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">GSK may terminate any program, other than the IONIS-TTR<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> program, at any time by providing written notice to us;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">GSK may terminate the IONIS-TTR<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> program by providing written notice to us after reviewing specific data from the Phase 3 study for the program; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Either we or GSK may terminate any program by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement with respect to the affected program, or the entire agreement if the other party becomes insolvent.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015, 2014 and 2013, we earned revenue of $33.3 million, $37.3 million and $35.3 million, respectively, from our relationship with GSK, which represented 12 percent, 17 percent and 24 percent, respectively, of our total revenue for those years.&#160;Our balance sheets at December 31, 2015 and 2014 included deferred revenue of $4.9 million and $10.0 million, respectively, related to our relationship with GSK.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Janssen Biotech, Inc., a pharmaceutical company of Johnson &amp; Johnson</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In December&#160;2014, we entered into a collaboration agreement with Janssen Biotech, Inc. to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders of the gastrointestinal tract. Janssen has the option to license drugs from us through the designation of a development candidate for up to three programs. Prior to option exercise we are responsible for the discovery activities to identify a development candidate. If Janssen exercises an option for one of the programs, it will be responsible for the global development, regulatory and commercial activities under that program. Under the terms of the agreement, we received $35 million in upfront payments, which we are amortizing through December 2018. We are eligible to receive nearly $800 million in license fees and substantive milestone payments for these programs, including up to $175 million for the achievement of development milestones, up to $420 million for the achievement of regulatory milestones and up to $180 million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties up to the near teens on sales from any drugs resulting from this collaboration. We will earn the next milestone payment of $5 million if Janssen chooses another target to advance under this collaboration.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our agreement with Janssen will continue until the earlier of the date that all of Janssen&#8217;s options to obtain the exclusive licenses under the agreement expire unexercised or, if Janssen exercises its option, until the expiration of all payment obligations under the agreement. In addition, the agreement, or any program under the agreement, may terminate early under the following situations:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Janssen may terminate the agreement or any program at any time by providing written notice to us; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Either we or Janssen may terminate any program by providing written notice to the other party upon the other party&#8217;s uncured failure to perform a material obligation under the agreement, or the entire agreement if the other party becomes insolvent.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015 we earned revenue of $8.9 million from our relationship with Janssen. During 2014 and 2013 we did not earn any revenue from our relationship with Janssen. Our balance sheet at December 31, 2015 included deferred revenue of $26.3 million related to our relationship with Janssen.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Roche</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In April&#160;2013, we formed an alliance with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, to develop treatments for Huntington's disease, or HD, based on our antisense technology. Roche has the option to license the drugs from us through the completion of the first Phase 1 trial. Under the agreement, we are responsible for the discovery and development of an antisense drug targeting huntingtin, or HTT, protein. We are currently evaluating a drug targeting HTT, IONIS-HTT<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>, in a Phase 1/2 clinical study in patients with early stage HD. If Roche exercises its option, it will be responsible for global development, regulatory and commercialization activities for any drug arising out of the collaboration.&#160;We are also working collaboratively with Roche on the discovery of an antisense drug utilizing Roche's "brain shuttle" program.&#160;Under the terms of the agreement, we received an upfront payment of $30 million in April&#160;2013, which we are amortizing through January 2017.&#160;We are eligible to receive up to $362 million in a license fee and substantive milestone payments including up to $67 million for the achievement of development milestones, up to $170 million for the achievement of regulatory milestones and up to $80 million for the achievement of commercialization milestones. In addition, we are eligible to receive up to $136.5 million in milestone payments for each additional drug successfully developed and up to $50 million in commercial milestone payments if a drug using Roche's proprietary brain shuttle technology is successfully commercialized.&#160;We are also eligible to receive tiered royalties up to the mid-teens on any product sales of drugs resulting from this alliance. Through December 2015, we have received $52 million in milestone payments and upfront fees under this alliance with Roche. We will earn the next milestone payment of $10 million if Roche initiates a Phase 2 trial for IONIS-HTT<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our alliance with Roche will continue until the earlier of the date Roche's option to obtain the exclusive license under the agreement expires unexercised or, if Roche exercises its option, until the expiration of all payment obligations under the agreement. In addition, the agreement may terminate early under the following situations:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Roche may terminate the agreement at any time by providing written notice to us;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Either we or Roche may terminate the agreement by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement or if the other party becomes insolvent; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">&#9679;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Either we or Roche may terminate the brain shuttle program if at least one development candidate is not designated under such program by a mutually agreed deadline.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015, 2014 and 2013, we earned revenue of $31.2 million, $8.7 million and $5.1 million, respectively from our relationship with Roche, which represented 11 percent, four percent and three percent, respectively, of our total revenue for those years.&#160;Our balance sheet at December 31, 2015 and 2014 included deferred revenue of $8.8 million and $17.0 million, respectively related to our relationship with Roche.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Satellite Company Collaborations</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">Achaogen,&#160;Inc.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In 2006, we exclusively licensed to Achaogen,&#160;Inc. specific know-how, patents and patent applications relating to aminoglycosides. In exchange, Achaogen agreed to certain payment obligations related to aminoglycosides Achaogen developed. Achaogen is developing plazomicin, an aminoglycoside Achaogen discovered based on the technology we licensed to Achaogen. In connection with the license, Achaogen issued to us $1.5 million of Achaogen Series&#160;A Preferred Stock. If Achaogen successfully develops and commercializes two drugs under our agreement, we will receive payments totaling up to $49.3 million for the achievement of key clinical, regulatory and sales events. Through December 2015, we have earned $7 million in milestone payments from Achaogen, including a $4 million milestone payment we earned in September 2014 when Achaogen initiated a Phase 3 study of plazomicin in patients with serious multi-drug resistant, gram-negative bacterial infections. We will earn the next milestone payment of $7.5 million if Achaogen obtains regulatory approval for plazomicin in a major market. We are also eligible to receive royalties on sales of drugs resulting from the program. Achaogen is solely responsible for the continued development of plazomicin.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015 and 2013, we did not earn any revenue from our relationship with Achaogen. During 2014 we earned revenue of $4 million from our relationship with Achaogen and we sold all of the Achaogen stock we owned resulting in net proceeds of $1.3 million.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">Alnylam Pharmaceuticals,&#160;Inc.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In March&#160;2004, we entered into an alliance with Alnylam to develop and commercialize RNAi therapeutics. Under the terms of the agreement, we exclusively licensed to Alnylam our patent estate relating to antisense motifs and mechanisms and oligonucleotide chemistry for double-stranded RNAi therapeutics in exchange for a $5 million technology access fee, participation in fees from Alnylam&#8217;s partnering programs, as well as future milestone and royalty payments from Alnylam. For each drug Alnylam develops under this alliance, we may receive up to $3.4 million in milestone payments, including up to $1.1 million for the achievement of development milestones and $2.3 million for regulatory milestones. We will earn the next milestone payment of $0.4 million if Alnylam initiates a Phase 1 study for a drug in Alnylam&#8217;s pipeline. We also have the potential to earn royalties on drug sales and a portion of payments that Alnylam receives from licenses of our technology it grants to its partners plus royalties. We retained rights to a limited number of double-stranded RNAi therapeutic targets and all rights to single-stranded RNAi, or ssRNAi, therapeutics.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In turn, Alnylam nonexclusively licensed to us its patent estate relating to antisense motifs and mechanisms and oligonucleotide chemistry to research, develop and commercialize single-stranded antisense therapeutics, ssRNAi therapeutics, and to research double-stranded RNAi compounds. We also received a license to develop and commercialize double-stranded RNAi drugs targeting a limited number of therapeutic targets on a nonexclusive basis. If we develop or commercialize an RNAi-based drug using Alnylam&#8217;s technology, we will pay Alnylam up to $3.4 million in milestone payments for specified development and regulatory events, plus royalties. To date, we do not have an RNAi-based drug in development.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In 2015, we and Alnylam entered into an alliance in which we formed an intellectual property cross-license under which we and Alnylam each obtained exclusive license rights to four therapeutic programs. Alnylam granted us an exclusive, royalty-bearing license to its chemistry, RNA targeting mechanism and target-specific intellectual property for oligonucleotides against four targets. In exchange, we granted Alnylam an exclusive, royalty-bearing license to our chemistry, RNA targeting mechanism and target-specific intellectual property for oligonucleotides against four targets. Alnylam also granted us a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for single-stranded antisense therapeutics. In turn, we granted Alnylam a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for double-stranded RNAi therapeutics. Through December 2015, we have received nearly $70 million from Alnylam.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015, 2014 and 2013, we earned revenue from our relationship with Alnylam totaling $1.3 million, $9.9 million and $1.5 million, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">Antisense Therapeutics Limited</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In 2001 we licensed ATL1102 and ATL1103 to ATL, an Australian company publicly traded on the Australian Stock Exchange. ATL is currently undertaking a chronic toxicology study in primates to support a potential Phase 2b trial of ATL1102 in patients with multiple sclerosis, or MS. In addition, ATL is currently developing ATL1103 for growth and sight disorders. We are eligible to receive royalties on sales of ATL1102 and ATL1103. We may also receive a portion of the fees ATL receives if it licenses ATL1102 or ATL1103. At December 31, 2015 and 2014, we owned less than ten percent of ATL&#8217;s equity. During 2015, 2014 and 2013, we did not earn any revenue from our relationship with ATL.&#160;</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">Atlantic Pharmaceuticals Limited</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In March&#160;2007, we licensed alicaforsen to Atlantic Pharmaceuticals, a UK-based specialty pharmaceutical company founded in 2006. Atlantic Pharmaceuticals is developing alicaforsen for the treatment of ulcerative colitis, or UC, and other inflammatory diseases. Atlantic Pharmaceuticals is initially developing alicaforsen for pouchitis, a UC indication, followed by UC and other inflammatory diseases. In exchange for the exclusive, worldwide license to alicaforsen, we received a $2 million upfront payment from Atlantic Pharmaceuticals in the form of equity. Under the agreement, we could receive milestone payments totaling up to $1.4 million for the achievement of regulatory milestones for multiple indications. We will earn the next milestone payment of $0.6 million if Atlantic Pharmaceuticals submits an NDA for alicaforsen with the FDA. In 2010, Atlantic Pharmaceuticals began supplying alicaforsen under international named patient supply regulations for patients with inflammatory bowel disease, or IBD, for which we receive royalties.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In 2010 and 2013, we agreed to sell Atlantic Pharmaceuticals alicaforsen drug substance in return for shares of Atlantic Pharmaceuticals&#8217; common stock. Additionally, in 2013 we received an advance payment in the form of equity for the initial royalties that we will earn from Atlantic Pharmaceuticals. We recorded a full valuation allowance for all of the equity we received from Atlantic Pharmaceuticals, including the upfront payment, because realization of value from the equity is uncertain. At December 31, 2015 and 2014, we owned approximately 11 percent and 12 percent, respectively, of Atlantic Pharmaceuticals&#8217; equity.&#160;We earned $0.7 million related to royalties and sales of drug substance in 2013. Because the payments were made in equity, we did not record any revenue. During 2015 and 2014, our revenue was negligible from our relationship with Atlantic Pharmaceuticals.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">OncoGenex Technologies Inc., a subsidiary of OncoGenex Pharmaceuticals Inc.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">Custirsen</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In November&#160;2001, we established a drug development collaboration with OncoGenex, a biotechnology company committed to the development of cancer therapeutics for patients with drug resistant and metastatic cancers, to co-develop and commercialize custirsen, an anti-cancer antisense drug that targets clusterin. OncoGenex is currently evaluating custirsen in two Phase 3 studies. In July&#160;2008, we and OncoGenex amended the co-development agreement pursuant to which OncoGenex became solely responsible for the costs, development and commercialization of custirsen. In exchange, OncoGenex agreed to pay us royalties on sales of custirsen and to share consideration it receives from licensing custirsen to a third party, except for consideration OncoGenex receives for the fair market value of equity and reimbursement of research and development expenses. Under the amended agreement, we assigned to OncoGenex our rights in the patents claiming the composition and therapeutic methods of using custirsen and granted OncoGenex a worldwide, nonexclusive license to our know-how and patents covering our core antisense technology and manufacturing technology solely for use with custirsen. In addition, we agreed that so long as OncoGenex or its commercialization partner is using commercially reasonable efforts to develop and commercialize custirsen, we will not research, develop or commercialize an antisense compound designed to modulate clusterin. The amended agreement will continue until OncoGenex or its commercialization partner is no longer developing or commercializing custirsen or until we terminate the agreement for OncoGenex&#8217;s uncured failure to make a payment required under the agreement.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">OGX-225</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In August&#160;2003, we and OncoGenex entered into a second and separate agreement for the development of an antisense anti-cancer drug, OGX-225. OncoGenex is responsible for all development costs and activities. OncoGenex issued to us $0.8 million of OncoGenex securities as payment for an upfront fee. In addition, OncoGenex will pay us milestone payments totaling up to $3.5 million for the achievement of key development and regulatory milestones, including up to $1.5 million for the achievement of development milestones and up to $2 million for the achievement of regulatory milestones. In addition, we are eligible to receive royalties on future product sales of OGX-225. As of December 31, 2015, OncoGenex had not achieved any milestone events related to OGX-225. We will earn the next milestone payment of $0.5 million if OncoGenex initiates a Phase 2 study for OGX-225.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">Apatorsen</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In January&#160;2005, we entered into a third and separate agreement with OncoGenex to allow for the development of an additional antisense anti-cancer drug, apatorsen. OncoGenex and collaborators are evaluating apatorsen in multiple Phase 2 studies in patients with cancer. OncoGenex is responsible for all development costs and activities. OncoGenex will pay us milestone payments totaling up to $5.8 million for the achievement of key development and regulatory milestones, including up to $1.3 million for the achievement of development milestones and up to $4.5 million for the achievement of regulatory milestones. In addition, we are eligible to receive royalties on future product sales of the drug. We will earn the next milestone payment of $1.3 million if OncoGenex initiates a Phase 3 study for apatorsen.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015, 2014 and 2013, we did not earn any revenue from our relationship with OncoGenex.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">Regulus Therapeutics Inc.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In September&#160;2007, we and Alnylam established Regulus as a company focused on the discovery, development and commercialization of microRNA-targeting therapeutics. We and Alnylam retain rights to develop and commercialize, on pre-negotiated terms, microRNA therapeutic products that Regulus decides not to develop either by itself or with a partner. Regulus is addressing therapeutic opportunities that arise from alterations in microRNA expression. Since microRNAs may act as master regulators of the genome, affecting the expression of multiple genes in a disease pathway, microRNA therapeutics define a new platform for drug discovery and development. MicroRNAs may also prove to be an attractive new tool for characterizing diseases. Regulus focuses its drug discovery and development efforts in numerous therapeutic areas, including cancer, fibrosis, and viral infections. Regulus currently has three drugs in clinical development. Regulus is evaluating RG-101 in a Phase 2 study in patients with HCV and in a Phase 1 study in patients with severe renal insufficiency or end-stage renal disease. Regulus is also evaluating RG-012 in a Phase 1 study to treat patients with Alport syndrome. Regulus and AstraZeneca are also evaluating RG-125 in a Phase 1 study for the treatment of NASH in patients with type 2 diabetes or pre-diabetes. We are eligible to receive royalties on any future product sales of these drugs.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015, 2014 and 2013, we did not earn any revenue from our relationship with Regulus. During 2015 and 2014, we sold a portion of our Regulus stock, resulting in a gain of $20.2 million and $19.9 million, respectively, and proceeds of $25.5 million and $22.9 million, respectively. As of December 31, 2015, we owned approximately 2.8 million shares, approximately five percent of Regulus&#8217; equity, with a net carrying value of $24.8 million.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">External Project Funding</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 36pt;">CHDI Foundation,&#160;Inc.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Starting in November&#160;2007, CHDI provided financial and scientific support to our Huntington&#8217;s disease drug discovery program through our development collaboration. In April&#160;2013, we formed an alliance with Roche to develop treatments for Huntington&#8217;s disease. Under the terms of our agreement with CHDI, we will reimburse CHDI for a portion of its support of our Huntington&#8217;s disease program out of the payments we receive from Roche. We made payments of $5 million and $3 million to CHDI in 2015 and 2013, respectively, associated with the progression of our Huntington&#8217;s disease program. If we achieve pre-specified milestones under our collaboration with Roche, we will make additional payments to CHDI up to $4 million, upon which our obligation to CHDI will be complete.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During 2015, our revenue earned from our relationship with CHDI was negligible and during 2014, we did not earn any revenue. During 2013, we earned revenue of $0.4 million from our relationship with CHDI.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">The Ludwig Institute; Center for Neurological Studies</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In October 2005, we entered into a collaboration agreement with the Ludwig Institute, the Center for Neurological Studies and researchers from these institutions to discover and develop antisense drugs for amyotrophic lateral sclerosis, or ALS, and other neurodegenerative diseases. Under this agreement, we agreed to pay the Ludwig Institute and Center for Neurological Studies modest milestone payments and royalties on any antisense drugs resulting from the collaboration.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Intellectual Property Sale and Licensing Agreements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Sales of Intellectual Property</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">Abbott Molecular Inc.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In January 2009, we sold our former subsidiary,&#160;Ibis Biosciences, to Abbott Molecular Inc., or AMI, pursuant to a stock purchase agreement for a total acquisition price of $215 million plus the earn out payments described below.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Under the stock purchase agreement, we are eligible to receive earn out payments from AMI equal to a percentage of Ibis&#8217; revenue related to sales of Ibis systems, which AMI launched in 2014 as IRIDICA, including instruments, assay kits and successor products. Once cumulative net sales reach $140 million, and through December 31, 2025, we are eligible to earn out payments in any year that net sales exceed $50 million for the applicable year. The earn out payments will equal five percent of Ibis&#8217; cumulative net sales over $140 million and up to $2.1 billion, and three percent of Ibis&#8217; cumulative net sales over $2.1 billion.&#160;AMI may reduce these earn out payments from five percent to as low as 2.5 percent and from three percent to as low as 1.5 percent, respectively, upon the occurrence of certain events. During 2015, 2014 and 2013, we did not earn any revenue from our relationship with AMI.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">In-Licensing Arrangements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">University of Massachusetts</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have a license agreement with the University of Massachusetts under which we acquired an exclusive license to the University of Massachusetts&#8217; patent rights related to nusinersen. If we successfully develop and commercialize a drug incorporating the technology we licensed from the University of Massachusetts, we will pay a milestone payment to the University of Massachusetts of $0.3 million for the achievement of a key regulatory milestone. In addition, we will pay the University of Massachusetts a portion of any sublicense revenue we receive in consideration for sublicensing its technology, and a royalty on sales of nusinersen&#160;in the United States if our product incorporates the technology we licensed from the University of Massachusetts.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Verva Pharmaceuticals Ltd.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have a license agreement with Verva under which we acquired an exclusive license to Verva&#8217;s antisense patent rights related to IONIS-FGFR4<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. If we successfully develop and commercialize a drug incorporating the technology Verva licensed to us, we will pay milestone payments to Verva totaling up to $6.1 million for the achievement of key patent, clinical, and regulatory milestones. If we convert our license from an exclusive license to a nonexclusive license we could significantly reduce the milestone payments due to Verva. In addition, we will also pay royalties to Verva on sales of IONIS-FGFR4<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>&#160;if our product incorporates the technology we licensed from Verva.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Cold Spring Harbor Laboratory</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have a collaboration and license agreement with the Cold Spring Harbor Laboratory under which we acquired an exclusive license to the Cold Spring Harbor Laboratory&#8217;s patent rights related to nusinersen. If we successfully develop and commercialize a drug incorporating the technology we licensed from the Cold Spring Harbor Laboratory, we will pay a portion of any sublicense revenue and post licensing milestone payments we receive in consideration for sublicensing the Cold Spring Harbor Laboratory&#8217;s technology up to $11.3 million and a royalty on sales of nusinersen&#160;if our product incorporates the technology we licensed from the Cold Spring Harbor Laboratory.</div><div><br /></div><div style="font-weight: bold;">7. Segment Information and Concentration of Business Risk</div></div> 120000 118000 120351480 118442726 118442726 120351480 300000000 300000000 300000000 300000000 0.001 0.001 120351480 118442726 120351480 118442726 18512177 -52044000 -141590000 -20317000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Concentration of credit risk</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, short-term investments and receivables. We place our cash equivalents and short-term investments with reputable financial institutions. We primarily invest our excess cash in commercial paper and debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody&#8217;s, Standard&#160;&amp; Poor&#8217;s, or S&amp;P, or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</div><div><br /></div></div> 0.13 0.2 0.02 0.37 0.25 0.58 0.33 0.22 0.24 0.17 0.12 0.04 0.11 0.03 0.17 0 0.11 0.58 0 0.33 0.12 0 0.03 0.13 0.37 0.22 0.24 0.99 0.04 0 0.25 0.2 0.02 0.99 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Basis of presentation</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The consolidated financial statements include the accounts of Ionis Pharmaceuticals,&#160;Inc. ("we", "us" or "our") and our wholly owned subsidiary,&#160;Akcea Therapeutics, Inc., which we formed in December 2014. In December 2015, we changed our name from Isis Pharmaceuticals, Inc. to Ionis Pharmaceuticals, Inc.</div><div><br /></div></div> 6744000 6550000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Annual debt and other obligation maturities, including fixed and determinable interest, at December 31, 2015 are as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">15,767</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,744</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,744</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,744</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">66,304</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">505,960</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Subtotal</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">608,263</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Less: current portion</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(9,029</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Less: fixed and determinable interest</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(37,655</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Less: unamortized portion of debt discount</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(163,672</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Plus: Deferred rent</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,006</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">399,913</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div></div> 15767000 6550000 505960000 91205000 66304000 7359000 6744000 6943000 608263000 125550000 6744000 6943000 48014000 327486000 50361000 347214000 50361000 48014000 327486000 347214000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">At December 31, 2015 we had the following convertible debt outstanding (amounts in millions except price per share data):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">1 Percent</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Convertible Senior Notes</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2&#190; Percent</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Convertible Senior Notes</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">Outstanding balance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">500</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">61</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">Issue date</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">November 2014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">August 2012</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">Maturity date</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">November 2021</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">October 2019</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">Interest rate</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">1 percent</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">2&#190; percent</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">Conversion price per share</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">66.81</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">16.63</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 12.05pt; text-indent: -12.05pt;">Total shares of common stock subject to conversion</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7.5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We account for our convertible notes using an accounting standard that requires us to assign a value to our convertible debt equal to the estimated fair value of similar debt instruments without the conversion feature and to record the remaining portion in equity. As a result, we recorded our convertible notes at a discount, which we are amortizing as additional non-cash interest expense over the expected life of the respective debt. We determined our nonconvertible debt borrowing rate using a combination of the present value of the debt&#8217;s cash flows and a Black-Scholes valuation model. The following table summarizes the nonconvertible borrowing rate, effective interest rate and amortization period of our debt discount for our convertible notes:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">1 Percent</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Convertible Senior Notes</div></td><td style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2&#190; Percent</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Convertible Senior Notes</div></td></tr><tr><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Nonconvertible debt borrowing rate</div></td><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">7.4 percent</div></td><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">8.0 percent</div></td></tr><tr><td style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Effective interest rate</div></td><td style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">7.8 percent</div></td><td style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">&#160;8.8 percent</div></td></tr><tr><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Amortization period of debt discount</div></td><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">7 years</div></td><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">7 years</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes information about the equity and liability components of our outstanding convertible notes, (in thousands). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center; text-indent: 16.1pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; font-style: italic; text-align: left;">2&#190; Percent Convertible Senior Notes</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Fair value of outstanding notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">215,320</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">223,900</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Principal amount of convertible notes outstanding</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">61,247</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">61,247</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Unamortized portion of debt discount</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,886</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">13,233</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Long-term debt</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">50,361</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Carrying value of equity component</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">18,714</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">18,714</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; font-style: italic; text-align: left;">1 Percent Convertible Senior Notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Fair value of outstanding notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">555,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">568,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Principal amount of convertible notes outstanding</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">500,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">500,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Unamortized portion of debt discount</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">152,786</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">172,514</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Long-term debt</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">347,214</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">327,486</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Carrying value of equity component</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">174,770</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">174,770</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div></div> -4032000 2000 372000 379000 0 263000 -7000 2000 -4295000 one, two, three, four, six, or twelve months 7500000 3700000 1 P7Y P7Y <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">3. Long-Term Obligations and Commitments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The carrying value of our long-term obligations was as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">1 percent convertible senior notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">347,214</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">327,486</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2&#190; percent convertible senior notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">50,361</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Long-term financing liability for leased facility</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">72,217</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">71,731</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Equipment financing arrangement</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">515</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,226</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Leases and other obligations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,341</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7,325</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">472,648</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">457,782</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Less: current portion</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(515</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,882</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Total Long-Term Obligations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">472,133</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">454,900</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Convertible Notes</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In November 2014, we completed a $500 million offering of convertible senior notes, which mature in 2021 and bear interest at 1 percent. We raised $487 million of proceeds, net of issuance costs. We used a substantial portion of the net proceeds from the issuance of the 1 percent convertible senior notes to repurchase $140 million in principal of our 2&#190; percent convertible senior notes at a price of $441.9 million, including accrued interest. As a result, the new principal balance of the 2&#190; percent notes is $61.2 million. We recognized an $8.3 million non-cash loss as a result of the early retirement of a portion of the 2&#190; percent notes.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">At December 31, 2015 we had the following convertible debt outstanding (amounts in millions except price per share data):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">1 Percent</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Convertible Senior Notes</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2&#190; Percent</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Convertible Senior Notes</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">Outstanding balance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">500</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">61</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">Issue date</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">November 2014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">August 2012</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">Maturity date</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">November 2021</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">October 2019</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">Interest rate</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">1 percent</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">2&#190; percent</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">Conversion price per share</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">66.81</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">16.63</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 12.05pt; text-indent: -12.05pt;">Total shares of common stock subject to conversion</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7.5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Interest is payable semi-annually in arrears on May 15 and November 15 of each year for the 1 percent notes and on April 1 and October 1 for the 2 &#190; percent notes.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The 1 percent notes are convertible at the option of the note holders prior to July&#160;1, 2021 only under certain conditions. On or after July&#160;1, 2021, the notes are initially convertible into approximately 7.5 million shares of common stock at a conversion price of approximately $66.81 per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the 1 percent notes prior to maturity, and no sinking fund is provided for them. If we undergo a fundamental change, holders may require us to purchase for cash all or any portion of their 1 percent notes at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The 2&#190; percent notes are convertible at the option of the note holders prior to July&#160;1, 2019 only under certain conditions. On or after July&#160;1, 2019, the notes are convertible into approximately 3.7 million shares of common stock at a conversion price of approximately $16.63 per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We can redeem the 2&#190; percent notes at our option, in whole or in part, on or after October&#160;5, 2016 if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the trading day immediately preceding the date we provide the redemption notice exceeds 130 percent of the applicable conversion price for the 2&#190; percent notes on each such day. The redemption price for the 2&#190; percent notes will equal 100 percent of the principal amount being redeemed, plus accrued and unpaid interest, plus $90 per each $1,000 principal amount being redeemed. Holders of the 2&#190; percent notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indenture governing these notes, at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">For the 2&#190; percent notes, the price of our common stock exceeded the conversion threshold price during the quarter ended December 31, 2015.&#160;As a result, the 2&#190; percent notes are convertible at the option of the holders during the quarter ending March&#160;31, 2016.&#160;As of December 31, 2015, the if-converted value of the 2&#190; percent notes, which assumes that the notes will be converted into shares of&#160;our common stock, exceeded the principal amount by $166.9 million. We did not include the potential effect of the conversion of our convertible notes into our common stock in the computation of diluted net loss per share because the effect would have been anti-dilutive.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We account for our convertible notes using an accounting standard that requires us to assign a value to our convertible debt equal to the estimated fair value of similar debt instruments without the conversion feature and to record the remaining portion in equity. As a result, we recorded our convertible notes at a discount, which we are amortizing as additional non-cash interest expense over the expected life of the respective debt. We determined our nonconvertible debt borrowing rate using a combination of the present value of the debt&#8217;s cash flows and a Black-Scholes valuation model. The following table summarizes the nonconvertible borrowing rate, effective interest rate and amortization period of our debt discount for our convertible notes:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">1 Percent</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Convertible Senior Notes</div></td><td style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2&#190; Percent</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Convertible Senior Notes</div></td></tr><tr><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Nonconvertible debt borrowing rate</div></td><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">7.4 percent</div></td><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">8.0 percent</div></td></tr><tr><td style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Effective interest rate</div></td><td style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">7.8 percent</div></td><td style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">&#160;8.8 percent</div></td></tr><tr><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Amortization period of debt discount</div></td><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">7 years</div></td><td style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">7 years</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Interest expense for the year ended December 31, 2015, 2014 and 2013 included $23.2 million, $9.6 million and $6.8 million, respectively, of non-cash interest expense related to the amortization of the debt discount and debt issuance costs for our convertible notes.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes information about the equity and liability components of our outstanding convertible notes, (in thousands). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center; text-indent: 16.1pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; font-style: italic; text-align: left;">2&#190; Percent Convertible Senior Notes</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Fair value of outstanding notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">215,320</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">223,900</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Principal amount of convertible notes outstanding</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">61,247</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">61,247</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Unamortized portion of debt discount</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,886</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">13,233</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Long-term debt</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">50,361</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Carrying value of equity component</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">18,714</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">18,714</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; font-style: italic; text-align: left;">1 Percent Convertible Senior Notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Fair value of outstanding notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">555,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">568,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Principal amount of convertible notes outstanding</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">500,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">500,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Unamortized portion of debt discount</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">152,786</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">172,514</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Long-term debt</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">347,214</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">327,486</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Carrying value of equity component</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">174,770</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">174,770</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Financing Arrangements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In June 2015, we entered into a five-year revolving line of credit agreement with Morgan Stanley Private Bank, National Association, or Morgan Stanley. We amended the credit agreement in February 2016 to increase the amount available for us to borrow. Under the amended credit agreement, we can borrow up to a maximum of $30 million of revolving credit for general working capital purposes. Under the credit agreement interest is payable monthly in arrears on the outstanding principal at a rate based on our option of:</div><div><br /></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 58.5pt; vertical-align: top; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 36pt;">(i)</div></td><td style="width: auto; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">a floating rate equal to the one-month London Interbank Offered Rate, or LIBOR, in effect plus 1.25 percent per annum;</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 58.5pt; vertical-align: top; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 36pt;">(ii)</div></td><td style="width: auto; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">a fixed rate equal to LIBOR plus 1.25 percent for a period of one, two, three, four, six, or twelve months as elected by us; or</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 58.5pt; vertical-align: top; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 36pt;">(iii)</div></td><td style="width: auto; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">a fixed rate equal to the LIBOR swap rate during the period of the loan.</div></td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Additionally, we will pay 0.25 percent per annum, payable quarterly in arrears, for any amount unused under the credit facility beginning after June 1, 2016. As of December 31, 2015 we had $8.5 million in outstanding borrowings under the credit facility, which were used to fund our capital equipment needs and is consistent with our historical practice to finance these costs. As of December 31, 2015, our outstanding borrowings under this credit facility were at a weighted average interest rate of 1.67 percent.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The credit agreement includes customary affirmative and negative covenants and restrictions. We are in compliance with all covenants of the credit agreement.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In October 2008, we entered into an equipment financing loan agreement. As of December 31, 2015, our outstanding borrowings under this loan agreement were at a weighted average interest rate of 4.39 percent. The carrying balance under this loan agreement at December 31, 2015 and 2014 was $0.5 million and $3.2 million, respectively. Our remaining outstanding balance is due in June 2016 and interest is payable monthly.&#160;</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Maturity Schedules</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Annual debt and other obligation maturities, including fixed and determinable interest, at December 31, 2015 are as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">15,767</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,744</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,744</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,744</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">66,304</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">505,960</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Subtotal</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">608,263</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Less: current portion</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(9,029</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Less: fixed and determinable interest</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(37,655</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Less: unamortized portion of debt discount</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(163,672</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Plus: Deferred rent</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,006</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">399,913</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Operating Leases</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We lease office, laboratory and manufacturing space under non-cancelable operating leases with terms through December 2031. We are located in three buildings in Carlsbad, California, which consists of laboratory, manufacturing and office space. Our facilities include a primary research and development facility, a manufacturing facility and a building adjacent to our manufacturing facility. We account for the lease of our primary research and development facility as a financing obligation as discussed below. Our manufacturing facility is used for our drug development business and was built to meet current Good Manufacturing Practices and the facility adjacent to our manufacturing facility has laboratory and office space that we use to support our manufacturing activities. The lease for our manufacturing facility expires in 2031 and has four five-year options to extend. Under the lease agreement, we have the option to purchase the facility at the end of each year from 2016 through 2020, and at the end of 2026 and 2031. The lease for the facility adjacent to our manufacturing facility has an initial term ending in June 2021 with an option to extend the lease for up to two five-year periods. Additionally, Akcea leases office space in a building in Cambridge, Massachusetts. The lease for Akcea has a three-year term and expires in July 2018. We also lease office equipment under non-cancelable operating leases with terms through June 2017.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Annual future minimum payments under operating leases as of December 31, 2015 are as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Operating</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Leases</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,879</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,878</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,597</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,474</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,527</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">16,125</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total minimum payments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,480</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Rent expense for the year ended December 31, 2015 was $2.0 million and was $1.8 million each of the years ended December 31, 2014 and 2013. We recognize rent expense on a straight line basis over the lease term for the lease on our manufacturing facility, the lease on our building adjacent to our manufacturing facility and Akcea&#8217;s office space, which resulted in a deferred rent balance of $2.0 million and $1.8 million at December 31, 2015 and 2014, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Research and Development Facility Lease Obligation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In March 2010, we entered into a lease agreement with an affiliate of BioMed Realty, L.P., or BioMed. Under the lease, BioMed constructed our primary research and development facility in Carlsbad, California. The lease expires in 2031 and has four five-year options to extend. Under the lease agreement, we have the option to purchase the facility and land at the end of each year from 2016 through 2020, and at the end of 2026 and 2031. To gain early access to the facility, we agreed to modify our lease with BioMed to accept additional responsibility. As a result, we recorded the costs for the facility as a fixed asset and we also recorded a corresponding liability in our non-current liabilities as a long-term financing obligation. In July 2011, we took possession of the facility and began depreciating the cost of the facility over its economic useful life. At December 31, 2015 and 2014, the facility and associated parcel of land had a net book value of $62.2 million and $64.4 million, respectively, which included $9.9 million and $7.7 million, respectively, of accumulated depreciation. We are applying our rent payments, which began on January 1, 2012, against the liability over the term of the lease.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In conjunction with the lease agreement with BioMed, we purchased a parcel of land for $10.1 million and subsequently sold it to BioMed. Since we have the option to purchase the facility, including the land, we have continuing involvement in the land, which requires us to account for the purchase and sale of the land as a financing transaction. As such, our property, plant and equipment at December 31, 2015 and 2014 included the value of the land. Additionally, we have recorded a corresponding amount in our non-current liabilities as a long-term financing obligation. Since land is not a depreciable asset, the value of the land and financing obligation we recorded will not change until we exercise our purchase option or the lease terminates.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Annual future rent payments as of December 31, 2015 for our primary research and development facility are as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Future Rent</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Payments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,550</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,550</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,943</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,943</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7,359</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">91,205</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total minimum payments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">125,550</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div></div> P5Y 1.3 140000000 140000000 20 2012-08-31 2014-11-30 0.0125 P30D 500000000 61200000 61247000 500000000 61247000 16.63 66.81 163672000 2019-10-31 2021-11-30 0.078 0.088 500000000 166900000 18714000 174770000 18714000 174770000 0.0275 0.01 0.0275 0.01 0.0275 172514000 13233000 10886000 152786000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Convertible debt</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We account for convertible debt instruments, including our 1 percent and 2&#190; percent notes, that may be settled in cash upon conversion (including partial cash settlement) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. We determine the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, we estimate fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We assign a value to the debt component of our convertible notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording our debt at a discount. We are amortizing the debt discount over the life of the convertible notes as additional non-cash interest expense utilizing the effective interest method. For additional information, see Note 3, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Long-Term Obligations and Commitments</font>.</div><div><br /></div></div> -5082000 0 -8948000 -11375000 0 -5916000 58836000 45110000 100000000 12000000 30000000 29000000 4500000 4300000 8800000 175000000 30000000 5000000 7600000 63300000 4400000 91600000 118100000 6700000 4900000 10000000 26300000 17000000 8800000 0 0 51713000 67322000 2006000 1800000 2000000 -2427000 -834000 0 127797000 134306000 218493000 231654000 467952000 421186000 19655000 15549000 153601000 93594000 404093000 315934000 31093000 21553000 73733000 55928000 5288000 27878000 1000000 1500000 600000 6591000 6380000 6984000 1047000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Basic and diluted net loss per share</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We compute basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period. As we incurred a net loss for 2015, 2014 and 2013, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. Common stock from the following would have had an anti-dilutive effect on net loss per share:</div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;"><font style="font-size: 10pt; font-family: Symbol;">&#61489;&#61472;</font>percent convertible senior notes (for 2014 and 2015);</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">2&#190; percent convertible senior notes;</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">Dilutive stock options;</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">Unvested restricted stock units; and</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">Employee Stock Purchase Plan, or ESPP.</td></tr></table></div><div><br /></div></div> -0.55 -0.33 -0.74 0.30 -0.27 -0.23 -0.14 -0.10 0.26 -0.59 -0.30 -0.10 -0.59 -0.23 0.25 0.29 -0.27 -0.14 -0.30 -0.002 -0.005 -0.016 -0.121 -0.017 -0.018 0 0.057 0.057 0.434 0.238 0.47 0 0 -0.044 -0.791 -0.433 -0.543 0.282 0.089 -0.004 0.35 0.35 0.35 P1Y3M18D P1Y2M12D 37.43 45700000 16000000 16065000 12302000 0 396000 1463000 1231000 104258000 0.08 0.074 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Fair value measurements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investment in equity securities in publicly held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. Our Level 3 investments include our investments in the equity securities of publicly held biotechnology companies for which we calculated a lack of marketability discount because there were restrictions on when we could trade the securities. Historically, we have determined the lack of marketability discount by using a Black-Scholes model to value a hypothetical put option to approximate the cost of hedging the stock until the restriction ends. The majority of our securities have been classified as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices. During 2015 and 2014, there were no transfers between our Level 1 and Level 2 investments. We recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.</div><div><br /></div><div style="text-align: left;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We measure the following major security types at fair value on a recurring basis. The following summary breaks down the fair-value hierarchy that we valued each security with at December 31, 2015 and 2014 (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">At</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quoted Prices in</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Active Markets</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant Other</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Observable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unobservable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Cash equivalents (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">88,902</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">88,902</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">438,426</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">438,426</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">89,253</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">89,253</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states (3)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">127,656</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">127,656</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Investment in Regulus Therapeutics Inc.</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,792</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,792</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">771,630</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">116,295</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">655,335</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">At</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quoted Prices in</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Active Markets</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant Other</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Observable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unobservable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Cash equivalents (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">104,680</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">104,680</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities (4)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372,002</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372,002</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">109,855</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">109,855</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury (5)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states (6)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">105,033</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">105,033</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Investment in Regulus Therapeutics Inc.</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">792,468</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11px; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">123,697</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">586,890</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 484.45pt;"><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(1)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Included in cash and cash equivalents on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(2)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(3)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$7.5 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(4)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(5)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$10 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(6)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$9.3 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In the first quarter of 2014, Achaogen completed an initial public offering. As a result, we stopped using the cost method of accounting for our equity investment in Achaogen and instead we began accounting for it at fair value. Until September 2014, the fair value of our investment in Achaogen included a lack of marketability discount because there were restrictions on when we could trade the securities. As such, we classified our Achaogen stock as a Level 3 investment. In September 2014, we reclassified our investment in Achaogen to a Level 1 investment because the contractual trading restrictions on the shares we owned ended and we subsequently sold all of our shares in 2014. </div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In November 2014, Regulus completed a public offering. As part of the offering, we sold shares of Regulus' common stock and became subject to trading restrictions on our remaining shares through January 2015. Therefore, at December 31, 2014, we recorded a lack of marketability discount on our investment in Regulus and classified it as a Level 3 investment. At the end of January 2015, we reclassified our investment in Regulus to a Level 1 investment because the contractual trading restrictions on the shares we owned ended.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2015 and 2014 (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Beginning balance of Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Transfers into Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">108,009</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10.8pt; text-indent: -8.9pt;">Total gains (losses) included in accumulated other comprehensive income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">22,377</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(24,897</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Transfers out of Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(104,258</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,231</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Ending balance of Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div><br /></div><div><br /></div></div> 0 0 0 0 0 108009000 22377000 -24897000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Fair value of financial instruments</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have estimated the fair value of our financial instruments. The amounts reported for cash, accounts receivable, accounts payable and accrued expenses approximate the fair value because of their short maturities. We report our investment securities at their estimated fair value based on quoted market prices for identical or similar instruments.</div><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We measure the following major security types at fair value on a recurring basis. The following summary breaks down the fair-value hierarchy that we valued each security with at December 31, 2015 and 2014 (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">At</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quoted Prices in</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Active Markets</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant Other</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Observable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unobservable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Cash equivalents (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">88,902</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">88,902</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">438,426</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">438,426</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">89,253</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">89,253</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states (3)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">127,656</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">127,656</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Investment in Regulus Therapeutics Inc.</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,792</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,792</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">771,630</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">116,295</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">655,335</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">At</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quoted Prices in</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Active Markets</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant Other</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Observable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unobservable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Cash equivalents (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">104,680</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">104,680</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities (4)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372,002</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372,002</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">109,855</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">109,855</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury (5)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states (6)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">105,033</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">105,033</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Investment in Regulus Therapeutics Inc.</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">792,468</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11px; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">123,697</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">586,890</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 484.45pt;"><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(1)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Included in cash and cash equivalents on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(2)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(3)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$7.5 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(4)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(5)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$10 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(6)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$9.3 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2015 and 2014 (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Beginning balance of Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Transfers into Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">108,009</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10.8pt; text-indent: -8.9pt;">Total gains (losses) included in accumulated other comprehensive income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">22,377</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(24,897</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Transfers out of Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(104,258</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,231</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Ending balance of Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div><br /></div><div><br /></div></div> 0 81881000 0 8200000 7800000 1200000 25000000 27500000 P10Y2M12D 1100000 1000000 1300000 1400000 20200000 19900000 20300000 21200000 2400000 -8292000 0 0 8300000 14918000 37173000 20140000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Long-lived assets</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We evaluate long-lived assets, which include property, plant and equipment, patent costs, and exclusive licenses acquired from third parties, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets. We recorded charges of $1.9 million, $1.3 million and $6.4 million for the years ended December 31, 2015, 2014 and 2013, respectively, related primarily to the write-down of intangible assets.</div><div><br /></div></div> 6400000 1300000 1100000 1900000 1300000 6400000 -66558000 -87906000 -54391000 29547000 69499000 28850000 372000 -15407000 -5914000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">5. Income Taxes</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The provisions for income taxes on income from continuing operations were as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Current:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr style="height: 13px;"><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Federal</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">379</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">263</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">State</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(4,295</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total current</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(4,032</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Deferred:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Federal</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(8,948</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(5,082</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">State</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,427</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(834</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total deferred</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(11,375</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(5,916</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Income tax expense (benefit)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(15,407</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(5,914</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In periods in which we have a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as other comprehensive income, intraperiod tax allocation rules require us to allocate the tax provision to the other categories of earnings. We then record a related tax benefit in continuing operations. During 2015, we recorded unrealized losses on our investments in available-for-sale securities in other comprehensive income, therefore we did not have to allocate our tax provision to our other categories of earnings. However, during 2014 and 2013, we recorded unrealized gains on our investments in available-for-sale securities and had to allocate our tax provision between continuing operations and other comprehensive income. As a result, for the years ended December 31, 2014 and 2013, we recorded a $12.8 million and $5.9 million tax benefit, respectively, in continuing operations and a $12.8 million and $5.9 million tax expense, respectively, in other comprehensive income.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">In December 2014, we reached an agreement with the State of California Franchise Tax Board with regard to California franchise tax we paid for the tax year ended December 31, 2009. As part of the agreement, we received a franchise tax refund of $4.3 million in 2015 and our research credit carry-forward to December 31, 2010 increased by $4.3 million. We recognized an income tax benefit for the refund in the fourth quarter of 2014. The increase in our research credit carry-forward increased our deferred tax assets but did not impact our consolidated balance sheet as we recorded a full valuation allowance on our deferred tax assets.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The reconciliation between our effective tax rate on income from continuing operations and the statutory U.S. tax rate is as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="22" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Pre-tax loss</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(87,906</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(54,391</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(66,558</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Statutory rate</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(30,767</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">35.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(19,035</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">35.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(23,295</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">35.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">State income tax net of federal benefit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3,125</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3,823</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net change in valuation allowance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">69,499</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(79.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">29,547</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(54.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">28,850</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(43.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Loss on debt extinguishment</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,406</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(4.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr><tr style="height: 12px;"><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Tax credits</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(41,284</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">47.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(23,628</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">43.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(15,839</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">23.8</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">California franchise tax refund</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,795</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Deferred tax true-up</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,496</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">977</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1.8</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">8,023</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(12.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,427</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1.6</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">246</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">170</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Effective rate</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(15,407</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">28.2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(5,914</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">8.9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Significant components of our deferred tax assets and liabilities as of December 31, 2015 and 2014 are as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr style="height: 20px;"><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Deferred Tax Assets:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Net operating loss carryovers</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">218,493</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">231,654</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">R&amp;D credits</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">153,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">93,594</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Deferred revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">45,110</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">58,836</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Stock-based compensation</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">31,093</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">21,553</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,655</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">15,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total deferred tax assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">467,952</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">421,186</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Deferred Tax Liabilities:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Convertible debt</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(55,928</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(73,733</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Unrealized gain in other comprehensive income</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(5,288</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(27,878</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Intangible and capital assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,643</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3,641</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Net deferred tax asset</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">404,093</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">315,934</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Valuation allowance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(404,093</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(315,934</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Net deferreds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div><br /></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have net deferred tax assets relating primarily to net operating loss carryforwards, or NOL&#8217;s, and research and development tax credit carryforwards. Subject to certain limitations, we may use these deferred tax assets to offset taxable income in future periods. Since we have a history of losses and the likelihood of future profitability is not assured, we have provided a full valuation allowance for the deferred tax assets in our balance sheet as of December 31, 2015. If we determine that we are able to realize a portion or all of these deferred tax assets in the future, we will record an adjustment to increase their recorded value and a corresponding adjustment to increase income or additional paid in capital, as appropriate, in that same period.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We recognize excess tax benefits associated with share-based compensation to stockholders' equity only when realized. We follow the with-and-without approach excluding any indirect effects of the excess tax deductions to determine when we should realize excess tax benefits relating to share-based compensation. Under this approach, we do not realize our excess tax benefits related to share-based compensation until after we utilize all other our tax benefits available to us. During the year ended December 31, 2015, we realized $0.4 million of such excess tax benefits, and accordingly, we recorded a corresponding credit to additional paid-in capital.&#160; As of December 31, 2015, we had $76.9 million of unrealized excess tax benefits associated with share-based compensation. We will account for the tax benefits as a credit to additional paid-in capital, if and when we realize them, rather than a reduction of the provision for income taxes.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">At December 31, 2015, we had federal and California tax net operating loss carryforwards of approximately $734.7 million and $886.5 million, respectively. Our federal tax loss carryforwards will begin to expire in 2023, unless we use them before then. Our California loss carryforwards continue to expire in 2015. At December 31, 2015, we also had federal and California research and development tax credit carryforwards of approximately $146.8 million and $44.7 million, respectively. Our Federal research and development tax credit carryforwards begin to expire in 2018. Our California research and development tax credit carryforwards are available indefinitely. In 2009, we had a substantial amount of taxable income and we used a portion of our Federal NOL carryforwards to reduce our federal income taxes.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">We analyze filing positions in all of the federal and state jurisdictions where we file income tax returns, and all open tax years in these jurisdictions to determine if we have any uncertain tax positions on any of our income tax returns. We recognize the impact of an uncertain tax position on an income tax return at the largest amount that the relevant taxing authority is more-likely-than not to sustain upon audit. We do not recognize uncertain income tax positions if they have less than 50 percent likelihood of the applicable tax authority sustaining our position.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes our gross unrecognized tax benefits (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Beginning balance of unrecognized tax benefits</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">27,365</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">23,964</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,872</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Decrease for prior period tax positions</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,653</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Increase for prior period tax positions</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">215</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">9,821</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Increase for current period tax positions</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">23,677</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5,054</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,271</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Ending balance of unrecognized tax benefits</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">51,257</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">27,365</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">23,964</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">At December 31, 2015 we had $33.3 million of tax benefits included in our unrecognized tax benefits that, if we recognized them, would reduce our annual effective tax rate subject to the valuation allowance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We do not foresee any material changes to our gross unrecognized tax benefits within the next twelve months. We recognize interest and/or penalties related to income tax matters in income tax expense. We did not recognize any accrued interest and penalties related to gross unrecognized tax benefits during the year ended December 31, 2015.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Due to the carryforward of unutilized net operating losses and research and development credits, we are subject to taxation in the United States and various state jurisdictions. Our tax years for 1998 and forward are subject to examination by the U.S. tax authorities and our tax years for 2002 and forward are subject to examination by the California tax authorities.</div><div><br /></div></div> 977000 1496000 8023000 246000 1427000 170000 -23295000 -19035000 -30767000 0 0 2406000 15839000 41284000 23628000 -3823000 -3125000 1000 9211000 66000 4824000 0 0 -4034000 -2345000 8358000 6691000 205000 153000 217000 22118000 -11415000 88344000 134000 4290000 3763000 609000 -1743000 1912000 1091000 4319000 1750000 3683000 418000 4189000 376000 3974000 37655000 36732000 19355000 22209000 6000000 6800000 6353000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Inventory valuation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We capitalize the costs of raw materials that we purchase for use in producing our drugs because until we use these raw materials they have alternative future uses. We include in inventory raw material costs for drugs that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single drug. For example, if one of our drugs failed, we could use the raw materials for that drug to manufacture our other drugs. We expense these costs when we deliver the drugs to our partners, or as we provide these drugs for our own clinical trials. We reflect our inventory on the balance sheet at the lower of cost or market value under the first-in, first-out method, or FIFO. We review inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value. We consider several factors in estimating the net realizable value, including shelf life of raw materials, alternative uses for our drugs and clinical trial materials, and historical write-offs. We did not record any inventory write-offs for the years ended December 31, 2015, 2014 or 2013. Total inventory was $6.9 million and $6.3 million as of December 31, 2015 and 2014, respectively.</div><div><br /></div><div><br /></div></div> 6290000 6899000 2682000 4302000 2085000 2800000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes the contract maturity of the available-for-sale securities we held as of December 31, 2015:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 50%; border-collapse: collapse;"><tr><td style="width: 87.43%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">One year or less</div></td><td style="width: 2.82%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 9.75%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">49 %</div></td></tr><tr><td style="width: 87.43%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">After one year but within two years</div></td><td style="width: 2.82%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 9.75%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">27 %</div></td></tr><tr><td style="width: 87.43%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">After two years but within three and a half years</div></td><td style="width: 2.82%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #cceeff;">&#160;</td><td style="width: 9.75%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">24 %</div></td></tr><tr><td style="width: 87.43%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total</div></td><td style="width: 2.82%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff;">&#160;</td><td style="width: 9.75%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">100 %</div></td></tr></table><div><br /></div></div> P5Y P5Y P3Y 0.0439 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">9. Legal Proceedings</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">From time to time, we are involved in legal proceedings arising in the ordinary course of our business. Periodically, we evaluate the status of each legal matter and assess our potential financial exposure. If the potential loss from any legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Significant judgment is required to determine the probability of a loss and whether the amount of the loss is reasonably estimable. The outcome of any proceeding is not determinable in advance. As a result, the assessment of a potential liability and the amount of accruals recorded are based only on the information available to us at the time. As additional information becomes available, we reassess the potential liability related to the legal proceeding, and may revise our estimates. We do not believe, relative to our current legal proceedings, that a loss is both probable and estimable. As such, as of December 31, 2015, we did not have a liability related to any of our current legal proceedings, including the following matters.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Gilead Litigation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In August 2013, Gilead Sciences Inc. filed a suit in the United States District Court of the Northern District of California related to United States Patent Nos. 7,105,499 and 8,481,712 that are jointly owned by Merck Sharp &amp; Dohme Corp. and Ionis Pharmaceuticals, Inc.&#160;In the suit Gilead is asking the court to determine that Gilead's activities do not infringe any valid claim of the named patents and that the patents are not valid. We and Merck Sharp &amp; Dohme Corp. filed our answer denying Gilead's noninfringement and invalidity contentions, contending that Gilead's commercial sale and offer for sale of sofosbuvir prior to the expiration of the '499 and '712 patents infringes those patents, and requesting monetary damages to compensate for such infringement. Under our agreement with Merck, Merck is responsible for the costs of this suit. Gilead filed a motion for summary judgment alleging invalidity of the asserted patents. In February 2016, the court denied the motion.&#160;In the same order, the court granted our motion for summary judgement for a finding of infringement, but noted that Gilead may still pursue its invalidity defenses at trial. The trial for this case is scheduled to begin March 7, 2016.</div><div><br /></div></div> 148876000 115332000 698029000 755315000 955809000 956105000 0.0025 8500000 30000000 0.0167 215320000 568000000 223900000 555000000 515000 2882000 9029000 35491000 -16975000 -14201000 35648000 31053000 31053000 36695000 -255726000 -60052000 -82848000 6285000 21125000 63493000 -38984000 -88278000 -60644000 0 0 -60644000 0 -38984000 0 0 0 0 -88278000 0 0 35648000 -35776000 -16717000 -12081000 31053000 -71433000 -26676000 -31280000 227724000 24726000 59588000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Impact of recently issued accounting standards</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In May 2014, the FASB issued accounting guidance on the recognition of revenue from customers. Under this guidance, an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects what the entity expects in exchange for the goods or services. This guidance also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance as originally issued is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">In July 2015, the FASB issued updated accounting guidance to allow for an optional one year deferral from the original effective date. As a result, we will adopt this guidance beginning on January 1, 2018. The guidance allows us to select one of two methods of adoption, either the full retrospective approach, meaning the guidance would be applied to all periods presented, or modified retrospective, meaning the cumulative effect of applying the guidance would be recognized as an adjustment to our opening retained earnings balance. We are currently determining the adoption method and timing as well as the effects the adoption will have on our consolidated financial statements and disclosures.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In August 2014, the FASB issued accounting guidance on how and when to disclose going-concern uncertainties in the financial statements. This guidance will require us to perform interim and annual assessments to determine our ability to continue as a going concern within one year from the date that we issue our financial statements. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016. We will adopt this guidance in our fiscal year beginning January&#160;1, 2017. We do not expect this guidance to have any effect on our consolidated financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In February 2015, the FASB issued accounting guidance which amends existing consolidation guidance for entities that are required to evaluate whether they should consolidate certain legal entities. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015. We will adopt this guidance in our fiscal year beginning January&#160;1, 2016. We do not expect this guidance to have any effect on our consolidated financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In April 2015, the FASB issued accounting guidance to simplify the presentation of debt issuance costs. The amended guidance requires us to present debt issuance costs as a direct deduction from the carrying amount of the related debt liability rather than as an asset. The guidance does not require us to change how we recognize and measure our debt issuance costs. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015, with early adoption permitted. We will adopt this guidance in our fiscal year beginning January&#160;1, 2016. We do not expect this guidance to have a material impact on our consolidated financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In April 2015, the FASB issued accounting guidance to clarify the accounting for fees paid in cloud computing arrangements. The amendment provides guidance to customers about whether a cloud computing arrangement includes a software license element consistent with the acquisition of other software licenses or if the arrangement excludes a software license and should be accounted for as a service contract. The guidance does not change the accounting for service contracts. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015. We will adopt this guidance in our fiscal year beginning January&#160;1, 2016 on a prospective basis. We do not expect this guidance to have a material impact on our consolidated financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In July 2015, the FASB issued accounting guidance to simplify the remeasurement of inventory. The amended guidance applies to entities that value inventory under methods other than last-in first-out (LIFO) or the retail inventory method and applies to us because we value our inventory under the FIFO method. The amended guidance requires us to measure our inventory at the lower of cost and net realizable value. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015 on a prospective basis. We will adopt this guidance in our fiscal year beginning January 1, 2016. We do not expect this guidance to have any effect on our consolidated financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In November 2015, the FASB issued accounting guidance to simplify the classification of deferred income tax assets and liabilities to always be classified as current, compared to the previous treatment, which required us to allocate our deferred tax assets between current and noncurrent. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016 on a prospective or retrospective basis, with early adoption permitted. We adopted this guidance on a prospective basis and reflected it in our consolidated balance sheet at December 31, 2015.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In January 2016, the FASB issued amended accounting guidance related to the recognition, measurement, presentation, and disclosure of certain financial instruments. The amended guidance requires us to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and for us to recognize the changes in fair value in our net income (loss), instead of recognizing changes in value through accumulated other comprehensive income, as we currently do under the existing guidance. The amended guidance also changes several disclosure requirements for financial instruments, including the methods and significant assumptions we use to estimate fair value. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2017. We will adopt this guidance on January 1, 2018 and we will make any adjustments to beginning balances through a cumulative-effect adjustment to accumulated deficit on that date. We are currently determining the effects the adoption will have on our consolidated financial statements and disclosures.</div><div><br /></div></div> 2 2 359465000 261891000 198951000 63726000 75782000 74781000 114511000 57828000 97259000 65556000 71913000 1879000 1878000 -47730000 -51666000 -75762000 -54384000 0 -21378000 -26033000 -38764000 -21697000 -12902000 -21493000 10080000 -29667000 -9330000 44646000 -62940000 -6650000 -48138000 16125000 24480000 1474000 1800000 2000000 1800000 1527000 734700000 886500000 1597000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">1. Organization and Significant Accounting Policies</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Basis of presentation</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The consolidated financial statements include the accounts of Ionis Pharmaceuticals,&#160;Inc. ("we", "us" or "our") and our wholly owned subsidiary,&#160;Akcea Therapeutics, Inc., which we formed in December 2014. In December 2015, we changed our name from Isis Pharmaceuticals, Inc. to Ionis Pharmaceuticals, Inc.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Organization and business activity</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We incorporated in California on January 10, 1989. In conjunction with our initial public offering, we reorganized as a Delaware corporation in April&#160;1991. We were organized principally to develop human therapeutic drugs using antisense technology.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Basic and diluted net loss per share</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We compute basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period. As we incurred a net loss for 2015, 2014 and 2013, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. Common stock from the following would have had an anti-dilutive effect on net loss per share:</div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;"><font style="font-size: 10pt; font-family: Symbol;">&#61489;&#61472;</font>percent convertible senior notes (for 2014 and 2015);</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">2&#190; percent convertible senior notes;</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">Dilutive stock options;</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">Unvested restricted stock units; and</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">Employee Stock Purchase Plan, or ESPP.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Revenue recognition</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In the instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;"><u>Arrangements with multiple deliverables</u></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our collaboration agreements typically contain multiple elements, or deliverables, including technology licenses or options to obtain technology licenses, research and development services, and in certain cases manufacturing services, and we allocate the consideration to each unit of accounting based on the relative selling price of each deliverable.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: left; text-indent: 36pt;">Identifying deliverables and units of accounting</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We evaluate the deliverables in our collaboration agreements to determine whether they meet the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. When the delivered items in an arrangement have "stand-alone value" to our customer, we account for the deliverables as separate units of accounting. Delivered items have stand-alone value if they are sold separately by any vendor or the customer could resell the delivered items on a stand-alone basis. For example, in May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> for the prevention of thrombosis. As part of the agreement, Bayer paid us a $100 million upfront payment in the second quarter of 2015. We are also eligible to receive milestone payments and tiered royalties on gross margins of IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. We are responsible for completing the ongoing development services for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx </sub>and for providing an initial supply of active pharmaceutical ingredient, or API. Bayer is responsible for all other development and commercialization activities for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. Since this agreement has multiple elements, we evaluated the deliverables in this arrangement when we entered into the agreement and determined that certain deliverables have stand-alone value.&#160;Below is a list of the three units of accounting under our agreement:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The exclusive license we granted to Bayer to develop and commercialize IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> for the treatment of thrombosis;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The development services we agreed to perform for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>; and&#160;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The initial supply of API.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We determined that each of these three units of accounting have stand-alone value. The exclusive license we granted to Bayer has stand-alone value because it is an exclusive license that gives Bayer the right to develop IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>&#160;or to sublicense its rights. The development services and the initial supply of API each have stand-alone value because Bayer or another third party could provide these items without our assistance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Measurement and allocation of arrangement consideration</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our collaborations may provide for various types of payments to us including upfront payments, funding of research and development, milestone payments, licensing fees and royalties on product sales. We initially allocate the amount of consideration that is fixed and determinable at the time the agreement is entered into and exclude contingent consideration. We allocate the consideration to each unit of accounting based on the relative selling price of each deliverable. We use the following hierarchy of values to estimate the selling price of each deliverable: (i)&#160;vendor-specific objective evidence of fair value; (ii)&#160;third-party evidence of selling price; and (iii)&#160;best estimate of selling price, or BESP. BESP reflects our best estimate of what the selling price would be if we regularly sold the deliverable on a stand-alone basis. We recognize the revenue allocated to each unit of accounting as we deliver the related goods or services. If we determine that we should treat certain deliverables as a single unit of accounting, then we recognize the revenue ratably over our estimated period of performance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We determined that the allocable arrangement consideration for the Bayer collaboration was $100 million and we allocated it based on the relative BESP of each unit of accounting. We engaged a third party, independent valuation expert to assist us with determining BESP. We estimated the selling price of the license granted for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> by using the relief from royalty method. Under this method, we estimated the amount of income, net of taxes, for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. We then discounted the projected income to present value. The significant inputs we used to determine the projected income of the license included:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Estimated future product sales;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Estimated royalties on future product sales;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Contractual milestone payments;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Expenses we expect to incur;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Income taxes; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">An appropriate discount rate.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We estimated the selling price of the ongoing development services by using our internal estimates of the cost to perform the specific services and estimates of expected cash outflows to third parties for services and supplies over the expected period that we will perform the development services. The significant inputs we used to determine the selling price of the ongoing development services included:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The number of internal hours we will spend performing these services;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The estimated cost of work we will perform;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The estimated cost of work that we will contract with third parties to perform; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The estimated cost of drug product we will use.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We determine the selling price of our API consistently for all of our partnerships. On an annual basis, we calculate our fully absorbed cost to manufacture API. We then determine the unit price we will charge our partners by dividing our fully absorbed costs by the quantity of API we expect to produce during the year.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">For purposes of determining BESP of the services we will perform and the API in our Bayer transaction, accounting guidance required us to include a markup for a reasonable profit margin.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Based on the units of accounting under the agreement, we allocated the $100 million upfront payment from Bayer as follows:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$91.2 million to the IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> exclusive license; </td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$4.3 million for ongoing development services; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$4.5</font> million for the delivery of API.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Assuming a constant selling price for the other elements in the arrangement, if there was an assumed ten percent increase or decrease in the estimated selling price of the IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>&#160;license, we determined that the revenue we would have allocated to the IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>&#160;license would change by approximately one percent, or $0.9 million, from the amount we recorded.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;"><u>Timing of revenue recognition</u></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We recognize revenue as we deliver each item under the arrangement and the related revenue is realizable and earned. For example, we recognized revenue for the exclusive license we granted Bayer for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> in the second quarter of 2015 because that was when we delivered the license. We also recognize revenue over time. Our collaborative agreements typically include a research and/or development project plan outlining the activities the agreement requires each party to perform during the collaboration. We must estimate our period of performance when the agreements we enter into do not clearly define such information. We estimate the period of time over which we will complete the activities for which we are responsible and use that period of time as our period of performance for purposes of revenue recognition. We then recognize revenue ratably over such period.&#160;We have made estimates of our continuing obligations under numerous agreements and in certain instances the timing of satisfying these obligations change as the development plans for our drugs progress. Accordingly, our estimates may change in the future. If our estimates and judgments change over the course of our collaboration agreements, it may affect the timing and amount of revenue that we recognize in future periods.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following are the periods over which we are recognizing revenue for each of our units of accounting under our Bayer agreement:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">We recognized the portion of the consideration attributed to the IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> license immediately because we delivered the license and earned the revenue;&#160;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">We are recognizing the amount attributed to the ongoing development services for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> over the period of time we are performing the services; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">We will recognize the amount attributed to the API supply when we deliver it to Bayer.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;"><u>Multiple agreements</u></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">From time to time, we may enter into separate agreements at or near the same time with the same customer. We evaluate such agreements to determine whether they should be accounted for individually as distinct arrangements or whether the separate agreements are, in substance, a single multiple element arrangement. We evaluate whether the negotiations are conducted jointly as part of a single negotiation, whether the deliverables are interrelated or interdependent, whether fees in one arrangement are tied to performance in another arrangement, and whether elements in one arrangement are essential to another arrangement. Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that they are, in effect, part of a single arrangement. For example, since early 2012, we have entered into four collaboration agreements with Biogen:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize nusinersen for spinal muscular atrophy, or SMA. As part of the collaboration, we received a $29 million upfront payment and we are responsible for global development of nusinersen through completion of Phase 2/3 clinical trials.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">In June 2012, we entered into a second and separate collaboration agreement with Biogen to develop and commercialize a novel antisense drug targeting DMPK, or dystrophia myotonica-protein kinase. As part of the collaboration, we received a $12 million upfront payment and we are responsible for global development of the drug through the completion of a Phase 2 clinical trial.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">In December 2012, we entered into a third and separate collaboration agreement with Biogen to discover and develop antisense drugs against three targets to treat neurological or neuromuscular disorders. As part of the collaboration, we received a $30 million upfront payment and we are responsible for the discovery of a lead antisense drug for each of three targets.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">In September 2013, we entered into a fourth and separate collaboration agreement with Biogen to leverage antisense technology to advance the treatment of neurological diseases.&#160;We granted Biogen exclusive rights to the use of our antisense technology to develop therapies for neurological diseases as part of this broad collaboration. We received a $100 million upfront payment and we are responsible for discovery and early development through the completion of a Phase 2 clinical trial for each antisense drug identified during the six-year term of this collaboration, while Biogen is responsible for the creation and development of small molecule treatments and biologics.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">All four of these collaboration agreements give Biogen the option to license one or more drugs resulting from the specific collaboration. If Biogen exercises an option, it will pay us a license fee and will assume future development, regulatory and commercialization responsibilities for the licensed drug. We are also eligible to receive milestone payments associated with the research and/or development of the drugs prior to licensing, milestone payments if Biogen achieves pre-specified regulatory milestones, and royalties on any product sales from any drugs resulting from these collaborations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We evaluated all four of the Biogen agreements to determine whether we should account for them as separate agreements. We determined that we should account for the agreements separately because we conducted the negotiations independently of one another, each agreement focuses on different drugs, there are no interrelated or interdependent deliverables, there are no provisions in any of these agreements that are essential to the other agreement, and the payment terms and fees under each agreement are independent of each other. We also evaluated the deliverables in each of these agreements to determine whether they met the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. For all four of these agreements, we determined that the options did not have stand-alone value because Biogen cannot pursue the development or commercialization of the drugs resulting from these collaborations until it exercises the respective option or options. As such, for each agreement we considered the deliverables to be a single unit of accounting and we are recognizing the upfront payment for each of the agreements over the respective estimated period of our performance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><u>Milestone payments</u></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and/ or commercialization events. These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraph.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Prior to the first stage in the life-cycle of our drugs, we perform a significant amount of work using our proprietary antisense technology to design chemical compounds that interact with specific genes that are good targets for drug discovery. From these research efforts, we hope to identify a development candidate. The designation of a development candidate is the first stage in the life-cycle of our drugs. A development candidate is a chemical compound that has demonstrated the necessary safety and efficacy in preclinical animal studies to warrant further study in humans.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During the first step of the development stage, we or our partners study our drugs in Investigational New Drug, or IND, -enabling studies, which are animal studies intended to support an IND application and/or the foreign equivalent. An approved IND allows us or our partners to study our development candidate in humans. If the regulatory agency approves the IND, we or our partners initiate Phase 1 clinical trials in which we typically enroll a small number of healthy volunteers to ensure the development candidate is safe for use in patients. If we or our partners determine that a development candidate is safe based on the Phase 1 data, we or our partners initiate Phase 2 studies that are generally larger scale studies in patients with the primary intent of determining the efficacy of the development candidate.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The final step in the development stage is Phase 3 studies to gather the necessary safety and efficacy data to request marketing authorization from the FDA and/or foreign equivalents. The Phase 3 studies typically involve large numbers of patients and can take up to several years to complete. If the data gathered during the trials demonstrates acceptable safety and efficacy results, we or our partner will submit an application to the FDA and/or its foreign equivalents for marketing authorization. This stage of the drug&#8217;s life-cycle is the regulatory stage.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">If a drug achieves marketing authorization, it moves into the commercialization stage, during which our partner will market and sell the drug to patients. Although our partner will ultimately be responsible for marketing and selling the partnered drug, our efforts to discover and develop a drug that is safe, effective and reliable contributes significantly to our partner&#8217;s ability to successfully sell the drug. The FDA and its foreign equivalents have the authority to impose significant restrictions on an approved drug through the product label and on advertising, promotional and distribution activities. Therefore, our efforts designing and executing the necessary animal and human studies are critical to obtaining claims in the product label from the regulatory agencies that would allow us or our partner to successfully commercialize our drug. Further, the patent protection afforded our drugs as a result of our initial patent applications and related prosecution activities in the United States and foreign jurisdictions are critical to our partner&#8217;s ability to sell our drugs without competition from generic drugs. The potential sales volume of an approved drug is dependent on several factors including the size of the patient population, market penetration of the drug, and the price charged for the drug.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Generally, the milestone events contained in our partnership agreements coincide with the progression of our drugs from development, to marketing authorization and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug progresses through the stages of its life-cycle, the value of the drug generally increases.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">Development milestones in our partnerships may include the following types of events:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Designation of a development candidate. Following the designation of a development candidate, IND-enabling animal studies for a new development candidate generally take 12 to 18 months to complete;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Initiation of a Phase 1 clinical trial. Generally, Phase 1 clinical trials take one to two years to complete;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Initiation or completion of a Phase 2 clinical trial. Generally, Phase 2 clinical trials take one to three years to complete;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Initiation or completion of a Phase 3 clinical trial. Generally, Phase 3 clinical trials take two to four years to complete.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">Regulatory milestones in our partnerships may include the following types of events:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Filing of regulatory applications for marketing authorization such as a New Drug Application, or NDA, in the United States or a Marketing Authorization Application, or MAA, in Europe. Generally, it takes six to twelve months to prepare and submit regulatory filings.</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Marketing authorization in a major market, such as the United States, Europe or Japan. Generally it takes one to two years after an application is submitted to obtain authorization from the applicable regulatory agency.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">Commercialization milestones in our partnerships may include the following types of events:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">First commercial sale in a particular market, such as in the United States or Europe.</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Product sales in excess of a pre-specified threshold, such as annual sales exceeding $1 billion. The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We assess whether a substantive milestone exists at the inception of our agreements. When a substantive milestone is achieved, we recognize revenue related to the milestone payment immediately. For our existing licensing and collaboration agreements in which we are involved in the discovery and/or development of the related drug or provide the partner with access to new technologies we discover, we have determined that the majority of future development, regulatory and commercialization milestones are substantive. For example, we consider most of the milestones associated with our strategic alliance with Biogen substantive because we are using our antisense drug discovery platform to discover and develop new drugs against targets for neurological diseases. We also consider milestones associated with our alliance with Alnylam Pharmaceuticals, Inc. substantive because we provide Alnylam ongoing access to our technology to develop and commercialize RNA interference, or RNAi, therapeutics. In evaluating if a milestone is substantive we consider whether:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Substantive uncertainty exists as to the achievement of the milestone event at the inception of the arrangement;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The achievement of the milestone involves substantive effort and can only be achieved based in whole or in part on our performance or the occurrence of a specific outcome resulting from our performance;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The amount of the milestone payment appears reasonable either in relation to the effort expended or to the enhancement of the value of the delivered items;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">There is no future performance required to earn the milestone; and</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">The consideration is reasonable relative to all deliverables and payment terms in the arrangement.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">If any of these conditions are not met, we do not consider the milestone to be substantive and we defer recognition of the milestone payment and recognize it as revenue over our estimated period of performance, if any. Further information about our collaborative arrangements can be found in Note 6, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements</font>.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><u>Licensing and royalty revenue</u></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We often enter into agreements to license our proprietary patent rights on an exclusive or non-exclusive basis in exchange for license fees and/or royalties. We generally recognize as revenue immediately those licensing fees and royalties for which we have no significant future performance obligations and are reasonably assured of collecting the resulting receivable. For example, during 2014, we recognized $9.5 million in revenue from Alnylam related to its license of our technology to one of its partners because we had no performance obligations and collectability was reasonably assured.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Research, development and patent expenses</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our research and development expenses include wages, benefits, facilities, supplies, external services, clinical trial and manufacturing costs and other expenses that are directly related to our research and development operations. We expense research and development costs as we incur them. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. For the years ended December 31, 2015, 2014 and 2013, research and development expenses were $319.5 million, $238.9 million and $173.7 million, respectively. A portion of the costs included in research and development expenses are costs associated with our collaboration agreements. For the years ended December 31, 2015, 2014 and 2013, research and development costs of approximately $161.7 million, $85.6 million and $51.0 million, respectively, were related to our collaborative agreements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We amortize patent costs over the useful life of the patent, beginning with the date the United States Patent and Trademark Office, or foreign equivalent, issues the patent. The weighted average remaining amortizable life of our issued patents was 10.2 years at December 31, 2015.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">The cost of our patents capitalized on our consolidated balance sheet at December 31, 2015 and 2014 was $27.5 million and $25.0 million, respectively. Accumulated amortization related to patents was $8.2 million and $7.8 million at December 31, 2015 and 2014, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Based on existing patents, estimated amortization expense related to patents in each of the next five years is as follows:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 50%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Years Ending December 31,</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Amortization</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. When we identify patents and patent applications that we are not actively pursuing, we write off any associated costs. In 2015, 2014 and 2013, patent expenses were $2.8 million, $2.9 million and $10.3 million, respectively, and included non-cash charges related to the write-down of our patent costs to their estimated net realizable values of $1.1 million, $1.3 million and $6.4 million, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Concentration of credit risk</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, short-term investments and receivables. We place our cash equivalents and short-term investments with reputable financial institutions. We primarily invest our excess cash in commercial paper and debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody&#8217;s, Standard&#160;&amp; Poor&#8217;s, or S&amp;P, or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Cash, cash equivalents and short-term investments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We consider all liquid investments with maturities of three months or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than three months from date of purchase. We classify our short-term investments as &#8220;available-for-sale&#8221; and carry them at fair market value based upon prices for identical or similar items on the last day of the fiscal period. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have equity investments in privately and publicly held biotechnology companies that we have received as part of a technology license or collaboration agreement. At December 31, 2015, we held ownership interests of less than 20 percent in each of the respective companies.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We account for our equity investments in publicly held companies at fair value and record unrealized gains and losses related to temporary increases and decreases in the stock of these publicly held companies as a separate component of comprehensive income (loss). We account for equity investments in privately held companies under the cost method of accounting because we own less than 20 percent and do not have significant influence over their operations. We hold one cost method investment in Atlantic Pharmaceuticals Limited. Realization of our equity position in this company is uncertain. When realization of our investment is uncertain, we record a full valuation allowance. In determining if and when a decrease in market value below our cost in our equity positions is temporary or other-than-temporary, we examine historical trends in the stock price, the financial condition of the company, near term prospects of the company and our current need for cash. If we determine that a decline in value in either a public or private investment is other-than-temporary, we recognize an impairment loss in the period in which the other-than-temporary decline occurs.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Inventory valuation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We capitalize the costs of raw materials that we purchase for use in producing our drugs because until we use these raw materials they have alternative future uses. We include in inventory raw material costs for drugs that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single drug. For example, if one of our drugs failed, we could use the raw materials for that drug to manufacture our other drugs. We expense these costs when we deliver the drugs to our partners, or as we provide these drugs for our own clinical trials. We reflect our inventory on the balance sheet at the lower of cost or market value under the first-in, first-out method, or FIFO. We review inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value. We consider several factors in estimating the net realizable value, including shelf life of raw materials, alternative uses for our drugs and clinical trial materials, and historical write-offs. We did not record any inventory write-offs for the years ended December 31, 2015, 2014 or 2013. Total inventory was $6.9 million and $6.3 million as of December 31, 2015 and 2014, respectively.</div><div><br /></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Property, plant and equipment</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center;">Estimated Useful Lives</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(in years)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Computer software, laboratory, manufacturing and other equipment</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">3 to 10</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">56,822</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">49,772</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Building and building systems</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">25 to 40</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,163</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,521</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr style="height: 13px;"><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Land improvements</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center; margin-left: 9pt; text-indent: -9pt;">20</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,853</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,853</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Leasehold improvements</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">5 to 20</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">39,061</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">37,935</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Furniture and fixtures</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">5 to 10</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5,842</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5,732</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">152,741</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">144,813</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Less accumulated depreciation</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(72,706</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(66,053</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">80,035</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">78,760</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Land</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,198</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,198</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr style="height: 18px;"><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">&#160;Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">90,233</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">88,958</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">We depreciate our leasehold improvements using the shorter of the estimated useful life or remaining lease term.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Fair value of financial instruments</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have estimated the fair value of our financial instruments. The amounts reported for cash, accounts receivable, accounts payable and accrued expenses approximate the fair value because of their short maturities. We report our investment securities at their estimated fair value based on quoted market prices for identical or similar instruments.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Long-lived assets</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We evaluate long-lived assets, which include property, plant and equipment, patent costs, and exclusive licenses acquired from third parties, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets. We recorded charges of $1.9 million, $1.3 million and $6.4 million for the years ended December 31, 2015, 2014 and 2013, respectively, related primarily to the write-down of intangible assets.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Use of estimates</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Stock-based compensation expense</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our ESPP based on the estimated fair value of the award on the date of grant. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our Consolidated Statements of Operations. We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We use the Black-Scholes model as our method of valuing option awards and stock purchase rights under our ESPP. On the grant date, we use our stock price and assumptions regarding a number of highly complex and subjective variables to determine the estimated fair value of stock-based payment awards. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Option-pricing models were developed for use in estimating the value of traded options that have no vesting or hedging restrictions and are fully transferable. Because our employee stock options have certain characteristics that are significantly different from traded options, and because changes in the subjective assumptions can materially affect the estimated value, in management&#8217;s opinion, the existing valuation models may not provide an accurate measure of the fair value of our employee stock options. Although we determine the estimated fair value of employee stock options using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We recognize compensation expense for option awards using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), an entity recognizes compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The fair value of RSUs is based on the market price of our common stock on the date of grant.&#160;The RSUs we have granted vest annually over a four-year period.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">See Note 4, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Stockholders&#8217; Equity,</font> for additional information regarding our share-based compensation plans.</div><div><br /></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Accumulated other comprehensive income (loss)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on investments, net of taxes, and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive income to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive income for the years ended December 31, 2015, 2014 and 2013 (in thousands):</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">&#160;</div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Beginning balance accumulated other comprehensive income</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">39,747</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">21,080</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">12,480</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 18pt; text-indent: -9pt;">Unrealized (losses) gains on securities, net of tax (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(33,101</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">40,079</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,253</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 18pt; text-indent: -9pt;">Amounts reclassified from accumulated other comprehensive (loss) income (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(20,211</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(21,412</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,653</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net other comprehensive (loss) income for the period</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(53,312</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">18,667</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">8,600</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Ending balance accumulated other comprehensive (loss) income</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(13,565</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">39,747</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">21,080</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 12pt;"><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(1)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Other comprehensive income includes income tax expense of $12.8 million and $5.9 million for the years ended December 31, 2014 and 2013, respectively. There was no tax expense for other comprehensive income for the year ended December 31, 2015.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(2)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Amounts for 2015 are included in the separate line called &#8220;Gain on investment in Regulus Therapeutics Inc.&#8221; on our Consolidated Statement of Operations. For 2014, $19.9 million is included in a separate line called &#8220;Gain on investment in Regulus Therapeutics Inc.&#8221;, with the remaining amount included in a separate line called &#8220;Gain on investments, net&#8221; on our Consolidated Statement of Operations. Amounts for 2013 are included in a separate line called &#8220;Gain on investments, net&#8221; on our Consolidated Statement of Operations.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Convertible debt</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We account for convertible debt instruments, including our 1 percent and 2&#190; percent notes, that may be settled in cash upon conversion (including partial cash settlement) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. We determine the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, we estimate fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We assign a value to the debt component of our convertible notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording our debt at a discount. We are amortizing the debt discount over the life of the convertible notes as additional non-cash interest expense utilizing the effective interest method. For additional information, see Note 3, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Long-Term Obligations and Commitments</font>.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Segment information</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In 2015, we began operating as two segments, our Ionis Core segment, previously referred to as Drug Discovery and Development, and Akcea Therapeutics, which consists of the operations of our wholly owned subsidiary, Akcea Therapeutics, Inc. We formed Akcea to develop and commercialize drugs for cardiometabolic disorders. We provide segment financial information and results for our Ionis Core segment and our Akcea Therapeutics segment based on the segregation of revenues and expenses that our chief decision maker reviews to assess operating performance and to make operating decisions. We use judgments and estimates in determining the allocation of shared expenses to the two segments.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Fair value measurements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investment in equity securities in publicly held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. Our Level 3 investments include our investments in the equity securities of publicly held biotechnology companies for which we calculated a lack of marketability discount because there were restrictions on when we could trade the securities. Historically, we have determined the lack of marketability discount by using a Black-Scholes model to value a hypothetical put option to approximate the cost of hedging the stock until the restriction ends. The majority of our securities have been classified as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices. During 2015 and 2014, there were no transfers between our Level 1 and Level 2 investments. We recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.</div><div><br /></div><div style="text-align: left;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We measure the following major security types at fair value on a recurring basis. The following summary breaks down the fair-value hierarchy that we valued each security with at December 31, 2015 and 2014 (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">At</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31, 2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quoted Prices in</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Active Markets</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant Other</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Observable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unobservable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Cash equivalents (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">88,902</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">88,902</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">438,426</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">438,426</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">89,253</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">89,253</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states (3)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">127,656</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">127,656</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Investment in Regulus Therapeutics Inc.</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,792</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,792</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">771,630</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">116,295</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">655,335</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">At</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quoted Prices in</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Active Markets</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant Other</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Observable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Significant</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unobservable</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Inputs</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Cash equivalents (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">104,680</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">104,680</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities (4)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372,002</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372,002</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">109,855</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">109,855</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury (5)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states (6)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">105,033</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">105,033</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Investment in Regulus Therapeutics Inc.</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11px; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 45%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">792,468</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11px; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">123,697</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">586,890</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 484.45pt;"><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(1)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Included in cash and cash equivalents on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(2)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(3)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$7.5 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(4)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(5)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$10 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(6)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$9.3 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In the first quarter of 2014, Achaogen completed an initial public offering. As a result, we stopped using the cost method of accounting for our equity investment in Achaogen and instead we began accounting for it at fair value. Until September 2014, the fair value of our investment in Achaogen included a lack of marketability discount because there were restrictions on when we could trade the securities. As such, we classified our Achaogen stock as a Level 3 investment. In September 2014, we reclassified our investment in Achaogen to a Level 1 investment because the contractual trading restrictions on the shares we owned ended and we subsequently sold all of our shares in 2014. </div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In November 2014, Regulus completed a public offering. As part of the offering, we sold shares of Regulus' common stock and became subject to trading restrictions on our remaining shares through January 2015. Therefore, at December 31, 2014, we recorded a lack of marketability discount on our investment in Regulus and classified it as a Level 3 investment. At the end of January 2015, we reclassified our investment in Regulus to a Level 1 investment because the contractual trading restrictions on the shares we owned ended.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2015 and 2014 (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Beginning balance of Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Transfers into Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">108,009</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10.8pt; text-indent: -8.9pt;">Total gains (losses) included in accumulated other comprehensive income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">22,377</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(24,897</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Transfers out of Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(104,258</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,231</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Ending balance of Level 3 investments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div><br /></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Impact of recently issued accounting standards</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In May 2014, the FASB issued accounting guidance on the recognition of revenue from customers. Under this guidance, an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects what the entity expects in exchange for the goods or services. This guidance also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance as originally issued is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">In July 2015, the FASB issued updated accounting guidance to allow for an optional one year deferral from the original effective date. As a result, we will adopt this guidance beginning on January 1, 2018. The guidance allows us to select one of two methods of adoption, either the full retrospective approach, meaning the guidance would be applied to all periods presented, or modified retrospective, meaning the cumulative effect of applying the guidance would be recognized as an adjustment to our opening retained earnings balance. We are currently determining the adoption method and timing as well as the effects the adoption will have on our consolidated financial statements and disclosures.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In August 2014, the FASB issued accounting guidance on how and when to disclose going-concern uncertainties in the financial statements. This guidance will require us to perform interim and annual assessments to determine our ability to continue as a going concern within one year from the date that we issue our financial statements. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016. We will adopt this guidance in our fiscal year beginning January&#160;1, 2017. We do not expect this guidance to have any effect on our consolidated financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In February 2015, the FASB issued accounting guidance which amends existing consolidation guidance for entities that are required to evaluate whether they should consolidate certain legal entities. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015. We will adopt this guidance in our fiscal year beginning January&#160;1, 2016. We do not expect this guidance to have any effect on our consolidated financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In April 2015, the FASB issued accounting guidance to simplify the presentation of debt issuance costs. The amended guidance requires us to present debt issuance costs as a direct deduction from the carrying amount of the related debt liability rather than as an asset. The guidance does not require us to change how we recognize and measure our debt issuance costs. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015, with early adoption permitted. We will adopt this guidance in our fiscal year beginning January&#160;1, 2016. We do not expect this guidance to have a material impact on our consolidated financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In April 2015, the FASB issued accounting guidance to clarify the accounting for fees paid in cloud computing arrangements. The amendment provides guidance to customers about whether a cloud computing arrangement includes a software license element consistent with the acquisition of other software licenses or if the arrangement excludes a software license and should be accounted for as a service contract. The guidance does not change the accounting for service contracts. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015. We will adopt this guidance in our fiscal year beginning January&#160;1, 2016 on a prospective basis. We do not expect this guidance to have a material impact on our consolidated financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In July 2015, the FASB issued accounting guidance to simplify the remeasurement of inventory. The amended guidance applies to entities that value inventory under methods other than last-in first-out (LIFO) or the retail inventory method and applies to us because we value our inventory under the FIFO method. The amended guidance requires us to measure our inventory at the lower of cost and net realizable value. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015 on a prospective basis. We will adopt this guidance in our fiscal year beginning January 1, 2016. We do not expect this guidance to have any effect on our consolidated financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In November 2015, the FASB issued accounting guidance to simplify the classification of deferred income tax assets and liabilities to always be classified as current, compared to the previous treatment, which required us to allocate our deferred tax assets between current and noncurrent. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016 on a prospective or retrospective basis, with early adoption permitted. We adopted this guidance on a prospective basis and reflected it in our consolidated balance sheet at December 31, 2015.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In January 2016, the FASB issued amended accounting guidance related to the recognition, measurement, presentation, and disclosure of certain financial instruments. The amended guidance requires us to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and for us to recognize the changes in fair value in our net income (loss), instead of recognizing changes in value through accumulated other comprehensive income, as we currently do under the existing guidance. The amended guidance also changes several disclosure requirements for financial instruments, including the methods and significant assumptions we use to estimate fair value. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2017. We will adopt this guidance on January 1, 2018 and we will make any adjustments to beginning balances through a cumulative-effect adjustment to accumulated deficit on that date. We are currently determining the effects the adoption will have on our consolidated financial statements and disclosures.</div><div><br /></div></div> 21412000 1653000 20211000 20211000 1653000 21412000 5900000 12800000 0 10253000 40079000 -33101000 14773000 15691000 5900000 12800000 10253000 40079000 -33101000 8600000 18667000 -53312000 0 0 0 18667000 -53312000 0 0 -53312000 0 0 18667000 0 8600000 0 8600000 -25527000 -22949000 0 10100000 7518000 7692000 1552000 425554000 391883000 493467000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">8. Employment Benefits</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have an employee 401(k) salary deferral plan, covering all employees. Employees may make contributions by withholding a percentage of their salary up to the IRS annual limit ($18,000 and $24,000 in 2015 for employees under 50 years old and employees 50 years old or over, respectively). We made approximately $1.5 million, $1.0 million and $0.6 million in matching contributions for the years ended December 31, 2015, 2014 and 2013, respectively.</div><div><br /></div></div> 0 0 15000000 0 0 0 0 487035000 487000000 215000000 0 8500000 0 173292000 0 0 150000000 23600000 62000000 22400000 172762000 419584000 294727000 1300000 22900000 25500000 24888000 23071000 62958000 63000000 23100000 24900000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center;">Estimated Useful Lives</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(in years)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Computer software, laboratory, manufacturing and other equipment</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">3 to 10</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">56,822</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">49,772</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Building and building systems</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">25 to 40</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,163</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,521</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr style="height: 13px;"><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Land improvements</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center; margin-left: 9pt; text-indent: -9pt;">20</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,853</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,853</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Leasehold improvements</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">5 to 20</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">39,061</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">37,935</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Furniture and fixtures</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">5 to 10</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5,842</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5,732</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">152,741</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">144,813</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Less accumulated depreciation</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(72,706</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(66,053</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">80,035</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">78,760</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Land</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,198</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,198</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr style="height: 18px;"><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">&#160;Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">90,233</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">88,958</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Property, plant and equipment</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center;">Estimated Useful Lives</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(in years)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Computer software, laboratory, manufacturing and other equipment</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">3 to 10</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">56,822</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">49,772</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Building and building systems</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">25 to 40</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,163</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,521</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr style="height: 13px;"><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Land improvements</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center; margin-left: 9pt; text-indent: -9pt;">20</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,853</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,853</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Leasehold improvements</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">5 to 20</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">39,061</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">37,935</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Furniture and fixtures</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">5 to 10</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5,842</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5,732</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">152,741</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">144,813</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Less accumulated depreciation</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(72,706</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(66,053</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">80,035</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">78,760</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Land</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,198</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,198</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr style="height: 18px;"><td valign="bottom" style="width: 58%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">&#160;Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 15%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">90,233</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">88,958</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">We depreciate our leasehold improvements using the shorter of the estimated useful life or remaining lease term.</div><div><br /></div></div> P10Y P20Y P25Y P5Y P10Y P40Y P3Y P5Y P20Y 88958000 90233000 78760000 80035000 62200000 64400000 152741000 10198000 2853000 5732000 56822000 10198000 48163000 49772000 37935000 2853000 48521000 39061000 5842000 144813000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">10. Quarterly Financial Data (Unaudited)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for the years ended December 31, 2015 and 2014 are as follows (in thousands, except per share data).</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">2015 Quarters</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">First</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Second</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Third</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fourth</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">62,583</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">120,428</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">49,121</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">51,571</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Operating expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">71,913</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">75,782</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">97,259</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">114,511</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Income (loss) from operations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(9,330</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">44,646</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(48,138</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(62,940</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Net income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(16,717</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">35,648</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(35,776</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(71,433</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Basic net income (loss) per share (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.14</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.59</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Diluted net income (loss) per share (1) (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.14</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.29</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.59</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr></table><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">2014 Quarters</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">First</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Second</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Third</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fourth</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">28,161</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">57,076</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">44,063</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">84,861</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Operating expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">57,828</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">63,726</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">65,556</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">74,781</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Income (loss) from operations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(29,667</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(6,650</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(21,493</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,080</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Net income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(31,280</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(12,081</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(26,676</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">31,053</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Basic net income (loss) per share (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.27</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.10</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.23</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.26</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Diluted net income (loss) per share (1) (3)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.27</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.10</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.23</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.25</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div style="text-align: justify; text-indent: 484.45pt;"><br /></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 4.5pt;">(1)</div></td><td style="width: auto; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.</div></td></tr></table></div><div><br /></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 4.5pt;">(2)</div></td><td style="width: auto; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">For the three months ended June 30, 2015, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended June 30, 2015 consisted of the following (in thousands):</div></td></tr></table></div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Three Months Ended June 30, 2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Income</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Numerator)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Shares</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Denominator)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Per-Share Amount</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">&#160;</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Income available to common shareholders</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">35,648</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">119,742</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Effect of diluted securities:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable upon exercise of stock options</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,974</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable upon restricted stock award issuance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">376</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable related to our ESPP</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable related to our 2&#190; percent notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,047</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,683</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9.1pt; text-indent: -9.1pt;">Income available to common shareholders, plus assumed conversions</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">36,695</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">127,779</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.29</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 36pt;">For the three months ended June 30, 2015, the calculation excludes the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.</div><div><br /></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 4.5pt;">(3)</div></td><td style="width: auto; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">For the three months ended December 31, 2014, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended December 31, 2014 consisted of the following (in thousands):</div></td></tr></table></div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Three Months Ended December 31, 2014</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Income</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Numerator)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Shares</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Denominator)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Per-Share Amount</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">&#160;</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Income available to common shareholders</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">31,053</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">118,223</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.26</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Effect of diluted securities:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable upon exercise of stock options</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">4,189</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable upon restricted stock award issuance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">418</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable related to our ESPP</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9.1pt; text-indent: -9.1pt;">Income available to common shareholders, plus assumed conversions</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">31,053</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">122,839</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.25</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 36pt;">For the three months ended December 31, 2014, the calculation excludes the 1 percent and 2&#190; percent convertible senior notes because the effect on diluted earnings per share was anti-dilutive.</div><div><br /></div></div> 3903000 11356000 11039000 10587000 9058000 441394000 0 0 441900000 51000000 85600000 319500000 173700000 238900000 161700000 3000000 5000000 -1006594000 -1094872000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Revenue recognition</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In the instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;"><u>Arrangements with multiple deliverables</u></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our collaboration agreements typically contain multiple elements, or deliverables, including technology licenses or options to obtain technology licenses, research and development services, and in certain cases manufacturing services, and we allocate the consideration to each unit of accounting based on the relative selling price of each deliverable.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: left; text-indent: 36pt;">Identifying deliverables and units of accounting</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We evaluate the deliverables in our collaboration agreements to determine whether they meet the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. When the delivered items in an arrangement have "stand-alone value" to our customer, we account for the deliverables as separate units of accounting. Delivered items have stand-alone value if they are sold separately by any vendor or the customer could resell the delivered items on a stand-alone basis. For example, in May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> for the prevention of thrombosis. As part of the agreement, Bayer paid us a $100 million upfront payment in the second quarter of 2015. We are also eligible to receive milestone payments and tiered royalties on gross margins of IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. We are responsible for completing the ongoing development services for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx </sub>and for providing an initial supply of active pharmaceutical ingredient, or API. Bayer is responsible for all other development and commercialization activities for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. Since this agreement has multiple elements, we evaluated the deliverables in this arrangement when we entered into the agreement and determined that certain deliverables have stand-alone value.&#160;Below is a list of the three units of accounting under our agreement:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The exclusive license we granted to Bayer to develop and commercialize IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> for the treatment of thrombosis;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The development services we agreed to perform for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>; and&#160;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The initial supply of API.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We determined that each of these three units of accounting have stand-alone value. The exclusive license we granted to Bayer has stand-alone value because it is an exclusive license that gives Bayer the right to develop IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>&#160;or to sublicense its rights. The development services and the initial supply of API each have stand-alone value because Bayer or another third party could provide these items without our assistance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Measurement and allocation of arrangement consideration</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our collaborations may provide for various types of payments to us including upfront payments, funding of research and development, milestone payments, licensing fees and royalties on product sales. We initially allocate the amount of consideration that is fixed and determinable at the time the agreement is entered into and exclude contingent consideration. We allocate the consideration to each unit of accounting based on the relative selling price of each deliverable. We use the following hierarchy of values to estimate the selling price of each deliverable: (i)&#160;vendor-specific objective evidence of fair value; (ii)&#160;third-party evidence of selling price; and (iii)&#160;best estimate of selling price, or BESP. BESP reflects our best estimate of what the selling price would be if we regularly sold the deliverable on a stand-alone basis. We recognize the revenue allocated to each unit of accounting as we deliver the related goods or services. If we determine that we should treat certain deliverables as a single unit of accounting, then we recognize the revenue ratably over our estimated period of performance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We determined that the allocable arrangement consideration for the Bayer collaboration was $100 million and we allocated it based on the relative BESP of each unit of accounting. We engaged a third party, independent valuation expert to assist us with determining BESP. We estimated the selling price of the license granted for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> by using the relief from royalty method. Under this method, we estimated the amount of income, net of taxes, for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>. We then discounted the projected income to present value. The significant inputs we used to determine the projected income of the license included:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Estimated future product sales;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Estimated royalties on future product sales;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Contractual milestone payments;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Expenses we expect to incur;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Income taxes; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">An appropriate discount rate.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We estimated the selling price of the ongoing development services by using our internal estimates of the cost to perform the specific services and estimates of expected cash outflows to third parties for services and supplies over the expected period that we will perform the development services. The significant inputs we used to determine the selling price of the ongoing development services included:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The number of internal hours we will spend performing these services;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The estimated cost of work we will perform;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The estimated cost of work that we will contract with third parties to perform; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The estimated cost of drug product we will use.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We determine the selling price of our API consistently for all of our partnerships. On an annual basis, we calculate our fully absorbed cost to manufacture API. We then determine the unit price we will charge our partners by dividing our fully absorbed costs by the quantity of API we expect to produce during the year.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">For purposes of determining BESP of the services we will perform and the API in our Bayer transaction, accounting guidance required us to include a markup for a reasonable profit margin.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Based on the units of accounting under the agreement, we allocated the $100 million upfront payment from Bayer as follows:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$91.2 million to the IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> exclusive license; </td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">$4.3 million for ongoing development services; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$4.5</font> million for the delivery of API.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Assuming a constant selling price for the other elements in the arrangement, if there was an assumed ten percent increase or decrease in the estimated selling price of the IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>&#160;license, we determined that the revenue we would have allocated to the IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub>&#160;license would change by approximately one percent, or $0.9 million, from the amount we recorded.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;"><u>Timing of revenue recognition</u></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We recognize revenue as we deliver each item under the arrangement and the related revenue is realizable and earned. For example, we recognized revenue for the exclusive license we granted Bayer for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> in the second quarter of 2015 because that was when we delivered the license. We also recognize revenue over time. Our collaborative agreements typically include a research and/or development project plan outlining the activities the agreement requires each party to perform during the collaboration. We must estimate our period of performance when the agreements we enter into do not clearly define such information. We estimate the period of time over which we will complete the activities for which we are responsible and use that period of time as our period of performance for purposes of revenue recognition. We then recognize revenue ratably over such period.&#160;We have made estimates of our continuing obligations under numerous agreements and in certain instances the timing of satisfying these obligations change as the development plans for our drugs progress. Accordingly, our estimates may change in the future. If our estimates and judgments change over the course of our collaboration agreements, it may affect the timing and amount of revenue that we recognize in future periods.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following are the periods over which we are recognizing revenue for each of our units of accounting under our Bayer agreement:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">We recognized the portion of the consideration attributed to the IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> license immediately because we delivered the license and earned the revenue;&#160;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">We are recognizing the amount attributed to the ongoing development services for IONIS-FXI<sub style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Rx</sub> over the period of time we are performing the services; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">We will recognize the amount attributed to the API supply when we deliver it to Bayer.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;"><u>Multiple agreements</u></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">From time to time, we may enter into separate agreements at or near the same time with the same customer. We evaluate such agreements to determine whether they should be accounted for individually as distinct arrangements or whether the separate agreements are, in substance, a single multiple element arrangement. We evaluate whether the negotiations are conducted jointly as part of a single negotiation, whether the deliverables are interrelated or interdependent, whether fees in one arrangement are tied to performance in another arrangement, and whether elements in one arrangement are essential to another arrangement. Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that they are, in effect, part of a single arrangement. For example, since early 2012, we have entered into four collaboration agreements with Biogen:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize nusinersen for spinal muscular atrophy, or SMA. As part of the collaboration, we received a $29 million upfront payment and we are responsible for global development of nusinersen through completion of Phase 2/3 clinical trials.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">In June 2012, we entered into a second and separate collaboration agreement with Biogen to develop and commercialize a novel antisense drug targeting DMPK, or dystrophia myotonica-protein kinase. As part of the collaboration, we received a $12 million upfront payment and we are responsible for global development of the drug through the completion of a Phase 2 clinical trial.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">In December 2012, we entered into a third and separate collaboration agreement with Biogen to discover and develop antisense drugs against three targets to treat neurological or neuromuscular disorders. As part of the collaboration, we received a $30 million upfront payment and we are responsible for the discovery of a lead antisense drug for each of three targets.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">In September 2013, we entered into a fourth and separate collaboration agreement with Biogen to leverage antisense technology to advance the treatment of neurological diseases.&#160;We granted Biogen exclusive rights to the use of our antisense technology to develop therapies for neurological diseases as part of this broad collaboration. We received a $100 million upfront payment and we are responsible for discovery and early development through the completion of a Phase 2 clinical trial for each antisense drug identified during the six-year term of this collaboration, while Biogen is responsible for the creation and development of small molecule treatments and biologics.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">All four of these collaboration agreements give Biogen the option to license one or more drugs resulting from the specific collaboration. If Biogen exercises an option, it will pay us a license fee and will assume future development, regulatory and commercialization responsibilities for the licensed drug. We are also eligible to receive milestone payments associated with the research and/or development of the drugs prior to licensing, milestone payments if Biogen achieves pre-specified regulatory milestones, and royalties on any product sales from any drugs resulting from these collaborations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We evaluated all four of the Biogen agreements to determine whether we should account for them as separate agreements. We determined that we should account for the agreements separately because we conducted the negotiations independently of one another, each agreement focuses on different drugs, there are no interrelated or interdependent deliverables, there are no provisions in any of these agreements that are essential to the other agreement, and the payment terms and fees under each agreement are independent of each other. We also evaluated the deliverables in each of these agreements to determine whether they met the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. For all four of these agreements, we determined that the options did not have stand-alone value because Biogen cannot pursue the development or commercialization of the drugs resulting from these collaborations until it exercises the respective option or options. As such, for each agreement we considered the deliverables to be a single unit of accounting and we are recognizing the upfront payment for each of the agreements over the respective estimated period of our performance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><u>Milestone payments</u></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and/ or commercialization events. These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraph.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Prior to the first stage in the life-cycle of our drugs, we perform a significant amount of work using our proprietary antisense technology to design chemical compounds that interact with specific genes that are good targets for drug discovery. From these research efforts, we hope to identify a development candidate. The designation of a development candidate is the first stage in the life-cycle of our drugs. A development candidate is a chemical compound that has demonstrated the necessary safety and efficacy in preclinical animal studies to warrant further study in humans.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During the first step of the development stage, we or our partners study our drugs in Investigational New Drug, or IND, -enabling studies, which are animal studies intended to support an IND application and/or the foreign equivalent. An approved IND allows us or our partners to study our development candidate in humans. If the regulatory agency approves the IND, we or our partners initiate Phase 1 clinical trials in which we typically enroll a small number of healthy volunteers to ensure the development candidate is safe for use in patients. If we or our partners determine that a development candidate is safe based on the Phase 1 data, we or our partners initiate Phase 2 studies that are generally larger scale studies in patients with the primary intent of determining the efficacy of the development candidate.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The final step in the development stage is Phase 3 studies to gather the necessary safety and efficacy data to request marketing authorization from the FDA and/or foreign equivalents. The Phase 3 studies typically involve large numbers of patients and can take up to several years to complete. If the data gathered during the trials demonstrates acceptable safety and efficacy results, we or our partner will submit an application to the FDA and/or its foreign equivalents for marketing authorization. This stage of the drug&#8217;s life-cycle is the regulatory stage.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">If a drug achieves marketing authorization, it moves into the commercialization stage, during which our partner will market and sell the drug to patients. Although our partner will ultimately be responsible for marketing and selling the partnered drug, our efforts to discover and develop a drug that is safe, effective and reliable contributes significantly to our partner&#8217;s ability to successfully sell the drug. The FDA and its foreign equivalents have the authority to impose significant restrictions on an approved drug through the product label and on advertising, promotional and distribution activities. Therefore, our efforts designing and executing the necessary animal and human studies are critical to obtaining claims in the product label from the regulatory agencies that would allow us or our partner to successfully commercialize our drug. Further, the patent protection afforded our drugs as a result of our initial patent applications and related prosecution activities in the United States and foreign jurisdictions are critical to our partner&#8217;s ability to sell our drugs without competition from generic drugs. The potential sales volume of an approved drug is dependent on several factors including the size of the patient population, market penetration of the drug, and the price charged for the drug.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Generally, the milestone events contained in our partnership agreements coincide with the progression of our drugs from development, to marketing authorization and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug progresses through the stages of its life-cycle, the value of the drug generally increases.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">Development milestones in our partnerships may include the following types of events:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Designation of a development candidate. Following the designation of a development candidate, IND-enabling animal studies for a new development candidate generally take 12 to 18 months to complete;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Initiation of a Phase 1 clinical trial. Generally, Phase 1 clinical trials take one to two years to complete;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Initiation or completion of a Phase 2 clinical trial. Generally, Phase 2 clinical trials take one to three years to complete;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Initiation or completion of a Phase 3 clinical trial. Generally, Phase 3 clinical trials take two to four years to complete.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">Regulatory milestones in our partnerships may include the following types of events:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Filing of regulatory applications for marketing authorization such as a New Drug Application, or NDA, in the United States or a Marketing Authorization Application, or MAA, in Europe. Generally, it takes six to twelve months to prepare and submit regulatory filings.</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Marketing authorization in a major market, such as the United States, Europe or Japan. Generally it takes one to two years after an application is submitted to obtain authorization from the applicable regulatory agency.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">Commercialization milestones in our partnerships may include the following types of events:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">First commercial sale in a particular market, such as in the United States or Europe.</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Product sales in excess of a pre-specified threshold, such as annual sales exceeding $1 billion. The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We assess whether a substantive milestone exists at the inception of our agreements. When a substantive milestone is achieved, we recognize revenue related to the milestone payment immediately. For our existing licensing and collaboration agreements in which we are involved in the discovery and/or development of the related drug or provide the partner with access to new technologies we discover, we have determined that the majority of future development, regulatory and commercialization milestones are substantive. For example, we consider most of the milestones associated with our strategic alliance with Biogen substantive because we are using our antisense drug discovery platform to discover and develop new drugs against targets for neurological diseases. We also consider milestones associated with our alliance with Alnylam Pharmaceuticals, Inc. substantive because we provide Alnylam ongoing access to our technology to develop and commercialize RNA interference, or RNAi, therapeutics. In evaluating if a milestone is substantive we consider whether:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Substantive uncertainty exists as to the achievement of the milestone event at the inception of the arrangement;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The achievement of the milestone involves substantive effort and can only be achieved based in whole or in part on our performance or the occurrence of a specific outcome resulting from our performance;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">The amount of the milestone payment appears reasonable either in relation to the effort expended or to the enhancement of the value of the delivered items;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">There is no future performance required to earn the milestone; and</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">The consideration is reasonable relative to all deliverables and payment terms in the arrangement.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">If any of these conditions are not met, we do not consider the milestone to be substantive and we defer recognition of the milestone payment and recognize it as revenue over our estimated period of performance, if any. Further information about our collaborative arrangements can be found in Note 6, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements</font>.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><u>Licensing and royalty revenue</u></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We often enter into agreements to license our proprietary patent rights on an exclusive or non-exclusive basis in exchange for license fees and/or royalties. We generally recognize as revenue immediately those licensing fees and royalties for which we have no significant future performance obligations and are reasonably assured of collecting the resulting receivable. For example, during 2014, we recognized $9.5 million in revenue from Alnylam related to its license of our technology to one of its partners because we had no performance obligations and collectability was reasonably assured.</div><div><br /></div></div> 2000000 11000000 40000000 2800000 10000000 3000000 5000000 1500000 4000000 283703000 214161000 147285000 6400000 27700000 29100000 11500000 106200000 37000000 123200000 91200000 93400000 32500000 0 0 37300000 35300000 33300000 0 0 8900000 8700000 5100000 31200000 0 4000000 0 9900000 1500000 1300000 0 0 0 0 0 0 0 0 0 400000 0 0 0 0 0 0 0 214161000 0 150471000 -4248000 287951000 28161000 84861000 49121000 120428000 44063000 62583000 57076000 51571000 P4Y6M P4Y8M12D P6Y10M24D P6M P7Y2M12D P6M P6Y10M24D P5Y1M6D P6M P4Y6M25D 0.25 0.25 0.85 179273000 P7Y P7Y P10Y P10Y P3Y3M25D <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Based on existing patents, estimated amortization expense related to patents in each of the next five years is as follows:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 50%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Years Ending December 31,</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Amortization</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes the stock option activity for the year ended December 31, 2015 (in thousands, except per share and contractual life data):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Number of</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Shares</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Average Exercise</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Price</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Per Share</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Remaining</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Contractual Term</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Years)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Aggregate</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Intrinsic</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Outstanding at December 31, 2014</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7,379</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19.52</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Granted</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,550</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">61.02</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Exercised</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,674</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">14.07</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Cancelled/forfeited/expired</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(214</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">42.43</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Outstanding at December 31, 2015</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">8,041</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">33.21</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">4.57</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">232,581</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Exercisable at December 31, 2015</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,940</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">16.43</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3.32</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">179,273</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">For the years ended December 31, 2015, 2014 and 2013, we used the following weighted-average assumptions in our Black-Scholes calculations:</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Employee Stock Options:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%; border-collapse: collapse;"><tr><td style="width: 54.36%; vertical-align: bottom;">&#160;</td><td colspan="5" style="width: 45.64%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td style="width: 4.31%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td style="width: 4.31%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Risk-free interest rate</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">1.5 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">1.7 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">1.1 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Dividend yield</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Volatility</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">53.8 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">50.1 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">51.1 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Expected life</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">4.5 years</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">4.7 years</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">5.1 years</div></td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Board of Director Stock Options:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%; border-collapse: collapse;"><tr><td style="width: 54.36%; vertical-align: bottom;">&#160;</td><td colspan="5" style="width: 45.64%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td style="width: 4.31%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td style="width: 4.31%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Risk-free interest rate</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">2.1 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">2.2 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">2.2 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Dividend yield</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Volatility</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">52.2 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">54.2 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">52.7 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Expected life</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">6.9 years</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">6.9 years</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">7.2 years</div></td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The provisions for income taxes on income from continuing operations were as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Current:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr style="height: 13px;"><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Federal</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">379</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">263</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">State</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(4,295</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total current</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(4,032</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Deferred:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Federal</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(8,948</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(5,082</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">State</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,427</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(834</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total deferred</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(11,375</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(5,916</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Income tax expense (benefit)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(15,407</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(5,914</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 36pt;">ESPP:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%; border-collapse: collapse;"><tr><td style="width: 54.19%; vertical-align: bottom;">&#160;</td><td colspan="5" style="width: 45.81%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td></tr><tr><td style="width: 54.19%; vertical-align: bottom;">&#160;</td><td style="width: 12.4%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td style="width: 4.35%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td style="width: 4.37%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td></tr><tr><td style="width: 54.19%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Risk-free interest rate</div></td><td style="width: 12.4%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.1 %</div></td><td style="width: 4.35%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.1 %</div></td><td style="width: 4.37%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.1 %</div></td></tr><tr><td style="width: 54.19%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Dividend yield</div></td><td style="width: 12.4%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.35%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.37%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td></tr><tr><td style="width: 54.19%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Volatility</div></td><td style="width: 12.4%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">51.7 %</div></td><td style="width: 4.35%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">60.1 %</div></td><td style="width: 4.37%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">62.9 %</div></td></tr><tr><td style="width: 54.19%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Expected life</div></td><td style="width: 12.4%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">6 months</div></td><td style="width: 4.35%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">6 months</div></td><td style="width: 4.37%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">6 months</div></td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Annual future minimum payments under operating leases as of December 31, 2015 are as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Operating</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Leases</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,879</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,878</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,597</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,474</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,527</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">16,125</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total minimum payments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,480</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The reconciliation between our effective tax rate on income from continuing operations and the statutory U.S. tax rate is as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="22" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Pre-tax loss</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(87,906</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(54,391</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(66,558</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Statutory rate</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(30,767</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">35.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(19,035</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">35.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(23,295</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">35.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">State income tax net of federal benefit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3,125</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3,823</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net change in valuation allowance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">69,499</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(79.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">29,547</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(54.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">28,850</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(43.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Loss on debt extinguishment</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,406</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(4.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr><tr style="height: 12px;"><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Tax credits</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(41,284</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">47.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(23,628</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">43.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(15,839</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">23.8</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">California franchise tax refund</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,795</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Deferred tax true-up</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,496</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">977</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1.8</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">8,023</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(12.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,427</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1.6</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">246</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">170</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td></tr><tr><td style="width: 28%; vertical-align: bottom; white-space: nowrap; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Effective rate</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">372</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(15,407</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">28.2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(5,914</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">8.9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">%</div></td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Significant components of our deferred tax assets and liabilities as of December 31, 2015 and 2014 are as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr style="height: 20px;"><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Deferred Tax Assets:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Net operating loss carryovers</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">218,493</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">231,654</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">R&amp;D credits</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">153,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">93,594</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Deferred revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">45,110</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">58,836</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Stock-based compensation</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">31,093</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">21,553</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,655</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">15,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total deferred tax assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">467,952</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">421,186</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Deferred Tax Liabilities:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Convertible debt</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(55,928</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(73,733</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Unrealized gain in other comprehensive income</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(5,288</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(27,878</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Intangible and capital assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,643</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3,641</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Net deferred tax asset</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">404,093</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">315,934</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Valuation allowance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(404,093</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(315,934</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Net deferreds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div><br /></div><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on investments, net of taxes, and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive income to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive income for the years ended December 31, 2015, 2014 and 2013 (in thousands):</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">&#160;</div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Beginning balance accumulated other comprehensive income</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">39,747</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">21,080</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">12,480</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 18pt; text-indent: -9pt;">Unrealized (losses) gains on securities, net of tax (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(33,101</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">40,079</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,253</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 18pt; text-indent: -9pt;">Amounts reclassified from accumulated other comprehensive (loss) income (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(20,211</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(21,412</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,653</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net other comprehensive (loss) income for the period</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(53,312</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">18,667</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">8,600</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Ending balance accumulated other comprehensive (loss) income</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(13,565</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">39,747</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">21,080</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 12pt;"><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(1)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Other comprehensive income includes income tax expense of $12.8 million and $5.9 million for the years ended December 31, 2014 and 2013, respectively. There was no tax expense for other comprehensive income for the year ended December 31, 2015.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(2)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Amounts for 2015 are included in the separate line called &#8220;Gain on investment in Regulus Therapeutics Inc.&#8221; on our Consolidated Statement of Operations. For 2014, $19.9 million is included in a separate line called &#8220;Gain on investment in Regulus Therapeutics Inc.&#8221;, with the remaining amount included in a separate line called &#8220;Gain on investments, net&#8221; on our Consolidated Statement of Operations. Amounts for 2013 are included in a separate line called &#8220;Gain on investments, net&#8221; on our Consolidated Statement of Operations.</td></tr></table></div><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Investments we consider to be temporarily impaired at December 31, 2015 are as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Less than 12 months of</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Temporary Impairment</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">More than 12 months of</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Temporary Impairment</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Total Temporary</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Impairment</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr style="height: 31px;"><td valign="bottom" style="width: 30%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Number of</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Investments</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Estimated</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Estimated</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Estimated</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">397</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">406,098</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,908</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">16,066</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(47</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">422,164</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,955</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">71,842</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(262</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,001</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">72,843</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(263</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Debt securities issued by states of the United States and political subdivisions of the states</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">230</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">59,882</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(173</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">29,634</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(158</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">89,516</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(331</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total temporarily impaired securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">648</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">540,423</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,346</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">46,701</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(206</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">587,124</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 7%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,552</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for the years ended December 31, 2015 and 2014 are as follows (in thousands, except per share data).</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">2015 Quarters</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">First</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Second</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Third</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fourth</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">62,583</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">120,428</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">49,121</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">51,571</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Operating expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">71,913</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">75,782</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">97,259</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">114,511</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Income (loss) from operations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(9,330</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">44,646</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(48,138</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(62,940</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Net income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(16,717</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">35,648</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(35,776</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(71,433</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Basic net income (loss) per share (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.14</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.59</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Diluted net income (loss) per share (1) (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.14</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.29</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.59</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr></table><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">2014 Quarters</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">First</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Second</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Third</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fourth</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Quarter</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">28,161</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">57,076</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">44,063</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">84,861</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Operating expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">57,828</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">63,726</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">65,556</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">74,781</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Income (loss) from operations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(29,667</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(6,650</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(21,493</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,080</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Net income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(31,280</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(12,081</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(26,676</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">31,053</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Basic net income (loss) per share (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.27</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.10</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.23</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.26</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Diluted net income (loss) per share (1) (3)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.27</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.10</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(0.23</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.25</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div style="text-align: justify; text-indent: 484.45pt;"><br /></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 4.5pt;">(1)</div></td><td style="width: auto; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.</div></td></tr></table></div><div><br /></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 4.5pt;">(2)</div></td><td style="width: auto; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">For the three months ended June 30, 2015, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended June 30, 2015 consisted of the following (in thousands):</div></td></tr></table></div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Three Months Ended June 30, 2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Income</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Numerator)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Shares</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Denominator)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Per-Share Amount</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">&#160;</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Income available to common shareholders</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">35,648</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">119,742</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Effect of diluted securities:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable upon exercise of stock options</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,974</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable upon restricted stock award issuance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">376</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable related to our ESPP</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable related to our 2&#190; percent notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,047</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,683</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9.1pt; text-indent: -9.1pt;">Income available to common shareholders, plus assumed conversions</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">36,695</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">127,779</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.29</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 36pt;">For the three months ended June 30, 2015, the calculation excludes the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.</div><div><br /></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 4.5pt;">(3)</div></td><td style="width: auto; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">For the three months ended December 31, 2014, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended December 31, 2014 consisted of the following (in thousands):</div></td></tr></table></div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Three Months Ended December 31, 2014</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Income</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Numerator)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Shares</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Denominator)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Per-Share Amount</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">&#160;</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Income available to common shareholders</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">31,053</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">118,223</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.26</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Effect of diluted securities:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable upon exercise of stock options</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">4,189</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable upon restricted stock award issuance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">418</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 8.9pt; text-indent: 0.1pt;">Shares issuable related to our ESPP</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9.1pt; text-indent: -9.1pt;">Income available to common shareholders, plus assumed conversions</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">31,053</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">122,839</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">0.25</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 36pt;">For the three months ended December 31, 2014, the calculation excludes the 1 percent and 2&#190; percent convertible senior notes because the effect on diluted earnings per share was anti-dilutive.</div><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes the RSU activity for the year ended December 31, 2015 (in thousands, except per share data):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Number of</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Shares</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Grant Date</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Per Share</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Non-vested at December 31, 2014</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">638</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">30.52</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Granted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">348</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">65.69</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Vested</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(196</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">27.40</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Cancelled/forfeited</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(39</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">42.87</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Non-vested at December 31, 2015</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">751</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">47.47</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes our gross unrecognized tax benefits (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Beginning balance of unrecognized tax benefits</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">27,365</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">23,964</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,872</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Decrease for prior period tax positions</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,653</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Increase for prior period tax positions</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">215</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">9,821</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Increase for current period tax positions</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">23,677</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5,054</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,271</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Ending balance of unrecognized tax benefits</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">51,257</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">27,365</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">23,964</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The carrying value of our long-term obligations was as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">1 percent convertible senior notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">347,214</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">327,486</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2&#190; percent convertible senior notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">50,361</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Long-term financing liability for leased facility</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">72,217</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">71,731</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Equipment financing arrangement</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">515</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,226</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Leases and other obligations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,341</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7,325</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">472,648</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">457,782</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Less: current portion</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(515</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,882</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Total Long-Term Obligations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">472,133</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">454,900</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes stock-based compensation expense for the years ended December 31, 2015, 2014 and 2013 (in thousands), which was allocated as follows and includes $6.5 million of stock-based compensation expense for Akcea employees in 2015:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="11" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Research, development and patents</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">43,638</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">25,843</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">9,673</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">General and administrative</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">15,676</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5,540</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,745</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">59,314</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">31,383</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">11,418</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following is our segment information for 2015 (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Ionis Core</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Akcea Therapeutics</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Elimination of Intercompany Activity</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Revenue:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Research and development</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">285,608</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(4,248</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">281,360</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Licensing and royalty</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,343</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,343</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 30pt; text-indent: -10pt;">Total segment revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">287,951</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(4,248</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">283,703</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Loss from operations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(21,378</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(54,384</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(75,762</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,004,150</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">55,354</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(103,399</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">956,105</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following is our segment information for 2014 and 2013 (in thousands) revised for comparative purposes to show operating expense for Akcea-related projects in 2014 and 2013:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">2014</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Ionis Core</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Akcea Therapeutics</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Revenue:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Research and development</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">202,514</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">202,514</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Licensing and royalty</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">11,647</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">11,647</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 30pt; text-indent: -10pt;">Total segment revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">214,161</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">214,161</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Loss from operations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(26,033</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(21,697</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(47,730</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr></table><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">2013</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Ionis Core</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Akcea Therapeutics</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Revenue:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Research and development</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">147,380</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">144,194</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Licensing and royalty</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,091</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,091</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 30pt; text-indent: -10pt;">Total segment revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">150,471</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">147,285</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Loss from operations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(38,764</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(12,902</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(51,666</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr></table><div><br /></div><div><br /></div><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10 percent or more of our total revenue, was as follows:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%; border-collapse: collapse;"><tr><td style="width: 59.22%; vertical-align: bottom;">&#160;</td><td colspan="2" style="width: 12.2%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td style="width: 2.1%; vertical-align: bottom;">&#160;</td><td colspan="2" style="width: 12.2%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td style="width: 2.1%; vertical-align: bottom;">&#160;</td><td colspan="2" style="width: 12.2%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner A</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">37 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">58 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">25 %</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner B</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">33 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0 %</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner C</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">12 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">17 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">24 %</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner D</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">11 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">4 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">3 %</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner E</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">2 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">13 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">20 %</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner F</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">22 %</div></td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Segment information</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In 2015, we began operating as two segments, our Ionis Core segment, previously referred to as Drug Discovery and Development, and Akcea Therapeutics, which consists of the operations of our wholly owned subsidiary, Akcea Therapeutics, Inc. We formed Akcea to develop and commercialize drugs for cardiometabolic disorders. We provide segment financial information and results for our Ionis Core segment and our Akcea Therapeutics segment based on the segregation of revenues and expenses that our chief decision maker reviews to assess operating performance and to make operating decisions. We use judgments and estimates in determining the allocation of shared expenses to the two segments.</div><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In 2015, we began reporting our financial results in two reportable segments, Ionis Core, previously referred to as Drug Discovery and Development, and Akcea Therapeutics, our wholly owned subsidiary. Segment loss from operations includes revenue less operating expenses attributable to each segment.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In our Ionis Core segment, we are exploiting a novel drug discovery platform we created to generate a broad pipeline of first-in-class or best-in-class drugs for us and our partners. Our Ionis Core segment generates revenue from a multifaceted partnering strategy.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We formed Akcea to develop and commercialize drugs for cardiometabolic disorders. Moving our lipid drugs into a company that we own and control ensures that our core focus at Ionis remains on innovation while allowing us to maintain control over and retain more value from our lipid drugs. To date, Akcea has not earned any revenue.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following is our segment information for 2015 (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Ionis Core</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Akcea Therapeutics</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Elimination of Intercompany Activity</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Revenue:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Research and development</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">285,608</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(4,248</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">281,360</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Licensing and royalty</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,343</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,343</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 30pt; text-indent: -10pt;">Total segment revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">287,951</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(4,248</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">283,703</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Loss from operations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(21,378</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(54,384</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(75,762</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,004,150</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">55,354</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(103,399</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">956,105</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following is our segment information for 2014 and 2013 (in thousands) revised for comparative purposes to show operating expense for Akcea-related projects in 2014 and 2013:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">2014</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Ionis Core</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Akcea Therapeutics</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Revenue:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Research and development</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">202,514</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">202,514</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Licensing and royalty</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">11,647</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">11,647</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 30pt; text-indent: -10pt;">Total segment revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">214,161</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">214,161</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Loss from operations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(26,033</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(21,697</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(47,730</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr></table><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">2013</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Ionis Core</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Akcea Therapeutics</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Total</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Revenue:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Research and development</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">147,380</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">144,194</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 20pt; text-indent: -10pt;">Licensing and royalty</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,091</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,091</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 30pt; text-indent: -10pt;">Total segment revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">150,471</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">147,285</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 10pt; text-indent: -10pt;">Loss from operations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(38,764</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(12,902</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(51,666</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr></table><div><br /></div><div><br /></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10 percent or more of our total revenue, was as follows:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%; border-collapse: collapse;"><tr><td style="width: 59.22%; vertical-align: bottom;">&#160;</td><td colspan="2" style="width: 12.2%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td style="width: 2.1%; vertical-align: bottom;">&#160;</td><td colspan="2" style="width: 12.2%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td style="width: 2.1%; vertical-align: bottom;">&#160;</td><td colspan="2" style="width: 12.2%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner A</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">37 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">58 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">25 %</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner B</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">33 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0 %</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner C</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">12 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">17 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">24 %</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner D</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">11 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">4 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">3 %</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner E</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">2 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">13 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">20 %</div></td></tr><tr><td style="width: 59.22%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Partner F</div></td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0 %</div></td><td style="width: 2.1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 2.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 10.11%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">22 %</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Contracts receivables at December 31, 2015 and December&#160;31, 2014 were comprised of approximately 99 percent for each year from two and three significant partners, respectively.</div><div><br /></div></div> P4Y P4Y P3Y P4Y P2Y P4Y 348000 44.94 65.69 17.42 638000 751000 14.07 11418000 59314000 31383000 30.52 47.47 42.43 2550000 150000 150000 712034 38621 42.87 39000 61.02 0.517 0.511 0.601 0.629 0.522 0.542 0.501 0.527 0.538 16.43 0 0 0 0 0 0 0 0 0 27.40 44025 309319 659254 2927597 3940000 0.1 859871 5989752 0 13462 481764 196000 20000000 5990000 3224596 1200000 11000000 2000000 5500000 0.017 0.022 0.001 0.001 0.001 0.022 0.015 0.011 0.021 214000 84700000 69600000 62800000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Stock-based compensation expense</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our ESPP based on the estimated fair value of the award on the date of grant. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our Consolidated Statements of Operations. We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We use the Black-Scholes model as our method of valuing option awards and stock purchase rights under our ESPP. On the grant date, we use our stock price and assumptions regarding a number of highly complex and subjective variables to determine the estimated fair value of stock-based payment awards. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Option-pricing models were developed for use in estimating the value of traded options that have no vesting or hedging restrictions and are fully transferable. Because our employee stock options have certain characteristics that are significantly different from traded options, and because changes in the subjective assumptions can materially affect the estimated value, in management&#8217;s opinion, the existing valuation models may not provide an accurate measure of the fair value of our employee stock options. Although we determine the estimated fair value of employee stock options using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We recognize compensation expense for option awards using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), an entity recognizes compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The fair value of RSUs is based on the market price of our common stock on the date of grant.&#160;The RSUs we have granted vest annually over a four-year period.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">See Note 4, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Stockholders&#8217; Equity,</font> for additional information regarding our share-based compensation plans.</div><div><br /></div><div><br /></div></div> 232581000 3832225 3619716 544812 44025 7379000 8041000 19.52 33.21 7.10 27.44 17.54 101481000 116471000 120351000 118443000 1674000 173283000 0 173292000 9000 0 9618000 62953000 0 24888000 2000 0 23073000 0 0 0 62958000 0 24890000 5000 2000 23071000 5372000 1908000 1972000 1972000 5372000 1908000 38372 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">4. Stockholders&#8217; Equity</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Preferred Stock</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We are authorized to issue up to 15,000,000 shares of &#8220;blank check&#8221; Preferred Stock. As of December 31, 2015, there were no shares of Preferred Stock outstanding. We have designated Series&#160;C Junior Participating Preferred Stock but have no issued or outstanding shares as of December 31, 2015.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Common Stock</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">At December 31, 2015 and 2014, we had 300,000,000 shares of common stock authorized, of which 120,351,480 and 118,442,726 were issued and outstanding, respectively. As of December 31, 2015, total common shares reserved for future issuance were 18,512,177.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">During the years ending December 31, 2015, 2014 and 2013, we issued 1,908,000, 1,972,000 and 5,372,000 shares of common stock, respectively, for stock option exercises, vesting of restricted stock units, and ESPP purchases. We received net proceeds from these transactions of $24.9 million, $23.1 million and $63.0 million in 2015, 2014 and 2013, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Stock Plans</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">1989 Stock Option Plan</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In June 1989, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that, as amended, provides for the issuance of non-qualified and incentive stock options for the purchase of up to 20,000,000 shares of common stock to our employees, directors, and consultants. The plan expires in January 2024. The 1989 Plan does not allow us to grant stock bonuses or restricted stock awards and prohibits us from repricing any options outstanding under the plan unless our stockholders approve the repricing. Options vest over a four-year period, with 25 percent exercisable at the end of one year from the date of the grant and the balance vesting ratably, on a monthly basis, thereafter and have a term of seven years. At December 31, 2015, a total of 3,619,716 options were outstanding, of which options to purchase 2,927,597 shares were exercisable, and 13,462 shares were available for future grant under the 1989 Plan.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">2000 Broad Based Equity Incentive Plan</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In January 2000, we adopted the 2000 Broad-Based Equity Incentive Plan (the 2000 Plan), which, as amended, provided for the issuance of non-qualified stock options for the purchase of up to 5,990,000 shares of common stock to our employees, directors, and consultants. Typically options expire seven or ten years from the date of grant. Options granted under this plan generally vest over a four-year period, with 25 percent exercisable at the end of one year from the date of the grant and the balance vesting ratably, on a monthly basis thereafter. At December 31, 2015, a total of 44,025 options were outstanding and exercisable, and no shares were available for future grant under the 2000 Plan. The 2000 Plan expired on January 5, 2010, so we may no longer grant new options under the 2000 Plan.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Change of Control Under 1989 Plan and 2000 Plan</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">With respect to both the 1989 Plan and 2000 Plan, in the event of:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">a sale, lease or other disposition of all or substantially all of our assets;</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">a merger or consolidation in which we are not the surviving corporation; or</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">reverse merger in which we are the surviving corporation but the shares of common stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise,</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">then any surviving corporation or acquiring corporation will assume any stock awards outstanding under the 2000 Plan and the 1989 Plan or will substitute similar stock awards (including an award to acquire the same consideration paid to the shareholders in the transaction for those outstanding under the 2000 Plan and the 1989 Plan). In the event any surviving corporation or acquiring corporation refuses to assume such stock awards or to substitute similar stock awards for those outstanding under the 2000 Plan and the 1989 Plan, then with respect to stock awards held by participants whose continuous service has not terminated, such stock awards automatically vest in full and the stock awards will terminate if not exercised (if applicable) at or prior to such event.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">2011 Equity Incentive Plan</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In March 2011, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance cash awards to our employees, directors, and consultants.&#160;In June 2015, after receiving approval from our stockholders, we amended our 2011 Equity Incentive Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2011 Equity Incentive Plan from 5,500,000 to 11,000,000. The plan expires in June&#160;2021. The 2011 Plan does not allow us to reduce the exercise price of any outstanding stock options or stock appreciation rights or cancel any outstanding stock options or stock appreciation rights that have an exercise price or strike price greater than the current fair market value of the common stock in exchange for cash or other stock awards unless our stockholders approve such action. Currently we anticipate awarding only options and restricted stock unit awards to our employees, directors and consultants. Under the 2011 Plan, stock options cannot vest in a period of less than two years and restricted stock unit awards cannot vest in a period of less than three years. We have granted restricted stock unit awards to our employees under the 2011 Plan which vest annually over a four-year period. At December 31, 2015, a total of 3,832,225 options were outstanding, of which 659,254 were exercisable, 712,034 restricted stock unit awards were outstanding, and 5,989,752 shares were available for future grant under the 2011 Plan.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Under the 2011 Plan, we may issue a stock award with additional acceleration of vesting and exercisability upon or after a change in control. In the absence of such provisions, no such acceleration will occur. The stock options and restricted stock unit awards we issue to our chief executive officer and chief operating officer will accelerate upon a change of control, as defined in the 2011 Plan.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">Corporate Transactions and Change in Control under 2011 Plan</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In the event of certain significant corporate transactions, our Board of Directors has the discretion to take one or more of the following actions with respect to outstanding stock awards under the 2011&#160;Plan:</div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">arrange for assumption, continuation, or substitution of a stock award by a surviving or acquiring entity (or its parent company);</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">arrange for the assignment of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award to the surviving or acquiring corporation (or its parent company);</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">accelerate the vesting and exercisability of a stock award followed by the termination of the stock award;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">arrange for the lapse of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award;</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">cancel or arrange for the cancellation of a stock award, to the extent not vested or not exercised prior to the effective date of the corporate transaction, in exchange for cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and</td></tr></table></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol; width: 18pt; vertical-align: top; color: #000000; align: right;">&#61623;</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">arrange for the surrender of a stock award in exchange for a payment equal to the excess of (a)&#160;the value of the property the holder of the stock award would have received upon the exercise of the stock award, over (b)&#160;any exercise price payable by such holder in connection with such exercise.</td></tr></table></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 54pt; text-indent: -18pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">2002 Non-Employee Directors&#8217; Stock Option Plan</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In September 2001, our Board of Directors adopted, and the stockholders subsequently approved, an amendment and restatement of the 1992 Non-Employee Directors&#8217; Stock Option Plan, which provides for the issuance of non-qualified stock options and restricted stock units to our non-employee directors. The name of the resulting plan is the 2002 Non-Employee Directors&#8217; Stock Option Plan (the 2002 Plan). In June 2015, after receiving approval from our stockholders, we amended our 2002 Non-Employee Directors Stock Option Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2002 Non-Employee Directors Stock Option Plan from 1,200,000 to 2,000,000. Options under this plan expire ten years from the date of grant. Options granted become exercisable in four equal annual installments beginning one year after the date of grant. At December 31, 2015, a total of 544,812 options were outstanding, of which 309,319 were exercisable, 38,621 restricted stock unit awards were outstanding, and 859,871 shares were available for future grant under the 2002 Plan.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">Employee Stock Purchase Plan</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">In June 2009, our Board of Directors adopted, and the stockholders subsequently approved, the amendment and restatement of the ESPP and we reserved an additional 150,000 shares of common stock for issuance thereunder. In each of the subsequent years, we reserved an additional 150,000 shares of common stock for the ESPP resulting in a total of 3,224,596 million shares authorized under the plan as of December 31, 2015. The ESPP permits full-time employees to purchase common stock through payroll deductions (which cannot exceed 10 percent of each employee&#8217;s compensation) at the lower of 85 percent of fair market value at the beginning of the purchase period or the end of each six-month purchase period. Under the amended and restated ESPP, employees must hold the stock they purchase for a minimum of six months from the date of purchase. During 2015, employees purchased and we issued to employees 38,372 shares under the ESPP at a weighted average price of $37.43 per share. At December 31, 2015, there were 481,764 shares available for purchase under the ESPP.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Stock Option Activity</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes the stock option activity for the year ended December 31, 2015 (in thousands, except per share and contractual life data):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Number of</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Shares</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Average Exercise</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Price</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Per Share</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Remaining</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Contractual Term</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(Years)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Aggregate</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Intrinsic</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Outstanding at December 31, 2014</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7,379</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19.52</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Granted</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,550</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">61.02</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Exercised</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,674</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">14.07</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Cancelled/forfeited/expired</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(214</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">42.43</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Outstanding at December 31, 2015</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">8,041</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">33.21</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">4.57</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">232,581</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Exercisable at December 31, 2015</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3,940</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">16.43</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3.32</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">179,273</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The weighted-average estimated fair values of options granted were $27.44, $17.54 and $7.10 for the years ended December 31, 2015, 2014 and 2013, respectively. The total intrinsic value of options exercised during the years ended December 31, 2015, 2014 and 2013 were $84.7 million, $62.8 million and $69.6 million, respectively, which we determined as of the date of exercise. The amount of cash received from the exercise of stock options was $23.6 million, $22.4 million and $62.0 million for the years ended December 31, 2015, 2014 and 2013, respectively. For the year ended December 31, 2015, the weighted-average fair value of options exercised was $64.69. As of December 31, 2015, total unrecognized compensation cost related to non-vested stock-based compensation plans was $45.7 million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of 1.3 years.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Restricted Stock Unit Activity</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes the RSU activity for the year ended December 31, 2015 (in thousands, except per share data):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Number of</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Shares</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Grant Date</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Per Share</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Non-vested at December 31, 2014</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">638</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">30.52</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Granted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">348</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">65.69</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Vested</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(196</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">27.40</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 18pt; text-indent: -9pt;">Cancelled/forfeited</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(39</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">42.87</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Non-vested at December 31, 2015</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">751</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">47.47</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">For the years ended December 31, 2015, 2014 and 2013, the weighted-average grant date fair value of RSUs granted was $65.69, $44.94 and $17.42 per RSU, respectively. As of December 31, 2015, total unrecognized compensation cost related to RSUs was $16.0 million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of 1.2 years.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Stock-based Compensation Expense and Valuation Information</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following table summarizes stock-based compensation expense for the years ended December 31, 2015, 2014 and 2013 (in thousands), which was allocated as follows and includes $6.5 million of stock-based compensation expense for Akcea employees in 2015:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="11" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Research, development and patents</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">43,638</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">25,843</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">9,673</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">General and administrative</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">15,676</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5,540</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1,745</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">59,314</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">31,383</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">11,418</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 54pt; text-indent: -18pt;">Determining Fair Value</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Valuation.</font> We measure stock-based compensation expense for equity-classified awards, principally related to stock options, RSUs, and stock purchase rights under the ESPP at the grant date, based on the estimated fair value of the award and we recognize the expense over the employee&#8217;s requisite service period. We value RSUs based on the market price of our common stock on the date of grant.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP. The expected term of stock options granted represents the period of time that we expect them to be outstanding. We estimate the expected term of options granted based on actual and projected exercise patterns. We recognize compensation expense for stock options granted, RSUs, and stock purchase rights under the ESPP using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), an entity recognizes compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">For the years ended December 31, 2015, 2014 and 2013, we used the following weighted-average assumptions in our Black-Scholes calculations:</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Employee Stock Options:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%; border-collapse: collapse;"><tr><td style="width: 54.36%; vertical-align: bottom;">&#160;</td><td colspan="5" style="width: 45.64%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td style="width: 4.31%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td style="width: 4.31%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Risk-free interest rate</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">1.5 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">1.7 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">1.1 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Dividend yield</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Volatility</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">53.8 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">50.1 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">51.1 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Expected life</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">4.5 years</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">4.7 years</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">5.1 years</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; text-indent: 36pt;">Board of Director Stock Options:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%; border-collapse: collapse;"><tr><td style="width: 54.36%; vertical-align: bottom;">&#160;</td><td colspan="5" style="width: 45.64%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td style="width: 4.31%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td style="width: 4.31%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Risk-free interest rate</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">2.1 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">2.2 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">2.2 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Dividend yield</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Volatility</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">52.2 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">54.2 %</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">52.7 %</div></td></tr><tr><td style="width: 54.36%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Expected life</div></td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">6.9 years</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">6.9 years</div></td><td style="width: 4.31%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">7.2 years</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: justify; margin-left: 36pt;">ESPP:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%; border-collapse: collapse;"><tr><td style="width: 54.19%; vertical-align: bottom;">&#160;</td><td colspan="5" style="width: 45.81%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">December 31,</div></td></tr><tr><td style="width: 54.19%; vertical-align: bottom;">&#160;</td><td style="width: 12.4%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td style="width: 4.35%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td style="width: 4.37%; vertical-align: bottom;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td></tr><tr><td style="width: 54.19%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Risk-free interest rate</div></td><td style="width: 12.4%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.1 %</div></td><td style="width: 4.35%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.1 %</div></td><td style="width: 4.37%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.1 %</div></td></tr><tr><td style="width: 54.19%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Dividend yield</div></td><td style="width: 12.4%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.35%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td><td style="width: 4.37%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">0.0 %</div></td></tr><tr><td style="width: 54.19%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Volatility</div></td><td style="width: 12.4%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">51.7 %</div></td><td style="width: 4.35%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">60.1 %</div></td><td style="width: 4.37%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">62.9 %</div></td></tr><tr><td style="width: 54.19%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Expected life</div></td><td style="width: 12.4%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">6 months</div></td><td style="width: 4.35%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">6 months</div></td><td style="width: 4.37%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td style="width: 12.34%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">6 months</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Risk-Free Interest Rate.</font> We base the risk-free interest rate assumption on observed interest rates appropriate for the term of our stock option plans or ESPP.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Dividend Yield.</font> We base the dividend yield assumption on our history and expectation of dividend payouts. We have not paid dividends in the past and do not expect to in the future.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Volatility.</font> We use an average of the historical stock price volatility of our stock for the Black-Scholes model. We computed the historical stock volatility based on the expected term of the awards.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Expected Life. </font>The expected term of stock options we have granted represents the period of time that we expect them to be outstanding. We estimated the expected term of options we have granted based on actual and projected exercise patterns.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Forfeitures.</font> We reduce stock-based compensation expense for estimated forfeitures. We estimate forfeitures at the time of grant and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We estimate forfeitures based on historical experience. Our historical forfeiture estimates have not been materially different from our actual forfeitures.</div><div><br /></div><div><br /></div></div> 12480000 -906966000 182766000 102000 1077150000 1309107000 120000 21080000 200790000 -1006594000 -1094872000 1224509000 39747000 118000 257780000 116000 1324804000 -967610000 -13565000 378390000 257780000 200790000 39747000 12480000 21080000 -13565000 146800000 44700000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The following is a summary of our investments (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Gross Unrealized</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">December 31, 2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Cost</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Estimated</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Available-for-sale securities (1):</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">181,670</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(250</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">181,425</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">50,559</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">50,541</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,604</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2,601</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">79,414</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">18</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(88</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">79,344</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total securities with a maturity of one year or less</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">314,247</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(360</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">313,911</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">258,703</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,705</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">257,001</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">38,956</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(244</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">38,712</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,552</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(243</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48,312</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total securities with a maturity of more than one year</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">346,211</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,192</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">344,025</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total available-for-sale securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">660,458</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,552</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">657,936</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Equity securities:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Regulus Therapeutics Inc.</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7,162</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">17,630</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,792</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total equity securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7,162</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">17,630</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">24,792</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total available-for-sale and equity securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">667,620</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">17,660</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(2,552</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">682,728</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Gross Unrealized</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">December 31, 2014</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Cost</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Estimated</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Available-for-sale securities (1):</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">219,856</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">89</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(89</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">219,856</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">47,496</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(27</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">47,476</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by the U.S. Treasury (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,008</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">45,196</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(53</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">45,162</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total securities with a maturity of one year or less</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">331,556</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">124</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(169</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">331,511</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Corporate debt securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">152,730</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">16</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(600</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">152,146</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by U.S. government agencies</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">62,530</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(151</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">62,379</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Debt securities issued by states of the United States and political subdivisions of the states</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">60,073</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">32</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(234</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">59,871</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total securities with a maturity of more than one year</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">275,333</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">48</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(985</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">274,396</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total available-for-sale securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">606,889</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">172</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,154</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">605,907</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Equity securities:</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Regulus Therapeutics Inc.</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">12,477</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">69,404</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total equity securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">12,477</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">69,404</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8212;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">81,881</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total available-for-sale and equity securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">619,366</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">69,576</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,154</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">687,788</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">(1)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">Our available-for-sale securities are held at amortized cost.</td></tr></table></div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; color: #000000; align: right;">(2)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: left;">Includes investments classified as cash equivalents on our consolidated balance sheet.</td></tr></table></div></div> 0 9821000 215000 0 10872000 27365000 23964000 51257000 5054000 23677000 3271000 33300000 1653000 0 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Use of estimates</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div><div><br /></div></div> 119742000 118223000 110502000 119719000 117691000 122839000 127779000 2 750000000 2900000000 1100000000 485000000 226000000 150000000 346000000 121000000 263000000 130000000 63000000 4200000 120000000 375000000 110000000 183500000 10000000 363500000 348000000 175000000 420000000 800000000 180000000 67000000 170000000 362000000 50000000 80000000 49300000 1400000 2000000 1500000 1300000 3500000 5800000 4500000 25000000 15000000 2000000 35000000 1400000 10000000 10000000 55000000 5000000 5000000 10000000 7500000 400000 600000 1300000 500000 1500000 2000000 800000 63500000 130000000 39000000 40000000 135000000 135000000 60000000 35000000 52000000 7000000 70000000 4 4 4 259000000 130000000 59000000 130000000 260000000 60000000 90000000 55000000 35000000 136500000 2300000 1100000 3400000 3400000 4000000 300000 6100000 3 6 4 5 2 3 2 1 1 4 4000000000 1000000000 100000000 65000000 38000000 0.05 0.1 0.1 0.12 0.11 0.05 700000 1 24792000 81881000 24792000 0 0 0 81881000 24792000 0 81881000 24800 3 3 454900000 472133000 399913000 48014000 2341000 457782000 50361000 327486000 71731000 515000 472648000 3226000 7325000 347214000 72217000 P1M 31000000 3 11900000 3 1 5000000 3 3 P6Y 11300000 140000000 2100000000 0.03 0.015 0.025 0.05 50000000 19316000 17186000 13068000 9553000 72217000 71731000 2882000 9029000 7669000 2341000 3 2 4 3 P6M P12M 0.1 91200000 3 0.01 900000 1000000000 P2Y P1Y 2343000 11647000 3091000 9500000 2343000 0 11647000 0 0 3091000 0 P2Y P18M P2Y P12M P1Y P1Y P3Y P4Y 322292000 184033000 241751000 20211000 0 19902000 75000 2378000 1256000 281360000 202514000 144194000 202514000 -4248000 147380000 0 0 285608000 0 -5900000 -12800000 4300000 4300000 76900000 404093000 315934000 3641000 2643000 2795000 0 0 0 0.051 0 1000 90 1 1 P5Y 4 3 2 64.69 2463000 52000 2428000 2513000 0 0 3810000 3586000 4056000 704000 2151000 1162000 1381000 1142000 1184000 2007000 1882000 1873000 0 -5914000 -12835000 -7199000 7453000 10580000 375000000 2 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Research, development and patent expenses</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Our research and development expenses include wages, benefits, facilities, supplies, external services, clinical trial and manufacturing costs and other expenses that are directly related to our research and development operations. We expense research and development costs as we incur them. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. For the years ended December 31, 2015, 2014 and 2013, research and development expenses were $319.5 million, $238.9 million and $173.7 million, respectively. A portion of the costs included in research and development expenses are costs associated with our collaboration agreements. For the years ended December 31, 2015, 2014 and 2013, research and development costs of approximately $161.7 million, $85.6 million and $51.0 million, respectively, were related to our collaborative agreements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We amortize patent costs over the useful life of the patent, beginning with the date the United States Patent and Trademark Office, or foreign equivalent, issues the patent. The weighted average remaining amortizable life of our issued patents was 10.2 years at December 31, 2015.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; text-indent: 36pt;">The cost of our patents capitalized on our consolidated balance sheet at December 31, 2015 and 2014 was $27.5 million and $25.0 million, respectively. Accumulated amortization related to patents was $8.2 million and $7.8 million at December 31, 2015 and 2014, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Based on existing patents, estimated amortization expense related to patents in each of the next five years is as follows:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 50%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Years Ending December 31,</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Amortization</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">(in millions)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">1.0</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. When we identify patents and patent applications that we are not actively pursuing, we write off any associated costs. In 2015, 2014 and 2013, patent expenses were $2.8 million, $2.9 million and $10.3 million, respectively, and included non-cash charges related to the write-down of our patent costs to their estimated net realizable values of $1.1 million, $1.3 million and $6.4 million, respectively.</div><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Cash, cash equivalents and short-term investments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We consider all liquid investments with maturities of three months or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than three months from date of purchase. We classify our short-term investments as &#8220;available-for-sale&#8221; and carry them at fair market value based upon prices for identical or similar items on the last day of the fiscal period. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We have equity investments in privately and publicly held biotechnology companies that we have received as part of a technology license or collaboration agreement. At December 31, 2015, we held ownership interests of less than 20 percent in each of the respective companies.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We account for our equity investments in publicly held companies at fair value and record unrealized gains and losses related to temporary increases and decreases in the stock of these publicly held companies as a separate component of comprehensive income (loss). We account for equity investments in privately held companies under the cost method of accounting because we own less than 20 percent and do not have significant influence over their operations. We hold one cost method investment in Atlantic Pharmaceuticals Limited. Realization of our equity position in this company is uncertain. When realization of our investment is uncertain, we record a full valuation allowance. In determining if and when a decrease in market value below our cost in our equity positions is temporary or other-than-temporary, we examine historical trends in the stock price, the financial condition of the company, near term prospects of the company and our current need for cash. If we determine that a decline in value in either a public or private investment is other-than-temporary, we recognize an impairment loss in the period in which the other-than-temporary decline occurs.</div><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: left;">Accumulated other comprehensive income (loss)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on investments, net of taxes, and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive income to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive income for the years ended December 31, 2015, 2014 and 2013 (in thousands):</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify;">&#160;</div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Beginning balance accumulated other comprehensive income</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">39,747</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">21,080</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">12,480</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 18pt; text-indent: -9pt;">Unrealized (losses) gains on securities, net of tax (1)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(33,101</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">40,079</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">10,253</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 18pt; text-indent: -9pt;">Amounts reclassified from accumulated other comprehensive (loss) income (2)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(20,211</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(21,412</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(1,653</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net other comprehensive (loss) income for the period</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(53,312</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">18,667</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">8,600</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left; margin-left: 9pt; text-indent: -9pt;">Ending balance accumulated other comprehensive (loss) income</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">(13,565</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">39,747</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">21,080</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 12pt;"><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(1)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Other comprehensive income includes income tax expense of $12.8 million and $5.9 million for the years ended December 31, 2014 and 2013, respectively. There was no tax expense for other comprehensive income for the year ended December 31, 2015.</td></tr></table></div><div><br /></div><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 36pt; vertical-align: top; color: #000000; align: right;">(2)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify;">Amounts for 2015 are included in the separate line called &#8220;Gain on investment in Regulus Therapeutics Inc.&#8221; on our Consolidated Statement of Operations. For 2014, $19.9 million is included in a separate line called &#8220;Gain on investment in Regulus Therapeutics Inc.&#8221;, with the remaining amount included in a separate line called &#8220;Gain on investments, net&#8221; on our Consolidated Statement of Operations. Amounts for 2013 are included in a separate line called &#8220;Gain on investments, net&#8221; on our Consolidated Statement of Operations.</td></tr></table></div><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: justify;">Organization and business activity</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">We incorporated in California on January 10, 1989. In conjunction with our initial public offering, we reorganized as a Delaware corporation in April&#160;1991. We were organized principally to develop human therapeutic drugs using antisense technology.</div><div><br /></div></div> P6M P6M 4 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Annual future rent payments as of December 31, 2015 for our primary research and development facility are as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 60%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Future Rent</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000; text-align: center;">Payments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,550</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,550</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,943</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">6,943</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">7,359</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">91,205</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; margin-left: 9pt; text-indent: -9pt;">Total minimum payments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">125,550</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div></div> 0 326444000 0 326444000 0 2800000 10300000 2900000 155000000 0.2 0.24 0.76 1 1 0.49 2 0.27 9000 4000 18000 24000 Includes investments classified as cash equivalents on our consolidated balance sheet. Our available-for-sale securities are held at amortized cost. $0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet. Included in short-term investments on our consolidated balance sheet. $9.3 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet. $7.5 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet. $10 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet. Included in cash and cash equivalents on our consolidated balance sheet. We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year. For the three months ended December 31, 2014, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. For the three months ended December 31, 2014, the calculation excludes the 1 percent and 2.75 percent convertible senior notes because the effect on diluted earnings per share would be anti-dilutive. For the three months ended June 30, 2015, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. For the three months ended June 30, 2015, the calculation excludes the 1 percent notes because the effect on diluted earnings per share would be anti-dilutive. Amounts for 2015 are included in the separate line called "Gain on investment in Regulus Therapeutics Inc." on our Consolidated Statement of Operations. For 2014, $19.9 million is included in a separate line called "Gain on investment in Regulus Therapeutics Inc.", with the remaining amount included in a separate line called "Gain on investments, net" on our Consolidated Statement of Operations. Amounts for 2013 are included in a separate line called "Gain on investments, net" on our Consolidated Statement of Operations. Other comprehensive income includes income tax expense of $12.8 million and $5.9 million for the years ended December 31, 2014 and 2013, respectively. There was no tax expense for other comprehensive income for the year ended December 31, 2015. Revenue from this relationship was negligible for the year. EX-101.SCH 9 ions-20151231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 040100 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 050000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 050100 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Organization and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Long-Term Obligations and Commitments link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Collaborative Arrangements and Licensing Agreements link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Segment Information and Concentration of Business Risk link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Employment Benefits link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 070100 - Disclosure - Organization and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 080100 - Disclosure - Organization and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - Long-Term Obligations and Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - Segment Information and Concentration of Business Risk (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Organization and Significant Accounting Policies, Basic and Diluted Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 090102 - Disclosure - Organization and Significant Accounting Policies, Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 090104 - Disclosure - Organization and Significant Accounting Policies, Research, Development and Patent Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 090106 - Disclosure - Organization and Significant Accounting Policies, Inventory Valuation (Details) link:presentationLink link:calculationLink link:definitionLink 090108 - Disclosure - Organization and Significant Accounting Policies, Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 090110 - Disclosure - Organization and Significant Accounting Policies, Long-Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 090112 - Disclosure - Organization and Significant Accounting Policies, Stock-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 090114 - Disclosure - Organization and Significant Accounting Policies, Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 090116 - Disclosure - Organization and Significant Accounting Policies, Convertible Debt and Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 090118 - Disclosure - Organization and Significant Accounting Policies, Fair Value Measurements on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 090120 - Disclosure - Organization and Significant Accounting Policies, Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Investments, Contract Maturity of Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 090202 - Disclosure - Investments, Summary of Investments and Investments Temporarily Impaired (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Long-Term Obligations and Commitments, Long-Term Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 090302 - Disclosure - Long-Term Obligations and Commitments (Details) Calc 2 link:presentationLink link:calculationLink link:definitionLink 090302 - Disclosure - Long-Term Obligations and Commitments, Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 090304 - Disclosure - Long-Term Obligations and Commitments, Financing Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 090308 - Disclosure - Long-Term Obligations and Commitments, Maturity Schedules (Details) link:presentationLink link:calculationLink link:definitionLink 090310 - Disclosure - Long-Term Obligations and Commitments, Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 090312 - Disclosure - Long-Term Obligations and Commitments, Research and Development Facility Lease Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Stockholders' Equity, Preferred and Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 090402 - Disclosure - Stockholders' Equity, Stock Plans (Details) link:presentationLink link:calculationLink link:definitionLink 090404 - Disclosure - Stockholders' Equity, Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 090406 - Disclosure - Stockholders' Equity, Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 090408 - Disclosure - Stockholders' Equity, Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 090410 - Disclosure - Stockholders' Equity, Stock-based Valuation Information (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Income Taxes, Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 090502 - Disclosure - Income Taxes, Reconciliation of Effective Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 090504 - Disclosure - Income Taxes, Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 090506 - Disclosure - Income Taxes, Tax Credit Carryforward (Details) link:presentationLink link:calculationLink link:definitionLink 090508 - Disclosure - Income Taxes, Gross Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - AstraZeneca (Details) link:presentationLink link:calculationLink link:definitionLink 090602 - Disclosure - Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Nusinersen) (Details) link:presentationLink link:calculationLink link:definitionLink 090604 - Disclosure - Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (IONIS-DMPK-2.5) (Details) link:presentationLink link:calculationLink link:definitionLink 090606 - Disclosure - Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Neurology) (Details) link:presentationLink link:calculationLink link:definitionLink 090608 - Disclosure - Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Strategic Neurology) (Details) link:presentationLink link:calculationLink link:definitionLink 090610 - Disclosure - Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Bayer (Details) link:presentationLink link:calculationLink link:definitionLink 090612 - Disclosure - Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Genzyme Corporation (Details) link:presentationLink link:calculationLink link:definitionLink 090614 - Disclosure - Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - GSK (Details) link:presentationLink link:calculationLink link:definitionLink 090616 - Disclosure - Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Janssen Biotech, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 090618 - Disclosure - Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Roche (Details) link:presentationLink link:calculationLink link:definitionLink 090620 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Achaogen, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 090622 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Alnylam Pharmaceuticals, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 090624 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Antisense Therapeutics Limited (Details) link:presentationLink link:calculationLink link:definitionLink 090626 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Atlantic Pharmaceuticals Limited (Details) link:presentationLink link:calculationLink link:definitionLink 090630 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - OncoGenex Technologies Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 090632 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Regulus Therapeutics Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 090634 - Disclosure - Collaborative Arrangements and Licensing Agreements, External Project Funding (Details) link:presentationLink link:calculationLink link:definitionLink 090636 - Disclosure - Collaborative Arrangements and Licensing Agreements, Intellectual Property Sale and Licensing Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Segment Information and Concentration of Business Risk (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - Employment Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - Quarterly Financial Data (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 ions-20151231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 ions-20151231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 ions-20151231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Ownership Interests in Private and Public Companies [Abstract] Investments Schedule [Abstract] Investments Investment [Text Block] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Award Type [Axis] Arrangements and Non-arrangement Transactions [Domain] Number of investments Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions Contracts Receivables [Member] Accounts Receivable [Member] Accounts payable Accounts Payable, Current Amortization of premium on investments, net Accretion (Amortization) of Discounts and Premiums, Investments Accrued liabilities Accrued Liabilities, Current Less accumulated depreciation Accumulated depreciation of facility Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Unrealized (Losses) Gains on Securities [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive (Loss) Income [Member] Accumulated Other Comprehensive Income (Loss) [Member] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid in Capital [Member] Additional Paid-in Capital [Member] 1 percent convertible senior notes, equity portion, net of issuance costs Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Excess tax benefits from shared-based compensation awards Stock-based compensation expense Allocated Share-based Compensation Expense Amortization of debt discount and debt issuance costs Amortization of Financing Costs and Discounts Amortization of convertible notes discount Amortization of Debt Discount (Premium) Amortization of long-term financing liability for leased facility Amortization of Leased Asset Amortization of debt issuance costs Amortization of Financing Costs Non-cash losses related to patents, licensing and property, plant and equipment Asset Impairment Charges Long-Lived Assets [Abstract] Asset Impairment Charges [Abstract] ASSETS Assets [Abstract] Total assets Assets, Fair Value Disclosure Total assets Total assets Total current assets Assets, Current Current assets: Assets, Current [Abstract] Estimated fair value, less than 12 months of temporary impairment Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Contract Maturity of Available-for-Sale Securities [Abstract] Available-for-sale Securities, Debt Maturities [Abstract] Gross unrealized gains Available-for-sale Equity Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized gains Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized losses Available-for-sale Equity Securities, Accumulated Gross Unrealized Loss, before Tax Estimated fair value Available-for-sale securities Available-for-sale Securities Gross unrealized losses Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax Estimated fair value, more than 12 months of temporary impairment Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Unrealized losses, less than 12 months of temporary impairment Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Gross unrealized gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized losses Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Cost Available-for-sale Equity Securities, Amortized Cost Basis Estimated fair value, total temporary impairment Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value Unrealized losses, total temporary impairment Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss Cost Available-for-sale Debt Securities, Amortized Cost Basis Cost Available-for-sale Securities, Amortized Cost Basis Temporarily Impaired Investments [Abstract] Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract] Unrealized losses, more than 12 months of temporary impairment Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Summary of Investments [Abstract] Estimated fair value Available-for-sale Securities, Equity Securities Estimated fair value Available-for-sale Securities, Debt Securities Short-term investments Available-for-sale Securities, Debt Securities, Current Balance Sheet Location [Axis] Balance Sheet Location [Domain] Building [Member] Building and Building Systems [Member] Building and Building Improvements [Member] California Franchise Tax Board [Member] California [Member] Counterparty Name [Axis] Cash and Cash Equivalents [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Cash and cash equivalents at end of year Cash and cash equivalents at beginning of year Cash and Cash Equivalents, at Carrying Value Supplemental disclosures of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Class of Stock [Domain] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Licensing Agreements [Line Items] Collaborative Arrangements and Licensing Agreements Collaborative Arrangement Disclosure [Text Block] Common stock, $0.001 par value; 300,000,000 shares authorized, 120,351,480 and 118,442,726 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively Common Stock, Value, Issued Common stock, shares issued (in shares) Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares authorized (in shares) Common stock, shares authorized to issue (in shares) Common Stock, Shares Authorized Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common Stock [Member] Common stock, shares outstanding (in shares) Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Common shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Common Stock [Abstract] Employment Benefits [Abstract] Deferred Tax Assets and Liabilities [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Concentration Risk Type [Domain] Concentration Risk Type [Axis] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration Risk [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk [Table] Concentration percentage Concentration percentage Concentration Risk Benchmark [Axis] Basis of Presentation Consolidation, Policy [Policy Text Block] Consolidation Items [Domain] Consolidation Items [Axis] 2017 Contractual Obligation, Due in Second Year Annual Future Rent Payments [Abstract] Maturity Schedules Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] 2016 Contractual Obligation, Due in Next Fiscal Year Thereafter Contractual Obligation, Due after Fifth Year 2020 Contractual Obligation, Due in Fifth Year 2018 Contractual Obligation, Due in Third Year Total minimum payments Contractual Obligation 2019 Contractual Obligation, Due in Fourth Year Convertible senior notes Long-term debt Convertible Debt, Noncurrent Convertible Notes [Abstract] Convertible Senior Notes [Member] Convertible Notes Corporate Debt Securities [Member] Corporate Debt Securities [Member] Credit Facility [Domain] Credit Facility [Axis] Total current Current Income Tax Expense (Benefit) Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Current [Abstract] Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Strategic Partner [Member] Customer Concentration Risk [Member] Term of fixed rate elected Total shares of common stock subject to conversion (in shares) Debt Instrument, Convertible, Number of Equity Instruments Debt Instrument, Redemption, Period [Domain] Debt Instrument [Line Items] Percentage of principal amount used as redemption price Debt Instrument, Redemption Price, Percentage Debt Instrument, Redemption, Period [Axis] Amortization period of debt discount Long-Term Obligations and Commitments Debt and Capital Leases Disclosures [Text Block] Term of agreement Debt Instrument, Term Threshold percentage of conversion price to trigger redemption Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Principal amount repurchased Long-Term Obligations and Commitments [Abstract] Threshold number of trading days to trigger redemption Debt Instrument, Convertible, Threshold Trading Days Schedule of Long-term Debt Instruments [Table] Issue date Basis spread on variable rate Debt Instrument [Axis] Threshold number of consecutive trading days to trigger redemption Debt Instrument, Convertible, Threshold Consecutive Trading Days Principal amount of convertible notes outstanding Long-term Debt, Gross Conversion price per share (in dollars per share) On or after October 5, 2016 [Member] Debt Instrument, Redemption, Period One [Member] Less: unamortized portion of debt discount Debt Instrument, Unamortized Discount Maturity date Effective interest rate Debt Instrument, Name [Domain] Face amount of offering Debt Instrument, Face Amount Available-for-sale Securities [Member] Debt Securities [Member] If-converted value of notes in excess of principal Debt Instrument, Convertible, If-converted Value in Excess of Principal Carrying value of equity component Debt Instrument, Convertible, Carrying Amount of Equity Component Interest rate on convertible senior notes Interest rate Unamortized portion of liability component Debt Instrument, Unamortized Discount (Premium), Net Convertible Debt Debt, Policy [Policy Text Block] Convertible Senior Notes [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Total deferred Deferred Income Tax Expense (Benefit) Deferred [Abstract] Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred revenue Deferred Tax Assets, Deferred Income Upfront fee recorded as deferred revenue Deferred revenue Deferred Revenue Net deferreds Deferred Tax Assets, Net Current portion of deferred contract revenue Deferred Revenue, Current Deferred rent Plus: Deferred rent Deferred Rent Credit State Deferred State and Local Income Tax Expense (Benefit) Long-term deferred contract revenue Deferred Revenue, Noncurrent Deferred Tax Assets [Abstract] Deferred Tax Assets, Gross [Abstract] Net operating loss carryovers Deferred Tax Assets, Operating Loss Carryforwards Total deferred tax assets Deferred Tax Assets, Gross Other Deferred Tax Assets, Other R&D credits Deferred Tax Assets, Tax Credit Carryforwards, Research Valuation allowance Deferred Tax Assets, Valuation Allowance Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Deferred Tax Liabilities [Abstract] Deferred Tax Liabilities, Gross [Abstract] Convertible debt Deferred Tax Liabilities, Financing Arrangements Unrealized gain in other comprehensive income Deferred Tax Liabilities, Other Comprehensive Income Matching contributions Defined Contribution Plan, Cost Recognized Depreciation Depreciation Dilutive effect of 2 3/4 percent notes Federal [Member] Domestic Tax Authority [Member] Basic and Diluted Net Loss per Share Basic and Diluted Net Loss per Share [Abstract] Basic and diluted net loss per share (in dollars per share) Earnings Per Share, Basic and Diluted Basic net income per share (in dollars per share) Basic net income (loss) per share (in dollars per share) Diluted net income per share (in dollars per share) Diluted net income (loss) per share (in dollars per share) Per-Share Amount [Abstract] Earnings Per Share [Abstract] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Deferred tax true-up Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent State income tax net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent Reconciliation Between Effective and Statutory Tax Rate Percentage [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Loss on debt extinguishment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Net change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Effective rate Effective Income Tax Rate Reconciliation, Percent Statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Stock Options [Member] Stock Options [Member] Employee Stock Option [Member] Weighted average period for recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Employee Stock Purchase Plan (ESPP) [Member] Employee Stock [Member] Purchase price (in dollars per share) Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased Unrecognized compensation expense related to non-vested stock options Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation cost related to non-vested RSUs Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Accrued compensation Employee-related Liabilities, Current Unrecognized Compensation Expense [Abstract] Investment, Name [Domain] Equity Component [Domain] Equity Securities [Member] Equity Securities [Member] Excess tax benefits from share-based compensation awards Excess Tax Benefit from Share-based Compensation, Financing Activities Asset Class [Axis] Transfers out of Level 3 investments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Asset Class [Domain] Nonconvertible debt borrowing rate Fair Value Inputs, Discount Rate Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Transfers from Level 2 to Level 1 Fair Value Measurements [Abstract] Fair Value, Net Asset (Liability) [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Transfers from Level 1 to Level 2 Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Recurring Basis [Member] Fair Value, Measurements, Recurring [Member] Transfers into Level 3 investments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Total gains (losses) included in accumulated other comprehensive income (loss) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Measurement Frequency [Axis] Fair Value, Hierarchy [Axis] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value Hierarchy [Domain] Fair Value, Measurement Frequency [Domain] Unobservable Inputs (Level 3) [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Assets Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Reconciliation of Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3) Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Significant Unobservable Inputs (Level 3) [Member] Fair Value, Inputs, Level 3 [Member] Quoted Prices in Active Markets (Level 1) [Member] Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) [Member] Fair Value, Inputs, Level 2 [Member] Beginning balance of Level 3 investments Ending balance of Level 3 investments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Estimated Amortization Expense [Abstract] 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Three Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Cost Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets by Major Class [Axis] Estimated useful life Finite-Lived Intangible Asset, Useful Life 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2016 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Furniture and Fixtures [Member] Furniture and Fixtures [Member] Gain from sale of common stock Gain on investments, net Gain (Loss) on Sale of Investments Loss on early retirement of debt Loss on early retirement of debt Gains (Losses) on Extinguishment of Debt General and administrative General and Administrative Expense General and Administrative [Member] General and Administrative Expense [Member] Elimination of Intercompany Activity [Member] Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Impairment charges Non-cash charges related to write-down Impairment of Intangible Assets, Finite-lived Income Statement Location [Axis] CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Loss before income tax (expense) benefit Pre tax loss Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income Taxes [Abstract] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Axis] Income Tax Authority [Axis] Income Statement Location [Domain] Net change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Reconciliation Between Effective and Statutory Tax Rate [Abstract] Effective Income Tax Rate Reconciliation, Amount [Abstract] Provision for Taxes on Income from Continuing Operations [Abstract] Income Tax Expense (Benefit), Continuing Operations [Abstract] Income tax expense (benefit) Income tax (expense) benefit Income Tax Expense (Benefit) Income Tax Authority [Domain] Income Taxes Income Tax Disclosure [Text Block] Deferred tax true-up Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Loss on debt extinguishment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount State income tax net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Accounts payable Increase (Decrease) in Accounts Payable Income taxes Accrued liabilities Increase (Decrease) in Accrued Liabilities Deferred rent Increase (Decrease) in Deferred Liabilities Deferred contract revenue Increase (Decrease) in Deferred Revenue Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accrued compensation Increase (Decrease) in Other Employee Related Liabilities Inventories Increase (Decrease) in Inventories Other current and long-term assets Increase (Decrease) in Other Operating Assets Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Shares issuable related to our 2 3/4 percent notes (in shares) Shares issuable related to stock-based compensation (in shares) Less: fixed and determinable interest Interest Payable Interest expense Interest Expense Interest paid Interest Paid Federal [Member] Inventory Valuation [Abstract] Inventory, Raw Materials and Supplies, Net of Reserves [Abstract] Inventory Valuation Inventory, Policy [Policy Text Block] Inventories Inventory, Raw Materials, Net of Reserves Investment income Investment Income, Net Investments [Domain] Common stock owned (in shares) Investment Holdings [Line Items] Investment Type [Axis] Investment Secondary Categorization [Axis] Investment Holdings [Table] Contract Maturity of Available-for-Sale Securities Investments Classified by Contractual Maturity Date [Table Text Block] Investments by Secondary Categorization [Domain] Investments [Abstract] LIBOR [Member] Term of lease extension Term of lease Convertible Debt [Abstract] Long-Term Obligations [Abstract] Weighted average interest rate Long-term Debt, Weighted Average Interest Rate Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Land [Member] Land Improvements [Member] Land Improvements [Member] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Leasehold Improvements [Member] Leasehold Improvements [Member] Operating Leases [Abstract] Legal Proceedings Legal Matters and Contingencies [Text Block] Total current liabilities Liabilities, Current Current liabilities: Liabilities, Current [Abstract] Total liabilities Liabilities LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Total liabilities and stockholders' equity Liabilities and Equity Line of Credit Facility [Table] Commitment fee percentage on unused capacity Financing Arrangements [Abstract] Line of Credit Facility [Abstract] Lender Name [Axis] Outstanding borrowings Maximum borrowing capacity Line of Credit Facility, Lender [Domain] Weighted average interest rate Line of Credit Facility [Line Items] Equipment Financing Arrangement [Member] Loans Payable [Member] Fair value of outstanding notes Less: current portion Long-term Debt and Capital Lease Obligations, Current Financing Arrangements [Abstract] Long-term Debt, Other Disclosures [Abstract] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Axis] Manufacturing Facility [Member] Annual Debt and Other Obligation Maturities [Abstract] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net (decrease) increase in cash and cash equivalents Net Cash Provided by (Used in) Continuing Operations Income available to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Income available to common shareholders, plus assumed conversions Net Income (Loss) Available to Common Stockholders, Diluted Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Income (Numerator) [Abstract] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net loss Net loss Net income (loss) Net Income (Loss) Attributable to Parent Investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Impact of Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Other income (expense): Nonoperating Income (Expense) [Abstract] Number of operating segments Number of reportable segments Expenses: Operating Expenses [Abstract] Total operating expenses Operating expenses Operating Expenses 2016 Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Segments [Member] 2017 Operating Leases, Future Minimum Payments, Due in Two Years Loss from operations Loss from operations Operating Income (Loss) Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Abstract] Annual Future Minimum Payments Under Operating Leases [Abstract] Operating Leases, Future Minimum Payments Receivable [Abstract] Total minimum payments Operating Leases, Future Minimum Payments Due 2019 Operating Leases, Future Minimum Payments, Due in Four Years Rent expense Operating Leased Assets [Line Items] 2020 Operating Leases, Future Minimum Payments, Due in Five Years Net operating loss carryforwards Operating Loss Carryforwards 2018 Operating Leases, Future Minimum Payments, Due in Three Years Organization and Significant Accounting Policies [Abstract] Organization and Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Reclassification adjustment for realized (gains) losses included in net loss Amounts reclassified from accumulated other comprehensive (loss) income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Research and Development Facility Lease Obligation [Abstract] Income tax expense included in other comprehensive income Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Other comprehensive (loss) income before reclassifications, net of tax Other Comprehensive Income (Loss), before Reclassifications, before Tax Other current assets Other Assets, Current Tax expense related to unrealized gains on investments in available-for-sale securities recorded in other comprehensive income Unrealized (losses) gains on investments, net of tax Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Net other comprehensive (loss) income for the period Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Change in unrealized gains (losses), net of tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Products and Services [Domain] Isis Pharmaceuticals, Inc. Stockholders' Equity [Member] Parent [Member] Patents [Member] Patents [Member] Proceeds from the sale of Regulus Therapeutics, Inc. Payments for (Proceeds from) Investments Purchase price of land Payments to Acquire Land Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Purchases of short-term investments Payments to Acquire Available-for-sale Securities, Debt Employment Benefits Pension and Other Postretirement Benefits Disclosure [Text Block] Plan Name [Axis] Plan Name [Domain] Preferred Stock [Abstract] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares authorized to issue (in shares) Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Preferred Stock [Member] Proceeds from issuance of 1 percent convertible senior notes, net of issuance costs Proceeds from Convertible Debt Sales price of interest owned in subsidiary Proceeds from Divestiture of Interest in Consolidated Subsidiaries Proceeds from borrowing on line of credit facility Proceeds from public common stock offering Equity investment in common stock Proceeds from Issuance of Common Stock Cash received from exercise of stock options Proceeds from Stock Options Exercised Proceeds from the sale of short-term investments Proceeds from Sale and Maturity of Available-for-sale Securities Total proceeds from sale of common stock Net proceeds from sale of stock Proceeds from Sale of Other Investments Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases Proceeds from equity awards Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Products and Services [Axis] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Estimated useful life Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Type [Domain] Property, plant and equipment, net Property, plant and equipment, net Net book value of facility and associated parcel of land Property, Plant and Equipment, Net Property, plant and equipment Property, Plant and Equipment, Gross Property, Plant and Equipment [Line Items] Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] Quarterly Financial Data (Unaudited) [Abstract] Range [Domain] Range [Axis] Contracts receivable Receivables, Long-term Contracts or Programs Gross Unrecognized Tax Benefits [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Principal payments on debt and capital lease obligations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Repurchase of $140 million principal amount of the 2 3/4 percent convertible senior notes Repayments of Subordinated Debt Repurchase of convertible senior notes Counterparty Name [Domain] Research, Development and Patent Expenses [Abstract] Research and Development Expense [Abstract] Research and development expense Research and development expenses Research and Development Expense Research Tax Credit Carryforward [Member] Research and Development [Member] Restricted Stock Awards [Member] Restricted Stock [Member] Restricted Stock Units [Member] RSUs [Member] Restricted Stock Units (RSUs) [Member] Accumulated Deficit [Member] Retained Earnings [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Revenue Recognition [Abstract] Revenue Recognition [Abstract] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Milestone payment earned Revenue Recognition, Milestone Method, Revenue Recognized Total revenue Revenue earned Revenue Revenues Revenue: Revenue [Abstract] Revolving Line of Credit [Member] Expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Average remaining contractual term, outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Percentage of fair market value used to determine purchase price of stock Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Aggregate intrinsic value, exercisable at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Award term Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Average remaining contractual term, exercisable at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Amortization Expense for Patents Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Revenue [Member] Sales Revenue, Goods, Net [Member] Stock Option Activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Weighted-Average Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Weighted-Average Assumptions - ESPP Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Future Minimum Payments Under Operating Leases Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Reconciliation Between Effective and Statutory Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Changes in Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Temporarily Impaired Investments Schedule of Temporary Impairment Losses, Investments [Table Text Block] Quarterly Financial Data Schedule of Quarterly Financial Information [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Restricted Stock Unit Activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Gross Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Operating Leased Assets [Table] Long-Term Obligations Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Stock-Based Compensation Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Investment, Name [Axis] Property, Plant and Equipment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segment Information Schedule of Stock by Class [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Revenue from Significant Partners Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Segment Information and Concentration of Business Risk [Abstract] Segments [Domain] Segment Reporting Information [Line Items] Segment Information Segment Reporting, Policy [Policy Text Block] Segment Information and Concentration of Business Risk Segment Information [Abstract] Series A preferred stock [Member] Series A Preferred Stock [Member] Series C Junior Participating Preferred Stock [Member] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Non-vested at end of period (in shares) Non-vested at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Stock-Based Compensation [Abstract] Share-based Compensation [Abstract] Share-based compensation expense Share-based Compensation Stock Plans [Abstract] Share-based Arrangements with Employees and Nonemployees [Abstract] Non-vested at beginning of period (in dollars per share) Non-vested at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Number of Shares [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Weighted Average Exercise Price Per Share [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Cancelled/forfeited/expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award [Line Items] One Year from Date of Grant [Member] Number of additional shares reserved for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Weighted Average Grant Date Fair Value per Share [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Number of awards outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Cancelled/forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Cancelled/forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Exercisable at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Exercisable at end of period (in shares) Number of options exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Maximum percentage of employee compensation used to purchase shares Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Average Remaining Contractual Term, Aggregate Intrinsic Value and Other [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Weighted-Average Assumptions [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Cancelled/forfeited/expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Stock-Based Compensation Expense Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Aggregate intrinsic value, outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Equity Award [Domain] Outstanding at end of period (in shares) Outstanding at beginning of period (in shares) Number of options outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at end of period (in dollars per share) Outstanding at beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Number of Shares [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Weighted average fair value of options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Balance (in shares) Balance (in shares) Shares, Issued State Jurisdiction [Member] California [Member] State and Local Jurisdiction [Member] Income Taxes [Abstract] State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract] Statement [Line Items] CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract] CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract] Equity Components [Axis] Statement [Table] Segments [Axis] CONSOLIDATED BALANCE SHEETS [Abstract] Class of Stock [Axis] Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of public common stock Stock Issued During Period, Value, New Issues Stock Appreciation Rights [Member] Issuance of public common stock (in shares) Stock Issued During Period, Shares, New Issues Stock Options [Member] Equity Option [Member] Issuance of common stock in connection with employee stock plans Stock Issued During Period, Value, Share-based Compensation, Gross Number of shares issued for stock option exercises, vesting of restricted stock units, and ESPP purchases (in shares) Stock Issued During Period, Shares, Share-based Compensation, Gross Issuance of common stock in connection with employee stock plans (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Shares purchased and issued under ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' equity: Stockholders' Equity [Abstract] Stockholders' Equity Attributable to Parent [Abstract] Balance Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stockholders' Equity [Abstract] Total stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Subsequent Event Type [Axis] Subsequent Event [Member] Subsequent Event Type [Domain] Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Table] Tax Period [Axis] Tax Period [Domain] Tax credit carryforwards Tax Credit Carryforward, Amount Tax Credit Carryforward, Name [Domain] Tax Year 2009 [Member] Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Abstract] Type of Arrangement and Non-arrangement Transactions [Axis] Summary of Investments Unrealized Gain (Loss) on Investments [Table Text Block] Increase for prior period tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Interest and penalties on unrecognized tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Ending balance of unrecognized tax benefits Beginning balance of unrecognized tax benefits Unrecognized Tax Benefits Increase for current period tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Unrecognized tax benefits that would reduce effective tax rate Decrease for prior period tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Use of Estimates Use of Estimates, Policy [Policy Text Block] Debt Securities issued by U.S. Government Agencies [Member] US Government Agencies Debt Securities [Member] Debt Securities issued by States of the United States and Political Subdivisions of the States [Member] US States and Political Subdivisions Debt Securities [Member] Debt Securities issued by the U.S. Treasury [Member] US Treasury Securities [Member] Vesting [Domain] Vesting [Axis] Variable Rate [Axis] Variable Rate [Domain] Shares (Denominator) [Abstract] Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Shares used in computing basic net income per share (in shares) Weighted Average Number of Shares Outstanding, Basic Shares used in computing basic and diluted net loss per share (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Effect of Diluted Securities [Abstract] Shares used in computing diluted net income per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Collaborative Arrangements and Licensing Agreements [Abstract] Represents the number of Phase 3 studies in which the drug is being evaluated. Number of Phase 3 studies in which drug is being evaluated Information by categories of milestones achieved. Achievement of Milestone [Axis] Different categories of achievement of milestones. Achievement of Milestone [Domain] Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved. Development and Regulatory Milestones [Member] A second generation antisense drug designed to inhibit the production of both Insulin Growth Factor Binding Protein -2 and -5 (IGFBP-2, IGFBP-5) for the treatment of cancer. OGX-225 [Member] A second-generation anti-cancer drug designed to inhibit production of heat shock protein 27 (Hsp27). Apatorsen [Member] Information by phases of arrangements. Phases of Arrangements [Axis] Different phases of arrangements. Phases of Arrangements [Domain] Relates to a Phase 2 study. Phase 2 Study [Member] Represents the information pertaining to certain regulatory events on the basis of which certain milestones are achieved. Regulatory Milestones [Member] Regulatory Milestones [Member] Collaborative Arrangement and Licensing Agreement [Abstract] Represents the maximum amount of payments receivable under the agreement. Maximum amount of payments receivable Represents the next potential milestone payment to be earned. Next potential milestone payment Next potential milestone Represents satellite collaborative arrangements and licensing agreements to which the entity is party. Satellite Company Collaborative Arrangement and Licensing Agreement [Member] Satellite Company Collaboration and Licensing Agreement [Member] Relates to a Phase 3 study. Phase 3 Study [Member] Represents the information related to OncoGenex Technologies Inc., a subsidiary of OncoGenex Pharmaceuticals Inc. OncoGenex Technologies Inc. [Member] An antisense drug designed to inhibit clusterin to improve survival in patients with advanced cancer. Custirsen [Member] Represents information pertaining to certain development events on the basis of which certain milestones are achieved. Development Milestones [Member] Development Milestones [Member] Represents the amount of upfront fees received during the period in the form of equity securities. Upfront Fee Received in Form of Equity Securities, Value Upfront fee in the form of equity securities Represents collaborative arrangements and licensing agreements to which the entity is party. Collaborative Arrangements and Licensing Agreements [Member] Collaborations and Licensing Agreements [Member] Information pertaining to collaborative arrangements amended by the entity in June 2015. Agreement Amended in June 2015 [Member] Information pertaining to collaborative arrangements entered into by the entity in June 2012. Collaborative Arrangement June 2012 [Member] Agreement Entered into in June 2012 [Member] Cumulative amount of milestone payments, license fees and/or upfront fees received under the collaborative arrangement as of the end of the reporting period. Cumulative payments and/or fees received Relates to a Phase 1/2 study. Phase 1/2 Study [Member] IONIS-DMPK-2.5, formerly IONIS-DMPK, is a generation 2.5 antisense drug designed to correct the underlying genetic defect that causes Myotonic Dystrophy Type 1, or DM1, a rare genetic neuromuscular disease primarily characterized by progressive muscle atrophy, weakness and myotonia. IONIS-DMPK-2.5 [Member] Represents information pertaining to Biogen. Biogen [Member] Represents information pertaining to certain licensing and substantive events on the basis of which certain milestones are achieved. License and Substantive Milestones [Member] License Fee and Substantive Milestones [Member] The number of therapeutic targets granted to the partner under the collaboration agreement. Number of therapeutic targets granted to partner under collaboration agreement Number of therapeutic targets granted by Ionis The number of therapeutic programs under the collaboration agreement. Number of therapeutic programs under collaboration agreement Number of therapeutic programs The number of therapeutic targets granted by the partner under the collaboration agreement. Number of therapeutic targets granted by partner under collaboration agreement Number of therapeutic targets granted to Ionis Relates to a Phase 1 study. Phase 1 [Member] Represents the maximum amount of payments receivable per drug or program under the agreement. Maximum amount of payments receivable per drug or program Maximum amount of payments receivable per drug Maximum amount of payments receivable per program Represents the maximum amount of milestone payments payable under the agreement. Maximum amount of milestone payments payable Represents activity related to Alnylam Pharmaceuticals, Inc.. Alnylam Pharmaceuticals, Inc. [Member] Represents information pertaining to certain pre-specified events on the basis of which certain milestones are achieved. Pre Specified Events [Member] Pre-Specified Events [Member] Relates to Phase 2 studies in infants and children with spinal muscular atrophy or SMA. Phase 2 Studies in Infants and Children with SMA [Member] Relates to Phase 2 studies in infants with spinal muscular atrophy or SMA. Phase 2 Studies in Infants with SMA [Member] Relates to Phase 2 studies in children with spinal muscular atrophy or SMA. Phase 2 Studies in Children with SMA [Member] Relates to an open-label extension study for the Phase 3 studies in infants and children with spinal muscular atrophy or SMA. Open-Label Extension Study for Phase 3 Studies in Infants and Children with SMA [Member] Drugs to treat undisclosed neurodegenerative diseases under collaboration agreements, including IONIS-BIIB4, IONIS-BIIB5, and IONIS-BIIB6, Drugs to Treat Undisclosed Neurodegenerative Diseases [Member] Drugs to treat neurological disorders under collaboration agreements, including nusinersen, IONIS-DMPK-2.5, IONIS-SOD1 (formerly IONIS-BIIB3), and three drugs to treat undisclosed neurodegenerative diseases, IONIS-BIIB4, IONIS-BIIB5, and IONIS-BIIB6. Drugs to Treat Neurological Disorders Under Collaborations [Member] Relates to studies in infants and children with spinal muscular atrophy or SMA. Studies in Infants and Children with SMA [Member] Information pertaining to collaborative arrangements entered into by the entity in January 2012. Collaborative Arrangement January 2012 [Member] Agreement Entered into in January 2012 [Member] Nusinersen is an antisense drug discovered in collaboration with Dr. Adrian R. Krainer at Cold Spring Harbor Laboratory, that is designed to treat spinal muscular atrophy or SMA, a severe motor-neuron disease that is the leading genetic cause of infant mortality. Nusinersen [Member] Represents the number of drugs currently in clinical development under the collaboration agreement. Number of drugs currently in clinical development Number of drugs currently in development Represents the number of Phase 2 studies in which the drug is being evaluated. Number of Phase 2 studies in which drug is being evaluated Number of Phase 2 open-label, multiple-dose, dose-escalation studies in which drug is being evaluated Represents the number of active collaborations with the collaborative partner. Number of Strategic Collaborations Number of collaborative agreements Number of strategic collaboration agreements Represents information pertaining to certain pre-licensing events on the basis of which certain milestones are achieved. Pre-Licensing Milestones [Member] IONIS-HBV and IONIS-HBV-L are two antisense drugs designed to reduce the production of viral proteins associated with hepatitis B virus, or HBV infection, a follow-on compound based on LICA technology. IONIS-GSK4-L and IONIS-RHO-2.5 are two antisense drugs designed to treat ocular diseases. IONIS-HBV, IONIS-HBV-L, IONIS-GSK4-L, and IONIS-RHO-2.5 [Member] IONIS-HBV and IONIS-HBV-L are two antisense drugs designed to reduce the production of viral proteins associated with hepatitis B virus, or HBV infection, a follow-on compound based on LICA technology. IONIS-HBV and IONIS-HBV-L [Member] Represents the minimum amount of payments receivable under the agreement. Minimum amount of payments receivable Represents the information related to GlaxoSmithKline. Glaxo Smith Kline [Member] GSK [Member] Represents the amount of upfront fees received during the period under the agreement. Upfront Fee Received Upfront fee received Represents the information pertaining to certain commercialization events on the basis of which certain milestones are achieved. Commercialization Milestones [Member] Commercialization Milestones [Member] IONIS-TTR is an antisense drug designed to treat TTR amyloidosis, a severe and rare genetic disease in which the patient inherits a mutant gene that produces a misfolded form of TTR, which progressively accumulates in tissues. IONIS-TTR [Member] Represents the information pertaining to Atlantic Pharmaceuticals Limited, formerly Atlantic Healthcare (UK) Limited. Atlantic Pharmaceuticals Limited [Member] The ownership percentage represented by the entity's equity investments in companies with which it conducts business and which are not accounted for under the equity method of accounting. Equity Investments Other than Equity Method, Ownership Percentage Ownership interest percentage Royalties earned and paid in equity that were not recorded as revenue. Royalties earned and paid in equity The number of development candidates that must be generated for the brain shuttle program by a mutually agreed deadline to prevent termination by either party under the collaborative arrangement. Number of development candidates that must be generated for brain shuttle program Pertaining to antisense drug targeting huntingtin, or HTT, protein. HTT [Member] Pertaining to the brain shuttle program. Brain Shuttle Program [Member] Represents information pertaining to certain development, regulatory and commercial events on the basis of which certain milestones are achieved. Development Regulatory and Commercial Milestones [Member] Development, Regulatory and Commercial Milestones [Member] Represents information pertaining to Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd. Roche [Member] Roche [Member] Represents information pertaining to collaborative arrangements entered into by the entity in April 2013. Agreement entered into in April 2013 [Member] Agreement Entered into in April 2013 [Member] Represents the information related to Regulus Therapeutics Inc. Regulus Therapeutics Inc. [Member] Represents an equity investment in a company with which the entity conducts business and is a significant shareholder. Significant Equity Investment Investment in Regulus Therapeutics Inc. Net carrying value Represents information pertaining to Janssen Biotech, Inc., a pharmaceutical company of Johnson & Johnson. Janssen Biotech, Inc. [Member] Represents information pertaining to collaborative arrangements entered into by the entity in December 2014. Collaborative Arrangement December 2014 [Member] Agreement Entered Into in December 2014 [Member] Represents the number of programs under which drugs are to be developed and commercialized under the collaborative agreement. Collaborative Arrangement, Number of programs under which drugs are to be developed and commercialized Number of programs under which drugs are to be developed and commercialized Amount of long-term debt, capital lease and other obligations due after one year or beyond the normal operating cycle, if longer. Long-term Debt and Other Obligations, Noncurrent Total Long-Term Obligations Total Details pertaining to leases and other obligations not separately disclosed in the financial statements. Leases and Other Obligations [Member] 2 3/4 percent convertible senior notes due October 2019. Convertible Senior Notes 2.75 Percent [Member] 2 3/4 Percent Convertible Senior Notes [Member] Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of long-term debt, capital lease and other obligations (with maturities initially due after one year or beyond the operating cycle if longer). Long-term Debt and Other Obligations Total long-term obligations, including current portion Carrying balance of loan 1 percent convertible senior notes due November 2021. Convertible Senior Notes 1 Percent [Member] 1 Percent Convertible Senior Notes [Member] Represents information pertaining to a long-term financing liability for a leased facility. Long Term Financing Liability for Leased Facility [Member] Long-term Financing Liability for Leased Facility [Member] Term of the variable rate. Term of variable rate Morgan Stanley Private Bank, National Association offers banking and credit products and services. The company was founded in 1996 and is based in Purchase, New York. Morgan Stanley Private Bank, National Association operates as a subsidiary of Morgan Stanley. Morgan Stanley Private Bank, National Association [Member] Morgan Stanley [Member] Represents the information pertaining to CHDI Foundation, Inc. CHDI Foundation Inc [Member] CHDI Foundation Inc [Member] Represents information pertaining to collaborative arrangements amended by the entity in January 2016. Collaborative Arrangement Amended January 2016 [Member] Amended Agreement Entered into in January 2016 [Member] Represents the cumulative amount of upfront fees received under the agreement. Cumulative upfront fees received Antisense drugs for cancer. Oncology [Member] Antisense therapies for treating cardiovascular and metabolic diseases primarily focused on targets in the kidney, and renal diseases. Cardiometabolic and Renal Diseases [Member] IONIS-STAT3-2.5, also called AZD9150 and formerly IONIS-STAT3, was designed to treat cancer by inhibiting the production of a gene critical for tumor cell growth and survival. Signal transducer and activator of transcription 3, or STAT3, is over-active in a variety of cancers, including brain, lung, breast, bone, liver and multiple myeloma and promotes tumor cell growth and prevents cell death. IONIS-STAT3-2.5 [Member] Represents information pertaining to collaborative arrangements entered into by the entity in July 2015. Collaborative Arrangement July 2015 [Member] Agreement Entered into in July 2015 [Member] Represents information pertaining to collaborative arrangements entered into by the entity in December 2012. Collaborative Arrangement December 2012 [Member] Agreement Entered into in December 2012 [Member] Represents the number of drugs that the collaborative partner has the option to license under a separate research program. Collaborative Arrangement, Number of Drugs under Option to License Number of drugs the collaborative partner may license under a separate research program Cumulative amount of previously deferred revenue from upfront fees the Company received that has been amortized into revenue after the Company performed development activities under the collaboration agreement. Upfront fee amortized into revenue Represents the number of separate units of accounting requiring the allocation of consideration for revenue recognition purposes under the multi-deliverable arrangement. Revenue Recognition, Multi-deliverable Arrangement, Number of Units of Accounting Number of units of accounting Milestone payments to be earned under the collaborative arrangement. Milestone payments to be earned Milestone payment to be earned Represents information pertaining to AstraZeneca. Astra Zeneca [Member] AstraZeneca [Member] Development and commercialization of novel antisense drugs to three targets to treat neurological or neuromuscular diseases. Neurology [Member] Represents the number of targets for the research and development of drugs under a collaborative agreement. Number of Targets for Collaborative Agreement Number of targets Represents the number of drugs currently being advanced under the collaboration agreement. Number of drugs currently being advanced Each antisense molecule that is chosen for drug discovery and development to advance the treatment of neurological diseases. Antisense Molecule [Member] Other modalities, such as small molecules or monoclonal antibodies, chosen for drug discovery and development to advance the treatment of neurological diseases. Other Modalities [Member] Strategic relationship focused on applying antisense technology to advance the treatment of neurological diseases. Strategic Neurology [Member] Term of the collaboration agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Term of collaboration agreement Represents information pertaining to certain research and development events on the basis of which certain milestones are achieved. Research and development milestones [Member] Research and Development Milestones [Member] Represents information pertaining to collaborative arrangements entered into by the entity in September 2013. Collaborative Arrangement September, 2013 [Member] Agreement Entered into in September 2013 [Member] Represents the maximum amount of sublicense revenue and post licensing milestone payments payable under the in-licensing arrangement. Maximum amount of sublicense revenue and post licensing milestone payments payable under in-licensing arrangement The cumulative net sales threshold of the former subsidiary that is used to calculate earn out payments so long as revenue for the applicable year exceeds $50 million. Cumulative net sales threshold used to calculate earn out payments The percentage of the former subsidiary's cumulative net sales over $2.1 billion that is used to calculate earn out payments so long as revenue for the applicable year exceeds $50 million. Percentage of cumulative net sales used to calculate earn out payments, tier 2 Percentage of cumulative net sales used to calculate earn out payments, over $2.1 billion License agreement under which the company acquires an exclusive license related to the patent rights for one of its products. In-Licensing Arrangement [Member] The percentage of the former subsidiary's cumulative net sales over the first tier of $140 million and up to $2.1 billion that is used to calculate earn out payments so long as revenue for the applicable year exceeds $50 million. Percentage of cumulative net sales used to calculate earn out payments, tier 1 Percentage of cumulative net sales used to calculate earn out payments, over $140 million and up to $2.1 billion The revenue threshold of the former subsidiary that is used to calculate earn out payments. Revenue threshold used to calculate earn out payments Represents the information pertaining to Cold Spring Harbor Laboratory. Cold Spring Harbor Laboratory [Member] Represents the information pertaining to Abbott Molecular Inc. Abbott Molecular Inc [Member] Abbott Molecular Inc. [Member] Represents the information pertaining to Verva Pharmaceuticals Ltd. Verva Pharmaceuticals Ltd [Member] Verva Pharmaceuticals Ltd. [Member] Represents the information pertaining to University of Massachusetts. University of Massachusetts [Member] Gross carrying amount, less accumulated amortization and any impairment charges, of the costs pertaining to the exclusive legal rights granted to the owner of a patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply for and receive patent rights, or to acquire such rights. Patents, Net Patents, net Primarily includes carrying amount of debt issuance costs and noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Deposits and Other Assets, Noncurrent Deposits and other assets Long-term financing obligation related to a lease agreement with an affiliate of of BioMed Realty, L.P. for the construction of the company's primary research and development facility in Carlsbad, California due in the next twelve months or greater than the normal operating cycle, if longer. In order to gain early access to the facility, the company modified the lease to accept additional responsibility. Long-term financing obligation, Noncurrent Long-term financing liability for leased facility Amount of long-term obligations, including debt and capital leases, due within one year or the normal operating cycle, if longer. Long-term Obligations, Current Current portion of long-term obligations Carrying amount of long-term obligations due in the next twelve months or greater than the normal operating cycle, if longer, excluding convertible senior notes and a long-term financing liability for a leased facility. Long-term Obligations, Noncurrent Long-term obligations, less current portion Represents the number of buildings leased and occupied by the entity. Leases, Number of Buildings Number of buildings in Carlsbad, California The number of options to extend the lease under the lessee's operating leasing arrangement. Lessee Leasing Arrangements, Operating Leases, Number of options to extend lease Number of options to extend lease Office and laboratory space leased under non-cancelable operating leases. Office and Laboratory Space [Member] Reportable segment which includes the operations of the Company's wholly-owned subsidiary, Akcea Therapeutics, Inc., which was formed to develop and commercialize drugs for cardiometabolic disorders. Akcea Therapeutics [Member] Represents the number of stages in the life-cycle of drugs, reflected in the categories of contractual milestones. Number of Stages of Life Cycle of Drugs Number of stages of life-cycle of drugs Represents the typical period within which regulatory filings are prepared and submitted. Period for Preparing and Submitting Filings Time to prepare and submit regulatory filings Represents activity related to Alnylam Pharmaceuticals, Inc.. Alnylam [Member] Represents information pertaining to Bayer HealthCare. Bayer HealthCare [Member] Bayer [Member] IONIS-FXI is an antisense drug designed to treat clotting disorders and the prevention of thrombosis. It targets Factor XI, a clotting factor produced in the liver that is an important component of the coagulation pathway. IONIS-FXI [Member] Represents the active pharmaceutical ingredient, or API, for IONIS-FXI, an antisense drug designed to treat clotting disorders and the prevention of thrombosis. IONIS-FXI Active Pharmaceutical Ingredient [Member] The percentage change in the selling price factor applied to a multiple-deliverable arrangement to determine the change to the allocation of the consideration to a specific unit of accounting that would result. Assumed Change in Estimated Selling Price of Product Assumed change in estimated selling price The portion of upfront fees received during the period under the terms of the agreement that are recognized as revenue during the period. Upfront Fee Recognized Upfront fee recognized Represents the number of categories of milestone events. Number of Categories of Milestone Events Number of categories of milestone events The percentage change to the allocation of the consideration to a specific unit of accounting that would result from a specified change in the selling price factor applied to a multiple-deliverable arrangement. Percentage Change in Amount of Revenue from Product for Assumed Change in Selling Price Percentage by which earned revenue would change based on assumed change in estimated selling price Represents information pertaining to the new development candidate phase as one type of event defining the achievement of development milestones. Development Milestones New Development Candidate [Member] Development Milestones - New Development Candidate [Member] Represents information pertaining to Phase 1 clinical studies as one type of event defining the achievement of development milestones. Development Milestones Phase One [Member] Development Milestones - Phase 1 [Member] Represents information pertaining to Phase 2 clinical studies as one type of event defining the achievement of development milestones. Development Milestones Phase Two [Member] Development Milestones - Phase 2 [Member] The amount of change to the allocation of the consideration to a specific unit of accounting that would result from a specified change in the selling price factor applied to a multiple-deliverable arrangement. Change in Amount of Revenue from Product for Assumed Change in Selling Price Amount by which earned revenue would change based on assumed change in estimated selling price Represents a pre-specified sales threshold that could be used as a pre-specified event to trigger a milestone payment. Pre-specified Sales Threshold Example of sales threshold as milestone event Represents the typical period within which approval is obtained once regulatory filings have been prepared and submitted. Period for Obtaining Regulatory Approval Time to obtain approval Represents information pertaining to Phase 3 clinical studies as one type of event defining the achievement of development milestones. Development Milestones Phase Three [Member] Development Milestones - Phase 3 [Member] Revenue from arrangements that include licensing and royalty revenues, profit sharing and/or earn out payments. Licensing revenue represents revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements typically include, but are not limited to, rights to use intellectual property on an exclusive or non-exclusive basis. Royalty, profit sharing and/or earn out payments are derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's intellectual property. Licensing and Royalty Revenue Licensing and royalty revenue Licensing and royalty Represents information pertaining to collaborative arrangements entered into by the entity in May 2015. Agreement entered into in May 2015 [Member] Agreement Entered into in May 2015 [Member] Represents the average period for completion of an animal study or clinical trial. Average Duration to Completion Completion period The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects. Also includes charges for amortization and write-downs of capitalized patent costs, as well as legal fees for patent litigation and patent defense. Research Development and Patent Expense Research, development and patent expenses This item represents the gain (loss) realized on the sale of the Company's investment in Regulus Therapeutics Inc., classified as available-for-sale equity securities. Gain (Loss) on Available-for-Sale Equity Securities, Significant Investment Gain on investment in Regulus Therapeutics Inc. Gain on investment in Regulus Therapeutics Inc. This item represents the gain (loss) realized on the sale of available-for-sale equity securities, excluding the Company's investment in Regulus Therapeutics Inc. Gain (Loss) on Available-for-Sale Equity Securities, Excluding Significant Investment Gain on investments, net Gain on investments, net Revenue recognized during the period from collaborations where the entity receives payments for expenditures relating to research and development activities, contractual milestone payments, and the manufacture and sale of drug inventory to collaboration partners. Research and Development Revenue under Collaborative Agreements Research and development revenue under collaborative agreements Research and development Amount of tax expense (benefit) for unrealized holding gain (loss) on available-for-sale securities included in continuing operations. Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax Tax benefit related to unrealized gains on investments in available-for-sale securities recorded in continuing operations The amount of cash received during the period as refunds for the overpayment of franchise taxes. Income Tax Examination, Franchise tax refund Franchise tax refund The increase (decrease) in the tax credit carryforward available to reduce future taxable income under enacted tax laws. Increase (Decrease) in Tax Credit Carryforward Increase in research credit carry over Unrealized excess tax benefits associated with share-based compensation that will be recognized as a credit to additional paid-in capital, if and when the benefits are realized, rather than a reduction of the provision for income taxes. Unrealized excess tax benefits associated with share-based compensation Represents the net amount of deferred tax assets (before reduction for valuation allowance) and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. Deferred Tax Assets (Liabilities), Net, before Valuation Allowance Net deferred tax asset The amount as of the balance sheet date of the estimated future tax effects attributable to the difference between the tax basis of capital assets and intangible assets and the basis of capital assets and intangible assets computed in accordance with generally accepted accounting principles. Deferred Tax Liabilities, Property, Plant and Equipment and Goodwill and Intangible Assets Intangible and capital assets Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to California franchise tax refunds. Income Tax Reconciliation, Franchise tax refund, Amount California franchise tax refund Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to California franchise tax refunds. Income Tax Reconciliation, Franchise tax refund, Percent California franchise tax refund The increment of principal amount of convertible notes being redeemed. Debt Instrument, Convertible, Principal amount being redeemed Principal amount being redeemed The additional payment per each increment of principal amount of convertible notes being redeemed. Debt Instrument, Convertible, Additional payment per principal amount being redeemed Additional payment per $1,000 principal amount being redeemed The percentage of the principal amount of the notes to be purchased, plus accrued and unpaid interest, upon the occurrence of certain fundamental changes, as set forth in the indenture governing the convertible notes. Debt Instrument, Convertible, Percentage of principal amount used a purchase price upon occurrence of fundamental change Percentage of principal amount used a purchase price upon occurrence of fundamental change Represents the aggregate of all long-term obligations of the entity, including capital leases and other financing arrangements, excluding the long-term financing liability for the entity's leased research and development facility. Long-Term Obligations, Excluding Financing Liability for Leased Facility [Member] Legal Proceedings [Abstract] Physical assets used in the normal conduct of business and not intended for resale, excluding land. Examples include, but are not limited to, buildings, land and leasehold improvements, machinery and equipment, office equipment, and furniture and fixtures. Property, Plant and Equipment, Excluding Land [Member] Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and purchased software applications and internally developed software for long-term internal use. Includes other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services, such as laboratory, manufacturing and other equipment. Equipment and Computer Software [Member] Computer Software, Laboratory, Manufacturing and Other Equipment [Member] Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Lessee Leasing Arrangements, Renewal Term Term of lease extension The number of options to extend the lease under the lessee's leasing arrangement. Lessee Leasing Arrangements, Number of options to extend lease Number of options to extend lease Facility constructed for the entity's primary research and development activities under a lease agreement with an affiliate of BioMed Realty, L.P. Primary Research and Development Facility [Member] Primary Research and Development Facility [Member] An arrangement whereby a member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as a form of compensation. Board of Director Stock Option [Member] Board of Director Stock Options [Member] Reflects the percentage that revenues in the period from Partner E is to net revenues, as defined by the entity. The risk is the materially adverse effects of loss of a significant partner. Partner E Concentration Risk [Member] Partner E [Member] Reflects the percentage that revenues in the period from Partner F is to net revenues, as defined by the entity. The risk is the materially adverse effects of loss of a significant partner. Partner F Concentration Risk [Member] Partner F [Member] Reportable segment in which the Company is exploiting a novel drug discovery platform created to generate a broad pipeline of first-in-class or best-in-class drugs for the Company and its partners. This segment generates revenue from a multifaceted partnering strategy. This strategy includes revenue from collaborations with preferred partners, traditional alliances and working with a consortium of companies that can exploit the Company's drugs and technology. Revenue from collaborations with preferred partners and traditional alliances may consist of upfront payments, milestone payments, licensing fees and royalties. Ionis Core [Member] Significant Partners [Abstract] Represents the number of significant partners. Number of Significant Partners Number of significant partners Reflects the percentage that revenues in the period from Partner B is to net revenues, as defined by the entity. The risk is the materially adverse effects of loss of a significant partner. Partner B Concentration Risk [Member] Partner B [Member] Reflects the percentage that revenues in the period from Partner C is to net revenues, as defined by the entity. The risk is the materially adverse effects of loss of a significant partner. Partner C Concentration Risk [Member] Partner C [Member] Reflects the percentage that revenues in the period from Partner D is to net revenues, as defined by the entity. The risk is the materially adverse effects of loss of a significant partner. Partner D Concentration Risk [Member] Partner D [Member] Reflects the percentage that contracts receivables in the period from Significant Partners is to contracts receivable, as defined by the entity. The risk is the materially adverse effects of loss of a significant partner. Significant Partners Concentration Risk [Member] Significant Partners [Member] Reflects the percentage that revenues in the period from Partner A is to net revenues, as defined by the entity. The risk is the materially adverse effects of loss of a significant partner. Partner A Concentration Risk [Member] Partner A [Member] The weighted average grant-date fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Fair Value Weighted-average fair value of options exercised (in dollars per share) The cash inflow associated with the sale of available-for-sale equity securities, excluding the Company's investment in Regulus Therapeutics Inc. Proceeds from Sale of Available-for-sale Equity Securities, Excluding Significant Investment Proceeds from the sale of strategic investments The cash inflow from a loan agreement to finance the purchase of equipment. Proceeds from Equipment Financing Arrangement Proceeds from equipment financing arrangement The cash outflow for acquisition of licenses and other assets not otherwise defined in the taxonomy. Payments to Acquire Licenses and Other Assets Acquisition of licenses and other assets, net Future cash outflow to pay for purchases of fixed assets and patents that have occurred. Non-cash Capital and Patent Expenditures Amounts accrued for capital and patent expenditures The aggregate expense that is charged against the earnings to allocate the cost of patents in a systematic and rational manner to the periods expected to benefit from such asset. Amortization of Patents Amortization of patents The aggregate expense that is charged against the earnings to allocate the cost of licenses in a systematic and rational manner to the periods expected to benefit from such asset. Amortization of Licenses Amortization of licenses Cash flow impact of deferred income tax expense (benefit) pertaining to unrealized gains or losses on securities. Deferred Income Tax Expense Benefit Unrealized Gains on Securities Tax benefit from other unrealized gains on securities The net change during the reporting period in the amount to be collected from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date. Increase (Decrease) in Contracts Receivable, Net Contracts receivable Represents information pertaining to collaborative arrangements entered into by the entity in January 2008. Collaborative Arrangement January 2008 [Member] Agreement Entered Into in January 2008 [Member] Represents information related to Genzyme Corporation, a Sanofi entity. Genzyme Corporation [Member] Cumulative amount of milestone payments, license fees and equity investment received under the collaborative arrangement as of the end of the reporting period. Cumulative payments, fees and equity investment received Represents the information pertaining to Achaogen, Inc. Achaogen Inc [Member] Represents the number of drugs to be developed and commercialized under the collaboration agreement, for which milestone payments would be received. Collaboration Agreement, Number of Drugs to be Developed and Commercialized Number of drugs to be developed and commercialized Disclosure of accounting policy for costs that the entity has incurred in research and development and for costs related to patents. Research, Development and Patent Expenses [Policy Text Block] Research, Development and Patent Expenses Disclosure of accounting policy for cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities. Cash, Cash Equivalents and Short Term Investments [Policy Text Block] Cash, Cash Equivalents and Short-Term Investments Disclosure of accounting policy for accumulated other comprehensive income (loss). Accumulated Other Comprehensive Income (Loss) [Policy Text Block] Accumulated Other Comprehensive Income (Loss) Disclosure of accounting policy regarding organization and business activity. Organization and business activity [Policy Text Block] Organization and Business Activity Represents information pertaining to research, development and patents. Research Development and Patents [Member] Research, Development and Patents [Member] Represents the 2000 Broad-Based Equity Incentive Plan in which non-qualified stock options are issued to the entity's employees, directors and consultants. Broad Based Equity Incentive Plan 2000 [Member] 2000 Broad Based Equity Incentive Plan [Member] Represents the period to purchase common stock under the plan. Share-based Compensation Arrangement by Share-based Payment Award, Purchase Period Purchase period Represents the holding period from the date of purchase for stock purchased under the plan. Share-based Compensation Arrangement by Share-based Payment Award, Holding Period Holding period for purchased stock Number of equal annual installments over which options become exercisable. Number of equal annual installments over which options become exercisable Represents the 2002 Non-Employee Directors Stock Option Plan, which provided for the issuance of stock options to the entity's non-employee directors for the purchase of common stock. Nonemployee Directors' Stock Option Plan 2002 [Member] 2002 Non-Employee Directors' Stock Option Plan [Member] Represents the stock option plan that provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance cash awards to employees, directors, and consultants. Equity Incentive Plan 2011 [Member] 2011 Equity Incentive Plan [Member] Represents the 1989 Stock Option Plan, which provides the issuance of non-qualified and incentive stock options for the purchase of common stock to the entity's employees, directors and consultants. Stock Option Plan 1989 [Member] 1989 Stock Option Plan [Member] Represents the 2009 Employee Stock Purchase Plan, as amended and restated, which permits full-time employees to purchase common stock through payroll deductions at a percentage of the fair market value. Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Tabular disclosure of future rent payments, as of the latest balance sheet date, in the aggregate and for each of the five succeeding fiscal years for the Company's primary research and development facility. Schedule of Future Rent Payments for Lease Obligation [Table Text Block] Future Rent Payments for Research and Development Facility Lease Obligation Adjustment to additional paid in capital resulting from the redemption of convertible debt instruments as two separate components - a debt component and an equity component. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Redemption 2 3/4 percent convertible senior notes redemption, equity portion 2 5/8 percent convertible subordinated notes due 2027. Convertible Subordinated Notes 2.625 Percent [Member] 2 5/8 Percent Convertible Subordinated Notes [Member] Patent [Abstract] Patents [Abstract] Includes charges for amortization and write-downs of capitalized patent costs as well as legal fees for patent litigation and patent defense. Patent Expenses Patent expenses Represents the amount of near-term payments that can be received under the agreement. Near-term payments The maximum percentage of gross margins of sales of the drug received as royalties under the collaborative arrangement. Percentage of gross margins of sales received as royalties Percentage of gross margins of sales received as royalties Represents information pertaining to certain licensing and substantive events on the basis of which certain milestones are achieved and other payments are received. License Fees, Milestone Payments and Other Payments [Member] License Fees, Substantive Milestone Payments and Other Payments [Member] Represents the information pertaining to Antisense Therapeutics Limited. Antisense Therapeutics Limited [Member] Represents the information related to Regulus Therapeutics Inc. Regulus Therapeutics [Member] Regulus Therapeutics Inc. [Member] Represents investment securities with an expected maturity of one year or less. Securities with Maturity of One Year or Less [Member] Represents investment securities with an expected maturity of more than one year. Securities with Maturity of More than One Year [Member] The percentage of available-for-sale debt securities that mature beyond two years but within three and one-half years of the balance sheet date. Available-for-sale Securities, Debt Maturities, after Two Through Three and One Half Years, Percentage After two years but within three and a half years The percentage of available-for-sale debt securities that mature within two years of the balance sheet date. Available-for-sale Securities, Debt Maturities, within Two Years, Percentage Percentage of available-for-sale securities with a maturity of less than two years Number of privately-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for under the cost method. Number of Privately Held Companies in which Entity has Equity Investment Number of privately-held companies in which the entity has an equity ownership interest of less than 20% The aggregate percentage of all available-for-sale debt securities, regardless of maturity. Available-for-sale Securities, Debt Maturities, Total, Percentage Total The percentage of available-for-sale debt securities that mature within one year of the balance sheet date. Available-for-sale Securities, Debt Maturities, within One Year, Percentage One year or less Number of publicly-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for as available-for-sale securities. Number of Publicly Held Companies in which Entity has Equity Investment Number of publicly-held companies in which the entity has an equity ownership interest of less than 20% The percentage of available-for-sale debt securities that mature beyond one year but within two years of the balance sheet date. Available-for-sale Securities, Debt Maturities, after One Through Two Years, Percentage After one year but within two years Document and Entity Information [Abstract] Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of shares issuable related to employee stock purchase plan. Incremental Common Shares Attributable to Employee Stock Purchase Plan Shares issuable related to our ESPP The limit of annual employee contributions to the plan per calendar year by eligible employees who are under 50 years of age. Defined Contribution Plan, Employee Contribution Limit by Plan Participants under Fifty Years Age Employee contribution limit per calendar year for employees under 50 years of age The limit of annual employee contributions to the plan per calendar year by eligible employees who are over 50 years of age. Defined Contribution Plan, Employee Contribution Limit by Plan Participants over Fifty Years Age Employee contribution limit per calendar year for employees over 50 years of age EX-101.PRE 13 ions-20151231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 14 image00002.jpg begin 644 image00002.jpg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end GRAPHIC 15 image00004.jpg begin 644 image00004.jpg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end GRAPHIC 16 image10.jpg begin 644 image10.jpg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end GRAPHIC 17 image11.jpg begin 644 image11.jpg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end GRAPHIC 18 image12.jpg begin 644 image12.jpg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image13.jpg begin 644 image13.jpg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

MBQL9(T(M,U'4)K*UED>2$N&

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end GRAPHIC 20 image14.jpg begin 644 image14.jpg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image00015.jpg begin 644 image00015.jpg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end GRAPHIC 22 image00016.jpg begin 644 image00016.jpg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image00017.jpg begin 644 image00017.jpg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end GRAPHIC 24 image00018.jpg begin 644 image00018.jpg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

X996*Q!;24M)@9W*H7++C^( CGK4&F>)K?48;><^3#%, M+A@S2D_+$^W=G;C!')R1C/?G":Z?UM_D-/JA]QIU]#<:?>V0MI9[>W:WDBFD M9%=3M.0P5B""H_AY!/2LJ7PS?^7"9%M+Y7DFFNK2:>2*!I796!P%;>%Q@!A[ M\&MF/Q+I,D$\PN)$2"'[0WFP21DQ_P!]0R@LONN>WK4)\7:*HDS[N):*QG:7X;U+14M9K;[!+<0?:(C#N:*)HI)-XP0K M%2#CC!&.,]ZA7PC=>59W%U;:5J-U$]P)8+E3Y++)(7#*2K%6''8\$C/>NAN= M>TVTN##-.VY0I=TB=TC!Z;W4%4]?F(XYJM'XFM/[0U6WG22&/3]@,K1/A]P' M3Y>3D@ #);MF@!ECHDMM=:;,(-/MEMUF\R&SC*("^W&T8YQCD\9ZX'2MZL&\ M\66%OIUU=Q;V:U>)9HIXW@9 [!0Q#J#C!)SC!Q5N/Q!IDEMW')X% &G16--XCM!923VZR2/%-%%)#+&\+KYCJH)5U!Q\V1QS MBG/XCL+> RW4H7][+&!"DDIQ&Q#$@+D 8Y.,#/4\$@&Y;@F7 &?E;^1IGER? MW&_*G6DBNRR1N&5D)5E/!&TX--\R3^^WYT 'ER?W&_*CRY/[C?E1YDG]]OSH M\R3^^WYT 'ER?W&_*CRY/[C?E1YDG]]OSH\R3^^WYT 'ER?W&_*CRY/[C?E1 MYDG]]OSH\R3^^WYT 'ER?W&_*CRY/[C?E1YDG]]OSH\R3^^WYT 'ER?W&_*C MRY/[C?E1YDG]]OSH\R3^^WYT 'ER?W&_*CRY/[C?E1YDG]]OSH\R3^^WYT ' MER?W&_*CRY/[C?E1YDG]]OSH\R3^^WYT 'ER?W&_*CRY/[C?E1YDG]]OSH\R M3^^WYT 'ER?W&_*CRY/[C?E1YDG]]OSH\R3^^WYT 'ER?W&_*MNQ4_88P00> M>OU-8GF2?WV_.MNP)-E&223SU^IH SK[0HKR3>W6JG_"*V]=+10!S7_"*V]' M_"*V]=+10!S7_"*V]'_"*V]=+10!S7_"*V]'_"*V]=+10!S7_"*V]'_"*V]= M+10!DZ?HT=D^Y:SE_P"2H2_]@9?_ $<:Z>L(:==?\)Y)J7E?Z&=,$ DW#[_F M%L8SGIWQBCJOG^3!_"_E^:.?B^(MZ]C%J;^&+A-(\WR9KS[2AV'?MRJ8RR]. M>.'-3OAXN6* ?Z?;P+:DNO[QD4Y'7CGCG M'6A[?UY%+XOZ[EJSU0'Q!%+?Z+);ZH-)::3RYS,RH)/]6%488G@Y'/.*KP^. M[R/6+&SU7P^^G0WSA+=I+V-ICN^Z6A'S*/7T/%-DTSQ!JM])>M:?V7K^3,7XY7GISD#CZUSMGX5UA)=&6#P99::ME>Q3W%Q]L26:;!^8JVT>TN(9GM[BW M=@QCD7J,CJ/>H3I]U_PG:ZEY7^B#33!YFX??\S=C&<].^,55TFUU32$U5UT[ MSWNM6>5$\]5_*I._P"/_I1-K?A^1T]<);6VL0_$32YM8OXY MYIK*X(@MT*PP %.%R?]<'_]!-<#X=^(GA6Q\):?8W.J;+F&T6-T M^SRG#!<$9"XKT&^C>:PN8HQEWB95&>I(-9WAVQN+'PEI]CE3^'+*VTGQ7JEGX<20Z3;6H$\/G,T?VO/W59B<-MX;TXS5%]/\7:=X&T;1 MM.TR4RX<7QANXXI$7<2%1R2 2#U .*WO#,VKVL']GOX/32+."$F';?QR[W&, M*<#.3R2Q_'K5OXFUY_U_E_5Y6R3\C3N_[=OM&M_L7V;3+Z;'VCS_ -_Y (.= MN,!F!QC/'6N9\/7DVB_#O6+L2R3SVD]XPDE.6=E=L,Q[G/)KMK*6XGLH9;JV M^S7#H#)!Y@?RV[C<.#CUKG=)\/SMX5U72=03R3>3W6#D-A)'8JW!]"#BIE?W MK=G^A2MI?O\ YG#VD>@^9I]]'_;EKJ9>)F\22P2-;RR' 8,6;&UB2O0#ISCK M[#7G]U9^+M7T9?#%YHUI;VY5(9M46Z5D9%(R5BQN!('&>_I7?@;5 '88JW;H M2K]1:***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% '+^$_P#CWKJ*Y?PG_P >]=10 G>O%?%?_(U: MC_UU/\A7M7>O%/%G_(U:C_UV/\A7J95_%EZ'C9U_!CZ_H8]%)17NGS0M%)10 M M%)10 M%)10 M%)10 M6;#_ )"-K_UV3^8JK5BP_P"0C:_]=D_F*F7PLJ'Q M(]9D_P!:_P#O&FTZ3_6O_O&FU\@?>!1110 4444 %%%% !1110 4444 2V_^ MO7\?Y5BZW97$_P!BO+-%DN;&?SDB9MOF@JRLN>@.&.,\9 SCK6U;_P"O7\?Y M5%0!A7%SK]Y#=&SL?L&VV<1"Z9&D>8_=QL9E"CWSDGI@5A'1=4GO9[@65_B7 M3;FW9[Z\1W:5]I&%5BB*<8&W XY P,]U12:&G8YZ6SO+*_TW4(+-[H0V;6LM MO$Z*ZYVD,NXA2,K@\CJ,9K(3P[JMWI\<$]NEM))#J"O^\#+&TLH9!QR01Z#Z MXKN**IN_]=Q+0X[6-/U77X)&.F/:/#83PJDDL9,TDB@84JQ 4;>K8ZCBK6H: M1>3#5?*MP?/T9;6+YE&9!YGR]>/O+STKIZ*EJZM_77_,:=OZ]/\ (X?_ (1Z MYMY;V.73+Z]6\VNI@U-H(QE%1DE4..!MZJK9!Z<8J[-8:Q9W.JG3K>5!,;9H MI8I(R=B!5=5\P_?P#@L,>^:ZNBF]1)6.";0M6(U)X-/N/WZV9A6]OA*[&*8L MV\[FV\Z9J>JWD^J"Q-L\:VXAM9I4W3>7+YAR5+*,]!SUY.*ZV MB@#DK[3=2U:ZN+_["]L2+6&."61"[!)Q(SG:Q4 #.!DG@^HIMOIVIZ7J0U)- M/>Z^>\0P1R1A@))MZ,"S 8('/.>1QUKKZ*%IM_5PWW'V9<[3(JK(8SN56R = MIR <#/Y4RI;?_6_\!;_T$U%0!4@U"*>XO855PUFX20D#!)0/QSZ,*AL]:M+R MV2X!\J%K5+LM*Z#:C9^\-V1C!R3Q[G!QE)HB7>KZY/<"_CWS)Y1BNIH5<"%! MD!& ;G(S[8K%ATR]%E9F2QG>.#3M/,T)B.7$M"\_(;V_KR M.KG\1Z5'8O>0WD-W$C1AOLTJN1O?8#P>F<_D?2KEGJ%EJ,;26-Y;W4:MM9H) M5< ^A(/6N&U"-=5O_$!MM/G*3C3]R26[*TN)3N8HP#8P,1Q=V[;44DX M$J$GCL ":=?VS2^)M(G\EG2&.1HV>;<&VJ"V&48R!CIZU3T+2A?V-A;26DD5G)%J4+ MJ%XB#S#"DC@' ./I1TN/K;S.YFN[:W+":XBBV1F5M[@80=6.>P]:C_M.P-A] MO%];?8\9^T>:OEXSC[V<=>*XN"#4-3TB;4;F!Y9H+FW@>-1N,D=O(/,( ZY? M><=]H%:&KQM>P:??6-M?VEM!?-+-Y-H!,V5*^:(F4D_,>Z[L<@=#0(Z/^U=. M%DM[]OM?LCYVS^--3N%DU5)I'O;=8R=L9&\(JJ5&0!EE!)'T)6[M;J+Q!- MJ#VMQ)9PZDDKJD3,67[,J!U4#+[6/;)Z^E']?E_F']?F;UKK^FW4%Y<+X>11&SNIIY[ M^"UU&SM%U@W#"*V'FE3 JB58V4[OF.2-I/)XR*MM8Q"W:^67Q LK7ADCNS9( M71_**;_)$8.TCY3E,YP>!S1T^[] Z_?^IV*W5N]H+I9XFMBF\3!P4V]C'G@'UJAH"W$VB;+VVBB+O(,) 8?,4L?G,9) M*ELY(///X5REMI.HO7)@]]PHZV_K^M@Z7 M_K^MSJV\2Z4..S'J> .O4'!&*DTKQ#IFL1Q&UNHO.D MC$OV9I%\U%/]Y021U'YU@VEMYV$X'"GU/'O3=) MTZ>WT[P>OV*2)H)',X\HJ8]T4F=W'&6(Z]\4+8'U.TK.;0_\NLOYBO/$JPE9O 4%T.B.8XA]?P._'C2 MU/\ R[2_F*D'C"U/_+O)^8KA8ZL)63P5'L;QQM9]3M1XLMC_ ,L)/SIP\4VY M_P"6$GYUQZ5,*AX2EV-5BZOW_P">#_G2_P#"2V__ #Q?\ZY84ZI^ MJTNQ7UJKW.\BNXY6V@_-@'%3URNGR,=6]STUL%%%%(84 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110!R_A/_ (]ZZBN7\)_\>]=10 G>O$_%G_(U:C_UV/\ (5[9WKQ/Q9_R M-6I?]=C_ "%>IE7\67H>+G?\&/K^AC44E%>\?-"T4E% "T4E% "T4E% "T4E M% "U8L/^0E:_]=D_F*K59T__ )"5K_UV3^8J9?"RH?$CUJ3_ %K_ .\:;3I/ M]:_^\:;7QY]Z%%%% !1110 4444 %%%% !1110!+;_Z]?Q_E452V_P#KU_'^ M514 %%%% !1110 4444 %%%% !1110 4444 2V_^M_X"W_H)J*I;?_6_\!;_ M -!-14 %5[VQMM1M6MKJ/S(F(.-Q4@@Y!!'((/((YJQ10!G)!8Z%;22I%ULF"@ MA@4E0S%<<\L<K%< N> .!D]#R!=S?FN;#0; M"!&$B0EA%$L43RLS$$]%!8DX)S1;:U8W8G\IIO,@7?)#);R)*%[$1LH8@X., M#DC%9_B*XM;2/1IY9XHK9+Y"97".E>;^*)K2XAU/]UIT-[;0KY;3AIKN0B-6#0KD&)1R=PR."2! MS5O4#HTE[XC>YV-J;^7]@)_UA?R$V^3WW[L9V\_=SQB@2UL>B5!#>P3W=Q;1 MONEMRHE&"-I89'UXKSZ[C:34+\:UJ.G6E^#']F:YLVEG5=BX-NRR*<[]W"@G M=USD4[48!;W>OB#R([IGM'N)%@^=H"%\URBD,4)SN /KS1_7]?J']?U^AZ-1 M7GR6NG-I^H"+7-,6P)@\P6%@PM%8.#\X$C*0PX< CC!:M[P?-&]C=10VUG'% M%-@2V$A:VE)4$F,'A1Z@9&<\DYH Z.BBB@ K;LO^0:OT;^9K$K;LO^0:OT;^ M9H0GL>'K4RU"M3+7V3/A*9.E6$JNE6$K&1V0+,=6$JO'5A*PD=42=*F%0I4P MK)FZ'BG4T4ZI+-;3O^0_]=17+^$_^/>NHH 3O7B7BW_D:]2_Z['^0KVWO7EOB M*TTI_$%ZTUO>-(9/F*7*J"?8&,X_.O2RR7+4>G0\C.8\U*.MM?T.*HKH?L.C M?\^U_P#^!:?_ !JC[#HW_/M?_P#@6G_QJO;]IY/\/\SYSV7]Y?C_ )'/45T/ MV'1O^?:__P# M/\ XU1]AT;_ )]K_P#\"T_^-4>T\G^'^8>R_O+\?\CGJ*Z' M[#HW_/M?_P#@6G_QJC[#HW_/M?\ _@6G_P :H]IY/\/\P]E_>7X_Y'/45T/V M'1O^?:__ / M/_C5'V'1O^?:_P#_ +3_P"-4>T\G^'^8>R_O+\?\CGJ*Z'[ M#HW_ #[7_P#X%I_\:H^PZ-_S[7__ (%I_P#&J/:>3_#_ ##V7]Y?C_D<]5G3 M_P#D)6O_ %V3^8K8^PZ-_P ^U_\ ^!:?_&JGL[+1Q>VY6VO@PD7&;I",Y_ZY MTI5-'H_P_P RH4O>7O+\?\CO)/\ 6O\ [QIM12ZA )G!MY#AB/\ 6C_XFF?V MC!_S[2?]_A_\37R9]P6**K_VC!_S[2?]_A_\31_:,'_/M)_W^'_Q- %BBJ_] MHP?\^TG_ '^'_P 31_:,'_/M)_W^'_Q- %BBJ_\ :,'_ #[2?]_A_P#$T?VC M!_S[2?\ ?X?_ !- %BBJ_P#:,'_/M)_W^'_Q-']HP?\ /M)_W^'_ ,30!8HJ MO_:,'_/M)_W^'_Q-']HP?\^TG_?X?_$T 7;?_7K^/\JBIEK?POE:=5_[1@_Y]I/\ O\/_ (FC M^T8/^?:3_O\ #_XF@"Q15?\ M&#_ )]I/^_P_P#B:/[1@_Y]I/\ O\/_ (F@ M"Q15?^T8/^?:3_O\/_B:/[1@_P"?:3_O\/\ XF@"Q15?^T8/^?:3_O\ #_XF MC^T8/^?:3_O\/_B: +%%5_[1@_Y]I/\ O\/_ (FC^T8/^?:3_O\ #_XF@"Q1 M5?\ M&#_ )]I/^_P_P#B:/[1@_Y]I/\ O\/_ (F@"Q15?^T8/^?:3_O\/_B: M/[1@_P"?:3_O\/\ XF@"Q6W8\Z>@^O\ ,USG]HP?\^TG_?X?_$UT6ER+-IT3 MJI4'/!.>Y[T <3>^%[&UEVQ64\@]3-_]:JPT2 ?\PV7_ +_G_"O2&B1NJBD\ MB/\ NC\JZ/K=?^=G*L%AU]A'G0T>$?\ ,-E_[_G_ IXTN,=--D_[_'_ KT M+R(_[H_*CR(_[H_*E]:K?S,I82@OLHX 6"CIIK_]_C_A3A:8_P"8:_\ W^/^ M%=[Y$?\ ='Y4>1'_ '1^5+ZQ5_F97U>E_*CA1 1_S#6_[_'_ I?*;_H&M_W M]/\ A7<^1'_='Y4>1'_='Y4O;U?YA^PI_P IQ&Q_^@:W_?T_X4;9/^@:W_?T M_P"%=OY$?]T?E1Y$?]T?E1[>IW#V-/L7O(^7.<<8KJATIBQ MJO0"GUD:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110!R_A/\ X]ZZBN7\)_\ 'O744 )WKRSQ%_R,-[_U MTKU/O7E?B+_D8;[_ *Z5Z66?Q'Z'D9Q_"CZF;FC-)17M'SPN:,TE% "YHS24 M4 +FC-)10 N:,TE% "YJ:S/^G6__ %T7^=05/9_\?UO_ -=%_G4RV94?B1TL M_P#Q\2_[Y_G4=23_ /'Q+_OG^=1U\J?;!1110 4444 %%%% !1110 4444 6 M+'_C\C_'^1JO5BQ_X_(_Q_D:KT %%%% !1110 4444 %%%% !1110 4444 6 M++_CX/\ USD_] -5ZL67_'P?^N%R1U% M7!>:QOM;"?[1:FXN2B7,HA,IC"%SPNY-V1C..G;- '3T5D&>\MM7TJREN1*) M()C,PC"^8R[,'';J>E9MK?:E?O8P_;WA\Z6[$DD<:;ML)D?3;1R1;75UY<^#C']*)FM+4XY'K]*@M[IM;N-*BD(S;H;F M[3TD7*!3_P #WG_@ H Z6BN+CTRP@\$?VE%:P07T5N9DN8XPLF\9(^8N6@UF]N]6:WBG_=2W M*F(A5.(@) XZ=S'UZ_-6.HEFLI[AIV ;P\6,2(BIT88 "\#OQ_+BD]OZ[7&E M=_UWL>@T5S^F2WEKJEG9S7K7,4]B9L/&J^6RE!A=H!Q\WS23P0K*=6^=$/F#BUS\K, MH.>!R #U%6(+O4UN-"GDU+S8]1+--!Y2!5S$S@(0,X''4D\#GKE=+C>AU-=A MHG&CP?\ O\ T(UX]X>EO+.Q\.YO6E@O T30&-0J (S J0-V?EYR2#D\"O7M M)_Y ,?\ NO\ S-.VMA/0D_MK2\X^WVW_ '\%']MZ7_S_ -O_ -_!7B;_ .L; MZFD%>Y_9,/YF?.?VY4_D1[;_ &UIG_/_ &__ '\%+_;6F?\ /_;_ /?P5XG2 MBE_9,/YF5_;53^5'M?\ ;.F?\_\ ;_\ ?P4?VSIG_/\ V_\ W\%>+BEI?V5# M^9E+.:G\J/9_[9TW_G^M_P#OX*7^V--_Y_K?_OX*\9%.'2E_9X_K\NQZ3_:%G_S]0_\ ?8H_ MM"S_ .?J+_OL5YP*<*/J$>Y7UZ78]%^WV?\ S\Q?]]BE^WVG_/S%_P!]BO.Q M3J7U&/E%4M,E:6T1F.215VN([ HHJ*.Y@EGE@CGC>6' EC5P63(R-P[9'K0!+ M1144-S!<>9Y$T7,-M I ,DT@11GIR>*JVOB#1;^X6WL]8T^XG M;.V.&Y1V..3@ YH T:*B2Y@DGE@CFC>:+'F1JX+)GID=1FI: "BBJ-EK6E:E M,T-CJ=E=2J-S)!.KL!ZD T 7J*BN+F"TMWN+F:.&%!EY)&"JH]R>!3H9HKB% M)H9$DBD4,CHP*L#T((ZB@!]%4X]5TZ6%)H]0M7B>7R4=9E*M)_=!SRWMUJX2 M ,DX H **JQ:G83_ &?RKZVD^TAC!LE4^;M^]MY^;'?%323PPM&LLJ1F5MD8 M9@-[8)P/4X!X]J )**@N[VTT^W-Q>W4-M"" 9)I B@GIR>*6VNK>]MTN+2>* M>!_NR1.&5NW!'!H FHHHH **** .7\)_\>]=17+^$_\ CWKJ* $[UY7XB_Y& M&^_ZZ5ZIWKRKQ'_R,-]_UTKTLL_B/T/(SC^%'U_0S**2BO:/GA:*2B@!:*2B M@!:*2B@!:*2B@!:GL_\ C^M_^NB_SJO4]G_Q_6__ %T7^=*6S*C\2.GG_P"/ MB7_?/\ZCJ2?_ (^)?]\_SJ.OE#[8**** "BBB@ HHHH **** "BBB@"Q8_\ M'Y'^/\C5>K%C_P ?D?X_R-5Z "BBB@ H/2BBA@<';WD+:3:"&XU=M9GQY&^2 MY\N20')^\?+*@(+G3)+DP7%DYMT#FV6"2:0C )+LIQ%G/&X$=\] MAJ2:':R:-'IC-+Y<6#'(& D1@)&0!VVA M=V=N0> < @<=,9% ^I#=ZU>6TNJ3E8/L>GJK%-A,DI*!L [L+R>N#U]J?I>K M7MQ?+;W$3R))&6\Q;">W6)A_"3)PV<\$8Z=.:OC2;8I>)*&E2\4+,KG@@*%[ M>PI++3&M) [ZA>W6U-B+.ZX4?10-QX'+9/YFCJ3T+]%%% PHHHH L67_ !\' M_KG)_P"@&J0MH1=M=!/WS((RV3]T$D#'3J35VR_X^#_USD_] -5Z ,Y]#TYU MG4VY GE$[[9&&)!_&N#\K>ZXS1_8>G_9C!Y+X,GFF3SG\W?TW>9G=G'&<].. ME:-% &?)HMA);V\'E.BV^?*:.9T=<]?G4AN>_//>GVVDV-GY/V> 1^1O\L!C MA=YRW?N:NT4 5#IMHT#P&']V\WGLNX\ON#9Z^H!I/[*LC"8?)_=FX^TD;V_U MF[?NZ_WN<=*N44 &YI9_#MI+-(\DC*26=B2>3WI;(.MR MS::7:64SS1)(TSKM,LTSROMZXW.20,]NE/M["VM9[B:&())<-NE.2=Q_I^'J M:Q+#6=3:VTN\O5M/L]^PC\N%DJ2K;BQ!!QTP,9ZG'*QZI,FA+JC7<$#7< MN]3=%F5$YVJB @LVT#@$$DD^U,"]%X=TV+RP(YVCC8,D4EU*\8(Y'R,Q7@\C MCBM0@,"",@\$&N9BU6\O=%U&Y)VW.FSL598WA$H50V&C8Y&0Q&#GU':NDBD6 M:%)4^ZZAA]#1T#J4[;1M/LWMWM[8(UO$88CN)VH3DCD_KUIAT'33&D?D,$6W M-L%$K@&(C&T\\]>_(K2HH KBQMUN8K@1_O88C"C;CPAP2/\ QT?E3WMH7NHK MEDS-$K(C9/ ;&>/^ BI:* *ATRT,QF$0\TS>?N+'_6;-F<9_N\8Z5C6'A^=- M2M;FXAMHA;%V7R;B20,6!!VH_$2\DX4GMZ5TE% %.+2K*&.SCCAPMF;@0Y;YSC[_/3TJ2=-+-K)((F:)KTHAA(4XV MKW(/'7 K$DN7EM[>!@H6 ,%(')R<\U(MTXM%ML+L67S0<_G^ MIUJJK67;]#4BTJ)+FYBDBN)5AF,9E$BQ( #CEFR">>G%2KI$ EN(AYUQ)%,Z M%(G4.JC'S;3RWT&.E46U>25G:6WMY&:5I5+*?D9L9P,X/0<'-/\ [5=KAIWM M;9I6D\T,5(*M^!YZ9P./RQD@95N M6Z9XQ6>JQQW&V7+HK$'RV'/T-3+J3E%$T,,[(24>522N3GL0",\X(-5*E6_'V:.![2!UCSC)<9)[G# 9K-P=K& MJFKW+=AI\-WY>Z*=5D?:)2ZHH], _?/K@UFD88CT-6H=2>$PLL$!>'_5NP)* MC.<=<=SU&:K%MS,V ,G.!3BI7=Q2<>56W 4ZFBG59(HIPIHIPI,: 4ZFBG4A MA2TE+0,6BBBD M.D_P"0?/\ [R?SIM.D_P"0?/\ [R?SK'$?PF;8?^(CK]'_ M ./&/Z5HUG:/_P >,?TK1KR#U@KC;:Z>QU[QQ=Q!3)!'#(H8<$K 2,^W%=E7 M.-X?NS=>*)?,AVZK$B0?,ZI=VK#3K;3(/)\2"$Y1E\Q MPR[&;;UR?O'K@#%=7<>'KN70O#]BLD ETZ>VDF)8[6$8PVWCD^F<50O/">J/ MI>H):SVBWCZP-2MC(6*8!4@/@9'0],U3MS?/]8_\$E7Y?E^C_P" 2IK5Y:7G MB)CIUA)>65O;.[1,(?-8H2V^1SC:O.">@K)T?QQJUWXB&B37/A^\N)X7,,FG M/*T<;A=PWL>&!_V3D8J_J/A#4]4AUMI[BSCGU!+5D"AFC\R(996!'W"W'?CM MVIFG>&_$O_"0:1J&HR:+#:Z=YB)9Z?&Z(JNI!89'7...!@4EOJ/IH8^@>(]3 M\.^!5N+Q-/D:XO7@LOWIC4.TC[VE9N H()&.U;OA[Q?=W6MQZ5JEUH=U)<(S MP3:1G&*K#P1J"=:LEL?"UE;R:T\J& MU-G8-"\;!@=Y;:N% R3S7?\ B729]9TI+6W>-9%N8929"0,)(&/0'G K8HCI M]_\ D#_3_,\_>;Q GCCQ#%H-O8O,4MGDEO681@!#\H"\ECGZ#!]:ZOPUJ[:] MX>L]2>$0R3*=\8.0K E3^HIFGZ3/:^)-8U%WC,-Z(1&JD[AL4@YX]_4U6T#2 MM6T31],T\/9.L4LANR2Y.QBS+LX'.2,Y]Z%L#-35],BUG2KC3IY9HH9UVNT+ M;6VYY&<'@]#[$UR&HZ5I!\4:3IWA_3K2"_L[E+F[GM8E3R(0#\KL!R7S@*>> M_O75:]#JEQHMS#HLT,%_(NV.68D*G/)X!YQG''6N8\.Z/XRT-+>S6+PTEGYH M:Y>,SF:3)^=BQZN1W/MVHCN#V-3X@?\ (AZO_P!J++&MFB(UQ#D[I)8PPC/3&!O/?^$4K7=GL_Z_KU&WHFNG_ _KY'.Z M.8]#T.WLXK:WGC7Q&UJOGINV#>1N7T88X-:LFO>)M3N[^31-.L)-+LI7MW%S M(RSW#+]_R\?*OH-W_P"J5O"U\;>./S;?*ZZ=2/S-_J]Y..GWN>G3WIC:!XDT MZ^O(=$U"PCTR^F:=S<1N9K=G^]Y>.&YY&[I_,=W'7^M%_P $-$]/ZU?_ "/ MP+ID=WX5\-7SD!K-)F0;!N)8LO7J!C/'I7%W-)J+)# M&P"1P1%'(55'4],L>3@5T?A32;C0O#%CIET\;SP*5=HR2IRQ/!(![^E+K6DS MZCJ&C7$+QJEC=^?(')!*[&7C ZY8=<5^3]GFAO58Q2IG(.5Y!!)^N:D\.Z-?V M5Q?:GJ]S!-J=^4\T6RD11J@(55SR>I.3Z_G,=%_7<'44VB@!U%-HH =13:* '44VB@!U3V?\ Q_6__75? MYU6J>R_X_K?_ *ZK_.E+9CC\2.JG_P"/B7_?/\ZCJ2?_ (^)?]\_SJ.OE#[< M**** "BBB@ HHHH **** "BBB@"Q8_\ 'Y'^/\C5>K-@I:]C &3S_(TGV&X_ MYY_^/"@"O15C[#%'V&X_ MYY_^/"@"O15C[#%'V&X_ MYY_^/"@"O15C[#%'V&X_ MYY_^/"@ LO\ CX/_ %SD_P#0#5>K]I9SK.28^/+<=1_=-0?8;C_GG_X\* *] M%6/L-Q_SS_\ 'A1]AN/^>?\ X\* *]%6/L-Q_P \_P#QX4?8;C_GG_X\* *] M%6/L-Q_SS_\ 'A1]AN/^>?\ X\* *]9-CHCZ>D44.JWQMXS\L++"5(SG!/E[ ML?CFM[[#%'V&X_YY_^/"BP'*Z!X?>TT_3_ +=-IQDD#/&*EMM%<6D=H\DUO]AG9K2XA922A!QPP(X#%3D=LBNE^PW' M_//_ ,>%'V&X_P">?_CPH YN71&M]/O+6TEN)7U&0">69P=F5"L_;L.@[D8 M'3;15C144851@#VJS]AN/^>?_CPH^PW'_//_ ,>% %>BK'V&X_YY_P#CPH^P MW'_//_QX4 5Z*L?8;C_GG_X\*/L-Q_SS_P#'A0!7HJQ]AN/^>?\ X\*/L-Q_ MSS_\>% %>NNT@9T.(>H%IK65EFU"R0YZ?O3_)*K_V$/^@I9?\ ?,W_ ,;KU.YTB"Y?A?\ ".VO]P4?\([: M_P!P4O[1KC_LVAY_>>?C3(O^@G:?]\2__$4X:=%_T$K7_OB7_P"(KOO^$=M? M[@H_X1VU_N"E_:%8K^SJ'F<%_9\/_02M?^^)?_B*<+&'_H)6O_?$O_Q%=W_P MCMK_ '!1_P ([:_W!1]?K#_L^B<*+* ?\Q*U_P"^)?\ XBG"T@_Z"5M_WQ+_ M /$5W'_".VO]P4?\([:_W!2^O5A_4*)Q/V6W_P"@C;?]\2__ !%.%O;_ /01 MMO\ OB7_ .(KM/\ A';7^X*/^$=M?[@I?7JH?4:)QGD6W_01M_\ OB7_ .(I M?*MO^@C;_P#?$O\ \179?\([:_W!1_PCMK_<%'UVJ/ZE2./\NV_Z"-O_ -\2 M_P#Q%+LM?^@C;_\ ?$O_ ,177_\ ".VO]P4?\([:_P!P4OKE4?U.D]>2^)3_ ,5)?_\ M76O2RS^(_0\C./X4?7]#+S1FFYHS7MGSH[-&:099@H&23@"M.]T&[L-0MK.9 MHC)<8",K$J"3C!..QZU+E%.S9<82DFTM$9N:,ULW?AFYM;>XE6[L;@V_,L<$ MVYT'0DC I8_"U[)%'NN+.*XE3?':R3;96';C'?ZUG[>G:]S3ZM6O;E,7-&:M M+IUP;>[F<");4A9 ^0=Q.-H]Z9)8WD,"SRVD\<+8Q(\9"G/3G%:*47U,W":Z M$&:,U8OK*73[GR92K9575T.592,@BJN::::NB9)Q=F.S5BR_X_[?_KJO\ZJY MJQ9'_3[?_KJO\Q2ELQQ^)'6S_P#'Q+_OG^=1U)/_ ,?$O^^?YU'7RA]N%%%% M !1110 4444 %%%% !1110!8L?\ C\C_ !_D:KU8L?\ C\C_ !_D:KT %%%% M !1110 4444 %%%% !1110 4444 6++_ (^#_P!*=_:UFRVKP3)<1W,WDQR0,'7=M8\D'_9 M- %ZBJG]IV;173PW,,QM03,L#U(JB?$MB=3DL(P9)8@AD998@ M%W$ #EP2H'4@4 ;-%0)>VDEV]HES"US&,O"L@+J/4KU'4?G2W=U%96< MUU.VV*%"[GV S0'D3453L=3M[_31?+NBBPV\384QE20P;TQ@TZ+4K">V:YAO M;:2!6VF5)5*@^F0<9Y'YT 6J*QQXGTF2[DMK>\@G:. SDQ3QD$#.0#NQG SS M@ =ZT/M]I]ICM317PS,%&<'W%6A=VQBCE%Q$8Y&V(P<89LXP#W.>U $U%5HM0L MI[J2UAO+>2XC^_$DH+K]0#D59H *[#1/^0/!_P "_P#0C7'UUVD$KH<1'4!R M/S- ,TJ*\=;Q9K8=@+^3@T#Q9K?_ #_R5ZG]DU>Z/%_MNC_*SV*BO'O^$KUO M_G_DIP\5ZW_S_P E']E5>Z*_MJC_ "L]?HKR(>*M:_Y_Y*7_ (2K6O\ G^DI M?V75[H?]L4OY6>N45Y(/%.L_\_TE.'BC6?\ G^DH_LNIW17]KTOY6>LT5Y1_ MPD^L_P#/])3AXFUC_G]DI?V94[H?]JTNS/5:*\L'B;5_^?V2G#Q+J_\ S^R4 MO[-J=T5_:=/LSU&BO,/^$DU;_G\>G#Q'JW_/X]+^SJG=#_M*GV9Z;17F@\1: MK_S^/3QXAU3_ )^WI?V?4[H?]HT^S/2**\Y_X2#5/^?MZ<-?U/\ Y^GH^H5. MZ'_:%/LST2BO/1KVI_\ /T].&O:E_P _3TOJ$^Z']?AV9Z!17 ?V[J7_ #]/ M3AKFH_\ /RU+ZC/NA_7H=F=[17"?VYJ/_/RU+_;>H_\ /RU'U&?=!]=AV.ZH MKAO[:U#_ )^6I?[:U#_GY:E]2GW']=AV.XHKB/[:U#_GX:E_MG4/^?AJ/J4^ MX?7(=CMJ*XG^V;__ )^&I?[9O_\ GX:CZE/N/ZY#L=K17%?VQ?\ _/PU']L7 M_P#S\-1]3GW#ZY#L=K17%_VQ?_\ /PU6[/69TCFDN)"ZKM S[FHGA90BY-E0 MQ,9RY4CJ:*@M9Q<0JX[BIZYCI"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@#E_"?_ ![UU%1>)C_Q4E_\ ]=:]=[UY#XG/_%2W_P#UU_I7IY7_ !'Z'D9S_"CZ_H9>:,TW M-&:]L^=-;P\MN=:@DNY4C@A)E8NP&=O('/4YQQ6_-?Z5J$5G<07,JR6U^LC" M[9%8J[9;&#T!Y]JXK-6+.RN=0F:*UC\QU0N1N P!U/-<]6BI2YV[6.FC7E&/ MLXQO?^D;NK^))&N;ZVMK>QCBDD*M-!'AY5![MGG-6[J"QU36$UI=7M(;=BDD MD4CXE0J!D!>_2N/S3HHY)YDBB0O([!54#DDTOJ\8IOK2+4UNG=%:)I+TRNX# M_=( 4CT')KBS-=6'VJSWJHDPDR JX.#D<\C@]Q4;VT\5M#X??(P )P!P!@<#@5#FNBG!QC9G)5FISNO+\%8=FI[(_Z?;_]=5_F M*K9J>Q/^GVW_ %U7^8JI;,B'Q([*?_CXE_WS_.HZDG_X^)?]\_SJ.ODS[@** MI1:O83:M-I<=P&O84#R1;3P..^,=Q^=9LWC;P[;7LEG-J(2>.0QNIB? 8'!Y MVX_'.* -^BLG5?$VC:*\::A?)$\B[E4*SG'KA0<#ZU/_ &SIW]D_VH+M&LMN M?-7)[XQ@K%C_Q M^1_C_(U7H **** "BBB@ HHHH **** "BBB@ HHHH L67_'P?^N7]O8JAG9]TAPB1QM([=SA5!)Q]* +-8LY?3=?EOY()Y M;:Y@2(M#$TIC9"QY506P0W4#J.>U7$UBQDABE28E99O(4%&#"3^Z01E3QWQ5 MZ@#G-0O[VYMHIDL'@A^TD).]JTTL:;#^\$0&5)/ R#@')':LRSL[UI7Q%>Y? M53,LT\(1BIMR Y"@ <^PQT/-=M11;^ON_P @O_7]>IRD";O"EQ8IIEPE[#IC M0.S6Y&6"D;%8CY\G)^7(_.DN;.Y:74B+:8AY+ KA#\VUANQ]._I764R*198E MD4,%89 =2I_$'D?C3OK<#"T11;R?8[BQF-Y'/.YN# =@#.6W"0\'<". 2?4< M5/KT-W??9-/M?D667S)I7C+HJ)\V#@C.6VC&1QFMFFR.(HVD8,54$D*I8_@! MR?H*0'(W%AJ5N]];31"\@FEBOL6\#*K;77S$P6;D@!L9YR:=J,$FJ2ZA%ED@9&F82Y)V, : M6>Y2:&00%D5?+502YX4KAA@G/H#FMY[F%+J*V9\32JSHN#R%QGG_ ($*8E[! M),\2,S/'+Y3A8V.UMH;DXX&".>G..M"T_KS!Z_UY%?6;62[TR00@&XB(F@S_ M 'U.X?GC'XUDD77]CW>HFQW7%Y<(YBFMVD,<88*I,?!)51NP.?V]):!&2Q@>6\@EQ\OF2# 7ZJQD/XBNDN+J&U,(F?:9I!$G!.6.<#C MZ5-0!Q^BV3K_ &7;7#ZQ]HLS\T;6\:Q1L 03YFP;E.>S$G//?'85'//%;0// M,X2-!N9CV%/4AE##.",\C%.]P%KK=)_Y ,?^Z_\ ,UQJ7$4D\L"M^\BQO4@C M&1P?<>X]".QKLM)_Y ,?^Z_\S0MQ/8\7?_6-]32"E?\ UC?4T@K[(^ '4HI* M44BT/%+2"EJ31#A3ATIHIPZ4C1#Q3Q3!3Q4LM#A3A313A4LT1JB"Q@L;.::* MYDDG#$^7,J@88CH5/\ZM3:+#$DG^EI&R7)A#39 (V@C@ G///;BJG]K3QZ?: M6]K<7$)B#;]CE0Q+$CH?2FB[3^S4MR',@N#*3V(( _/BN7EJ7OY_J=:E3M:W M3]/\QZ:!TD\LB1B23_P$'CW/%2_V5*A83300D2-$/,8_,PZX(&! MU')QUJU_:]L9KB6-KB!Y)VDW1(N]U."%+9RO3MGKTIZZM;B\N)Q+=+'+*7:$ MHKI(IQP03@'WYJ'*KV_K^O4T4*7?^M?ZZ%*+3WD2-C-%&TN?*1R5D>7;-\K#)([C!YQG![5EEB[EB2 M23DDG)JHN;OS$R4$ERE^XL8TO;>WMY&D654(QC/TYI\,UFED(Q+/%(X(E980Q M8>@.X8'\ZS?-;4U7+?0;!8&X946Y@$CL51"QRWY @9]R*K8P<'M6I9:E!:"W MVM.GEMEUC11YO)Y+9ST/3D<5F,078KG!/&:<7)MWV%)1Y58!3J:*=5DBBG"F MBG"DQH!3J:*=2&%+24M Q:***0"TZ3_D'S_[R?SIM.D_Y!\_^\G\ZQQ'\)FV M'_B(Z_1_^/&/Z5HUG:/_ ,>,?TK1KR#U@KEK'4Y+?Q!XMDN99I+:R$$BQ;LA M!Y.Y@H)P,_A74UQSV5W]N\;M]EFVW,$8@/EG$I$!!"_WN>.*3;2;7;_(<5=I M,ET_XA:5J-[96Z6>IPQ7I"V]U/:E89'Q]T-GDYR.F,CKWK*UCQ4^CV\C:<-8 MN6;6_(G+1K-M *[HX_0,#A1USGI5R[T^Z;PMX1A6TF,EO=6;2H(CF(*N&+#' M&.^>E9M[8ZA#I.I7"Z==S&'Q(MX(8XB7EB#+R@_B_"J=E+T?ZQ_S)6L?Z[,Z M"+Q!IMI=ZU?74^H0);PV\L\5U]R'C#UI+'QQ:WER;:72-:LIVB> M6&.[L]AN-HR5CY.6QVK$U!-:E;Q1?:7:7\,EU#9O'A#'*4V_O A/\87(XR0? M?%9NB6)?QQHNH6VA>((HXUECNK_5M[2RL8SMW D@ =,C .<=J2U=A]+F[X<\ M=))X4FU/6H[R)H9F0/);[?/)=MB1@?>( "GT(Y[FMK1?%EIK-XUDUEJ.G783 MS%@U"W\II$Z%EY.0#7#OI.J7OA)=/&G:I!)[6]$7B\Q6B.3+KLZJJEEQA4*DMGN01C ^E$=?Z\@EI_7F='X[ MDGC\,XM[JXM9)+J"(RV\A1U#2*#@CV-8>NZ)=>$]-.L67BG6YKB"1 EO?W0F MCGR<%-I Y(/'^36YX[L'U/PS]D2WDN!)=0!XXU))3S%W=.<8SS1I_P /?"NE MWT5[::1&MQ$=R,\KR!3ZX9B,CL<<41[^?Z('^G^9ES>*_P"QO%^N0SPZG?X6 MW:*TLXS,8UV$NVW.%&2,GU(KK]+U*VUC3+?4+-R]O.F]"1@_B/7-8^DVDT?C M3Q%U*XTG1;F]M;&:^N(U_=V\*%F= MB<#@ G'<^PKB_#.KLFII=:EX?\37&L796*2\GT[9% I/W$^;Y(QU)ZGDFB/Q M _A.I\9W$UKX-U:>WFDAFCMV*21L593Z@CI6;K?BS1_^$1OOLOB"Q^V?8W\O MRKU/,W[>,8.&2::2W8)'&I9F/H .M9NM^$]'_X1&^^ MR^'['[9]C?R_*LD\S?MXQ@9SG\:F6S_KN4MX_P!=A?[(U7Q!8:1OUJ[LM/%C M')(UG,4N)9B!RS$'Y<>_)//:HO#^HW6FGQ!:M<7^LV6ER(L$NWS;AV*Y>//& M\J6'PILM3$^^_EMXD2:=MW[ MQV"AF)],YY]*[&?,EC)M5LM&<*1SR.GUKC4T&[U#X3V6F?9?],CMXG%M<#9N M9&#;&!Z9QCGUJ._R_4:Z?/\ 0SM!O+1_$]M%HWC>YU.YWL+VUOY6:.5/XC#\ MH7(/( )X[X'/I5<#<7MYXIN]'L;;PWJ6F_8;R*YEGO(1%'$J=5C(/S9Z<=O: MN^JN@NH4444AA1110!R_A/\ X]ZZBN7\)_\ 'O744 )WKQ_Q0?\ BIM0_P"N MO]*]@[UXYXH/_%3ZA_UU/\J]/*_XC]#Q\Y_A1]?T,O-&:9FC->X?.C\UT_A. MRGN;36)+6,R3_9O)C4$#)<\\GZ5RN:,UG5@YP<4[&M&HJAJSJ$BQW6HWY=&U"RL(XI'3'$K95F^H'%<6FI M3)I,FG*J>3)*)6;!W$@8 ZXQ^%-M;^6T@NH4"%+F/RW##W!!'OQ7-+#3E)SD M_P#AM/\ @Z'9#%TX04(IV]>NMNGIJ=_H<%QIVD1EG,VGO:-.^/*5&)4Y3;M+ ML??(Z5RU]MA\(Z;$XQ-+/),H[A.GZD5@JP5U8J& .2IS@^W%3WU_-J%SYTVT M84*B(,*BCHJCL!51P[C/FON[_G_F9RQ494^2VRMWWM_E^)#FC-,S1FNLXA^: MGL3_ ,3"V_ZZK_,55S5BQ/\ Q,+;_KJO\Q4RV94/B1V\_P#Q\2_[Y_G4$TJ0 M0232':D:EF/H!R:GG_X^)?\ ?/\ .HZ^29]P>6:?=ZA;7]AXAN-,:&UN+QVD MO#.IWQRX4 IU &%/X5IV.A7^MG7(%UEK;3Y-2F6:V6V5B_S G#GD9X_*O0** M--OZZ!K_ %\SB([ZQ\*>)]2DU8/## M-+)VMC82V^?E%&M@*MMXCLI+>T:X\RWGN8TD2!HV+'<< # ^;GTZ#DXK8K&'AR'- ML[7UZ\MJBI!*SKNC //\.#N& F<' MBL_Q7N/A^0(0'\Z#:6&0#YJ=N]9FI&^M-4FDN9X)IFTNX\N2VB:(Q;<')!9L MY)&#GC%*_P#7RN.USK:*YI+;-WIMC+>7GE7%N\\A^U2!I90$X#;LJ,%CM4@> MW%5(KN:\AAL@]Y=2++.(62[,"R1(X4/)(OS'&CL):JYV%,BFBG M3?#(DBY*[D8$9!P1^!&*XW1;F;4TTVSN[V8P,MRP>*Y8-*R2;5'F+AF 4Y]^ MIZ57T^2ZEBT^PM91-;2O=R!S>/;F=A,#QSU-=4!@ >GJ: %HHHH L67_ !\'_KG) M_P"@&N=UQ[2.[LY+F[N+!E#B.]0H$7(&48N"HSP1D?P\'/7HK+_CX/\ USD_ M] -5Z .&G:"[M[6:^6QN88M4C7[>L*I'<*4 +G.1U 4D'!*CTQ3+>/??,;K4 M;&WU87K<&S9KO&_Y0&#Y*%,=%V[>O0UWE%"T_KT_R!Z_UZ_YG#BTMTMGU!8E M%XNN;%GQ\ZJ;C:5![ @GCIR:=)]EVR;=G_"2?;SL_P">^WS./?R_+_X#BNVH MH6EOZ[?Y ]7_ %Y_YG&61M;;Q&JP-9WLTEQ*'=-T=W#DL3Y@_C0< 9P/NXSQ M6:1:1:9I]Q+)93S"PBVV=V&1R!NYMY!R')Q]T$Y Z<5Z+10M$'.Z(ZE0I!8?]\[A7*"&1[34HY0?]'LY[L@]FFB7'Z^;7H5%'?^OZZ MM+?U_74X&^MK-3K4?EQ)/*]D?E 5V0LFX@CG&>_K70:5;06/B35+6TA2"W\B M"3RHU"J&)<$X'&2%'Y5O44[BMI8P]5@DN/$6F)%=S6S>1<'?"$)ZQ\?,K#]* MR/*FAOWC$[SS#5_EDE"@L?LG&=H _2NSI",@@YY]#2Z?UWN5;_*?=YO?=NSC=SUQ3M$L[>UM_"US!"L=Q.SI-*!\TBF)SACU M(R!@=L#%=-;:.L%Q%-+>W=UY&?)6X92(\C&5(HDOXRSNP55&&ZDU2U_4M'OHM-9KVVN+1+]1.8Y0ZJ#&_WL'[OKGC&<\9K MJ:K7=C%>26KR,X-M,)DVD7YRK98&COJL0A\L?N MSA,G9VV^8!TXSFJ?BJ6VGDU7]W8PW<"?(TP:6ZD(4,#$N08U'/S#(X)('-=Q M>6D5]:26TV[8XZJ<%2#D$>X(!'TJ900H!)8@=3WH_K\O\@,B1L^(]->(Y,EK M+YA]4!0@_F?U->BZ3_R 8_\ =?\ F:XI+2-+V6[)9I9%" MCY%'8>V?A_P3S,4M>E_V1JO_02N M_P#O\W^-']D:K_T$KO\ [_-_C2_M;^Y^/_ *62_W_P /^">;"G#I7H_]D:K_ M -!*[_[_ #?XT?V1JO\ T$KO_O\ -_C2_M7^Y^/_ !K)_[_ .'_ 3SL4\5 MZ#_9&J_]!*[_ ._S?XT?V1JO_02N_P#O\W^-+^U/[GX_\ I91_?_ _X)P I MPKO?[(U7_H)7?_?YO\:/[(U7_H)7?_?YO\:7]I_W/Q_X!2RK^_\ A_P3A13Q M7;_V1JO_ $$KO_O\W^-']D:K_P!!*[_[_-_C2_M/^[^/_ *_LS^_^'_!.*6G MBNR_LC5?^@E=_P#?YO\ &C^R-5_Z"5W_ -_F_P :7]H_W?Q_X _[-_O?A_P3 MD!3Q76?V1JO_ $$KO_O\W^-']D:K_P!!*[_[_-_C2_M'^[^/_ '_ &=_>_#_ M ()RHIPKJ/[(U7_H)7?_ '^;_&C^R-5_Z"5W_P!_F_QI?VA_=_'_ (!7]G_W MOP_X)S(IPKI/[(U7_H)7?_?YO\:/[(U7_H)7?_?YO\:/K_\ =_'_ ( _J'][ M\/\ @G.BG5T']D:K_P!!*[_[_-_C1_9&J_\ 02N_^_S?XTOK_P#=_'_@!]1_ MO?@8 IPK=_LC5?\ H)7?_?YO\:/[(U7_ *"5W_W^;_&CZ]_=_$?U'^]^!A"G M5M_V1JO_ $$KO_O\W^-']D:K_P!!*[_[_-_C2^O?W?Q#ZE_>_ Q*6MK^R-5_ MZ"5W_P!_F_QH_LC5?^@E=_\ ?YO\:/KW]W\1_4O[WX&-16S_ &1JO_02N_\ MO\W^-']D:K_T$KO_ +_-_C1]=_N_B'U+^]^!CTZ3_D'S_P"\G\ZUO[(U7_H) M7?\ W^;_ !I#H=_-A9[R>5,YVO(S#\C6=3%<\7&Q=/"\DE*YM:/_ ,>,?TK1 MJM96_P!G@5/059KD.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** .7\)_\>]=17+^$_\ CWKJ* $[UXUXI/\ MQ5&H?]=3_*O9>]>,>*C_ ,51J/\ UU/\J]/*_P"(_0\?.?X,?7]#*S1FF9HS M7NGS8_-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\U8L3_Q,+;_KJO\ M,54S5BP/_$QM?^NJ_P Q4R^%E0^)'>3_ /'Q+_OG^=1U)/\ \?$O^^?YU'7R M)]T%%%% !1110 4444 %%%% !1110!8L?^/R/\?Y&J]6+'_C\C_'^1JK(66- MBHRP!('J:&[*X#J*Y>PTO3;[PY#J5[M2[EB$\M_D+-&W4D.>5"],= !C&*BU M[5KRW2]GTZ\O)3:QABL-O'Y*8 ;]X[\L3G^ Y [>I;6P+4ZBXMX+N!H+F&.: M%OO1R*&4_4&H;?2M.M$E2VL+6%)1MD6.%5#CT.!SU/YUB7FHWT#ZS>"Y;R;! M%:*W"+M8F,$[SC=@$YX([U3U2&ZLKV22:^-XPT>Z8&:*/@C9G@ KTX(/?)- M +4ZNXL;2\@$%S:P3PJ01'+&&48Z<'BHY],T^ZABAN+&VFBB&(TDA5E3MP". M*Q);S4)+;4KR&]\A=/ "0"-"DFV-7._(S@YQ\I&!3'UJ^,[V*R%+JYF@:U)0 M92%QEN,8.W9)U]J?6PKZ7-^73;"> P365M)"7,AC>)2I8]6P1U]Z)-,L)K46 MLMC;/;ABXB:)2FXY.<8QG)/YUSEYJU['?1S6MU>36_VU('_T:-+=5,FPJ"W[ MQB/[RDC/IT$Z:C?V>ID:E+=1[GD$<9@1K>5?FV!'7YE; !^<\\X'3$]+CZG0 MQVMO$(A'!$@A7;%M0#8/0>@X'2I:YR*YU)?"UQJSZAYCRV!N$3REQ"^TM\I MY7IPV3QUJ'6[ZX:V>W,G[J;1KB9UVCEP$ /_ (\?SIN][?UU_P @6MOZ[?YG M4T5Q^L:K>VUM=36%U>.UI$K-'#;Q^3'A02)'?EB<]$.0.WKL6A[QT MM[9D"0(B8;<@)W$@GJ>,$4["OH=#8+NNL9 _=OR3_LFD^R_]/$'_ 'W19?\ M'P?^N///Y-14/VNV M_P"?B+_OL4?:[;_GXB_[[%'*^P^9=R:BH?M=M_S\1?\ ?8I?M5O_ ,]XO^^Q M1ROL',NY+147VJW_ .>\7_?8H^U6_P#SWB_[[%'*^P\?_?8 MH^TP?\]X_P#OL4T?\ WV*.5AS(EHJ+ M[1!_SVC_ .^A2_:(/^>T?_?0HY6',B2BH_M$'_/:/_OH4?:(/^>T?_?0HLPY MD245']HA_P">T?\ WT*/M$/_ #VC_P"^A19A=$E%1_:(?^>T?_?0H^T0_P#/ M:/\ [Z%%F%T245']HA_Y[1_]]"E66-_NNK8]#FBS"Z'T444AA1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R_ MA/\ X]ZZBN7\)_\ 'O744 )WKQ?Q7_R-.H_]=3_*O:.]>*^*_P#D:M1_ZZG^ M0KU,J_BR]#QLZ_@Q]?T,BBFYHS7NGS8ZBFYHS0 ZBFYHS0 ZBFYHS0 ZBFYH MS0 ZK-A_R$;7_KJG\Q53-6;#_D(VO_79/YBIE\+*A\2._G_X^)?]\_SJ.I)_ M^/B7_?/\ZCKY ^["BBB@ HHHH **** "BBB@ HHHH L6/_'Y'^/\C5>K%C_Q M^1_C_(U7H S7T#39)GD:!\._F/$)G$3-UR8\["F M]0O"IN8%9(Y,G*ANO\JLT4 9;^'=+DD+O;NW[SS0AF?8 MC[MVY5W84Y[@#J?4U)%HMA#=BY2)]X=I%4RN45FSEE0G:"B@"Q9?\?!_ZYR?^@&J]6++_ (^#_P!@#=HK+@U M1TFU-+T)']CQ*"HQF$KD$\GD$,#]*I6M_K5[/!"'L[61K1;F19+=Y""S'"\. MO0 9]\T =#16?I=]+=?:8+I$6ZM9?*E\O.UN P89Y ((XYQZGK3'UVT2=(66 M4.UT;7&!PV,Y//0Y'YB@#3HKF;[Q0Z6^)6\2O;WFHK)G>[3R+"XN+:2PCO%6 M)5\Q0Q;.XE@O0#@<]<9H_K^ON Z*BHK:XBO+6&YA;=%,@=#CJ",BJNE7TM\E MV950>3=20KM!Y53@9]Z.M@Z7+]%8R^([0P6 MU:%IQXP[MYC?,>I[T!V_O'\Z1_P#6-]32"OLC MX&X_>W]X_G3@[?WC^=,I12*3) [?WC^=.WM_>/YTP4M2:)D@=O[Q_.G!VQ]X M_G48IPZ5)HB0.W]X_G3P[?WC^=1BGBDS1#P[?WC^=/#M_>/YU&*<*AEHD#M_ M>/YT\,W]X_G6S%'*NDV#VZ6 +A]YN!#EOG./O\]/2I)TTLVLD@B9HFO2B&$A M3C:O<@\=<"N=U5>UCJ5%VO?^K7,56;^\?SIX9O[Q_.M2+2HDN;F*2*XE6&8Q MF42+$@ ..6;()YZ<5*ND0"6XB'G7$D4SH4B=0ZJ,?-M/+?08Z4G6@4J,S(#- M_>/YT\,W]X_G6G#I4/D0-.^UI@3N,\. !6;J:7L:*GK:YF!F_O'\Z<&;^\?SK2L-/A MN_+W13JLC[1*75%'I@'[Y]<<C#$>AIJ2;L@<&E<<&;U/YT[V5SW%6ZSM'_X\8_I6C7D'K!1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R_A/_ (]ZZBN7\)_\ M>]=10 G>O%/%G_(U:C_UV/\ (5[7WKQ/Q9_R-6H_]=C_ "%>IE7\67H>-G?\ M&/K^ACT4E%>\?-7%HI** N+1244!<6BDHH"XM%)10%Q:L6'_ "$;7_KLG\Q5 M:K%A_P A*U_Z[)_,5,OA94'[R/0I_P#CXE_WS_.HZDG_ ./B7_?/\ZCKX\^\ M"BBB@ HHHH **** "BBB@ HHHH L6/\ Q^1_C_(U7JQ8_P#'Y'^/\C5>@ HH MHH **** "BBB@ HHHH **** "BBB@"Q9?\?!_P"N MHH Q=6T::_N8'BF"HRB&[W=9(MP;C Z\$=N&-27-MJ,6LF]LX;69&MUA*S3M M&00Q.>$;/6M:B@#/TNQEM?M,]TZ-=74OFR^7G:O 4*,\D <\9]!TK-U/0;N MZOKJYMIH5WHCPAR1B8,O)P.F(T''O7144 CF[OP[.]O-#;/"%^QP01!R1\T; MEN>#@'(YY^E2W.BW=S9ZZA:!9-15?+&\D*?+"G)QZ@]NE;]%%P6A3U*TDO-' MN[.,J))H'B4L> 2I'/M45S82S2Z8ZL@%K*7?)/(\MEX_%A6C10'2QQ9+>'8A M:_:[%;B2Q2.19Y&3YE! :/Y?WG4_*,'@=,UI:-H]S;PV\LFU97:Z=& 8]-OEGG\:W**=[NX6TLV9^SK8MJ4K-) MN;S %E+%0N,SP#TXJRMI'Y;_4);>RMK>2"-5M[4DD.I8 9(&XMN'. BUA:_\ (_N9GBG#I5\:)>^MK_X&0_\ Q5.&BWGK:_\ @9%_\52^L4?Y MU]Z+6&K_ ,C^YE$4\5=_L:\_O6O_ (&1?_%4X:/=_P!ZU_\ R+_ .*J?K%' M^9?>BUAJW\C^YE(4X5<&D77]ZU_\"XO_ (JG#2;K^_:_^!<7_P 54^WI?S+[ MT:+#UOY']S(I+EY;>W@8*%@#!2!R@X.:?_:KM<-.]K;-*TGFABI!5OP//3.#FH!ID_P#STM?_ M +B_P#BJ<-.G_YZ6O\ X%Q?_%5GS4.Z^\UY:_6+^XE74G**)H89V0DH\JDE MUK_P"!4?\ \53A:/\ \]K7_P " MH_\ XJA5*2=U)?>/V=5JSB_N(13JE^R-_P ]K7_P*C_^*IWV5O\ GM:_^!4? M_P 51[:G_,OO#V53^5_<0BG"I?LS?\]K7_P*C_\ BJ7[,?\ GO:_^!4?_P 5 M2]K3_F7WC]E4_E?W$(IU2?9S_P ][7_P*C_^*I?LY_Y[VO\ X%1__%4>UI_S M+[P]E4_E?W$5+4OV<_\ />U_\"H__BJ/(_Z;VO\ X%1__%4O:T_YE]X_95/Y M61T5+Y'_ $WM?_ J/_XJCR/^F]K_ .!4?_Q5'M:?\R^\/93_ )61TZ3_ )!\ M_P#O)_.G^3_TWM?_ )C_P#BJ;.JI82J9H&9F3"I,C$\^@)K&O4@Z;2:-J%. M:J)M'7:/_P >,?TK1K.T?_CQC^E:->6>F%%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '+^$_^/>NHKE_"?_'O M744 )WKQ+Q;_ ,C7J7_78_R%>V]Z\SU^Z*:]>+]GLVQ)U>TB8GZDKDUZ66-J MH[=CR,XBG2C=]?T.$HKJOMC?\^MA_P" ,/\ \31]L;_GUL/_ !A_P#B:]KG MEV_'_@'SOLX=W]W_ 3E:*ZK[8W_ #ZV'_@##_\ $T?;&_Y];#_P!A_^)HYY M=OQ_X >SAW?W?\$Y6BNJ^V-_SZV'_@##_P#$T?;&_P"?6P_\ 8?_ (FCGEV_ M'_@![.'=_=_P3E:*ZK[8W_/K8?\ @##_ /$T?;&_Y];#_P 8?\ XFCGEV_' M_@![.'=_=_P3E:*ZK[8W_/K8?^ ,/_Q-'VQO^?6P_P# &'_XFCGEV_'_ ( > MSAW?W?\ !.5JSI__ "$K7_KLG\Q70_;&_P"?6P_\ 8?_ (FIK2\8WD ^S6(S M(O2RA!Z_[M*4Y6>GX_\ *C3AS+5_=_P3D*^:_[F#[QZ MPK_A3,K_ ,\8/^_*?X5\H?;F)16WE?\ GC!_WY3_ HRO_/&#_ORG^% &)16 MWE?^>,'_ 'Y3_"C*_P#/&#_ORG^% &)16WE?^>,'_?E/\*,K_P \8/\ ORG^ M% &)16WE?^>,'_?E/\*,K_SQ@_[\I_A0!B45MY7_ )XP?]^4_P *,K_SQ@_[ M\I_A0!F6/_'Y'^/\C5>N@MROGK^ZA'7I$H[?2HLK_P \8/\ ORG^% &)16WE M?^>,'_?E/\*,K_SQ@_[\I_A0!B45MY7_ )XP?]^4_P *,K_SQ@_[\I_A0!B4 M5MY7_GC!_P!^4_PHRO\ SQ@_[\I_A0!B45MY7_GC!_WY3_"C*_\ /&#_ +\I M_A0!B45MY7_GC!_WY3_"C*_\\8/^_*?X4 8E%;>5_P">,'_?E/\ "C*_\\8/ M^_*?X4 9EE_Q\'_KG)_Z :KUT$!7S?\ 50CY6Z1*.Q]JBRO_ #Q@_P"_*?X4 M 8E%;>5_YXP?]^4_PHRO_/&#_ORG^% &)16WE?\ GC!_WY3_ HRO_/&#_OR MG^% &)16WE?^>,'_ 'Y3_"C*_P#/&#_ORG^% &)16WE?^>,'_?E/\*,K_P \ M8/\ ORG^% &)16WE?^>,'_?E/\*,K_SQ@_[\I_A0!B45MY7_ )XP?]^4_P * M,K_SQ@_[\I_A0!B45MY7_GC!_P!^4_PHRO\ SQ@_[\I_A0!B45MY7_GC!_WY M3_"C*_\ /&#_ +\I_A0!B45MY7_GC!_WY3_"C*_\\8/^_*?X4 8E=?HHSHT M_P![_P!"-9>5_P">,'_?E/\ "MS3_P#CQCP%'7A5 '4]A0!2N]$@NI"[CFJW M_",VW]VM^B@# _X1FV_NT?\ ",VW]VM^B@# _P"$9MO[M'_",VW]VM^B@# _ MX1FV_NT?\(S;?W:WZ* ,#_A&;;^[1_PC-M_=K?HH P/^$9MO[M'_ C-M_=K M?HH P/\ A&;;^[1_PC-M_=K?HH P/^$9MO[M'_",VW]VM^B@# _X1FV_NT?\ M(S;?W:WZ* ,#_A&;;^[1_P (S;?W:WZ* ,#_ (1FV_NT?\(S;?W:WZ* ,#_A M&;;^[1_PC-M_=K?HH P/^$9MO[M'_",VW]VM^B@# _X1FV_NT?\ ",VW]VM^ MB@# _P"$9MO[M'_",VW]VM^B@# _X1FV_NT?\(S;?W:WZ* ,#_A&;;^[3D\- MVRMD+TK=HH B@A6",(O05+110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 NHKE_"?_ ![UU% " M=Z\K\1?\C#??]=*]4[UY7XC/_%0WW_72O2RS^(_0\C./X4?4S**3-&:]H^>% MHI,T9H 6BDS1F@!:*3-&: %HI,T9H 6I[/\ X_K?_KHO\ZKYJ:S/^G6__71? MYTI;,J/Q([^3_6O_ +QIM.D_UK_[QIM?*'VP4444 %%%% !1110 4444 %%% M% $MO_KU_'^515+;_P"O7\?Y5%0 4444 %%%% !169'XBT.:X6WBUG3WF9MB MQK=(6+>@&@1S+*SJH?Y" 2R$ Y /!(P>O;Z5)7"7XD>_P!12RQ_ M:QOXC9?-C!%NF_)]-F[\2/:J4ZZ=)=0B6YTRUTG["GV(:G:F1,Y;S-IWH%ES MC/5C^=']?A<2U1Z.[!$9V.%49)J*TNH;ZSAN[=]\$R"2-L$94C(.#S7#LM@D MNWQ'<"YC&G1_8)[F)HV=OFWE%;YA+]S_ &^E=/X5_P"11T?'_/E%_P"@"G;? M^NX=OZ[&O1112 **** "BBB@ K;L2%T]&/0 G]36)6S:?\@L?[K?S--;B>Q@ M'X@Z."1LN>#_ '!_C1_PL'1_[ES_ -\#_&O,'_UC?4T@KZ+^S*'F?*?VQB?+ M[CU'_A8.C_W+G_O@?XT?\+ TC^Y<_P#? _QKS"E%+^S*'F4LWQ/E]QZ?_P ) M]I']RY_[X'^-+_PGND_W+G_O@?XUYD*6E_9M#S+6:XCR^X]-_P"$\TG^Y<_] M\#_&C_A.])_N7'_? _QKS04X=*7]G4/,M9IB/+[CTK_A.M*_N7'_ 'P/\:7_ M (3G2O[EQ_WP/\:\W%/%3_9U'S*69U_(]&_X3?2_[EQ_WP/\:7_A-M+_ +EQ M_P!\#_&O.A3A2_L^CYE+,:_D>B?\)KI?]VX_[X'^-+_PF>F?W9_^^!_C7#0Z M=?7$0DAL[B2,]&2)B#^(%1F*14WM&X4-MR5XSZ?6I^HT+V_4T^O8BU_T.^_X M3+3#_#/_ -\#_&E_X3#3?[L__? _QK@%IXI?4:(UCZQWO_"7Z=_=G_[X'^-+ M_P );IW]V?\ [X'^-<(*>*7U&D5]>JG<_P#"6:=_=F_[X'^-'_"5Z?\ W9O^ M^!_C7%%'3;N5AN&1D=1ZU.MGP])O^^?\ Z]<:*=2^ITA_7*IV/_"36']V;_OD?XT?\)+8^DW_ 'R/\:X\ M4X4OJ=,?UNH=?_PDMCZ2_P#?/_UZ/^$DL?27_OD?XUR IU+ZG3#ZW4.M_P"$ MDL?27_OG_P"O2_\ "1V/I+_WS_\ 7KD:6CZI3'];J'6_\)'8^DO_ 'S_ /7H M_P"$CL?27_OG_P"O7)T4?5*8?6ZAUG_"167I+_WS_P#7J>#6;6XW;-XVXSN& M.M<;3R[)83E3@[D_G65;#0A!R1I1Q$YS29WJ.LB[E.13JS](8M9(3Z5H5P'> M%%%<7)JWC'4-=U:UT9-"6UL9EB!O!-O)**W\)QW]J.M@.THKB)/%VL66B:T+ M^SLX]8TLQ;O++-!*LC?*P&0PXSP3V_"NLMM4L+RXEMK:^MIKB'B6*.56:,]/ MF .1SZT 6Z**YCQ;XN7P]:3QVEI+>:BD!G$2QMY<:<_O)&Z!1M/&IBR\.RZI*%_=VWG%>Q.W./SXK#FU+QC=S);:9I^G0O!!&US<:@ MLJQR2,N2L07/"]R2>N.W+:L["6JN=;16-X;UF?6+&.@[T[6/%>G:;X;N-:@N;6\AC^5/+N%VR/\ MW0PR,_G0]'8%J;M%9[ZYI,5A#?3:G916LW$A_*K=O<07=NEQ M;31S0N,I)&P96'L1P: N2T5CSZK/'XNM-)"1_9YK.2=F(.X,K*!@YQCD]J9J M&L7%IXKT?2T2(P7L<[2,P.X%%!&.<=_0T?U_7W ;=%<3-K?C,VT^L0Z7ID.E MQ!I/LEVTJ7;1IG.>-JD@$C(XR.M=38ZK:7]O9R)*B27< N(X78!RA .=O7C( MH!Z%VBN3N_&>?$EAI>GVDDL$EVUMLZJNJ MQ:-H%O:2:@T)N));QF$44><#.WDDG./I1TN'6QT5%8OA[4-6NX[JWUNP6VO; M6389(0WD3J1D-&3SCL1V_0;5 !1110 4444 NHKE_"?_'O744 ) MWKRGQ&?^*BOO^NE>K=Z\G\2'_BH[[_KK7I99_$?H>1G'\*/J9N:,TW-&:]L^ M>'9HS3E%%# \\%UJ'_" M&:?9W-I:0Z;<[(6O_M#.8 6X9DV#!)X!W$ D$G%3>*[V<1:O=V4EXC6 "M<2 M:B8(HG"JP5(USYA.[G>!G. >F.V-G:FS-H;:$VI7882@V%?3;TQ5=]$TF283 M/I=DTHC\H.;="P3&W;G'3'&/2C^OZ_K_ (+.=IQ\PX MZ5TL=O#"S-%#&A?&XJH&[ P,_0<5!9Z7I^GO(]E86MLTGWVAA5"WUP.:.I/0 MMT444#"BBB@"6W_UO_ 6_P#03452V_\ K?\ @+?^@FHJ "BBB@ J*XN8+.W> M>YGC@A09:25PJK]2>!4M8WBG_D 2?]=H?_1J4 7;+5M-U(N+#4+6Z*8WB"97 MVYZ9P>*N5SVO(DFN:)'"VV\:616*'#B QMOYZ@9V?CBLBWO=0OK66S.I_9;G M2K.6*YN9'POGDE$=R>VU2_/]X&C^OZ_K<+:G:RS10)OFD2-,A=SL ,DX Y]2 M0*(IHIE9HI$D"L4)1@<,#@CZ@\5PT\LD-I=Z?<17D-PD]I*4EO3=1%3<* R. MWSC./NMCIP.IJ2&62^UFQL[G4;N.*6YU%2D=RT9EV2C:N00>!G&".!CID4+4 M.AVIFB69(6D02N"RH6&Y@,9('?&1^8I#/$)U@,J"9E+K&6&XJ, D#K@9'YUP M4FL:E;V9>VNIIA;PZ@L$C$OYBQN@1S_?*C/)SG!]33M3_P")-J)N=+O9[FX7 M1)YD$\[3D?-'B0;B3@X)P./EX'6CL_ZZ_P"0[?U\['?T5P-T=4L-*O)DO88H MY--FE&W5Y;F20A05ECWH-N,\[3CYAQTIU_:SVXU;;J>I8@TA;Q/],DXF_>?- MUZ?*/E^[[=*'IO\ UO\ Y"6NW];?YG3N/V97*E\@HF(O_K&^II!2O\ ZQOJ:05]D? #J44E**1:'BEI!2U)HAPI MPZ4T4X=*1HAXIXI@IXJ66APIPIHIPJ6:(VY%M3I&F&XFGC(63 CB#9^<]RPQ M5N343+8M)'\L1[VV!MP7/ M&?7'K7.Z-]^_ZG4JS6W;]+'1?9X[2\N %A6)KMHXU^S":1\$?* W '/J#]:D M\JWCO9[5(8XF:Y=(S+;[XY!QA-W5>O;UK!2]NU$@6ZF E.9,2'Y\]<^M/2^O M%W[;J<>9]_$A^;Z^M9.C+N:JM'HOZU-E(K6UAM(WC:0R[@X2V67S#N(*ABP( M[=/7-9 <0W)9%R%8[1(H/YCI2175Q#&T<4\L:-]Y4<@'ZBF"JC!J]R9332LC M:F8W&I6LTQW8MUE?MD $G^6*9!/*IAO;J0[(V+0QC@NGTJQ'?WD482.[G1!T59" *ATW:QHJBO=FKIL:M):I,L)%PQ81K;[ MV8$D$EC]T#'8_A6.PP[#&,'%.6\N538MQ,$)W;0YQGKGZYIF2Q))))Y)-$8M M-MA*:<4A13J:*=5DBBG"FBG"DQH!3J:*=2&%+24M Q:***0"TZ3_ )!\_P#O M)_.FTZ3_ )!\_P#O)_.L<1_"9MA_XB.OT?\ X\8_I6C6=H__ !XQ_2M&O(/6 M"O/;73-=O_%7B5])\1?V7&MX@>/[$D^\^4G.6/'TKT*HHK:"&262*"..29MT MK(@!:[*XMH+N!H+F&.:% M_O1R(&4]^0:'MH)9HII((WEASY3L@+)D8.#VR/2A;W#I8(+F"ZB\RWFCFCW% M=T;AAD'!&1W!XK&\:_\ (D:U_P!>7;P1PQ[BVV- HR3DG [ MD\TL\$-S \$\22PR+M>.10RL/0@]12DKJPXNSN8WZ)C\:@\2>+X[74_[!L;ZRM+YD#3W=Y*J1VJGN Q&]\=%^A/%=5]F@\R* M3R(]\((B;8,H#P0#VZ=JHW/AW0[RX>XNM&TZ>=SEY);5&9OJ2,FJD[LF*LB' MPQ!I%KHZP:/>0WD*.3+<1S+*9)3RS,P_B.<_E7%VJ^%?-\1KXG%F=4-[+N%U M@S^7C]WY6>?NXQLYZ>U>B66G6.FPM#86=O:Q,VXI!$J*3ZX Z\"FSZ7I]U=Q M7=Q8VLUS%_JYI(59T^A(R*4M6-;'E$-Q;_\ "*>#K26#2MSI/(L^LNWV= &( M(*@A6<@\;NF/>JD%O9OX>\:]? MDT;2YK&.QETVSDLXSN2!H%,:GGD+C ZG\Z=%I.FP1R1Q:?:1I)&(I%2%0'0# M 4C'(P3QTYIMWOY@M+>1YUKDVBW6NV-G9CPW;6B:?N2[U ;X@C.?]1'D1E@0 M2<\GIV-:_P *WC;P_J"PW*7,2ZC*$E2(1*PPI!"#A >N.V:ZF7P_HLUM#;2Z M182009\J)[9"L>>NT8P,^U6[>SM;3S/LUM##YC;G\M NXXQDXZG %"TO_76X MK:+^NECCO$FD_P!L^/=,MO[0O['%A,_FV,WE2<.G&<'CFJB:#_8?Q#\/C^UM M5U#S8;GG4+GS=F$'W>!C.>?H*[TVT#7*W)@C-PBE%E*#<%/4 ]<<#BDDM+:: M>.>6WBDFC#*DC("RAN" >V>]):6^?XW_ ,QO7\/T."OO$VF>*[J;3GUFPL-" MB?9<2272)->8ZHH)!6/U;J>@XS7:0'26GM#;FR:8V_\ HQ0J6,/'W,<[/N]. M.E5O^$3\-_\ 0OZ5_P" 4?\ A6A'86<+PO%:0(T,?E1,L8!1./E7T' X'I0M M@>Y@>*?^0UX7_P"PD?\ T4]8?B33M&E\>M_PD=TT&FW>GJ$5YS##,Z.Q*NP( MY&X$#/>N^EMH)WB>:".1X6WQLZ E&QC(ST.">13+RQM-1@\B]M8+F'(/ESQA MUR.^#Q2_S_2P?U^-SE/ YMHM1UNRT>=IM!MY(A:$2&1$U@B@@082.) JK] .!4M4Q!1112&%%%% '+^$_P#CWKJ*Y?PG M_P >]=10 G>O)?$I_P"*DO\ _KK7K7>O(?$Q_P"*EO\ _KK_ $KTLL_B/T/( MSC^%'U_0S=U&ZF9J[I%F=1U:UM!TDD ;_=ZG],U[4FHJ[/GHIR=D5=U&ZNZU MVTN&U+2+^>W\EEO! 0"#E-^4/'MFI)H(I]5U74+=0-D%Q;W"CLX'RM^('Y@U MR+&+E3L=[R^7,XWZKIW_ ,C@=U&ZNR6[O-+&DVFF36MG;SVRS//. $E?&6#, M0?IQZ_2K-J6T^]U]WN(-..(7\R",RH@;/0$NGE?O^=CA-U&ZNDU;Q%MU*UN--O/-N8X?+FN_(">;D_W2.U;M]J5W-J^M MV$DN;:*P9T3:.#M7OC/,DR?ZU_P#>--ITI DW=I(.T4NW,;?0Y*G_@-6[* MUMM=N]"T?5VD;3H]$BN(;192@GEQ@]""Q ' S_6A:J_];-_H-JSM_6]CU"BO M()GLH_!/B?3[K>**2"1;+4$">0KNORK\Q/)!.3ZCW)VO#'A2ZAUN69M _ ML33)+1H+BW_M W'VDMT/!^7 ^G7CO1_7X"/1:*\@F\):'#<>,Q'8X&FP(UI^ M]?\ =DQ$GOSSZYKT"QDAA\ VLEQ<2VT"Z&O$,XT];F2VN-+%U!!;.TQN54_P"L8-C$AZ!0,=>>U67U7^U_ M&WAFX^P7UEC[6GE7L/EN?D7G&3QS3MK;^NO^0'>45GWVLV6G7,5O.9VFE1G2 M."VDF)4$ G"*<#D=?6K5I=07UI%=6T@D@F4.CCN#2 MV_P#KU_'^515+;8^T M+DXZ_P J-D7_ #V_\=- $5%2[(O^>W_CIHV1?\]O_'30!%14NR+_ )[?^.FC M9%_SV_\ '30!%14NR+_GM_XZ:-D7_/;_ ,=- $5%2[(O^>W_ (Z:-D7_ #V_ M\=- $5%2[(O^>W_CIHV1?\]O_'30!%14NR+_ )[?^.FC9%_SV_\ '30 6_\ MK?\ @+?^@FHJLP)'YG$N?E;^$^AJ/9%_SV_\=- $5%2[(O\ GM_XZ:-D7_/; M_P =- $517%M!>6[P7,$<\+C#1RH&5OJ#P:M;(O^>W_CIHV1?\]O_'30!G6> MDZ=IOF'3["TM&<88P0*F['3. ,U%I^EBUCNCAR36[LB_Y[?^.FC9 M%_SV_P#'30!42UMXS$4MXE,*>7%M0#8IQPOH.!P/05#:Z3IMC(9+33[2WD.< MM#"J$YQGD#O@?D*T=D7_ #V_\=-&R+_GM_XZ: ,R'1=*MDG2#3+.);@;9EC@ M51(/1L#GJ>OK5A[.VD\S?;0MYD?E/N0'R+_GM_XZ:-D7_/;_QTT 5H((;:!(+>)(H4&U(XU"JH M] !TJ2I=D7_/;_QTT;(O^>W_ (Z: (J*EV1?\]O_ !TT;(O^>W_CIH BK;LA MG3D!Z$$?J:R=D7_/;_QTUL6( LHP#N'/./>W_AC3[2=E$=])SU$RC_V2 MJ?\ 8UA_SZW_ /W_ $_^(KU%[:*0Y90:9]B@_N"NKZ[B/YCC_L_"_P B/,O[ M&L?^?6^_[_I_\11_8]C_ ,^M]_W_ %_^(KTW[%!_<%'V*#^X*/KN(_F#^S\- M_(CS/^R;+_GUOO\ O^O_ ,12_P!E67_/I??]_P!?_B*]+^Q0?W!1]B@_N"E] MC?8H/[@H^Q0?W!2^MUOYA_4Z'\IYU]CM/^?.\_[_ *__ !%+]DM? M^?.\_P"_Z_\ Q%>B?8H/[@H^Q0?W!1]:K?S#^J4/Y3SP6UJ/^7.\_P"_Z_\ MQ%.\BV_Y\KO_ +_K_P#$5Z#]B@_N"C[%!_<%'UJM_,'U6C_*>?\ DVW_ #Y7 M?_?]?_B*7R[?_GRN_P#O^O\ \17?_8H/[@H^Q0?W!2^LUOYA_5:/\IP.RW_Y M\KO_ +_K_P#$4;8/^?*Z_P"_Z_\ Q%=]]B@_N"C[%!_<%'UFK_,'U:E_*<%B M#_GQNO\ O^O_ ,12_N/^?&Z_[_K_ /$5WGV*#^X*/L4']P4?6:O\P_J]+^4X M3,'_ #XW7_?]?_B*-T/_ #XW7_?Y?_B:[O[%!_<%'V*#^X*7UBK_ #!]7I=C MA=\/_/C=?]_E_P#B:/,A_P"?&Z_[_+_\37=?8H/[@H^Q0?W!1]8J]P^KTNQP MWF0_\^-S_P!_E_\ B:/-B_Y\+G_O\/\ XFNY^Q0?W!1]B@_N"CZQ5[A["GV. M&\V+_GPN?^_P_P#B:7SHO^?"Y_[_ _^)KN/L4']P4?8H/[@H^L5>X>PI]CA M_.B_Y\+G_O\ #_XFCSHO^?"Y_P"_P_\ B:[C[%!_<%'V*#^X*/;U.X_84^QQ M'GQ?\^%S_P!_A_\ $TCR^; T$5G,A=E)9Y W0_[HKN/L4']P4HLH0?N"IE6G M)6;'&C"+ND0:2A2S0,,'%7Z15"C %+69H%%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '+^$_^/>NHKE_"?_'O M744 )WKQ[Q0?^*FU#_KK_2O8>]>-^*3_ ,5/J'_74_RKT\K_ (C]#Q\Y_A1] M3+S5BSO[BPF,UM)Y6<#0P3;8S M(LI&T'YE.0>13X]:OXIKN9+@A[L%9SM&'!Z\8P/PK-S1FI=.+W1:JS5K-Z&O M8>(]6TR#R+2\9(LY"%58#Z9!Q^%5CJEZR72/<.XNMOG%_F+[>G)YJCFC-'LH M7O9![:I91YG9>9(&PIW)N+R9I9<8R0!@> M@ X%4LT9I1I0B[I)#E6J25I2;OYC\U8L3_Q,+;_KJO\ ,54S4]B?^)A;?]=5 M_F*#R.16:_A[2WTBWTIK7_0[=E:*,2," MI4Y!W YZ^]:LG^M?_>--KY(^Y,P^'M*-E?V9M ;>_E:6Y0NQWNV,GKD=!TQB MH;[PKH>I:;;:?>:?'+;6JA(068,B@8P&!W=AWYQS6S10!BP^$M"M](DTJ'3H MX[.4@R(K,&-3!"-W\NXV MMGYOEX"_>7@_,3FNSHH6G]>O^8/4EM_]>OX_RJ*I;?\ UZ_C_*HJ "BBB@ H MK&\57MQI_AZ:YMIGAE$D2B2- [ -(JG"D')P3V-9-MKLMIJ%VGVV]O((K![G MR]0M?LTA93T3]VF1CKP<<>]*_P#7XCL=?16 FMZE(;6%-+@^UW2-/'&UV0J1 M +R[>7PV6 V@-]:&\13'3%NX[2WB\N1XKHWEV(8K=U.T@O@DY/3 P1UQTIO0 M2U-^BN:LO%,NJVUE_9]E%)=W*RNT;W.(T6-MC'S%5MP+8Q@WTZ MU6^>U2_N);DXO;E;>.-(Y67!8 Y(X !S@G/>@#LZ*YN#Q4]^EBNFVD-Q-=& M56S=8CC:/&[YU5MRG/! YXX&>.C&<#( /?!H 6BBB@"6W_UO_ 6_]!-15+;_ M .M_X"W_ *":BH **** "BBB@ HHHH **H:Y<2V>@:C

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end GRAPHIC 25 image00019.jpg begin 644 image00019.jpg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end GRAPHIC 26 image00020.jpg begin 644 image00020.jpg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

XML 33 R2.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 128,797 $ 142,998
Short-term investments 650,386 585,834
Contracts receivable 11,356 3,903
Inventories 6,899 6,290
Investment in Regulus Therapeutics Inc. 24,792 81,881
Other current assets 14,773 15,691
Total current assets 837,003 836,597
Property, plant and equipment, net 90,233 88,958
Patents, net 19,316 17,186
Deposits and other assets 9,553 13,068
Total assets 956,105 955,809
Current liabilities:    
Accounts payable 28,355 17,984
Accrued compensation 16,065 12,302
Accrued liabilities 28,105 30,451
Current portion of long-term obligations 9,029 2,882
Current portion of deferred contract revenue 67,322 51,713
Total current liabilities 148,876 115,332
Long-term deferred contract revenue 134,306 127,797
Long-term obligations, less current portion 2,341 7,669
Long-term financing liability for leased facility 72,217 71,731
Total liabilities 755,315 698,029
Stockholders' equity:    
Common stock, $0.001 par value; 300,000,000 shares authorized, 120,351,480 and 118,442,726 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively 120 118
Additional paid-in capital 1,309,107 1,224,509
Accumulated other comprehensive income (loss) (13,565) 39,747
Accumulated deficit (1,094,872) (1,006,594)
Total stockholders' equity 200,790 257,780
Total liabilities and stockholders' equity 956,105 955,809
1 Percent Convertible Senior Notes [Member]    
Current liabilities:    
Convertible senior notes 347,214 327,486
2 3/4 Percent Convertible Senior Notes [Member]    
Current liabilities:    
Convertible senior notes $ 50,361 $ 48,014
XML 34 R3.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2015
Dec. 31, 2014
Stockholders' equity:    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 300,000,000 300,000,000
Common stock, shares issued (in shares) 120,351,480 118,442,726
Common stock, shares outstanding (in shares) 120,351,480 118,442,726
Convertible Senior Notes [Member] | 1 Percent Convertible Senior Notes [Member]    
LIABILITIES AND STOCKHOLDERS' EQUITY    
Interest rate on convertible senior notes 1.00% 1.00%
Convertible Senior Notes [Member] | 2 3/4 Percent Convertible Senior Notes [Member]    
LIABILITIES AND STOCKHOLDERS' EQUITY    
Interest rate on convertible senior notes 2.75% 2.75%
XML 35 R4.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Revenue:      
Research and development revenue under collaborative agreements $ 281,360 $ 202,514 $ 144,194
Licensing and royalty revenue 2,343 11,647 3,091
Total revenue 283,703 214,161 147,285
Expenses:      
Research, development and patent expenses 322,292 241,751 184,033
General and administrative 37,173 20,140 14,918
Total operating expenses 359,465 261,891 198,951
Loss from operations (75,762) (47,730) (51,666)
Other income (expense):      
Investment income 4,302 2,682 2,085
Interest expense (36,732) (22,209) (19,355)
Gain on investments, net 75 1,256 2,378
Gain on investment in Regulus Therapeutics Inc. 20,211 19,902 0
Loss on early retirement of debt 0 (8,292) 0
Loss before income tax (expense) benefit (87,906) (54,391) (66,558)
Income tax (expense) benefit (372) 15,407 5,914
Net loss $ (88,278) $ (38,984) $ (60,644)
Basic and diluted net loss per share (in dollars per share) $ (0.74) $ (0.33) $ (0.55)
Shares used in computing basic and diluted net loss per share (in shares) 119,719 117,691 110,502
XML 36 R5.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]      
Net loss $ (88,278) $ (38,984) $ (60,644)
Unrealized (losses) gains on investments, net of tax (33,101) 40,079 10,253
Reclassification adjustment for realized (gains) losses included in net loss (20,211) (21,412) (1,653)
Comprehensive loss $ (141,590) $ (20,317) $ (52,044)
XML 37 R6.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Common Stock [Member]
Additional Paid in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2012 $ 102 $ 1,077,150 $ 12,480 $ (906,966) $ 182,766
Balance (in shares) at Dec. 31, 2012 101,481        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss $ 0 0 0 (60,644) (60,644)
Change in unrealized gains (losses), net of tax 0 0 8,600 0 8,600
Issuance of common stock in connection with employee stock plans $ 5 62,953 0 0 62,958
Issuance of common stock in connection with employee stock plans (in shares) 5,372        
Issuance of public common stock $ 9 173,283 0 0 173,292
Issuance of public common stock (in shares) 9,618        
Share-based compensation expense $ 0 11,418 0 0 11,418
Balance at Dec. 31, 2013 $ 116 1,324,804 21,080 (967,610) 378,390
Balance (in shares) at Dec. 31, 2013 116,471        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss $ 0 0 0 (38,984) (38,984)
Change in unrealized gains (losses), net of tax 0 0 18,667 0 18,667
Issuance of common stock in connection with employee stock plans $ 2 23,071 0 0 23,073
Issuance of common stock in connection with employee stock plans (in shares) 1,972        
2 3/4 percent convertible senior notes redemption, equity portion $ 0 (326,444) 0 0 (326,444)
1 percent convertible senior notes, equity portion, net of issuance costs 0 170,232 0 0 170,232
Share-based compensation expense 0 31,383 0 0 31,383
Excess tax benefits from shared-based compensation awards 0 1,463 0 0 1,463
Balance at Dec. 31, 2014 $ 118 1,224,509 39,747 (1,006,594) 257,780
Balance (in shares) at Dec. 31, 2014 118,443        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss $ 0 0 0 (88,278) (88,278)
Change in unrealized gains (losses), net of tax 0 0 (53,312) 0 (53,312)
Issuance of common stock in connection with employee stock plans $ 2 24,888 0 0 24,890
Issuance of common stock in connection with employee stock plans (in shares) 1,908        
Share-based compensation expense $ 0 59,314 0 0 59,314
Excess tax benefits from shared-based compensation awards 0 396 0 0 396
Balance at Dec. 31, 2015 $ 120 $ 1,309,107 $ (13,565) $ (1,094,872) $ 200,790
Balance (in shares) at Dec. 31, 2015 120,351        
XML 38 R7.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - Convertible Senior Notes [Member]
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
2 3/4 Percent Convertible Senior Notes [Member]      
Increase (Decrease) in Stockholders' Equity [Roll Forward]      
Interest rate on convertible senior notes 2.75% 2.75% 2.75%
1 Percent Convertible Senior Notes [Member]      
Increase (Decrease) in Stockholders' Equity [Roll Forward]      
Interest rate on convertible senior notes 1.00% 1.00%  
XML 39 R8.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Operating activities:      
Net loss $ (88,278) $ (38,984) $ (60,644)
Adjustments to reconcile net loss to net cash provided by operating activities:      
Depreciation 6,984 6,380 6,591
Amortization of patents 1,381 1,142 1,184
Amortization of licenses 1,873 1,882 2,007
Amortization of premium on investments, net 7,812 7,470 5,572
Amortization of debt issuance costs 1,133 595 415
Amortization of long-term financing liability for leased facility 6,665 6,622 6,567
Share-based compensation expense 59,314 31,383 11,418
Gain on investment in Regulus Therapeutics Inc. (20,211) (19,902) 0
Loss on early retirement of debt 0 8,292 0
Gain on investments, net (75) (1,256) (2,378)
Non-cash losses related to patents, licensing and property, plant and equipment 1,881 1,305 6,306
Tax benefit from other unrealized gains on securities 0 (12,835) (5,914)
Changes in operating assets and liabilities:      
Contracts receivable (7,453) 7,199 (10,580)
Inventories (609) 1,743 (1,912)
Other current and long-term assets (4,319) (1,750) (1,091)
Accounts payable 9,211 4,824 66
Income taxes 0 (4,034) 0
Accrued compensation 3,763 134 4,290
Deferred rent 205 153 217
Accrued liabilities (2,345) 8,358 6,691
Deferred contract revenue 22,118 (11,415) 88,344
Net cash provided by operating activities 21,125 6,285 63,493
Investing activities:      
Purchases of short-term investments (493,467) (391,883) (425,554)
Proceeds from the sale of short-term investments 419,584 294,727 172,762
Purchases of property, plant and equipment (7,692) (7,518) (1,552)
Acquisition of licenses and other assets, net (4,056) (3,586) (3,810)
Proceeds from the sale of Regulus Therapeutics, Inc. 25,527 22,949 0
Proceeds from the sale of strategic investments 52 2,463 2,428
Net cash used in investing activities (60,052) (82,848) (255,726)
Financing activities:      
Proceeds from equity awards 24,888 23,071 62,958
Proceeds from issuance of 1 percent convertible senior notes, net of issuance costs 0 487,035 0
Repurchase of $140 million principal amount of the 2 3/4 percent convertible senior notes 0 (441,394) 0
Proceeds from borrowing on line of credit facility 8,500 0 0
Proceeds from public common stock offering 0 0 173,292
Proceeds from equipment financing arrangement 0 0 2,513
Excess tax benefits from share-based compensation awards 396 1,463 0
Principal payments on debt and capital lease obligations (9,058) (10,587) (11,039)
Net cash provided by financing activities 24,726 59,588 227,724
Net (decrease) increase in cash and cash equivalents (14,201) (16,975) 35,491
Cash and cash equivalents at beginning of year 142,998 159,973 124,482
Cash and cash equivalents at end of year 128,797 142,998 159,973
Supplemental disclosures of cash flow information:      
Interest paid 6,800 6,353 6,000
Supplemental disclosures of non-cash investing and financing activities:      
Amounts accrued for capital and patent expenditures 1,162 2,151 704
2 3/4 Percent Convertible Senior Notes [Member]      
Adjustments to reconcile net loss to net cash provided by operating activities:      
Amortization of convertible notes discount 2,347 6,723 6,344
1 Percent Convertible Senior Notes [Member]      
Adjustments to reconcile net loss to net cash provided by operating activities:      
Amortization of convertible notes discount $ 19,728 $ 2,256 $ 0
XML 40 R9.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2015
Dec. 31, 2014
Nov. 30, 2014
Dec. 31, 2013
2 3/4 Percent Convertible Senior Notes [Member]        
Financing activities:        
Principal amount repurchased   $ 140    
Convertible Senior Notes [Member] | 1 Percent Convertible Senior Notes [Member]        
Adjustments to reconcile net loss to net cash provided by operating activities:        
Interest rate on convertible senior notes 1.00% 1.00%    
Convertible Senior Notes [Member] | 2 3/4 Percent Convertible Senior Notes [Member]        
Adjustments to reconcile net loss to net cash provided by operating activities:        
Interest rate on convertible senior notes 2.75% 2.75%   2.75%
Financing activities:        
Principal amount repurchased     $ 140  
XML 41 R10.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies
12 Months Ended
Dec. 31, 2015
Organization and Significant Accounting Policies [Abstract]  
Organization and Significant Accounting Policies
1. Organization and Significant Accounting Policies

Basis of presentation
 
The consolidated financial statements include the accounts of Ionis Pharmaceuticals, Inc. ("we", "us" or "our") and our wholly owned subsidiary, Akcea Therapeutics, Inc., which we formed in December 2014. In December 2015, we changed our name from Isis Pharmaceuticals, Inc. to Ionis Pharmaceuticals, Inc.

Organization and business activity
 
We incorporated in California on January 10, 1989. In conjunction with our initial public offering, we reorganized as a Delaware corporation in April 1991. We were organized principally to develop human therapeutic drugs using antisense technology.

Basic and diluted net loss per share

We compute basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period. As we incurred a net loss for 2015, 2014 and 2013, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. Common stock from the following would have had an anti-dilutive effect on net loss per share:

percent convertible senior notes (for 2014 and 2015);
2¾ percent convertible senior notes;
Dilutive stock options;
Unvested restricted stock units; and
Employee Stock Purchase Plan, or ESPP.

Revenue recognition

We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In the instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.

Arrangements with multiple deliverables

Our collaboration agreements typically contain multiple elements, or deliverables, including technology licenses or options to obtain technology licenses, research and development services, and in certain cases manufacturing services, and we allocate the consideration to each unit of accounting based on the relative selling price of each deliverable.

Identifying deliverables and units of accounting

We evaluate the deliverables in our collaboration agreements to determine whether they meet the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. When the delivered items in an arrangement have "stand-alone value" to our customer, we account for the deliverables as separate units of accounting. Delivered items have stand-alone value if they are sold separately by any vendor or the customer could resell the delivered items on a stand-alone basis. For example, in May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXIRx for the prevention of thrombosis. As part of the agreement, Bayer paid us a $100 million upfront payment in the second quarter of 2015. We are also eligible to receive milestone payments and tiered royalties on gross margins of IONIS-FXIRx. We are responsible for completing the ongoing development services for IONIS-FXIRx and for providing an initial supply of active pharmaceutical ingredient, or API. Bayer is responsible for all other development and commercialization activities for IONIS-FXIRx. Since this agreement has multiple elements, we evaluated the deliverables in this arrangement when we entered into the agreement and determined that certain deliverables have stand-alone value. Below is a list of the three units of accounting under our agreement:

The exclusive license we granted to Bayer to develop and commercialize IONIS-FXIRx for the treatment of thrombosis;
The development services we agreed to perform for IONIS-FXIRx; and 
The initial supply of API.

We determined that each of these three units of accounting have stand-alone value. The exclusive license we granted to Bayer has stand-alone value because it is an exclusive license that gives Bayer the right to develop IONIS-FXIRx or to sublicense its rights. The development services and the initial supply of API each have stand-alone value because Bayer or another third party could provide these items without our assistance.

Measurement and allocation of arrangement consideration

Our collaborations may provide for various types of payments to us including upfront payments, funding of research and development, milestone payments, licensing fees and royalties on product sales. We initially allocate the amount of consideration that is fixed and determinable at the time the agreement is entered into and exclude contingent consideration. We allocate the consideration to each unit of accounting based on the relative selling price of each deliverable. We use the following hierarchy of values to estimate the selling price of each deliverable: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price, or BESP. BESP reflects our best estimate of what the selling price would be if we regularly sold the deliverable on a stand-alone basis. We recognize the revenue allocated to each unit of accounting as we deliver the related goods or services. If we determine that we should treat certain deliverables as a single unit of accounting, then we recognize the revenue ratably over our estimated period of performance.

We determined that the allocable arrangement consideration for the Bayer collaboration was $100 million and we allocated it based on the relative BESP of each unit of accounting. We engaged a third party, independent valuation expert to assist us with determining BESP. We estimated the selling price of the license granted for IONIS-FXIRx by using the relief from royalty method. Under this method, we estimated the amount of income, net of taxes, for IONIS-FXIRx. We then discounted the projected income to present value. The significant inputs we used to determine the projected income of the license included:

Estimated future product sales;
Estimated royalties on future product sales;
Contractual milestone payments;
Expenses we expect to incur;
Income taxes; and
An appropriate discount rate.

We estimated the selling price of the ongoing development services by using our internal estimates of the cost to perform the specific services and estimates of expected cash outflows to third parties for services and supplies over the expected period that we will perform the development services. The significant inputs we used to determine the selling price of the ongoing development services included:

The number of internal hours we will spend performing these services;
The estimated cost of work we will perform;
The estimated cost of work that we will contract with third parties to perform; and
The estimated cost of drug product we will use.

We determine the selling price of our API consistently for all of our partnerships. On an annual basis, we calculate our fully absorbed cost to manufacture API. We then determine the unit price we will charge our partners by dividing our fully absorbed costs by the quantity of API we expect to produce during the year.

For purposes of determining BESP of the services we will perform and the API in our Bayer transaction, accounting guidance required us to include a markup for a reasonable profit margin.

Based on the units of accounting under the agreement, we allocated the $100 million upfront payment from Bayer as follows:

$91.2 million to the IONIS-FXIRx exclusive license;
$4.3 million for ongoing development services; and
$4.5 million for the delivery of API.

Assuming a constant selling price for the other elements in the arrangement, if there was an assumed ten percent increase or decrease in the estimated selling price of the IONIS-FXIRx license, we determined that the revenue we would have allocated to the IONIS-FXIRx license would change by approximately one percent, or $0.9 million, from the amount we recorded.

Timing of revenue recognition

We recognize revenue as we deliver each item under the arrangement and the related revenue is realizable and earned. For example, we recognized revenue for the exclusive license we granted Bayer for IONIS-FXIRx in the second quarter of 2015 because that was when we delivered the license. We also recognize revenue over time. Our collaborative agreements typically include a research and/or development project plan outlining the activities the agreement requires each party to perform during the collaboration. We must estimate our period of performance when the agreements we enter into do not clearly define such information. We estimate the period of time over which we will complete the activities for which we are responsible and use that period of time as our period of performance for purposes of revenue recognition. We then recognize revenue ratably over such period. We have made estimates of our continuing obligations under numerous agreements and in certain instances the timing of satisfying these obligations change as the development plans for our drugs progress. Accordingly, our estimates may change in the future. If our estimates and judgments change over the course of our collaboration agreements, it may affect the timing and amount of revenue that we recognize in future periods.

The following are the periods over which we are recognizing revenue for each of our units of accounting under our Bayer agreement:

We recognized the portion of the consideration attributed to the IONIS-FXIRx license immediately because we delivered the license and earned the revenue; 
We are recognizing the amount attributed to the ongoing development services for IONIS-FXIRx over the period of time we are performing the services; and
We will recognize the amount attributed to the API supply when we deliver it to Bayer.

Multiple agreements

From time to time, we may enter into separate agreements at or near the same time with the same customer. We evaluate such agreements to determine whether they should be accounted for individually as distinct arrangements or whether the separate agreements are, in substance, a single multiple element arrangement. We evaluate whether the negotiations are conducted jointly as part of a single negotiation, whether the deliverables are interrelated or interdependent, whether fees in one arrangement are tied to performance in another arrangement, and whether elements in one arrangement are essential to another arrangement. Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that they are, in effect, part of a single arrangement. For example, since early 2012, we have entered into four collaboration agreements with Biogen:

In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize nusinersen for spinal muscular atrophy, or SMA. As part of the collaboration, we received a $29 million upfront payment and we are responsible for global development of nusinersen through completion of Phase 2/3 clinical trials.

In June 2012, we entered into a second and separate collaboration agreement with Biogen to develop and commercialize a novel antisense drug targeting DMPK, or dystrophia myotonica-protein kinase. As part of the collaboration, we received a $12 million upfront payment and we are responsible for global development of the drug through the completion of a Phase 2 clinical trial.

In December 2012, we entered into a third and separate collaboration agreement with Biogen to discover and develop antisense drugs against three targets to treat neurological or neuromuscular disorders. As part of the collaboration, we received a $30 million upfront payment and we are responsible for the discovery of a lead antisense drug for each of three targets.

In September 2013, we entered into a fourth and separate collaboration agreement with Biogen to leverage antisense technology to advance the treatment of neurological diseases. We granted Biogen exclusive rights to the use of our antisense technology to develop therapies for neurological diseases as part of this broad collaboration. We received a $100 million upfront payment and we are responsible for discovery and early development through the completion of a Phase 2 clinical trial for each antisense drug identified during the six-year term of this collaboration, while Biogen is responsible for the creation and development of small molecule treatments and biologics.

All four of these collaboration agreements give Biogen the option to license one or more drugs resulting from the specific collaboration. If Biogen exercises an option, it will pay us a license fee and will assume future development, regulatory and commercialization responsibilities for the licensed drug. We are also eligible to receive milestone payments associated with the research and/or development of the drugs prior to licensing, milestone payments if Biogen achieves pre-specified regulatory milestones, and royalties on any product sales from any drugs resulting from these collaborations.

We evaluated all four of the Biogen agreements to determine whether we should account for them as separate agreements. We determined that we should account for the agreements separately because we conducted the negotiations independently of one another, each agreement focuses on different drugs, there are no interrelated or interdependent deliverables, there are no provisions in any of these agreements that are essential to the other agreement, and the payment terms and fees under each agreement are independent of each other. We also evaluated the deliverables in each of these agreements to determine whether they met the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. For all four of these agreements, we determined that the options did not have stand-alone value because Biogen cannot pursue the development or commercialization of the drugs resulting from these collaborations until it exercises the respective option or options. As such, for each agreement we considered the deliverables to be a single unit of accounting and we are recognizing the upfront payment for each of the agreements over the respective estimated period of our performance.

Milestone payments

Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and/ or commercialization events. These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraph.

Prior to the first stage in the life-cycle of our drugs, we perform a significant amount of work using our proprietary antisense technology to design chemical compounds that interact with specific genes that are good targets for drug discovery. From these research efforts, we hope to identify a development candidate. The designation of a development candidate is the first stage in the life-cycle of our drugs. A development candidate is a chemical compound that has demonstrated the necessary safety and efficacy in preclinical animal studies to warrant further study in humans.

During the first step of the development stage, we or our partners study our drugs in Investigational New Drug, or IND, -enabling studies, which are animal studies intended to support an IND application and/or the foreign equivalent. An approved IND allows us or our partners to study our development candidate in humans. If the regulatory agency approves the IND, we or our partners initiate Phase 1 clinical trials in which we typically enroll a small number of healthy volunteers to ensure the development candidate is safe for use in patients. If we or our partners determine that a development candidate is safe based on the Phase 1 data, we or our partners initiate Phase 2 studies that are generally larger scale studies in patients with the primary intent of determining the efficacy of the development candidate.

The final step in the development stage is Phase 3 studies to gather the necessary safety and efficacy data to request marketing authorization from the FDA and/or foreign equivalents. The Phase 3 studies typically involve large numbers of patients and can take up to several years to complete. If the data gathered during the trials demonstrates acceptable safety and efficacy results, we or our partner will submit an application to the FDA and/or its foreign equivalents for marketing authorization. This stage of the drug’s life-cycle is the regulatory stage.

If a drug achieves marketing authorization, it moves into the commercialization stage, during which our partner will market and sell the drug to patients. Although our partner will ultimately be responsible for marketing and selling the partnered drug, our efforts to discover and develop a drug that is safe, effective and reliable contributes significantly to our partner’s ability to successfully sell the drug. The FDA and its foreign equivalents have the authority to impose significant restrictions on an approved drug through the product label and on advertising, promotional and distribution activities. Therefore, our efforts designing and executing the necessary animal and human studies are critical to obtaining claims in the product label from the regulatory agencies that would allow us or our partner to successfully commercialize our drug. Further, the patent protection afforded our drugs as a result of our initial patent applications and related prosecution activities in the United States and foreign jurisdictions are critical to our partner’s ability to sell our drugs without competition from generic drugs. The potential sales volume of an approved drug is dependent on several factors including the size of the patient population, market penetration of the drug, and the price charged for the drug.

Generally, the milestone events contained in our partnership agreements coincide with the progression of our drugs from development, to marketing authorization and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug progresses through the stages of its life-cycle, the value of the drug generally increases.

Development milestones in our partnerships may include the following types of events:

Designation of a development candidate. Following the designation of a development candidate, IND-enabling animal studies for a new development candidate generally take 12 to 18 months to complete;
Initiation of a Phase 1 clinical trial. Generally, Phase 1 clinical trials take one to two years to complete;
Initiation or completion of a Phase 2 clinical trial. Generally, Phase 2 clinical trials take one to three years to complete;
Initiation or completion of a Phase 3 clinical trial. Generally, Phase 3 clinical trials take two to four years to complete.

Regulatory milestones in our partnerships may include the following types of events:

Filing of regulatory applications for marketing authorization such as a New Drug Application, or NDA, in the United States or a Marketing Authorization Application, or MAA, in Europe. Generally, it takes six to twelve months to prepare and submit regulatory filings.
Marketing authorization in a major market, such as the United States, Europe or Japan. Generally it takes one to two years after an application is submitted to obtain authorization from the applicable regulatory agency.

Commercialization milestones in our partnerships may include the following types of events:

First commercial sale in a particular market, such as in the United States or Europe.
Product sales in excess of a pre-specified threshold, such as annual sales exceeding $1 billion. The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.

We assess whether a substantive milestone exists at the inception of our agreements. When a substantive milestone is achieved, we recognize revenue related to the milestone payment immediately. For our existing licensing and collaboration agreements in which we are involved in the discovery and/or development of the related drug or provide the partner with access to new technologies we discover, we have determined that the majority of future development, regulatory and commercialization milestones are substantive. For example, we consider most of the milestones associated with our strategic alliance with Biogen substantive because we are using our antisense drug discovery platform to discover and develop new drugs against targets for neurological diseases. We also consider milestones associated with our alliance with Alnylam Pharmaceuticals, Inc. substantive because we provide Alnylam ongoing access to our technology to develop and commercialize RNA interference, or RNAi, therapeutics. In evaluating if a milestone is substantive we consider whether:

Substantive uncertainty exists as to the achievement of the milestone event at the inception of the arrangement;
The achievement of the milestone involves substantive effort and can only be achieved based in whole or in part on our performance or the occurrence of a specific outcome resulting from our performance;
The amount of the milestone payment appears reasonable either in relation to the effort expended or to the enhancement of the value of the delivered items;
There is no future performance required to earn the milestone; and
The consideration is reasonable relative to all deliverables and payment terms in the arrangement.

If any of these conditions are not met, we do not consider the milestone to be substantive and we defer recognition of the milestone payment and recognize it as revenue over our estimated period of performance, if any. Further information about our collaborative arrangements can be found in Note 6, Collaborative Arrangements and Licensing Agreements.

Licensing and royalty revenue

We often enter into agreements to license our proprietary patent rights on an exclusive or non-exclusive basis in exchange for license fees and/or royalties. We generally recognize as revenue immediately those licensing fees and royalties for which we have no significant future performance obligations and are reasonably assured of collecting the resulting receivable. For example, during 2014, we recognized $9.5 million in revenue from Alnylam related to its license of our technology to one of its partners because we had no performance obligations and collectability was reasonably assured.

Research, development and patent expenses

Our research and development expenses include wages, benefits, facilities, supplies, external services, clinical trial and manufacturing costs and other expenses that are directly related to our research and development operations. We expense research and development costs as we incur them. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. For the years ended December 31, 2015, 2014 and 2013, research and development expenses were $319.5 million, $238.9 million and $173.7 million, respectively. A portion of the costs included in research and development expenses are costs associated with our collaboration agreements. For the years ended December 31, 2015, 2014 and 2013, research and development costs of approximately $161.7 million, $85.6 million and $51.0 million, respectively, were related to our collaborative agreements.

We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We amortize patent costs over the useful life of the patent, beginning with the date the United States Patent and Trademark Office, or foreign equivalent, issues the patent. The weighted average remaining amortizable life of our issued patents was 10.2 years at December 31, 2015.

The cost of our patents capitalized on our consolidated balance sheet at December 31, 2015 and 2014 was $27.5 million and $25.0 million, respectively. Accumulated amortization related to patents was $8.2 million and $7.8 million at December 31, 2015 and 2014, respectively.

Based on existing patents, estimated amortization expense related to patents in each of the next five years is as follows:

Years Ending December 31,
 
Amortization
(in millions)
 
2016
 
$
1.4
 
2017
 
$
1.3
 
2018
 
$
1.2
 
2019
 
$
1.1
 
2020
 
$
1.0
 

We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. When we identify patents and patent applications that we are not actively pursuing, we write off any associated costs. In 2015, 2014 and 2013, patent expenses were $2.8 million, $2.9 million and $10.3 million, respectively, and included non-cash charges related to the write-down of our patent costs to their estimated net realizable values of $1.1 million, $1.3 million and $6.4 million, respectively.

Concentration of credit risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, short-term investments and receivables. We place our cash equivalents and short-term investments with reputable financial institutions. We primarily invest our excess cash in commercial paper and debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody’s, Standard & Poor’s, or S&P, or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.

Cash, cash equivalents and short-term investments

We consider all liquid investments with maturities of three months or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than three months from date of purchase. We classify our short-term investments as “available-for-sale” and carry them at fair market value based upon prices for identical or similar items on the last day of the fiscal period. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.

We have equity investments in privately and publicly held biotechnology companies that we have received as part of a technology license or collaboration agreement. At December 31, 2015, we held ownership interests of less than 20 percent in each of the respective companies.

We account for our equity investments in publicly held companies at fair value and record unrealized gains and losses related to temporary increases and decreases in the stock of these publicly held companies as a separate component of comprehensive income (loss). We account for equity investments in privately held companies under the cost method of accounting because we own less than 20 percent and do not have significant influence over their operations. We hold one cost method investment in Atlantic Pharmaceuticals Limited. Realization of our equity position in this company is uncertain. When realization of our investment is uncertain, we record a full valuation allowance. In determining if and when a decrease in market value below our cost in our equity positions is temporary or other-than-temporary, we examine historical trends in the stock price, the financial condition of the company, near term prospects of the company and our current need for cash. If we determine that a decline in value in either a public or private investment is other-than-temporary, we recognize an impairment loss in the period in which the other-than-temporary decline occurs.

Inventory valuation

We capitalize the costs of raw materials that we purchase for use in producing our drugs because until we use these raw materials they have alternative future uses. We include in inventory raw material costs for drugs that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single drug. For example, if one of our drugs failed, we could use the raw materials for that drug to manufacture our other drugs. We expense these costs when we deliver the drugs to our partners, or as we provide these drugs for our own clinical trials. We reflect our inventory on the balance sheet at the lower of cost or market value under the first-in, first-out method, or FIFO. We review inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value. We consider several factors in estimating the net realizable value, including shelf life of raw materials, alternative uses for our drugs and clinical trial materials, and historical write-offs. We did not record any inventory write-offs for the years ended December 31, 2015, 2014 or 2013. Total inventory was $6.9 million and $6.3 million as of December 31, 2015 and 2014, respectively.


Property, plant and equipment

We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):

  Estimated Useful Lives  
December 31,
 
  
(in years)
  
2015
  
2014
 
Computer software, laboratory, manufacturing and other equipment
 
3 to 10
  
$
56,822
  
$
49,772
 
Building and building systems
 
25 to 40
   
48,163
   
48,521
 
Land improvements
  
20
   
2,853
   
2,853
 
Leasehold improvements
 
5 to 20
   
39,061
   
37,935
 
Furniture and fixtures
 
5 to 10
   
5,842
   
5,732
 
       
152,741
   
144,813
 
Less accumulated depreciation
      
(72,706
)
  
(66,053
)
       
80,035
   
78,760
 
Land
      
10,198
   
10,198
 
 Total
     
$
90,233
  
$
88,958
 

We depreciate our leasehold improvements using the shorter of the estimated useful life or remaining lease term.

Fair value of financial instruments
 
We have estimated the fair value of our financial instruments. The amounts reported for cash, accounts receivable, accounts payable and accrued expenses approximate the fair value because of their short maturities. We report our investment securities at their estimated fair value based on quoted market prices for identical or similar instruments.

Long-lived assets
 
We evaluate long-lived assets, which include property, plant and equipment, patent costs, and exclusive licenses acquired from third parties, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets. We recorded charges of $1.9 million, $1.3 million and $6.4 million for the years ended December 31, 2015, 2014 and 2013, respectively, related primarily to the write-down of intangible assets.

Use of estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Stock-based compensation expense

We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our ESPP based on the estimated fair value of the award on the date of grant. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our Consolidated Statements of Operations. We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.

We use the Black-Scholes model as our method of valuing option awards and stock purchase rights under our ESPP. On the grant date, we use our stock price and assumptions regarding a number of highly complex and subjective variables to determine the estimated fair value of stock-based payment awards. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Option-pricing models were developed for use in estimating the value of traded options that have no vesting or hedging restrictions and are fully transferable. Because our employee stock options have certain characteristics that are significantly different from traded options, and because changes in the subjective assumptions can materially affect the estimated value, in management’s opinion, the existing valuation models may not provide an accurate measure of the fair value of our employee stock options. Although we determine the estimated fair value of employee stock options using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.

We recognize compensation expense for option awards using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), an entity recognizes compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.

The fair value of RSUs is based on the market price of our common stock on the date of grant. The RSUs we have granted vest annually over a four-year period.

See Note 4, Stockholders’ Equity, for additional information regarding our share-based compensation plans.


Accumulated other comprehensive income (loss)

Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on investments, net of taxes, and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive income to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive income for the years ended December 31, 2015, 2014 and 2013 (in thousands):
 
  
Year Ended December 31,
 
  
2015
  
2014
  
2013
 
Beginning balance accumulated other comprehensive income
 
$
39,747
  
$
21,080
  
$
12,480
 
Unrealized (losses) gains on securities, net of tax (1)
  
(33,101
)
  
40,079
   
10,253
 
Amounts reclassified from accumulated other comprehensive (loss) income (2)
  
(20,211
)
  
(21,412
)
  
(1,653
)
Net other comprehensive (loss) income for the period
  
(53,312
)
  
18,667
   
8,600
 
Ending balance accumulated other comprehensive (loss) income
 
$
(13,565
)
 
$
39,747
  
$
21,080
 


(1)Other comprehensive income includes income tax expense of $12.8 million and $5.9 million for the years ended December 31, 2014 and 2013, respectively. There was no tax expense for other comprehensive income for the year ended December 31, 2015.

(2)Amounts for 2015 are included in the separate line called “Gain on investment in Regulus Therapeutics Inc.” on our Consolidated Statement of Operations. For 2014, $19.9 million is included in a separate line called “Gain on investment in Regulus Therapeutics Inc.”, with the remaining amount included in a separate line called “Gain on investments, net” on our Consolidated Statement of Operations. Amounts for 2013 are included in a separate line called “Gain on investments, net” on our Consolidated Statement of Operations.

Convertible debt

We account for convertible debt instruments, including our 1 percent and 2¾ percent notes, that may be settled in cash upon conversion (including partial cash settlement) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. We determine the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, we estimate fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense.

We assign a value to the debt component of our convertible notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording our debt at a discount. We are amortizing the debt discount over the life of the convertible notes as additional non-cash interest expense utilizing the effective interest method. For additional information, see Note 3, Long-Term Obligations and Commitments.

Segment information

In 2015, we began operating as two segments, our Ionis Core segment, previously referred to as Drug Discovery and Development, and Akcea Therapeutics, which consists of the operations of our wholly owned subsidiary, Akcea Therapeutics, Inc. We formed Akcea to develop and commercialize drugs for cardiometabolic disorders. We provide segment financial information and results for our Ionis Core segment and our Akcea Therapeutics segment based on the segregation of revenues and expenses that our chief decision maker reviews to assess operating performance and to make operating decisions. We use judgments and estimates in determining the allocation of shared expenses to the two segments.

Fair value measurements

We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investment in equity securities in publicly held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. Our Level 3 investments include our investments in the equity securities of publicly held biotechnology companies for which we calculated a lack of marketability discount because there were restrictions on when we could trade the securities. Historically, we have determined the lack of marketability discount by using a Black-Scholes model to value a hypothetical put option to approximate the cost of hedging the stock until the restriction ends. The majority of our securities have been classified as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices. During 2015 and 2014, there were no transfers between our Level 1 and Level 2 investments. We recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.


We measure the following major security types at fair value on a recurring basis. The following summary breaks down the fair-value hierarchy that we valued each security with at December 31, 2015 and 2014 (in thousands):

  
At
December 31, 2015
  
Quoted Prices in
Active Markets
(Level 1)
  
Significant Other
Observable
Inputs
(Level 2)
  
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents (1)
 
$
88,902
  
$
88,902
  
$
  
$
 
Corporate debt securities (2)
  
438,426
   
   
438,426
   
 
Debt securities issued by U.S. government agencies (2)
  
89,253
   
   
89,253
   
 
Debt securities issued by the U.S. Treasury (2)
  
2,601
   
2,601
   
   
 
Debt securities issued by states of the United States and political subdivisions of the states (3)
  
127,656
   
   
127,656
   
 
Investment in Regulus Therapeutics Inc.
  
24,792
   
24,792
   
   
 
Total
 
$
771,630
  
$
116,295
  
$
655,335
  
$
 

  
At
December 31, 2014
  
Quoted Prices in
Active Markets
(Level 1)
  
Significant Other
Observable
Inputs
(Level 2)
  
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents (1)
 
$
104,680
  
$
104,680
  
$
  
$
 
Corporate debt securities (4)
  
372,002
   
   
372,002
   
 
Debt securities issued by U.S. government agencies (2)
  
109,855
   
   
109,855
   
 
Debt securities issued by the U.S. Treasury (5)
  
19,017
   
19,017
   
   
 
Debt securities issued by states of the United States and political subdivisions of the states (6)
  
105,033
   
   
105,033
   
 
Investment in Regulus Therapeutics Inc.
  
81,881
   
   
   
81,881
 
Total
 
$
792,468
  
$
123,697
  
$
586,890
  
$
81,881
 


(1)Included in cash and cash equivalents on our consolidated balance sheet.

(2)Included in short-term investments on our consolidated balance sheet.

(3)$7.5 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(4)$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(5)$10 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(6)$9.3 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

In the first quarter of 2014, Achaogen completed an initial public offering. As a result, we stopped using the cost method of accounting for our equity investment in Achaogen and instead we began accounting for it at fair value. Until September 2014, the fair value of our investment in Achaogen included a lack of marketability discount because there were restrictions on when we could trade the securities. As such, we classified our Achaogen stock as a Level 3 investment. In September 2014, we reclassified our investment in Achaogen to a Level 1 investment because the contractual trading restrictions on the shares we owned ended and we subsequently sold all of our shares in 2014.

In November 2014, Regulus completed a public offering. As part of the offering, we sold shares of Regulus' common stock and became subject to trading restrictions on our remaining shares through January 2015. Therefore, at December 31, 2014, we recorded a lack of marketability discount on our investment in Regulus and classified it as a Level 3 investment. At the end of January 2015, we reclassified our investment in Regulus to a Level 1 investment because the contractual trading restrictions on the shares we owned ended.

The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2015 and 2014 (in thousands):

  
Year Ended
December 31,
 
  
2015
  
2014
 
Beginning balance of Level 3 investments
 
$
81,881
  
$
 
Transfers into Level 3 investments
  
   
108,009
 
Total gains (losses) included in accumulated other comprehensive income (loss)
  
22,377
   
(24,897
)
Transfers out of Level 3 investments
  
(104,258
)
  
(1,231
)
Ending balance of Level 3 investments
 
$
  
$
81,881
 



Impact of recently issued accounting standards
 
In May 2014, the FASB issued accounting guidance on the recognition of revenue from customers. Under this guidance, an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects what the entity expects in exchange for the goods or services. This guidance also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance as originally issued is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016.
In July 2015, the FASB issued updated accounting guidance to allow for an optional one year deferral from the original effective date. As a result, we will adopt this guidance beginning on January 1, 2018. The guidance allows us to select one of two methods of adoption, either the full retrospective approach, meaning the guidance would be applied to all periods presented, or modified retrospective, meaning the cumulative effect of applying the guidance would be recognized as an adjustment to our opening retained earnings balance. We are currently determining the adoption method and timing as well as the effects the adoption will have on our consolidated financial statements and disclosures.

In August 2014, the FASB issued accounting guidance on how and when to disclose going-concern uncertainties in the financial statements. This guidance will require us to perform interim and annual assessments to determine our ability to continue as a going concern within one year from the date that we issue our financial statements. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016. We will adopt this guidance in our fiscal year beginning January 1, 2017. We do not expect this guidance to have any effect on our consolidated financial statements.

In February 2015, the FASB issued accounting guidance which amends existing consolidation guidance for entities that are required to evaluate whether they should consolidate certain legal entities. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015. We will adopt this guidance in our fiscal year beginning January 1, 2016. We do not expect this guidance to have any effect on our consolidated financial statements.

In April 2015, the FASB issued accounting guidance to simplify the presentation of debt issuance costs. The amended guidance requires us to present debt issuance costs as a direct deduction from the carrying amount of the related debt liability rather than as an asset. The guidance does not require us to change how we recognize and measure our debt issuance costs. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015, with early adoption permitted. We will adopt this guidance in our fiscal year beginning January 1, 2016. We do not expect this guidance to have a material impact on our consolidated financial statements.

In April 2015, the FASB issued accounting guidance to clarify the accounting for fees paid in cloud computing arrangements. The amendment provides guidance to customers about whether a cloud computing arrangement includes a software license element consistent with the acquisition of other software licenses or if the arrangement excludes a software license and should be accounted for as a service contract. The guidance does not change the accounting for service contracts. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015. We will adopt this guidance in our fiscal year beginning January 1, 2016 on a prospective basis. We do not expect this guidance to have a material impact on our consolidated financial statements.

In July 2015, the FASB issued accounting guidance to simplify the remeasurement of inventory. The amended guidance applies to entities that value inventory under methods other than last-in first-out (LIFO) or the retail inventory method and applies to us because we value our inventory under the FIFO method. The amended guidance requires us to measure our inventory at the lower of cost and net realizable value. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015 on a prospective basis. We will adopt this guidance in our fiscal year beginning January 1, 2016. We do not expect this guidance to have any effect on our consolidated financial statements.

In November 2015, the FASB issued accounting guidance to simplify the classification of deferred income tax assets and liabilities to always be classified as current, compared to the previous treatment, which required us to allocate our deferred tax assets between current and noncurrent. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016 on a prospective or retrospective basis, with early adoption permitted. We adopted this guidance on a prospective basis and reflected it in our consolidated balance sheet at December 31, 2015.

In January 2016, the FASB issued amended accounting guidance related to the recognition, measurement, presentation, and disclosure of certain financial instruments. The amended guidance requires us to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and for us to recognize the changes in fair value in our net income (loss), instead of recognizing changes in value through accumulated other comprehensive income, as we currently do under the existing guidance. The amended guidance also changes several disclosure requirements for financial instruments, including the methods and significant assumptions we use to estimate fair value. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2017. We will adopt this guidance on January 1, 2018 and we will make any adjustments to beginning balances through a cumulative-effect adjustment to accumulated deficit on that date. We are currently determining the effects the adoption will have on our consolidated financial statements and disclosures.

XML 42 R11.htm IDEA: XBRL DOCUMENT v3.3.1.900
Investments
12 Months Ended
Dec. 31, 2015
Investments [Abstract]  
Investments
2. Investments

As of December 31, 2015, we have primarily invested our excess cash in debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody’s, S&P or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.


The following table summarizes the contract maturity of the available-for-sale securities we held as of December 31, 2015:

One year or less
 
49 %
After one year but within two years
 
27 %
After two years but within three and a half years
 
24 %
Total
 
100 %

As illustrated above, at December 31, 2015, 76 percent of our available-for-sale securities had a maturity of less than two years.

All of our available-for-sale securities are available to us for use in our current operations. As a result, we categorize all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.

At December 31, 2015, we had an ownership interest of less than 20 percentin one private company and two public companies with which we conduct business. The privately held company is Atlantic Pharmaceuticals Limited and the publicly traded companies are Antisense Therapeutics Limited and Regulus. We account for equity investments in the privately held company under the cost method of accounting and we account for equity investments in the publicly traded companies at fair value. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments.

During 2015, 2014 and 2013, we realized a net gain on investments we sold of $20.3 million, $21.2 million, and $2.4 million, respectively. Our net gain for 2015 and 2014 was primarily from the $20.2 million and $19.9 million gain we realized when we sold a portion of our stock in Regulus, respectively. We have reflected this gain in a separate line called “Gain on investment in Regulus Therapeutics Inc.”, on our Consolidated Statements of Operations. Our net gain on investments for 2013 related to the sale of stock in several of our satellite companies. As of December 31, 2015, we owned approximately five percent of Regulus’ equity, with a carrying balance of $24.8 million on our consolidated balance sheet.

The following is a summary of our investments (in thousands):

   
Gross Unrealized
   
December 31, 2015
 
Cost
  
Gains
  
Losses
  
Estimated
Fair Value
 
Available-for-sale securities (1):
        
Corporate debt securities
 
$
181,670
  
$
5
  
$
(250
)
 
$
181,425
 
Debt securities issued by U.S. government agencies
  
50,559
   
1
   
(19
)
  
50,541
 
Debt securities issued by the U.S. Treasury
  
2,604
   
   
(3
)
  
2,601
 
Debt securities issued by states of the United States and political subdivisions of the states (2)
  
79,414
   
18
   
(88
)
  
79,344
 
Total securities with a maturity of one year or less
  
314,247
   
24
   
(360
)
  
313,911
 
Corporate debt securities
  
258,703
   
3
   
(1,705
)
  
257,001
 
Debt securities issued by U.S. government agencies
  
38,956
   
   
(244
)
  
38,712
 
Debt securities issued by states of the United States and political subdivisions of the states
  
48,552
   
3
   
(243
)
  
48,312
 
Total securities with a maturity of more than one year
  
346,211
   
6
   
(2,192
)
  
344,025
 
Total available-for-sale securities
 
$
660,458
  
$
30
  
$
(2,552
)
 
$
657,936
 
Equity securities:
                
Regulus Therapeutics Inc.
 
$
7,162
  
$
17,630
  
$
  
$
24,792
 
Total equity securities
 
$
7,162
  
$
17,630
  
$
  
$
24,792
 
Total available-for-sale and equity securities
 
$
667,620
  
$
17,660
  
$
(2,552
)
 
$
682,728
 

   
Gross Unrealized
   
December 31, 2014
 
Cost
  
Gains
  
Losses
  
Estimated
Fair Value
 
Available-for-sale securities (1):
        
Corporate debt securities (2)
 
$
219,856
  
$
89
  
$
(89
)
 
$
219,856
 
Debt securities issued by U.S. government agencies
  
47,496
   
7
   
(27
)
  
47,476
 
Debt securities issued by the U.S. Treasury (2)
  
19,008
   
9
   
   
19,017
 
Debt securities issued by states of the United States and political subdivisions of the states (2)
  
45,196
   
19
   
(53
)
  
45,162
 
Total securities with a maturity of one year or less
  
331,556
   
124
   
(169
)
  
331,511
 
Corporate debt securities
  
152,730
   
16
   
(600
)
  
152,146
 
Debt securities issued by U.S. government agencies
  
62,530
   
   
(151
)
  
62,379
 
Debt securities issued by states of the United States and political subdivisions of the states
  
60,073
   
32
   
(234
)
  
59,871
 
Total securities with a maturity of more than one year
  
275,333
   
48
   
(985
)
  
274,396
 
Total available-for-sale securities
 
$
606,889
  
$
172
  
$
(1,154
)
 
$
605,907
 
Equity securities:
                
Regulus Therapeutics Inc.
 
$
12,477
  
$
69,404
  
$
  
$
81,881
 
Total equity securities
 
$
12,477
  
$
69,404
  
$
  
$
81,881
 
Total available-for-sale and equity securities
 
$
619,366
  
$
69,576
  
$
(1,154
)
 
$
687,788
 

(1)Our available-for-sale securities are held at amortized cost.

(2)Includes investments classified as cash equivalents on our consolidated balance sheet.
Investments we consider to be temporarily impaired at December 31, 2015 are as follows (in thousands):

    
Less than 12 months of
Temporary Impairment
  
More than 12 months of
Temporary Impairment
  
Total Temporary
Impairment
 
  
Number of
Investments
  
Estimated
Fair Value
  
Unrealized
Losses
  
Estimated
Fair Value
  
Unrealized
Losses
  
Estimated
Fair Value
  
Unrealized
Losses
 
Corporate debt securities
  
397
  
$
406,098
  
$
(1,908
)
 
$
16,066
  
$
(47
)
 
$
422,164
  
$
(1,955
)
Debt securities issued by U.S. government agencies
  
19
   
71,842
   
(262
)
  
1,001
   
(1
)
  
72,843
   
(263
)
Debt securities issued by the U.S. Treasury
  
2
   
2,601
   
(3
)
  
   
   
2,601
   
(3
)
Debt securities issued by states of the United States and political subdivisions of the states
  
230
   
59,882
   
(173
)
  
29,634
   
(158
)
  
89,516
   
(331
)
Total temporarily impaired securities
  
648
  
$
540,423
  
$
(2,346
)
 
$
46,701
  
$
(206
)
 
$
587,124
  
$
(2,552
)

We believe that the decline in value of these securities is temporary and primarily related to the change in market interest rates since purchase. We believe it is more likely than not that we will be able to hold these securities to maturity. Therefore, we anticipate full recovery of their amortized cost basis at maturity.

XML 43 R12.htm IDEA: XBRL DOCUMENT v3.3.1.900
Long-Term Obligations and Commitments
12 Months Ended
Dec. 31, 2015
Long-Term Obligations and Commitments [Abstract]  
Long-Term Obligations and Commitments
3. Long-Term Obligations and Commitments

The carrying value of our long-term obligations was as follows (in thousands):

  
December 31,
 
  
2015
  
2014
 
1 percent convertible senior notes
 
$
347,214
  
$
327,486
 
2¾ percent convertible senior notes
  
50,361
   
48,014
 
Long-term financing liability for leased facility
  
72,217
   
71,731
 
Equipment financing arrangement
  
515
   
3,226
 
Leases and other obligations
  
2,341
   
7,325
 
Total
 
$
472,648
  
$
457,782
 
Less: current portion
  
(515
)
  
(2,882
)
Total Long-Term Obligations
 
$
472,133
  
$
454,900
 

Convertible Notes

In November 2014, we completed a $500 million offering of convertible senior notes, which mature in 2021 and bear interest at 1 percent. We raised $487 million of proceeds, net of issuance costs. We used a substantial portion of the net proceeds from the issuance of the 1 percent convertible senior notes to repurchase $140 million in principal of our 2¾ percent convertible senior notes at a price of $441.9 million, including accrued interest. As a result, the new principal balance of the 2¾ percent notes is $61.2 million. We recognized an $8.3 million non-cash loss as a result of the early retirement of a portion of the 2¾ percent notes.

At December 31, 2015 we had the following convertible debt outstanding (amounts in millions except price per share data):

  
1 Percent
Convertible Senior Notes
  
2¾ Percent
Convertible Senior Notes
 
Outstanding balance
 
$
500
  
$
61
 
Issue date
 
November 2014
  
August 2012
 
Maturity date
 
November 2021
  
October 2019
 
Interest rate
 
1 percent
  
2¾ percent
 
Conversion price per share
 
$
66.81
  
$
16.63
 
Total shares of common stock subject to conversion
  
7.5
   
3.7
 

Interest is payable semi-annually in arrears on May 15 and November 15 of each year for the 1 percent notes and on April 1 and October 1 for the 2 ¾ percent notes.

The 1 percent notes are convertible at the option of the note holders prior to July 1, 2021 only under certain conditions. On or after July 1, 2021, the notes are initially convertible into approximately 7.5 million shares of common stock at a conversion price of approximately $66.81 per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the 1 percent notes prior to maturity, and no sinking fund is provided for them. If we undergo a fundamental change, holders may require us to purchase for cash all or any portion of their 1 percent notes at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.

The 2¾ percent notes are convertible at the option of the note holders prior to July 1, 2019 only under certain conditions. On or after July 1, 2019, the notes are convertible into approximately 3.7 million shares of common stock at a conversion price of approximately $16.63 per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We can redeem the 2¾ percent notes at our option, in whole or in part, on or after October 5, 2016 if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the trading day immediately preceding the date we provide the redemption notice exceeds 130 percent of the applicable conversion price for the 2¾ percent notes on each such day. The redemption price for the 2¾ percent notes will equal 100 percent of the principal amount being redeemed, plus accrued and unpaid interest, plus $90 per each $1,000 principal amount being redeemed. Holders of the 2¾ percent notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indenture governing these notes, at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest.

For the 2¾ percent notes, the price of our common stock exceeded the conversion threshold price during the quarter ended December 31, 2015. As a result, the 2¾ percent notes are convertible at the option of the holders during the quarter ending March 31, 2016. As of December 31, 2015, the if-converted value of the 2¾ percent notes, which assumes that the notes will be converted into shares of our common stock, exceeded the principal amount by $166.9 million. We did not include the potential effect of the conversion of our convertible notes into our common stock in the computation of diluted net loss per share because the effect would have been anti-dilutive.

We account for our convertible notes using an accounting standard that requires us to assign a value to our convertible debt equal to the estimated fair value of similar debt instruments without the conversion feature and to record the remaining portion in equity. As a result, we recorded our convertible notes at a discount, which we are amortizing as additional non-cash interest expense over the expected life of the respective debt. We determined our nonconvertible debt borrowing rate using a combination of the present value of the debt’s cash flows and a Black-Scholes valuation model. The following table summarizes the nonconvertible borrowing rate, effective interest rate and amortization period of our debt discount for our convertible notes:

 
1 Percent
Convertible Senior Notes
2¾ Percent
Convertible Senior Notes
Nonconvertible debt borrowing rate
7.4 percent
8.0 percent
Effective interest rate
7.8 percent
 8.8 percent
Amortization period of debt discount
7 years
7 years

Interest expense for the year ended December 31, 2015, 2014 and 2013 included $23.2 million, $9.6 million and $6.8 million, respectively, of non-cash interest expense related to the amortization of the debt discount and debt issuance costs for our convertible notes.

The following table summarizes information about the equity and liability components of our outstanding convertible notes, (in thousands). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement:

  
December 31,
 
  
2015
  
2014
 
2¾ Percent Convertible Senior Notes
    
Fair value of outstanding notes
 
$
215,320
  
$
223,900
 
Principal amount of convertible notes outstanding
 
$
61,247
  
$
61,247
 
Unamortized portion of debt discount
 
$
10,886
  
$
13,233
 
Long-term debt
 
$
50,361
  
$
48,014
 
Carrying value of equity component
 
$
18,714
  
$
18,714
 
         
1 Percent Convertible Senior Notes
        
Fair value of outstanding notes
 
$
555,000
  
$
568,000
 
Principal amount of convertible notes outstanding
 
$
500,000
  
$
500,000
 
Unamortized portion of debt discount
 
$
152,786
  
$
172,514
 
Long-term debt
 
$
347,214
  
$
327,486
 
Carrying value of equity component
 
$
174,770
  
$
174,770
 

Financing Arrangements

In June 2015, we entered into a five-year revolving line of credit agreement with Morgan Stanley Private Bank, National Association, or Morgan Stanley. We amended the credit agreement in February 2016 to increase the amount available for us to borrow. Under the amended credit agreement, we can borrow up to a maximum of $30 million of revolving credit for general working capital purposes. Under the credit agreement interest is payable monthly in arrears on the outstanding principal at a rate based on our option of:

(i)
a floating rate equal to the one-month London Interbank Offered Rate, or LIBOR, in effect plus 1.25 percent per annum;
(ii)
a fixed rate equal to LIBOR plus 1.25 percent for a period of one, two, three, four, six, or twelve months as elected by us; or
(iii)
a fixed rate equal to the LIBOR swap rate during the period of the loan.

Additionally, we will pay 0.25 percent per annum, payable quarterly in arrears, for any amount unused under the credit facility beginning after June 1, 2016. As of December 31, 2015 we had $8.5 million in outstanding borrowings under the credit facility, which were used to fund our capital equipment needs and is consistent with our historical practice to finance these costs. As of December 31, 2015, our outstanding borrowings under this credit facility were at a weighted average interest rate of 1.67 percent.

The credit agreement includes customary affirmative and negative covenants and restrictions. We are in compliance with all covenants of the credit agreement.

In October 2008, we entered into an equipment financing loan agreement. As of December 31, 2015, our outstanding borrowings under this loan agreement were at a weighted average interest rate of 4.39 percent. The carrying balance under this loan agreement at December 31, 2015 and 2014 was $0.5 million and $3.2 million, respectively. Our remaining outstanding balance is due in June 2016 and interest is payable monthly. 

Maturity Schedules

Annual debt and other obligation maturities, including fixed and determinable interest, at December 31, 2015 are as follows (in thousands):

2016
 
$
15,767
 
2017
  
6,744
 
2018
  
6,744
 
2019
  
6,744
 
2020
  
66,304
 
Thereafter
  
505,960
 
Subtotal
 
$
608,263
 
Less: current portion
  
(9,029
)
Less: fixed and determinable interest
  
(37,655
)
Less: unamortized portion of debt discount
  
(163,672
)
Plus: Deferred rent
  
2,006
 
Total
 
$
399,913
 

Operating Leases

We lease office, laboratory and manufacturing space under non-cancelable operating leases with terms through December 2031. We are located in three buildings in Carlsbad, California, which consists of laboratory, manufacturing and office space. Our facilities include a primary research and development facility, a manufacturing facility and a building adjacent to our manufacturing facility. We account for the lease of our primary research and development facility as a financing obligation as discussed below. Our manufacturing facility is used for our drug development business and was built to meet current Good Manufacturing Practices and the facility adjacent to our manufacturing facility has laboratory and office space that we use to support our manufacturing activities. The lease for our manufacturing facility expires in 2031 and has four five-year options to extend. Under the lease agreement, we have the option to purchase the facility at the end of each year from 2016 through 2020, and at the end of 2026 and 2031. The lease for the facility adjacent to our manufacturing facility has an initial term ending in June 2021 with an option to extend the lease for up to two five-year periods. Additionally, Akcea leases office space in a building in Cambridge, Massachusetts. The lease for Akcea has a three-year term and expires in July 2018. We also lease office equipment under non-cancelable operating leases with terms through June 2017.

Annual future minimum payments under operating leases as of December 31, 2015 are as follows (in thousands):

  
Operating
Leases
 
2016
 
$
1,879
 
2017
  
1,878
 
2018
  
1,597
 
2019
  
1,474
 
2020
  
1,527
 
Thereafter
  
16,125
 
Total minimum payments
 
$
24,480
 

Rent expense for the year ended December 31, 2015 was $2.0 million and was $1.8 million each of the years ended December 31, 2014 and 2013. We recognize rent expense on a straight line basis over the lease term for the lease on our manufacturing facility, the lease on our building adjacent to our manufacturing facility and Akcea’s office space, which resulted in a deferred rent balance of $2.0 million and $1.8 million at December 31, 2015 and 2014, respectively.

Research and Development Facility Lease Obligation

In March 2010, we entered into a lease agreement with an affiliate of BioMed Realty, L.P., or BioMed. Under the lease, BioMed constructed our primary research and development facility in Carlsbad, California. The lease expires in 2031 and has four five-year options to extend. Under the lease agreement, we have the option to purchase the facility and land at the end of each year from 2016 through 2020, and at the end of 2026 and 2031. To gain early access to the facility, we agreed to modify our lease with BioMed to accept additional responsibility. As a result, we recorded the costs for the facility as a fixed asset and we also recorded a corresponding liability in our non-current liabilities as a long-term financing obligation. In July 2011, we took possession of the facility and began depreciating the cost of the facility over its economic useful life. At December 31, 2015 and 2014, the facility and associated parcel of land had a net book value of $62.2 million and $64.4 million, respectively, which included $9.9 million and $7.7 million, respectively, of accumulated depreciation. We are applying our rent payments, which began on January 1, 2012, against the liability over the term of the lease.

In conjunction with the lease agreement with BioMed, we purchased a parcel of land for $10.1 million and subsequently sold it to BioMed. Since we have the option to purchase the facility, including the land, we have continuing involvement in the land, which requires us to account for the purchase and sale of the land as a financing transaction. As such, our property, plant and equipment at December 31, 2015 and 2014 included the value of the land. Additionally, we have recorded a corresponding amount in our non-current liabilities as a long-term financing obligation. Since land is not a depreciable asset, the value of the land and financing obligation we recorded will not change until we exercise our purchase option or the lease terminates.

Annual future rent payments as of December 31, 2015 for our primary research and development facility are as follows (in thousands):

  
Future Rent
Payments
 
2016
 
$
6,550
 
2017
  
6,550
 
2018
  
6,943
 
2019
  
6,943
 
2020
  
7,359
 
Thereafter
  
91,205
 
Total minimum payments
 
$
125,550
 

XML 44 R13.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stockholders' Equity
12 Months Ended
Dec. 31, 2015
Stockholders' Equity [Abstract]  
Stockholders' Equity
4. Stockholders’ Equity

Preferred Stock

We are authorized to issue up to 15,000,000 shares of “blank check” Preferred Stock. As of December 31, 2015, there were no shares of Preferred Stock outstanding. We have designated Series C Junior Participating Preferred Stock but have no issued or outstanding shares as of December 31, 2015.

Common Stock

At December 31, 2015 and 2014, we had 300,000,000 shares of common stock authorized, of which 120,351,480 and 118,442,726 were issued and outstanding, respectively. As of December 31, 2015, total common shares reserved for future issuance were 18,512,177.

During the years ending December 31, 2015, 2014 and 2013, we issued 1,908,000, 1,972,000 and 5,372,000 shares of common stock, respectively, for stock option exercises, vesting of restricted stock units, and ESPP purchases. We received net proceeds from these transactions of $24.9 million, $23.1 million and $63.0 million in 2015, 2014 and 2013, respectively.

Stock Plans

1989 Stock Option Plan

In June 1989, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that, as amended, provides for the issuance of non-qualified and incentive stock options for the purchase of up to 20,000,000 shares of common stock to our employees, directors, and consultants. The plan expires in January 2024. The 1989 Plan does not allow us to grant stock bonuses or restricted stock awards and prohibits us from repricing any options outstanding under the plan unless our stockholders approve the repricing. Options vest over a four-year period, with 25 percent exercisable at the end of one year from the date of the grant and the balance vesting ratably, on a monthly basis, thereafter and have a term of seven years. At December 31, 2015, a total of 3,619,716 options were outstanding, of which options to purchase 2,927,597 shares were exercisable, and 13,462 shares were available for future grant under the 1989 Plan.

2000 Broad Based Equity Incentive Plan

In January 2000, we adopted the 2000 Broad-Based Equity Incentive Plan (the 2000 Plan), which, as amended, provided for the issuance of non-qualified stock options for the purchase of up to 5,990,000 shares of common stock to our employees, directors, and consultants. Typically options expire seven or ten years from the date of grant. Options granted under this plan generally vest over a four-year period, with 25 percent exercisable at the end of one year from the date of the grant and the balance vesting ratably, on a monthly basis thereafter. At December 31, 2015, a total of 44,025 options were outstanding and exercisable, and no shares were available for future grant under the 2000 Plan. The 2000 Plan expired on January 5, 2010, so we may no longer grant new options under the 2000 Plan.

Change of Control Under 1989 Plan and 2000 Plan

With respect to both the 1989 Plan and 2000 Plan, in the event of:

a sale, lease or other disposition of all or substantially all of our assets;

a merger or consolidation in which we are not the surviving corporation; or

reverse merger in which we are the surviving corporation but the shares of common stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise,

then any surviving corporation or acquiring corporation will assume any stock awards outstanding under the 2000 Plan and the 1989 Plan or will substitute similar stock awards (including an award to acquire the same consideration paid to the shareholders in the transaction for those outstanding under the 2000 Plan and the 1989 Plan). In the event any surviving corporation or acquiring corporation refuses to assume such stock awards or to substitute similar stock awards for those outstanding under the 2000 Plan and the 1989 Plan, then with respect to stock awards held by participants whose continuous service has not terminated, such stock awards automatically vest in full and the stock awards will terminate if not exercised (if applicable) at or prior to such event.

2011 Equity Incentive Plan

In March 2011, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance cash awards to our employees, directors, and consultants. In June 2015, after receiving approval from our stockholders, we amended our 2011 Equity Incentive Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2011 Equity Incentive Plan from 5,500,000 to 11,000,000. The plan expires in June 2021. The 2011 Plan does not allow us to reduce the exercise price of any outstanding stock options or stock appreciation rights or cancel any outstanding stock options or stock appreciation rights that have an exercise price or strike price greater than the current fair market value of the common stock in exchange for cash or other stock awards unless our stockholders approve such action. Currently we anticipate awarding only options and restricted stock unit awards to our employees, directors and consultants. Under the 2011 Plan, stock options cannot vest in a period of less than two years and restricted stock unit awards cannot vest in a period of less than three years. We have granted restricted stock unit awards to our employees under the 2011 Plan which vest annually over a four-year period. At December 31, 2015, a total of 3,832,225 options were outstanding, of which 659,254 were exercisable, 712,034 restricted stock unit awards were outstanding, and 5,989,752 shares were available for future grant under the 2011 Plan.

Under the 2011 Plan, we may issue a stock award with additional acceleration of vesting and exercisability upon or after a change in control. In the absence of such provisions, no such acceleration will occur. The stock options and restricted stock unit awards we issue to our chief executive officer and chief operating officer will accelerate upon a change of control, as defined in the 2011 Plan.

Corporate Transactions and Change in Control under 2011 Plan

In the event of certain significant corporate transactions, our Board of Directors has the discretion to take one or more of the following actions with respect to outstanding stock awards under the 2011 Plan:

arrange for assumption, continuation, or substitution of a stock award by a surviving or acquiring entity (or its parent company);
arrange for the assignment of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award to the surviving or acquiring corporation (or its parent company);
accelerate the vesting and exercisability of a stock award followed by the termination of the stock award;
arrange for the lapse of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award;
cancel or arrange for the cancellation of a stock award, to the extent not vested or not exercised prior to the effective date of the corporate transaction, in exchange for cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and
arrange for the surrender of a stock award in exchange for a payment equal to the excess of (a) the value of the property the holder of the stock award would have received upon the exercise of the stock award, over (b) any exercise price payable by such holder in connection with such exercise.
 
2002 Non-Employee Directors’ Stock Option Plan

In September 2001, our Board of Directors adopted, and the stockholders subsequently approved, an amendment and restatement of the 1992 Non-Employee Directors’ Stock Option Plan, which provides for the issuance of non-qualified stock options and restricted stock units to our non-employee directors. The name of the resulting plan is the 2002 Non-Employee Directors’ Stock Option Plan (the 2002 Plan). In June 2015, after receiving approval from our stockholders, we amended our 2002 Non-Employee Directors Stock Option Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2002 Non-Employee Directors Stock Option Plan from 1,200,000 to 2,000,000. Options under this plan expire ten years from the date of grant. Options granted become exercisable in four equal annual installments beginning one year after the date of grant. At December 31, 2015, a total of 544,812 options were outstanding, of which 309,319 were exercisable, 38,621 restricted stock unit awards were outstanding, and 859,871 shares were available for future grant under the 2002 Plan.

Employee Stock Purchase Plan

In June 2009, our Board of Directors adopted, and the stockholders subsequently approved, the amendment and restatement of the ESPP and we reserved an additional 150,000 shares of common stock for issuance thereunder. In each of the subsequent years, we reserved an additional 150,000 shares of common stock for the ESPP resulting in a total of 3,224,596 million shares authorized under the plan as of December 31, 2015. The ESPP permits full-time employees to purchase common stock through payroll deductions (which cannot exceed 10 percent of each employee’s compensation) at the lower of 85 percent of fair market value at the beginning of the purchase period or the end of each six-month purchase period. Under the amended and restated ESPP, employees must hold the stock they purchase for a minimum of six months from the date of purchase. During 2015, employees purchased and we issued to employees 38,372 shares under the ESPP at a weighted average price of $37.43 per share. At December 31, 2015, there were 481,764 shares available for purchase under the ESPP.

Stock Option Activity

The following table summarizes the stock option activity for the year ended December 31, 2015 (in thousands, except per share and contractual life data):

  
Number of
Shares
  
Weighted
Average Exercise
Price
Per Share
 
Average
Remaining
Contractual Term
(Years)
 
Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2014
  
7,379
  
$
19.52
   
Granted
  
2,550
  
$
61.02
   
Exercised
  
(1,674
)
 
$
14.07
   
Cancelled/forfeited/expired
  
(214
)
 
$
42.43
   
Outstanding at December 31, 2015
  
8,041
  
$
33.21
   
4.57
  
$
232,581
 
Exercisable at December 31, 2015
  
3,940
  
$
16.43
   
3.32
  
$
179,273
 

The weighted-average estimated fair values of options granted were $27.44, $17.54 and $7.10 for the years ended December 31, 2015, 2014 and 2013, respectively. The total intrinsic value of options exercised during the years ended December 31, 2015, 2014 and 2013 were $84.7 million, $62.8 million and $69.6 million, respectively, which we determined as of the date of exercise. The amount of cash received from the exercise of stock options was $23.6 million, $22.4 million and $62.0 million for the years ended December 31, 2015, 2014 and 2013, respectively. For the year ended December 31, 2015, the weighted-average fair value of options exercised was $64.69. As of December 31, 2015, total unrecognized compensation cost related to non-vested stock-based compensation plans was $45.7 million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of 1.3 years.

Restricted Stock Unit Activity

The following table summarizes the RSU activity for the year ended December 31, 2015 (in thousands, except per share data):

  
Number of
Shares
  
Weighted
Average
Grant Date
Fair Value
Per Share
 
Non-vested at December 31, 2014
  
638
  
$
30.52
 
Granted
  
348
  
$
65.69
 
Vested
  
(196
)
 
$
27.40
 
Cancelled/forfeited
  
(39
)
 
$
42.87
 
Non-vested at December 31, 2015
  
751
  
$
47.47
 

For the years ended December 31, 2015, 2014 and 2013, the weighted-average grant date fair value of RSUs granted was $65.69, $44.94 and $17.42 per RSU, respectively. As of December 31, 2015, total unrecognized compensation cost related to RSUs was $16.0 million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of 1.2 years.

Stock-based Compensation Expense and Valuation Information

The following table summarizes stock-based compensation expense for the years ended December 31, 2015, 2014 and 2013 (in thousands), which was allocated as follows and includes $6.5 million of stock-based compensation expense for Akcea employees in 2015:

 
Year Ended
December 31,
 
 
2015
 
2014
 
2013
 
Research, development and patents
 
$
43,638
  
$
25,843
  
$
9,673
 
General and administrative
  
15,676
   
5,540
   
1,745
 
Total
 
$
59,314
  
$
31,383
  
$
11,418
 


Determining Fair Value

Valuation. We measure stock-based compensation expense for equity-classified awards, principally related to stock options, RSUs, and stock purchase rights under the ESPP at the grant date, based on the estimated fair value of the award and we recognize the expense over the employee’s requisite service period. We value RSUs based on the market price of our common stock on the date of grant.

We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP. The expected term of stock options granted represents the period of time that we expect them to be outstanding. We estimate the expected term of options granted based on actual and projected exercise patterns. We recognize compensation expense for stock options granted, RSUs, and stock purchase rights under the ESPP using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), an entity recognizes compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.

For the years ended December 31, 2015, 2014 and 2013, we used the following weighted-average assumptions in our Black-Scholes calculations:

Employee Stock Options:

 
December 31,
 
2015
 
2014
 
2013
Risk-free interest rate
1.5 %
 
1.7 %
 
1.1 %
Dividend yield
0.0 %
 
0.0 %
 
0.0 %
Volatility
53.8 %
 
50.1 %
 
51.1 %
Expected life
4.5 years
 
4.7 years
 
5.1 years

Board of Director Stock Options:

 
December 31,
 
2015
 
2014
 
2013
Risk-free interest rate
2.1 %
 
2.2 %
 
2.2 %
Dividend yield
0.0 %
 
0.0 %
 
0.0 %
Volatility
52.2 %
 
54.2 %
 
52.7 %
Expected life
6.9 years
 
6.9 years
 
7.2 years

ESPP:

 
December 31,
 
2015
 
2014
 
2013
Risk-free interest rate
0.1 %
 
0.1 %
 
0.1 %
Dividend yield
0.0 %
 
0.0 %
 
0.0 %
Volatility
51.7 %
 
60.1 %
 
62.9 %
Expected life
6 months
 
6 months
 
6 months

Risk-Free Interest Rate. We base the risk-free interest rate assumption on observed interest rates appropriate for the term of our stock option plans or ESPP.

Dividend Yield. We base the dividend yield assumption on our history and expectation of dividend payouts. We have not paid dividends in the past and do not expect to in the future.

Volatility. We use an average of the historical stock price volatility of our stock for the Black-Scholes model. We computed the historical stock volatility based on the expected term of the awards.

Expected Life. The expected term of stock options we have granted represents the period of time that we expect them to be outstanding. We estimated the expected term of options we have granted based on actual and projected exercise patterns.

Forfeitures. We reduce stock-based compensation expense for estimated forfeitures. We estimate forfeitures at the time of grant and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We estimate forfeitures based on historical experience. Our historical forfeiture estimates have not been materially different from our actual forfeitures.


XML 45 R14.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes
12 Months Ended
Dec. 31, 2015
Income Taxes [Abstract]  
Income Taxes
5. Income Taxes

The provisions for income taxes on income from continuing operations were as follows (in thousands):

  
Year Ended December 31,
 
  
2015
  
2014
  
2013
 
Current:
      
Federal
 
$
379
  
$
263
  
$
 
State
  
(7
)
  
(4,295
)
  
2
 
Total current
  
372
   
(4,032
)
  
2
 
             
Deferred:
            
Federal
  
   
(8,948
)
  
(5,082
)
State
  
   
(2,427
)
  
(834
)
Total deferred
  
   
(11,375
)
  
(5,916
)
Income tax expense (benefit)
 
$
372
  
$
(15,407
)
 
$
(5,914
)

In periods in which we have a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as other comprehensive income, intraperiod tax allocation rules require us to allocate the tax provision to the other categories of earnings. We then record a related tax benefit in continuing operations. During 2015, we recorded unrealized losses on our investments in available-for-sale securities in other comprehensive income, therefore we did not have to allocate our tax provision to our other categories of earnings. However, during 2014 and 2013, we recorded unrealized gains on our investments in available-for-sale securities and had to allocate our tax provision between continuing operations and other comprehensive income. As a result, for the years ended December 31, 2014 and 2013, we recorded a $12.8 million and $5.9 million tax benefit, respectively, in continuing operations and a $12.8 million and $5.9 million tax expense, respectively, in other comprehensive income.

In December 2014, we reached an agreement with the State of California Franchise Tax Board with regard to California franchise tax we paid for the tax year ended December 31, 2009. As part of the agreement, we received a franchise tax refund of $4.3 million in 2015 and our research credit carry-forward to December 31, 2010 increased by $4.3 million. We recognized an income tax benefit for the refund in the fourth quarter of 2014. The increase in our research credit carry-forward increased our deferred tax assets but did not impact our consolidated balance sheet as we recorded a full valuation allowance on our deferred tax assets.

The reconciliation between our effective tax rate on income from continuing operations and the statutory U.S. tax rate is as follows (in thousands):

  
Year Ended December 31,
 
  
2015
  
2014
  
2013
 
Pre-tax loss
 
$
(87,906
)
   
$
(54,391
)
   
$
(66,558
)
  
                   
Statutory rate
  
(30,767
)
  
35.0
%
  
(19,035
)
  
35.0
%
  
(23,295
)
  
35.0
%
State income tax net of federal benefit
  
1
   
0.0
%
  
(3,125
)
  
5.7
%
  
(3,823
)
  
5.7
%
Net change in valuation allowance
  
69,499
   
(79.1
)%
  
29,547
   
(54.3
)%
  
28,850
   
(43.3
)%
Loss on debt extinguishment
  
   
0.0
%
  
2,406
   
(4.4
)%
  
   
0.0
%
Tax credits
  
(41,284
)
  
47.0
%
  
(23,628
)
  
43.4
%
  
(15,839
)
  
23.8
%
California franchise tax refund
  
   
0.0
%
  
(2,795
)
  
5.1
%
  
   
0.0
%
Deferred tax true-up
  
1,496
   
(1.7
)%
  
977
   
(1.8
)%
  
8,023
   
(12.1
)%
Other
  
1,427
   
(1.6
)%
  
246
   
(0.5
)%
  
170
   
(0.2
)%
Effective rate
 
$
372
   
(0.4
)%
 
$
(15,407
)
  
28.2
%
 
$
(5,914
)
  
8.9
%

Significant components of our deferred tax assets and liabilities as of December 31, 2015 and 2014 are as follows (in thousands):

  
Year Ended
December 31,
 
  
2015
  
2014
 
Deferred Tax Assets:
    
Net operating loss carryovers
 
$
218,493
  
$
231,654
 
R&D credits
  
153,601
   
93,594
 
Deferred revenue
  
45,110
   
58,836
 
Stock-based compensation
  
31,093
   
21,553
 
Other
  
19,655
   
15,549
 
Total deferred tax assets
 
$
467,952
  
$
421,186
 
         
Deferred Tax Liabilities:
        
Convertible debt
 
$
(55,928
)
 
$
(73,733
)
Unrealized gain in other comprehensive income
  
(5,288
)
  
(27,878
)
Intangible and capital assets
  
(2,643
)
  
(3,641
)
Net deferred tax asset
 
$
404,093
  
$
315,934
 
Valuation allowance
  
(404,093
)
  
(315,934
)
         
Net deferreds
 
$
  
$
 



We have net deferred tax assets relating primarily to net operating loss carryforwards, or NOL’s, and research and development tax credit carryforwards. Subject to certain limitations, we may use these deferred tax assets to offset taxable income in future periods. Since we have a history of losses and the likelihood of future profitability is not assured, we have provided a full valuation allowance for the deferred tax assets in our balance sheet as of December 31, 2015. If we determine that we are able to realize a portion or all of these deferred tax assets in the future, we will record an adjustment to increase their recorded value and a corresponding adjustment to increase income or additional paid in capital, as appropriate, in that same period.

We recognize excess tax benefits associated with share-based compensation to stockholders' equity only when realized. We follow the with-and-without approach excluding any indirect effects of the excess tax deductions to determine when we should realize excess tax benefits relating to share-based compensation. Under this approach, we do not realize our excess tax benefits related to share-based compensation until after we utilize all other our tax benefits available to us. During the year ended December 31, 2015, we realized $0.4 million of such excess tax benefits, and accordingly, we recorded a corresponding credit to additional paid-in capital.  As of December 31, 2015, we had $76.9 million of unrealized excess tax benefits associated with share-based compensation. We will account for the tax benefits as a credit to additional paid-in capital, if and when we realize them, rather than a reduction of the provision for income taxes.

At December 31, 2015, we had federal and California tax net operating loss carryforwards of approximately $734.7 million and $886.5 million, respectively. Our federal tax loss carryforwards will begin to expire in 2023, unless we use them before then. Our California loss carryforwards continue to expire in 2015. At December 31, 2015, we also had federal and California research and development tax credit carryforwards of approximately $146.8 million and $44.7 million, respectively. Our Federal research and development tax credit carryforwards begin to expire in 2018. Our California research and development tax credit carryforwards are available indefinitely. In 2009, we had a substantial amount of taxable income and we used a portion of our Federal NOL carryforwards to reduce our federal income taxes.

We analyze filing positions in all of the federal and state jurisdictions where we file income tax returns, and all open tax years in these jurisdictions to determine if we have any uncertain tax positions on any of our income tax returns. We recognize the impact of an uncertain tax position on an income tax return at the largest amount that the relevant taxing authority is more-likely-than not to sustain upon audit. We do not recognize uncertain income tax positions if they have less than 50 percent likelihood of the applicable tax authority sustaining our position.

The following table summarizes our gross unrecognized tax benefits (in thousands):

  
Year Ended December 31,
 
  
2015
  
2014
  
2013
 
Beginning balance of unrecognized tax benefits
 
$
27,365
  
$
23,964
  
$
10,872
 
Decrease for prior period tax positions
  
   
(1,653
)
  
 
Increase for prior period tax positions
  
215
   
   
9,821
 
Increase for current period tax positions
  
23,677
   
5,054
   
3,271
 
Ending balance of unrecognized tax benefits
 
$
51,257
  
$
27,365
  
$
23,964
 

At December 31, 2015 we had $33.3 million of tax benefits included in our unrecognized tax benefits that, if we recognized them, would reduce our annual effective tax rate subject to the valuation allowance.

We do not foresee any material changes to our gross unrecognized tax benefits within the next twelve months. We recognize interest and/or penalties related to income tax matters in income tax expense. We did not recognize any accrued interest and penalties related to gross unrecognized tax benefits during the year ended December 31, 2015.

Due to the carryforward of unutilized net operating losses and research and development credits, we are subject to taxation in the United States and various state jurisdictions. Our tax years for 1998 and forward are subject to examination by the U.S. tax authorities and our tax years for 2002 and forward are subject to examination by the California tax authorities.

XML 46 R15.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements
12 Months Ended
Dec. 31, 2015
Collaborative Arrangements and Licensing Agreements [Abstract]  
Collaborative Arrangements and Licensing Agreements
6. Collaborative Arrangements and Licensing Agreements

Strategic Partnerships

AstraZeneca

Cardiometabolic and Renal Diseases Collaboration

In July 2015, we and AstraZeneca formed a strategic collaboration to discover and develop antisense therapies for treating cardiovascular and metabolic diseases primarily focused on targets in the kidney, and renal diseases. As part of the agreement, we granted AstraZeneca an exclusive license to a preclinical program and the option to license a drug for each target advanced under this research collaboration. Upon acceptance of a drug development candidate, AstraZeneca will be responsible for all further global development, regulatory and commercialization activities for such drug. Under the terms of the agreement, we received a $65 million upfront payment. Since this agreement has multiple elements, we evaluated the deliverables in this arrangement and determined that none of the deliverables have stand-alone value because of the early stage of research for this collaboration. Therefore, we concluded there is one unit of accounting and we are amortizing the $65 million upfront payment through August 2021. We are eligible to receive license fees and substantive milestone payments of up to more than $4 billion, including up to $1.1 billion for the achievement of development milestones and up to $2.9 billion for regulatory milestones. We will earn the next milestone payment of $25 million under this collaboration upon identification of the first drug candidate to move into development. In addition, we are eligible to receive tiered royalties up to the low teens on sales from any product that AstraZeneca successfully commercializes under this collaboration agreement.

Oncology Collaboration

In December 2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense drugs for cancer. As part of the agreement, we granted AstraZeneca an exclusive license to develop and commercialize IONIS-STAT3-2.5Rx for the treatment of cancer and an option to license up to three anti-cancer drugs under a separate research program. AstraZeneca is responsible for all global development, regulatory and commercialization activities for IONIS-STAT3-2.5Rx. We and AstraZeneca have evaluated IONIS-STAT3-2.5Rx in patients with advanced metastatic hepatocellular carcinoma and advanced lymphoma. AstraZeneca is evaluating IONIS-STAT3-2.5Rx in combination with MEDI4736, AstraZeneca's investigational anti-PD-L1 drug, in patients with head and neck cancer. For the research program, we are responsible for identifying a development candidate for each of the three anti-cancer research programs. AstraZeneca has the option to license drugs resulting from each of the three anti-cancer research programs, and if AstraZeneca exercises its option for a drug, it will be responsible for all further global development, regulatory and commercialization activities for such drug.

Under the terms of the agreement, we received $31 million in upfront payments. We recorded revenue of $11.5 million upon receipt of these payments and we have amortized $11.9 million into revenue as we have performed development activities under this collaboration. We are recognizing the remaining $7.6 million related to the option to license three drugs under the research program through December 2016. In January 2016, we and AstraZeneca amended the agreement for the research program. Under the amended terms of the agreement, we can earn an additional $5 million in milestone payments for advancing a drug under our research program.

We are eligible to receive milestone payments and license fees from AstraZeneca as programs advance in development. In addition, we are eligible to receive tiered royalties up to the low to mid-teens on sales from any drugs resulting from these programs. If AstraZeneca successfully develops IONIS-STAT3-2.5Rx and the three drugs under the research program, we could receive license fees and substantive milestone payments of nearly $750 million, including up to $226 million for the achievement of development milestones and up to $485 million for the achievement of regulatory milestones. From inception through December 2015, we have received $63.5 million in milestone payments and upfront fees under this oncology collaboration. We will earn the next milestone payment of $15 million if we further advance a cancer drug under our research program with AstraZeneca.

Each of our agreements with AstraZeneca will continue until the expiration of all payment obligations under the applicable agreement. In addition, the agreement, or any program under the applicable agreement, may terminate early under the following situations:

AstraZeneca may terminate the agreement or any program at any time by providing written notice to us;
AstraZeneca may terminate the agreement or any program by providing written notice if we undergo a change of control with a third party; and
Either we or AstraZeneca may terminate the agreement or any program by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement, or the entire agreement if the other party becomes insolvent.

During 2015, 2014 and 2013 we earned revenue of $6.4 million, $27.7 million and $29.1 million, respectively, from our relationship with AstraZeneca, which represented two percent, 13 percent and 20 percent, respectively, of our total revenue for those periods. Our balance sheets at December 31, 2015 and 2014 included deferred revenue of $63.3 million and $4.4 million, respectively, related to our relationship with AstraZeneca.

Biogen

We have established four strategic collaborations with Biogen focused on using antisense technology to advance the treatment of neurological and neuromuscular disorders. These collaborations combine our expertise in creating antisense drugs with Biogen's expertise in developing therapies for neurological disorders. We and Biogen are currently developing six drugs to treat neurological diseases under these collaborations, including nusinersen, IONIS-DMPK-2.5Rx, IONIS-SOD1Rx, formerly ISIS-BIIB3Rx, and three drugs to treat undisclosed neurodegenerative diseases, IONIS-BIIB4Rx, IONIS-BIIB5Rx, and IONIS-BIIB6Rx. In addition to these six drugs, we and Biogen are evaluating numerous additional targets for the development of drugs to treat neurological diseases.

Nusinersen

In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize nusinersen for the treatment of SMA. We are currently conducting a Phase 3 study evaluating nusinersen in infants with SMA, which we expect to be fully enrolled in the second quarter of 2016. We are also conducting a Phase 3 study evaluating nusinersen in children with SMA, for which we have completed target enrollment. In addition, we are evaluating nusinersen in two Phase 2 open-label studies, one in children with SMA and one in infants with SMA. Patients from all of these studies continue to have access to nusinersen through open-label extension dosing. We are responsible for completing the studies we are currently conducting. Biogen has the option to license nusinersen. If Biogen exercises its option, it will pay us a license fee and will assume all other global development, regulatory and commercialization responsibilities. Biogen may exercise this option upon completion of and data review of the first successful Phase 2/3 trial or completion of both Phase 2/3 trials. An amendment in December 2014 provided for additional opt-in scenarios, based on the filing or the acceptance of a new drug application or marketing authorization application with the FDA or EMA. In June 2015, we and Biogen amended the development plan for nusinersen to include conducting the open-label extension study for the Phase 3 studies in infants and children. As a result of the change to the development plan, we earned an $11 million milestone payment when we initiated the Phase 3 open-label extension study and we are eligible to earn additional milestone and other payments.

Under the terms of the agreement, we received an upfront payment of $29 million, which we are amortizing through February 2017. We are also eligible to receive a license fee, milestone payments and tiered royalties up to the mid-teens on any sales of nusinersen. Over the term of the collaboration, we are eligible to receive up to $346 million in a license fee and payments, including up to $121 million in substantive milestone and other payments associated with the clinical development of nusinersen prior to licensing and up to $150 million in substantive milestone payments if Biogen achieves pre-specified regulatory milestones. From inception through December 2015, we have received more than $130 million in milestone payments and upfront fees for advancing nusinersen. In 2015, we earned $40 million for advancing the studies we are conducting in infants and children with SMA. In addition we earned a $2 million milestone payment in February 2016 for further advancing the Phase 3 study of nusinersen in infants. We will earn the next milestone payment of $2 million if we further advance the Phase 3 study of nusinersen in infants.

IONIS-DMPK-2.5Rx

In June 2012, we and Biogen entered into a second and separate collaboration agreement to develop and commercialize a novel antisense drug, IONIS-DMPK-2.5Rx, targeting DMPK for the treatment of myotonic dystrophy type 1, or DM1. We are responsible for global development of the drug through the completion of the first Phase 2 clinical trial. We are currently evaluating IONIS-DMPK-2.5Rx in a Phase 1/2 clinical study in patients with DM1. Biogen has the option to license the drug through the completion of the first Phase 2 trial. If Biogen exercises its option, it will assume all other global development, regulatory and commercialization responsibilities. Under the terms of the agreement, we received an upfront payment of $12 million, which we are amortizing through October 2018. In June 2015, we and Biogen amended the development plan for IONIS-DMPK-2.5Rx under which we are eligible to earn additional milestone payments of up to $4.2 million for further advancing the Phase 1/2 study of IONIS-DMPK-2.5Rx. Over the term of the collaboration, we are eligible to receive up to $263 million in a license fee and substantive milestone payments, including up to $63 million in development milestone payments and up to $130 million in milestone payments if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on any sales of IONIS-DMPK-2.5Rx. From inception through December 2015, we have received nearly $39 million in milestone payments and upfront fees for advancing IONIS-DMPK-2.5Rx, including a $2.8 million milestone payment we earned in November 2015. We will earn the next milestone payment of $1.4 million if we further advance the Phase 1/2 study for IONIS-DMPK-2.5Rx and we will earn a $35 million milestone payment if we initiate a Phase 2 study for IONIS-DMPK-2.5Rx.

Neurology

In December 2012, we and Biogen entered into a third and separate collaboration agreement to develop and commercialize novel antisense drugs to up to three targets to treat neurological or neuromuscular diseases. We are responsible for the development of each of the drugs through the completion of the initial Phase 2 clinical study for such drug. Biogen has the option to license a drug from each of the three programs through the completion of the first Phase 2 study for each program. We are currently advancing IONIS-BIIB4Rx under this collaboration. If Biogen exercises its option for a drug, it will assume all further global development, regulatory and commercialization responsibilities for that drug. Under the terms of the agreement, we received an upfront payment of $30 million, which we are amortizing through December 2020. Over the term of the collaboration, we are eligible to receive up to $259 million in a license fee and substantive milestone payments per program. We are eligible to receive up to $59 million in development milestone payments to support research and development of each program, including amounts related to the cost of clinical trials. We are also eligible to receive up to $130 million in milestone payments per program if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any drugs resulting from each of the three programs. In February 2015, we earned a $10 million milestone payment when we initiated an IND-enabling toxicology study of IONIS-BIIB4Rx, a drug for an undisclosed target designed to treat a neurodegenerative disease. From inception through December 2015, we have received $40 million in milestone payments and upfront fees under this collaboration, not including the $3 million milestone payment we earned in February 2016. We will earn the next milestone payment of up to $10 million for the continued development of IONIS-BIIB4Rx.

Strategic Neurology

In September 2013, we and Biogen entered into a fourth and separate collaboration agreement, which is a long-term strategic relationship focused on applying antisense technology to advance the treatment of neurological diseases. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for neurological diseases and has the option to license drugs resulting from this collaboration. The exclusivity for neurological diseases will last through September 2019, and may be extended for any drug development programs being pursued under the collaboration. We will usually be responsible for drug discovery and early development of antisense drugs and Biogen will have the option to license antisense drugs after Phase 2 proof of concept. We are currently advancing three drugs, IONIS-SOD1Rx, IONIS-BIIB5Rx, and IONIS-BIIB6Rx under this collaboration. If Biogen exercises its option for a drug, it will assume all further global development, regulatory and commercialization responsibilities for that drug. Biogen will be responsible for all of the drug discovery and development activities for drugs using other modalities.

Under the terms of the agreement, we received an upfront payment of $100 million and are eligible to receive milestone payments, license fees and royalty payments for all drugs developed through this collaboration, with the specific amounts dependent upon the modality of the molecule advanced by Biogen. If we have a change of control during the first six years of the collaboration, we may be required to refund Biogen a portion of the $100 million upfront payment, with the amount of the potential refund decreasing ratably as we progress through the initial six-year term of the collaboration. We are amortizing the $100 million upfront payment through September 2019. Because the amortization period for the upfront payment will never be less than the initial six-year term of the collaboration, the amount of revenue we recognize from the upfront payment will never exceed the amount that Biogen could potentially require us to refund.

For each antisense molecule that is chosen for drug discovery and development under this collaboration, we are eligible to receive up to approximately $260 million in a license fee and substantive milestone payments. We are eligible to receive up to approximately $60 million for the achievement of research and development milestones, including amounts related to the cost of clinical trials, and up to $130 million for the achievement of regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any antisense drugs developed under this collaboration. If other modalities are chosen, such as small molecules or monoclonal antibodies, we are eligible to receive up to $90 million in substantive milestone payments, including up to $35 million for the achievement of research and development milestones and up to $55 million for the achievement of regulatory milestones. In addition, we are eligible to receive tiered single-digit royalties on sales from any drugs using non-antisense modalities developed under this collaboration. From inception through December 2015, we have received $135 million in milestone payments and upfront fees under this collaboration. In December 2015, we earned a $5 million milestone payment for validating a fifth target under this collaboration. We will earn the next milestone payment of up to $10 million if we choose another target to advance under this collaboration.

Each of our agreements with Biogen will continue until the earlier of the date all of Biogen's options to obtain the exclusive licenses under the applicable agreement expire unexercised or, if Biogen exercises its option, until the expiration of all payment obligations under the applicable agreement. In addition, each agreement, or any program under an agreement, may terminate early under the following situations:

Biogen may terminate the agreement or any program at any time by providing written notice to us;
Under specific circumstances, if we are acquired by a third party with a product that directly competes with a compound being developed under the agreement, Biogen may terminate the affected program by providing written notice to us;
If, within a specified period of time, any required clearance of a transaction contemplated by an agreement under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, is not received, then either we or Biogen may terminate the affected program by providing written notice to the other party; and
Either we or Biogen may terminate any program by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement with respect to the affected program, or the entire agreement if the other party becomes insolvent.

During 2015, 2014 and 2013, we earned revenue of $106.2 million, $123.2 million and $37.0 million, respectively, from our relationship with Biogen, which represented 37 percent, 58 percent and 25 percent, respectively, of our total revenue for those periods. Our balance sheets at December 31, 2015 and 2014 included deferred revenue of $91.6 million and $118.1 million, respectively, related to our relationship with Biogen.

Research, Development and Commercialization Partners

Bayer

In May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXIRx for the prevention of thrombosis. We are responsible for completing our ongoing Phase 2 study of IONIS-FXIRx in patients with end-stage renal disease on hemodialysis. Bayer is responsible for all other development and commercialization activities for IONIS-FXIRx.

Under the terms of the agreement, we are eligible to receive $155 million in near-term payments, including a $100 million upfront payment we received in the second quarter of 2015 and a $55 million milestone payment that we are eligible to receive upon advancement of the program following the Phase 2 study in patients with end-stage renal disease on hemodialysis. We recorded revenue of $91.2 million related to the license for IONIS-FXIRx in June 2015 and we are recognizing the remaining $8.8 million related to the ongoing development activities for IONIS-FXIRx through July 2016.

Over the term of the agreement, we are eligible to receive up to $375 million in license fees, substantive milestone payments and other payments, including up to $120 million for the achievement of development milestones and up to $110 million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties in the low-to-high 20 percent range on gross margins of IONIS-FXIRx. We will earn the next milestone payment of $55 million upon the advancement of the program following the ongoing Phase 2 study of IONIS-FXIRx in patients with end-stage renal disease on hemodialysis.

Our agreement with Bayer will continue until the expiration of all payment obligations under the agreement. In addition, the agreement, or any program under the agreement, may terminate early under the following situations:

Bayer may terminate the agreement or any program at any time by providing written notice to us;
Either we or Bayer may terminate the agreement or any program by providing written notice to the other party upon the other party’s uncured failure to perform a material obligation under the agreement, or the entire agreement if the other party becomes insolvent.

During 2015 we earned revenue of $93.4 million, from our relationship with Bayer, which represented 33 percent of our total revenue for the period. Our consolidated balance sheet at December 31, 2015 included deferred revenue of $6.7 million related to our relationship with Bayer.

Genzyme Corporation, a Sanofi company

In January 2008, we entered into an alliance with Genzyme focused on the licensing and co-development of Kynamro. The license and co-development agreement provided Genzyme with exclusive worldwide rights for all therapeutic purposes to our patents and know-how related to Kynamro. The transaction included a $175 million licensing fee and a $150 million equity investment by Genzyme in our stock. From inception through December 2015, we have received $375 million in a license fee, milestone payments and an equity investment for advancing Kynamro in development. In January 2016, we terminated our license agreement with Genzyme.

During 2015 and 2014, we did not earn any revenue from our relationship with Genzyme. During 2013, we earned revenue of $32.5 million from our relationship with Genzyme, which represented 22 percent of our total revenue for that year.

GSK

In March 2010, we entered into an alliance with GSK using our antisense drug discovery platform to discover and develop new drugs against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness. Our alliance currently comprises five drugs in development, including our Phase 3 drug IONIS-TTRRx. GSK has the exclusive option to license drugs resulting from this alliance at Phase 2 proof-of-concept for a license fee. If GSK exercises its exclusive option for any drugs resulting from this alliance, it will be responsible for all further global development, regulatory and commercialization activities for such drug. Under the terms of the agreement, we received $38 million in upfront and expansion payments, which we are amortizing through March 2017.

In October 2012, we and GSK amended the original agreement to reflect an accelerated clinical development plan for IONIS-TTRRx. We are currently evaluating IONIS-TTRRx in a broad Phase 3 development program. We have completed target enrollment in the Phase 3 study in patients with FAP. From inception through December 2015, we have earned $60 million from GSK related to the development of IONIS-TTRRx, primarily in milestone payments. We are also eligible to earn an additional $10 million pre-licensing milestone payment associated with our ongoing study of IONIS-TTRRx. In addition, under the amended agreement, we and GSK increased the regulatory and commercial milestone payments we can earn should IONIS-TTRRx receive marketing authorization and meet pre-agreed sales targets. In September 2015, we and GSK amended the development plan for IONIS-TTRRx to support the Phase 3 cardiomyopathy study, which GSK plans to conduct.

In addition to IONIS-TTRRx, we have four drugs in development with GSK. We are developing two antisense drugs we designed to reduce the production of viral proteins associated with hepatitis B virus, or HBV, infection; IONIS-HBVRx and IONIS-HBV-LRx, a follow-on drug using our LICA technology. We are also developing IONIS-GSK4-LRx and IONIS-RHO-2.5Rx, which are antisense drugs we designed to treat ocular diseases.

Under our agreement, if GSK successfully develops all five drugs for one or more indications and achieves pre-agreed sales targets, we could receive license fees and substantive milestone payments of more than $1.0 billion, including up to $183.5 million for the achievement of development milestones, up to $363.5 million for the achievement of regulatory milestones and up to $348 million for the achievement of commercialization milestones. Through December 2015, we have received $135 million in milestone payments and upfront fees under this alliance with GSK, not including a $1.5 million payment we earned in January 2016 when GSK further advanced IONIS-HBV-LRx. We will earn the next milestone payment of up to $5 million if we further advance a program under this collaboration. In addition, we are eligible to receive tiered royalties up to the mid-teens on sales from any product that GSK successfully commercializes under this alliance.

Our alliance with GSK will continue until the earlier of the date that all of GSK's options to obtain the exclusive licenses under the agreement expire unexercised or, if GSK exercises its option, until the expiration of all payment obligations under the agreement. In addition, the agreement, or any program under the agreement, may terminate early under the following situations:

GSK may terminate any program, other than the IONIS-TTRRx program, at any time by providing written notice to us;
GSK may terminate the IONIS-TTRRx program by providing written notice to us after reviewing specific data from the Phase 3 study for the program; and
Either we or GSK may terminate any program by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement with respect to the affected program, or the entire agreement if the other party becomes insolvent.

During 2015, 2014 and 2013, we earned revenue of $33.3 million, $37.3 million and $35.3 million, respectively, from our relationship with GSK, which represented 12 percent, 17 percent and 24 percent, respectively, of our total revenue for those years. Our balance sheets at December 31, 2015 and 2014 included deferred revenue of $4.9 million and $10.0 million, respectively, related to our relationship with GSK.

Janssen Biotech, Inc., a pharmaceutical company of Johnson & Johnson

In December 2014, we entered into a collaboration agreement with Janssen Biotech, Inc. to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders of the gastrointestinal tract. Janssen has the option to license drugs from us through the designation of a development candidate for up to three programs. Prior to option exercise we are responsible for the discovery activities to identify a development candidate. If Janssen exercises an option for one of the programs, it will be responsible for the global development, regulatory and commercial activities under that program. Under the terms of the agreement, we received $35 million in upfront payments, which we are amortizing through December 2018. We are eligible to receive nearly $800 million in license fees and substantive milestone payments for these programs, including up to $175 million for the achievement of development milestones, up to $420 million for the achievement of regulatory milestones and up to $180 million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties up to the near teens on sales from any drugs resulting from this collaboration. We will earn the next milestone payment of $5 million if Janssen chooses another target to advance under this collaboration.

Our agreement with Janssen will continue until the earlier of the date that all of Janssen’s options to obtain the exclusive licenses under the agreement expire unexercised or, if Janssen exercises its option, until the expiration of all payment obligations under the agreement. In addition, the agreement, or any program under the agreement, may terminate early under the following situations:

Janssen may terminate the agreement or any program at any time by providing written notice to us; and
Either we or Janssen may terminate any program by providing written notice to the other party upon the other party’s uncured failure to perform a material obligation under the agreement, or the entire agreement if the other party becomes insolvent.

During 2015 we earned revenue of $8.9 million from our relationship with Janssen. During 2014 and 2013 we did not earn any revenue from our relationship with Janssen. Our balance sheet at December 31, 2015 included deferred revenue of $26.3 million related to our relationship with Janssen.

Roche

In April 2013, we formed an alliance with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, to develop treatments for Huntington's disease, or HD, based on our antisense technology. Roche has the option to license the drugs from us through the completion of the first Phase 1 trial. Under the agreement, we are responsible for the discovery and development of an antisense drug targeting huntingtin, or HTT, protein. We are currently evaluating a drug targeting HTT, IONIS-HTTRx, in a Phase 1/2 clinical study in patients with early stage HD. If Roche exercises its option, it will be responsible for global development, regulatory and commercialization activities for any drug arising out of the collaboration. We are also working collaboratively with Roche on the discovery of an antisense drug utilizing Roche's "brain shuttle" program. Under the terms of the agreement, we received an upfront payment of $30 million in April 2013, which we are amortizing through January 2017. We are eligible to receive up to $362 million in a license fee and substantive milestone payments including up to $67 million for the achievement of development milestones, up to $170 million for the achievement of regulatory milestones and up to $80 million for the achievement of commercialization milestones. In addition, we are eligible to receive up to $136.5 million in milestone payments for each additional drug successfully developed and up to $50 million in commercial milestone payments if a drug using Roche's proprietary brain shuttle technology is successfully commercialized. We are also eligible to receive tiered royalties up to the mid-teens on any product sales of drugs resulting from this alliance. Through December 2015, we have received $52 million in milestone payments and upfront fees under this alliance with Roche. We will earn the next milestone payment of $10 million if Roche initiates a Phase 2 trial for IONIS-HTTRx.

Our alliance with Roche will continue until the earlier of the date Roche's option to obtain the exclusive license under the agreement expires unexercised or, if Roche exercises its option, until the expiration of all payment obligations under the agreement. In addition, the agreement may terminate early under the following situations:

Roche may terminate the agreement at any time by providing written notice to us;
Either we or Roche may terminate the agreement by providing written notice to the other party upon the other party's uncured failure to perform a material obligation under the agreement or if the other party becomes insolvent; and
Either we or Roche may terminate the brain shuttle program if at least one development candidate is not designated under such program by a mutually agreed deadline.

During 2015, 2014 and 2013, we earned revenue of $31.2 million, $8.7 million and $5.1 million, respectively from our relationship with Roche, which represented 11 percent, four percent and three percent, respectively, of our total revenue for those years. Our balance sheet at December 31, 2015 and 2014 included deferred revenue of $8.8 million and $17.0 million, respectively related to our relationship with Roche.

Satellite Company Collaborations

Achaogen, Inc.

In 2006, we exclusively licensed to Achaogen, Inc. specific know-how, patents and patent applications relating to aminoglycosides. In exchange, Achaogen agreed to certain payment obligations related to aminoglycosides Achaogen developed. Achaogen is developing plazomicin, an aminoglycoside Achaogen discovered based on the technology we licensed to Achaogen. In connection with the license, Achaogen issued to us $1.5 million of Achaogen Series A Preferred Stock. If Achaogen successfully develops and commercializes two drugs under our agreement, we will receive payments totaling up to $49.3 million for the achievement of key clinical, regulatory and sales events. Through December 2015, we have earned $7 million in milestone payments from Achaogen, including a $4 million milestone payment we earned in September 2014 when Achaogen initiated a Phase 3 study of plazomicin in patients with serious multi-drug resistant, gram-negative bacterial infections. We will earn the next milestone payment of $7.5 million if Achaogen obtains regulatory approval for plazomicin in a major market. We are also eligible to receive royalties on sales of drugs resulting from the program. Achaogen is solely responsible for the continued development of plazomicin.

During 2015 and 2013, we did not earn any revenue from our relationship with Achaogen. During 2014 we earned revenue of $4 million from our relationship with Achaogen and we sold all of the Achaogen stock we owned resulting in net proceeds of $1.3 million.

Alnylam Pharmaceuticals, Inc.

In March 2004, we entered into an alliance with Alnylam to develop and commercialize RNAi therapeutics. Under the terms of the agreement, we exclusively licensed to Alnylam our patent estate relating to antisense motifs and mechanisms and oligonucleotide chemistry for double-stranded RNAi therapeutics in exchange for a $5 million technology access fee, participation in fees from Alnylam’s partnering programs, as well as future milestone and royalty payments from Alnylam. For each drug Alnylam develops under this alliance, we may receive up to $3.4 million in milestone payments, including up to $1.1 million for the achievement of development milestones and $2.3 million for regulatory milestones. We will earn the next milestone payment of $0.4 million if Alnylam initiates a Phase 1 study for a drug in Alnylam’s pipeline. We also have the potential to earn royalties on drug sales and a portion of payments that Alnylam receives from licenses of our technology it grants to its partners plus royalties. We retained rights to a limited number of double-stranded RNAi therapeutic targets and all rights to single-stranded RNAi, or ssRNAi, therapeutics.

In turn, Alnylam nonexclusively licensed to us its patent estate relating to antisense motifs and mechanisms and oligonucleotide chemistry to research, develop and commercialize single-stranded antisense therapeutics, ssRNAi therapeutics, and to research double-stranded RNAi compounds. We also received a license to develop and commercialize double-stranded RNAi drugs targeting a limited number of therapeutic targets on a nonexclusive basis. If we develop or commercialize an RNAi-based drug using Alnylam’s technology, we will pay Alnylam up to $3.4 million in milestone payments for specified development and regulatory events, plus royalties. To date, we do not have an RNAi-based drug in development.

In 2015, we and Alnylam entered into an alliance in which we formed an intellectual property cross-license under which we and Alnylam each obtained exclusive license rights to four therapeutic programs. Alnylam granted us an exclusive, royalty-bearing license to its chemistry, RNA targeting mechanism and target-specific intellectual property for oligonucleotides against four targets. In exchange, we granted Alnylam an exclusive, royalty-bearing license to our chemistry, RNA targeting mechanism and target-specific intellectual property for oligonucleotides against four targets. Alnylam also granted us a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for single-stranded antisense therapeutics. In turn, we granted Alnylam a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for double-stranded RNAi therapeutics. Through December 2015, we have received nearly $70 million from Alnylam.

During 2015, 2014 and 2013, we earned revenue from our relationship with Alnylam totaling $1.3 million, $9.9 million and $1.5 million, respectively.

Antisense Therapeutics Limited

In 2001 we licensed ATL1102 and ATL1103 to ATL, an Australian company publicly traded on the Australian Stock Exchange. ATL is currently undertaking a chronic toxicology study in primates to support a potential Phase 2b trial of ATL1102 in patients with multiple sclerosis, or MS. In addition, ATL is currently developing ATL1103 for growth and sight disorders. We are eligible to receive royalties on sales of ATL1102 and ATL1103. We may also receive a portion of the fees ATL receives if it licenses ATL1102 or ATL1103. At December 31, 2015 and 2014, we owned less than ten percent of ATL’s equity. During 2015, 2014 and 2013, we did not earn any revenue from our relationship with ATL. 

Atlantic Pharmaceuticals Limited

In March 2007, we licensed alicaforsen to Atlantic Pharmaceuticals, a UK-based specialty pharmaceutical company founded in 2006. Atlantic Pharmaceuticals is developing alicaforsen for the treatment of ulcerative colitis, or UC, and other inflammatory diseases. Atlantic Pharmaceuticals is initially developing alicaforsen for pouchitis, a UC indication, followed by UC and other inflammatory diseases. In exchange for the exclusive, worldwide license to alicaforsen, we received a $2 million upfront payment from Atlantic Pharmaceuticals in the form of equity. Under the agreement, we could receive milestone payments totaling up to $1.4 million for the achievement of regulatory milestones for multiple indications. We will earn the next milestone payment of $0.6 million if Atlantic Pharmaceuticals submits an NDA for alicaforsen with the FDA. In 2010, Atlantic Pharmaceuticals began supplying alicaforsen under international named patient supply regulations for patients with inflammatory bowel disease, or IBD, for which we receive royalties.

In 2010 and 2013, we agreed to sell Atlantic Pharmaceuticals alicaforsen drug substance in return for shares of Atlantic Pharmaceuticals’ common stock. Additionally, in 2013 we received an advance payment in the form of equity for the initial royalties that we will earn from Atlantic Pharmaceuticals. We recorded a full valuation allowance for all of the equity we received from Atlantic Pharmaceuticals, including the upfront payment, because realization of value from the equity is uncertain. At December 31, 2015 and 2014, we owned approximately 11 percent and 12 percent, respectively, of Atlantic Pharmaceuticals’ equity. We earned $0.7 million related to royalties and sales of drug substance in 2013. Because the payments were made in equity, we did not record any revenue. During 2015 and 2014, our revenue was negligible from our relationship with Atlantic Pharmaceuticals.

OncoGenex Technologies Inc., a subsidiary of OncoGenex Pharmaceuticals Inc.

Custirsen

In November 2001, we established a drug development collaboration with OncoGenex, a biotechnology company committed to the development of cancer therapeutics for patients with drug resistant and metastatic cancers, to co-develop and commercialize custirsen, an anti-cancer antisense drug that targets clusterin. OncoGenex is currently evaluating custirsen in two Phase 3 studies. In July 2008, we and OncoGenex amended the co-development agreement pursuant to which OncoGenex became solely responsible for the costs, development and commercialization of custirsen. In exchange, OncoGenex agreed to pay us royalties on sales of custirsen and to share consideration it receives from licensing custirsen to a third party, except for consideration OncoGenex receives for the fair market value of equity and reimbursement of research and development expenses. Under the amended agreement, we assigned to OncoGenex our rights in the patents claiming the composition and therapeutic methods of using custirsen and granted OncoGenex a worldwide, nonexclusive license to our know-how and patents covering our core antisense technology and manufacturing technology solely for use with custirsen. In addition, we agreed that so long as OncoGenex or its commercialization partner is using commercially reasonable efforts to develop and commercialize custirsen, we will not research, develop or commercialize an antisense compound designed to modulate clusterin. The amended agreement will continue until OncoGenex or its commercialization partner is no longer developing or commercializing custirsen or until we terminate the agreement for OncoGenex’s uncured failure to make a payment required under the agreement.

OGX-225

In August 2003, we and OncoGenex entered into a second and separate agreement for the development of an antisense anti-cancer drug, OGX-225. OncoGenex is responsible for all development costs and activities. OncoGenex issued to us $0.8 million of OncoGenex securities as payment for an upfront fee. In addition, OncoGenex will pay us milestone payments totaling up to $3.5 million for the achievement of key development and regulatory milestones, including up to $1.5 million for the achievement of development milestones and up to $2 million for the achievement of regulatory milestones. In addition, we are eligible to receive royalties on future product sales of OGX-225. As of December 31, 2015, OncoGenex had not achieved any milestone events related to OGX-225. We will earn the next milestone payment of $0.5 million if OncoGenex initiates a Phase 2 study for OGX-225.

Apatorsen

In January 2005, we entered into a third and separate agreement with OncoGenex to allow for the development of an additional antisense anti-cancer drug, apatorsen. OncoGenex and collaborators are evaluating apatorsen in multiple Phase 2 studies in patients with cancer. OncoGenex is responsible for all development costs and activities. OncoGenex will pay us milestone payments totaling up to $5.8 million for the achievement of key development and regulatory milestones, including up to $1.3 million for the achievement of development milestones and up to $4.5 million for the achievement of regulatory milestones. In addition, we are eligible to receive royalties on future product sales of the drug. We will earn the next milestone payment of $1.3 million if OncoGenex initiates a Phase 3 study for apatorsen.

During 2015, 2014 and 2013, we did not earn any revenue from our relationship with OncoGenex.

Regulus Therapeutics Inc.

In September 2007, we and Alnylam established Regulus as a company focused on the discovery, development and commercialization of microRNA-targeting therapeutics. We and Alnylam retain rights to develop and commercialize, on pre-negotiated terms, microRNA therapeutic products that Regulus decides not to develop either by itself or with a partner. Regulus is addressing therapeutic opportunities that arise from alterations in microRNA expression. Since microRNAs may act as master regulators of the genome, affecting the expression of multiple genes in a disease pathway, microRNA therapeutics define a new platform for drug discovery and development. MicroRNAs may also prove to be an attractive new tool for characterizing diseases. Regulus focuses its drug discovery and development efforts in numerous therapeutic areas, including cancer, fibrosis, and viral infections. Regulus currently has three drugs in clinical development. Regulus is evaluating RG-101 in a Phase 2 study in patients with HCV and in a Phase 1 study in patients with severe renal insufficiency or end-stage renal disease. Regulus is also evaluating RG-012 in a Phase 1 study to treat patients with Alport syndrome. Regulus and AstraZeneca are also evaluating RG-125 in a Phase 1 study for the treatment of NASH in patients with type 2 diabetes or pre-diabetes. We are eligible to receive royalties on any future product sales of these drugs.

During 2015, 2014 and 2013, we did not earn any revenue from our relationship with Regulus. During 2015 and 2014, we sold a portion of our Regulus stock, resulting in a gain of $20.2 million and $19.9 million, respectively, and proceeds of $25.5 million and $22.9 million, respectively. As of December 31, 2015, we owned approximately 2.8 million shares, approximately five percent of Regulus’ equity, with a net carrying value of $24.8 million.

External Project Funding

CHDI Foundation, Inc.

Starting in November 2007, CHDI provided financial and scientific support to our Huntington’s disease drug discovery program through our development collaboration. In April 2013, we formed an alliance with Roche to develop treatments for Huntington’s disease. Under the terms of our agreement with CHDI, we will reimburse CHDI for a portion of its support of our Huntington’s disease program out of the payments we receive from Roche. We made payments of $5 million and $3 million to CHDI in 2015 and 2013, respectively, associated with the progression of our Huntington’s disease program. If we achieve pre-specified milestones under our collaboration with Roche, we will make additional payments to CHDI up to $4 million, upon which our obligation to CHDI will be complete.

During 2015, our revenue earned from our relationship with CHDI was negligible and during 2014, we did not earn any revenue. During 2013, we earned revenue of $0.4 million from our relationship with CHDI.

The Ludwig Institute; Center for Neurological Studies

In October 2005, we entered into a collaboration agreement with the Ludwig Institute, the Center for Neurological Studies and researchers from these institutions to discover and develop antisense drugs for amyotrophic lateral sclerosis, or ALS, and other neurodegenerative diseases. Under this agreement, we agreed to pay the Ludwig Institute and Center for Neurological Studies modest milestone payments and royalties on any antisense drugs resulting from the collaboration.

Intellectual Property Sale and Licensing Agreements

Sales of Intellectual Property

Abbott Molecular Inc.

In January 2009, we sold our former subsidiary, Ibis Biosciences, to Abbott Molecular Inc., or AMI, pursuant to a stock purchase agreement for a total acquisition price of $215 million plus the earn out payments described below.

Under the stock purchase agreement, we are eligible to receive earn out payments from AMI equal to a percentage of Ibis’ revenue related to sales of Ibis systems, which AMI launched in 2014 as IRIDICA, including instruments, assay kits and successor products. Once cumulative net sales reach $140 million, and through December 31, 2025, we are eligible to earn out payments in any year that net sales exceed $50 million for the applicable year. The earn out payments will equal five percent of Ibis’ cumulative net sales over $140 million and up to $2.1 billion, and three percent of Ibis’ cumulative net sales over $2.1 billion. AMI may reduce these earn out payments from five percent to as low as 2.5 percent and from three percent to as low as 1.5 percent, respectively, upon the occurrence of certain events. During 2015, 2014 and 2013, we did not earn any revenue from our relationship with AMI.

In-Licensing Arrangements

University of Massachusetts

We have a license agreement with the University of Massachusetts under which we acquired an exclusive license to the University of Massachusetts’ patent rights related to nusinersen. If we successfully develop and commercialize a drug incorporating the technology we licensed from the University of Massachusetts, we will pay a milestone payment to the University of Massachusetts of $0.3 million for the achievement of a key regulatory milestone. In addition, we will pay the University of Massachusetts a portion of any sublicense revenue we receive in consideration for sublicensing its technology, and a royalty on sales of nusinersen in the United States if our product incorporates the technology we licensed from the University of Massachusetts.

Verva Pharmaceuticals Ltd.

We have a license agreement with Verva under which we acquired an exclusive license to Verva’s antisense patent rights related to IONIS-FGFR4Rx. If we successfully develop and commercialize a drug incorporating the technology Verva licensed to us, we will pay milestone payments to Verva totaling up to $6.1 million for the achievement of key patent, clinical, and regulatory milestones. If we convert our license from an exclusive license to a nonexclusive license we could significantly reduce the milestone payments due to Verva. In addition, we will also pay royalties to Verva on sales of IONIS-FGFR4Rx if our product incorporates the technology we licensed from Verva.

Cold Spring Harbor Laboratory

We have a collaboration and license agreement with the Cold Spring Harbor Laboratory under which we acquired an exclusive license to the Cold Spring Harbor Laboratory’s patent rights related to nusinersen. If we successfully develop and commercialize a drug incorporating the technology we licensed from the Cold Spring Harbor Laboratory, we will pay a portion of any sublicense revenue and post licensing milestone payments we receive in consideration for sublicensing the Cold Spring Harbor Laboratory’s technology up to $11.3 million and a royalty on sales of nusinersen if our product incorporates the technology we licensed from the Cold Spring Harbor Laboratory.

7. Segment Information and Concentration of Business Risk
XML 47 R16.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Information and Concentration of Business Risk
12 Months Ended
Dec. 31, 2015
Segment Information and Concentration of Business Risk [Abstract]  
Segment Information and Concentration of Business Risk

In 2015, we began reporting our financial results in two reportable segments, Ionis Core, previously referred to as Drug Discovery and Development, and Akcea Therapeutics, our wholly owned subsidiary. Segment loss from operations includes revenue less operating expenses attributable to each segment.

In our Ionis Core segment, we are exploiting a novel drug discovery platform we created to generate a broad pipeline of first-in-class or best-in-class drugs for us and our partners. Our Ionis Core segment generates revenue from a multifaceted partnering strategy.

We formed Akcea to develop and commercialize drugs for cardiometabolic disorders. Moving our lipid drugs into a company that we own and control ensures that our core focus at Ionis remains on innovation while allowing us to maintain control over and retain more value from our lipid drugs. To date, Akcea has not earned any revenue.

The following is our segment information for 2015 (in thousands):

2015
 
Ionis Core
  
Akcea Therapeutics
  
Elimination of Intercompany Activity
  
Total
 
Revenue:
        
Research and development
 
$
285,608
  
$
  
$
(4,248
)
 
$
281,360
 
Licensing and royalty
  
2,343
   
   
   
2,343
 
Total segment revenue
 
$
287,951
  
$
  
$
(4,248
)
 
$
283,703
 
Loss from operations
 
$
(21,378
)
 
$
(54,384
)
 
$
  
$
(75,762
)
Total assets
 
$
1,004,150
  
$
55,354
  
$
(103,399
)
 
$
956,105
 

The following is our segment information for 2014 and 2013 (in thousands) revised for comparative purposes to show operating expense for Akcea-related projects in 2014 and 2013:

2014
 
Ionis Core
  
Akcea Therapeutics
  
Total
 
Revenue:
      
Research and development
 
$
202,514
  
$
  
$
202,514
 
Licensing and royalty
  
11,647
   
   
11,647
 
Total segment revenue
 
$
214,161
  
$
  
$
214,161
 
Loss from operations
 
$
(26,033
)
 
$
(21,697
)
 
$
(47,730
)

2013
 
Ionis Core
  
Akcea Therapeutics
  
Total
 
Revenue:
      
Research and development
 
$
147,380
  
$
  
$
144,194
 
Licensing and royalty
  
3,091
   
   
3,091
 
Total segment revenue
 
$
150,471
  
$
  
$
147,285
 
Loss from operations
 
$
(38,764
)
 
$
(12,902
)
 
$
(51,666
)



We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10 percent or more of our total revenue, was as follows:

 
2015
 
2014
 
2013
Partner A
 
37 %
  
58 %
  
25 %
Partner B
 
33 %
  
0 %
  
0 %
Partner C
 
12 %
  
17 %
  
24 %
Partner D
 
11 %
  
4 %
  
3 %
Partner E
 
2 %
  
13 %
  
20 %
Partner F
 
0 %
  
0 %
  
22 %

Contracts receivables at December 31, 2015 and December 31, 2014 were comprised of approximately 99 percent for each year from two and three significant partners, respectively.

XML 48 R17.htm IDEA: XBRL DOCUMENT v3.3.1.900
Employment Benefits
12 Months Ended
Dec. 31, 2015
Employment Benefits [Abstract]  
Employment Benefits
8. Employment Benefits

We have an employee 401(k) salary deferral plan, covering all employees. Employees may make contributions by withholding a percentage of their salary up to the IRS annual limit ($18,000 and $24,000 in 2015 for employees under 50 years old and employees 50 years old or over, respectively). We made approximately $1.5 million, $1.0 million and $0.6 million in matching contributions for the years ended December 31, 2015, 2014 and 2013, respectively.

XML 49 R18.htm IDEA: XBRL DOCUMENT v3.3.1.900
Legal Proceedings
12 Months Ended
Dec. 31, 2015
Legal Proceedings [Abstract]  
Legal Proceedings
9. Legal Proceedings

From time to time, we are involved in legal proceedings arising in the ordinary course of our business. Periodically, we evaluate the status of each legal matter and assess our potential financial exposure. If the potential loss from any legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Significant judgment is required to determine the probability of a loss and whether the amount of the loss is reasonably estimable. The outcome of any proceeding is not determinable in advance. As a result, the assessment of a potential liability and the amount of accruals recorded are based only on the information available to us at the time. As additional information becomes available, we reassess the potential liability related to the legal proceeding, and may revise our estimates. We do not believe, relative to our current legal proceedings, that a loss is both probable and estimable. As such, as of December 31, 2015, we did not have a liability related to any of our current legal proceedings, including the following matters.

Gilead Litigation

In August 2013, Gilead Sciences Inc. filed a suit in the United States District Court of the Northern District of California related to United States Patent Nos. 7,105,499 and 8,481,712 that are jointly owned by Merck Sharp & Dohme Corp. and Ionis Pharmaceuticals, Inc. In the suit Gilead is asking the court to determine that Gilead's activities do not infringe any valid claim of the named patents and that the patents are not valid. We and Merck Sharp & Dohme Corp. filed our answer denying Gilead's noninfringement and invalidity contentions, contending that Gilead's commercial sale and offer for sale of sofosbuvir prior to the expiration of the '499 and '712 patents infringes those patents, and requesting monetary damages to compensate for such infringement. Under our agreement with Merck, Merck is responsible for the costs of this suit. Gilead filed a motion for summary judgment alleging invalidity of the asserted patents. In February 2016, the court denied the motion. In the same order, the court granted our motion for summary judgement for a finding of infringement, but noted that Gilead may still pursue its invalidity defenses at trial. The trial for this case is scheduled to begin March 7, 2016.

XML 50 R19.htm IDEA: XBRL DOCUMENT v3.3.1.900
Quarterly Financial Data (Unaudited)
12 Months Ended
Dec. 31, 2015
Quarterly Financial Data (Unaudited) [Abstract]  
Quarterly Financial Data (Unaudited)
10. Quarterly Financial Data (Unaudited)

The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for the years ended December 31, 2015 and 2014 are as follows (in thousands, except per share data).

2015 Quarters
 
First
Quarter
  
Second
Quarter
  
Third
Quarter
  
Fourth
Quarter
 
Revenue
 
$
62,583
  
$
120,428
  
$
49,121
  
$
51,571
 
Operating expenses
 
$
71,913
  
$
75,782
  
$
97,259
  
$
114,511
 
Income (loss) from operations
 
$
(9,330
)
 
$
44,646
  
$
(48,138
)
 
$
(62,940
)
Net income (loss)
 
$
(16,717
)
 
$
35,648
  
$
(35,776
)
 
$
(71,433
)
Basic net income (loss) per share (1)
 
$
(0.14
)
 
$
0.30
  
$
(0.30
)
 
$
(0.59
)
Diluted net income (loss) per share (1) (2)
 
$
(0.14
)
 
$
0.29
  
$
(0.30
)
 
$
(0.59
)

2014 Quarters
 
First
Quarter
  
Second
Quarter
  
Third
Quarter
  
Fourth
Quarter
 
Revenue
 
$
28,161
  
$
57,076
  
$
44,063
  
$
84,861
 
Operating expenses
 
$
57,828
  
$
63,726
  
$
65,556
  
$
74,781
 
Income (loss) from operations
 
$
(29,667
)
 
$
(6,650
)
 
$
(21,493
)
 
$
10,080
 
Net income (loss)
 
$
(31,280
)
 
$
(12,081
)
 
$
(26,676
)
 
$
31,053
 
Basic net income (loss) per share (1)
 
$
(0.27
)
 
$
(0.10
)
 
$
(0.23
)
 
$
0.26
 
Diluted net income (loss) per share (1) (3)
 
$
(0.27
)
 
$
(0.10
)
 
$
(0.23
)
 
$
0.25
 

(1)
We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.

(2)
For the three months ended June 30, 2015, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended June 30, 2015 consisted of the following (in thousands):

Three Months Ended June 30, 2015
 
Income
(Numerator)
  
Shares
(Denominator)
  
Per-Share Amount
 
 
      
Income available to common shareholders
 
$
35,648
   
119,742
  
$
0.30
 
Effect of diluted securities:
            
Shares issuable upon exercise of stock options
      
3,974
     
Shares issuable upon restricted stock award issuance
      
376
     
Shares issuable related to our ESPP
      
4
     
Shares issuable related to our 2¾ percent notes
  
1,047
   
3,683
     
Income available to common shareholders, plus assumed conversions
 
$
36,695
   
127,779
  
$
0.29
 

For the three months ended June 30, 2015, the calculation excludes the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.

(3)
For the three months ended December 31, 2014, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended December 31, 2014 consisted of the following (in thousands):

Three Months Ended December 31, 2014
 
Income
(Numerator)
  
Shares
(Denominator)
  
Per-Share Amount
 
 
      
Income available to common shareholders
 
$
31,053
   
118,223
  
$
0.26
 
Effect of diluted securities:
            
Shares issuable upon exercise of stock options
      
4,189
     
Shares issuable upon restricted stock award issuance
      
418
     
Shares issuable related to our ESPP
      
9
     
Income available to common shareholders, plus assumed conversions
 
$
31,053
   
122,839
  
$
0.25
 

For the three months ended December 31, 2014, the calculation excludes the 1 percent and 2¾ percent convertible senior notes because the effect on diluted earnings per share was anti-dilutive.

XML 51 R20.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2015
Organization and Significant Accounting Policies [Abstract]  
Basis of Presentation
Basis of presentation
 
The consolidated financial statements include the accounts of Ionis Pharmaceuticals, Inc. ("we", "us" or "our") and our wholly owned subsidiary, Akcea Therapeutics, Inc., which we formed in December 2014. In December 2015, we changed our name from Isis Pharmaceuticals, Inc. to Ionis Pharmaceuticals, Inc.

Organization and Business Activity
Organization and business activity
 
We incorporated in California on January 10, 1989. In conjunction with our initial public offering, we reorganized as a Delaware corporation in April 1991. We were organized principally to develop human therapeutic drugs using antisense technology.

Basic and Diluted Net Loss per Share
Basic and diluted net loss per share

We compute basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period. As we incurred a net loss for 2015, 2014 and 2013, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. Common stock from the following would have had an anti-dilutive effect on net loss per share:

percent convertible senior notes (for 2014 and 2015);
2¾ percent convertible senior notes;
Dilutive stock options;
Unvested restricted stock units; and
Employee Stock Purchase Plan, or ESPP.

Revenue Recognition
Revenue recognition

We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In the instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.

Arrangements with multiple deliverables

Our collaboration agreements typically contain multiple elements, or deliverables, including technology licenses or options to obtain technology licenses, research and development services, and in certain cases manufacturing services, and we allocate the consideration to each unit of accounting based on the relative selling price of each deliverable.

Identifying deliverables and units of accounting

We evaluate the deliverables in our collaboration agreements to determine whether they meet the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. When the delivered items in an arrangement have "stand-alone value" to our customer, we account for the deliverables as separate units of accounting. Delivered items have stand-alone value if they are sold separately by any vendor or the customer could resell the delivered items on a stand-alone basis. For example, in May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXIRx for the prevention of thrombosis. As part of the agreement, Bayer paid us a $100 million upfront payment in the second quarter of 2015. We are also eligible to receive milestone payments and tiered royalties on gross margins of IONIS-FXIRx. We are responsible for completing the ongoing development services for IONIS-FXIRx and for providing an initial supply of active pharmaceutical ingredient, or API. Bayer is responsible for all other development and commercialization activities for IONIS-FXIRx. Since this agreement has multiple elements, we evaluated the deliverables in this arrangement when we entered into the agreement and determined that certain deliverables have stand-alone value. Below is a list of the three units of accounting under our agreement:

The exclusive license we granted to Bayer to develop and commercialize IONIS-FXIRx for the treatment of thrombosis;
The development services we agreed to perform for IONIS-FXIRx; and 
The initial supply of API.

We determined that each of these three units of accounting have stand-alone value. The exclusive license we granted to Bayer has stand-alone value because it is an exclusive license that gives Bayer the right to develop IONIS-FXIRx or to sublicense its rights. The development services and the initial supply of API each have stand-alone value because Bayer or another third party could provide these items without our assistance.

Measurement and allocation of arrangement consideration

Our collaborations may provide for various types of payments to us including upfront payments, funding of research and development, milestone payments, licensing fees and royalties on product sales. We initially allocate the amount of consideration that is fixed and determinable at the time the agreement is entered into and exclude contingent consideration. We allocate the consideration to each unit of accounting based on the relative selling price of each deliverable. We use the following hierarchy of values to estimate the selling price of each deliverable: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price, or BESP. BESP reflects our best estimate of what the selling price would be if we regularly sold the deliverable on a stand-alone basis. We recognize the revenue allocated to each unit of accounting as we deliver the related goods or services. If we determine that we should treat certain deliverables as a single unit of accounting, then we recognize the revenue ratably over our estimated period of performance.

We determined that the allocable arrangement consideration for the Bayer collaboration was $100 million and we allocated it based on the relative BESP of each unit of accounting. We engaged a third party, independent valuation expert to assist us with determining BESP. We estimated the selling price of the license granted for IONIS-FXIRx by using the relief from royalty method. Under this method, we estimated the amount of income, net of taxes, for IONIS-FXIRx. We then discounted the projected income to present value. The significant inputs we used to determine the projected income of the license included:

Estimated future product sales;
Estimated royalties on future product sales;
Contractual milestone payments;
Expenses we expect to incur;
Income taxes; and
An appropriate discount rate.

We estimated the selling price of the ongoing development services by using our internal estimates of the cost to perform the specific services and estimates of expected cash outflows to third parties for services and supplies over the expected period that we will perform the development services. The significant inputs we used to determine the selling price of the ongoing development services included:

The number of internal hours we will spend performing these services;
The estimated cost of work we will perform;
The estimated cost of work that we will contract with third parties to perform; and
The estimated cost of drug product we will use.

We determine the selling price of our API consistently for all of our partnerships. On an annual basis, we calculate our fully absorbed cost to manufacture API. We then determine the unit price we will charge our partners by dividing our fully absorbed costs by the quantity of API we expect to produce during the year.

For purposes of determining BESP of the services we will perform and the API in our Bayer transaction, accounting guidance required us to include a markup for a reasonable profit margin.

Based on the units of accounting under the agreement, we allocated the $100 million upfront payment from Bayer as follows:

$91.2 million to the IONIS-FXIRx exclusive license;
$4.3 million for ongoing development services; and
$4.5 million for the delivery of API.

Assuming a constant selling price for the other elements in the arrangement, if there was an assumed ten percent increase or decrease in the estimated selling price of the IONIS-FXIRx license, we determined that the revenue we would have allocated to the IONIS-FXIRx license would change by approximately one percent, or $0.9 million, from the amount we recorded.

Timing of revenue recognition

We recognize revenue as we deliver each item under the arrangement and the related revenue is realizable and earned. For example, we recognized revenue for the exclusive license we granted Bayer for IONIS-FXIRx in the second quarter of 2015 because that was when we delivered the license. We also recognize revenue over time. Our collaborative agreements typically include a research and/or development project plan outlining the activities the agreement requires each party to perform during the collaboration. We must estimate our period of performance when the agreements we enter into do not clearly define such information. We estimate the period of time over which we will complete the activities for which we are responsible and use that period of time as our period of performance for purposes of revenue recognition. We then recognize revenue ratably over such period. We have made estimates of our continuing obligations under numerous agreements and in certain instances the timing of satisfying these obligations change as the development plans for our drugs progress. Accordingly, our estimates may change in the future. If our estimates and judgments change over the course of our collaboration agreements, it may affect the timing and amount of revenue that we recognize in future periods.

The following are the periods over which we are recognizing revenue for each of our units of accounting under our Bayer agreement:

We recognized the portion of the consideration attributed to the IONIS-FXIRx license immediately because we delivered the license and earned the revenue; 
We are recognizing the amount attributed to the ongoing development services for IONIS-FXIRx over the period of time we are performing the services; and
We will recognize the amount attributed to the API supply when we deliver it to Bayer.

Multiple agreements

From time to time, we may enter into separate agreements at or near the same time with the same customer. We evaluate such agreements to determine whether they should be accounted for individually as distinct arrangements or whether the separate agreements are, in substance, a single multiple element arrangement. We evaluate whether the negotiations are conducted jointly as part of a single negotiation, whether the deliverables are interrelated or interdependent, whether fees in one arrangement are tied to performance in another arrangement, and whether elements in one arrangement are essential to another arrangement. Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that they are, in effect, part of a single arrangement. For example, since early 2012, we have entered into four collaboration agreements with Biogen:

In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize nusinersen for spinal muscular atrophy, or SMA. As part of the collaboration, we received a $29 million upfront payment and we are responsible for global development of nusinersen through completion of Phase 2/3 clinical trials.

In June 2012, we entered into a second and separate collaboration agreement with Biogen to develop and commercialize a novel antisense drug targeting DMPK, or dystrophia myotonica-protein kinase. As part of the collaboration, we received a $12 million upfront payment and we are responsible for global development of the drug through the completion of a Phase 2 clinical trial.

In December 2012, we entered into a third and separate collaboration agreement with Biogen to discover and develop antisense drugs against three targets to treat neurological or neuromuscular disorders. As part of the collaboration, we received a $30 million upfront payment and we are responsible for the discovery of a lead antisense drug for each of three targets.

In September 2013, we entered into a fourth and separate collaboration agreement with Biogen to leverage antisense technology to advance the treatment of neurological diseases. We granted Biogen exclusive rights to the use of our antisense technology to develop therapies for neurological diseases as part of this broad collaboration. We received a $100 million upfront payment and we are responsible for discovery and early development through the completion of a Phase 2 clinical trial for each antisense drug identified during the six-year term of this collaboration, while Biogen is responsible for the creation and development of small molecule treatments and biologics.

All four of these collaboration agreements give Biogen the option to license one or more drugs resulting from the specific collaboration. If Biogen exercises an option, it will pay us a license fee and will assume future development, regulatory and commercialization responsibilities for the licensed drug. We are also eligible to receive milestone payments associated with the research and/or development of the drugs prior to licensing, milestone payments if Biogen achieves pre-specified regulatory milestones, and royalties on any product sales from any drugs resulting from these collaborations.

We evaluated all four of the Biogen agreements to determine whether we should account for them as separate agreements. We determined that we should account for the agreements separately because we conducted the negotiations independently of one another, each agreement focuses on different drugs, there are no interrelated or interdependent deliverables, there are no provisions in any of these agreements that are essential to the other agreement, and the payment terms and fees under each agreement are independent of each other. We also evaluated the deliverables in each of these agreements to determine whether they met the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting. For all four of these agreements, we determined that the options did not have stand-alone value because Biogen cannot pursue the development or commercialization of the drugs resulting from these collaborations until it exercises the respective option or options. As such, for each agreement we considered the deliverables to be a single unit of accounting and we are recognizing the upfront payment for each of the agreements over the respective estimated period of our performance.

Milestone payments

Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and/ or commercialization events. These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraph.

Prior to the first stage in the life-cycle of our drugs, we perform a significant amount of work using our proprietary antisense technology to design chemical compounds that interact with specific genes that are good targets for drug discovery. From these research efforts, we hope to identify a development candidate. The designation of a development candidate is the first stage in the life-cycle of our drugs. A development candidate is a chemical compound that has demonstrated the necessary safety and efficacy in preclinical animal studies to warrant further study in humans.

During the first step of the development stage, we or our partners study our drugs in Investigational New Drug, or IND, -enabling studies, which are animal studies intended to support an IND application and/or the foreign equivalent. An approved IND allows us or our partners to study our development candidate in humans. If the regulatory agency approves the IND, we or our partners initiate Phase 1 clinical trials in which we typically enroll a small number of healthy volunteers to ensure the development candidate is safe for use in patients. If we or our partners determine that a development candidate is safe based on the Phase 1 data, we or our partners initiate Phase 2 studies that are generally larger scale studies in patients with the primary intent of determining the efficacy of the development candidate.

The final step in the development stage is Phase 3 studies to gather the necessary safety and efficacy data to request marketing authorization from the FDA and/or foreign equivalents. The Phase 3 studies typically involve large numbers of patients and can take up to several years to complete. If the data gathered during the trials demonstrates acceptable safety and efficacy results, we or our partner will submit an application to the FDA and/or its foreign equivalents for marketing authorization. This stage of the drug’s life-cycle is the regulatory stage.

If a drug achieves marketing authorization, it moves into the commercialization stage, during which our partner will market and sell the drug to patients. Although our partner will ultimately be responsible for marketing and selling the partnered drug, our efforts to discover and develop a drug that is safe, effective and reliable contributes significantly to our partner’s ability to successfully sell the drug. The FDA and its foreign equivalents have the authority to impose significant restrictions on an approved drug through the product label and on advertising, promotional and distribution activities. Therefore, our efforts designing and executing the necessary animal and human studies are critical to obtaining claims in the product label from the regulatory agencies that would allow us or our partner to successfully commercialize our drug. Further, the patent protection afforded our drugs as a result of our initial patent applications and related prosecution activities in the United States and foreign jurisdictions are critical to our partner’s ability to sell our drugs without competition from generic drugs. The potential sales volume of an approved drug is dependent on several factors including the size of the patient population, market penetration of the drug, and the price charged for the drug.

Generally, the milestone events contained in our partnership agreements coincide with the progression of our drugs from development, to marketing authorization and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug progresses through the stages of its life-cycle, the value of the drug generally increases.

Development milestones in our partnerships may include the following types of events:

Designation of a development candidate. Following the designation of a development candidate, IND-enabling animal studies for a new development candidate generally take 12 to 18 months to complete;
Initiation of a Phase 1 clinical trial. Generally, Phase 1 clinical trials take one to two years to complete;
Initiation or completion of a Phase 2 clinical trial. Generally, Phase 2 clinical trials take one to three years to complete;
Initiation or completion of a Phase 3 clinical trial. Generally, Phase 3 clinical trials take two to four years to complete.

Regulatory milestones in our partnerships may include the following types of events:

Filing of regulatory applications for marketing authorization such as a New Drug Application, or NDA, in the United States or a Marketing Authorization Application, or MAA, in Europe. Generally, it takes six to twelve months to prepare and submit regulatory filings.
Marketing authorization in a major market, such as the United States, Europe or Japan. Generally it takes one to two years after an application is submitted to obtain authorization from the applicable regulatory agency.

Commercialization milestones in our partnerships may include the following types of events:

First commercial sale in a particular market, such as in the United States or Europe.
Product sales in excess of a pre-specified threshold, such as annual sales exceeding $1 billion. The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.

We assess whether a substantive milestone exists at the inception of our agreements. When a substantive milestone is achieved, we recognize revenue related to the milestone payment immediately. For our existing licensing and collaboration agreements in which we are involved in the discovery and/or development of the related drug or provide the partner with access to new technologies we discover, we have determined that the majority of future development, regulatory and commercialization milestones are substantive. For example, we consider most of the milestones associated with our strategic alliance with Biogen substantive because we are using our antisense drug discovery platform to discover and develop new drugs against targets for neurological diseases. We also consider milestones associated with our alliance with Alnylam Pharmaceuticals, Inc. substantive because we provide Alnylam ongoing access to our technology to develop and commercialize RNA interference, or RNAi, therapeutics. In evaluating if a milestone is substantive we consider whether:

Substantive uncertainty exists as to the achievement of the milestone event at the inception of the arrangement;
The achievement of the milestone involves substantive effort and can only be achieved based in whole or in part on our performance or the occurrence of a specific outcome resulting from our performance;
The amount of the milestone payment appears reasonable either in relation to the effort expended or to the enhancement of the value of the delivered items;
There is no future performance required to earn the milestone; and
The consideration is reasonable relative to all deliverables and payment terms in the arrangement.

If any of these conditions are not met, we do not consider the milestone to be substantive and we defer recognition of the milestone payment and recognize it as revenue over our estimated period of performance, if any. Further information about our collaborative arrangements can be found in Note 6, Collaborative Arrangements and Licensing Agreements.

Licensing and royalty revenue

We often enter into agreements to license our proprietary patent rights on an exclusive or non-exclusive basis in exchange for license fees and/or royalties. We generally recognize as revenue immediately those licensing fees and royalties for which we have no significant future performance obligations and are reasonably assured of collecting the resulting receivable. For example, during 2014, we recognized $9.5 million in revenue from Alnylam related to its license of our technology to one of its partners because we had no performance obligations and collectability was reasonably assured.

Research, Development and Patent Expenses
Research, development and patent expenses

Our research and development expenses include wages, benefits, facilities, supplies, external services, clinical trial and manufacturing costs and other expenses that are directly related to our research and development operations. We expense research and development costs as we incur them. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. For the years ended December 31, 2015, 2014 and 2013, research and development expenses were $319.5 million, $238.9 million and $173.7 million, respectively. A portion of the costs included in research and development expenses are costs associated with our collaboration agreements. For the years ended December 31, 2015, 2014 and 2013, research and development costs of approximately $161.7 million, $85.6 million and $51.0 million, respectively, were related to our collaborative agreements.

We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We amortize patent costs over the useful life of the patent, beginning with the date the United States Patent and Trademark Office, or foreign equivalent, issues the patent. The weighted average remaining amortizable life of our issued patents was 10.2 years at December 31, 2015.

The cost of our patents capitalized on our consolidated balance sheet at December 31, 2015 and 2014 was $27.5 million and $25.0 million, respectively. Accumulated amortization related to patents was $8.2 million and $7.8 million at December 31, 2015 and 2014, respectively.

Based on existing patents, estimated amortization expense related to patents in each of the next five years is as follows:

Years Ending December 31,
 
Amortization
(in millions)
 
2016
 
$
1.4
 
2017
 
$
1.3
 
2018
 
$
1.2
 
2019
 
$
1.1
 
2020
 
$
1.0
 

We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. When we identify patents and patent applications that we are not actively pursuing, we write off any associated costs. In 2015, 2014 and 2013, patent expenses were $2.8 million, $2.9 million and $10.3 million, respectively, and included non-cash charges related to the write-down of our patent costs to their estimated net realizable values of $1.1 million, $1.3 million and $6.4 million, respectively.

Concentration of Credit Risk
Concentration of credit risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, short-term investments and receivables. We place our cash equivalents and short-term investments with reputable financial institutions. We primarily invest our excess cash in commercial paper and debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody’s, Standard & Poor’s, or S&P, or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.

Cash, Cash Equivalents and Short-Term Investments
Cash, cash equivalents and short-term investments

We consider all liquid investments with maturities of three months or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than three months from date of purchase. We classify our short-term investments as “available-for-sale” and carry them at fair market value based upon prices for identical or similar items on the last day of the fiscal period. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.

We have equity investments in privately and publicly held biotechnology companies that we have received as part of a technology license or collaboration agreement. At December 31, 2015, we held ownership interests of less than 20 percent in each of the respective companies.

We account for our equity investments in publicly held companies at fair value and record unrealized gains and losses related to temporary increases and decreases in the stock of these publicly held companies as a separate component of comprehensive income (loss). We account for equity investments in privately held companies under the cost method of accounting because we own less than 20 percent and do not have significant influence over their operations. We hold one cost method investment in Atlantic Pharmaceuticals Limited. Realization of our equity position in this company is uncertain. When realization of our investment is uncertain, we record a full valuation allowance. In determining if and when a decrease in market value below our cost in our equity positions is temporary or other-than-temporary, we examine historical trends in the stock price, the financial condition of the company, near term prospects of the company and our current need for cash. If we determine that a decline in value in either a public or private investment is other-than-temporary, we recognize an impairment loss in the period in which the other-than-temporary decline occurs.

Inventory Valuation
Inventory valuation

We capitalize the costs of raw materials that we purchase for use in producing our drugs because until we use these raw materials they have alternative future uses. We include in inventory raw material costs for drugs that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single drug. For example, if one of our drugs failed, we could use the raw materials for that drug to manufacture our other drugs. We expense these costs when we deliver the drugs to our partners, or as we provide these drugs for our own clinical trials. We reflect our inventory on the balance sheet at the lower of cost or market value under the first-in, first-out method, or FIFO. We review inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value. We consider several factors in estimating the net realizable value, including shelf life of raw materials, alternative uses for our drugs and clinical trial materials, and historical write-offs. We did not record any inventory write-offs for the years ended December 31, 2015, 2014 or 2013. Total inventory was $6.9 million and $6.3 million as of December 31, 2015 and 2014, respectively.


Property, Plant and Equipment
Property, plant and equipment

We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):

  Estimated Useful Lives  
December 31,
 
  
(in years)
  
2015
  
2014
 
Computer software, laboratory, manufacturing and other equipment
 
3 to 10
  
$
56,822
  
$
49,772
 
Building and building systems
 
25 to 40
   
48,163
   
48,521
 
Land improvements
  
20
   
2,853
   
2,853
 
Leasehold improvements
 
5 to 20
   
39,061
   
37,935
 
Furniture and fixtures
 
5 to 10
   
5,842
   
5,732
 
       
152,741
   
144,813
 
Less accumulated depreciation
      
(72,706
)
  
(66,053
)
       
80,035
   
78,760
 
Land
      
10,198
   
10,198
 
 Total
     
$
90,233
  
$
88,958
 

We depreciate our leasehold improvements using the shorter of the estimated useful life or remaining lease term.

Fair Value of Financial Instruments
Fair value of financial instruments
 
We have estimated the fair value of our financial instruments. The amounts reported for cash, accounts receivable, accounts payable and accrued expenses approximate the fair value because of their short maturities. We report our investment securities at their estimated fair value based on quoted market prices for identical or similar instruments.

Long-Lived Assets
Long-lived assets
 
We evaluate long-lived assets, which include property, plant and equipment, patent costs, and exclusive licenses acquired from third parties, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets. We recorded charges of $1.9 million, $1.3 million and $6.4 million for the years ended December 31, 2015, 2014 and 2013, respectively, related primarily to the write-down of intangible assets.

Use of Estimates
Use of estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Stock-Based Compensation Expense
Stock-based compensation expense

We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our ESPP based on the estimated fair value of the award on the date of grant. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our Consolidated Statements of Operations. We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.

We use the Black-Scholes model as our method of valuing option awards and stock purchase rights under our ESPP. On the grant date, we use our stock price and assumptions regarding a number of highly complex and subjective variables to determine the estimated fair value of stock-based payment awards. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Option-pricing models were developed for use in estimating the value of traded options that have no vesting or hedging restrictions and are fully transferable. Because our employee stock options have certain characteristics that are significantly different from traded options, and because changes in the subjective assumptions can materially affect the estimated value, in management’s opinion, the existing valuation models may not provide an accurate measure of the fair value of our employee stock options. Although we determine the estimated fair value of employee stock options using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.

We recognize compensation expense for option awards using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), an entity recognizes compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.

The fair value of RSUs is based on the market price of our common stock on the date of grant. The RSUs we have granted vest annually over a four-year period.

See Note 4, Stockholders’ Equity, for additional information regarding our share-based compensation plans.


Accumulated Other Comprehensive Income (Loss)
Accumulated other comprehensive income (loss)

Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on investments, net of taxes, and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive income to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive income for the years ended December 31, 2015, 2014 and 2013 (in thousands):
 
  
Year Ended December 31,
 
  
2015
  
2014
  
2013
 
Beginning balance accumulated other comprehensive income
 
$
39,747
  
$
21,080
  
$
12,480
 
Unrealized (losses) gains on securities, net of tax (1)
  
(33,101
)
  
40,079
   
10,253
 
Amounts reclassified from accumulated other comprehensive (loss) income (2)
  
(20,211
)
  
(21,412
)
  
(1,653
)
Net other comprehensive (loss) income for the period
  
(53,312
)
  
18,667
   
8,600
 
Ending balance accumulated other comprehensive (loss) income
 
$
(13,565
)
 
$
39,747
  
$
21,080
 


(1)Other comprehensive income includes income tax expense of $12.8 million and $5.9 million for the years ended December 31, 2014 and 2013, respectively. There was no tax expense for other comprehensive income for the year ended December 31, 2015.

(2)Amounts for 2015 are included in the separate line called “Gain on investment in Regulus Therapeutics Inc.” on our Consolidated Statement of Operations. For 2014, $19.9 million is included in a separate line called “Gain on investment in Regulus Therapeutics Inc.”, with the remaining amount included in a separate line called “Gain on investments, net” on our Consolidated Statement of Operations. Amounts for 2013 are included in a separate line called “Gain on investments, net” on our Consolidated Statement of Operations.

Convertible Debt
Convertible debt

We account for convertible debt instruments, including our 1 percent and 2¾ percent notes, that may be settled in cash upon conversion (including partial cash settlement) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. We determine the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, we estimate fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense.

We assign a value to the debt component of our convertible notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording our debt at a discount. We are amortizing the debt discount over the life of the convertible notes as additional non-cash interest expense utilizing the effective interest method. For additional information, see Note 3, Long-Term Obligations and Commitments.

Segment Information
Segment information

In 2015, we began operating as two segments, our Ionis Core segment, previously referred to as Drug Discovery and Development, and Akcea Therapeutics, which consists of the operations of our wholly owned subsidiary, Akcea Therapeutics, Inc. We formed Akcea to develop and commercialize drugs for cardiometabolic disorders. We provide segment financial information and results for our Ionis Core segment and our Akcea Therapeutics segment based on the segregation of revenues and expenses that our chief decision maker reviews to assess operating performance and to make operating decisions. We use judgments and estimates in determining the allocation of shared expenses to the two segments.

Fair Value Measurements
Fair value measurements

We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investment in equity securities in publicly held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. Our Level 3 investments include our investments in the equity securities of publicly held biotechnology companies for which we calculated a lack of marketability discount because there were restrictions on when we could trade the securities. Historically, we have determined the lack of marketability discount by using a Black-Scholes model to value a hypothetical put option to approximate the cost of hedging the stock until the restriction ends. The majority of our securities have been classified as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices. During 2015 and 2014, there were no transfers between our Level 1 and Level 2 investments. We recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.


We measure the following major security types at fair value on a recurring basis. The following summary breaks down the fair-value hierarchy that we valued each security with at December 31, 2015 and 2014 (in thousands):

  
At
December 31, 2015
  
Quoted Prices in
Active Markets
(Level 1)
  
Significant Other
Observable
Inputs
(Level 2)
  
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents (1)
 
$
88,902
  
$
88,902
  
$
  
$
 
Corporate debt securities (2)
  
438,426
   
   
438,426
   
 
Debt securities issued by U.S. government agencies (2)
  
89,253
   
   
89,253
   
 
Debt securities issued by the U.S. Treasury (2)
  
2,601
   
2,601
   
   
 
Debt securities issued by states of the United States and political subdivisions of the states (3)
  
127,656
   
   
127,656
   
 
Investment in Regulus Therapeutics Inc.
  
24,792
   
24,792
   
   
 
Total
 
$
771,630
  
$
116,295
  
$
655,335
  
$
 

  
At
December 31, 2014
  
Quoted Prices in
Active Markets
(Level 1)
  
Significant Other
Observable
Inputs
(Level 2)
  
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents (1)
 
$
104,680
  
$
104,680
  
$
  
$
 
Corporate debt securities (4)
  
372,002
   
   
372,002
   
 
Debt securities issued by U.S. government agencies (2)
  
109,855
   
   
109,855
   
 
Debt securities issued by the U.S. Treasury (5)
  
19,017
   
19,017
   
   
 
Debt securities issued by states of the United States and political subdivisions of the states (6)
  
105,033
   
   
105,033
   
 
Investment in Regulus Therapeutics Inc.
  
81,881
   
   
   
81,881
 
Total
 
$
792,468
  
$
123,697
  
$
586,890
  
$
81,881
 


(1)Included in cash and cash equivalents on our consolidated balance sheet.

(2)Included in short-term investments on our consolidated balance sheet.

(3)$7.5 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(4)$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(5)$10 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(6)$9.3 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

In the first quarter of 2014, Achaogen completed an initial public offering. As a result, we stopped using the cost method of accounting for our equity investment in Achaogen and instead we began accounting for it at fair value. Until September 2014, the fair value of our investment in Achaogen included a lack of marketability discount because there were restrictions on when we could trade the securities. As such, we classified our Achaogen stock as a Level 3 investment. In September 2014, we reclassified our investment in Achaogen to a Level 1 investment because the contractual trading restrictions on the shares we owned ended and we subsequently sold all of our shares in 2014.

In November 2014, Regulus completed a public offering. As part of the offering, we sold shares of Regulus' common stock and became subject to trading restrictions on our remaining shares through January 2015. Therefore, at December 31, 2014, we recorded a lack of marketability discount on our investment in Regulus and classified it as a Level 3 investment. At the end of January 2015, we reclassified our investment in Regulus to a Level 1 investment because the contractual trading restrictions on the shares we owned ended.

The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2015 and 2014 (in thousands):

  
Year Ended
December 31,
 
  
2015
  
2014
 
Beginning balance of Level 3 investments
 
$
81,881
  
$
 
Transfers into Level 3 investments
  
   
108,009
 
Total gains (losses) included in accumulated other comprehensive income (loss)
  
22,377
   
(24,897
)
Transfers out of Level 3 investments
  
(104,258
)
  
(1,231
)
Ending balance of Level 3 investments
 
$
  
$
81,881
 



Impact of Recently Issued Accounting Standards
Impact of recently issued accounting standards
 
In May 2014, the FASB issued accounting guidance on the recognition of revenue from customers. Under this guidance, an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects what the entity expects in exchange for the goods or services. This guidance also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance as originally issued is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016.
In July 2015, the FASB issued updated accounting guidance to allow for an optional one year deferral from the original effective date. As a result, we will adopt this guidance beginning on January 1, 2018. The guidance allows us to select one of two methods of adoption, either the full retrospective approach, meaning the guidance would be applied to all periods presented, or modified retrospective, meaning the cumulative effect of applying the guidance would be recognized as an adjustment to our opening retained earnings balance. We are currently determining the adoption method and timing as well as the effects the adoption will have on our consolidated financial statements and disclosures.

In August 2014, the FASB issued accounting guidance on how and when to disclose going-concern uncertainties in the financial statements. This guidance will require us to perform interim and annual assessments to determine our ability to continue as a going concern within one year from the date that we issue our financial statements. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016. We will adopt this guidance in our fiscal year beginning January 1, 2017. We do not expect this guidance to have any effect on our consolidated financial statements.

In February 2015, the FASB issued accounting guidance which amends existing consolidation guidance for entities that are required to evaluate whether they should consolidate certain legal entities. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015. We will adopt this guidance in our fiscal year beginning January 1, 2016. We do not expect this guidance to have any effect on our consolidated financial statements.

In April 2015, the FASB issued accounting guidance to simplify the presentation of debt issuance costs. The amended guidance requires us to present debt issuance costs as a direct deduction from the carrying amount of the related debt liability rather than as an asset. The guidance does not require us to change how we recognize and measure our debt issuance costs. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015, with early adoption permitted. We will adopt this guidance in our fiscal year beginning January 1, 2016. We do not expect this guidance to have a material impact on our consolidated financial statements.

In April 2015, the FASB issued accounting guidance to clarify the accounting for fees paid in cloud computing arrangements. The amendment provides guidance to customers about whether a cloud computing arrangement includes a software license element consistent with the acquisition of other software licenses or if the arrangement excludes a software license and should be accounted for as a service contract. The guidance does not change the accounting for service contracts. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015. We will adopt this guidance in our fiscal year beginning January 1, 2016 on a prospective basis. We do not expect this guidance to have a material impact on our consolidated financial statements.

In July 2015, the FASB issued accounting guidance to simplify the remeasurement of inventory. The amended guidance applies to entities that value inventory under methods other than last-in first-out (LIFO) or the retail inventory method and applies to us because we value our inventory under the FIFO method. The amended guidance requires us to measure our inventory at the lower of cost and net realizable value. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2015 on a prospective basis. We will adopt this guidance in our fiscal year beginning January 1, 2016. We do not expect this guidance to have any effect on our consolidated financial statements.

In November 2015, the FASB issued accounting guidance to simplify the classification of deferred income tax assets and liabilities to always be classified as current, compared to the previous treatment, which required us to allocate our deferred tax assets between current and noncurrent. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2016 on a prospective or retrospective basis, with early adoption permitted. We adopted this guidance on a prospective basis and reflected it in our consolidated balance sheet at December 31, 2015.

In January 2016, the FASB issued amended accounting guidance related to the recognition, measurement, presentation, and disclosure of certain financial instruments. The amended guidance requires us to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and for us to recognize the changes in fair value in our net income (loss), instead of recognizing changes in value through accumulated other comprehensive income, as we currently do under the existing guidance. The amended guidance also changes several disclosure requirements for financial instruments, including the methods and significant assumptions we use to estimate fair value. The guidance is effective for fiscal years, and interim periods within that year, beginning after December 15, 2017. We will adopt this guidance on January 1, 2018 and we will make any adjustments to beginning balances through a cumulative-effect adjustment to accumulated deficit on that date. We are currently determining the effects the adoption will have on our consolidated financial statements and disclosures.

XML 52 R21.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2015
Organization and Significant Accounting Policies [Abstract]  
Amortization Expense for Patents
Based on existing patents, estimated amortization expense related to patents in each of the next five years is as follows:

Years Ending December 31,
 
Amortization
(in millions)
 
2016
 
$
1.4
 
2017
 
$
1.3
 
2018
 
$
1.2
 
2019
 
$
1.1
 
2020
 
$
1.0
 

Property, Plant and Equipment
We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):

  Estimated Useful Lives  
December 31,
 
  
(in years)
  
2015
  
2014
 
Computer software, laboratory, manufacturing and other equipment
 
3 to 10
  
$
56,822
  
$
49,772
 
Building and building systems
 
25 to 40
   
48,163
   
48,521
 
Land improvements
  
20
   
2,853
   
2,853
 
Leasehold improvements
 
5 to 20
   
39,061
   
37,935
 
Furniture and fixtures
 
5 to 10
   
5,842
   
5,732
 
       
152,741
   
144,813
 
Less accumulated depreciation
      
(72,706
)
  
(66,053
)
       
80,035
   
78,760
 
Land
      
10,198
   
10,198
 
 Total
     
$
90,233
  
$
88,958
 

Changes in Accumulated Other Comprehensive Income (Loss)
Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on investments, net of taxes, and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive income to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive income for the years ended December 31, 2015, 2014 and 2013 (in thousands):
 
  
Year Ended December 31,
 
  
2015
  
2014
  
2013
 
Beginning balance accumulated other comprehensive income
 
$
39,747
  
$
21,080
  
$
12,480
 
Unrealized (losses) gains on securities, net of tax (1)
  
(33,101
)
  
40,079
   
10,253
 
Amounts reclassified from accumulated other comprehensive (loss) income (2)
  
(20,211
)
  
(21,412
)
  
(1,653
)
Net other comprehensive (loss) income for the period
  
(53,312
)
  
18,667
   
8,600
 
Ending balance accumulated other comprehensive (loss) income
 
$
(13,565
)
 
$
39,747
  
$
21,080
 


(1)Other comprehensive income includes income tax expense of $12.8 million and $5.9 million for the years ended December 31, 2014 and 2013, respectively. There was no tax expense for other comprehensive income for the year ended December 31, 2015.

(2)Amounts for 2015 are included in the separate line called “Gain on investment in Regulus Therapeutics Inc.” on our Consolidated Statement of Operations. For 2014, $19.9 million is included in a separate line called “Gain on investment in Regulus Therapeutics Inc.”, with the remaining amount included in a separate line called “Gain on investments, net” on our Consolidated Statement of Operations. Amounts for 2013 are included in a separate line called “Gain on investments, net” on our Consolidated Statement of Operations.

Assets Measured at Fair Value on a Recurring Basis
We measure the following major security types at fair value on a recurring basis. The following summary breaks down the fair-value hierarchy that we valued each security with at December 31, 2015 and 2014 (in thousands):

  
At
December 31, 2015
  
Quoted Prices in
Active Markets
(Level 1)
  
Significant Other
Observable
Inputs
(Level 2)
  
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents (1)
 
$
88,902
  
$
88,902
  
$
  
$
 
Corporate debt securities (2)
  
438,426
   
   
438,426
   
 
Debt securities issued by U.S. government agencies (2)
  
89,253
   
   
89,253
   
 
Debt securities issued by the U.S. Treasury (2)
  
2,601
   
2,601
   
   
 
Debt securities issued by states of the United States and political subdivisions of the states (3)
  
127,656
   
   
127,656
   
 
Investment in Regulus Therapeutics Inc.
  
24,792
   
24,792
   
   
 
Total
 
$
771,630
  
$
116,295
  
$
655,335
  
$
 

  
At
December 31, 2014
  
Quoted Prices in
Active Markets
(Level 1)
  
Significant Other
Observable
Inputs
(Level 2)
  
Significant
Unobservable
Inputs
(Level 3)
 
Cash equivalents (1)
 
$
104,680
  
$
104,680
  
$
  
$
 
Corporate debt securities (4)
  
372,002
   
   
372,002
   
 
Debt securities issued by U.S. government agencies (2)
  
109,855
   
   
109,855
   
 
Debt securities issued by the U.S. Treasury (5)
  
19,017
   
19,017
   
   
 
Debt securities issued by states of the United States and political subdivisions of the states (6)
  
105,033
   
   
105,033
   
 
Investment in Regulus Therapeutics Inc.
  
81,881
   
   
   
81,881
 
Total
 
$
792,468
  
$
123,697
  
$
586,890
  
$
81,881
 


(1)Included in cash and cash equivalents on our consolidated balance sheet.

(2)Included in short-term investments on our consolidated balance sheet.

(3)$7.5 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(4)$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(5)$10 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

(6)$9.3 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

Reconciliation of Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)
The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2015 and 2014 (in thousands):

  
Year Ended
December 31,
 
  
2015
  
2014
 
Beginning balance of Level 3 investments
 
$
81,881
  
$
 
Transfers into Level 3 investments
  
   
108,009
 
Total gains (losses) included in accumulated other comprehensive income (loss)
  
22,377
   
(24,897
)
Transfers out of Level 3 investments
  
(104,258
)
  
(1,231
)
Ending balance of Level 3 investments
 
$
  
$
81,881
 



XML 53 R22.htm IDEA: XBRL DOCUMENT v3.3.1.900
Investments (Tables)
12 Months Ended
Dec. 31, 2015
Investments [Abstract]  
Contract Maturity of Available-for-Sale Securities
The following table summarizes the contract maturity of the available-for-sale securities we held as of December 31, 2015:

One year or less
 
49 %
After one year but within two years
 
27 %
After two years but within three and a half years
 
24 %
Total
 
100 %

Summary of Investments
The following is a summary of our investments (in thousands):

   
Gross Unrealized
   
December 31, 2015
 
Cost
  
Gains
  
Losses
  
Estimated
Fair Value
 
Available-for-sale securities (1):
        
Corporate debt securities
 
$
181,670
  
$
5
  
$
(250
)
 
$
181,425
 
Debt securities issued by U.S. government agencies
  
50,559
   
1
   
(19
)
  
50,541
 
Debt securities issued by the U.S. Treasury
  
2,604
   
   
(3
)
  
2,601
 
Debt securities issued by states of the United States and political subdivisions of the states (2)
  
79,414
   
18
   
(88
)
  
79,344
 
Total securities with a maturity of one year or less
  
314,247
   
24
   
(360
)
  
313,911
 
Corporate debt securities
  
258,703
   
3
   
(1,705
)
  
257,001
 
Debt securities issued by U.S. government agencies
  
38,956
   
   
(244
)
  
38,712
 
Debt securities issued by states of the United States and political subdivisions of the states
  
48,552
   
3
   
(243
)
  
48,312
 
Total securities with a maturity of more than one year
  
346,211
   
6
   
(2,192
)
  
344,025
 
Total available-for-sale securities
 
$
660,458
  
$
30
  
$
(2,552
)
 
$
657,936
 
Equity securities:
                
Regulus Therapeutics Inc.
 
$
7,162
  
$
17,630
  
$
  
$
24,792
 
Total equity securities
 
$
7,162
  
$
17,630
  
$
  
$
24,792
 
Total available-for-sale and equity securities
 
$
667,620
  
$
17,660
  
$
(2,552
)
 
$
682,728
 

   
Gross Unrealized
   
December 31, 2014
 
Cost
  
Gains
  
Losses
  
Estimated
Fair Value
 
Available-for-sale securities (1):
        
Corporate debt securities (2)
 
$
219,856
  
$
89
  
$
(89
)
 
$
219,856
 
Debt securities issued by U.S. government agencies
  
47,496
   
7
   
(27
)
  
47,476
 
Debt securities issued by the U.S. Treasury (2)
  
19,008
   
9
   
   
19,017
 
Debt securities issued by states of the United States and political subdivisions of the states (2)
  
45,196
   
19
   
(53
)
  
45,162
 
Total securities with a maturity of one year or less
  
331,556
   
124
   
(169
)
  
331,511
 
Corporate debt securities
  
152,730
   
16
   
(600
)
  
152,146
 
Debt securities issued by U.S. government agencies
  
62,530
   
   
(151
)
  
62,379
 
Debt securities issued by states of the United States and political subdivisions of the states
  
60,073
   
32
   
(234
)
  
59,871
 
Total securities with a maturity of more than one year
  
275,333
   
48
   
(985
)
  
274,396
 
Total available-for-sale securities
 
$
606,889
  
$
172
  
$
(1,154
)
 
$
605,907
 
Equity securities:
                
Regulus Therapeutics Inc.
 
$
12,477
  
$
69,404
  
$
  
$
81,881
 
Total equity securities
 
$
12,477
  
$
69,404
  
$
  
$
81,881
 
Total available-for-sale and equity securities
 
$
619,366
  
$
69,576
  
$
(1,154
)
 
$
687,788
 

(1)Our available-for-sale securities are held at amortized cost.

(2)Includes investments classified as cash equivalents on our consolidated balance sheet.
Temporarily Impaired Investments
Investments we consider to be temporarily impaired at December 31, 2015 are as follows (in thousands):

    
Less than 12 months of
Temporary Impairment
  
More than 12 months of
Temporary Impairment
  
Total Temporary
Impairment
 
  
Number of
Investments
  
Estimated
Fair Value
  
Unrealized
Losses
  
Estimated
Fair Value
  
Unrealized
Losses
  
Estimated
Fair Value
  
Unrealized
Losses
 
Corporate debt securities
  
397
  
$
406,098
  
$
(1,908
)
 
$
16,066
  
$
(47
)
 
$
422,164
  
$
(1,955
)
Debt securities issued by U.S. government agencies
  
19
   
71,842
   
(262
)
  
1,001
   
(1
)
  
72,843
   
(263
)
Debt securities issued by the U.S. Treasury
  
2
   
2,601
   
(3
)
  
   
   
2,601
   
(3
)
Debt securities issued by states of the United States and political subdivisions of the states
  
230
   
59,882
   
(173
)
  
29,634
   
(158
)
  
89,516
   
(331
)
Total temporarily impaired securities
  
648
  
$
540,423
  
$
(2,346
)
 
$
46,701
  
$
(206
)
 
$
587,124
  
$
(2,552
)

XML 54 R23.htm IDEA: XBRL DOCUMENT v3.3.1.900
Long-Term Obligations and Commitments (Tables)
12 Months Ended
Dec. 31, 2015
Long-Term Obligations and Commitments [Abstract]  
Long-Term Obligations
The carrying value of our long-term obligations was as follows (in thousands):

  
December 31,
 
  
2015
  
2014
 
1 percent convertible senior notes
 
$
347,214
  
$
327,486
 
2¾ percent convertible senior notes
  
50,361
   
48,014
 
Long-term financing liability for leased facility
  
72,217
   
71,731
 
Equipment financing arrangement
  
515
   
3,226
 
Leases and other obligations
  
2,341
   
7,325
 
Total
 
$
472,648
  
$
457,782
 
Less: current portion
  
(515
)
  
(2,882
)
Total Long-Term Obligations
 
$
472,133
  
$
454,900
 

Convertible Notes
At December 31, 2015 we had the following convertible debt outstanding (amounts in millions except price per share data):

  
1 Percent
Convertible Senior Notes
  
2¾ Percent
Convertible Senior Notes
 
Outstanding balance
 
$
500
  
$
61
 
Issue date
 
November 2014
  
August 2012
 
Maturity date
 
November 2021
  
October 2019
 
Interest rate
 
1 percent
  
2¾ percent
 
Conversion price per share
 
$
66.81
  
$
16.63
 
Total shares of common stock subject to conversion
  
7.5
   
3.7
 

We account for our convertible notes using an accounting standard that requires us to assign a value to our convertible debt equal to the estimated fair value of similar debt instruments without the conversion feature and to record the remaining portion in equity. As a result, we recorded our convertible notes at a discount, which we are amortizing as additional non-cash interest expense over the expected life of the respective debt. We determined our nonconvertible debt borrowing rate using a combination of the present value of the debt’s cash flows and a Black-Scholes valuation model. The following table summarizes the nonconvertible borrowing rate, effective interest rate and amortization period of our debt discount for our convertible notes:

 
1 Percent
Convertible Senior Notes
2¾ Percent
Convertible Senior Notes
Nonconvertible debt borrowing rate
7.4 percent
8.0 percent
Effective interest rate
7.8 percent
 8.8 percent
Amortization period of debt discount
7 years
7 years

The following table summarizes information about the equity and liability components of our outstanding convertible notes, (in thousands). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement:

  
December 31,
 
  
2015
  
2014
 
2¾ Percent Convertible Senior Notes
    
Fair value of outstanding notes
 
$
215,320
  
$
223,900
 
Principal amount of convertible notes outstanding
 
$
61,247
  
$
61,247
 
Unamortized portion of debt discount
 
$
10,886
  
$
13,233
 
Long-term debt
 
$
50,361
  
$
48,014
 
Carrying value of equity component
 
$
18,714
  
$
18,714
 
         
1 Percent Convertible Senior Notes
        
Fair value of outstanding notes
 
$
555,000
  
$
568,000
 
Principal amount of convertible notes outstanding
 
$
500,000
  
$
500,000
 
Unamortized portion of debt discount
 
$
152,786
  
$
172,514
 
Long-term debt
 
$
347,214
  
$
327,486
 
Carrying value of equity component
 
$
174,770
  
$
174,770
 

Maturity Schedules
Annual debt and other obligation maturities, including fixed and determinable interest, at December 31, 2015 are as follows (in thousands):

2016
 
$
15,767
 
2017
  
6,744
 
2018
  
6,744
 
2019
  
6,744
 
2020
  
66,304
 
Thereafter
  
505,960
 
Subtotal
 
$
608,263
 
Less: current portion
  
(9,029
)
Less: fixed and determinable interest
  
(37,655
)
Less: unamortized portion of debt discount
  
(163,672
)
Plus: Deferred rent
  
2,006
 
Total
 
$
399,913
 

Future Minimum Payments Under Operating Leases
Annual future minimum payments under operating leases as of December 31, 2015 are as follows (in thousands):

  
Operating
Leases
 
2016
 
$
1,879
 
2017
  
1,878
 
2018
  
1,597
 
2019
  
1,474
 
2020
  
1,527
 
Thereafter
  
16,125
 
Total minimum payments
 
$
24,480
 

Future Rent Payments for Research and Development Facility Lease Obligation
Annual future rent payments as of December 31, 2015 for our primary research and development facility are as follows (in thousands):

  
Future Rent
Payments
 
2016
 
$
6,550
 
2017
  
6,550
 
2018
  
6,943
 
2019
  
6,943
 
2020
  
7,359
 
Thereafter
  
91,205
 
Total minimum payments
 
$
125,550
 

XML 55 R24.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2015
Stockholders' Equity [Abstract]  
Stock Option Activity
The following table summarizes the stock option activity for the year ended December 31, 2015 (in thousands, except per share and contractual life data):

  
Number of
Shares
  
Weighted
Average Exercise
Price
Per Share
 
Average
Remaining
Contractual Term
(Years)
 
Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2014
  
7,379
  
$
19.52
   
Granted
  
2,550
  
$
61.02
   
Exercised
  
(1,674
)
 
$
14.07
   
Cancelled/forfeited/expired
  
(214
)
 
$
42.43
   
Outstanding at December 31, 2015
  
8,041
  
$
33.21
   
4.57
  
$
232,581
 
Exercisable at December 31, 2015
  
3,940
  
$
16.43
   
3.32
  
$
179,273
 

Restricted Stock Unit Activity
The following table summarizes the RSU activity for the year ended December 31, 2015 (in thousands, except per share data):

  
Number of
Shares
  
Weighted
Average
Grant Date
Fair Value
Per Share
 
Non-vested at December 31, 2014
  
638
  
$
30.52
 
Granted
  
348
  
$
65.69
 
Vested
  
(196
)
 
$
27.40
 
Cancelled/forfeited
  
(39
)
 
$
42.87
 
Non-vested at December 31, 2015
  
751
  
$
47.47
 

Stock-Based Compensation Expense
The following table summarizes stock-based compensation expense for the years ended December 31, 2015, 2014 and 2013 (in thousands), which was allocated as follows and includes $6.5 million of stock-based compensation expense for Akcea employees in 2015:

 
Year Ended
December 31,
 
 
2015
 
2014
 
2013
 
Research, development and patents
 
$
43,638
  
$
25,843
  
$
9,673
 
General and administrative
  
15,676
   
5,540
   
1,745
 
Total
 
$
59,314
  
$
31,383
  
$
11,418
 

Weighted-Average Assumptions - ESPP
ESPP:

 
December 31,
 
2015
 
2014
 
2013
Risk-free interest rate
0.1 %
 
0.1 %
 
0.1 %
Dividend yield
0.0 %
 
0.0 %
 
0.0 %
Volatility
51.7 %
 
60.1 %
 
62.9 %
Expected life
6 months
 
6 months
 
6 months

Employee Stock Options [Member]  
Stockholders' Equity [Abstract]  
Weighted-Average Assumptions
For the years ended December 31, 2015, 2014 and 2013, we used the following weighted-average assumptions in our Black-Scholes calculations:

Employee Stock Options:

 
December 31,
 
2015
 
2014
 
2013
Risk-free interest rate
1.5 %
 
1.7 %
 
1.1 %
Dividend yield
0.0 %
 
0.0 %
 
0.0 %
Volatility
53.8 %
 
50.1 %
 
51.1 %
Expected life
4.5 years
 
4.7 years
 
5.1 years

Board of Director Stock Options [Member]  
Stockholders' Equity [Abstract]  
Weighted-Average Assumptions
Board of Director Stock Options:

 
December 31,
 
2015
 
2014
 
2013
Risk-free interest rate
2.1 %
 
2.2 %
 
2.2 %
Dividend yield
0.0 %
 
0.0 %
 
0.0 %
Volatility
52.2 %
 
54.2 %
 
52.7 %
Expected life
6.9 years
 
6.9 years
 
7.2 years

XML 56 R25.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2015
Income Taxes [Abstract]  
Provision for Income Taxes
The provisions for income taxes on income from continuing operations were as follows (in thousands):

  
Year Ended December 31,
 
  
2015
  
2014
  
2013
 
Current:
      
Federal
 
$
379
  
$
263
  
$
 
State
  
(7
)
  
(4,295
)
  
2
 
Total current
  
372
   
(4,032
)
  
2
 
             
Deferred:
            
Federal
  
   
(8,948
)
  
(5,082
)
State
  
   
(2,427
)
  
(834
)
Total deferred
  
   
(11,375
)
  
(5,916
)
Income tax expense (benefit)
 
$
372
  
$
(15,407
)
 
$
(5,914
)

Reconciliation Between Effective and Statutory Tax Rate
The reconciliation between our effective tax rate on income from continuing operations and the statutory U.S. tax rate is as follows (in thousands):

  
Year Ended December 31,
 
  
2015
  
2014
  
2013
 
Pre-tax loss
 
$
(87,906
)
   
$
(54,391
)
   
$
(66,558
)
  
                   
Statutory rate
  
(30,767
)
  
35.0
%
  
(19,035
)
  
35.0
%
  
(23,295
)
  
35.0
%
State income tax net of federal benefit
  
1
   
0.0
%
  
(3,125
)
  
5.7
%
  
(3,823
)
  
5.7
%
Net change in valuation allowance
  
69,499
   
(79.1
)%
  
29,547
   
(54.3
)%
  
28,850
   
(43.3
)%
Loss on debt extinguishment
  
   
0.0
%
  
2,406
   
(4.4
)%
  
   
0.0
%
Tax credits
  
(41,284
)
  
47.0
%
  
(23,628
)
  
43.4
%
  
(15,839
)
  
23.8
%
California franchise tax refund
  
   
0.0
%
  
(2,795
)
  
5.1
%
  
   
0.0
%
Deferred tax true-up
  
1,496
   
(1.7
)%
  
977
   
(1.8
)%
  
8,023
   
(12.1
)%
Other
  
1,427
   
(1.6
)%
  
246
   
(0.5
)%
  
170
   
(0.2
)%
Effective rate
 
$
372
   
(0.4
)%
 
$
(15,407
)
  
28.2
%
 
$
(5,914
)
  
8.9
%

Deferred Tax Assets and Liabilities
Significant components of our deferred tax assets and liabilities as of December 31, 2015 and 2014 are as follows (in thousands):

  
Year Ended
December 31,
 
  
2015
  
2014
 
Deferred Tax Assets:
    
Net operating loss carryovers
 
$
218,493
  
$
231,654
 
R&D credits
  
153,601
   
93,594
 
Deferred revenue
  
45,110
   
58,836
 
Stock-based compensation
  
31,093
   
21,553
 
Other
  
19,655
   
15,549
 
Total deferred tax assets
 
$
467,952
  
$
421,186
 
         
Deferred Tax Liabilities:
        
Convertible debt
 
$
(55,928
)
 
$
(73,733
)
Unrealized gain in other comprehensive income
  
(5,288
)
  
(27,878
)
Intangible and capital assets
  
(2,643
)
  
(3,641
)
Net deferred tax asset
 
$
404,093
  
$
315,934
 
Valuation allowance
  
(404,093
)
  
(315,934
)
         
Net deferreds
 
$
  
$
 



Gross Unrecognized Tax Benefits
The following table summarizes our gross unrecognized tax benefits (in thousands):

  
Year Ended December 31,
 
  
2015
  
2014
  
2013
 
Beginning balance of unrecognized tax benefits
 
$
27,365
  
$
23,964
  
$
10,872
 
Decrease for prior period tax positions
  
   
(1,653
)
  
 
Increase for prior period tax positions
  
215
   
   
9,821
 
Increase for current period tax positions
  
23,677
   
5,054
   
3,271
 
Ending balance of unrecognized tax benefits
 
$
51,257
  
$
27,365
  
$
23,964
 

XML 57 R26.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Information and Concentration of Business Risk (Tables)
12 Months Ended
Dec. 31, 2015
Segment Information and Concentration of Business Risk [Abstract]  
Segment Information
The following is our segment information for 2015 (in thousands):

2015
 
Ionis Core
  
Akcea Therapeutics
  
Elimination of Intercompany Activity
  
Total
 
Revenue:
        
Research and development
 
$
285,608
  
$
  
$
(4,248
)
 
$
281,360
 
Licensing and royalty
  
2,343
   
   
   
2,343
 
Total segment revenue
 
$
287,951
  
$
  
$
(4,248
)
 
$
283,703
 
Loss from operations
 
$
(21,378
)
 
$
(54,384
)
 
$
  
$
(75,762
)
Total assets
 
$
1,004,150
  
$
55,354
  
$
(103,399
)
 
$
956,105
 

The following is our segment information for 2014 and 2013 (in thousands) revised for comparative purposes to show operating expense for Akcea-related projects in 2014 and 2013:

2014
 
Ionis Core
  
Akcea Therapeutics
  
Total
 
Revenue:
      
Research and development
 
$
202,514
  
$
  
$
202,514
 
Licensing and royalty
  
11,647
   
   
11,647
 
Total segment revenue
 
$
214,161
  
$
  
$
214,161
 
Loss from operations
 
$
(26,033
)
 
$
(21,697
)
 
$
(47,730
)

2013
 
Ionis Core
  
Akcea Therapeutics
  
Total
 
Revenue:
      
Research and development
 
$
147,380
  
$
  
$
144,194
 
Licensing and royalty
  
3,091
   
   
3,091
 
Total segment revenue
 
$
150,471
  
$
  
$
147,285
 
Loss from operations
 
$
(38,764
)
 
$
(12,902
)
 
$
(51,666
)



Revenue from Significant Partners
We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10 percent or more of our total revenue, was as follows:

 
2015
 
2014
 
2013
Partner A
 
37 %
  
58 %
  
25 %
Partner B
 
33 %
  
0 %
  
0 %
Partner C
 
12 %
  
17 %
  
24 %
Partner D
 
11 %
  
4 %
  
3 %
Partner E
 
2 %
  
13 %
  
20 %
Partner F
 
0 %
  
0 %
  
22 %

XML 58 R27.htm IDEA: XBRL DOCUMENT v3.3.1.900
Quarterly Financial Data (Unaudited) (Tables)
12 Months Ended
Dec. 31, 2015
Quarterly Financial Data (Unaudited) [Abstract]  
Quarterly Financial Data
The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for the years ended December 31, 2015 and 2014 are as follows (in thousands, except per share data).

2015 Quarters
 
First
Quarter
  
Second
Quarter
  
Third
Quarter
  
Fourth
Quarter
 
Revenue
 
$
62,583
  
$
120,428
  
$
49,121
  
$
51,571
 
Operating expenses
 
$
71,913
  
$
75,782
  
$
97,259
  
$
114,511
 
Income (loss) from operations
 
$
(9,330
)
 
$
44,646
  
$
(48,138
)
 
$
(62,940
)
Net income (loss)
 
$
(16,717
)
 
$
35,648
  
$
(35,776
)
 
$
(71,433
)
Basic net income (loss) per share (1)
 
$
(0.14
)
 
$
0.30
  
$
(0.30
)
 
$
(0.59
)
Diluted net income (loss) per share (1) (2)
 
$
(0.14
)
 
$
0.29
  
$
(0.30
)
 
$
(0.59
)

2014 Quarters
 
First
Quarter
  
Second
Quarter
  
Third
Quarter
  
Fourth
Quarter
 
Revenue
 
$
28,161
  
$
57,076
  
$
44,063
  
$
84,861
 
Operating expenses
 
$
57,828
  
$
63,726
  
$
65,556
  
$
74,781
 
Income (loss) from operations
 
$
(29,667
)
 
$
(6,650
)
 
$
(21,493
)
 
$
10,080
 
Net income (loss)
 
$
(31,280
)
 
$
(12,081
)
 
$
(26,676
)
 
$
31,053
 
Basic net income (loss) per share (1)
 
$
(0.27
)
 
$
(0.10
)
 
$
(0.23
)
 
$
0.26
 
Diluted net income (loss) per share (1) (3)
 
$
(0.27
)
 
$
(0.10
)
 
$
(0.23
)
 
$
0.25
 

(1)
We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.

(2)
For the three months ended June 30, 2015, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended June 30, 2015 consisted of the following (in thousands):

Three Months Ended June 30, 2015
 
Income
(Numerator)
  
Shares
(Denominator)
  
Per-Share Amount
 
 
      
Income available to common shareholders
 
$
35,648
   
119,742
  
$
0.30
 
Effect of diluted securities:
            
Shares issuable upon exercise of stock options
      
3,974
     
Shares issuable upon restricted stock award issuance
      
376
     
Shares issuable related to our ESPP
      
4
     
Shares issuable related to our 2¾ percent notes
  
1,047
   
3,683
     
Income available to common shareholders, plus assumed conversions
 
$
36,695
   
127,779
  
$
0.29
 

For the three months ended June 30, 2015, the calculation excludes the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.

(3)
For the three months ended December 31, 2014, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended December 31, 2014 consisted of the following (in thousands):

Three Months Ended December 31, 2014
 
Income
(Numerator)
  
Shares
(Denominator)
  
Per-Share Amount
 
 
      
Income available to common shareholders
 
$
31,053
   
118,223
  
$
0.26
 
Effect of diluted securities:
            
Shares issuable upon exercise of stock options
      
4,189
     
Shares issuable upon restricted stock award issuance
      
418
     
Shares issuable related to our ESPP
      
9
     
Income available to common shareholders, plus assumed conversions
 
$
31,053
   
122,839
  
$
0.25
 

For the three months ended December 31, 2014, the calculation excludes the 1 percent and 2¾ percent convertible senior notes because the effect on diluted earnings per share was anti-dilutive.

XML 59 R28.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Basic and Diluted Net Loss per Share (Details) - Convertible Senior Notes [Member]
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
1 Percent Convertible Senior Notes [Member]      
Basic and Diluted Net Loss per Share [Abstract]      
Interest rate on convertible senior notes 1.00% 1.00%  
2 3/4 Percent Convertible Senior Notes [Member]      
Basic and Diluted Net Loss per Share [Abstract]      
Interest rate on convertible senior notes 2.75% 2.75% 2.75%
XML 60 R29.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Revenue Recognition (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2015
USD ($)
Sep. 30, 2013
USD ($)
Dec. 31, 2012
USD ($)
Target
Jun. 30, 2012
USD ($)
Jan. 31, 2012
USD ($)
Jun. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
AccountingUnit
Agreement
Category
Stage
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Revenue Recognition [Abstract]                  
Licensing and royalty revenue             $ 2,343,000 $ 11,647,000 $ 3,091,000
Collaborations and Licensing Agreements [Member]                  
Revenue Recognition [Abstract]                  
Number of categories of milestone events | Category             3    
Number of stages of life-cycle of drugs | Stage             3    
Collaborations and Licensing Agreements [Member] | Development Milestones - New Development Candidate [Member] | Minimum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             12 months    
Collaborations and Licensing Agreements [Member] | Development Milestones - New Development Candidate [Member] | Maximum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             18 months    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 1 [Member] | Minimum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             1 year    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 1 [Member] | Maximum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             2 years    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 2 [Member] | Minimum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             1 year    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 2 [Member] | Maximum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             3 years    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 3 [Member] | Minimum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             2 years    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 3 [Member] | Maximum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             4 years    
Collaborations and Licensing Agreements [Member] | Regulatory Milestones [Member] | Minimum [Member]                  
Revenue Recognition [Abstract]                  
Time to prepare and submit regulatory filings             6 months    
Time to obtain approval             1 year    
Collaborations and Licensing Agreements [Member] | Regulatory Milestones [Member] | Maximum [Member]                  
Revenue Recognition [Abstract]                  
Time to prepare and submit regulatory filings             12 months    
Time to obtain approval             2 years    
Collaborations and Licensing Agreements [Member] | Commercialization Milestones [Member]                  
Revenue Recognition [Abstract]                  
Example of sales threshold as milestone event             $ 1,000,000,000    
Bayer [Member] | Agreement Entered into in May 2015 [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee received           $ 100,000,000      
Number of units of accounting | AccountingUnit             3    
Bayer [Member] | Agreement Entered into in May 2015 [Member] | IONIS-FXI [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recognized           91,200,000      
Upfront fee recorded as deferred revenue $ 8,800,000         $ 4,300,000      
Assumed change in estimated selling price           10.00%      
Percentage by which earned revenue would change based on assumed change in estimated selling price           1.00%      
Amount by which earned revenue would change based on assumed change in estimated selling price           $ 900,000      
Bayer [Member] | Agreement Entered into in May 2015 [Member] | IONIS-FXI Active Pharmaceutical Ingredient [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recorded as deferred revenue           $ 4,500,000      
Biogen [Member] | Collaborations and Licensing Agreements [Member]                  
Revenue Recognition [Abstract]                  
Number of collaborative agreements | Agreement             4    
Biogen [Member] | Agreement Entered into in January 2012 [Member] | Nusinersen [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recorded as deferred revenue         $ 29,000,000        
Biogen [Member] | Agreement Entered into in June 2012 [Member] | IONIS-DMPK-2.5 [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recorded as deferred revenue       $ 12,000,000          
Biogen [Member] | Agreement Entered into in December 2012 [Member] | Neurology [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recorded as deferred revenue     $ 30,000,000            
Number of targets | Target     3            
Biogen [Member] | Agreement Entered into in September 2013 [Member] | Strategic Neurology [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recorded as deferred revenue   $ 100,000,000              
Term of collaboration agreement             6 years    
Alnylam [Member]                  
Revenue Recognition [Abstract]                  
Licensing and royalty revenue               $ 9,500,000  
XML 61 R30.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Research, Development and Patent Expenses (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Research, Development and Patent Expenses [Abstract]      
Research and development expenses $ 319.5 $ 238.9 $ 173.7
Estimated Amortization Expense [Abstract]      
Non-cash charges related to write-down $ 1.9 1.3 6.4
Patents [Member]      
Patents [Abstract]      
Estimated useful life 10 years 2 months 12 days    
Cost $ 27.5 25.0  
Accumulated amortization 8.2 7.8  
Estimated Amortization Expense [Abstract]      
2016 1.4    
2017 1.3    
2018 1.2    
2019 1.1    
2020 1.0    
Patent expenses 2.8 2.9 10.3
Non-cash charges related to write-down 1.1 1.3 6.4
Collaborations and Licensing Agreements [Member]      
Research, Development and Patent Expenses [Abstract]      
Research and development expenses $ 161.7 $ 85.6 $ 51.0
XML 62 R31.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Inventory Valuation (Details) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Inventory Valuation [Abstract]    
Inventories $ 6,899 $ 6,290
XML 63 R32.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Property, Plant and Equipment [Abstract]    
Less accumulated depreciation $ (72,706) $ (66,053)
Property, plant and equipment, net 90,233 88,958
Property, Plant and Equipment, Excluding Land [Member]    
Property, Plant and Equipment [Abstract]    
Property, plant and equipment 152,741 144,813
Property, plant and equipment, net 80,035 78,760
Computer Software, Laboratory, Manufacturing and Other Equipment [Member]    
Property, Plant and Equipment [Abstract]    
Property, plant and equipment $ 56,822 49,772
Computer Software, Laboratory, Manufacturing and Other Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 3 years  
Computer Software, Laboratory, Manufacturing and Other Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 10 years  
Building and Building Systems [Member]    
Property, Plant and Equipment [Abstract]    
Property, plant and equipment $ 48,163 48,521
Building and Building Systems [Member] | Minimum [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 25 years  
Building and Building Systems [Member] | Maximum [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 40 years  
Land Improvements [Member]    
Property, Plant and Equipment [Abstract]    
Property, plant and equipment $ 2,853 2,853
Estimated useful life 20 years  
Leasehold Improvements [Member]    
Property, Plant and Equipment [Abstract]    
Property, plant and equipment $ 39,061 37,935
Leasehold Improvements [Member] | Minimum [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 5 years  
Leasehold Improvements [Member] | Maximum [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 20 years  
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Abstract]    
Property, plant and equipment $ 5,842 5,732
Furniture and Fixtures [Member] | Minimum [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 5 years  
Furniture and Fixtures [Member] | Maximum [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 10 years  
Land [Member]    
Property, Plant and Equipment [Abstract]    
Property, plant and equipment $ 10,198 $ 10,198
XML 64 R33.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Long-Lived Assets (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Long-Lived Assets [Abstract]      
Impairment charges $ 1.9 $ 1.3 $ 6.4
XML 65 R34.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Stock-based Compensation (Details)
12 Months Ended
Dec. 31, 2015
RSUs [Member]  
Stock-Based Compensation [Abstract]  
Vesting period 4 years
XML 66 R35.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance $ 257,780    
Amounts reclassified from accumulated other comprehensive (loss) income (20,211) $ (21,412) $ (1,653)
Ending balance 200,790 257,780  
Income tax expense included in other comprehensive income 0 12,800 5,900
Gain on investment in Regulus Therapeutics Inc. 20,211 19,902 0
Accumulated Other Comprehensive (Loss) Income [Member]      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance 39,747 21,080 12,480
Ending balance (13,565) 39,747 21,080
Unrealized (Losses) Gains on Securities [Member]      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Other comprehensive (loss) income before reclassifications, net of tax [1] (33,101) 40,079 10,253
Amounts reclassified from accumulated other comprehensive (loss) income [2] (20,211) (21,412) (1,653)
Net other comprehensive (loss) income for the period $ (53,312) $ 18,667 $ 8,600
[1] Other comprehensive income includes income tax expense of $12.8 million and $5.9 million for the years ended December 31, 2014 and 2013, respectively. There was no tax expense for other comprehensive income for the year ended December 31, 2015.
[2] Amounts for 2015 are included in the separate line called "Gain on investment in Regulus Therapeutics Inc." on our Consolidated Statement of Operations. For 2014, $19.9 million is included in a separate line called "Gain on investment in Regulus Therapeutics Inc.", with the remaining amount included in a separate line called "Gain on investments, net" on our Consolidated Statement of Operations. Amounts for 2013 are included in a separate line called "Gain on investments, net" on our Consolidated Statement of Operations.
XML 67 R36.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Convertible Debt and Segment Information (Details) - Segment
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Segment Information [Abstract]      
Number of operating segments 2    
Convertible Senior Notes [Member] | 1 Percent Convertible Senior Notes [Member]      
Convertible Debt [Abstract]      
Interest rate on convertible senior notes 1.00% 1.00%  
Convertible Senior Notes [Member] | 2 3/4 Percent Convertible Senior Notes [Member]      
Convertible Debt [Abstract]      
Interest rate on convertible senior notes 2.75% 2.75% 2.75%
XML 68 R37.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Fair Value Measurements on a Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Organization and Significant Accounting Policies [Abstract]    
Transfers from Level 1 to Level 2 $ 0 $ 0
Transfers from Level 2 to Level 1 0 0
Fair Value Measurements [Abstract]    
Available-for-sale securities 682,728 687,788
Investment in Regulus Therapeutics Inc. 24,792 81,881
Recurring Basis [Member]    
Fair Value Measurements [Abstract]    
Cash equivalents [1] 88,902 104,680
Investment in Regulus Therapeutics Inc. 24,792 81,881
Total assets 771,630 792,468
Recurring Basis [Member] | Corporate Debt Securities [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 438,426 [2] 372,002 [3]
Recurring Basis [Member] | Corporate Debt Securities [Member] | Cash and Cash Equivalents [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities   800
Recurring Basis [Member] | Debt Securities issued by U.S. Government Agencies [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities [2] 89,253 109,855
Recurring Basis [Member] | Debt Securities issued by the U.S. Treasury [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 2,601 [2] 19,017 [4]
Recurring Basis [Member] | Debt Securities issued by the U.S. Treasury [Member] | Cash and Cash Equivalents [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities   10,000
Recurring Basis [Member] | Debt Securities issued by States of the United States and Political Subdivisions of the States [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 127,656 [5] 105,033 [6]
Recurring Basis [Member] | Debt Securities issued by States of the United States and Political Subdivisions of the States [Member] | Cash and Cash Equivalents [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 7,500 9,300
Recurring Basis [Member] | Quoted Prices in Active Markets (Level 1) [Member]    
Fair Value Measurements [Abstract]    
Cash equivalents 88,902 104,680
Investment in Regulus Therapeutics Inc. 24,792 0
Total assets 116,295 123,697
Recurring Basis [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Corporate Debt Securities [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 0 0
Recurring Basis [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities issued by U.S. Government Agencies [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 0 0
Recurring Basis [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities issued by the U.S. Treasury [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 2,601 19,017
Recurring Basis [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities issued by States of the United States and Political Subdivisions of the States [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 0 0
Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member]    
Fair Value Measurements [Abstract]    
Cash equivalents 0 0
Investment in Regulus Therapeutics Inc. 0 0
Total assets 655,335 586,890
Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | Corporate Debt Securities [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 438,426 372,002
Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | Debt Securities issued by U.S. Government Agencies [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 89,253 109,855
Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | Debt Securities issued by the U.S. Treasury [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 0 0
Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | Debt Securities issued by States of the United States and Political Subdivisions of the States [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 127,656 105,033
Recurring Basis [Member] | Significant Unobservable Inputs (Level 3) [Member]    
Fair Value Measurements [Abstract]    
Cash equivalents 0 0
Investment in Regulus Therapeutics Inc. 0 81,881
Total assets 0 81,881
Recurring Basis [Member] | Significant Unobservable Inputs (Level 3) [Member] | Corporate Debt Securities [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 0 0
Recurring Basis [Member] | Significant Unobservable Inputs (Level 3) [Member] | Debt Securities issued by U.S. Government Agencies [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 0 0
Recurring Basis [Member] | Significant Unobservable Inputs (Level 3) [Member] | Debt Securities issued by the U.S. Treasury [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities 0 0
Recurring Basis [Member] | Significant Unobservable Inputs (Level 3) [Member] | Debt Securities issued by States of the United States and Political Subdivisions of the States [Member]    
Fair Value Measurements [Abstract]    
Available-for-sale securities $ 0 $ 0
[1] Included in cash and cash equivalents on our consolidated balance sheet.
[2] Included in short-term investments on our consolidated balance sheet.
[3] $0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.
[4] $10 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.
[5] $7.5 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.
[6] $9.3 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.
XML 69 R38.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (Details) - Equity Securities [Member] - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Unobservable Inputs (Level 3) [Roll Forward]    
Beginning balance of Level 3 investments $ 81,881 $ 0
Transfers into Level 3 investments 0 108,009
Total gains (losses) included in accumulated other comprehensive income (loss) 22,377 (24,897)
Transfers out of Level 3 investments (104,258) (1,231)
Ending balance of Level 3 investments $ 0 $ 81,881
XML 70 R39.htm IDEA: XBRL DOCUMENT v3.3.1.900
Investments, Contract Maturity of Available-for-Sale Securities (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2015
USD ($)
Company
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Contract Maturity of Available-for-Sale Securities [Abstract]      
One year or less 49.00%    
After one year but within two years 27.00%    
After two years but within three and a half years 24.00%    
Total 100.00%    
Percentage of available-for-sale securities with a maturity of less than two years 76.00%    
Ownership Interests in Private and Public Companies [Abstract]      
Number of privately-held companies in which the entity has an equity ownership interest of less than 20% | Company 1    
Number of publicly-held companies in which the entity has an equity ownership interest of less than 20% | Company 2    
Gain on investments, net $ 20,300 $ 21,200 $ 2,400
Gain on investment in Regulus Therapeutics Inc. 20,211 19,902 $ 0
Investment in Regulus Therapeutics Inc. $ 24,792 $ 81,881  
Regulus Therapeutics Inc. [Member]      
Ownership Interests in Private and Public Companies [Abstract]      
Ownership interest percentage 5.00%    
XML 71 R40.htm IDEA: XBRL DOCUMENT v3.3.1.900
Investments, Summary of Investments and Investments Temporarily Impaired (Details)
$ in Thousands
Dec. 31, 2015
USD ($)
Investment
Dec. 31, 2014
USD ($)
Summary of Investments [Abstract]    
Cost [1] $ 660,458 $ 606,889
Gross unrealized gains [1] 30 172
Gross unrealized losses [1] (2,552) (1,154)
Estimated fair value [1] 657,936 605,907
Cost 667,620 619,366
Gross unrealized gains 17,660 69,576
Gross unrealized losses (2,552) (1,154)
Estimated fair value $ 682,728 687,788
Temporarily Impaired Investments [Abstract]    
Number of investments | Investment 648  
Estimated fair value, less than 12 months of temporary impairment $ 540,423  
Unrealized losses, less than 12 months of temporary impairment (2,346)  
Estimated fair value, more than 12 months of temporary impairment 46,701  
Unrealized losses, more than 12 months of temporary impairment (206)  
Estimated fair value, total temporary impairment 587,124  
Unrealized losses, total temporary impairment (2,552)  
Securities with Maturity of One Year or Less [Member]    
Summary of Investments [Abstract]    
Cost [1] 314,247 331,556
Gross unrealized gains [1] 24 124
Gross unrealized losses [1] (360) (169)
Estimated fair value [1] 313,911 331,511
Securities with Maturity of More than One Year [Member]    
Summary of Investments [Abstract]    
Cost [1] 346,211 275,333
Gross unrealized gains [1] 6 48
Gross unrealized losses [1] (2,192) (985)
Estimated fair value [1] $ 344,025 274,396
Corporate Debt Securities [Member]    
Temporarily Impaired Investments [Abstract]    
Number of investments | Investment 397  
Estimated fair value, less than 12 months of temporary impairment $ 406,098  
Unrealized losses, less than 12 months of temporary impairment (1,908)  
Estimated fair value, more than 12 months of temporary impairment 16,066  
Unrealized losses, more than 12 months of temporary impairment (47)  
Estimated fair value, total temporary impairment 422,164  
Unrealized losses, total temporary impairment (1,955)  
Corporate Debt Securities [Member] | Securities with Maturity of One Year or Less [Member]    
Summary of Investments [Abstract]    
Cost [1] 181,670 219,856 [2]
Gross unrealized gains [1] 5 89 [2]
Gross unrealized losses [1] (250) (89) [2]
Estimated fair value [1] 181,425 219,856 [2]
Corporate Debt Securities [Member] | Securities with Maturity of More than One Year [Member]    
Summary of Investments [Abstract]    
Cost [1] 258,703 152,730
Gross unrealized gains [1] 3 16
Gross unrealized losses [1] (1,705) (600)
Estimated fair value [1] $ 257,001 152,146
Debt Securities issued by U.S. Government Agencies [Member]    
Temporarily Impaired Investments [Abstract]    
Number of investments | Investment 19  
Estimated fair value, less than 12 months of temporary impairment $ 71,842  
Unrealized losses, less than 12 months of temporary impairment (262)  
Estimated fair value, more than 12 months of temporary impairment 1,001  
Unrealized losses, more than 12 months of temporary impairment (1)  
Estimated fair value, total temporary impairment 72,843  
Unrealized losses, total temporary impairment (263)  
Debt Securities issued by U.S. Government Agencies [Member] | Securities with Maturity of One Year or Less [Member]    
Summary of Investments [Abstract]    
Cost [1] 50,559 47,496
Gross unrealized gains [1] 1 7
Gross unrealized losses [1] (19) (27)
Estimated fair value [1] 50,541 47,476
Debt Securities issued by U.S. Government Agencies [Member] | Securities with Maturity of More than One Year [Member]    
Summary of Investments [Abstract]    
Cost [1] 38,956 62,530
Gross unrealized gains [1] 0 0
Gross unrealized losses [1] (244) (151)
Estimated fair value [1] $ 38,712 62,379
Debt Securities issued by the U.S. Treasury [Member]    
Temporarily Impaired Investments [Abstract]    
Number of investments | Investment 2  
Estimated fair value, less than 12 months of temporary impairment $ 2,601  
Unrealized losses, less than 12 months of temporary impairment (3)  
Estimated fair value, more than 12 months of temporary impairment 0  
Unrealized losses, more than 12 months of temporary impairment 0  
Estimated fair value, total temporary impairment 2,601  
Unrealized losses, total temporary impairment (3)  
Debt Securities issued by the U.S. Treasury [Member] | Securities with Maturity of One Year or Less [Member]    
Summary of Investments [Abstract]    
Cost [1] 2,604 19,008 [2]
Gross unrealized gains [1] 0 9 [2]
Gross unrealized losses [1] (3) 0 [2]
Estimated fair value [1] $ 2,601 19,017 [2]
Debt Securities issued by States of the United States and Political Subdivisions of the States [Member]    
Temporarily Impaired Investments [Abstract]    
Number of investments | Investment 230  
Estimated fair value, less than 12 months of temporary impairment $ 59,882  
Unrealized losses, less than 12 months of temporary impairment (173)  
Estimated fair value, more than 12 months of temporary impairment 29,634  
Unrealized losses, more than 12 months of temporary impairment (158)  
Estimated fair value, total temporary impairment 89,516  
Unrealized losses, total temporary impairment (331)  
Debt Securities issued by States of the United States and Political Subdivisions of the States [Member] | Securities with Maturity of One Year or Less [Member]    
Summary of Investments [Abstract]    
Cost [1],[2] 79,414 45,196
Gross unrealized gains [1],[2] 18 19
Gross unrealized losses [1],[2] (88) (53)
Estimated fair value [1],[2] 79,344 45,162
Debt Securities issued by States of the United States and Political Subdivisions of the States [Member] | Securities with Maturity of More than One Year [Member]    
Summary of Investments [Abstract]    
Cost [1] 48,552 60,073
Gross unrealized gains [1] 3 32
Gross unrealized losses [1] (243) (234)
Estimated fair value [1] 48,312 59,871
Equity Securities [Member]    
Summary of Investments [Abstract]    
Cost 7,162 12,477
Gross unrealized gains 17,630 69,404
Gross unrealized losses 0 0
Estimated fair value 24,792 81,881
Equity Securities [Member] | Regulus Therapeutics Inc. [Member]    
Summary of Investments [Abstract]    
Cost 7,162 12,477
Gross unrealized gains 17,630 69,404
Gross unrealized losses 0 0
Estimated fair value $ 24,792 $ 81,881
[1] Our available-for-sale securities are held at amortized cost.
[2] Includes investments classified as cash equivalents on our consolidated balance sheet.
XML 72 R41.htm IDEA: XBRL DOCUMENT v3.3.1.900
Long-Term Obligations and Commitments, Long-Term Obligations (Details) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Long-Term Obligations [Abstract]    
Total long-term obligations, including current portion $ 472,648 $ 457,782
Less: current portion (515) (2,882)
Total Long-Term Obligations 472,133 454,900
Convertible Senior Notes [Member] | 1 Percent Convertible Senior Notes [Member]    
Long-Term Obligations [Abstract]    
Total long-term obligations, including current portion 347,214 327,486
Convertible Senior Notes [Member] | 2 3/4 Percent Convertible Senior Notes [Member]    
Long-Term Obligations [Abstract]    
Total long-term obligations, including current portion 50,361 48,014
Long-term Financing Liability for Leased Facility [Member]    
Long-Term Obligations [Abstract]    
Total long-term obligations, including current portion 72,217 71,731
Equipment Financing Arrangement [Member]    
Long-Term Obligations [Abstract]    
Total long-term obligations, including current portion 515 3,226
Leases and Other Obligations [Member]    
Long-Term Obligations [Abstract]    
Total long-term obligations, including current portion $ 2,341 $ 7,325
XML 73 R42.htm IDEA: XBRL DOCUMENT v3.3.1.900
Long-Term Obligations and Commitments, Convertible Notes (Details)
1 Months Ended 12 Months Ended
Nov. 30, 2014
USD ($)
Dec. 31, 2015
USD ($)
shares
d
$ / shares
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Convertible Notes [Abstract]        
Proceeds from issuance of 1 percent convertible senior notes, net of issuance costs   $ 0 $ 487,035,000 $ 0
Loss on early retirement of debt   0 (8,292,000) 0
Amortization of debt discount and debt issuance costs   23,200,000 9,600,000 $ 6,800,000
1 Percent Convertible Senior Notes [Member]        
Convertible Notes [Abstract]        
Long-term debt   347,214,000 327,486,000  
2 3/4 Percent Convertible Senior Notes [Member]        
Convertible Notes [Abstract]        
Principal amount repurchased     140,000,000  
Long-term debt   50,361,000 48,014,000  
Convertible Senior Notes [Member] | 1 Percent Convertible Senior Notes [Member]        
Convertible Notes [Abstract]        
Face amount of offering $ 500,000,000      
Proceeds from issuance of 1 percent convertible senior notes, net of issuance costs 487,000,000      
Principal amount of convertible notes outstanding   $ 500,000,000 $ 500,000,000  
Issue date   Nov. 30, 2014    
Maturity date   Nov. 30, 2021    
Interest rate   1.00% 1.00%  
Conversion price per share (in dollars per share) | $ / shares   $ 66.81    
Total shares of common stock subject to conversion (in shares) | shares   7,500,000    
Percentage of principal amount used a purchase price upon occurrence of fundamental change   100.00%    
Nonconvertible debt borrowing rate   7.40%    
Effective interest rate   7.80%    
Amortization period of debt discount   7 years    
Fair value of outstanding notes   $ 555,000,000 $ 568,000,000  
Unamortized portion of liability component   152,786,000 172,514,000  
Long-term debt   347,214,000 327,486,000  
Carrying value of equity component   174,770,000 174,770,000  
Convertible Senior Notes [Member] | 2 3/4 Percent Convertible Senior Notes [Member]        
Convertible Notes [Abstract]        
Principal amount repurchased 140,000,000      
Repurchase of convertible senior notes 441,900,000      
Principal amount of convertible notes outstanding 61,200,000 $ 61,247,000 $ 61,247,000  
Loss on early retirement of debt $ 8,300,000      
Issue date   Aug. 31, 2012    
Maturity date   Oct. 31, 2019    
Interest rate   2.75% 2.75% 2.75%
Conversion price per share (in dollars per share) | $ / shares   $ 16.63    
Total shares of common stock subject to conversion (in shares) | shares   3,700,000    
Percentage of principal amount used a purchase price upon occurrence of fundamental change   100.00%    
If-converted value of notes in excess of principal   $ 166,900,000    
Nonconvertible debt borrowing rate   8.00%    
Effective interest rate   8.80%    
Amortization period of debt discount   7 years    
Fair value of outstanding notes   $ 215,320,000 $ 223,900,000  
Unamortized portion of liability component   10,886,000 13,233,000  
Long-term debt   50,361,000 48,014,000  
Carrying value of equity component   $ 18,714,000 $ 18,714,000  
Convertible Senior Notes [Member] | 2 3/4 Percent Convertible Senior Notes [Member] | On or after October 5, 2016 [Member]        
Convertible Notes [Abstract]        
Threshold number of trading days to trigger redemption | d   20    
Threshold number of consecutive trading days to trigger redemption   30 days    
Threshold percentage of conversion price to trigger redemption   130.00%    
Percentage of principal amount used as redemption price   100.00%    
Additional payment per $1,000 principal amount being redeemed   $ 90    
Principal amount being redeemed   $ 1,000    
XML 74 R43.htm IDEA: XBRL DOCUMENT v3.3.1.900
Long-Term Obligations and Commitments, Financing Arrangements (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Feb. 25, 2016
Dec. 31, 2014
Financing Arrangements [Abstract]      
Carrying balance of loan $ 472,648   $ 457,782
Equipment Financing Arrangement [Member]      
Financing Arrangements [Abstract]      
Weighted average interest rate 4.39%    
Carrying balance of loan $ 515   $ 3,226
Morgan Stanley [Member] | Revolving Line of Credit [Member]      
Financing Arrangements [Abstract]      
Term of agreement 5 years    
Commitment fee percentage on unused capacity 0.25%    
Outstanding borrowings $ 8,500    
Weighted average interest rate 1.67%    
Morgan Stanley [Member] | Revolving Line of Credit [Member] | Subsequent Event [Member]      
Financing Arrangements [Abstract]      
Maximum borrowing capacity   $ 30,000  
Morgan Stanley [Member] | Revolving Line of Credit [Member] | LIBOR [Member]      
Financing Arrangements [Abstract]      
Term of variable rate 1 month    
Basis spread on variable rate 1.25%    
Term of fixed rate elected one, two, three, four, six, or twelve months    
XML 75 R44.htm IDEA: XBRL DOCUMENT v3.3.1.900
Long-Term Obligations and Commitments, Maturity Schedules (Details) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Annual Debt and Other Obligation Maturities [Abstract]    
Less: current portion $ (515) $ (2,882)
Total 472,133 $ 454,900
Long-Term Obligations, Excluding Financing Liability for Leased Facility [Member]    
Annual Debt and Other Obligation Maturities [Abstract]    
2016 15,767  
2017 6,744  
2018 6,744  
2019 6,744  
2020 66,304  
Thereafter 505,960  
Total minimum payments 608,263  
Less: current portion (9,029)  
Less: fixed and determinable interest (37,655)  
Less: unamortized portion of debt discount (163,672)  
Plus: Deferred rent 2,006  
Total $ 399,913  
XML 76 R45.htm IDEA: XBRL DOCUMENT v3.3.1.900
Long-Term Obligations and Commitments, Operating Leases (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2015
USD ($)
Building
Option
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Annual Future Minimum Payments Under Operating Leases [Abstract]      
2016 $ 1,879    
2017 1,878    
2018 1,597    
2019 1,474    
2020 1,527    
Thereafter 16,125    
Total minimum payments 24,480    
Office and Laboratory Space [Member]      
Annual Future Minimum Payments Under Operating Leases [Abstract]      
Rent expense 2,000 $ 1,800 $ 1,800
Deferred rent $ 2,000 $ 1,800  
Office and Laboratory Space [Member] | Akcea Therapeutics [Member]      
Operating Leases [Abstract]      
Number of buildings in Carlsbad, California | Building 3    
Office and Laboratory Space [Member] | Manufacturing Facility [Member]      
Operating Leases [Abstract]      
Number of options to extend lease | Option 4    
Term of lease extension 5 years    
Office and Laboratory Space [Member] | Building [Member]      
Operating Leases [Abstract]      
Number of options to extend lease | Option 2    
Term of lease extension 5 years    
Office and Laboratory Space [Member] | Building [Member] | Akcea Therapeutics [Member]      
Operating Leases [Abstract]      
Term of lease 3 years    
XML 77 R46.htm IDEA: XBRL DOCUMENT v3.3.1.900
Long-Term Obligations and Commitments, Research and Development Facility Lease Obligation (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Mar. 31, 2010
USD ($)
Dec. 31, 2015
USD ($)
Option
Dec. 31, 2014
USD ($)
Research and Development Facility Lease Obligation [Abstract]      
Net book value of facility and associated parcel of land   $ 90,233 $ 88,958
Accumulated depreciation of facility   $ 72,706 66,053
Purchase price of land $ 10,100    
Primary Research and Development Facility [Member]      
Research and Development Facility Lease Obligation [Abstract]      
Number of options to extend lease | Option   4  
Term of lease extension   5 years  
Net book value of facility and associated parcel of land   $ 62,200 64,400
Accumulated depreciation of facility   9,900 $ 7,700
Annual Future Rent Payments [Abstract]      
2016   6,550  
2017   6,550  
2018   6,943  
2019   6,943  
2020   7,359  
Thereafter   91,205  
Total minimum payments   $ 125,550  
XML 78 R47.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stockholders' Equity, Preferred and Common Stock (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Common Stock [Abstract]      
Common stock, shares authorized to issue (in shares) 300,000,000 300,000,000  
Common stock, shares issued (in shares) 120,351,480 118,442,726  
Common stock, shares outstanding (in shares) 120,351,480 118,442,726  
Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases $ 24,888 $ 23,071 $ 62,958
Preferred Stock [Member]      
Preferred Stock [Abstract]      
Preferred stock, shares authorized to issue (in shares) 15,000,000    
Preferred stock, shares issued (in shares)   0  
Preferred stock, shares outstanding (in shares) 0    
Series C Junior Participating Preferred Stock [Member]      
Preferred Stock [Abstract]      
Preferred stock, shares issued (in shares)   0  
Preferred stock, shares outstanding (in shares)   0  
Common Stock [Member]      
Common Stock [Abstract]      
Common stock, shares authorized to issue (in shares) 300,000,000 300,000,000  
Common stock, shares issued (in shares) 120,351,480 118,442,726  
Common stock, shares outstanding (in shares) 120,351,480 118,442,726  
Common shares reserved for future issuance (in shares) 18,512,177    
Number of shares issued for stock option exercises, vesting of restricted stock units, and ESPP purchases (in shares) 1,908,000 1,972,000 5,372,000
Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases $ 24,900 $ 23,100 $ 63,000
XML 79 R48.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stockholders' Equity, Stock Plans (Details)
1 Months Ended 12 Months Ended
Jun. 30, 2009
shares
Dec. 31, 2015
Installment
$ / shares
shares
Jun. 30, 2015
shares
May. 31, 2015
shares
Dec. 31, 2014
shares
Stock Options [Member]          
Stock Plans [Abstract]          
Number of options outstanding (in shares)   8,041,000     7,379,000
Number of options exercisable (in shares)   3,940,000      
Restricted Stock Units [Member]          
Stock Plans [Abstract]          
Vesting period   4 years      
1989 Stock Option Plan [Member]          
Stock Plans [Abstract]          
Number of shares authorized (in shares)   20,000,000      
Vesting period   4 years      
Award term   7 years      
Number of options outstanding (in shares)   3,619,716      
Number of options exercisable (in shares)   2,927,597      
Number of shares available for grant (in shares)   13,462      
1989 Stock Option Plan [Member] | One Year from Date of Grant [Member]          
Stock Plans [Abstract]          
Vesting percentage   25.00%      
2000 Broad Based Equity Incentive Plan [Member]          
Stock Plans [Abstract]          
Number of shares authorized (in shares)   5,990,000      
Vesting period   4 years      
Number of options outstanding (in shares)   44,025      
Number of options exercisable (in shares)   44,025      
Number of shares available for grant (in shares)   0      
2000 Broad Based Equity Incentive Plan [Member] | One Year from Date of Grant [Member]          
Stock Plans [Abstract]          
Vesting percentage   25.00%      
2000 Broad Based Equity Incentive Plan [Member] | Minimum [Member]          
Stock Plans [Abstract]          
Award term   7 years      
2000 Broad Based Equity Incentive Plan [Member] | Maximum [Member]          
Stock Plans [Abstract]          
Award term   10 years      
2011 Equity Incentive Plan [Member]          
Stock Plans [Abstract]          
Number of shares authorized (in shares)     11,000,000 5,500,000  
Number of options outstanding (in shares)   3,832,225      
Number of options exercisable (in shares)   659,254      
Number of shares available for grant (in shares)   5,989,752      
Number of awards outstanding (in shares)   712,034      
2011 Equity Incentive Plan [Member] | Stock Options [Member] | Minimum [Member]          
Stock Plans [Abstract]          
Vesting period   2 years      
2011 Equity Incentive Plan [Member] | Restricted Stock Units [Member]          
Stock Plans [Abstract]          
Vesting period   4 years      
2011 Equity Incentive Plan [Member] | Restricted Stock Units [Member] | Minimum [Member]          
Stock Plans [Abstract]          
Vesting period   3 years      
2002 Non-Employee Directors' Stock Option Plan [Member]          
Stock Plans [Abstract]          
Number of shares authorized (in shares)     2,000,000 1,200,000  
Award term   10 years      
Number of options outstanding (in shares)   544,812      
Number of options exercisable (in shares)   309,319      
Number of shares available for grant (in shares)   859,871      
Number of awards outstanding (in shares)   38,621      
2002 Non-Employee Directors' Stock Option Plan [Member] | One Year from Date of Grant [Member]          
Stock Plans [Abstract]          
Number of equal annual installments over which options become exercisable | Installment   4      
Employee Stock Purchase Plan [Member]          
Stock Plans [Abstract]          
Number of shares authorized (in shares)   3,224,596      
Number of shares available for grant (in shares)   481,764      
Number of additional shares reserved for issuance (in shares) 150,000 150,000      
Maximum percentage of employee compensation used to purchase shares   10.00%      
Percentage of fair market value used to determine purchase price of stock   85.00%      
Purchase period   6 months      
Holding period for purchased stock   6 months      
Shares purchased and issued under ESPP (in shares)   38,372      
Purchase price (in dollars per share) | $ / shares   $ 37.43      
XML 80 R49.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stockholders' Equity, Stock Option Activity (Details) - Stock Options [Member] - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Number of Shares [Abstract]      
Outstanding at beginning of period (in shares) 7,379    
Granted (in shares) 2,550    
Exercised (in shares) (1,674)    
Cancelled/forfeited/expired (in shares) (214)    
Outstanding at end of period (in shares) 8,041 7,379  
Exercisable at end of period (in shares) 3,940    
Weighted Average Exercise Price Per Share [Abstract]      
Outstanding at beginning of period (in dollars per share) $ 19.52    
Granted (in dollars per share) 61.02    
Exercised (in dollars per share) 14.07    
Cancelled/forfeited/expired (in dollars per share) 42.43    
Outstanding at end of period (in dollars per share) 33.21 $ 19.52  
Exercisable at end of period (in dollars per share) $ 16.43    
Average Remaining Contractual Term, Aggregate Intrinsic Value and Other [Abstract]      
Average remaining contractual term, outstanding at end of period 4 years 6 months 25 days    
Average remaining contractual term, exercisable at end of period 3 years 3 months 25 days    
Aggregate intrinsic value, outstanding at end of period $ 232,581    
Aggregate intrinsic value, exercisable at end of period $ 179,273    
Weighted average fair value of options granted (in dollars per share) $ 27.44 $ 17.54 $ 7.10
Intrinsic value of options exercised $ 84,700 $ 62,800 $ 69,600
Cash received from exercise of stock options $ 23,600 $ 22,400 $ 62,000
Weighted-average fair value of options exercised (in dollars per share) $ 64.69    
Unrecognized Compensation Expense [Abstract]      
Unrecognized compensation expense related to non-vested stock options $ 45,700    
Weighted average period for recognition 1 year 3 months 18 days    
XML 81 R50.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stockholders' Equity, Restricted Stock Unit Activity (Details) - Restricted Stock Units [Member] - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Number of Shares [Abstract]      
Non-vested at beginning of period (in shares) 638    
Granted (in shares) 348    
Vested (in shares) (196)    
Cancelled/forfeited (in shares) (39)    
Non-vested at end of period (in shares) 751 638  
Weighted Average Grant Date Fair Value per Share [Abstract]      
Non-vested at beginning of period (in dollars per share) $ 30.52    
Granted (in dollars per share) 65.69 $ 44.94 $ 17.42
Vested (in dollars per share) 27.40    
Cancelled/forfeited (in dollars per share) 42.87    
Non-vested at end of period (in dollars per share) $ 47.47 $ 30.52  
Unrecognized Compensation Expense [Abstract]      
Unrecognized compensation cost related to non-vested RSUs $ 16.0    
Weighted average period for recognition 1 year 2 months 12 days    
XML 82 R51.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stockholders' Equity, Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Stock-Based Compensation [Abstract]      
Stock-based compensation expense $ 59,314 $ 31,383 $ 11,418
Research, Development and Patents [Member]      
Stock-Based Compensation [Abstract]      
Stock-based compensation expense 43,638 25,843 9,673
General and Administrative [Member]      
Stock-Based Compensation [Abstract]      
Stock-based compensation expense 15,676 $ 5,540 $ 1,745
Akcea Therapeutics [Member]      
Stock-Based Compensation [Abstract]      
Stock-based compensation expense $ 6,500    
XML 83 R52.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stockholders' Equity, Stock-based Valuation Information (Details)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Employee Stock Options [Member]      
Weighted-Average Assumptions [Abstract]      
Risk-free interest rate 1.50% 1.70% 1.10%
Dividend yield 0.00% 0.00% 0.00%
Volatility 53.80% 50.10% 51.10%
Expected life 4 years 6 months 4 years 8 months 12 days 5 years 1 month 6 days
Board of Director Stock Options [Member]      
Weighted-Average Assumptions [Abstract]      
Risk-free interest rate 2.10% 2.20% 2.20%
Dividend yield 0.00% 0.00% 0.00%
Volatility 52.20% 54.20% 52.70%
Expected life 6 years 10 months 24 days 6 years 10 months 24 days 7 years 2 months 12 days
Employee Stock Purchase Plan (ESPP) [Member]      
Weighted-Average Assumptions [Abstract]      
Risk-free interest rate 0.10% 0.10% 0.10%
Dividend yield 0.00% 0.00% 0.00%
Volatility 51.70% 60.10% 62.90%
Expected life 6 months 6 months 6 months
XML 84 R53.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes, Provision for Income Taxes (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Current [Abstract]        
Federal   $ 379 $ 263 $ 0
State   (7) (4,295) 2
Total current   372 (4,032) 2
Deferred [Abstract]        
Federal   0 (8,948) (5,082)
State   0 (2,427) (834)
Total deferred   0 (11,375) (5,916)
Income tax expense (benefit)   372 (15,407) (5,914)
Tax benefit related to unrealized gains on investments in available-for-sale securities recorded in continuing operations     (12,800) (5,900)
Tax expense related to unrealized gains on investments in available-for-sale securities recorded in other comprehensive income     $ 12,800 $ 5,900
State Jurisdiction [Member] | California Franchise Tax Board [Member] | Tax Year 2009 [Member]        
Income Taxes [Abstract]        
Franchise tax refund   $ 4,300    
Research Tax Credit Carryforward [Member] | California Franchise Tax Board [Member] | Tax Year 2009 [Member]        
Income Taxes [Abstract]        
Increase in research credit carry over $ 4,300      
XML 85 R54.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes, Reconciliation of Effective Tax Rate (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Reconciliation Between Effective and Statutory Tax Rate [Abstract]      
Pre tax loss $ (87,906) $ (54,391) $ (66,558)
Statutory rate (30,767) (19,035) (23,295)
State income tax net of federal benefit 1 (3,125) (3,823)
Net change in valuation allowance 69,499 29,547 28,850
Loss on debt extinguishment 0 2,406 0
Tax credits (41,284) (23,628) (15,839)
California franchise tax refund 0 (2,795) 0
Deferred tax true-up 1,496 977 8,023
Other 1,427 246 170
Income tax expense (benefit) $ 372 $ (15,407) $ (5,914)
Reconciliation Between Effective and Statutory Tax Rate Percentage [Abstract]      
Statutory rate 35.00% 35.00% 35.00%
State income tax net of federal benefit 0.00% 5.70% 5.70%
Net change in valuation allowance (79.10%) (54.30%) (43.30%)
Loss on debt extinguishment 0.00% (4.40%) 0.00%
Tax credits 47.00% 43.40% 23.80%
California franchise tax refund 0.00% 5.10% 0.00%
Deferred tax true-up (1.70%) (1.80%) (12.10%)
Other (1.60%) (0.50%) (0.20%)
Effective rate (0.40%) 28.20% 8.90%
XML 86 R55.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes, Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Deferred Tax Assets [Abstract]    
Net operating loss carryovers $ 218,493 $ 231,654
R&D credits 153,601 93,594
Deferred revenue 45,110 58,836
Stock-based compensation 31,093 21,553
Other 19,655 15,549
Total deferred tax assets 467,952 421,186
Deferred Tax Liabilities [Abstract]    
Convertible debt (55,928) (73,733)
Unrealized gain in other comprehensive income (5,288) (27,878)
Intangible and capital assets (2,643) (3,641)
Net deferred tax asset 404,093 315,934
Valuation allowance (404,093) (315,934)
Net deferreds 0 0
Excess tax benefits from shared-based compensation awards 396 $ 1,463
Unrealized excess tax benefits associated with share-based compensation $ 76,900  
XML 87 R56.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes, Tax Credit Carryforward (Details)
$ in Millions
Dec. 31, 2015
USD ($)
Research and Development [Member] | Federal [Member]  
Tax Credit Carryforward [Abstract]  
Tax credit carryforwards $ 146.8
Research and Development [Member] | California [Member]  
Tax Credit Carryforward [Abstract]  
Tax credit carryforwards 44.7
Federal [Member]  
Operating Loss Carryforwards [Abstract]  
Net operating loss carryforwards 734.7
California [Member]  
Operating Loss Carryforwards [Abstract]  
Net operating loss carryforwards $ 886.5
XML 88 R57.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes, Gross Unrecognized Tax Benefits (Details) - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Gross Unrecognized Tax Benefits [Roll Forward]      
Beginning balance of unrecognized tax benefits $ 27,365,000 $ 23,964,000 $ 10,872,000
Decrease for prior period tax positions 0 (1,653,000) 0
Increase for prior period tax positions 215,000 0 9,821,000
Increase for current period tax positions 23,677,000 5,054,000 3,271,000
Ending balance of unrecognized tax benefits 51,257,000 $ 27,365,000 $ 23,964,000
Unrecognized tax benefits that would reduce effective tax rate 33,300,000    
Interest and penalties on unrecognized tax benefits $ 0    
XML 89 R58.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - AstraZeneca (Details)
$ in Thousands
1 Months Ended 3 Months Ended 7 Months Ended 12 Months Ended
Jul. 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Jun. 30, 2013
USD ($)
Dec. 31, 2015
USD ($)
AccountingUnit
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
Drug
Jan. 31, 2016
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                              
Revenue earned   $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 84,861 $ 44,063 $ 57,076 $ 28,161   $ 283,703 $ 214,161 $ 147,285    
AstraZeneca [Member] | Collaborations and Licensing Agreements [Member]                              
Collaborative Arrangement and Licensing Agreement [Abstract]                              
Revenue earned                     6,400 27,700 $ 29,100    
Deferred revenue   63,300       $ 4,400         $ 63,300 $ 4,400      
AstraZeneca [Member] | Collaborations and Licensing Agreements [Member] | Revenue [Member] | Strategic Partner [Member]                              
Collaborative Arrangement and Licensing Agreement [Abstract]                              
Concentration percentage                     2.00% 13.00% 20.00%    
AstraZeneca [Member] | Agreement Entered into in December 2012 [Member] | Oncology [Member]                              
Collaborative Arrangement and Licensing Agreement [Abstract]                              
Maximum amount of payments receivable   750,000                 $ 750,000        
Next potential milestone   15,000                 15,000        
Number of drugs the collaborative partner may license under a separate research program | Drug                           3  
Cumulative upfront fees received   31,000                 31,000        
Revenue earned                   $ 11,500          
Upfront fee amortized into revenue   11,900                 11,900        
Deferred revenue   7,600                 7,600        
Cumulative payments and/or fees received   63,500                 63,500        
AstraZeneca [Member] | Agreement Entered into in December 2012 [Member] | Oncology [Member] | Development Milestones [Member]                              
Collaborative Arrangement and Licensing Agreement [Abstract]                              
Maximum amount of payments receivable   226,000                 226,000        
AstraZeneca [Member] | Agreement Entered into in December 2012 [Member] | Oncology [Member] | Regulatory Milestones [Member]                              
Collaborative Arrangement and Licensing Agreement [Abstract]                              
Maximum amount of payments receivable   485,000                 485,000        
AstraZeneca [Member] | Amended Agreement Entered into in January 2016 [Member] | Oncology [Member] | Subsequent Event [Member]                              
Collaborative Arrangement and Licensing Agreement [Abstract]                              
Milestone payment to be earned                             $ 5,000
AstraZeneca [Member] | Agreement Entered into in July 2015 [Member] | Cardiometabolic and Renal Diseases [Member]                              
Collaborative Arrangement and Licensing Agreement [Abstract]                              
Upfront fee received $ 65,000                            
Next potential milestone   25,000                 $ 25,000        
Number of units of accounting | AccountingUnit                     1        
AstraZeneca [Member] | Agreement Entered into in July 2015 [Member] | Cardiometabolic and Renal Diseases [Member] | License Fee and Substantive Milestones [Member]                              
Collaborative Arrangement and Licensing Agreement [Abstract]                              
Minimum amount of payments receivable   4,000,000                 $ 4,000,000        
AstraZeneca [Member] | Agreement Entered into in July 2015 [Member] | Cardiometabolic and Renal Diseases [Member] | Development Milestones [Member]                              
Collaborative Arrangement and Licensing Agreement [Abstract]                              
Maximum amount of payments receivable   1,100,000                 1,100,000        
AstraZeneca [Member] | Agreement Entered into in July 2015 [Member] | Cardiometabolic and Renal Diseases [Member] | Regulatory Milestones [Member]                              
Collaborative Arrangement and Licensing Agreement [Abstract]                              
Maximum amount of payments receivable   $ 2,900,000                 $ 2,900,000        
XML 90 R59.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Nusinersen) (Details) - Biogen [Member]
$ in Millions
1 Months Ended 12 Months Ended
Feb. 29, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jan. 31, 2012
USD ($)
Dec. 31, 2015
USD ($)
Agreement
Drug
Study
Nusinersen [Member] | Studies in Infants and Children with SMA [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Milestone payment earned       $ 40
Nusinersen [Member] | Open-Label Extension Study for Phase 3 Studies in Infants and Children with SMA [Member] | Subsequent Event [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Milestone payment earned $ 2      
Nusinersen [Member] | Development Milestones [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Maximum amount of payments receivable       121
Nusinersen [Member] | Regulatory Milestones [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Maximum amount of payments receivable       150
Nusinersen [Member] | License Fee and Substantive Milestones [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Maximum amount of payments receivable       $ 346
Collaborations and Licensing Agreements [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Number of strategic collaboration agreements | Agreement       4
Collaborations and Licensing Agreements [Member] | Drugs to Treat Neurological Disorders Under Collaborations [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Number of drugs currently in development | Drug       6
Collaborations and Licensing Agreements [Member] | Drugs to Treat Undisclosed Neurodegenerative Diseases [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Number of drugs currently in development | Drug       3
Agreement Entered into in January 2012 [Member] | Phase 2 Studies in Infants and Children with SMA [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Number of Phase 2 open-label, multiple-dose, dose-escalation studies in which drug is being evaluated | Study       2
Agreement Entered into in January 2012 [Member] | Phase 2 Studies in Infants with SMA [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Number of Phase 2 open-label, multiple-dose, dose-escalation studies in which drug is being evaluated | Study       1
Agreement Entered into in January 2012 [Member] | Phase 2 Studies in Children with SMA [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Number of Phase 2 open-label, multiple-dose, dose-escalation studies in which drug is being evaluated | Study       1
Agreement Entered into in January 2012 [Member] | Nusinersen [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Upfront fee recorded as deferred revenue     $ 29  
Milestone payment earned   $ 11    
Next potential milestone       $ 2
Agreement Entered into in January 2012 [Member] | Nusinersen [Member] | Minimum [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Cumulative payments and/or fees received       $ 130
XML 91 R60.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (IONIS-DMPK-2.5) (Details) - Biogen [Member] - USD ($)
$ in Millions
1 Months Ended
Nov. 30, 2015
Jun. 30, 2012
Dec. 31, 2015
Agreement Entered into in June 2012 [Member] | IONIS-DMPK-2.5 [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Upfront fee recorded as deferred revenue   $ 12.0  
Next potential milestone     $ 35.0
Agreement Entered into in June 2012 [Member] | IONIS-DMPK-2.5 [Member] | License Fee and Substantive Milestones [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Maximum amount of payments receivable     263.0
Cumulative payments and/or fees received     39.0
Agreement Entered into in June 2012 [Member] | IONIS-DMPK-2.5 [Member] | Development Milestones [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Maximum amount of payments receivable     63.0
Agreement Entered into in June 2012 [Member] | IONIS-DMPK-2.5 [Member] | Regulatory Milestones [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Maximum amount of payments receivable     130.0
Agreement Amended in June 2015 [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Milestone payment earned $ 2.8    
Agreement Amended in June 2015 [Member] | IONIS-DMPK-2.5 [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Maximum amount of payments receivable     4.2
Next potential milestone     $ 1.4
XML 92 R61.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Neurology) (Details) - Biogen [Member] - Agreement Entered into in December 2012 [Member] - Neurology [Member]
$ in Millions
1 Months Ended
Feb. 29, 2016
USD ($)
Feb. 28, 2015
USD ($)
Dec. 31, 2012
USD ($)
Target
Drug
Dec. 31, 2015
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]        
Number of targets | Target     3  
Number of programs under which drugs are to be developed and commercialized | Drug     3  
Upfront fee recorded as deferred revenue     $ 30  
Milestone payment earned   $ 10    
Cumulative payments and/or fees received       $ 40
Next potential milestone       10
Subsequent Event [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Milestone payment earned $ 3      
License Fee and Substantive Milestones [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Maximum amount of payments receivable per program       259
Development Milestones [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Maximum amount of payments receivable per program       59
Regulatory Milestones [Member]        
Collaborative Arrangement and Licensing Agreement [Abstract]        
Maximum amount of payments receivable per program       $ 130
XML 93 R62.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Strategic Neurology) (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2015
USD ($)
Sep. 30, 2013
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Drug
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Revenue earned     $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 84,861 $ 44,063 $ 57,076 $ 28,161 $ 283,703 $ 214,161 $ 147,285
Biogen [Member] | Collaborations and Licensing Agreements [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Revenue earned                     106,200 123,200 $ 37,000
Deferred revenue $ 91,600   91,600       $ 118,100       $ 91,600 $ 118,100  
Biogen [Member] | Collaborations and Licensing Agreements [Member] | Revenue [Member] | Strategic Partner [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Concentration percentage                     37.00% 58.00% 25.00%
Biogen [Member] | Agreement Entered into in September 2013 [Member] | Strategic Neurology [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Number of drugs currently being advanced | Drug                     3    
Upfront fee recorded as deferred revenue   $ 100,000                      
Term of collaboration agreement                     6 years    
Cumulative payments and/or fees received 135,000   135,000               $ 135,000    
Milestone payment earned 5,000                        
Next potential milestone 10,000   10,000               10,000    
Biogen [Member] | Agreement Entered into in September 2013 [Member] | Antisense Molecule [Member] | License Fee and Substantive Milestones [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable per drug 260,000   260,000               260,000    
Biogen [Member] | Agreement Entered into in September 2013 [Member] | Antisense Molecule [Member] | Research and Development Milestones [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable per drug 60,000   60,000               60,000    
Biogen [Member] | Agreement Entered into in September 2013 [Member] | Antisense Molecule [Member] | Regulatory Milestones [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable per drug 130,000   130,000               130,000    
Biogen [Member] | Agreement Entered into in September 2013 [Member] | Other Modalities [Member] | Pre-Specified Events [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable per drug 90,000   90,000               90,000    
Biogen [Member] | Agreement Entered into in September 2013 [Member] | Other Modalities [Member] | Research and Development Milestones [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable per drug 35,000   35,000               35,000    
Biogen [Member] | Agreement Entered into in September 2013 [Member] | Other Modalities [Member] | Regulatory Milestones [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable per drug $ 55,000   $ 55,000               $ 55,000    
XML 94 R63.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Bayer (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2015
May. 31, 2015
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Revenue earned     $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 84,861 $ 44,063 $ 57,076 $ 28,161 $ 283,703 $ 214,161 $ 147,285
Agreement Entered into in May 2015 [Member] | License Fees, Substantive Milestone Payments and Other Payments [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable   $ 375,000                      
Agreement Entered into in May 2015 [Member] | Development Milestones [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable   120,000                      
Agreement Entered into in May 2015 [Member] | Commercialization Milestones [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable   110,000                      
Bayer HealthCare [Member] | Collaborations and Licensing Agreements [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Revenue earned                     93,400    
Deferred revenue     6,700               $ 6,700    
Bayer HealthCare [Member] | Collaborations and Licensing Agreements [Member] | Revenue [Member] | Strategic Partner [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Concentration percentage                     33.00%    
Bayer HealthCare [Member] | Agreement Entered into in May 2015 [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Near-term payments   $ 155,000                      
Upfront fee received         100,000                
Next potential milestone     $ 55,000               $ 55,000    
Revenue earned $ 91,200                        
Bayer HealthCare [Member] | Agreement Entered into in May 2015 [Member] | Minimum [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Percentage of gross margins of sales received as royalties   20.00%                      
Bayer HealthCare [Member] | Agreement Entered into in May 2015 [Member] | IONIS-FXI [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Upfront fee recorded as deferred revenue $ 8,800       $ 4,300                
XML 95 R64.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Genzyme Corporation (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2008
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Equity investment in common stock                   $ 0 $ 0 $ 173,292,000
Revenue earned   $ 51,571,000 $ 49,121,000 $ 120,428,000 $ 62,583,000 $ 84,861,000 $ 44,063,000 $ 57,076,000 $ 28,161,000 283,703,000 214,161,000 147,285,000
Genzyme Corporation [Member] | Collaborations and Licensing Agreements [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Upfront fee recorded as deferred revenue $ 175,000,000                      
Equity investment in common stock $ 150,000,000                      
Cumulative payments, fees and equity investment received   $ 375,000,000               375,000,000    
Revenue earned                   $ 0 $ 0 $ 32,500,000
Genzyme Corporation [Member] | Collaborations and Licensing Agreements [Member] | Revenue [Member] | Strategic Partner [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Concentration percentage                       22.00%
XML 96 R65.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - GSK (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2016
USD ($)
Mar. 31, 2010
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Drug
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Revenue earned     $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 84,861 $ 44,063 $ 57,076 $ 28,161 $ 283,703 $ 214,161 $ 147,285
GSK [Member] | Collaborations and Licensing Agreements [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Number of drugs currently in development | Drug                     5    
Upfront fee received   $ 38,000                      
Cumulative payments and/or fees received     135,000               $ 135,000    
Next potential milestone     5,000               5,000    
Revenue earned                     33,300 37,300 $ 35,300
Deferred revenue     4,900       $ 10,000       $ 4,900 $ 10,000  
GSK [Member] | Collaborations and Licensing Agreements [Member] | Subsequent Event [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Milestone payment earned $ 1,500                        
GSK [Member] | Collaborations and Licensing Agreements [Member] | Revenue [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Concentration percentage                     12.00% 17.00% 24.00%
GSK [Member] | Collaborations and Licensing Agreements [Member] | Pre Specified Events [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Minimum amount of payments receivable     1,000,000               $ 1,000,000    
GSK [Member] | Collaborations and Licensing Agreements [Member] | Pre-Licensing Milestones [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable     10,000               10,000    
GSK [Member] | Collaborations and Licensing Agreements [Member] | Development Milestones [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable     183,500               183,500    
GSK [Member] | Collaborations and Licensing Agreements [Member] | Regulatory Milestones [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable     363,500               363,500    
GSK [Member] | Collaborations and Licensing Agreements [Member] | Commercialization Milestones [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable     348,000               348,000    
GSK [Member] | Collaborations and Licensing Agreements [Member] | IONIS-TTR [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Cumulative payments and/or fees received     $ 60,000               $ 60,000    
GSK [Member] | Collaborations and Licensing Agreements [Member] | IONIS-HBV, IONIS-HBV-L, IONIS-GSK4-L, and IONIS-RHO-2.5 [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Number of drugs currently in development | Drug                     4    
GSK [Member] | Collaborations and Licensing Agreements [Member] | IONIS-HBV and IONIS-HBV-L [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Number of drugs currently in development | Drug                     2    
XML 97 R66.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Janssen Biotech, Inc. (Details)
3 Months Ended 12 Months Ended
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Drug
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Revenue earned $ 51,571,000 $ 49,121,000 $ 120,428,000 $ 62,583,000 $ 84,861,000 $ 44,063,000 $ 57,076,000 $ 28,161,000 $ 283,703,000 $ 214,161,000 $ 147,285,000
Janssen Biotech, Inc. [Member] | Agreement Entered Into in December 2014 [Member]                      
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Number of programs under which drugs are to be developed and commercialized | Drug                 3    
Cumulative payments and/or fees received 35,000,000               $ 35,000,000    
Maximum amount of payments receivable 800,000,000               800,000,000    
Next potential milestone 5,000,000               5,000,000    
Revenue earned                 8,900,000 $ 0 $ 0
Deferred revenue 26,300,000               26,300,000    
Janssen Biotech, Inc. [Member] | Agreement Entered Into in December 2014 [Member] | Development Milestones [Member]                      
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Maximum amount of payments receivable 175,000,000               175,000,000    
Janssen Biotech, Inc. [Member] | Agreement Entered Into in December 2014 [Member] | Regulatory Milestones [Member]                      
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Maximum amount of payments receivable 420,000,000               420,000,000    
Janssen Biotech, Inc. [Member] | Agreement Entered Into in December 2014 [Member] | Commercialization Milestones [Member]                      
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Maximum amount of payments receivable $ 180,000,000               $ 180,000,000    
XML 98 R67.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Roche (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2013
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Candidate
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Revenue earned   $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 84,861 $ 44,063 $ 57,076 $ 28,161 $ 283,703 $ 214,161 $ 147,285
Roche [Member] | Collaborations and Licensing Agreements [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Revenue earned                   31,200 8,700 $ 5,100
Deferred revenue   8,800       $ 17,000       $ 8,800 $ 17,000  
Roche [Member] | Collaborations and Licensing Agreements [Member] | Revenue [Member] | Strategic Partner [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Concentration percentage                   11.00% 4.00% 3.00%
Roche [Member] | Agreement Entered into in April 2013 [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Upfront fee recorded as deferred revenue $ 30,000                      
Maximum amount of payments receivable 362,000                      
Cumulative payments and/or fees received   52,000               $ 52,000    
Next potential milestone $ 10,000                      
Roche [Member] | Agreement Entered into in April 2013 [Member] | Development, Regulatory and Commercial Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable per drug   136,500               136,500    
Roche [Member] | Agreement Entered into in April 2013 [Member] | HTT [Member] | Development Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable   67,000               67,000    
Roche [Member] | Agreement Entered into in April 2013 [Member] | HTT [Member] | Regulatory Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable   170,000               170,000    
Roche [Member] | Agreement Entered into in April 2013 [Member] | HTT [Member] | Commercialization Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable   80,000               80,000    
Roche [Member] | Agreement Entered into in April 2013 [Member] | Brain Shuttle Program [Member] | Commercialization Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable   $ 50,000               $ 50,000    
Number of development candidates that must be generated for brain shuttle program | Candidate                   1    
XML 99 R68.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Achaogen, Inc. (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2014
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Drug
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2006
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Revenue earned   $ 51,571,000 $ 49,121,000 $ 120,428,000 $ 62,583,000 $ 84,861,000 $ 44,063,000 $ 57,076,000 $ 28,161,000 $ 283,703,000 $ 214,161,000 $ 147,285,000  
Achaogen Inc [Member] | Satellite Company Collaboration and Licensing Agreement [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Cumulative payments and/or fees received   7,000,000               $ 7,000,000      
Milestone payment earned $ 4,000,000                        
Number of drugs to be developed and commercialized | Drug                   2      
Next potential milestone   7,500,000               $ 7,500,000      
Revenue earned                   0 4,000,000 $ 0  
Net proceeds from sale of stock                     $ 1,300,000    
Achaogen Inc [Member] | Satellite Company Collaboration and Licensing Agreement [Member] | Pre Specified Events [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Maximum amount of payments receivable   $ 49,300,000               $ 49,300,000      
Achaogen Inc [Member] | Satellite Company Collaboration and Licensing Agreement [Member] | Series A preferred stock [Member]                          
Collaborative Arrangement and Licensing Agreement [Abstract]                          
Upfront fee in the form of equity securities                         $ 1,500,000
XML 100 R69.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Alnylam Pharmaceuticals, Inc. (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2004
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Target
Program
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Revenue earned   $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 84,861 $ 44,063 $ 57,076 $ 28,161 $ 283,703 $ 214,161 $ 147,285
Alnylam Pharmaceuticals, Inc. [Member] | Satellite Company Collaboration and Licensing Agreement [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Upfront fee recorded as deferred revenue $ 5,000                      
Next potential milestone   400               $ 400    
Number of therapeutic targets granted to Ionis | Target                   4    
Number of therapeutic targets granted by Ionis | Target                   4    
Number of therapeutic programs | Program                   4    
Cumulative payments and/or fees received   70,000               $ 70,000    
Revenue earned                   1,300 $ 9,900 $ 1,500
Alnylam Pharmaceuticals, Inc. [Member] | Satellite Company Collaboration and Licensing Agreement [Member] | Pre Specified Events [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable per drug   3,400               3,400    
Maximum amount of milestone payments payable   $ 3,400               $ 3,400    
Alnylam Pharmaceuticals, Inc. [Member] | Satellite Company Collaboration and Licensing Agreement [Member] | Development Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable per drug     1,100                  
Alnylam Pharmaceuticals, Inc. [Member] | Satellite Company Collaboration and Licensing Agreement [Member] | Regulatory Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable per drug     $ 2,300                  
XML 101 R70.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Antisense Therapeutics Limited (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Revenue earned $ 51,571,000 $ 49,121,000 $ 120,428,000 $ 62,583,000 $ 84,861,000 $ 44,063,000 $ 57,076,000 $ 28,161,000 $ 283,703,000 $ 214,161,000 $ 147,285,000
Antisense Therapeutics Limited [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member]                      
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Revenue earned                 $ 0 $ 0 $ 0
Antisense Therapeutics Limited [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | Maximum [Member]                      
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Ownership interest percentage 10.00%       10.00%       10.00% 10.00%  
XML 102 R71.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Atlantic Pharmaceuticals Limited (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2007
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Revenue earned   $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 84,861 $ 44,063 $ 57,076 $ 28,161 $ 283,703 $ 214,161 $ 147,285
Atlantic Pharmaceuticals Limited [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Upfront fee in the form of equity securities $ 2,000                      
Next potential milestone   $ 600               $ 600    
Ownership interest percentage   11.00%       12.00%       11.00% 12.00%  
Royalties earned and paid in equity                       $ 700
Revenue earned [1]                    
Atlantic Pharmaceuticals Limited [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | Regulatory Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable   $ 1,400               $ 1,400    
[1] Revenue from this relationship was negligible for the year.
XML 103 R72.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - OncoGenex Technologies Inc. (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2003
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Study
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Revenue earned   $ 51,571,000 $ 49,121,000 $ 120,428,000 $ 62,583,000 $ 84,861,000 $ 44,063,000 $ 57,076,000 $ 28,161,000 $ 283,703,000 $ 214,161,000 $ 147,285,000
OncoGenex Technologies Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Revenue earned                   $ 0 $ 0 $ 0
OncoGenex Technologies Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | Custirsen [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Number of Phase 3 studies in which drug is being evaluated | Study                   2    
OncoGenex Technologies Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | OGX-225 [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Upfront fee in the form of equity securities $ 800,000                      
OncoGenex Technologies Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | OGX-225 [Member] | Phase 2 Study [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Next potential milestone   500,000               $ 500,000    
OncoGenex Technologies Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | OGX-225 [Member] | Development and Regulatory Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable   3,500,000               3,500,000    
OncoGenex Technologies Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | OGX-225 [Member] | Development Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable   1,500,000               1,500,000    
OncoGenex Technologies Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | OGX-225 [Member] | Regulatory Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable   2,000,000               2,000,000    
OncoGenex Technologies Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | Apatorsen [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable   5,800,000               5,800,000    
OncoGenex Technologies Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | Apatorsen [Member] | Phase 3 Study [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Next potential milestone   1,300,000               1,300,000    
OncoGenex Technologies Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | Apatorsen [Member] | Development Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable   1,300,000               1,300,000    
OncoGenex Technologies Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | Apatorsen [Member] | Regulatory Milestones [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of payments receivable   $ 4,500,000               $ 4,500,000    
XML 104 R73.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Regulus Therapeutics Inc. (Details)
shares in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2015
USD ($)
shares
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Drug
shares
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Revenue earned $ 51,571,000 $ 49,121,000 $ 120,428,000 $ 62,583,000 $ 84,861,000 $ 44,063,000 $ 57,076,000 $ 28,161,000 $ 283,703,000 $ 214,161,000 $ 147,285,000
Net carrying value $ 24,792,000       $ 81,881,000       $ 24,792,000 81,881,000  
Regulus Therapeutics Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member]                      
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Number of drugs currently in development | Drug                 3    
Revenue earned                 $ 0 0 $ 0
Gain from sale of common stock                 20,200,000 19,900,000  
Total proceeds from sale of common stock                 $ 25,500,000 $ 22,900,000  
Common stock owned (in shares) | shares 2.8               2.8    
Net carrying value $ 24,800               $ 24,800    
Regulus Therapeutics Inc. [Member] | Satellite Company Collaborative Arrangement and Licensing Agreement [Member] | Maximum [Member]                      
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Ownership interest percentage 5.00%               5.00%    
XML 105 R74.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, External Project Funding (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Research and development expense                 $ 319,500,000 $ 238,900,000 $ 173,700,000
Revenue earned $ 51,571,000 $ 49,121,000 $ 120,428,000 $ 62,583,000 $ 84,861,000 $ 44,063,000 $ 57,076,000 $ 28,161,000 283,703,000 214,161,000 147,285,000
Collaborations and Licensing Agreements [Member]                      
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Research and development expense                 161,700,000 85,600,000 51,000,000
CHDI Foundation Inc [Member] | Collaborations and Licensing Agreements [Member]                      
Collaborative Arrangement and Licensing Agreement [Abstract]                      
Research and development expense                 5,000,000 3,000,000  
Maximum amount of milestone payments payable $ 4,000,000               4,000,000    
Revenue earned                 $ 0 $ 0 $ 400,000
XML 106 R75.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaborative Arrangements and Licensing Agreements, Intellectual Property Sale and Licensing Agreements (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2009
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Revenue earned   $ 51,571,000 $ 49,121,000 $ 120,428,000 $ 62,583,000 $ 84,861,000 $ 44,063,000 $ 57,076,000 $ 28,161,000 $ 283,703,000 $ 214,161,000 $ 147,285,000
Abbott Molecular Inc. [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Sales price of interest owned in subsidiary $ 215,000,000                      
Revenue earned                   0 $ 0 $ 0
Abbott Molecular Inc. [Member] | Minimum [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Cumulative net sales threshold used to calculate earn out payments                   $ 140,000,000    
Percentage of cumulative net sales used to calculate earn out payments, over $140 million and up to $2.1 billion                   2.50%    
Percentage of cumulative net sales used to calculate earn out payments, over $2.1 billion                   1.50%    
Abbott Molecular Inc. [Member] | Maximum [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Cumulative net sales threshold used to calculate earn out payments                   $ 2,100,000,000    
Revenue threshold used to calculate earn out payments                   $ 50,000,000    
Percentage of cumulative net sales used to calculate earn out payments, over $140 million and up to $2.1 billion                   5.00%    
Percentage of cumulative net sales used to calculate earn out payments, over $2.1 billion                   3.00%    
University of Massachusetts [Member] | In-Licensing Arrangement [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of milestone payments payable   300,000               $ 300,000    
Verva Pharmaceuticals Ltd. [Member] | In-Licensing Arrangement [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of milestone payments payable   6,100,000               6,100,000    
Cold Spring Harbor Laboratory [Member] | In-Licensing Arrangement [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Maximum amount of sublicense revenue and post licensing milestone payments payable under in-licensing arrangement   $ 11,300,000               $ 11,300,000    
XML 107 R76.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Information and Concentration of Business Risk (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Segment
Partner
Dec. 31, 2014
USD ($)
Partner
Dec. 31, 2013
USD ($)
Segment Information and Concentration of Business Risk [Abstract]                      
Number of reportable segments | Segment                 2    
Revenue [Abstract]                      
Research and development                 $ 281,360 $ 202,514 $ 144,194
Licensing and royalty                 2,343 11,647 3,091
Total revenue $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 84,861 $ 44,063 $ 57,076 $ 28,161 283,703 214,161 147,285
Loss from operations (62,940) $ (48,138) $ 44,646 $ (9,330) 10,080 $ (21,493) $ (6,650) $ (29,667) (75,762) (47,730) (51,666)
Total assets 956,105       $ 955,809       956,105 955,809  
Operating Segments [Member] | Ionis Core [Member]                      
Revenue [Abstract]                      
Research and development                 285,608 202,514 147,380
Licensing and royalty                 2,343 11,647 3,091
Total revenue                 287,951 214,161 150,471
Loss from operations                 (21,378) (26,033) (38,764)
Total assets 1,004,150               1,004,150    
Operating Segments [Member] | Akcea Therapeutics [Member]                      
Revenue [Abstract]                      
Research and development                 0 0 0
Licensing and royalty                 0 0 0
Total revenue                 0 0 0
Loss from operations                 (54,384) $ (21,697) $ (12,902)
Total assets 55,354               55,354    
Elimination of Intercompany Activity [Member]                      
Revenue [Abstract]                      
Research and development                 (4,248)    
Licensing and royalty                 0    
Total revenue                 (4,248)    
Loss from operations                 0    
Total assets $ (103,399)               $ (103,399)    
Revenue [Member] | Partner A [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 37.00% 58.00% 25.00%
Revenue [Member] | Partner B [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 33.00% 0.00% 0.00%
Revenue [Member] | Partner C [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 12.00% 17.00% 24.00%
Revenue [Member] | Partner D [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 11.00% 4.00% 3.00%
Revenue [Member] | Partner E [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 2.00% 13.00% 20.00%
Revenue [Member] | Partner F [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 0.00% 0.00% 22.00%
Contracts Receivables [Member] | Significant Partners [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 99.00% 99.00%  
Number of significant partners | Partner                 2 3  
XML 108 R77.htm IDEA: XBRL DOCUMENT v3.3.1.900
Employment Benefits (Details) - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Employment Benefits [Abstract]      
Employee contribution limit per calendar year for employees under 50 years of age $ 18,000    
Employee contribution limit per calendar year for employees over 50 years of age 24,000    
Matching contributions $ 1,500,000 $ 1,000,000 $ 600,000
XML 109 R78.htm IDEA: XBRL DOCUMENT v3.3.1.900
Quarterly Financial Data (Unaudited) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Quarterly Financial Data (Unaudited) [Abstract]                      
Revenue $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 84,861 $ 44,063 $ 57,076 $ 28,161 $ 283,703 $ 214,161 $ 147,285
Operating expenses 114,511 97,259 75,782 71,913 74,781 65,556 63,726 57,828 359,465 261,891 198,951
Loss from operations (62,940) (48,138) 44,646 (9,330) 10,080 (21,493) (6,650) (29,667) (75,762) (47,730) (51,666)
Net income (loss) $ (71,433) $ (35,776) $ 35,648 $ (16,717) $ 31,053 $ (26,676) $ (12,081) $ (31,280) $ (88,278) $ (38,984) $ (60,644)
Basic net income (loss) per share (in dollars per share) [1] $ (0.59) $ (0.30) $ 0.30 $ (0.14) $ 0.26 $ (0.23) $ (0.10) $ (0.27)      
Diluted net income (loss) per share (in dollars per share) [1] (0.59) (0.30) $ 0.29 [2] (0.14) $ 0.25 [3] (0.23) (0.10) (0.27)      
Income (Numerator) [Abstract]                      
Income available to common shareholders     $ 35,648   $ 31,053            
Dilutive effect of 2 3/4 percent notes     1,047                
Income available to common shareholders, plus assumed conversions     $ 36,695   $ 31,053            
Shares (Denominator) [Abstract]                      
Shares used in computing basic net income per share (in shares)     119,742   118,223            
Effect of Diluted Securities [Abstract]                      
Shares issuable related to our ESPP     4   9            
Shares issuable related to our 2 3/4 percent notes (in shares)     3,683                
Shares used in computing diluted net income per share (in shares)     127,779   122,839            
Per-Share Amount [Abstract]                      
Basic net income per share (in dollars per share) [1] (0.59) (0.30) $ 0.30 (0.14) $ 0.26 (0.23) (0.10) (0.27)      
Diluted net income per share (in dollars per share) [1] $ (0.59) $ (0.30) $ 0.29 [2] $ (0.14) $ 0.25 [3] $ (0.23) $ (0.10) $ (0.27)      
Convertible Senior Notes [Member] | 1 Percent Convertible Senior Notes [Member]                      
Convertible Senior Notes [Abstract]                      
Interest rate on convertible senior notes 1.00%       1.00%       1.00% 1.00%  
Convertible Senior Notes [Member] | 2 3/4 Percent Convertible Senior Notes [Member]                      
Convertible Senior Notes [Abstract]                      
Interest rate on convertible senior notes 2.75%       2.75%       2.75% 2.75% 2.75%
Stock Options [Member]                      
Effect of Diluted Securities [Abstract]                      
Shares issuable related to stock-based compensation (in shares)     3,974   4,189            
Restricted Stock Awards [Member]                      
Effect of Diluted Securities [Abstract]                      
Shares issuable related to stock-based compensation (in shares)     376   418            
[1] We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.
[2] For the three months ended June 30, 2015, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. For the three months ended June 30, 2015, the calculation excludes the 1 percent notes because the effect on diluted earnings per share would be anti-dilutive.
[3] For the three months ended December 31, 2014, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. For the three months ended December 31, 2014, the calculation excludes the 1 percent and 2.75 percent convertible senior notes because the effect on diluted earnings per share would be anti-dilutive.
EXCEL 110 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 112 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 114 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 496 453 1 true 160 0 false 21 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://isispharm.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://isispharm.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://isispharm.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 030000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveLoss CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 040000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 040100 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 7 false false R8.htm 050000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://isispharm.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 050100 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 9 false false R10.htm 060100 - Disclosure - Organization and Significant Accounting Policies Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies Organization and Significant Accounting Policies Notes 10 false false R11.htm 060200 - Disclosure - Investments Sheet http://isispharm.com/role/Investments Investments Notes 11 false false R12.htm 060300 - Disclosure - Long-Term Obligations and Commitments Sheet http://isispharm.com/role/LongtermObligationsAndCommitments Long-Term Obligations and Commitments Notes 12 false false R13.htm 060400 - Disclosure - Stockholders' Equity Sheet http://isispharm.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 060500 - Disclosure - Income Taxes Sheet http://isispharm.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 060600 - Disclosure - Collaborative Arrangements and Licensing Agreements Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreements Collaborative Arrangements and Licensing Agreements Notes 15 false false R16.htm 060700 - Disclosure - Segment Information and Concentration of Business Risk Sheet http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRisk Segment Information and Concentration of Business Risk Notes 16 false false R17.htm 060800 - Disclosure - Employment Benefits Sheet http://isispharm.com/role/EmploymentBenefits Employment Benefits Notes 17 false false R18.htm 060900 - Disclosure - Legal Proceedings Sheet http://isispharm.com/role/LegalProceedings Legal Proceedings Notes 18 false false R19.htm 061000 - Disclosure - Quarterly Financial Data (Unaudited) Sheet http://isispharm.com/role/QuarterlyFinancialDataUnaudited Quarterly Financial Data (Unaudited) Notes 19 false false R20.htm 070100 - Disclosure - Organization and Significant Accounting Policies (Policies) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies Organization and Significant Accounting Policies (Policies) Policies http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies 20 false false R21.htm 080100 - Disclosure - Organization and Significant Accounting Policies (Tables) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables Organization and Significant Accounting Policies (Tables) Tables http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies 21 false false R22.htm 080200 - Disclosure - Investments (Tables) Sheet http://isispharm.com/role/InvestmentsTables Investments (Tables) Tables http://isispharm.com/role/Investments 22 false false R23.htm 080300 - Disclosure - Long-Term Obligations and Commitments (Tables) Sheet http://isispharm.com/role/LongtermObligationsAndCommitmentsTables Long-Term Obligations and Commitments (Tables) Tables http://isispharm.com/role/LongtermObligationsAndCommitments 23 false false R24.htm 080400 - Disclosure - Stockholders' Equity (Tables) Sheet http://isispharm.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://isispharm.com/role/StockholdersEquity 24 false false R25.htm 080500 - Disclosure - Income Taxes (Tables) Sheet http://isispharm.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://isispharm.com/role/IncomeTaxes 25 false false R26.htm 080700 - Disclosure - Segment Information and Concentration of Business Risk (Tables) Sheet http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskTables Segment Information and Concentration of Business Risk (Tables) Tables http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRisk 26 false false R27.htm 081000 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) Sheet http://isispharm.com/role/QuarterlyFinancialDataUnauditedTables Quarterly Financial Data (Unaudited) (Tables) Tables http://isispharm.com/role/QuarterlyFinancialDataUnaudited 27 false false R28.htm 090100 - Disclosure - Organization and Significant Accounting Policies, Basic and Diluted Net Loss per Share (Details) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails Organization and Significant Accounting Policies, Basic and Diluted Net Loss per Share (Details) Details 28 false false R29.htm 090102 - Disclosure - Organization and Significant Accounting Policies, Revenue Recognition (Details) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails Organization and Significant Accounting Policies, Revenue Recognition (Details) Details 29 false false R30.htm 090104 - Disclosure - Organization and Significant Accounting Policies, Research, Development and Patent Expenses (Details) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails Organization and Significant Accounting Policies, Research, Development and Patent Expenses (Details) Details 30 false false R31.htm 090106 - Disclosure - Organization and Significant Accounting Policies, Inventory Valuation (Details) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails Organization and Significant Accounting Policies, Inventory Valuation (Details) Details 31 false false R32.htm 090108 - Disclosure - Organization and Significant Accounting Policies, Property, Plant and Equipment (Details) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails Organization and Significant Accounting Policies, Property, Plant and Equipment (Details) Details 32 false false R33.htm 090110 - Disclosure - Organization and Significant Accounting Policies, Long-Lived Assets (Details) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails Organization and Significant Accounting Policies, Long-Lived Assets (Details) Details 33 false false R34.htm 090112 - Disclosure - Organization and Significant Accounting Policies, Stock-based Compensation (Details) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationDetails Organization and Significant Accounting Policies, Stock-based Compensation (Details) Details 34 false false R35.htm 090114 - Disclosure - Organization and Significant Accounting Policies, Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveIncomeLossDetails Organization and Significant Accounting Policies, Accumulated Other Comprehensive Income (Loss) (Details) Details 35 false false R36.htm 090116 - Disclosure - Organization and Significant Accounting Policies, Convertible Debt and Segment Information (Details) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtAndSegmentInformationDetails Organization and Significant Accounting Policies, Convertible Debt and Segment Information (Details) Details 36 false false R37.htm 090118 - Disclosure - Organization and Significant Accounting Policies, Fair Value Measurements on a Recurring Basis (Details) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsOnRecurringBasisDetails Organization and Significant Accounting Policies, Fair Value Measurements on a Recurring Basis (Details) Details 37 false false R38.htm 090120 - Disclosure - Organization and Significant Accounting Policies, Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (Details) Sheet http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsUsingSignificantUnobservableInputsLevel3Details Organization and Significant Accounting Policies, Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (Details) Details 38 false false R39.htm 090200 - Disclosure - Investments, Contract Maturity of Available-for-Sale Securities (Details) Sheet http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails Investments, Contract Maturity of Available-for-Sale Securities (Details) Details 39 false false R40.htm 090202 - Disclosure - Investments, Summary of Investments and Investments Temporarily Impaired (Details) Sheet http://isispharm.com/role/InvestmentsSummaryOfInvestmentsAndInvestmentsTemporarilyImpairedDetails Investments, Summary of Investments and Investments Temporarily Impaired (Details) Details 40 false false R41.htm 090300 - Disclosure - Long-Term Obligations and Commitments, Long-Term Obligations (Details) Sheet http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails Long-Term Obligations and Commitments, Long-Term Obligations (Details) Details 41 false false R42.htm 090302 - Disclosure - Long-Term Obligations and Commitments, Convertible Notes (Details) Notes http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails Long-Term Obligations and Commitments, Convertible Notes (Details) Details 42 false false R43.htm 090304 - Disclosure - Long-Term Obligations and Commitments, Financing Arrangements (Details) Sheet http://isispharm.com/role/LongtermObligationsAndCommitmentsFinancingArrangementsDetails Long-Term Obligations and Commitments, Financing Arrangements (Details) Details 43 false false R44.htm 090308 - Disclosure - Long-Term Obligations and Commitments, Maturity Schedules (Details) Sheet http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails Long-Term Obligations and Commitments, Maturity Schedules (Details) Details 44 false false R45.htm 090310 - Disclosure - Long-Term Obligations and Commitments, Operating Leases (Details) Sheet http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails Long-Term Obligations and Commitments, Operating Leases (Details) Details 45 false false R46.htm 090312 - Disclosure - Long-Term Obligations and Commitments, Research and Development Facility Lease Obligation (Details) Sheet http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentFacilityLeaseObligationDetails Long-Term Obligations and Commitments, Research and Development Facility Lease Obligation (Details) Details 46 false false R47.htm 090400 - Disclosure - Stockholders' Equity, Preferred and Common Stock (Details) Sheet http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails Stockholders' Equity, Preferred and Common Stock (Details) Details 47 false false R48.htm 090402 - Disclosure - Stockholders' Equity, Stock Plans (Details) Sheet http://isispharm.com/role/StockholdersEquityStockPlansDetails Stockholders' Equity, Stock Plans (Details) Details 48 false false R49.htm 090404 - Disclosure - Stockholders' Equity, Stock Option Activity (Details) Sheet http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails Stockholders' Equity, Stock Option Activity (Details) Details 49 false false R50.htm 090406 - Disclosure - Stockholders' Equity, Restricted Stock Unit Activity (Details) Sheet http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails Stockholders' Equity, Restricted Stock Unit Activity (Details) Details 50 false false R51.htm 090408 - Disclosure - Stockholders' Equity, Stock-based Compensation Expense (Details) Sheet http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails Stockholders' Equity, Stock-based Compensation Expense (Details) Details 51 false false R52.htm 090410 - Disclosure - Stockholders' Equity, Stock-based Valuation Information (Details) Sheet http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails Stockholders' Equity, Stock-based Valuation Information (Details) Details 52 false false R53.htm 090500 - Disclosure - Income Taxes, Provision for Income Taxes (Details) Sheet http://isispharm.com/role/IncomeTaxesProvisionForIncomeTaxesDetails Income Taxes, Provision for Income Taxes (Details) Details 53 false false R54.htm 090502 - Disclosure - Income Taxes, Reconciliation of Effective Tax Rate (Details) Sheet http://isispharm.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails Income Taxes, Reconciliation of Effective Tax Rate (Details) Details 54 false false R55.htm 090504 - Disclosure - Income Taxes, Deferred Tax Assets and Liabilities (Details) Sheet http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails Income Taxes, Deferred Tax Assets and Liabilities (Details) Details 55 false false R56.htm 090506 - Disclosure - Income Taxes, Tax Credit Carryforward (Details) Sheet http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardDetails Income Taxes, Tax Credit Carryforward (Details) Details 56 false false R57.htm 090508 - Disclosure - Income Taxes, Gross Unrecognized Tax Benefits (Details) Sheet http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails Income Taxes, Gross Unrecognized Tax Benefits (Details) Details 57 false false R58.htm 090600 - Disclosure - Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - AstraZeneca (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsStrategicPartnershipsAstrazenecaDetails Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - AstraZeneca (Details) Details 58 false false R59.htm 090602 - Disclosure - Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Nusinersen) (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsStrategicPartnershipsBiogenNusinersenDetails Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Nusinersen) (Details) Details 59 false false R60.htm 090604 - Disclosure - Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (IONIS-DMPK-2.5) (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsStrategicPartnershipsBiogenIonisdmpk25Details Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (IONIS-DMPK-2.5) (Details) Details 60 false false R61.htm 090606 - Disclosure - Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Neurology) (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsStrategicPartnershipsBiogenNeurologyDetails Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Neurology) (Details) Details 61 false false R62.htm 090608 - Disclosure - Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Strategic Neurology) (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsStrategicPartnershipsBiogenStrategicNeurologyDetails Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Strategic Neurology) (Details) Details 62 false false R63.htm 090610 - Disclosure - Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Bayer (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsResearchDevelopmentAndCommercializationPartnersBayerDetails Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Bayer (Details) Details 63 false false R64.htm 090612 - Disclosure - Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Genzyme Corporation (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsResearchDevelopmentAndCommercializationPartnersGenzymeCorporationDetails Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Genzyme Corporation (Details) Details 64 false false R65.htm 090614 - Disclosure - Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - GSK (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsResearchDevelopmentAndCommercializationPartnersGskDetails Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - GSK (Details) Details 65 false false R66.htm 090616 - Disclosure - Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Janssen Biotech, Inc. (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsResearchDevelopmentAndCommercializationPartnersJanssenBiotechIncDetails Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Janssen Biotech, Inc. (Details) Details 66 false false R67.htm 090618 - Disclosure - Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Roche (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsResearchDevelopmentAndCommercializationPartnersRocheDetails Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Roche (Details) Details 67 false false R68.htm 090620 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Achaogen, Inc. (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsSatelliteCompanyCollaborationsAchaogenIncDetails Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Achaogen, Inc. (Details) Details 68 false false R69.htm 090622 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Alnylam Pharmaceuticals, Inc. (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsSatelliteCompanyCollaborationsAlnylamPharmaceuticalsIncDetails Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Alnylam Pharmaceuticals, Inc. (Details) Details 69 false false R70.htm 090624 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Antisense Therapeutics Limited (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsSatelliteCompanyCollaborationsAntisenseTherapeuticsLimitedDetails Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Antisense Therapeutics Limited (Details) Details 70 false false R71.htm 090626 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Atlantic Pharmaceuticals Limited (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsSatelliteCompanyCollaborationsAtlanticPharmaceuticalsLimitedDetails Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Atlantic Pharmaceuticals Limited (Details) Details 71 false false R72.htm 090630 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - OncoGenex Technologies Inc. (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsSatelliteCompanyCollaborationsOncogenexTechnologiesIncDetails Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - OncoGenex Technologies Inc. (Details) Details 72 false false R73.htm 090632 - Disclosure - Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Regulus Therapeutics Inc. (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsSatelliteCompanyCollaborationsRegulusTherapeuticsIncDetails Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Regulus Therapeutics Inc. (Details) Details 73 false false R74.htm 090634 - Disclosure - Collaborative Arrangements and Licensing Agreements, External Project Funding (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsExternalProjectFundingDetails Collaborative Arrangements and Licensing Agreements, External Project Funding (Details) Details 74 false false R75.htm 090636 - Disclosure - Collaborative Arrangements and Licensing Agreements, Intellectual Property Sale and Licensing Agreements (Details) Sheet http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsIntellectualPropertySaleAndLicensingAgreementsDetails Collaborative Arrangements and Licensing Agreements, Intellectual Property Sale and Licensing Agreements (Details) Details 75 false false R76.htm 090700 - Disclosure - Segment Information and Concentration of Business Risk (Details) Sheet http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskDetails Segment Information and Concentration of Business Risk (Details) Details http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskTables 76 false false R77.htm 090800 - Disclosure - Employment Benefits (Details) Sheet http://isispharm.com/role/EmploymentBenefitsDetails Employment Benefits (Details) Details http://isispharm.com/role/EmploymentBenefits 77 false false R78.htm 091000 - Disclosure - Quarterly Financial Data (Unaudited) (Details) Sheet http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails Quarterly Financial Data (Unaudited) (Details) Details http://isispharm.com/role/QuarterlyFinancialDataUnauditedTables 78 false false All Reports Book All Reports ions-20151231.xml ions-20151231.xsd ions-20151231_cal.xml ions-20151231_def.xml ions-20151231_lab.xml ions-20151231_pre.xml true true ZIP 116 0000874015-16-000112-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000874015-16-000112-xbrl.zip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�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�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end

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end GRAPHIC 27 image00021.jpg begin 644 image00021.jpg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end GRAPHIC 28 image00022.jpg begin 644 image00022.jpg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end GRAPHIC 29 image00023.jpg begin 644 image00023.jpg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image00024.jpg begin 644 image00024.jpg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end GRAPHIC 31 image00025.jpg begin 644 image00025.jpg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end XML 32 R1.htm IDEA: XBRL DOCUMENT v3.3.1.900
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2015
Feb. 19, 2016
Jun. 30, 2015
Document and Entity Information [Abstract]      
Entity Registrant Name IONIS PHARMACEUTICALS INC    
Entity Central Index Key 0000874015    
Document Type 10-K    
Document Period End Date Dec. 31, 2015    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Large Accelerated Filer    
Entity Public Float     $ 5,760,508,916
Entity Common Stock, Shares Outstanding   120,658,638  
Document Fiscal Year Focus 2015    
Document Fiscal Period Focus FY